Regulation of transcription by SRF and MRTF

Tea Toteva

University College London and The Francis Crick Institute PhD Supervisor: Richard Treisman

A thesis submitted for the degree of Doctor of Philosophy University College London February 2021

Declaration

I Tea Toteva confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.

Abstract

The serum response factor (SRF) is a transcription factor involved in the regulation of cell proliferation and migration. At cytoskeletal genes, SRF acts cooperatively with the actin-regulated myocardin-related transcription factors MRTF-A and MRTF-B. In addition to regulating MRTFs' subcellular localization, G-actin also controls their nuclear activities. Previous work showed that nuclear accumulation of MRTF-A in the absence of an activating signal is sufficient for its association with genomic loci but not for target gene activation, demonstrating a repressive effect of nuclear actin on MRTF activity. However, the exact mechanism is unclear. The data presented below demonstrates that G-actin interferes with ternary complex formation between SRF and MRTF on DNA. In response to G-actin depletion, MRTF is recruited to target gene promoters and activates gene expression, whereas increasing the concentration of G-actin inhibits MRTF recruitment to target promoters. We used inhibition of the Crm1 nuclear export receptor and reconstitution of MRTF-A/MRTF-B null cells with a constitutively nuclear MRTF-NLS to induce MRTF nuclear accumulation in the absence of an activating signal. Under resting G-actin levels, nuclear MRTF is recruited to target promoters, albeit at reduced levels, and induces non-productive transcription. TTseq and RNAseq experiments demonstrate that while RNA Polymerase II is engaged in elongation, no pre-mRNA accumulates. This inhibited transcriptional state correlates with aberrant Pol II CTD phosphorylation, Mtr4 recruitment and degradation of the nascent transcripts by the nuclear exosome. Inhibition of phosphorylation at Ser7 of the Pol II CTD is sufficient to induce Mtr4-mediated degradation of MRTFdependent transcripts under induced conditions.

Impact Statement

The serum response factor (SRF) is a transcription factor involved in the regulation of cell proliferation and migration. At cytoskeletal genes, SRF acts cooperatively with the actin-regulated myocardin-related transcription factors MRTF-A and MRTF-B (Miralles et al., 2003). The data presented below demonstrates that in addition to regulating MRTF subcellular localization, G-actin regulates MRTF activity in the nucleus. While G-actin depletion is required for productive RNA synthesis, under resting G-actin levels, nuclear MRTF is recruited to target promoters and induces non-productive transcription. Under this condition, RNA Polymerase II is engaged in elongation, but no pre-mRNA accumulates.

MRTF-SRF signalling is required for various actin-based processes in the cell including adhesion, chemotaxis and migration (Alberti et al., 2005; Costello et al., 2015; Gau et al., 2017; Knöll et al., 2006). In addition, MRTF/SRF signalling is also involved in invasion and metastasis of cancer cells (Haak et al., 2017; Medjkane et al., 2009; Mokalled et al., 2010).

MRTF is constitutively localized in the nucleus in cancer-associated fibroblasts (CAFs) and MDA-MB-231 breast cancer cells. Nevertheless, these cells are still responsive to changes in G-actin concentration (Foster et al., 2017; Medjkane et al., 2009), suggesting that specific cell types might employ actin-dependent mechanisms to control MRTF activity in the nucleus. Understanding the nuclear regulation of MRTF could potentially contribute to modulating the contractile and pro-invasive behaviour of CAFs and breast cancer cells.

We found that the non-productive transcriptional state at MRTF target genes correlates with aberrant Pol II CTD phosphorylation, Mtr4 recruitment and degradation of the nascent transcripts by the nuclear exosome. Moreover, inhibition of phosphorylation at serine 7 of the Pol II CTD was sufficient to induce Mtr4-mediated degradation of MRTF-dependent transcripts under induced conditions.

Phosphorylation is the best characterized modification of the Pol II CTD. Distinct phospho-marks serve to regulate different stages of the transcription cycle and couple transcription and processing of the newly-synthesised transcript. Hence, understanding the role of CTD phosphorylations is essential to understanding the mechanisms that control gene expression.

While phosphorylation of Ser5 and Ser2 of the Pol II CTD have been extensively studied, little is known about phosphorylation of Ser7 (Gomes et al., 2006; Kim & Sharp, 2001; Kim et al., 2002; Komarnitsky et al., 2000; Schroeder et al., 2000). Phospho-serine 7 is present at all actively transcribed genes. However, apart from its role in transcription and RNA processing at snRNA genes, its function is unknown (Egloff et al., 2007). Our findings suggest that it might be involved in protecting MRTF-dependent transcripts from being targeted for degradation by Mtr4 and the nuclear exosome.

Mtr4 is essential for all functions of the nuclear exosome. It is required for recruiting the exosome to its targets, through facilitating access of multiple exosome adapter complexes to the core exosome, and threading the RNA substrate into the exosome (Ogami et al., 2017; Weick et al., 2018). In addition to its well-characterized role in regulating the turn-over of non-coding RNAs, our data suggests that Mtr4 is also involved in the regulation of specific protein-coding transcripts, consistent with recent publications (Fan et al., 2017; J. Wang et al., 2019; Yu et al., 2020). Regulation by Mtr4 provides an additional layer of regulation on gene expression, which might be particularly important in response to stress or during development, when the RNA pool needs to be tightly regulated.

Acknowledgement

I thank Richard for the opportunity to work in his lab and all his help and support during my PhD.

I thank Francesco Gualdrini for the analysis of the genomic data in the thesis, as well as Philip East and Aengus Stewart for their contribution, Ana Vidakovic for the Rpb1 and Rpb1-S7A plasmids and her help generating cell lines, both Ana and Lea Gregersen for their help with the TTseq experiments, Dora Sideri and Radhika Warrier for their help with the RIP experiments, Patrick Costello for his help with generating cell lines, Charlie Foster for his help with gel contraction assays, Roman Fedoryshchak for his help with microscopy, the staff at the Advanced sequencing and the FACS STPs in the Crick.

I am grateful to Jesper Svejstrup, Caroline Hill and Tariq Enver for the guidance, helpful suggestions and discussions and all members of the Svejstrup and the van Werven labs for their help with reagents, protocols, experiments and ideas.

Thank you to everyone in the lab, Patrick, Diane, Maria, Julie, Jessica, Roman and Lucy for their support and encouragement. Thank you to Fabien Moretto and Naomi Chambers for all their help and a special thank you to Fernandez.

Table of Contents

Abstract	
Impact Statement	4
Acknowledgement	6
Table of Contents	7
Table of figures	11
Abbreviations	
Chapter 1.Introduction	
1.1 The MRTF/SRF signalling pathway	
The Serum Response Factor	
SRF integrates ERK and Rho Signalling	
The MRTFs are G-actin binding RPEL proteins	
MRTFs and TCFs regulate distinct target genes	
The role of TCFs and MRTFs in the cell	
MRTF regulation	
Regulation of MRTF activity in the nucleus	
1.2 RNA Polymerase II	
The RNA Polymerase II CTD code	
CTD kinases	
CTD phosphatases	
1.3 The transcription cycle	
Initiation	
Promoter-proximal pausing	
Pause-release	
Elongation	
Co-transcriptional chromatin remodeling	
1.4 Co-transcriptional RNA processing	
Capping Splicing	
3' end processing	
1.5 The nuclear exosome	
Core nuclear exosome	
Exosome adapter complexes	50
The role of the CBC in exosome recruitment	
Chapter 2.Materials & Methods	
2.1 Cell culture and growth curves	
2.2 Drug treatments	
2.3 Immunofluorescence	64
2.4 siRNA and transient transfection	
2.5 Cell fractionation	
2.6 Western blot	
2.7 Contractility assay	
2.8 RNA extraction, cDNA synthesis and qPCR	
2.9 Chromatin Immunoprecipitation (ChIP)	
2.10 TT _{chem} -seq	

2.11 Library preparation and sequencing	70
2.12 Data analysis	
RNAseq and TTseq	71
ChIPseq	81
2.13 Immunoprecipitation (IP)	90
2.14 UV-RIP	90
2.15 Plasmids and molecular cloning	91
2.16 List of plasmids	94
2.17 Stable cell line generation	
2.18 Genotyping	110
2.19 List of primers	
2.20 List of siRNA	
2.21 List of antibodies	
Chapter 3.Nuclear MRTF induces non-productive RNA synthesis	
3.1 Nuclear MRTF does not activate target gene expression	
3.2 G-actin inhibits MRTF recruitment to target genes	123
3.3 Nuclear MRTF induces transcription but not productive RNA	
synthesis	128
The transcriptional response to CD	
The transcriptional response to LMB	
Chapter 4.Constitutively nuclear MRTF does not induce productive RN	
synthesis	
4.1 Characterization of cells with constitutively nuclear MRTF 4.2 Constitutively nuclear MRTF is recruited to target gene promoter 150	
4.3 Constitutively nuclear MRTF induces non-productive transcription 152	on
Defining a stringent CD-induced gene set in dKO ^{MRTF} and dKO ^{MRTF-NLS} 152	
MRTF-NLS induces non-productive transcription	
Chapter 5.The nuclear exosome regulates transcription at MRTF target	
genes	
5.1 Inactivating the nuclear exosome rescues non-productive	
transcription in LMB-treated cells	164
	470
5.2 Genome-wide expression analysis in Mtr4-depleted cells	
CD- and LMB-induced changes in gene expression in Mtr4-depleted ce 172	
Mtr4 depletion restores productive RNA synthesis at LMB-induced gene	
Effect of Mtr4 depletion in resting cells	
5.3 Mtr4 is recruited to transcripts of MRTF target genes	
5.4 Nrde2 depletion inhibits activation of MRTF target genes	
Chapter 6.Evidence that the nuclear exosome regulates transcription in	
dKO ^{MRTF-NLS} cells	
6.1 Inactivating the nuclear exosome rescues the pre-mRNA synthes defect in dKO ^{MRTF-NLS} cells	Sis

6.2 Genome-wide expression analysis in dKO ^{MRTF-NLS} cells depleted	
Mtr4	
6.3 Appendix	201
Chapter 7.Recruitment of the exosome correlates with aberrant	
phosphorylation of the Pol II CTD at MRTF target genes	
7.1 Chromatin remodeling is not defective in LMB-treated cells	
7.2 Pol II pause-release occurs in LMB-treated cells	210
7.3 The non-productive transcriptional state in LMB-treated cells	
correlates with aberrant phosphorylation of the Pol II CTD	
7.4 Mtr4 and Nrde2 depletion does not affect Pol II recruitment at MF	
target genes	222
7.5 The non-productive transcriptional state in dKO ^{MRTF-NLS} cells	
correlates with aberrant phosphorylation of the Pol II CTD	
Chapter 8.Phospho-Ser7 of the Pol II CTD is required for productive R	
synthesis at MRTF target genes	
8.1 The effect of CDK inhibitors on MRTF target gene expression	
8.2 Generation of NIH3T3 cells expressing Rpb1-S7A mutant	241
8.3 Inhibition of phosphorylation at Ser7 of the Pol II CTD perturbs	
MRTF target gene activation	
8.4 Depletion of Mtr4 restores productive RNA synthesis at MRTF ta	
genes in Ser7P-depleted cells	
8.5 Depletion of Nrde2 does not exacerbate the transcriptional defection	
Ser7P-depleted cells	
Chapter 9.Discussion	
9.1 Regulation of MRTF activity in the nucleus	256
O a stin in hill its tampany as we have a time between MDTE and ODE an	
G-actin inhibits ternary complex formation between MRTF and SRF on	
DNA	256
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes	256 s at
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels	256 s at 259
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex?	256 at 259 260
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription	256 at 259 260 261 261
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription The transcriptional response to CD	256 at 259 260 261 262 262
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription The transcriptional response to CD The non-productive transcriptional state at MRTF target genes	256 at 259 260 261 262 262 262
DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription The transcriptional response to CD The non-productive transcriptional state at MRTF target genes 9.3 Mtr4 regulates MRTF target gene expression	256 at 259 260 261 262 262 262
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription The transcriptional response to CD The non-productive transcriptional state at MRTF target genes 9.3 Mtr4 regulates MRTF target gene expression Inactivation of the NEXT and CBCA complexes restores productive 	256 at 259 260 261 262 262 262 262 263
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription The transcriptional response to CD	256 at 259 260 261 262 262 262 262 263
 DNA. Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels. Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction 9.2 Nuclear MRTF induces non-productive transcription The transcriptional response to CD. The non-productive transcriptional state at MRTF target genes 9.3 Mtr4 regulates MRTF target gene expression Inactivation of the NEXT and CBCA complexes restores productive transcription at MRTF target genes. Is the NEXT or the PAXT complex involved in MRTF target gene 	256 at 259 260 261 262 262 262 263 263
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 263
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 263 264 265
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 264 265 nal
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 264 265 nal 266
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 263 264 265 nal 266 267
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 263 264 265 nal 266 267 267
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 263 264 265 nal 266 267 267
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 264 265 nal 266 267 267 267 267
 DNA Under resting G-actin levels, nuclear MRTF is recruited to target genes reduced levels Does LMB induce an unstable MRTF-SRF-DNA complex? Biological significance of regulated MRTF-SRF interaction	256 at 259 260 261 262 262 262 263 263 263 264 265 nal 266 267 267 267

Chromatin remodeling at MRTF target genes is not impaired in the inhib state	oited .271
Pol II pause-release into elongation is not defective in the inhibited transcriptional state	.271
The inhibited transcriptional state does not reflect defective activity of CDK7 or CDK9	.272
	.273
Ser2P and transcription termination	.274
Ser7P of the Pol II CTD is required for productive transcription at MRTF	
	.275
How might defective Ser7P arise in the non-productive transcriptional state?	.276
	.278
Transition into productive elongation might involve exchange of Mtr4 for	the .278
Phosphorylation of Ser7 of the Pol II CTD protects MRTF-dependent	
	.279
	.283
• • •	.329

Table of figures

Figure 1 SRF integrates Rho and Ras signalling	
Figure 2 MRTF-A regulation.	
Figure 3 Sequence of the Rpb1 CTD	34
Figure 4 RNA Pol II CTD modifications	37
Figure 5 CTD kinases and phosphatases	40
Figure 6 The transcription cycle.	44
Figure 7 Histone remodeling on actively transcribed genes	49
Figure 8 Pre-mRNA processing	55
Figure 9 Exosome adapter complexes	60
Figure 10 Mutually exclusive CBCA containing complexes	62
Figure 11 Principal component analysis (PCA) of RNAseq samples in NIH37	r3 cells
	73
Figure 12 Heatmap of Poisson distance of RNAseq samples in NIH3T3 cells	s 74
Figure 13 Principal component analysis (PCA) of TTseq samples in NIH3T3	cells75
Figure 14 Heatmap of Poisson distance of TTseq samples in NIH3T3 cells	76
Figure 15 Principal component analysis (PCA) of RNAseq samples in dKO ^M	RTF and
dKO ^{MRTF-NLS} cells	77
Figure 16 Heatmap of Poisson distance of RNAseq samples in dKO ^{MRTF} and	
dKO ^{MRTF-NLS} cells	78
Figure 17 Principal component analysis (PCA) of TTseq samples in dKOMRT	^F and
dKO ^{MRTF-NLS} cells	79
Figure 18 Heatmap of Poisson distance of TTseq samples in dKO ^{MRTF} and	
dKO ^{MRTF-NLS} cells	80
Figure 19 Principal component analysis (PCA) of Ser5P ChIPseq samples in	า
NIH3T3 cells	82
Figure 20 Heatmap of Poisson distance of Ser5P ChIPseq samples in NIH3	T3 cells
	83
Figure 21 Principal component analysis (PCA) of Ser2P ChIPseq samples in	า
NIH3T3 cells	84
Figure 22 Heatmap of Poisson distance of Ser2P ChIPseq samples in NIH3	T3 cells
	85

Figure 23 Principal component analysis (PCA) of Ser7P ChIPseq samples in
NIH3T3 cells
Figure 24 Heatmap of Poisson distance of Ser7P ChIPseq samples in NIH3T3 cells
Figure 25 Principal component analysis (PCA) of total Pol II ChIPseq samples in
NIH3T3 cells
Figure 26 Heatmap of Poisson distance of total Pol II ChIPseq samples in NIH3T3
cells
Figure 27 MRTF subcellular localization
Figure 28 Nuclear MRTF does not activate target genes
Figure 29 MRTF recruitment to target gene promoters in response to stimulation
Figure 30 SRF recruitment to target gene promoters in response to stimulation . 125
Figure 31 G-actin inhibits MRTF target gene activation 127
Figure 32 G-actin inhibits SRF/MRTF recruitment to target genes
Figure 33 The response to CD stimulation by RNAseq
Figure 34 The response to CD stimulation by TTseq 131
Figure 35 Defining a stringent CD-induced gene set
Figure 36 LMB stimulation does not induce gene activation
Figure 37 LMB induces nascent RNA synthesis
Figure 38 Nuclear MRTF induces non-productive RNA synthesis
Figure 39 The transcriptional response to LMB and CD141
Figure 40 Reconstitution of MRTF-A/B null cells 145
Figure 41 MRTF subcellular localization
Figure 42 Nuclear MRTF does not activate target genes
Figure 43 Nuclear MRTF is recruited to target gene promoters
Figure 44 dKO ^{MRTF} RNAseq
Figure 45 dKO ^{MRTF-NLS} RNAseq
Figure 46 Defining a stringent CD-induced gene set
Figure 47 dKO ^{MRTF} TTseq159
Figure 48 dKO ^{MRTF-NLS} TTseq
Figure 49 Constitutively nuclear MRTF induces non-productive transcription 163
Figure 50 Inactivation of the nuclear exosome restores pre-mRNA accumulation in
LMB-treated cells

Figure 51 Inactivation of Dis3, the NEXT or CBCA complexes restores pre-mRNA
accumulation in LMB-treated cells
Figure 52 Inactivation of the NEXT but not the PAXT complex rescues pre-mRNA
accumulation in LMB-treated cells
Figure 53 CD- and LMB- induced gene expression changes in Mtr4-depleted cells
Figure 54 Mtr4 depletion restores productive RNA synthesis at MRTF target genes
in LMB-treated cells
Figure 55 Mtr4 depletion supresses CD induction at MRTF target genes 177
Figure 56 Mtr4 depletion restores productive transcription at a subset of LMB-
inducible genes
Figure 57 Transcriptional changes induced by Mtr4 depletion
Figure 58 Mtr4 is recruited to MRTF-dependent transcripts in response to LMB. 186
Figure 59 Nrde2 depletion inhibits MRTF target gene expression in response to
stimulation
Figure 60 Inactivating the nuclear exosome restores pre-mRNA accumulation at
MRTF target genes in dKO ^{MRTF-NLS} cells
Figure 61 The transcriptional response to CD and LatB in Mtr4-depleted dKO ^{MRTF-}
Figure 61 The transcriptional response to CD and LatB in Mtr4-depleted dKO ^{MRTF-}
^{NLS} cells
^{NLS} cells
 ^{NLS} cells
 ^{NLS} cells
 ^{NLS} cells
NLS cells 195 Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-depleted 198 dKO ^{MRTF-NLS} cells 198 Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO ^{MRTF-NLS} cells. 200 200 Figure 64 Gene expression analysis at the 180 stringent CD-induced gene set in Mtr4-depleted dKO ^{MRTF-NLS} cells 202
 ^{NLS} cells
NLS cells 195 Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells 198 Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO ^{MRTF-NLS} cells. 200 200 Figure 64 Gene expression analysis at the 180 stringent CD-induced gene set in Mtr4-depleted dKO ^{MRTF-NLS} cells 202 Figure 65 Gene expression analysis at the 312 stringent CD-induced gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 204
NLS cells 195 Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells 198 Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO ^{MRTF-NLS} cells. 200 198 Figure 64 Gene expression analysis at the 180 stringent CD-induced gene set in Mtr4-depleted dKO ^{MRTF-NLS} cells 202 Figure 65 Gene expression analysis at the 312 stringent CD-induced gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 204 Figure 66 Gene expression analysis at the 455 LMB-induced Mtr4-controlled gene 204
NLS cells 195 Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells 198 Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO ^{MRTF-NLS} cells. 200 198 Figure 64 Gene expression analysis at the 180 stringent CD-induced gene set in Mtr4-depleted dKO ^{MRTF-NLS} cells 202 Figure 65 Gene expression analysis at the 312 stringent CD-induced gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 204 Figure 66 Gene expression analysis at the 455 LMB-induced Mtr4-controlled gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 204
NLS cells 195 Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells 198 Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO ^{MRTF-NLS} cells. 200 198 Figure 64 Gene expression analysis at the 180 stringent CD-induced gene set in Mtr4-depleted dKO ^{MRTF-NLS} cells 202 Figure 65 Gene expression analysis at the 312 stringent CD-induced gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 204 Figure 66 Gene expression analysis at the 455 LMB-induced Mtr4-controlled gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 206 Figure 67 Chromatin remodeling in LMB-treated cells 209
NLS cells 195 Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells 198 Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO ^{MRTF-NLS} cells. 200 198 Figure 64 Gene expression analysis at the 180 stringent CD-induced gene set in Mtr4-depleted dKO ^{MRTF-NLS} cells 202 Figure 65 Gene expression analysis at the 312 stringent CD-induced gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 204 Figure 66 Gene expression analysis at the 455 LMB-induced Mtr4-controlled gene set from NIH3T3 cells in Mtr4-depleted dKO ^{MRTF-NLS} cells 206 Figure 67 Chromatin remodeling in LMB-treated cells 209 Figure 68 Pol II undergoes pause-release in LMB-treated cells 212
 NLS cells

Figure 73 Depletion of Mtr4 and Nrde2 does not affect Pol II recruitment	24
Figure 74 Pol II recruitment and phosphorylation at MRTF target genes in dKO ^{MRT}	F
cells22	28
Figure 75 Pol II recruitment and phosphorylation at MRTF target genes in dKO ^{MRT}	F-
^{NLS} cells	30
Figure 76 Pol II recruitment and phosphorylation at MRTF target genes in dKO ^{MRT}	F-
^{XXX} cells	32
Figure 77 The effect of CDK inhibitors on MRTF target gene expression	34
Figure 78 THZ1 inhibits Pol II recruitment at MRTF target genes	36
Figure 79 FP inhibits Pol II elongation at MRTF target genes	37
Figure 80 THZ531 does not affect Pol II elongation at MRTF target genes23	38
Figure 81 GW843682X does not affect Pol II elongation MRTF target genes 24	40
Figure 82 Generation of WT-ON and S7A-ON cells	42
Figure 83 MRTF target gene expression in WT-ON and S7A-ON cells 24	44
Figure 84 MRTF target gene expression in WT-off and S7A-off cells 24	45
Figure 85 Ser7P inhibition alters the Pol II profile at MRTF target genes	49
Figure 86 Mtr4 depletion restores MRTF target gene expression in S7A-ON cells	
	51
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off	51
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off	
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells	52
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells	52 54
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells	52 54 58
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 25 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- ON cells 25 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA	52 54 58 69
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 25 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- ON cells 25 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA	52 54 58 69
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 28 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- 28 ON cells 28 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA	52 54 58 69 82
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 28 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- 28 ON cells 28 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA	52 54 58 69 82
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 28 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- 28 ON cells 28 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA. 28 Figure 90 Kinetic competition between the exosome and the export machinery . 26 26 Figure 91 Regulation of transcription at MRTF target genes 28 Figure 92 Gene ontology analysis of genes upregulated in response to CD in 28 NIH3T3 cells by RNAseq 26	52 54 58 69 82 85
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 28 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- 28 ON cells 28 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA	52 54 58 69 82 85
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 25 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- 26 ON cells 25 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA. 25 Figure 90 Kinetic competition between the exosome and the export machinery . 26 Figure 91 Regulation of transcription at MRTF target genes. 26 Figure 92 Gene ontology analysis of genes upregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26 Figure 93 Gene ontology analysis of genes downregulated in response to CD in 26	52 54 58 69 82 85 85
Figure 87 Mtr4 depletion does not affect MRTF target gene expression in WT-off and S7A-off cells 25 Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A- 26 ON cells 25 Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA	52 54 58 69 82 85 85

Figure 96 Gene ontology analysis of genes upregulated in response to LMB in
NIH3T3 cells by TTseq 293
Figure 97 Gene ontology analysis of genes downregulated in response to LMB
treatment in NIH3T3 cells by TTseq 295
Figure 98 Gene ontology analysis of genes upregulated in response to CD
treatment in dKO ^{MRTF} cells by RNAseq
Figure 99 Gene ontology analysis of genes downregulated in response to CD
treatment in dKO ^{MRTF} cells by RNAseq
Figure 100 Gene ontology analysis of genes upregulated in response to CD in
dKO ^{MRTF-NLS} cells by RNAseq
Figure 101 Gene ontology analysis of genes downregulated in response to CD in
dKO ^{MRTF-NLS} cells by RNAseq
Figure 102 Gene ontology analysis of genes upregulated in response to CD in
dKO ^{MRTF} cells by TTseq
Figure 103 Gene ontology analysis of genes downregulated in response to CD in
dKO ^{MRTF} cells by TTseq
Figure 104 Gene ontology analysis of genes upregulated in response to CD in
dKO ^{MRTF-NLS} cells by TTseq
Figure 105 Gene ontology analysis of genes downregulated in response to CD in
dKO ^{MRTF-NLS} cells by TTseq
Figure 106 Gene ontology analysis of genes upregulated in response to CD in
Mtr4-depeted NIH3T3 cells by RNAseq
Figure 107 Gene ontology analysis of genes downregulated in response to CD in
Mtr4-depeted NIH3T3 cells by RNAseq
Figure 108 Gene ontology analysis of genes upregulated in response to LMB in
Mtr4-depeted NIH3T3 cells by RNAseq
Figure 109 Gene ontology analysis of genes downregulated in response to LMB in
Mtr4-depeted NIH3T3 cells by RNAseq
Figure 110 Gene ontology analysis of genes upregulated by Mtr4 depletion 321
Figure 111 Gene ontology analysis of genes upregulated in response to CD,
relative to LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells
Figure 112 Gene ontology analysis of genes active in untreated cells, relative to
LatB-treated cells, in Mtr4-depleted dKO ^{MRTF-NLS} cells

Figure 113 Gene ontology analysis of the 55 Mtr4-controlled MRTF-NLS-induce	эd
genes	. 327
Figure 114 Correlation plots of full datasets	. 328

Abbreviations

4SU-4-thiouridine 4TU-4-thiouracil Abl1-Abelson murine leukemia viral oncogene homolog 1 Abl2-ABL proto-oncogene 2 non-receptor tyrosine kinase AF9-ALL fused gene from chromosome 9 AFF1-AF4/FMR2 Family Member 1 ATP-adenosine triphosphate Brd4- bromodomain-containing protein 4 CBC-cap-binding complex CBCA-CBC and Ars2 CBP-CREB-binding protein CD-cytochalasin D CDK12-cyclin-dependent kinase 12 CDK13-cyclin-dependent kinase 13 CDK7-cyclin-dependent kinase 7 CDK8-cyclin-dependent kinase 8 CDK9-cyclin-dependent kinase 9 Chd1-chromodomain helicase DNA binding protein 1 ChIP-chromatin immunoprecipitation Cobl- Cordon-bleu protein CoTC-co-transcriptional cleavage CPA-cleavage and polyadenylation complex CPSF-cleavage and polyadenylation specificity factor Crm1-chromosomal region maintenance 1 CstF-cleavage stimulation factor CTD-carboxy-terminal domain Ctdp1-CTD phosphatase subunit 1 DAPI-4',6-diamidino-2-phenylindole DMEM-Dulbecco's modified eagle medium DNAPK- DNA-dependent protein kinase DSIF- DRB sensitivity-inducing factor

ECL-enhanced chemiluminescence

EDTA-ethylenediaminetetraacetic acid

EGTA-ethylene glycol tetraacetic acid

ELL-eleven-nineteen lysine-rich leukemia

ENL-eleven-nineteen leukemia

ERK-extracellular-signal-regulated kinase

eRNA-enhancer RNA

Ets-erythroblast transformation specific

F-actin-filamentous actin

FACT-facilitates chromatin transcription

FBS-fetal bovine serum

FP-flavopiridol

G-actin-globular actin

GSK-3 beta- Glycogen synthase kinase-3 beta

GTPase-guanosine triphosphate hydrolase

H2Bub-histone H2B monoubiquitinated at lysine 120

H3-histone 3

H3K122Ac-histone H3 acetylated at lysine 122

H3K14Ac-histone H3 acetylated at lysine 14

H3K16Ac-histone H3 acetylated at lysine 16

H3K27Ac-histone H3 acetylated at lysine 27

H3K36me3-histone H3 trimethylated at lysine 36

H3K4me3-histone H3 trimethylated at lysine 4

H3K56Ac-histone H3 acetylated at lysine 56

H3K79me3-histone H3 trimethylated at lysine 79

H3K9Ac-histone H3 acetylated at lysine 9

H4-histone 4

HEPES-4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HEXIM1- hexamethylene bisacetamide (HMBA) inducible protein 1

HP1-heterochromatin protein

HRP-horseradish peroxidase

IEG-immediate-early gene

- IF-immunofluorescence
- IP-immunoprecipitation

LatB-latrunculin B

LIMK-LIM kinase

LINC complex- linker of nucleoskeleton and cytoskeleton complex

lincRNA-long intergenic non-coding RNA

LMB-leptomycin B

MAPK-mitogen-activated protein kinase

MDA-MB-231-human triple-negative breast cancer (TNBC) cell line

mDia1-mammalian diaphanous

MEF-mouse embryonic fibroblast

MICAL2- molecule interacting with CasL

MLL-mixed lineage leukaemia

MOPS-3-(N-morpholino) propanesulfonic acid

mRNA-messenger RNA

MRTF myocardin-related transcription factor

MTSEA- 2-((Biotinoyl) amino) ethyl methanethiosulfonate

N-WASP- Neural Wiskott-Aldrich Syndrome Protein

Ncbp-nuclear cap binding protein

ncRNA-non-coding RNA

NELF-negative elongation factor

NES-nuclear export sequence

NEXT-nuclear exosome targeting complex

NF-kB- nuclear factor kappa-light-chain-enhancer of activated B cells

NIH3T3-mouse fibroblast 3-day transfer, inoculum 3×10⁵ cells

NLS-nuclear localization sequence

Npl3-nucleolar protein 3

NRDE2-nuclear exosome regulator 2

PAF-polymerase-associated factor

PAP-the poly(A) polymerase

PARP-poly (ADP-ribose) polymerase

PAS-polyadenylation site

PAXT-poly(A) exosome targeting complex

PBS-phosphate-buffered saline

PBST-PBS Tween-20

PHAX-phosphorylated adapter RNA export protein

PIC-pre-initiation complex

Pin1- Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1

Plk3-polo-like kinase 3

PNUTS- phosphatase 1 Nuclear Targeting Subunit

Pol II-RNA polymerase II

Poly(A)-polyadenylation

PP1-protein phosphatase 1

PRC-polycomb repressive complex

PROMPT-promoter upstream transcripts

pTEF-b- positive transcription elongation factor

RIP-RNA immunoprecipitation

ROCK-Rho-associated protein kinase

RPAP- RNA polymerase II-associated protein 1

RPRD-regulation of nuclear pre-mRNA domain containing protein

rRNA-ribosomal RNA

SCP- Sterol Carrier Protein

SDS-sodium dodecyl sulfate

SEC-super elongating complex

Ser2P- RNA polymerase II C-terminal domain phosphorylated at serine 2

Ser5P-RNA polymerase II C-terminal domain phosphorylated at serine 5

Ser7P- RNA polymerase II C-terminal domain phosphorylated at serine 7

siRNA-small interfering RNA

SKIP-SKI-interacting protein

SLBP-stem-loop binding protein

snoRNA-small nucleolar RNAs

snRNA-small nuclear RNA

SRE-serum response element

SRF-serum response factor

SRSF2-serine/arginine-rich splicing factor 2

SWI/SNF-SWItch/Sucrose Non-Fermentable

TBP-TATA-binding protein

TCF-ternary complex factor

TFIIA- transcription factor IIA

TFIIB-transcription factor II B

TFIID-transcription factor II D

TFIIE-transcription factor II E

TFIIF-transcription factor II F

TFIIH-transcription factor II human

Thr4P- RNA polymerase II C-terminal domain phosphorylated at threonine 4

TOP1-DNA topoisomerase 1

TPA-12-o-tetradecanoylphorbol-13-acetate

TRAMP-Trf4/Air2/Mtr4p Polyadenylation complex

TREX-transcription export complex

TSS-transcription start site

TSSa-RNA- transcription start site associated RNA

Tyr1P- RNA polymerase II C-terminal domain phosphorylated at tyrosine 1

WAVE2- WASP-family verprolin- homologous protein 2

WB-western blot

XPB-xeroderma pigmentosum type B

XPD-xeroderma pigmentosum group D

YAP1- yes-associated protein 1

YPD-yeast extract peptone dextrose

Chapter 1. Introduction

1.1 The MRTF/SRF signalling pathway

The complicated interplay among a limited number of signalling molecules is responsible for the diversity of cellular responses to physiological and environmental cues. The transcription factor SRF integrates signalling through two distinct antagonistic pathways, the Ras-ERK and the Rho-actin signalling cascades, to control the balance between cell proliferative and migratory phenotypes (Figure 1).

The Serum Response Factor

The serum response factor (SRF) was first identified as a transcriptional regulator of the growth factor-inducible gene *c-Fos* (Treisman, 1986). It is a conserved, ubiquitously expressed protein which belongs to the MADS-box family of transcription factors (Norman et al., 1988; Shore & Sharrocks, 1995). SRF mediates signal-stimulated transcriptional activation of immediate-early genes (IEGs), as well as cytoskeletal and cell type-specific genes. Thus, it is an important regulator of cell proliferation, migration and differentiation and plays a key role in muscle-specific and neuronal gene expression (Greenberg et al., 1987; Mohun et al., 1987; Norman et al., 1988; Treisman, 1986, 1990).

At target genes, SRF associates with the serum response element (SRE), a 5' flanking sequence of the gene that is required for its efficient transcriptional activation (Gilman et al., 1986; Greenberg et al., 1987; Norman et al., 1988; Treisman, 1985). More specifically, it binds to the consensus sequence CC(A/T)6GG, named the CArG-box (Pellegrini et al., 1995; Pollock & Treisman, 1991; Treisman, 1985).

Despite its constitutively nuclear localization, SRF appears to have little activity on its own. Instead, target gene activation is promoted by ternary complex formation with two families of ubiquitous signal-regulated co-factors, the Ternary complex factor (TCF) family of Ets-proteins ELK-1, NET and SAP-1 (ELK1, ELK3, and ELK4) and the myocardin-related transcription factors (MRTF-A and MRTF-B), as

well as myocardin itself, which is constitutively active and muscle-specific (Olson & Nordheim, 2010; Posern & Treisman, 2006). The TCFs and MRTFs compete for binding to the SRF MADS-box domain and thus allow coupling of SRF to distinct signalling pathways (Gineitis & Treisman, 2001; Gualdrini et al., 2016; Hill et al., 1994; Miralles et al., 2003; Shaw et al., 1989; Wang & Olson, 2004; Zaromytidou et al., 2006).

SRF integrates ERK and Rho Signalling

At IEGs such as *c-Fos* and *Egr-1*, SRF co-operates with the TCFs (Figure 1). They respond to Ras-ERK signaling to control cell growth, proliferation and survival (Kortenjann et al., 1994; Marais et al., 1993; Treisman, 1994). In the ternary complex, the TCF interacts with both SRF and an Ets-binding motif adjacent to the SRF DNA-binding site (Dalton & Treisman, 1992; Hassler & Richmond, 2001; Hipskind et al., 1991; Shaw et al., 1989). TCF activity is regulated through phosphorylation of their C-terminal transcriptional activation domains by MAP kinases. While this phosphorylation does not regulate DNA binding, it potentiates their transcriptional activation function (Marais et al., 1993; Price et al., 1996; Raingeaud et al., 1996; Treisman, 1994). The TCFs are partially functionally redundant and are also able to function independently of SRF (Boros et al., 2009; Buchwalter et al., 2005; Costello et al., 2010; Weinl et al., 2014).

However, some SRE-containing promoters also respond to stimulation in the absence of the TCFs (Graham & Gilman, 1991; Hill et al., 1993; Hill et al., 1995; Olson & Nordheim, 2010). At cytoskeletal genes, SRF co-operates with the MRTFs (Figure 1). As discussed in the following sections, MRTF-A and MRTF-B are regulated similarly and appear to be mostly functionally redundant. The MRTFs respond to signaling through Rho-family GTPases and are involved in the control of cell morphology, adhesion and migration (Miralles et al., 2003; Olson & Nordheim, 2010; Schratt et al., 2002; Wang et al., 2002).




Figure 1 SRF integrates Rho and Ras signalling

Two co-factor families, the MRTFs, which respond to Rho activation and subsequent changes in actin dynamics, and the TCFs, which respond to Ras activation, compete for binding to SRF. SRF cooperates with the MRTFs at cytoskeletal genes and thus MRTF-SRF signalling is involved in the regulation of cell morphology and motility. At immediate early genes, SRF cooperates with the TCFs, and TCF-SRF signalling is involved in the control of cell growth and proliferation.

The MRTFs are G-actin binding RPEL proteins

The MRTFs belong to the RPEL family of proteins which act as G-actin sensors. They contain RPEL motifs, sequences that bind G-actin (Mouilleron et al., 2008), and it is generally thought that their activity is regulated by competition between G-actin and additional regulatory proteins. For instance, G-actin competes with the protein phosphatase 1 (PP1) for binding to Phactrs, which regulate cytoplasmic cytoskeletal dynamics, and with Rac1 for binding to ArhGAPs, which regulate actin-dependent cell surface structures (Diring et al., 2019; Huet et al., 2013; Wiezlak et al., 2012). Similarly, importin α/β binding to MRTF is inhibited by G-actin (Hirano & Matsuura, 2011; Panayiotou et al., 2016).

Chapter 1 Introduction

The MRTFs can interact with up to five monomeric G-actin molecules through an RPEL domain located at the N-terminus of the protein (Figure 2A). Each of the three RPEL motif and the two intervening spacer sequences can bind a single G-actin molecule (Mouilleron et al., 2008; Mouilleron et al., 2011). Embedded within the RPEL domain, is an extended bipartite nuclear localization signal (NLS), composed of two basic elements B2 and B3, which is required for importin α/β - mediated nuclear import of MRTF. In addition, a hydrophobic region, called the Q-box, also affects MRTF nuclear localization (Guettler et al., 2008; Miralles et al., 2003; Panayiotou et al., 2016). Furthermore, the Q-box promotes interactions with SRF. However, the element required for the formation of ternary complex with MRTF, SRF and DNA is the B1 box (Miralles et al., 2003; Zaromytidou et al., 2006).

MRTFs and TCFs regulate distinct target genes

SRF responds to signalling from both the mitogen-activated ERK cascade and the Rho signalling pathway. Because the TCFs and MRTFs compete for a common surface of SRF, they interact with SRF in a mutually exclusive manner, thus potentially providing target gene specificity (Esnault et al., 2014; Gineitis & Treisman, 2001; Gualdrini et al., 2016; Miralles et al., 2003; Sotiropoulos et al., 1999; Wang & Olson, 2004; Zaromytidou et al., 2006).

Nevertheless, the basis for differential recruitment of the TCFs and MRTFs remains unclear. Unlike the TCFs, the MRTFs do not have a defined sequence-specific DNA binding motif (Esnault et al., 2014). Nevertheless, they contact DNA directly, provided that the DNA is appropriately bent at a 72° angle by SRF binding (Pellegrini et al., 1995; Zaromytidou et al., 2006).




Figure 2 MRTF-A regulation. (A) Schematic representation of MRTF-A. Located at the N-terminus, three RPEL motifs (in red), separated by spacer regions (in purple) are involved in actin binding. Each RPEL motif and each spacer region can be bound by one molecule of actin (pink circles), forming a pentavalent complex. A basic region comprising B3 and B2 contains a bipartite nuclear localization sequence. Another basic region B1 is involved in SRF binding. Glutamine-rich Q domain promotes nuclear export and regulates interaction with SRF. SAP domain-a putative DNA binding motif; LZ - leucine zipper domain required for dimerization; TAD - transactivation domain. (B) MRTF regulation. Importin α/β and monomeric G-actin compete for binding to MRTF-A. A decrease in the cellular pool of monomeric G-actin, such as due to activation of Rho GTPases and subsequent actin polymerization, allows for importin α/β -mediated nuclear import of MRTF-A, its interaction with SRF and target gene activation. G-actin binding to MRTF-A promotes its export into the cytoplasm through the Crm1 nuclear export receptor.

SRF binding *in vivo* occurs both at perfectly conserved and slightly degenerated CArG motifs and it appears that the quality of the consensus reflects the binding co-operation with SRF co-transcriptional activators (Esnault et al., 2014). Conserved consensus sequence better correlates with co-activators with no DNA preferences such as the MRTFs. On the other hand, degenerated consensus correlates with loci at which SRF co-operates with the TCFs, which have DNA sequence specificity.

In addition, SRF binding sites could be classified as constitutive, which are mainly associated with TCF activity, and inducible, at which SRF binding is potentiated by complex formation with the MRTFs. The majority of SRF binding events are inducible and exhibit a better match to the CArG box than constitutive sites.

Thus, SRF target genes are coupled predominantly to one pathway or the other (Gineitis & Treisman, 2001; Sotiropoulos et al., 1999), with MRTF-SRF signaling regulating cytoskeletal genes and the TCF-SRF pathway controlling genes involved in cell proliferation and survival (Esnault et al., 2014; Medjkane et al., 2009; Olson & Nordheim, 2010).

Nevertheless, at some target genes, both co-factor families can variably access SRF, depending on cellular context. Genomic studies of TCF knock-out cells suggest that the TCFs acts as general inhibitors of MRTF recruitment at target genes (Gualdrini et al., 2016). Similarly, a fraction of MRTF-SRF target genes such as *Cyr61* and *Ctgf* are also regulated by the mechanosensitive transcription factor YAP (Esnault et al., 2014; Foster et al., 2017).

The role of TCFs and MRTFs in the cell

TCF-SRF signalling is involved in thymocyte positive selection (Costello et al., 2010; Costello et al., 2004) and T cell differentiation (Maurice et al., 2018), whereas MRTF-SRF signaling is required for various actin-based processes in the cell, including adhesion, chemotaxis and migration, as well as invasion and metastasis of cancer cells (Haak et al., 2017; Medjkane et al., 2009; Mokalled et al., 2010).

Co-ablation of MRTF-A and MRTF-B largely phenocopies SRF deletion in vivo. For instance, deletion of SRF in the brain results in impaired neuronal cell migration and neurite outgrowth (Alberti et al., 2005; Knöll et al., 2006). While mice lacking a single MRTF isoform exhibit normal brain development, co-ablation of MRTF-A and MRTF-B causes abnormalities that phenocopy the defect in SRF null mice, suggesting that MRTF-A and MRTF-B act redundantly to support normal brain development (Mokalled et al., 2010). Similarly, animals lacking both MRTFs recapitulate the defect in bone colonization of hematopoietic stem cells observed in SRF knock-out mice (Costello et al., 2015). Inactivation of SRF or both MRTF-A and MRTF-B leads to impaired angiogenesis and filopodia formation in endothelial cells (Franco et al., 2013), defects in retinal vascularization (Weinl et al., 2013) and plasma membrane blebbing and entotic invasion (Hinojosa et al., 2017). That developmental defects in mice caused by conditional deletion of SRF can be reproduced only when both MRTFs are ablated suggests that MRTF-A and MRTF-B act redundantly and is consistent with structural similarities between the two isoforms and studies demonstrating that inactivation of both MRTFs is required for a complete inhibition of serum- and RhoA-mediated activation of reporter genes (Cen et al., 2003).

Nevertheless, there is a unique requirement for MRTF-A and MRTF-B in specific contexts. MRTF-B is indispensable for the development of a subset of neural crestderived vascular smooth muscle cells (Li et al., 2005; Oh et al., 2005), while MRTF-A is essential for myofibroblast differentiation (Li et al., 2006; Sun et al., 2006). MRTF-B deletion results in embryonic lethality at E13.5 and E14.5. Mutant mice display defects in differentiation of neural-crest-derived smooth muscle cells and anatomical abnormalities in branchial arch arteries and the cardiac outflow tract (Li et al., 2005; Oh et al., 2005). In contrast, MRTF-A mice are viable and fertile but exhibit defects in differentiation of myoepithelial cells of the mammary gland during pregnancy and lactation (Li et al., 2006; Sun et al., 2006). While this could reflect a unique function of MRTF-A and MRTF-B in mammary myoepithelial cells and neural crest-derived vascular smooth muscle cells, respectively, it could also suggest that in specific contexts loss of one MRTF isoform reduces the level of MRTF family members below a threshold required to support extensive proliferation and differentiation.

28

Chapter 1 Introduction

MRTF regulation

In fibroblasts, MRTF constantly shuttles between the nucleus and the cytoplasm and its subcellular localization is controlled by free monomeric G-actin (Figure 2B) (Vartiainen et al., 2007). Since the RPEL domain of MRTF overlaps with its NLS sequences, G-actin competes with importin α/β for MRTF binding (Hirano & Matsuura, 2011; Mouilleron et al., 2008; Mouilleron et al., 2011; Pawłowski et al., 2010). In addition, an actin-independent mechanism of MRTF nuclear import has been described, which depends on the Ddx19 RNA helicase. Ddx19 facilitates the interaction between MRTF and importin α/β through mediating a conformational change in the MRTF protein (Rajakylä et al., 2015).

Actin also regulates the export of MRTF from the nucleus. MRTF harbors several Crm1-dependent nuclear export sequences (NES) and G-actin binding to MRTF is required for its export through the Crm1 nuclear receptor (Panayiotou et al., 2016; Vartiainen et al., 2007). In fact, it appears that MRTF localization is mainly regulated through export rather than import and it is the high basal MRTF export rate that maintains its cytoplasmic localization in unstimulated cells (Vartiainen et al., 2007).

While under resting conditions MRTF is predominantly in the cytoplasm, activation of Rho by mitogenic stimuli or mechanical cues and subsequent actin polymerization results in MRTF nuclear accumulation. Depletion of the free monomeric G-actin pool upon Rho activation promotes MRTF-importin interaction and nuclear import, allowing complex formation with SRF and activation of gene expression (Cen et al., 2003; Du et al., 2004; Miralles et al., 2003; Vartiainen et al., 2007). Downstream of Rho, two effector pathways mediate actin polymerization: the formin mDia1 pathway which nucleates actin filaments and the ROCK-LIMK-cofilin pathway which de-stabilizes F-actin (Copeland & Treisman, 2002; Geneste et al., 2002; Sotiropoulos et al., 1999; Tominaga et al., 2000). However, Rho signaling is not essential for the activation of SRF-MRTF signaling. Depletion of the G-actin pool is both required and sufficient for the transcriptional response at MRTF target genes.

29

Monomeric G-actin and polymerized F-actin inhibits and activates SRF-MRTF signalling, respectively (Miralles et al., 2003; Posern et al., 2004; Posern et al., 2002; Stern et al., 2009). Increased G-actin levels by overexpression of wild-type β-actin or ectopic expression of the non-polymerizable actin mutants R62D, G13R and actin-VP16 inhibits MRTF nuclear accumulation and SRF activation by directly binding to MRTF (Miralles et al., 2003; Posern et al., 2002). On the other hand, expression of actins S14C, V159N and G15S, which stabilize F-actin, promotes MRTF nuclear accumulation and SRF target gene activation (Posern et al., 2004). Moreover, overexpression of WH2-domain containing proteins, such as the actin nucleation factors N-WASP, WAVE2, Spire and Cobl, promote MRTF activation through competition for G-actin binding (Weissbach et al., 2016).

Chemicals which interfere with the actin treadmilling cycle can also influence MRTF activity. Latrunculin B (LatB) prevents actin polymerization by sequestering monomeric G-actin. It blocks the G-actin ATP binding cleft and inhibts its addition to growing filaments, thus increasing the concentration of G-actin and inhibiting MRTF (Morton et al., 2000; Spector et al., 1989; Spector et al., 1983). On the other hand, serum-induced actin polymerization, or disruption of the MRTF-actin complex by treatment with Jasplakinolide, Swinholide A or Cytochalasin D (CD) promotes MRTF nuclear accumulation (Cen et al., 2003; Miralles et al., 2003; Posern et al., 2004; Sotiropoulos et al., 1999; Vartiainen et al., 2007). Similarly to LatB, CD also disrupts actin filaments. Its mode of action is however different. CD promotes ATP hydrolysis and directly binds to G-actin, at the cleft contacted by MRTF's RPEL motifs, thus preventing MRTF/G-actin binding and activating MRTF (Brenner & Korn, 1980; Tellam & Frieden, 1982).

Even though it does not affect the actin treadmilling cycle, Leptomycin B (LMB) can be used to modulate MRTF activity since it targets the Crm1 nuclear export receptor, through which MRTF export from the nucleus is mediated (Vartiainen et al., 2007). LMB blocks Crm1 by covalently binding to the sulfhydryl group of Cys529 of Crm1 (Kudo et al., 1999). LMB-induced nuclear MRTF does not activate transcription at target genes (Vartiainen et al., 2007). An additional layer of MRTF regulation is added by post-translational modifications. With 26 phosphorylation sites mapped, some of which ERK-dependent, it was shown that phosphorylation acts both positively and negatively on MRTF activity. ERK-mediated phosphorylation of S98 within the RPEL domain activates MRTF by reducing its affinity for G-actin, while S33 phosphorylation of one of the six Crm1dependent NESs promotes MRTF nuclear export (Panayiotou et al., 2016). Similarly, S545 phosphorylation has also been reported to promote MRTF export from the nucleus (Muehlich et al., 2008). Additionally, MRTF protein levels are regulated through GSK-3β-mediated phosphorylation, which promotes MRTF ubiquitination and proteasomal degradation (Charbonney et al., 2011).

Regulation of MRTF activity in the nucleus

In addition to regulating MRTF subcellular localization, G-actin also regulates the nuclear activity of MRTF. In NIH3T3 mouse fibroblasts, MRTF stays predominantly nuclear for several hours after stimulation, even though transcriptional activation is transient (Gineitis & Treisman, 2001; Miralles et al., 2003; Vartiainen et al., 2007). Moreover, nuclear accumulation of MRTF in the absence of an activating signal is not sufficient for target gene activation. Fusing MRTF with an additional NLS or blocking Crm1-mediated nuclear export with LMB does not elicit a transcriptional response (Posern et al., 2002; Vartiainen et al., 2007). In contrast, MRTF mutant protein harbouring point mutations in its RPEL motifs (MRTF-XXX), which cannot bind G-actin, is not only constitutively nuclear, but also constitutively transcriptionally active (Miralles et al., 2003; Vartiainen et al., 2007).

Several studies provide direct evidence for regulation of MRTF by actin in the nucleus. First, FRET studies demonstrate that MRTF-actin interaction occurs in the nucleus (Vartiainen et al., 2007). MRTF activity is promoted by NLS-tagged mutant actins G15S and S14C, which promote F-actin formation, while over-expression of NLS-actin inhibits MRTF target genes (Sharili et al., 2016). Similarly, formins and nucleoskeletal proteins such as the LINC complex, which mediate actin polymerization in the nucleus, stimulate MRTF activity (Baarlink et al., 2013; Plessner et al., 2015), and so does the monooxygenase MICAL2, which causes nuclear G-actin depletion (Lundquist et al., 2014). These data demonstrate a

31

repressive effect of nuclear actin on MRTF activity, however the exact mechanism is unclear.

1.2 RNA Polymerase II

The essential function of sequence-specific transcription factors such as SRF and MRTF is to direct RNA Polymerase to target gene promoters and promote transcription. As discussed below, Pol II is recruited via the interaction between sequence-specific transcription factors and the Mediator complex, which serves as a scaffold in the assembly of the pre-initiation complex (PIC) (Allen & Taatjes, 2015; Malik & Roeder, 2010; Taatjes, 2010). Mediator facilitates PIC formation through its interactions with general transcription factors, Pol II itself and cohesin, which maintains enhancer-promoter looping (Kagey et al., 2010). In addition, transcription factors promote open chromatin structure, through recruiting histone modifiers such as p300 and Brd4 (Barboric et al., 2001; Col et al., 2017; Huang et al., 2009; Wu et al., 2015), and can stimulate transcription elongation through recruitment of pTEFb, which regulates the transition from initiation into elongation (Hargreaves et al., 2009; Rahl et al., 2010).

While the general principles of transcription are conserved, the transcriptional machinery in eukaryotes is more complex than that in prokaryotes. In bacteria, there is only one RNA polymerase enzyme, whereas in eukaryotic organisms, the RNA Polymerase I, II and III are responsible for the transcription of different RNA classes (Roeder, 2019).

The most abundant RNAs in the cell are the ribososmal RNAs (rRNA), the majority of which is produced by RNA polymerase I. 5S rRNA and tRNA are transcribed by RNA polymerase III, while all messenger RNA (mRNA) and most regulatory RNA, including miRNA, snRNA and snoRNA, are made by RNA polymerase II (Pol II). Pol II is highly conserved among species and consists of 12 subunits, Rpb1-12. The largest subunit Rpb1 and Rpb2 form the catalytic centre of the Pol II (Carter & Drouin, 2009; Cramer et al., 2008; Cramer et al., 2001; Jasiak et al., 2006; Kuhn et al., 2007; Osman & Cramer, 2020b).

The RNA Polymerase II CTD code

Mammalian cells contain two forms of Pol II, hypo-phosphorylated (Pol IIA) and hyper-phosphorylated (Pol II0), the latter being associated with active transcription (Cadena & Dahmus, 1987; Kim & Dahmus, 1986; Payne et al., 1989). The majority of phosphorylation events occur within the carboxy-terminal domain (CTD) of the Rpb1 subunit of Pol II.

The length and the complexity of the Pol II CTD increases with the complexity of the organism (Eick & Geyer, 2013). The CTD consists of 52 heptad repeats of the sequence $Y^1S^2P^3T^4S^5P^6S^7$ in mammalian cells and 26 repeats in yeast (Allison et al., 1988; Bartolomei et al., 1988; Corden et al., 1985). In addition to being longer, the CTD in mammalian cells deviates from the consensus in its distal part (Figure 3). The last 31 heptad repeats are non-consensus, with substitutions at positions 2, 4,5 and 7 (Corden et al., 1985). While deletion of the Pol II CTD is lethal, cells expressing Rpb1 consisting of approximately half the number of CTD repeats are viable. At least 8 or 26 repeats are required for viability in yeast and mouse, respectively (West & Corden, 1995).

Hun Rpb1		Saccharomyces cerevisiae Rpb1 CTD
1 YSPTSP <mark>A</mark>	27 YTPTSPN	1 FSPTSPT
2 YEPRSPGG	28 YSPTSPS	2 YSPTSP <mark>A</mark>
3 YTPQSPS	29 YSPTSPS	3 YSPTSPS
4 YSPTSPS	30 YSPTSPS	4 YSPTSPS
5 YSPTSPS	31 YSP <mark>S</mark> SP <mark>R</mark>	5 YSPTSPS
6 YSPTSP <mark>N</mark>	32 YTP <mark>Q</mark> SPT	6 YSPTSPS
7 YSPTSPS		7 YSPTSPS
8 YSPTSPS	34 YSP <mark>S</mark> SPS	8 YSPTSPS
9 YSPTSPS	35 YSPTSP <mark>K</mark>	9 YSPTSPS
10 YSPTSPS	36 YTPTSPS	10 YSPTSPS
11 YSPTSPS	37 YSP <mark>S</mark> SP <mark>E</mark>	11 YSPTSPS
12 YSPTSPS	38 YTPTSP <mark>K</mark>	12 YSPTSPS
13 YSPTSPS	39 YSPTSP <mark>K</mark>	13 YSPTSPS
14 YSPTSPS		14 YSPTSPS
15 YSPTSPS	41 YSPTSPT	15 YSPTSPS
16 YSPTSPS	42 YSPT <mark>T</mark> PK	16 YSPTSPS
17 YSPTSPS	43 YSPTSPT	17 YSPTSP <mark>A</mark>
18 YSPTSPS	44 YSPTSP <mark>V</mark>	18 YSPTSPS
19 YSPTSPS	45 YTPTSP <mark>K</mark>	19 YSPTSPS
20 YSPTSPS	46 YSPTSPT	20 YSPTSPS
21 YSPTSPS	47 YSPTSP <mark>K</mark>	21 YSPTSPS
22 YSPTSPN	48 YSPTSPT	22 YSPTSPN
23 YSPTSP <mark>N</mark>	49 YSPTSP <mark>KGST</mark>	23 YSPTSPS
24 YTPTSPS	50 YSPTSP <mark>G</mark>	24 YSPTSP <mark>G</mark>
	51 YSPTSPT	25 YSPGSPA
26 YSPTSP <mark>N</mark>	52 YSLTSPAISPDDSDEEN	26 YSPKQDEQKHNENENSR

Figure 3 Sequence of the Rpb1 CTD

Comparison of the Rpb1 CTDs of human and yeast. Divergence from the consensus heptad repeat is shown in red.

Each of the residues within the Pol II CTD are subject to post-translational modification and distinct modifications correlate with different stages of the transcription cycle (Figure 4) (Zaborowska et al., 2016). The stages of the transcription cycle and the factors involved are discussed below (see 1.3 The transcription cycle).

Phosphorylation is the best characterized CTD modification. Serine 5 (Ser5) is phosphorylated early in the transcription cycle and is associated with initiation of transcription (Hengartner et al., 1998; Komarnitsky et al., 2000; Lu et al., 1992; Schroeder et al., 2000), chromatin de-condensation (Ng, Robert, et al., 2003) and 5' end processing of the nascent RNA (Komarnitsky et al., 2000). Consistently, Pol II is phosphorylated on Ser5 along the gene, with a distinct peak at the transcription start site (TSS). In contrast, phospho-serine 2 (Ser2P) starts accumulating in the gene body and peaks towards the 3' region of the gene. It plays a key role during transcriptional elongation and termination (Gomes et al., 2006; Kim et al., 2002; Komarnitsky et al., 2000). Phospho-serine 7 (Ser7P) distribution along the gene is similar to that of Ser5P (Akhtar et al., 2009; Chapman et al., 2007). In contrast to lack of Ser5P and Ser2P, ablation of phospho-Ser7 does not reduce mRNA levels globally (Egloff et al., 2007). However, it is essential for transcription and RNA processing at snRNA genes, specifically (Egloff et al., 2007).

One of the less characterized modifications of the Pol II CTD is tyrosine 1 (Tyr1) phosphorylation (Baskaran et al., 1993). Tyr1P is predominantly found at promoters and it is involved in the control of bidirectional and anti-sense transcription (Descostes et al., 2014; Hsin, Li, et al., 2014). Lack of Tyr1P results in a readthrough phenotype in the anti-sense direction at 5' ends of genes and the sense direction at 3' ends. Tyr1P is thus required for the inhibition of pervasive transcription. It also plays a role in transcription termination and it is required for Pol II stability (Descostes et al., 2014; Mayer et al., 2012).

In addition, the Pol II CTD is phosphorylated on threonine 4 (Thr4) (Zhang & Corden, 1991). Thr4P is found predominately at the 3' ends of genes (Heidemann et al., 2013; Hintermair et al., 2012). Similarly to Ser2P, Thr4P plays a role in elongation and termination (Hintermair et al., 2012; Nemec et al., 2017; Schlackow

et al., 2017). Furthermore, it is required for transcription and 3' end formation at histone genes (Hsin et al., 2011) and during M-phase progression (Hintermair et al., 2016).

Isomerization of prolines 3 and 6 by the peptidyl-prolyl isomerase Pin1 (Morris et al., 1999; Wu et al., 2000) impacts on the overall phosphorylation status of the Pol II by regulating the binding of CTD modifying enzymes (Bataille et al., 2012; Krishnamurthy et al., 2009; Xu et al., 2003; Xu & Manley, 2007). In addition, the Pol II CTD can be glycosylated. This occurs prior to Pol II recruitment to genes. It is thought that glycosylation sterically blocks CTD phosphorylation and its removal regulates transcription initiation (Ranuncolo et al., 2012).

Residues within the non-consensus CTD repeats can also be modified. Methylation of arginine 7 has been implicated in transcription termination and in regulation of snRNA and snoRNA genes, while lysine 7 methylation is thought to play a role in early stages of transcription (Dias et al., 2015; Sims et al., 2011). Because of its enrichment at TSSs, Lys7 acetylation is believed to be involved in initiation of transcription (Voss et al., 2015). In addition, it is required for the expression of the *Egr1* and *c-Fos* genes (Schröder et al., 2013). Lys7 can also be ubiquitinated, which leads to Rpb1 degradation by the proteasome (H. Li et al., 2007).




Figure 4 RNA Pol II CTD modifications

(A) Modifications the Pol II CTD and their functions. In the figure phosphorylation is indicated by (P), isomerization (I), methylation (Me), acetylation (Ac), ubiquitination (Ub) and glycosylation (G). (B) Pol II CTD phosphorylations. Phospho-serine 5 (Ser5P) peaks at the transcription start site (TSS) and stays on along the gene body, with a small peak at the 3' end of the gene. Phospho-serine 7 (Ser7P) has a similar profile. Phospho-tyrosine 1 (Tyr1P) is present at the 5'end of the gene, with a peak at the TSS. Phospho-serine 2 (Ser2P) and phospho-threonine 4 (Thr4P) have a similar profile. These marks start accumulating in the gene body and peak at the 3' end of the gene.

Mass spectrometry analyses show that all five phospho-marks are found along the entire length of the Pol II CTD, with Ser5P and Ser2P being the most abundant ones (Schüller et al., 2016; Suh et al., 2016). In cells, the majority of heptad repeats are phosphorylated on only one residue and Ser5P and Ser2P predominate in mono-phosphorylated repeats. These two phosphorylation events appear to be distinct, separated spatially on the CTD, as well as temporally during the transcriptional cycle (Czudnochowski et al., 2012; Schüller et al., 2016). Even though more rarely, all possible double-phosphorylations are detected within the same heptad (Schüller et al., 2016; Suh et al., 2016). Thr4P frequently co-occurs with Ser2P, while Tyr1P is often found on Ser5P containing repeats (Schüller et al., 2016). However, triple phosphorylations within the same heptads are not detected (Schüller et al., 2016).

CTD phospho-marks appear to be placed in succession, with some of the modifications being preferentially deposited on pre-phosphorylated heptad repeats. Thus, Ser5P precedes Ser7P (Boeing et al., 2010) and Ser2 phosphorylation (Komarnitsky et al., 2000). Ser7 phosphorylation, which is dependent on pre-phosphorylation of Ser5 (Akhtar et al., 2009; Boeing et al., 2010; Chapman et al., 2007), primes Ser2 phosphorylation (Akhtar et al., 2009; Boeing et al., 2010; Bösken et al., 2014; Chapman et al., 2007). Inhibition of Ser2P decreases levels of Thr4P, while it does not affect Ser5P or Ser7P levels (Krajewska et al., 2019). Furthermore, Thr4P is strictly associated with the occurrence of the Ser2P mark, suggesting that phosphorylation of Ser2 precedes that of Thr4 (Hintermair et al., 2012).

CTD kinases

The CTD modifications are dynamic and various kinases act during the transcriptional cycle to ensure appropriate regulation of the Pol II. The phosphorylation state of the CTD orchestrates the temporal and spatial recruitment of various factors that mediate transcription and RNA processing throughout the transcriptional cycle. Therefore, changes in CTD phosphorylation by site-specific kinases and phosphatases are critical for the accurate transmission of information during transcription.

Chapter 1 Introduction

Ser5 is phosphorylated by the cyclin-dependent kinase 7 (CDK7) (Komarnitsky et al., 2000; Lu et al., 1992; Ramanathan et al., 2001; Schroeder et al., 2000; Schwartz et al., 2003). In addition to Ser5, CDK7 also phosphorylates Ser7 of the Pol II CTD (Akhtar et al., 2009; Boeing et al., 2010; Glover-Cutter et al., 2009). However, since inhibition of CDK7 does not completely abolish Ser7P, there appear to be additional unidentified Ser7 kinases (Boeing et al., 2010; Tietjen et al., 2010).

There are three kinases responsible for phosphorylation of Ser2, the positive transcription elongation factor (pTEF-b), which comprises the catalytically active cyclin-dependent kinase 9 (CDK9) and its regulator cyclin T (Marshall et al., 1996; Ramanathan et al., 2001; Shim et al., 2002), and CDK12/13 (Bartkowiak et al., 2010; Blazek et al., 2011; Bowman et al., 2013; Zhang et al., 2016). CDK9 and CDK12 have distinct distribution along the gene. While both kinases are found along the gene body, CDK12 is not observed near transcription start sites (Bartkowiak et al., 2010; Gomes et al., 2006). Furthermore, unlike inhibition of CDK9 which affects transcription globally, in the absence of CDK12/13 only a subset of genes involved in DNA replication, recombination and repair are affected (Blazek et al., 2011; Liang et al., 2015; Zhang et al., 2016).

Apart from CDK7, CDK9 and CDK12, CDK8 can also phosphorylate the Pol II CTD, both at Ser2 and Ser5, with a preference for the latter (Liao et al., 1995; Ramanathan et al., 2001; Rickert et al., 1999; Sun et al., 1998). In addition, the MAP Kinases ERK1 and ERK2 are capable of phosphorylating Ser5 (Trigon et al., 1998), while Serines 7 and 2 can be phosphorylated by the DNA-dependent Protein Kinase (DNAPK) (Egloff et al., 2010; Trigon et al., 1998). It has been proposed that DYRK1A is a gene-specific kinase that controls Ser5 and Ser2 phosphorylation (Di Vona et al., 2015). Finally, Brd4 can phosphorylate Ser2 of the Pol II CTD upon CDK9 inactivation (Devaiah et al., 2012).

In cells, the majority of Thr4 phosphorylation is mediated by the polo-like kinase 3 (Plk3) (Heidemann et al., 2013; Hintermair et al., 2012). However, CDK9 is also able to phosphorylate Thr4 *in vitro* (Hsin et al., 2011).

The only known Tyr1 kinases are the Abl1/2 kinases (Baskaran et al., 1993). Nevertheless, the Pol II CTD is phosphorylated on Tyr1 in c-Abl knock-out mouse cells so, as is the case with Ser7 phosphorylation, there must be additional unidentified Tyr1 kinases (Baskaran et al., 1993).

Defining the specificity of CDKs for a particular residue within the Pol II CTD and their distinct role in the transcription cycle has proven challenging. Due to structural similarities among CDKs, chemical inhibitors often have dose-dependent off-target effects. Furthermore, kinase specificity *in vitro* does not always correlate with *in vivo* data (Galbraith et al., 2019; Whittaker et al., 2017).




Figure 5 CTD kinases and phosphatases

Kinases and phosphatases shown to target Ser5, Ser7, Ser2, Thr4 and Tyr1 of the Pol II CTD.

Chapter 1 Introduction

CTD phosphatases

The first phosphorylation event in the transcription cycle occurs at Ser5 of the CTD. Ser5P peaks at the TSS, with its levels gradually reducing along the gene to allow for additional modifications of the CTD to occur as the Pol II transitions into elongation. Ser5 dephosphorylation occurs during elongation, accompanying phosphorylation of Ser2 (Cho et al., 2001). A family of small CTD phosphatases SCP1-3 preferentially dephosphorylate Ser5P (Kamenski et al., 2004; Krishnamurthy et al., 2004; Mosley et al., 2009; Yeo et al., 2003). In addition, S5P is a target of RPAP1 and RPAP2 phosphatases (Egloff et al., 2012; Mosley et al., 2009). RPAP2 directly interacts with Ser7 phosphorylated Pol II CTD and plays a role in snRNA gene expression (Egloff et al., 2012), while RPAP1 acts as a Ser5 phosphatase at developmental genes, specifically (Lynch et al., 2018). Three additional RNA Pol II interacting proteins RPRD1A, RPRD1B and RPRD2 target Ser5P and stimulate its dephosphorylation by RPAP2 (Ni et al., 2011; Ni et al., 2014).

Ssu72 is another CTD phosphatase which targets both Ser5P (Krishnamurthy et al., 2004; Mosley et al., 2009; Wani et al., 2014; Yeo et al., 2003) and Ser7P (Bataille et al., 2012; Wani et al., 2014; Zhang et al., 2012). Nevertheless, it exhibits a strong preference for Ser5 (Xiang et al., 2012).

Fcp1/Ctdp1 is known to dephosphorylate Ser2P at 3' end of genes (Cho et al., 2001; Ghosh et al., 2008; Hausmann & Shuman, 2002). However, it seems to be a promiscuous phosphatase which exhibits a preference for Ser2P but is also capable of acting on additional phospho-residues within the CTD. Lack of Fcp1 results in an increase of Ser2 phosphorylation and frequency of triply phosphorylated CTD heptad repeats (Suh et al., 2016), as well as increased Thr4P levels (Hsin, Xiang, et al., 2014). It is also involved in the recycling of Pol II at the end of the transcriptional cycle (Bataille et al., 2012; Cho et al., 2001; Cho et al., 1999; Lin et al., 2002).

1.3 The transcription cycle

Pol II catalyses RNA synthesis, however it is unable to transcribe on its own (Weil et al., 1979). The transcription cycle consists of a series of rate-limiting steps, during which transcription factors and co-activators enhance transcription rate by lowering the energy barriers that these steps represent.

Initially, Pol II needs to gain access to the promoter. Promoter remodeling and the factors involved are discussed below (see Co-transcriptional chromatin remodeling). Pol II is recruited by the Mediator complex and general transcription factors, which form the pre-initiation complex (PIC). Mediator contributes to stabilization of the PIC and promotes CDK7-dependent Pol II phosphorylation. Phosphorylation at Ser5 of the Pol II CTD facilitates the transition into initiation. The next regulatory step is promoter-proximal pausing, during which 5' end RNA processing occurs and the Pol II CTD gets further phosphorylated at Ser7. Pol II pause-release into elongation requires the recruitment of CDK9 and phosphorylation at Ser2 of the Pol II CTD. During elongation, numerous factors which increase Pol II processivity through the chromatin template are recruited. Termination is the final regulatory step in the transcription cycle. Pol II dissociates from the DNA template and its CTD is de-phosphorylated. At certain genes, the terminating Pol II is recycled for subsequent rounds of transcription via DNA looping between promoter and termination regions (Cramer, 2019; Eick & Geyer, 2013; Osman & Cramer, 2020a; Srivastava & Ahn, 2015).

<u>Initiation</u>

The first step of the transcription cycle is the formation of the pre-initiation complex (PIC) at the gene promoter (Sainsbury et al., 2015). PIC assembly and Pol II recruitment is promoted by the Mediator complex. Mediator is recruited by TFs bound to enhancer regions. In addition, it also interacts with most components of the PIC and it is thus required for enhancer-promoter looping (Allen & Taatjes, 2015; Jeronimo & Robert, 2017; Pokholok et al., 2002; Wong et al., 2014). Promoter-enhancer interactions are maintained by cohesin, which also physically interacts with the Mediator complex (Kagey et al., 2010; Phillips-Cremins et al., 2013; Rollins et al., 2004).

42

The PIC consists of Pol II and general transcription factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH (Pokholok et al., 2002). The TATA-binding protein (TBP) subunit of TFIID is involved in the recognition of core promoter elements (Nakajima et al., 1988; Parker & Topol, 1984). TFIIB promotes Pol II recruitment, while TFIIF stabilizes the Pol II-containing complex. Finally, TFIIE and TFIIH are recruited. TFIIH is the largest GTF and its activity is stimulated by TFIIE. TFIIH contains three catalytically active subunits, CDK7 and two DNA helicases (XPB and XPD), which are responsible for DNA unwinding at the transcription start site (TSS) and the formation of the open promoter complex. (Goodrich & Tjian, 1994; Kim et al., 2000). Pol II enters the pre-initiation complex in a hypo-phosphorylated form and its transition into initiation is dependent on CDK7-mediated phosphorylation of Ser5 of the Pol II CTD (Figure 6A) (Hengartner et al., 1998; Lu et al., 1992).




Figure 6 The transcription cycle. (A) The first step of the transcription cycle is the formation of the pre-initiation complex (PIC) at the gene promoter. The PIC consists of Pol II and general transcription factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH. The TATA-binding protein (TBP) subunit of TFIID is involved in the recognition of core promoter elements. TFIIB promotes Pol II recruitment, while TFIIF stabilizes the Pol II-containing complex. Finally, TFIIE and TFIIH are recruited. TFIIH is the largest GTF and its activity is stimulated by TFIIE. TFIIH contains three catalytically active subunits, CDK7 and two DNA helicases (XPB and XPD), which are responsible for DNA unwinding at the transcription start site (TSS) and the formation of the open promoter complex. Although TFs do not directly bind Pol II, one mechanism by which they can promote its recruitment is by binding to the Mediator complex. Mediator enables Pol II recruitment via interaction with the C-terminal domain (CTD) of the Rpb1 subunit of the Pol II. Mediator promotes stable PIC formation by directly interacting with multiple PIC factors. Pol Il enters the pre-initiation complex in a hypo-phosphorylated form and during transcription initiation, the Pol II CTD is phosphorylated at Serine 5 by the CDK7 subunit of the general transcription factor TFIIH. (B) Slightly downstream of the transcription start site Pol II pauses. Promoter-proximal pausing is mediated by the negative elongation factor (NELF) and the DRB sensitivity-inducing factor (DSIF). The CTD of the paused Pol II is phosphorylated at Ser5 and Ser7. The nascent RNA gets capped. (C) Pause-release is dependent on CDK9. CDK9 phosphorylates NELF which causes its release from Pol II, DSIF and Serine 2 of the Pol II CTD, allowing Pol II to transition into elongation. (D) During elongation Pol II is in its hyper-phosphorylated form. It is bound by the super elongating complex (SEC) which promotes Pol II processivity. Co-transcriptional splicing is carried out by the spliceosome complex. (E) After transcribing the polyadenylation signal, the cleavage and polyadenylation complex (CPA) is recruited. Following cleavage of the transcript, the Xrn2 exonuclease degrades the uncapped RNA, eventually catching up with Pol II and causing its release from the DNA template. The Pol II CTD is dephosphorylated and Pol II gets recycled for subsequent rounds of transcription.

Promoter-proximal pausing

At many eukaryotic genes, Pol II is present at a disproportionally high amount at the TSS of the gene, as compared to the gene body (Core & Adelman, 2019). Pol II pauses 20-120 nucleotides downstream of the TSS (Plet et al., 1995; Schwartz et al., 2003). Promoter-proximal pausing was first described at heat-shock inducible genes in Drosophila (Rougvie & Lis, 1988) and the growth factor inducible genes cmyc and c-fos in mammalian cells (Albert et al., 1997; Brown et al., 1996; Cheng & Sharp, 2003; Krumm et al., 1992; Plet et al., 1995). However, it is now known that

Chapter 1 Introduction

pausing occurs at most metazoan genes and that Pol II promoter-proximal pausing is the first regulatory step after transcription initiation (Core et al., 2008; Guenther et al., 2007; Muse et al., 2007; Zeitlinger et al., 2007). Nevertheless, the duration and stability of the promoter-proximal pausing is variable. Some promoterproximally stalled polymerases are stably associated with genes and have a slow turnover rate (Buckley et al., 2014; Chen et al., 2015; Jonkers et al., 2014; Ni et al., 2008), while others undergo multiple cycles of initiation and pre-mature termination (Brannan et al., 2012; Plet et al., 1995; Wagschal et al., 2012).

The significance of Pol II pausing has remained unclear. One possibility is that promoter-proximal pausing could facilitate further rounds of transcription by maintaining an open chromatin structure (Guenther et al., 2007; Muse et al., 2007; Zeitlinger et al., 2007). Thus, it could provide a way for rapid activation of gene expression on inducible genes (Core & Lis, 2008), as well as facilitate coordinated patterns of activation amongst groups of cells (Chen et al., 2008; Lagha et al., 2013). Alternatively, paused polymerase might reduce inappropriate transcription initiation by sterically inhibiting the binding of additional Pol II complexes (Chopra et al., 2009; Lagha et al., 2013). Furthermore, pausing potentially represents a transcriptional checkpoint to ensure that Pol II is competent for productive elongation.

The paused Pol II is phosphorylated at Ser5 (Plet et al., 1995; Schwartz et al., 2003) and Ser7 (Glover-Cutter et al., 2009) and it is bound by the negative elongation factor (NELF) (Yamaguchi, Takagi, et al., 1999; Yamaguchi, Wada, et al., 1999). In addition, the DRB sensitivity-inducing factor (DSIF), which consists of Spt4 and Spt5, is also associated with the paused polymerase (Hartzog et al., 1998; Wada et al., 1998; Yamaguchi, Wada, et al., 1999). NELF and DSIF function cooperatively to inhibit Pol II elongation (Figure 6B) (Muse et al., 2007). However, while NELF is restricted to the TSS of the gene, Spt5 has a profile identical to the one of the elongating polymerase (Gomes et al., 2006). Furthermore, Spt5 is a key elongation factor in yeast (Mason & Struhl, 2005). In mammalian cells, its positive effect on elongation is conserved and it is dependent on its phosphorylation by the CDK9 subunit of p-TEFb (Yamada et al., 2006).

Pause-release

p-TEFb regulates the transition of the paused polymerase into elongation (Barboric et al., 2001; Chen et al., 2018; Eberhardy & Farnham, 2002; Lis et al., 2000). It is recruited to promoter regions of target genes where it phosphorylates the Pol II CTD in response to various stimuli (Barboric et al., 2001; Eberhardy & Farnham, 2002; Lis et al., 2000). In addition to Ser2 of the Pol II CTD (Andrulis et al., 2000; Kim & Sharp, 2001), CDK9 phosphorylates NELF (Boehm et al., 2003; Ivanov et al., 2000; Wu et al., 2003) and Spt5 (Andrulis et al., 2000; Ivanov et al., 2000; Wu et al., 2003) and Spt5 (Andrulis et al., 2000; Ivanov et al., 2000; Kim & Sharp, 2001) (Figure 6C). This phosphorylation releases NELF from the polymerase (Fujinaga et al., 2004), while phosphorylated DSIF functions as a positive elongation factor associated with the travelling Pol II as the nascent RNA is being synthesized (Ping & Rana, 2001; Pokholok et al., 2002; Yamada et al., 2006).

p-TEFb activity is controlled by sequestering it in an inactive complex with the RNA binding protein HEXIM1/2 and the 7SK small nuclear RNA (Michels et al., 2004; Nguyen et al., 2001; Yang et al., 2001; Yik et al., 2003) and its release from this complex is dependent on stress signalling (Biglione et al., 2007; Yang et al., 2001; Yik et al., 2003). Thus, the balance between active and inactive p-TEFb in cells can be regulated by external stimuli such as UV and transcriptional inhibitors, as well as post-translational modifications of CDK9 (Chen et al., 2008).

Sequence-specific transcription factors can contribute to regulating Pol II release into elongation by stimulating p-TEFb recruitment. p-TEFb is recruited to promoters by transcription factors including NF-kB (Barboric et al., 2001) and c-Myc or by chromatin remodelers such as Brd4 (Hargreaves et al., 2009) which directly interact with p-TEFb and recruit it to the promoter regions of their target genes (Eberhardy & Farnham, 2001). Furthermore, the transition into elongation is facilitated by the Mediator complex which interacts with pTEF-b, elongation factors and histone modifying complexes (Donner et al., 2010; Takahashi et al., 2011).

Chapter 1 Introduction

Elongation

A number of factors associate with Pol II during the elongation phase which have specific functions in promoting speed, processivity and resolving stalling of Pol II along the gene (Chen et al., 2018). Phosphorylated Spt5 remains associated with Pol II throughout the transcription cycle and it is required for productive elongation (Henriques et al., 2018; Shetty et al., 2017). Spt5 controls the rate of Pol II elongation (Baluapuri et al., 2019), which influences not only overall levels of mRNA (Danko et al., 2013), but also splicing (de la Mata et al., 2003; Howe et al., 2003; Shukla & Oberdoerffer, 2012) and 3' end processing of the transcript (Lee et al., 2007; Nag et al., 2007). In addition, dephosphorylation of Spt5 by PNUTS-PP1, which causes a decrease in the speed of Pol II, is involved in the release of Pol II from the DNA template during transcriptional termination (Cortazar et al., 2019; Hazelbaker et al., 2013). Apart from influencing the speed of the elongating Pol II, Spt5 enhances its processivity by binding to the DNA exit region of Pol II, facilitating re-winding of upstream DNA and preventing aberrant backtracking of Pol II (Bernecky et al., 2017; Ehara et al., 2017; Fitz et al., 2018).

Occasionally, Pol II may stall during elongation due to pause sites within the gene body. TFIIS facilitates Pol II backtracking at such pause sites (Kettenberger et al., 2004). It stimulates cleavage and re-alignment of the nascent transcript with the active site of Pol II which allows for elongation to resume (Adelman et al., 2005; Conaway et al., 1993; Fish & Kane, 2002; Reines et al., 1989). In addition to TFIIS, Elongin and members of the ELL protein family (eleven-nineteen lysine-rich leukemia) such as ELL1 are also involved in alleviation of transient Pol II pausing along the gene (Luo et al., 2012). ELL1 interacts with the elongating Pol II as a part of a multiprotein complex called the super elongating complex (SEC) (Figure 6D). SEC consists of AFF1 and AFF4 (AF4/FMR2 family members 1 and 4), ENL (eleven-nineteen leukemia) or AF9 (ALL fused gene from chromosome 9), ELL1 or ELL2 and pTEF-b (Lin et al., 2010; Luo et al., 2012).

Phospho-serine 2 is required for Pol II elongation (Dengl et al., 2009; Kizer et al., 2005; Li et al., 2003). Pol II CTD phosphorylated at Ser2 is a prerequisite for the recruitment of additional elongation factors, which promote Pol II processivity

47

through chromatin, such as the PAF and FACT complexes and the histone chaperone Spt6 (Adelman et al., 2006; Ardehali & Lis, 2009; Belotserkovskaya et al., 2003; Bortvin & Winston, 1996; Pokholok et al., 2002; Reinberg & Sims, 2006; Saunders et al., 2003; Sun et al., 2010; Yoh et al., 2007; Zhu, Mandal, et al., 2005).

The polymerase associated factor (PAF) complex has an intrinsic ability to stimulate transcription from a chromatin template and it is involved in histone ubiquitination (Chu et al., 2007; Krogan et al., 2003; Laribee et al., 2005; Ng, Robert, et al., 2003; Wood et al., 2005). It also serves as a platform for the recruitment of additional chromatin remodelers such as the histone chaperone complex FACT (facilitates chromatin transcription) and the Set2 methyltransferase (He et al., 2011). Additionally, PAF also plays a role in RNA metabolism by recruiting pre-mRNA processing factors (Zhu, Mandal, et al., 2005).

Furthermore, the elongating Pol II interacts with topoisomerases such as TOP1, which resolve DNA supercoiling accumulating ahead and behind the travelling Pol II (Liu & Wang, 1987; Ljungman & Hanawalt, 1996; Solier et al., 2013); helicases, which prevent the formation of RNA:DNA hybrids during elongation, thereby ensuring efficient transcription of long genes and preventing deleterious DNA recombination (Huertas & Aguilera, 2003; Ljungman & Hanawalt, 1996) and poly(ADP-ribose) polymerase (PARP), which not only targets NELF (Gibson et al., 2016), thus promoting pause-release, but also chromatin remodelers and histones (Hottiger, 2015; Wright et al., 2016).

Co-transcriptional chromatin remodeling

A large proportion of the factors associated with the elongating Pol II are involved in chromatin remodeling. Dense nucleosome occupancy obstructs the elongating polymerase and inversely correlates with transcription rates (Bernstein et al., 2004; Lee et al., 2004). Modifications of histones alter the physical and chemical properties of chromatin and influence its compaction and accessibility. Thus, actively transcribed and transcriptionally silenced regions of the genome have distinct chromatin signatures (B. Li et al., 2007) (Figure 7). Nevertheless, it is not clear to what extent chromatin signatures are a cause or a consequence of transcriptional activity.




Figure 7 Histone remodeling on actively transcribed genes. Active gene promoters are characterized by acetylation of histone 3 lysine 27 (H3K27Ac) and trimethylation of histone 3 lysine 4 (H3K4me3). Within gene bodies, histone 2 is modified by monoubiquitylation (H2Bub), while histone 3 lysine 79 tri-methylation (H3K79me3) and histone 3 lysine 36 tri-methylation (H3K36me3) are found at the 5' and 3' end of actively transcribed genes, respectively.

Initially, pioneer factors, a class of transcription factors, which appear to be able to access their binding sites even in closed chromatin, facilitate the recruitment of other transcription factors. The chromatin remodeling SWI/SNF complex disrupts the first nucleosomes following the pause site (Brown & Kingston, 1997), while other histone remodelers such as Chd1 (Simic et al., 2003), Ino80 (Kobor et al., 2004; Papamichos-Chronakis et al., 2011) and SWR (Mizuguchi et al., 2004) are involved in histone variant exchange. Histone variants H3.3 (Daury et al., 2006; Mito et al., 2005; Talbert & Henikoff, 2010; Wirbelauer et al., 2005) and H2A.Z (Jin et al., 2009; Meneghini et al., 2003), whose incorporation within the nucleosome reduces its stability, are commonly found within actively transcribed genes.

H3 and H4 histone tails also interfere with transcription and their acetylation supresses this effect (Lee et al., 1993; Protacio et al., 2000; Wasylyk & Chambon,

1979). Histones H3 and H4 at active gene promoters are commonly acetylated at histone H3 lysine 9, 14, 16 and 27 (H3K9Ac, H3K14Ac, H3K16Ac and H3K27Ac) (Bernstein et al., 2005; Gelbart et al., 2009; Liang et al., 2004; Pokholok et al., 2005; Tie et al., 2009; Wang et al., 2008; Zippo et al., 2009) by histone acetyltransferases such as Gcn5, TAF1 and p300/CBP (Sterner & Berger, 2000; Strahl & Allis, 2000). In addition, trimethylation of H3K4 (H3K4me3) at TSSs by MLL1, MLL2 and Set1 histone methyltransferases strongly correlates with transcriptional activity (Bernstein et al., 2005; Liang et al., 2004; Milne et al., 2002; Nakamura et al., 2002; Pokholok et al., 2005; Santos-Rosa et al., 2002; Vakoc et al., 2006). These promoter-associated chromatin modifications are dependent on Ser5P of the Pol II CTD, which serves as a docking site for acetyltransferases and methyltransferases (Ng, Robert, et al., 2003).

Similarly, Ser2P of the CTD is required for the recruitment of enzymes associated with chromatin remodeling downstream of promoters. H3K36me3 (Pokholok et al., 2005; Rando & Chang, 2009; Vakoc et al., 2006) and H2B monoubiquitylated at K120 (Fuchs et al., 2014; Kao et al., 2004; J. Kim et al., 2009; Pavri et al., 2006; Xiao et al., 2005; Zhu, Zheng, et al., 2005) are present within the gene bodies of actively transcribed genes. These modifications are deposited by Set2 methyltransferase (Li et al., 2003; Strahl et al., 2002; Xiao et al., 2003) and the PAF complex (Laribee et al., 2005; Pavri et al., 2006; Wood et al., 2005), respectively, which are recruited through Ser2P of the Pol II CTD (Kizer et al., 2005; Li et al., 2003; Xiao et al., 2003).

Apart from histone tails, modifications within the globular domain of histones also impact on transcription. For example, acetylation at H3K56 (Schneider et al., 2006; Williams et al., 2008; Xu et al., 2005) and H3K122 are associated with actively transcribed genes (Tropberger et al., 2013). H3K122Ac co-localizes with H3K4me3 and histone variants H2A.Z and H3.3 and promotes H3K27Ac and nucleosome eviction, thus facilitating access of the transcriptional machinery (Tropberger et al., 2013). In a similar way, H3K56Ac is involved in the disassembly of H3/H4 at promoter regions of active genes (Williams et al., 2008). Active transcription also correlates with H3K79me3 within gene bodies (Pokholok et al., 2005; Schübeler et al., 2004; Steger et al., 2008). In contrast to H3K36me3 which is enriched towards the 3' end of genes, H3K79me3 occupies the 5' region of the gene body (Vakoc et al., 2006). It is catalysed by Dot1L (Feng et al., 2002; Ng, Ciccone, et al., 2003; Steger et al., 2008), which interacts with AF9 and ENL components of the SEC complex (Krogan et al., 2003; Mohan et al., 2010).

Histone modifications also play a role in pre-mRNA processing events. H3K36me3 promotes co-transcriptional splicing (Guo et al., 2014; Jelinic et al., 2011; Kumar et al., 2012; Luco et al., 2010).Similarly, H2Bub is involved in regulating splicing (Lee et al., 2012), 3' end formation (Pirngruber et al., 2009) and RNA nuclear export (Vitaliano-Prunier et al., 2012).

Histone modifications are often interdependent and facilitate further chromatin remodeling. H3K79me3 co-occurs with H3 and H4 acetylation and H3K4me3 (Schübeler et al., 2004), while monoubiquitylation of H2B is required for correct H3K4 and H3K79 methylation. (Dover et al., 2002; Lee et al., 2007; Ng, Robert, et al., 2003; Sun & Allis, 2002). Furthermore, MLL1 (H3K4 methyltransferase) and MOF (H4K16 acetyltransferase) physically interact and are both required for efficient activation of a target genes (Dou et al., 2005). Conversely, certain modifications can inhibit others. For example, H3S10P inhibits H3K9me3 and H3K27me3, which are abundant at silenced heterochromatin loci and are associated with the heterochromatin protein 1 (HP1) and the polycomb repressive complex (PRC) (Bannister et al., 2001; Kuzmichev et al., 2002; Lachner et al., 2000).

Global histone acetylases, deacetylases and methylases restore chromatin structure at the end of the transcription cycle (Katan-Khaykovich & Struhl, 2002; Vogelauer et al., 2000).

Termination

Termination is the last step in the regulation of the transcription cycle (Figure 6E). Aberrant termination could lead to readthrough transcription and inhibit expression of downstream genes through transcriptional interference (Greger et al., 1998; Greger & Proudfoot, 1998; Shearwin et al., 2005), collision with polymerases transcribing opposite strands of the DNA or with DNA replication forks, leading to DNA damage and genome instability (Hobson et al., 2012; Prescott & Proudfoot, 2002).

Termination of transcription is tightly coupled to 3' end processing of the nascent transcript (see 3' end processing). Pol II becomes competent for termination after transcribing the polyadenylation (poly(A)) signal, which is then recognised and bound by the 3' processing machinery. Pcf11, a component of the cleavage and polyadenylation complex (CPA), is involved not only in 3' processing (Amrani et al., 1997; de Vries et al., 2000; Gross & Moore, 2001) and mRNA export (Johnson et al., 2009; Volanakis et al., 2017), but also in transcription termination (West & Proudfoot, 2008; Zhang et al., 2005; Zhang & Gilmour, 2006). Pcf11 directly interacts with Ser2P of the Pol II CTD (Meinhart & Cramer, 2004), and is required for poly(A) site recognition (Kamieniarz-Gdula et al., 2019; West & Proudfoot, 2008).

Two complementary mechanisms leading to transcription termination have been proposed, which involve a conformational change in the elongating Pol II and the collision of the Xrn2 exonuclease with Pol II, respectively. In the allosteric model, passage through the poly(A) site and subsequent recruitment of the cleavage and polyadenylation complex (CPA) at the CTD causes a conformational change within the Pol II active site, resulting in Pol II release from DNA (Logan et al., 1987; Zhang et al., 2015). This allosteric change is dependent on the dephosphorylation of the Pol II associated elongation factor Spt5 (Cortazar et al., 2019).

In the torpedo model, the nuclear 5'->3' Xrn2 exonuclease is recruited at poly(A) sites and following cleavage of the transcript progressively degrades the uncapped 5' end of the nascent RNA. Thus, termination is dependent on kinetic competition between degradation of the nascent RNA by Xrn2 and its extension by Pol II (Fong et al., 2015). When Xrn2 catches up with Pol II, it induces the release of Pol II from DNA and transcription termination (Connelly & Manley, 1988; Fong et al., 2015; Kim et al., 2004; West et al., 2004). According to this model the termination site would be determined by the relative rates of Xrn2-mediated degradation and Pol II elongation. Thus, the speed of the elongating Pol II influences termination. Fast

transcription prolongs the competition between Xrn2 and Pol II, resulting in a more distant termination, while slowing down of Pol II causes a more proximal termination (Fong et al., 2015).

The collision of Xrn2 with the elongating Pol II is promoted by transcription pause sites near the poly(A) site which slow down Pol II, causing its accumulation at the 3' end of genes (Anamika et al., 2012; Coudreuse et al., 2010; Glover-Cutter et al., 2008; Gromak et al., 2006). The Pol II speed is affected by at least two factors. First, transcription pause sites downstream of the poly(A) site which decrease its processivity; second, PNUTS-PP1 mediated Spt5 dephosphorylation which also slows down the Pol II elongation rate. An allosteric change in Pol II, mediated by poly(A) site-dependent Spt5 dephosphorylation, slows down elongation, allowing Xrn2 to catch up with Pol II and dislodge it (Cortazar et al., 2019).

A subset of coding genes use an alternative of poly(A) site-dependent termination, for which an AU-rich sequence acts to mediate co-transcriptional cleavage (CoTC). It is again dependent on rapid 5'->3' degradation of the transcript for Pol II release (Nojima et al., 2013; White et al., 2013).

Pol II dissociation from the DNA template and CTD dephosphorylation marks the end of the transcription cycle. At certain genes, the terminating Pol II is recycled for subsequent rounds of transcription via DNA looping between promoter and termination regions. Gene looping occurs as a result of the physical interaction between initiation and termination factors. It is established in a TFIIB-dependent manner. Not only is TFIIB part of the PIC at promoter regions, but it also physically interacts with cleavage and polyadenylation factors at the 3'end of genes (O'Reilly & Greaves, 2007; Tan-Wong et al., 2008; Wang et al., 2010). Gene-looping contributes to transcriptional memory and stimulates re-initiation of transcription (Ansari & Hampsey, 2005; Tan-Wong et al., 2009). Furthermore, it represses pervasive antisense transcription by establishing promoter directionality and bringing in termination factors in promoter-proximal regions (Tan-Wong et al., 2012).

1.4 Co-transcriptional RNA processing

Pre-mRNA processing occurs concomitantly with transcription, reflecting the association of processing factors with the Pol II CTD at different stages during the transcription cycle (Hirose & Manley, 1998; Hirose et al., 1999; Rodriguez et al., 2000). The three major pre-mRNA processing events are 5' capping, intron splicing, 3' end cleavage and polyadenylation, all independently stimulated by the Pol II CTD (Fong & Bentley, 2001).

<u>Capping</u>

The 5' cap is added on the transcript immediately after it emerges from the Pol II exit channel (Jove & Manley, 1984; Rasmussen & Lis, 1993) and it functions to protect the nascent transcript from degradation by 5'->3' exonucleases (Ramanathan et al., 2016) (Figure 8A).

Capping of the nascent RNA is a promoter-proximal event (Glover-Cutter et al., 2008; Jove & Manley, 1984) and correctly capped nascent RNA is a prerequisite for pause-release (Pei et al., 2003). Ser5P of the Pol II CTD is required for the recruitment of the capping enzyme and it promotes its activity (Cho et al., 1997; Ho & Shuman, 1999; Lu et al., 1991; McCracken et al., 1997; Rodriguez et al., 2000; Yue et al., 1997).

Apart from protecting the nascent RNA from exonucleases, the 5' cap is required for subsequent RNA processing events. The 5' cap promotes pre-mRNA splicing (Fresco & Buratowski, 1996; Inoue et al., 1989; Izaurralde et al., 1994; Konarska et al., 1984; Ohno et al., 1987; Pabis et al., 2013), 3' end processing and polyadenylation (Flaherty et al., 1997; Glover-Cutter et al., 2008; Narita et al., 2007; Topisirovic et al., 2011), intranuclear transport (Boulon et al., 2004) and nonsensemediated decay (Hosoda et al., 2005). In addition, it is involved in RNA surveillance by the nuclear exosome (Andersen et al., 2013), nuclear export (Chen et al., 2006; Cheng et al., 2006; Jarmolowski et al., 1994) and efficient initiation of translation (K. M. Kim et al., 2009; Muthukrishnan et al., 1975; Shatkin & Manley, 2000).




Figure 8 Pre-mRNA processing

(A) Pre-mRNA capping. RNA triphosphatase (RTPase) removes the y-phosphate from the 5' end of the nascent RNA to generate 5' diphosphate and inorganic phosphate. The guanyltransferase (GTase) transfers a GMP from GTP to the 5' diphosphate through a lysine-GMP covalent intermediate. The guanine-N7 MTase (N7MTase) adds a methyl group N7 amine of the guanine cap. The m7G-specific 2'O methyltransferase (2'OMTase) methylates the ribonucleotide at the 2'O position of the ribose to generate the complete cap structure. (B) pre-mRNA splicing. Initially, the 5' splice site of the intron (5'SS) is bound by the U1 snRNP and the splicing factors SF1, U2AF2 and U2AF1 recognise the branch point sequence (BP), the polypyrimidine tract (Py) and the 3'end splice site (3'SS), respectively, to form the commitment complex (Complex E). Next, the U2 snRNP displaces SF1 and the pre-spliceosome is assembled (Complex A). Then, the U4/U5/U6 snRNP trimer is recruited to form the pre-catalytic spliceosome (Complex B). The activated spliceosome (Complex C) is formed after rearrangements that detach U1 and U4. U6 binds at the 5'SS and to U2 and U5 binds the intron. The 5' end of the intron is ligated to the BP, U5 binds at the 3'SS and the 5'SS is cleaved. The intron is excised and removed as a lariat RNA and the two exons are ligated. The lariat is degraded and the U2, U5, and U6 snRNPs are recycled for subsequent rounds of splicing.

Chapter 1 Introduction

<u>Splicing</u>

Most mammalian genes contain multiple introns and accurate splicing is critical for the assembly of the coding sequence in the mRNA. Splicing defects lead to exon skipping, intron retention or alternative splice forms of the transcript, all of which affect the functionality and stability of the mRNA.

The spliceosome is composed of five U snRNPs (U1, U2, U4, U5, and U6), each containing a small stable RNA bound by several RBPs (Figure 8B)(Herzel et al., 2017; Saldi et al., 2016). The majority of splicing is carried out co-transcriptionally during Pol II elongation (Alpert et al., 2017; Brugiolo et al., 2013; Khodor et al., 2011). Ser2 phosphorylation of the Pol II CTD is required for the recruitment of splicing factors to the nascent RNA and efficient splicing (Ahn et al., 2004; Gu et al., 2013; Ni et al., 2004). The spliceosome and the exon junction complex interact with the Ser2 kinase CDK12 (Bartkowiak et al., 2010; Eifler et al., 2015; Liang et al., 2015) and CDK12 inhibition leads to splicing defects (Chen et al., 2006; Chen et al., 2007; Greenleaf, 2019). Specifically, Ser2P is essential for the recruitment of U2 snRNA and U2AF2, while it is dispensable for the early spliceosome assembly, such as recruitment of U1 snRNA (Gu et al., 2013). Early spliceosome recruitment is dependent on Ser5P instead (Harlen et al., 2016).

In the same way that promoter-proximal pausing stimulates 5' cap formation, transient pausing at intron-exon junctions contributes to recognition of splicing sites and improves splicing accuracy (Khodor et al., 2011; Kwak et al., 2013). Moreover, splicing factors SKIP (Brès et al., 2005), Npl3 (Dermody et al., 2008) and SRSF2 (Lin et al., 2008) have stimulatory effects on transcription elongation, while their depletion causes increased Pol II pausing within gene bodies and defective elongation (Lin et al., 2008).

3' end processing

3' end cleavage and polyadenylation of transcripts is necessary for successful transcription termination (Nojima et al., 2015) and regulates transcript stability, nuclear export and efficiency of translation (Colgan & Manley, 1997; Zhao et al., 1999).

Chapter 1 Introduction

In mammalian cells, pre-mRNA 3' processing is carried out by cleavage and polyadenylation specificity factor (CPSF) and cleavage stimulation factor (CstF), which are involved in the recognition of the poly(A) site (PAS) on the pre-mRNA (Hirose & Manley, 2000), cleavage factors CF I and CF II, which have endonuclease activity (Mandel et al., 2006) and the poly(A) polymerase (PAP) (Colgan & Manley, 1997; Takagaki et al., 1989; Zhao et al., 1999). The 3' end processing machinery co-transcriptionally monitors nascent transcripts for specific sequences and, upon recognition of the PAS, endonucleolytic cleavage of the nascent mRNA 3' end followed by poly(A) tail synthesis takes place (Cho et al., 1999). The poly(A) tail serves to protect the mRNA from degradation and promotes translation after mRNA export (Colgan & Manley, 1997; Proudfoot, 1996).

3' end cleavage and polyadenylation factors are recruited in a Ser2P-dependent manner and directly interact with the Ser2 kinase CDK12 (Bartkowiak et al., 2010; Eifler et al., 2015; Liang et al., 2015). Lack of Ser2P impairs 3' cleavage (Gu et al., 2013) and polyadenylation (Ahn et al., 2004; Ni et al., 2004; Skaar & Greenleaf, 2002). Thus, Ser2P is required for efficient 3' end processing (Ahn et al., 2004; Barillà et al., 2001; Fong & Bentley, 2001; Gomes et al., 2006; Kim et al., 2010; Komarnitsky et al., 2000; Licatalosi et al., 2002). The efficiency of 3' end processing is further stimulated by appropriate co-transcriptional splicing (Licatalosi et al., 2002) and the two RNA processing events are coupled through interactions between CPSF and a component of the U2 snRNP (Kyburz et al., 2006).

Not all Pol II transcripts are polyadenylated and alternative processing mechanisms have been defined for histone and snRNA genes. Histone genes end with a 3' stem-loop sequence, which is recognized by stem-loop binding protein (SLBP) and U7 snRNP, and 3' end formation is mediated by a cleavage complex containing CPSF73, CPSF100, and Symplekin (Marzluff et al., 2008). At histone genes, Thr4P is involved in 3' end processing and mutations in Thr4 inhibit recruitment of CPSF and cause failure to generate 3' ends (Hintermair et al., 2012; Hsin et al., 2011). At snRNA genes, 3' end formation is dependent on the "3' box", located just downstream of the snRNA-encoding region (Egloff et al., 2008). This sequence is

57

recognized, cleaved and processed by the Integrator complex, which is recruited in a Ser7P-dependent manner (Egloff et al., 2007; Egloff et al., 2010).

1.5 The nuclear exosome

Pol II can initiate transcription non-specifically and bidirectionally on nucleosomedepleted chromatin (Core & Lis, 2008; Preker et al., 2008; Seila et al., 2008). Such promiscuous transcription generates non-coding RNAs (ncRNAs). Some ncRNAs play a role in regulating transcription, for instance through recruiting regulatory factors to chromatin (Chu et al., 2015; McHugh et al., 2015), sequestering of transcriptional regulators (Holz-Schietinger et al., 2012; Sigova et al., 2015), transcriptional interference (Latos et al., 2012) and genome organization (Dowen et al., 2014; Kagey et al., 2010). However, the majority of ncRNAs are unstable and rapidly degraded by the nuclear exosome (Neil et al., 2009; Xu et al., 2009). These include transcription start site associated RNA (TSSa-RNA) (Seila et al., 2008; Valen et al., 2011), products of anti-sense transcription (Tan-Wong et al., 2012), enhancer RNAs (eRNAs) (Sigova et al., 2013) and promoter upstream transcripts (PROMPTs) (Flynn et al., 2011; Preker et al., 2011; Preker et al., 2008).

The nuclear exosome also functions in the processing of many stable RNAs, ribosomal RNA (rRNA), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs), as well as rapidly degrading mis-spliced pre-mRNAs (Bousquet-Antonelli et al., 2000) and pre-mRNAs with aberrant poly(A) tails (Hilleren et al., 2001). The factors that determine the fate of the transcript and how the exosome recognizes its substrates remain poorly understood.

Core nuclear exosome

The RNA exosome is an evolutionary conserved RNA degradation complex composed of a catalytically inactive barrel-shaped core of nine subunits: CsL4, Rrp4, Rrp40, Rrp41, Rrp46, Mtr3, Rrp42, Rrp43 and Rrp45 (Exosc1-9) (Anderson et al., 2006; Greimann & Lima, 2008; Kilchert et al., 2016). The catalytic activity of the exosome is achieved through its association with non-core subunits Rrp6 (Exosc10), which is an exonuclease localized mainly in the nucleolus (Chlebowski et al., 2010; Mitchell et al., 1997; Schneider et al., 2009; Tomecki et al., 2010), or

Dis3 family proteins. Both Dis3L and Dis3L2 are cytoplasmic exonucleases (Lubas et al., 2013; Staals et al., 2010; Tomecki et al., 2010), while Dis3 is exclusively nuclear, with nucleolar exclusion, and possesses both exo- and endonuclease activity (Greimann & Lima, 2008; Lebreton et al., 2008; Schaeffer et al., 2009).

Exosome adapter complexes

The nuclear exosome associates with a variety of co-factors to achieve its function, among which the Mtr4 ATP-dependent RNA helicase. Mtr4 is essential for exosomal degradation *in vivo*. It is involved in the unwinding of the RNA substrate and mediating its access to the core exosome (Gerlach et al., 2018; Johnson & Jackson, 2013; Schneider & Tollervey, 2014; Weick et al., 2018). Mtr4 is negatively regulated by NRDE2, which binds to Mtr4, inhibits its recruitment to RNA and prevents its interaction with Rrp6 and Dis3 (J. Wang et al., 2019).

In mammalian cells, three nuclear exosome adapter complexes have been characterized and Mtr4 is part of all of them (Figure 9)(Ogami et al., 2018). In the nucleoli, Mtr4 associates with the RNA binding protein Zcchc7 (Air1/2 in yeast) and the poly(A) polymerase Papd5 (Trf4/5 in yeast), forming the TRAMP complex (Trf4/Air2/Mtr4p Polyadenylation complex). It is required for the 3' end processing and decay of rRNA via the addition of an unstructured oligo(A) tail at 3' ends of its RNA substrates (LaCava et al., 2005; Lubas et al., 2011; Shcherbik et al., 2010; Vanácová et al., 2005; Wyers et al., 2005). In the nucleoplasm, the PAXT (poly(A) exosome targeting) and NEXT (nuclear exosome targeting) complexes are found. In the PAXT complex, Zfc3h1 protein mediates the interaction between Mtr4 and the poly(A)-binding protein Pabpn1. While PAXT substrates are mature, polyadenylated RNAs (Giacometti et al., 2017; Meola et al., 2016; Silla et al., 2018), the NEXT complex is involved in the degradation of newly synthesised, unstable transcripts. Its substrates include PROMPTs, eRNAs and lincRNAs, as well as aberrantly processed snRNA, snoRNA and histone RNA (Giacometti et al., 2017; Lubas et al., 2015; Lubas et al., 2011). In the NEXT complex, the adapter protein Zcchc8 mediates the interaction between Mtr4 and the RNA binding protein Rmb7 (Falk et al., 2016; Lubas et al., 2011). It is recruited to RNA via the capbinding complex (CBC) in association with Ars2 and Zc3h18 co-factors (Andersen et al., 2013; Hallais et al., 2013; Lubas et al., 2015).




Figure 9 Exosome adapter complexes

The RNA helicase Mtr4 is part of all three nuclear exosome adapter complexes. The TRAMP complex, which is restricted to the nucleolus, consists of the RNA binding protein Papd5, the adapter protein Zcchc7 and Mtr4. Both the NEXT and the PAXT complexes are nuclear. In the NEXT complex, Mtr4 interacts with the RNA binding protein Rmb7 and the adapter protein Zcchc8. The PAXT complex is composed of the RNA binding protein Pabpn1, the adapter protein Zfc3h1 and Mtr4. Mtr4 directly interacts with the exosome and it is responsible for threading the RNA through the core exosome to its catalytic subunit Rrp6 (Exosc10) in the nucleolus or Dis3 in the nucleus. Mtr4 activity is inhibited by Nrde2, which binds to Mtr4 and prevents its association with RNA and the exosome.

The role of the CBC in exosome recruitment

The 5' cap of the nascent RNA is bound by nuclear cap-binding proteins Ncbp1 and Ncbp2, which form the CBC (Izaurralde et al., 1994). In addition to protecting the nascent transcript from de-capping and subsequent 5'->3' degradation, distinct CBC-containing complexes target RNAs either for export into the cytoplasm or for exosomal degradation. The CBC interacts with the Ars2 adapter protein, forming the CBCA complex (Giacometti et al., 2017; Gruber et al., 2009; Schulze et al., 2018). Subsequently, the CBCA forms higher order complexes with distinct RNA processing factors (Figure 10) (Schulze et al., 2018). The competition between RNA export factors and the exosome co-factors is important for the sorting of RNAs into the export or degradation pathways (Fan et al., 2017; Giacometti et al., 2017; Silla et al., 2018).

Ars2-dependent recruitment of the DROSHA complex targets RNAs to the miRNA processing pathway (Gruber et al., 2009; O'Sullivan et al., 2015), whereas at snRNA and snoRNA, CBCA recruits the PHAX complex. PHAX is involved in 3' end processing and export of the RNA through mediating the interaction between the CBC and the Crm1 nuclear export receptor (Boulon et al., 2004; Hallais et al., 2013; Ohno et al., 2000). Similarly, Ars2 mediates binding of the FLASH complex to CBC, which is involved in 3' end processing and export of histone mRNAs (Kiriyama et al., 2009; Yang et al., 2009), while the exosome adapter complexes NEXT and PAXT are recruited to their target RNAs through Zc3h18 bound CBCA complex (Andersen et al., 2013; Falk et al., 2016; Hrossova et al., 2015; Meola et al., 2016).

The mRNA nuclear export complex (TREX), PHAX and Zc3h18 compete for binding to the CBCA complex. Furthermore, Mtr4-containing complexes TRAMP, PAXT and NEXT interact with Zfc3h18 in a mutually exclusive manner (Fan et al., 2017; Giacometti et al., 2017; Meola et al., 2016; Schulze et al., 2018; Strässer & Hurt, 2000). Such differential recruitment of distinct RNA processing complexes at the 5' cap of the nascent transcript is thought to provide specificity and play an important role in determining the fate of the transcript. However, the mechanism through which the RNA substrate is recognized by these RNA processing complexes is not well understood.




Figure 10 Mutually exclusive CBCA containing complexes. The m7G cap of the nascent RNA is bound by the cap binding complex (CBC). The CBC interacts with the Ars2 protein to form the CBCA complex through which additional co-factors are recruited. For mRNAs, the CBCA recruits TREX which mediates nuclear export. At snRNAs/snoRNAs and histone mRNAs, the CBCA recruits the PHAX and FLASH RNA processing complexes, respectively. RNAs are targeted for exosomal degradation through recruitment of Zc3h18 to the CBCA complex. Through Zc3h18, the PAXT and the NEXT exosome adapter complexes are recruited which then thread the RNA through the exosome to facilitate its degradation by the Dis3 catalytic subunit of the nuclear exosome. While the NEXT complex associates with nascent, unprocessed RNAs, the PAXT complex binds to processed, polyadenylated RNAs.

Chapter 2. Materials & Methods

2.1 Cell culture and growth curves

NIH3T3 and MEF cell lines were cultured in DMEM (Dulbecco's Modified Eagle Medium, 41966-029, Sigma) supplemented with 10% FBS (Fetal Bovine Serum, 10270106, Thermo Fisher Scientific) and penicillin-streptomycin (P4333, Sigma) at 37^oC 10% CO₂. Phoenix cells were grown at 37^oC 5% CO₂. Cells were passaged every 3rd day. Growth medium was aspirated, plates were washed with PBS (phosphate-buffered saline) and incubated in trypsin EDTA (R001100, Thermo Fisher Scientific) in a tissue culture incubator for 3 min. Trypsin was inactivated by addition of growth medium, cells were spun down at 300g for 5 min, resuspended in growth medium and plated in tissue culture dishes, as needed. For growth curves, cells were counted using Neubauer cell counting chamber.

2.2 Drug treatments

For antibiotic selection, zeocin (ant-zn-1, InvivoGen) was used at 100 μg/ml; blasticidin (ant-bl-1, InvivoGen) at 3 μg/ml; hygromycin (10687-010, Thermo Fisher Scientific) at 100 μg/ml. Tamoxifen (H6278, Sigma) was used at a final concentration of 1μM. Doxycycline (D9891, Sigma) was used at 2 μg/ml. For serum shock, cells were starved overnight in DMEM supplemented with 0.3% FBS and subsequently stimulated with 15% FBS for 30 minutes. Cells were treated with CD (Cytochalasin D, 250255, Merck) at 3μM for 30 min; LMB (Leptomycin B, 9676, Cell Signalling) at 50nM for 30 min (*Note on LMB: LMB was diluted 1/500 in EtOH in a glass vial before adding to the growth media); LatB (Latrunculin B, 428020, VWR International) at 0.5μM for 30 min; TPA (12-o-tetradecanoylphorbol-13acetate, P8139 , Sigma) was used at 50 ng/ml; FP (Flavopiridol, 10009197, Cambridge Bioscience) at 0.5μM for 1h; THZ1 (A8882, Generon) at 0.5μM for 1h; THZ531 (HY-103618, Generon) at 1μM for 1h; GW843682X (G2171, Sigma) at 10μM for 1h.

2.3 Immunofluorescence

Cells, seeded on glass coverslips and treated as indicated in the figures, were fixed with 4% paraformaldehyde (199431LT, VWR International) for 10 min at room temperature, washed twice in PBS (phosphate-buffered saline), permeabilized in 0.2% Triton X-100 (X100-100ML, Sigma) for 20 min at room temperature and incubated in blocking solution (10% FBS, 0.5% fish skin gelatine (G7765, Sigma) in PBS) for 1h at room temperature. Coverslips were then incubated with primary antibody for 1h at room temperature in blocking solution, washed three times in 0.1% Triton X-100 and incubated with secondary antibody and DAPI stain (4',6-diamidino-2-phenylindole, D9542, Sigma) for 1h at room temperature in blocking buffer. Following three washes with 0.1% Triton X-100, three washes with PBS and one wash with dH₂0, coverslips were mounted on glass slides using Mowiol medium (475904, Calbiochem). Imaging was done using Leica SP8 confocal microscope. Images were processed using ImageJ.

2.4 siRNA and transient transfection

Cells were transfected with siRNA oligonucleotides using Lipofectamine RNAiMAX transfection reagent (13778-150, Invitrogen), according to the manufacturer's instructions. Cells were diluted in DMEM, supplemented with 10% FBS, so that they reach confluence 48h post-seeding. siRNA duplex to a final concentration of 10 nM and lipofectamine RNAiMAX reagent were mixed in OptiMEM (31985-047, Sigma), incubated for 30 min at room temperature and added to the cell suspension. Cells were then plated and efficiency of the knock-down was assessed by Western blot or qPCR 48h post-transfection.

For transient transfection, cells were seeded at 25% confluence in 10 cm dishes in DMEM, supplemented with 10% FBS. The following day, 3 μ g plasmid DNA and 1:200 Fugene transfection reagent (E2311, Promega) were mixed in OptiMEM, incubated at room temperature for 30 min, added directly to the cell medium and incubated overnight at 37^oC 10% CO₂.

2.5 Cell fractionation

Cells were trypsinized and spun down at 300g for 5 min. Cell pellets were resuspended in 2PCV of hypotonic buffer (10 mM HEPES-KOH pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, protease inhibitors (11873580001, Roche), phosphatase inhibitors (A32961, Thermo Fisher Scientific) and incubated on ice for 20 min to achieve cell swelling. Cells were lysed by pipetting up and down 20 times. Nuclei were pelleted by centrifugation at 3000g for 15 min at 4^oC. The cytoplasmic fraction in the supernatant was removed and pelleted nuclei were washed twice in hypotonic buffer and then resuspended in 2PCV nucleoplasmic extraction buffer (20 mM HEPES-KOH pH 7.5, 1.5 mM MgCl₂, 10% glycerol, 150 mM potassium acetate, 0.05% NP-40, protease inhibitors (11873580001, Roche), phosphatase inhibitors (A32961, Thermo Fisher Scientific)) and incubated for 20 min at 4°C shaking. Nucleoplasm (supernatant) was recovered through centrifugation at 20000g for 20 min 4°C and EDTA to 1 mM was added. Pellets were resuspended in 1PCV chromatin digestion buffer (20 mM HEPES-KOH pH 7.5, 1.5 mM MgCl₂, 10% glycerol, 150 mM NaCl, 0.05% NP-40, protease inhibitors (11873580001, Roche), phosphatase inhibitors (A32961, Thermo Fisher Scientific)), 125 units/ml benzonase (70664-3, Merck) was added and samples were incubated for 30 min on ice. Low salt chromatin was recovered through centrifugation at 20000g for 20 min at 4°C and EDTA to 3 mM was added. Pellets were resuspended in 1PCV of 500 mM NaCl buffer (20 mM HEPES-KOH pH 7.5, 3 mM EDTA, 1.5 mM MgCl₂, 10% glycerol, 500 mM NaCl, 0.05% NP-40, protease inhibitors (11873580001, Roche), phosphatase inhibitors (A32961, Thermo Fisher Scientific)) and incubated for 30 min on ice. 2.3V of salt dilution buffer (20 mM HEPES-KOH pH 7.5, 3 mM EDTA, 1.5 mM MgCl₂, 10% glycerol, 0.05% NP-40, protease inhibitors (11873580001, Roche), phosphatase inhibitors (A32961, Thermo Fisher Scientific)) was added and samples were cleared by centrifugation at 20000g for 20 min. Low and high salt chromatin fractions were pooled and used for Western blot analysis.

2.6 Western blot

Cells were trypsinized and spun down at 300g for 5 min. Cell pellets were resuspended and lysed in RIPA buffer (1% Nonidet P-40, 1% Na deoxycholate,

0.1% SDS, 150 mM NaCl, 0.01 M sodium phosphate pH 7.2, 2 mM EDTA, protease inhibitor (11873580001, Roche)) for 1h at 4^oC shaking and lysates were then pre-cleared by centrifugation at 12000g for 10min. Protein concentration was measured using Bradford reagent (500-0006, Biorad). 10-20 µg total protein was used for blotting. Lysates were mixed with laemmli buffer (2% SDS, 10% glycerol, 60 mM Tris-HCl pH 6.8, 0.02% bromophenol blue) and incubated at 100°C for 10 min, prior to loading on a 4-12% Bis Tris protein gel (NP0323BOX, Life Technologies). Gels were run at 180V for 1h in MOPS buffer (NP0001, Life Technologies), transferred using wet transfer to a nitrocellulose membrane (10600003, VWR International) at 300mA for 1.5h in transfer buffer (25 mM Tris-HCI, 192 mM Glycine, 10% Methanol). Membranes were blocked in 5% semiskimmed milk in PBST (0.1% Tween-20 in PBS) for 1h at room temperature and then incubated with primary antibody in blocking buffer overnight at 4°C. The following day, membranes were washed three times in PBST (0.1% Tween-20 in PBS), incubated with secondary-HRP conjugated antibody for 1h at room temperature in blocking buffer, washed three times with PBST and signal was visualized using ECL reagent (RPN2106, VWR International) on a film (28906837, VWR International). SeeBlue pre-stained protein standard (LC5925, Thermo Fisher Scientific) was used as reference.

2.7 Contractility assay

50 000 cells were embedded in collagen I/Matrigel mixture (20mM Hepes pH 7.5, 0.4% NaHCO₃, 4.6 mg/ml collagen (354249, Thermo Fisher Scientific), 2.2 mg/ml Matrigel (354234, Thermo Fisher Scientific), 10% FCS in DMEM) and seeded on a 24 well glass-bottom MatTek dish (P24G-1.5-13-F, MatTek). Gels were left to set for 30 min in a tissue culture incubator, after which tissue culture medium was added. Original gel size, as seen at 3h post-seeding, was compared to gel size 48h post-seeding. Gel sizes were obtained using ImageJ software and gel contraction values represent percentage of the original gel size.

2.8 RNA extraction, cDNA synthesis and qPCR

Total RNA was purified using Genelute mammalian total RNA extraction kit (RTN350-1KT, Sigma), according to the manufacturer's instructions. 200 ng RNA

was used for cDNA synthesis, performed using Transcriptor First Strand cDNA Synthesis Kit (04897030001, Roche). Samples were treated with 1 U DNase I (AM2224, Ambion) in 1X DNase I buffer (AM8170G, Ambion) for 15 min at 37°C. DNase I was inactivated with 5mM EDTA at 72°C for 10 min. Random hexamer primers (60µM) were annealed at 65°C for 10 min. Finally, the reverse transcription reaction was carried out as follows: 10 units reverse transcriptase, 1mM dNTPs, 20 units protector RNase inhibitor and 8mM MgCl₂ were added to the samples in a total volume of 20 ul and the samples were incubated at 25°C for 10 min, 55°C for 30 min, followed by inactivation of the reverse transcriptase at 85°C for 5 min. cDNA was diluted 10 times in TE buffer (10 mM Tris-HCl pH 8, 1 mM EDTA) and qPCR reactions were set up as follows: 2 μl cDNA, 0.2 μM primer mix (10μM of each primer) and 5 µl PowerUp SYBR Green Master Mix (A25742, Life Technologies) in a total volume of 10 µl. Initial denaturation was carried out at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 10 sec and annealing, extension and read fluorescence at 60°C for 25 sec. gPCRs were done using QuantStudio 3 Real-Time PCR system. Standard curve was generated using genomic DNA or cDNA dilutions. Samples were normalized to Gapdh.

2.9 Chromatin Immunoprecipitation (ChIP)

The ChIP protocol was adapted from (Schmidt et al., 2009). Cells were fixed in 1% formaldehyde (F/1501/PB17, Thermo Fisher Scientific) in PBS at room temperature. After 10 min, the reaction was quenched using 0.25 M Glycine, cells were washed twice with PBS, scraped in ice-cold PBS, supplemented with protease inhibitor (5056489001, Roche), pelleted at 2000g for 5 min and frozen at - 80°C. Cell pellets were defrosted, resuspended and lysed in 7ml LB1 buffer (50 mM Hepes-KOH, pH 7.5; 140 mM NaCl; 1mM EDTA; 10% Glycerol; 0.5% NP-40 or Igepal CA-630; 0.25% Triton X-100, protease inhibitor (11873580001, Roche)) for 15 min at 4°C with rotation and pelleted at 2000g for 5min. Cell pellets were resuspended in 7ml LB2 buffer (10 mM Tris-HCL, pH8.0; 200 mM NaCl; 1 mM EDTA; 0.5 mM EGTA, protease inhibitor (11873580001, Roche)), pelleted by centrifugation at 2000g for 5 min and resuspended in 300 µl LB3 buffer (10 mM Tris-HCl, pH 8; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% Na-Deoxycholate; 0.5% N-lauroylsarcosine, protease inhibitor (11873580001, Roche)).

Shearing of chromatin was performed using Bioruptor sonicator (Diagenode). For NIH3T3 and MEF cells, 20x10⁶ cells were sonicated for 10 min (30" ON/30" OFF) at high energy, for MDA-MB-231 20x10⁶ cells were sonicated for 8 min at high energy. 1:5 input sample was reverse-crosslinked in FA/SDS-like buffer (50 mM Hepes KOH pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% Na deoxycholate) and 20 µg proteinase K (19133, Qiagen) overnight at 65°C. Chromatin was pre-cleared with 25ul dynabeads (10009D, Thermo Fisher Scientific), previously blocked in 0.1% BSA (bovine serum albumin), for 1h at 4°C. 50 µl dynabeads were coupled to 10 µg antibody for 1h at 4°C in 0.1% BSA. Pre-cleared chromatin and antibodycoupled dynabeads were incubated overnight at 4^oC shaking. The following day, the IPs were washed 5 times with RIPA buffer (50 mM Hepes-KOH, pH 7.5; 500 mM LiCl; 1mM EDTA; 1% NP-40 or Igepal CA-630; 0.7% Na-Deoxycholate) and once with TBS (20 mM Tris-HCl, pH 7.6; 150 mM NaCl) on a magnetic rack and chromatin was eluted in 130µl elution buffer (25 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% SDS) at 65°C for 30 min. For reverse-crosslinking, the elution was incubated with 20 µg proteinase K at 65^oC overnight. The DNA was extracted using PCR purification kit (28106, Qiagen). Efficiency of sonication was evaluated on a 2% agarose gel, stained with ethidium bromide, and integrity of the target protein was checked by Western blot. Samples were used for qPCR, as described above, and normalized to input.

2.10TT_{chem}-seq

TT_{chem}- seq was performed as described in (Gregersen et al., 2020). Nascent RNA was pulse-labelled with 4-thiouridine (4SU). 1mM 4SU (GN6085, Glentham Life Sciences) was added directly to the tissue culture medium for 15 min, after which cells were lysed in 1ml TRIzol (15596018, Thermo Fisher Scientific). 200 ul chloroform (43685, Thermo Fisher Scientific) was added, samples were mixed and spun down at 12000g for 15 min at 4^oC. The aqueous phase was combined with an equal volume of chloroform/isoamyl alcohol (24:1) (C0549, Sigma-Aldrich), mixed and spun down at 12000g for 10 min at 4^oC. 1.1 volume of isopropanol (P/7500/PC17, Thermo Fisher Scientific) was added to the aqueous phase. Samples were mixed, incubated for 20 min at room temperature and spun down at 12000g for 30 min. RNA pellets were washed with 80% ethanol, air-dried and

68

resuspended in 50-100 µl RNase-free water. RNA concentration was measured using Qubit RNA BR Assay Kit (Q10210, Thermo Fisher Scientific) and RNA integrity was checked on a 2100 Bioanalyzer, using an Agilent RNA 6000 Nano Kit (5067-1511, Agilent), according to the manufacturer's instruction.

A 50 ml mid-log phase *S. cerevisiae* BY4741 culture in YPD medium supplemented with 2% glucose was labelled with 5mM 4TU (4-thiouracil, 440736, Sigma) for 5 min at 30°C. Cells were spun down at 5000g for 5 min. Pellets were resuspended in 1 ml TES buffer (10 mM Tris HCl pH 7.5, 10 mM EDTA, 0.5% SDS). 1 ml acid phenol (AM9720, Thermo Fisher Scientific) was added, samples were incubated at 65°C for 45 min at 1400rpm shaking and spun down at 12000g for 10 min at 4°C. The aqueous phase was mixed with 1 ml 100% ethanol and 3M NaAc and incubated overnight at 4°C. Samples were then spun down at 12000g for 30 min, RNA pellets were washed with 80% ethanol, air-dried and resuspended in RNase-free water. RNA concentration was measured using Qubit RNA BR Assay Kit.

For each sample, 100 μ g of 4SU-labeled mammalian RNA and 1 μ g of *S. cerevisiae* 4TU-labeled RNA were mixed in a total volume of 100 μ l. To fragment the RNA, 160mM NaOH was used for 20 min on ice. The reaction was quenched with 400mM Tris pH 6.8 and the fragmented RNA was purified using Micro Bio-Gel spin columns (732-6223, Biorad), according to manufacturer's instructions. To biotinylate the fragmented RNA, 3 μ l biotin buffer (833 mM Tris-HCl, pH 7.4, and 83.3 mM EDTA) and 5 ug MTSEA biotin-XX linker (BT90066, Biotium) was added to the 200 μ l RNA. Samples were mixed and incubated at room temperature for 30 min, protected from light. Excess free biotin was removed by mixing the samples with an equal volume of phenol/chloroform/isoamyl alcohol (15593031, Thermo Fisher Scientific), centrifugation at 12000g for 10 min and precipitation of the RNA in the aqueous phase with isopropanol. RNA pellets were reconstituted in 50 μ l RNAse-free water.

Efficiency of 4SU and 4TU incorporation was assessed by dot blot. 10 μ g of mammalian RNA or 1 μ g of yeast RNA was spotted on a Hybond-N membrane (RPN203N, GE Healthcare). The membrane was UV-crosslinked at 0.2 J/cm2 (254 nm) in a Stratalinker, blocked in blocking buffer (10% SDS, 1 mM EDTA in PBS) for

69

30 min at room temperature and probed with 1/50000 of 1 mg/ml HRP-conjugated streptavidin (N100, Thermo Fisher Scientific) in blocking buffer for 30 min at room temperature. The membrane was then washed three times in wash buffer 1 (1% SDS in PBS) and three times in wash buffer 2 (0.1% SDS in PBS), with each wash lasting 10 min at room temperature. The signal of the biotin-bound HRP-conjugated streptavidin was visualized using ECL reagent (RPN2106, VWR International) on film (28906837, VWR International).

In order to purify the biotinylated RNA, the RNA was denatured at 65° C for 10 min and incubated with 200 µl µMACS streptavidin MicroBeads (130-074-101, Miltenyi) on a rotating wheel for 30 min at room temperature. Samples were placed on a µMACS magnetic separator, washed twice with pull-out wash buffer (100 mM Tris-HCl pH 7.4, 10 mM EDTA, 1 M NaCl and 0.1% Tween 20), pre-warmed at 55° C, and eluted in 200 µl 100 mM DTT. Nascent RNA was purified using RNeasy MinElute Cleanup Kit (74204, Qiagen). RNA concentration was measured using Qubit RNA Assay Kit and the size of the purified 4SU-RNA on a Bioanalyzer, using Agilent RNA 6000 Pico Kit, according to the manufacturer's instructions.

2.11 Library preparation and sequencing

For TT_{chem} - seq, 100 ng of 4SU RNA was used to prepare libraries for sequencing using KAPA RNA HyperPrep Kit (08098107702, Roche) together with the KAPA Dual-Indexed Adapter Kit (08278555702, Roche), according to manufacturer's instructions. Samples were sequenced in single-end mode at 50 million reads per sample on a HiSeq platform.

ChIP-seq libraries were prepared from 1 ng ChIP sample using NEBNext Ultra II DNA Library Prep Kit for Illumina (E7645L), according to manufacturer's instructions. Samples were sequenced in single-end mode at 25 million reads per sample on a HiSeq platform.

cDNA libraries for RNA-seq were prepared from 100 ng total RNA, extracted with Genelute mammalian total RNA extraction kit (RTN350-1KT, Sigma), using KAPA RNA HyperPrep Kit with RiboErase (Roche). Samples were sequenced in single-

end mode at 30 million reads per sample on a HiSeq platform. Sequencing was performed by the Sequencing STP.

2.12 Data analysis

RNAseq and TTseq

RNAseq and TTseq data analysis was performed by Francesco Gualdrini. For QC and reproducibility of RNAseg biological replicates in NIH3T3 cells see Figure 11 and Figure 12. For QC and reproducibility of RNAseq biological replicates in dKO^{MRTF} and dKO^{MRTF-NLS} cells see Figure 15 and Figure 16. One replicate of untreated and LatB-treated sample in dKO^{MRTF}, dKO^{MRTF-NLS} and Mtr4-depleted dKO^{MRTF-NLS} cells was excluded due to possible sample swap. For QC and reproducibility of TTseg biological replicates in NIH3T3 cells see Figure 13 and Figure 14. For QC and reproducibility of RNAseg biological replicates in dKO^{MRTF} and dKO^{MRTF-NLS} cells see Figure 17 and Figure 18. One replicate of untreated and LatB-treated sample in dKO^{MRTF-NLS} cells and one replicate of CD-treated sample in dKO^{MRTF-NLS} cells was excluded from the analysis. Adapter and quality trimming of RNAseq and TTseq reads was performed with Trim Galore. rRNA removal was done using SortMeRNA. RNAseg reads were aligned to the mm10 mouse genome using STAR (default settings). Reads were counted into transcript gene features using functions part of the GRanges library (Bioconductor) in R using the summarizeOverlaps function. For RNAseq, reads strictly falling within exons were defined as exonic reads per gene/transcript and reads containing intronic features were defined as intronic reads per gene/transcript. Normalization was done against a set of invariant genes across samples, assuming a quasi-normal distribution of gene read counts, as described in (Gualdrini et al., 2016). Frequency distribution of invariant genes across conditions follow a log-normal distribution. Gene counts falling within one standard deviation of the theoretical log-normal were considered to scale samples. Differential gene expression analysis was performed with Deseq2 (comparing each condition to untreated cells; adjusted p value (padj) \leq 0.01; minimum fold change of 1). Volcano plots were generated using Prism by plotting log₂(fold change) vs log₁₀(padj value). Venn diagrams were plotted in

Illustrator. Linear regression analyses and Spearman's rank order correlation analyses of log₂(fold change) expression between conditions were performed using Prism. Slope, 95% confidence lines and Spearman's correlation coefficient (r) are shown in figures. TTseq read coverage profiles genome alignment BAM files were merged across biological replicates and visualized using Integrative Genomic Viewer (IGV). Heatmaps and violin plots were generated in Prism. Z-scores were calculated using the formula $z = (x-\mu)/\sigma$, where x is the raw value, μ is the population mean, and σ is the population standard deviation. For plots showing distance to SRF binding site, previously published SRF binding coordinates as assessed by ChIPseq in NIH3T3 cells in response to stimulation were used (Esnault et al., 2014). Genes were separated into associated with direct SRF binding (their TSS is found within 5kb of the nearest SRF binding site), near (their TSS is found between 5kb and 70kb of the nearest SRF binding site) and far (their TSS is found beyond 70kb of the nearest SRF binding site). In figures genes associated with direct, near and far SRF binding are shown as % of genes identified in the analysis. For plots showing FCS-inducible LatB-sensitive genes, previously published RNAseq dataset in NIH3T3 cells was used (Esnault et al., 2014). In figures FCS-inducible LatB-sensitive genes are shown as % of genes identified in the analysis. Gene ontology analysis and transcription factor binding motif search were performed using the Molecular Signatures Database (MSigDB) (Liberzon et al., 2011; Subramanian et al., 2005).




Figure 11 Principal component analysis (PCA) of RNAseq samples in NIH3T3 cells

Shown is the clustering of three biological replicates (R1, R2, R3) for individual treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated); MTR4CD (siMtr4 for 48h, 3µM Cytochalasin D for 30 min); MTR4LMB (siMtr4 for 48h, Leptomycin B for 30 min); MTR4UT (siMtr4 for 48h). Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. RNAseq data analysis was performed by Francesco Gualdrini.




Figure 12 Heatmap of Poisson distance of RNAseq samples in NIH3T3 cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between three biological replicates (R1, R2, R3) in different treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated); MTR4CD (siMtr4 for 48h, 3µM Cytochalasin D for 30 min); MTR4LMB (siMtr4 for 48h, Leptomycin B for 30 min); MTR4UT (siMtr4 for 48h). Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. RNAseq data analysis was performed by Francesco Gualdrini.






Figure 13 Principal component analysis (PCA) of TTseq samples in NIH3T3 cells

Shown is the clustering of three biological replicates (R1, R2, R3) for individual treatments. CD (3μ M Cytochalasin D, 30 min); LatB (0.5μ M Latrunculin B, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated). Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. TTseq data analysis was performed by Francesco Gualdrini.






A hierarchical clustering heatmap showing differences in the transcriptional profile between three biological replicates (R1, R2, R3) in different treatments. CD (3μ M Cytochalasin D, 30 min); LatB (0.5μ M Latrunculin B, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated). Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. TTseq data analysis was performed by Francesco Gualdrini.





and dKO^{MRTF-NLS} cells

Shown is the clustering of three biological replicates (R1, R2, R3) for individual treatments. CD (3μ M Cytochalasin D, 30 min); LatB (0.5μ M Latrunculin B, 30 min); UT (untreated) in dKO^{MRTF} cells. NLSCD (3μ M Cytochalasin D, 30 min); NLSLatB (0.5μ M Latrunculin B, 30 min); NLSUT (untreated); NLSMTR4CD (siMtr4 for 48h, 3μ M Cytochalasin D, 30 min); NLSMTR4LatB (siMtr4 for 48h, 0.5μ M Latrunculin B for 30 min); NLSMTR4LatB (siMtr4 for 48h, 0.5μ M Latrunculin B for 30 min); NLSMTR4UT (siMtr4 for 48h) in dKO^{MRTF-NLS} cells. Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. RNAseq data analysis was performed by Francesco Gualdrini.





dKO^{MRTF-NLS} cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between three biological replicates (R1, R2, R3) in different treatments. dKOMEF_MRTF_CD (3µM Cytochalasin D, 30 min); dKOMEF_MRTF_LatB (0.5 µM Latrunculin B, 30 min); dKOMEF_MRTF_UT (untreated) in dKO^{MRTF} cells. dKOMEF_MRTF_NLS_CD (3µM Cytochalasin D, 30 min); dKOMEF_MRTF_NLS_LatB (0.5 µM Latrunculin B, 30 min); dKOMEF_MRTF_NLS_UT (untreated); dKOMEF_MRTF_NLS_MTR4_CD (siMtr4 for 48h, 3µM Cytochalasin D, 30 min); dKOMEF_MRTF_NLS_MTR4_LatB (siMtr4 for 48h, 0.5 µM Latrunculin B for 30 min); dKOMEF_MRTF_NLS_MTR4_LatB (siMtr4 for 48h, 0.5 µM Latrunculin B for 30 min); dKOMEF_MRTF_NLS_MTR4_UT (siMtr4 for 48h) in dKO^{MRTF-NLS} cells. Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. RNAseq data analysis was performed by Francesco Gualdrini.





Figure 17 Principal component analysis (PCA) of TTseq samples in dKO^{MRTF} and

dKO^{MRTF-NLS} cells

Shown is the clustering of three biological replicates (R1, R2, R3) for individual treatments. CD (3μ M Cytochalasin D, 30 min); LatB (0.5μ M Latrunculin B, 30 min); UT (untreated) in dKO^{MRTF} cells. NLSCD (3μ M Cytochalasin D, 30 min); NLSLatB (0.5μ M Latrunculin B, 30 min); NLSUT (untreated) in dKO^{MRTF-NLS} cells. Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. TTseq data analysis was performed by Francesco Gualdrini.





dKO^{MRTF-NLS} cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between three biological replicates (R1, R2, R3) in different treatments. dKOMEF_MRTF_CD (3µM Cytochalasin D, 30 min); dKOMEF_MRTF_LatB (0.5 µM Latrunculin B, 30 min); dKOMEF_MRTF_UT (untreated) in dKO^{MRTF} cells. dKOMEF_MRTF_NLS_CD (3µM Cytochalasin D, 30 min); dKOMEF_MRTF_NLS_LatB (0.5 µM Latrunculin B, 30 min); dKOMEF_MRTF_NLS_UT (untreated) in dKO^{MRTF-NLS} cells. Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar gene expression profiles, whereas distant samples show distinct expression profiles. TTseq data analysis was performed by Francesco Gualdrini.

<u>ChlPseq</u>

ChIPseq data analysis was performed by Francesco Gualdrini. For QC and reproducibility of biological replicates see Figure 19 and Figure 20 for Ser5P ChIPseq samples, Figure 21 and Figure 22 for Ser2P ChIPseq samples, Figure 23 and Figure 24 for Ser7P ChIPseq samples and Figure 25 and Figure 26 for total Pol II ChIPseq samples. Adapter and quality trimming of ChIPseq reads was performed with Trim Galore. Reads were aligned to the mm10 mouse genome using BWA MEM (default settings). Duplicated reads were marked with Picard. Reads were filtered to remove blacklist regions from the Encode database, unmapped reads, low quality reads, multimappers, reads with insert size > 2kb, pairs mapping to different chromosomes. ChIPseg reads were counted at TSS (-150bp + 500 bp); Gene body (+150bp from TSS and -500 from the TES); TES (-500bp +7000bp) using CountOverlap function part of the GRanges library in Bioconductor/R. Normalization was performed as for RNAseq and TTseq using whole reads (TSS+gene body+TES) for total Pol II and Ser5P and TES only for Ser2P and Ser7P. Metaprofiles where generated using functionalities of the genomation library in Bioconductor/R. For ChIP metaprofiles the TSS was defined as the region spanning 500bp upstream to 500bp downstream of the TSS. The gene body was defined as the region 500bp downstream of the TSS to 500bp upstream of the TTS and shown in figures as normalized to 100%. The TTS was defined as the region 500bp upstream of the TTS to 7000bp downstream of the TTS.




Figure 19 Principal component analysis (PCA) of Ser5P ChIPseq samples in NIH3T3 cells

Shown is the clustering of biological replicates (R1, R2, R3, R4, R5) for individual treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated) in NIH3T3 cells. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 20 Heatmap of Poisson distance of Ser5P ChIPseq samples in NIH3T3 cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between biological replicates (R1, R2, R3) in different treatments. CD (3μ M Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated). Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 21 Principal component analysis (PCA) of Ser2P ChIPseq samples in NIH3T3 cells

Shown is the clustering of biological replicates (R1, R2, R3, R4, R5) for individual treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated) in NIH3T3 cells. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 22 Heatmap of Poisson distance of Ser2P ChIPseq samples in NIH3T3 cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between biological replicates (R1, R2, R3, R4, R5) in different treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated). Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 23 Principal component analysis (PCA) of Ser7P ChIPseq samples in NIH3T3 cells

Shown is the clustering of biological replicates (R1, R2, R3, R4, R5) for individual treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated) in NIH3T3 cells. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 24 Heatmap of Poisson distance of Ser7P ChIPseq samples in NIH3T3 cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between biological replicates (R1, R2, R3) in different treatments. CD (3μ M Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated). Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 25 Principal component analysis (PCA) of total Pol II ChIPseq samples in NIH3T3 cells

Shown is the clustering of biological replicates (R1, R2, R3, R4, R5) for individual treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated) in NIH3T3 cells. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.




Figure 26 Heatmap of Poisson distance of total Pol II ChIPseq samples in NIH3T3 cells

A hierarchical clustering heatmap showing differences in the transcriptional profile between biological replicates (R1, R2, R3, R4, R5) in different treatments. CD (3µM Cytochalasin D, 30 min); LMB (50nM Leptomycin B, 30 min); UT (untreated). Poisson distances are shown from low to high, indicated by darker to lighter blue shading. Samples clustering closely have similar read profiles, whereas distant samples show distinct profiles. ChIPseq data analysis was performed by Francesco Gualdrini.

2.13 Immunoprecipitation (IP)

For co-IPs, 50 µl dynabeads (10009D, Thermo Fisher Scientific) were blocked in 0.1% BSA in PBS and coupled to 10 µg antibody for 1h at 4^oC with shaking. Cells were trypsinized, pelleted by centrifugation at 300g for 5min, resuspended and lysed in RIPA buffer (50 mM Hepes-KOH, pH 7.5; 500 mM LiCl; 1mM EDTA; 1% NP-40 or Igepal CA-630; 0.7% Na-Deoxycholate, protease inhibitors (11873580001, Roche)) for 1h at 4°C shaking. Lysates were cleared by centrifugation at 13000g for 15 min at 4°C and protein concentration was measured using Bradford reagent (500-0006, Biorad). 1 mg total protein was used per IP. Samples were pre-cleared by incubation with 25 µl dynabeads, previously blocked in 0.1% BSA, for 1h at 4^oC. Pre-cleared samples were incubated with antibodycoupled dynabeads overnight at 4^oC with shaking. The following day, IPs were washed 3 times with RIPA buffer (50 mM Hepes-KOH, pH 7.5; 500 mM LiCl; 1mM EDTA; 1% NP-40 or Igepal CA-630; 0.7% Na-Deoxycholate) and once with TBS (20 mM Tris-HCl, pH 7.6; 150 mM NaCl) on a magnetic rack and elution was performed in 100 µl elution buffer (25 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% SDS) at 65°C for 30 min. Samples were then used for Western blotting. IgG IP was used as a control.

2.14UV-RIP

The UV-RIP protocol was adapted from (Ule et al., 2005). For Mtr4 RNA IP, cells were UV-crosslinked at 254nm 150mJ/cm² and scraped in ice-cold PBS, supplemented with protease inhibitors (11873580001, Roche) and RNase inhibitors. Pellets were resuspended and lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% Na deoxycholate) for 15 min at 4^oC and sonicated for 8 min (30"ON/30"OFF) at low energy using Bioruptor sonicator (Diagenode). Lysates were pre-cleared and incubated with antibody, as described in section 2.9. IPs were washed twice with High-salt buffer (50 mM Tris-HCl pH 7.4, 1M NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 0.5% Na deoxycholate) and twice in PNK buffer (20 mM Tris-HCl pH 7.4, 10 mM MgCl₂, 0.2% Tween-20) and eluted in elution buffer (25 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% SDS) with

20µg proteinase K (19133, Qiagen) for 1h at 55⁰C. RNA was purified using RNeasy MinElute Cleanup Kit (74204, Qiagen).

2.15 Plasmids and molecular cloning

MRTF-A siRAR cDNA sequence (Pawłowski et al., 2010):

RPEL1

RPEL2

RPEL3

ATGCCCCCTTCCGTCATTGCTGTGAATGGGCTGGACGGAGGAGGGGGCTGGC GAAAATGACGACGAGCCAGTGCTCCTGTCTCTGTCTGCGGCCCCCAGCCCCC AGAGCGAAGCTGTTGCCAATGAACTGCAGGAGCTGTCCCTGCAGCCCGAGCT GACTCTAGGCCTCCATCCTGGGAGGAACCCCCAATTTACCTCCACTTAGTGAGC GGAAGAATGTGCTGCAGTTGAAGCTCCAGCAGCGGCGGACCCGGGAGGAAC **TG**GTGAGCCAAGGGATCATGCCGCCTTTGAAAAGCCCCGCTGCATTTCATGA GCAGAGAAGAAGCCTGGAGCGGGCCAGGACCGAGGACTATTTGAAACGGAA GATCCGTTCCCGGCCCGAGAGAGCAGAGCTGGTCAGGATGCACATTCTGGAA GAGACCTCGGCTGAGCCTTCGCTCCAGGCCAAGCAGCTGAAGCTGAAGAGAGA GCCAGGCTGGCTGATGACCTCAATGAAAAGATTGCACAGAGGCCTGGCCCCA TGGAACTAGTAGAAAAGAATATCCTGCCTGTGGAGTCCAGCCTGAAGGAGGC TATCATTGTGGGCCAGGTAAATTACCCAAAGGTAGCAGACAGTTCCTCCTCG CCAGGGTTCAGTGCCATCACCCTTGGAGTCCCGAGTCAGTGATCCACTGCCC AGTGCCACCTCCATATCACCCACTCAGGTTCTTTCTCAACTCCCAATGGCTCC GGATCCTGGAGAGACGCTTTTTCTGGCAGAGCAGCCTCCTCTGCCTCCCGCA CCTCTGCTGCCCCCAAGCCTAGCCAATGGAAGCATCGTCCCCACTGCCAAGC CTGCTCCCACACTCATCAAGCAAAGCCAACCCAAGTCTGCCAGCGAGAAATC ACAGCGCAGCAAGAAGGCCAAGGAGCTGAAGCCAAAGGTGAAGAAGCTCAA GTACCACCAGTACATCCCCCCGGACCAGAAGCAGGACAAGGGGGGCGCCCGC CATGGACTCCTCCTATGCCAAGATCCTGCAGCAGCAGCAGCTCTTCCTGCAG CTGCAGATCCTCAACCAGCAGCAGCAGCAGCAGCAGCAACAGCACTACAACT ACCAGGCCATCCTGCCTGCCCCCCCAGCCCTCGGCTGAGACTCCTGGAAG CAGTGCCCCTACCCCATCACGCAGCCTCTCCACCAGTAGCAGCCCCAGCTCA GGCACCCCAGGGCCCAGCGGGCTGGCACGCCAGAGCACCGCACTAGCT

GCCAAACCAGGAGCCCTGCCAGCCAACCTGGATGACATGAAGGTGGCAGAG CTGAAGCAAGAACTGAAGTTGCGGTCCCTTCCCGTCTCAGGCACCAAGACAG AGCTGATAGAACGCCTGCGTGCCTACCAAGACCAAGTCAGCCCAGCTCCAGG AGCCCCCAAGGCCCCTGCCACCACCTCTGTGCTGTCCAAGGCTGGTGAGGTA GTGGTCGCCTTCCCTGCGGCCCTGCTAAGCACAGGGTCAGCTCTTGTAACAG CAGGCCTTGCACCAGCTGAGATGGTGGTGGCCACAGTAACCAGCAATGGCAT GGTGAAGTTTGGCAGCACAGGCTCCACACCCCCGTGTCTCCCACCCCTTCA GAGCGCTCACTGCTCAGCACGGGTGATGAGAATTCCACACCTGGGGATGCCT TTGGTGAAATGGTGACATCGCCGCTGACACAGCTCACCCTGCAGGCCTCCCC ACTGCAGATCGTGAAGGAGGAGGGTGCCCGTGCTGCGTCCTGCTGTCTAAGC CCTGGTGCTCGGGCTGAGCTGGAGGGGCTGGACAAGGACCAGATGCTGCAG GAGAAGGACAAGCAGATTGAGGAGCTGACCCGAATGCTCCAACAGAAGCAGC AGCTGGTTGAGCTGCTGCGGCTACAGCTGGAGCAGCAGAAGCGGGCCCAGC AGCCAGCCCCAGCCAGCCCCTGTGAAGAGGGAAAGTGGTTTCTCCAGTTG CCAGCTGAGCTGCCAGCCCCAGGGCTCTGCCCATGCTTTTGGCTCTGGCCTA GTGGTTCCCACTACCAACCATGGAGACACTCAGGCCCCAGCGCCAGAGTCCC CACCTGTGGTGGTGAAGCAGGAAGCTGGGCCACCTGAGCCAGATCTGGCCC CCAGCTCCCAGCTGCTCTTGGGCTCCCAGGGCACCAGCTTCCTCAAGAGGGT CAGCCCTCCTACCCTGGTCACTGACTCTACAGGGACTCACCTCATCCTCACTG TGACCAATAAGAGTGCTGATGGCCCTGGCTTGCCTGCAGGGAGCCCCCAGCA GCCCTTGTCCCAGCCTGGTTCTCCAGCCCCTGGTCCACCTGCCCAGATGGAC CTGGAGCACCCACCTCAGCCTCCGTTTGCAACCCCCACATCTCTGCTGAAGA AGGAGCCCCCTGGTTATGAAGAGACTGTGACCCAGCAGCCTAAGCAGCAGGA AAATGGCTCCTCCAGTCAGCACATGGATGATCTGTTTGATATTCTTATTCAGAG TGGAGAGATTTCAGCAGATTTCAAAGAGCCACCATCCCTACCAGGCAAGGAAA AGTCACCTCCAGCAGCAGCAGCGTATGGGCCTCCATTGACACCACAACCCTC GCCTTTGAGTGAACTCCCCCAAGCTGCTCCTCCACCAGGCTCCCCCACCCTC CCAGGGCGCCTTGAAGACTTCCTGGAGAGCAGCACAGGGCTGCCCCTGCTG ACAAGTGGGCACGAGGGACCAGAACCCCTTTCCCTCATTGATGACCTCCACA GCCAGATGCTGAGCAGCTCCGCCATCCTGGACCACCCCCATCACCCATGGA CACCTCTGAATTGCACTTTGCTCCTGAGCCCAGCAGTGGTATGGGCCTGGAC CTGGCTGTTGGCCACCTGGACAGCATGGACTGGCTGGAGCTGTCGTCTGGTG GCCCTGTGCTCAGCCTGGCTCCCCTCAGCACTGCAGCCCCCAGCCTCTTCTC

GATGGACTTCCTGGATGGACACGACTTGCAGCTCCACTGGGATTCCTGCTTGT AA

MRTF-XXX contains three point-mutations Arginine to Alanine, one in each RPEL motif: RPEL1 (RRTREEL->ARTREEL), RPEL2 (RPERAEL-> APERAEL), RPEL3 (RPGPMEL-> APGPMEL).

<u>SV40 NLS sequence</u>: CCTAAGAAAAAGCGGAAGGTG

HA-tag sequence: TACCCATACGATGTTCCTGACTATGCG

MRTF-A and MRTF-XXX siRAR cDNA, SV40 NLS and HA tag sequences were obtained from Treisman lab plasmids generated by Francesco Gualdrini by PCR using KOD DNA polymerase (71086-3, Millipore) and inserted between XhoI and NotI restriction enzyme sites in the pMY-IRES-GFP vector (RTV-021, Cell Biolabs) using In-fusion cloning system (639647, Takara), according to the manufacturer's protocol.


Stbl3 competent *E.coli* cells (C737303, Thermo Fisher Scientific) were thawed on ice, mixed with DNA and incubated on ice for 30 min. Cells were heat-shocked at 42°C for 45 sec, followed by a 2 min incubation on ice. 250 ul SOC medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) was added and cells were incubated at 37°C shaking for 1h, before plating on agar plates (1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract, 1% w/v NaCl, 1.5% w/v Bacto-agar), supplemented with 100 ug/ml ampicillin (A0166-25G, Sigma), and incubated at 37°C overnight. Bacterial colonies were picked and grown in LB medium (1% w/v Bacto-tryptone, 0.5% w/v Bacto-yeast extract, 1% w/v NaCl), supplemented with 100 ug/ml ampicillin overnight at 37°C shaking. Plasmid mini-preps were done using QIAprep Spin Miniprep Kit (27106, Qiagen) and plasmids were sequenced by the Genomics Equipment park STP.


2.16 List of plasmids


pMY-IRES-GFP lentiviral expression vector (RTV-021, Cell Biolabs) was used to constitutively express MRTF, MRTF-NLS and MRTF-XXX in dKO MEF cells. It expresses the Ampicillin resistance gene for selection in bacteria and EGFP for selection in mammalian cells.

pcDNA6/TR vector (V102520, Thermo Fisher Scientific) was used to generate the Flp-in 3T3 TR cell line. It constitutively expresses the tetracycline repressor protein under a strong CMV promoter, the Ampicillin resistance gene for selection in bacteria and the Blasticidin resistance gene for selection in mammalian cells.

pOG44 plasmid (V6005-20, Thermo Fisher Scientific) expresses the Flp recombinase under a CMV promoter and the Ampicillin resistance gene for selection in bacteria. When co-transfected with pFRT plasmid, containing a gene of interest, into mammalian Flp-in host cell line, it mediates integration of the pFRT vector into the genome via Flp recombination target sites. It was used in combination with pFRT-TO-RPB1 and pFRT-TO-RPB1-S7A plasmids to generate NIH3T3 cells expressing wild-type Rpb1 and Rpb1-S7A mutant.







pFRT-TO-RPB1 and pFRT-TO-RPB1-S7A plasmids express a wild-type Rpb1 and a mutant Rbp1 in which Ser7 is mutated to alanine in all 26 Ser7-containing repeats of the Rpb1 CTD, respectively, under the control of a doxycycline-inducible CMV promoter. In addition, they contain point mutations making them resistant to siRNAs (GTGACGAAATGAATCTTCA and TTATCGAAGTGATTGAAAA). These plasmids were generated by Ana Tufegdzic Vidakovic.

Wild-type Rpb1 cDNA sequence:

CTD repeats are numbered and Ser7-containing repeats are highlighted in yellow.

GCATGCACGGGGGTGGCCCCCCCCCGGGGGGACAGCGCATGCCCGCTGCGC ACCATCAAGAGAGTCCAGTTCGGAGTCCTGAGTCCGGATGAACTGAAGCGAA CTGGCCGCTGCCAAACATGTGCAGGAAACATGACAGAGTGTCCTGGCCACTT TGGCCACATTGAACTGGCCAAGCCTGTGTTTCACGTGGGCTTCCTGGTGAAG ACAATGAAAGTTTTGCGCTGTGTCTGCTTCTTCTGCTCCAAACTGCTTGTGGA CTCTAACAACCCAAAGATCAAGGATATCCTGGCTAAGTCCAAGGGACAGCCCA AGAAGCGGCTCACACATGTCTACGACCTTTGCAAGGGCAAAAACATATGCGA GGGTGGGGGGGGGGGGGGGGGGCAACAACTCGGTGGGAACAACCTGAGGGTGA CGAGGATCTGACCAAAGAAAAGGGCCATGGTGGCTGTGGGCGGTACCAGCC CAGGATCCGGCGTTCTGGCCTAGAGCTGTATGCGGAATGGAAGCACGTTAAT GAGGACTCTCAGGAGAAGAAGATCCTGCTGAGTCCAGAGCGAGTGCATGAGA TCTTCAAACGCATCTCAGATGAGGAGTGTTTTGTGCTGGGCATGGAGCCCCG CTATGCACGGCCAGAGTGGATGATTGTCACAGTGCTGCCTGTGCCCCCGCTC TCCGTGCGGCCTGCTGTTGTGATGCAGGGCTCTGCCCGTAACCAGGATGACC TGACTCACAAACTGGCTGACATCGTGAAGATCAACAATCAGCTGCGGCGCAAT GAGCAGAACGGCGCAGCGGCCCATGTCATTGCAGAGGATGTGAAGCTCCTC CAGTTCCATGTGGCCACCATGGTGGACAATGAGCTGCCTGGCTTGCCCCGTG CCATGCAGAAGTCTGGGCGTCCCCTCAAGTCCCTGAAGCAGCGGTTGAAGGG CAAGGAAGGCCGGGTGCGAGGGAACCTGATGGGCAAAAGAGTGGACTTCTC GGCCCGTACTGTCATCACCCCCGACCCCAACCTCTCCATTGACCAGGTTGGC GTGCCCCGCTCCATTGCTGCCAACATGACCTTTGCGGAGATTGTCACCCCCTT

CAACATTGACAGACTTCAAGAACTAGTGCGCAGGGGGAACAGCCAGTACCCA GGCGCCAAGTACATCCTCCGAGACAATGGTGATCGCATTGACTTGCGTTTCCA CCCCAAGCCCAGTGACCTTCACCTGCAGACCGGCTATAAGGTGGAACGGCAC ATGTGTGATGGGGGACATTGTTATCTTCAACCGGCAGCCAACTCTGCACAAAAT GTCCATGATGGGGCATCGGGTCCGCATTCTCCCATGGTCTACCTTTCGCTTGA ATCTTAGTGTGACAACTCCGTACAATGCAGACTTTGACGGTGACGAAATGAAT CTTCACCTGCCACAGTCTCTGGAGACGCGAGCAGAGATCCAGGAGCTGGCCA TGGTTCCTCGCATGATTGTCACCCCCCAGAGCAATCGGCCTGTCATGGGTATT GTGCAGGACACACTCACAGCAGTGCGCAAATTCACCAAGAGAGACGTCTTCC TGGAGCGGGGTGAAGTGATGAACCTCCTGATGTTCCTGTCGACGTGGGATGG GAAGGTCCCACAGCCGGCCATCCTAAAGCCCCGGCCCCTGTGGACAGGCAA GCAAATCTTCTCCCTCATCATACCTGGTCACATCAATTGTATCCGTACCCACAG CACCCATCCCGATGATGAAGACAGTGGCCCTTACAAGCACATCTCTCCTGGG GACACCAAGGTGGTGGTGGAGAATGGGGAGCTGATCATGGGCATCCTGTGTA GATGGGTCATGACATCACTCGCCTCTTCTACTCCAACATTCAGACTGTCATTAA CAACTGGCTCCTCATCGAGGGTCATACTATTGGCATTGGGGACTCCATTGCTG ATTCTAAGACTTACCAGGACATTCAGAACACTATTAAGAAGGCCAAGCAGGAC GTTATCGAAGTGATTGAAAAGGCACACAACAATGAGCTGGAGCCCACCCCAG GGAACACTCTGCGGCAGACGTTTGAGAATCAGGTGAACCGCATTCTTAACGAT GCCCGAGACAAGACTGGCTCCTCTGCTCAGAAATCCCTGTCTGAATACAACAA CTTCAAGTCTATGGTCGTGTCCGGAGCTAAAGGTTCCAAGATTAACATCTCCC AGGTCATTGCTGTCGTTGGACAGCAGAACGTCGAGGGCAAGCGGATTCCATT TGGCTTCAAGCACCGGACTCTGCCTCACTTCATCAAGGATGACTACGGGCCT GAGAGCCGTGGCTTTGTGGAGAACTCCTACCTAGCCGGCCTCACACCCACTG AGTTCTTTTTCCACGCCATGGGGGGGCTCGTGAGGGGCTCATTGACACGGCTGT CAAGACTGCTGAGACTGGATACATCCAGCGGCGGCTGATCAAGTCCATGGAG TCAGTGATGGTGAAGTACGACGCGACTGTGCGGAACTCCATCAACCAGGTGG TGCAGCTGCGCTACGGCGAAGACGGCCTGGCAGGCGAGAGCGTTGAGTTCC AGAACCTGGCTACGCTTAAGCCTTCCAACAAGGCTTTTGAGAAGAAGTTCCGC TTTGATTATACCAATGAGAGGGCCCTGCGGCGCACTCTGCAGGAGGACCTGG TGAAGGACGTGCTGAGCAACGCACACATCCAGAACGAGTTGGAGCGGGAATT TGAGCGGATGCGGGAGGATCGGGAGGTGCTCAGGGTCATCTTCCCAACTGG AGACAGCAAGGTCGTCCTCCCCTGTAACCTGCTGCGGATGATCTGGAATGCT

CAGAAAATCTTCCACATCAACCCACGCCTTCCCTCCGACCTGCACCCCATCAA AGTGGTGGAGGGAGTCAAGGAATTGAGCAAGAAGCTGGTGATTGTGAATGGG GATGACCCACTAAGTCGACAGGCCCAGGAAAATGCCACGCTGCTCTTCAACA TCCACCTGCGGTCCACGTTGTGTTCCCGCCGCATGGCAGAGGAGTTTCGGCT CAGTGGGGAGGCCTTCGACTGGCTGCTTGGGGAGATTGAGTCCAAGTTCAAC CAAGCCATTGCGCATCCCGGGGGAAATGGTGGGGGGCTCTGGCTGCGCAGTCC CTTGGAGAACCTGCCACCCAGATGACCTTGAATACCTTCCACTATGCTGGTGT GTCTGCCAAGAATGTGACGCTGGGTGTGCCCCGACTTAAGGAGCTCATCAAC ATTTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTC CGCTCGTGATGCTGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCATACA ACGTTGAGGAAGGTGACTGCCAACACAGCCATCTACTATGACCCCCAACCCCC AGAGCACGGTGGTGGCAGAGGATCAGGAATGGGTGAATGTCTACTATGAAAT GCCTGACTTTGATGTGGCCCGAATCTCCCCCTGGCTGTTGCGGGTGGAGCTG GATCGGAAGCACATGACTGACCGGAAGCTCACCATGGAGCAGATTGCTGAAA AGATCAATGCTGGTTTTGGTGACGACTTGAACTGCATCTTTAATGATGACAATG CAGAGAAGCTGGTGCTCCGTATTCGCATCATGAACAGTGATGAGAACAAGAT GCAAGAAGAGGAAGAGGTGGTGGACAAGATGGATGATGATGTCTTCCTGCGC TGCATCGAGTCCAACATGCTGACAGATATGACCCTGCAGGGCATCGAGCAGA TCAGCAAGGTGTACATGCACTTGCCACAGACAGACAAGAAGAAGATCATC ATCACGGAGGATGGGGAATTCAAGGCCCTGCAGGAGTGGATCCTGGAGACG GACGGCGTGAGCTTGATGCGGGTGCTGTCAGAGAAAGACGTGGATCCAGTAC GCACAACGTCGAATGACATTGTGGAGATCTTCACGGTGCTGGGCATTGAAGC CGTGCGGAAGGCCCTGGAGCGGGAGCTGTACCACGTCATCTCCTTTGATGGC TCCTATGTCAATTACCGACACTTGGCTCTCTTGTGTGATACCATGACCTGTCGT GGCCACTTGATGGCCATCACCCGACACGGAGTCAACCGCCAGGACACAGGA CCACTCATGAAGTGTTCCTTTGAGGAAACGGTGGACGTGCTTATGGAAGCAG CCGCACACGGTGAGAGTGACCCCATGAAGGGGGGTCTCTGAGAATATCATGCT GGGCCAGCTGGCTCCGGCCGGCACTGGCTGCTTTGACCTCCTGCTTGATGCA GAGAAGTGCAAGTATGGCATGGAGATCCCCACCAATATCCCCGGCCTGGGGG CTGCTGGACCCACCGGCATGTTCTTTGGTTCAGCACCCAGTCCCATGGGTGG AATCTCTCCTGCCATGACACCTTGGAACCAGGGTGCAACCCCTGCCTATGGC GCCTGGTCCCCCAGTGTTGGGAGTGGAATGACCCCAGGGGCAGCCGGCTTC TCTCCCAGTGCTGCGTCAGATGCCAGCGGCTTCAGCCCAGGTTACTCCCCTG

CCTGGTCTCCCACACCGGGGCTCCCCGGGGGTCCCCCAGGTCCCTCAAGCCCCT ACATCCCTTCACCAGGTGGTGCCATGTCTCCCAGC 1 TACTCGCCAACGTCACCTGCC 2 TACGAGCCCCGCTCTCCTGGGGGGC 3 TACACACCCCAGAGTCCCTCT 4 TATTCCCCCACTTCACCCTCC 5 TACTCCCCTACCTCTCCATCC 6 TATTCTCCAACCAGTCCCAAC 7 TATAGTCCCACATCACCCAGC 8 TATTCGCCAACGTCACCCAGC 9 TACTCACCGACCTCTCCCAGC 10 TACTCACCCACCTCTCCCAGC 11 TACTCGCCCACCTCTCCCAGC 12 TACTCGCCCACCTCTCCCAGC 13 TACTCACCCACTTCCCCAGCC 14 TACTCGCCCACTTCCCCTAGC 15 TACTCGCCAACGTCTCCCAGC **16 TACTCGCCGACATCTCCCAGC** 17 TACTCGCCAACTTCACCCAGC **18 TATTCTCCCACTTCTCCCAGC 19 TACTCACCTACCTCTCCAAGC** 20 TATTCACCCACCTCCCCAGC 21 TACTCACCCACTTCCCCAAGT 22 TACTCACCCACCAGCCCGAAC 23 TATTCTCCAACCAGTCCCAAT 24 TACACCCCAACATCACCCAGC 25 TACAGCCCGACATCACCCAGC 26 TATTCACCTACTAGTCCCAAC 27 TACACACCTACCAGCCCTAAC 28 TACAGCCCAACCTCTCCAAGC 29 TACTCTCCAACATCACCCAGC 30 TATTCCCCGACCTCACCAAGT 31 TACTCCCCTTCCAGCCCACGA 32 TACACACCACAGTCTCCAACC

33 TATACCCCAAGCTCACCCAGC

34 TACAGCCCCAGCTCGCCCAGC

35 TACAGCCCAACCTCACCCAAG

36 TACACCCCAACCAGTCCTTCT

37 TACAGTCCCAGCTCCCCAGAG

38 TATACCCCAACCTCTCCCAAG

39 TACTCACCTACCAGTCCCAAA

40 TATTCACCCACCTCTCCCAAG

41 TACTCGCCTACCAGTCCCACC

42 TATTCACCCACCACCCCAAAA

43 TACTCCCCAACATCTCCTACT

44 TATTCCCCAACCTCTCCAGTC

45 TACACCCCAACCTCTCCCAAG

- 46 TACTCACCTACTAGCCCCACT
- 47 TACTCGCCCACTTCCCCCAAG
- 48 TACTCGCCCACCAGCCCCACC
- 49 TACTCGCCCACCTCCCCAAAGGCTCAACC
- 50 TACTCTCCCACTTCCCCTGGT
- 51 TACTCGCCCACCAGCCCCACC

52TACAGTCTCACAAGCCCGGCTATCAGCCCGGATGACAGTGACGAGGAGAA CTGA

S7A-Rpb1 cDNA sequence:

CTD repeats are numbered and Ser7-containing repeats are highlighted in yellow. Ser7 to Ala mutations are in red.

CTCTAACAACCCAAAGATCAAGGATATCCTGGCTAAGTCCAAGGGACAGCCCA AGAAGCGGCTCACACATGTCTACGACCTTTGCAAGGGCAAAAACATATGCGA GGGTGGGGGGGGGGGGGGGGGGCAACAACTCGGTGTGGGACAACCTGAGGGTGA CGAGGATCTGACCAAAGAAAAGGGCCATGGTGGCTGTGGGCGGTACCAGCC CAGGATCCGGCGTTCTGGCCTAGAGCTGTATGCGGAATGGAAGCACGTTAAT GAGGACTCTCAGGAGAAGAAGATCCTGCTGAGTCCAGAGCGAGTGCATGAGA TCTTCAAACGCATCTCAGATGAGGAGTGTTTTGTGCTGGGCATGGAGCCCCG CTATGCACGGCCAGAGTGGATGATTGTCACAGTGCTGCCTGTGCCCCGCTC TCCGTGCGGCCTGCTGTTGTGATGCAGGGCTCTGCCCGTAACCAGGATGACC TGACTCACAAACTGGCTGACATCGTGAAGATCAACAATCAGCTGCGGCGCAAT GAGCAGAACGGCGCAGCGGCCCATGTCATTGCAGAGGATGTGAAGCTCCTC CAGTTCCATGTGGCCACCATGGTGGACAATGAGCTGCCTGGCTTGCCCCGTG CCATGCAGAAGTCTGGGCGTCCCCTCAAGTCCCTGAAGCAGCGGTTGAAGGG CAAGGAAGGCCGGGTGCGAGGGAACCTGATGGGCAAAAGAGTGGACTTCTC GGCCCGTACTGTCATCACCCCCGACCCCAACCTCTCCATTGACCAGGTTGGC GTGCCCCGCTCCATTGCTGCCAACATGACCTTTGCGGAGATTGTCACCCCCTT CAACATTGACAGACTTCAAGAACTAGTGCGCAGGGGGAACAGCCAGTACCCA GGCGCCAAGTACATCCTCCGAGACAATGGTGATCGCATTGACTTGCGTTTCCA CCCCAAGCCCAGTGACCTTCACCTGCAGACCGGCTATAAGGTGGAACGGCAC ATGTGTGATGGGGGACATTGTTATCTTCAACCGGCAGCCAACTCTGCACAAAAT GTCCATGATGGGGGCATCGGGTCCGCATTCTCCCATGGTCTACCTTTCGCTTGA ATCTTAGTGTGACAACTCCGTACAATGCAGACTTTGACGGTGACGAAATGAAT CTTCACCTGCCACAGTCTCTGGAGACGCGAGCAGAGATCCAGGAGCTGGCCA TGGTTCCTCGCATGATTGTCACCCCCCAGAGCAATCGGCCTGTCATGGGTATT GTGCAGGACACACTCACAGCAGTGCGCAAATTCACCAAGAGAGACGTCTTCC TGGAGCGGGGTGAAGTGATGAACCTCCTGATGTTCCTGTCGACGTGGGATGG GAAGGTCCCACAGCCGGCCATCCTAAAGCCCCGGCCCCTGTGGACAGGCAA GCAAATCTTCTCCCTCATCATACCTGGTCACATCAATTGTATCCGTACCCACAG CACCCATCCCGATGATGAAGACAGTGGCCCTTACAAGCACATCTCTCCTGGG GACACCAAGGTGGTGGTGGAGAATGGGGGGGGCTGATCATGGGCATCCTGTGTA GATGGGTCATGACATCACTCGCCTCTTCTACTCCAACATTCAGACTGTCATTAA CAACTGGCTCCTCATCGAGGGTCATACTATTGGCATTGGGGACTCCATTGCTG ATTCTAAGACTTACCAGGACATTCAGAACACTATTAAGAAGGCCAAGCAGGAC

GTTATCGAAGTGATTGAAAAGGCACACAACAATGAGCTGGAGCCCACCCCAG GGAACACTCTGCGGCAGACGTTTGAGAATCAGGTGAACCGCATTCTTAACGAT GCCCGAGACAAGACTGGCTCCTCTGCTCAGAAATCCCTGTCTGAATACAACAA CTTCAAGTCTATGGTCGTGTCCGGAGCTAAAGGTTCCAAGATTAACATCTCCC AGGTCATTGCTGTCGTTGGACAGCAGAACGTCGAGGGCAAGCGGATTCCATT TGGCTTCAAGCACCGGACTCTGCCTCACTTCATCAAGGATGACTACGGGCCT GAGAGCCGTGGCTTTGTGGAGAACTCCTACCTAGCCGGCCTCACACCCACTG AGTTCTTTTTCCACGCCATGGGGGGGTCGTGAGGGGCTCATTGACACGGCTGT CAAGACTGCTGAGACTGGATACATCCAGCGGCGGCTGATCAAGTCCATGGAG TCAGTGATGGTGAAGTACGACGCGACTGTGCGGAACTCCATCAACCAGGTGG TGCAGCTGCGCTACGGCGAAGACGGCCTGGCAGGCGAGAGCGTTGAGTTCC AGAACCTGGCTACGCTTAAGCCTTCCAACAAGGCTTTTGAGAAGAAGTTCCGC TTTGATTATACCAATGAGAGGGCCCTGCGGCGCACTCTGCAGGAGGACCTGG TGAAGGACGTGCTGAGCAACGCACACATCCAGAACGAGTTGGAGCGGGAATT TGAGCGGATGCGGGAGGATCGGGAGGTGCTCAGGGTCATCTTCCCAACTGG AGACAGCAAGGTCGTCCTCCCCTGTAACCTGCTGCGGATGATCTGGAATGCT CAGAAAATCTTCCACATCAACCCACGCCTTCCCTCCGACCTGCACCCCATCAA AGTGGTGGAGGGAGTCAAGGAATTGAGCAAGAAGCTGGTGATTGTGAATGGG GATGACCCACTAAGTCGACAGGCCCAGGAAAATGCCACGCTGCTCTTCAACA TCCACCTGCGGTCCACGTTGTGTTCCCGCCGCATGGCAGAGGAGTTTCGGCT CAGTGGGGGGGCCTTCGACTGGCTGCTTGGGGGGGGAGATTGAGTCCAAGTTCAAC CAAGCCATTGCGCATCCCGGGGGAAATGGTGGGGGGCTCTGGCTGCGCAGTCC CTTGGAGAACCTGCCACCCAGATGACCTTGAATACCTTCCACTATGCTGGTGT GTCTGCCAAGAATGTGACGCTGGGTGTGCCCCGACTTAAGGAGCTCATCAAC ATTTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTC CGCTCGTGATGCTGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCATACA ACGTTGAGGAAGGTGACTGCCAACACAGCCATCTACTATGACCCCCAACCCCC AGAGCACGGTGGTGGCAGAGGATCAGGAATGGGTGAATGTCTACTATGAAAT GCCTGACTTTGATGTGGCCCGAATCTCCCCCTGGCTGTTGCGGGTGGAGCTG GATCGGAAGCACATGACTGACCGGAAGCTCACCATGGAGCAGATTGCTGAAA AGATCAATGCTGGTTTTGGTGACGACTTGAACTGCATCTTTAATGATGACAATG CAGAGAAGCTGGTGCTCCGTATTCGCATCATGAACAGTGATGAGAACAAGAT GCAAGAAGAGGAAGAGGTGGTGGACAAGATGGATGATGATGTCTTCCTGCGC TGCATCGAGTCCAACATGCTGACAGATATGACCCTGCAGGGCATCGAGCAGA

TCAGCAAGGTGTACATGCACTTGCCACAGACAGACAAGAAGAAGATCATC ATCACGGAGGATGGGGAATTCAAGGCCCTGCAGGAGTGGATCCTGGAGACG GACGGCGTGAGCTTGATGCGGGTGCTGTCAGAGAAAGACGTGGATCCAGTAC GCACAACGTCGAATGACATTGTGGAGATCTTCACGGTGCTGGGCATTGAAGC CGTGCGGAAGGCCCTGGAGCGGGAGCTGTACCACGTCATCTCCTTTGATGGC TCCTATGTCAATTACCGACACTTGGCTCTCTTGTGTGATACCATGACCTGTCGT GGCCACTTGATGGCCATCACCCGACACGGAGTCAACCGCCAGGACACAGGA CCACTCATGAAGTGTTCCTTTGAGGAAACGGTGGACGTGCTTATGGAAGCAG CCGCACACGGTGAGAGTGACCCCATGAAGGGGGGTCTCTGAGAATATCATGCT GGGCCAGCTGGCTCCGGCCGGCACTGGCTGCTTTGACCTCCTGCTTGATGCA GAGAAGTGCAAGTATGGCATGGAGATCCCCACCAATATCCCCGGCCTGGGGG CTGCTGGACCCACCGGCATGTTCTTTGGTTCAGCACCCAGTCCCATGGGTGG AATCTCTCCTGCCATGACACCTTGGAACCAGGGTGCAACCCCTGCCTATGGC GCCTGGTCCCCCAGTGTTGGGAGTGGAATGACCCCAGGGGCAGCCGGCTTC TCTCCCAGTGCTGCGTCAGATGCCAGCGGCTTCAGCCCAGGTTACTCCCCTG CCTGGTCTCCCACACCGGGGTCCCCGGGGTCCCCAGGTCCCTCAAGCCCCT ACATCCCTTCACCAGGTGGTGCCATGTCTCCCAGC

1 TACTCGCCAACGTCACCTGCC

2 TACGAGCCCCGCTCTCCTGGGGGC

3 TACACACCCCAGAGTCCCGCT

4 TATTCCCCCACTTCACCCGCC

5 TACTCCCCTACCTCTCCAGCC

6 TATTCTCCAACCAGTCCCAAC

7 TATAGTCCCACATCACCCGCC

8 TATTCGCCAACGTCACCCGCC

9 TACTCACCGACCTCTCCCGCC

10 TACTCACCCACCTCTCCCGCC

11 TACTCGCCCACCTCTCCCGCC

12 TACTCGCCCACCTCTCCCGCC

13 TACTCACCCACTTCCCCAGCC

14 TACTCGCCCACTTCCCCTAGC

15 TACTCGCCAACGTCTCCCAGC


16 TACTCGCCGACATCTCCCGCC

17 TACTCGCCAACTTCACCCGCC

18 TATTCTCCCACTTCTCCCGCC 19 TACTCACCTACCTCTCCAGCC 20 TATTCACCCACCTCCCCCGCC 21 TACTCACCCACTTCCCCAGCA 22 TACTCACCCACCAGCCCGAAC 23 TATTCTCCAACCAGTCCCAAT 24 TACACCCCAACATCACCCGCC 25 TACAGCCCGACATCACCCGCC 26 TATTCACCTACTAGTCCCAAC 27 TACACACCTACCAGCCCTAAC 28 TACAGCCCAACCTCTCCAGCC 29 TACTCTCCAACATCACCCGCC 30 TATTCCCCGACCTCACCAGCA 31 TACTCCCCTTCCAGCCCACGA 32 TACACACCACAGTCTCCAACC 33 TATACCCCAAGCTCACCCGCC 34 TACAGCCCCAGCTCGCCCGCC 35 TACAGCCCAACCTCACCCAAG 36 TACACCCCAACCAGTCCTGCT 37 TACAGTCCCAGCTCCCCAGAG 38 TATACCCCAACCTCTCCCAAG 39 TACTCACCTACCAGTCCCAAA 40 TATTCACCCACCTCTCCCAAG 41 TACTCGCCTACCAGTCCCACC 42 TATTCACCCACCACCCAAAA 43 TACTCCCCAACATCTCCTACT 44 TATTCCCCAACCTCTCCAGTC 45 TACACCCCAACCTCTCCCAAG **46 TACTCACCTACTAGCCCCACT** 47 TACTCGCCCACTTCCCCCAAG 48 TACTCGCCCACCAGCCCCACC 49 TACTCGCCCACCTCCCCCAAAGGCTCAACC 50 TACTCTCCCACTTCCCCTGGT 51 TACTCGCCCACCAGCCCCACC

52TACAGTCTCACAAGCCCGGCTATCAGCCCGGATGACAGTGACGAGGAGAA CTGA

For lentivirus production in Phoenix cells, pCMV-VSV-G and psPAX2 plasmids were used. pCMV-VSV-G plasmid (631530, Clonetech) expresses the G glycoprotein of the vesicular stomatitis virus (VSV-G), which mediates fusion of viral and cellular membranes, under the control of the CMV promoter. It expresses the Ampicillin resistance gene for selection in bacteria. psPAX2 (12260, Addgene) is a lentiviral packaging plasmid. It expresses the Ampicillin resistance gene for selection in bacteria.



2.17 Stable cell line generation

MRTF-A/MRTF-B knock-out MEF cells reconstituted with wild-type MRTF-A (dKO^{MRTF}), MRTF fused to an additional NLS (dKO^{MRTF-NLS}) or MRTF harbouring point mutations in its RPEL domain (dKO^{MRTF-XXX}) were generated through lentiviral infection. MEF cells with the genotype MRTF-A^{-/-}, MRTF-B^{fl/fl}, 6-Gt(Rosa)26Sor^{tm9(cre/ESR1)Arte} were seeded at 25% confluence and treated with 1 μ M tamoxifen to achieve MRTF-B knock-out and simultaneously infected with virus, containing MRTF-A-expressing plasmids.

Phoenix cells were transfected with 0.6 μ g pCMV-VSV-G plasmid, 3 μ g psPAX2 plasmid and 6 μ g pMY-MRTF, pMY-MRTF-NLS, pMY-MRTF-XXX or pMY plasmid, using Fugene transfection reagent (E2311, Promega), as described in section 2.4. Transfected cells were incubated overnight at 37°C, 5% CO₂. 24h post-transfection, media was aspirated and replaced with fresh DMEM, supplemented with 10% FBS. Virus was harvested 48h post-transfection. Viral supernatant was centrifuged at 500g for 5 min, filtered through a 0.45 um PES filter, diluted 1:4 in DMEM, mixed with polybrene at 10 μ g/ml and used to infect MEF cells. Three consecutive infections 24h apart were carried out. Cells were expanded, genotyped to confirm MRTF-B knock-out and FACS sorted to select GFP-positive cells. MRTF protein levels were assessed by Western blot. Cell sorting by FACS was performed by the staff at the FACS STP.

Flp-in NIH3T3 cells (R76107, Invitrogen) were transfected with 3 μ g pCDNA6/TR plasmid using Fugene, as described in section 2.4. Cells expressing the Tet repressor were selected using blasticidin at 3 μ g/ml and zeocin at 100 μ g/ml to generate Flp-in TR cells. Flp-in TR cells were co-transfected with 4.5 μ g pOG44 and 500 ng pFRT-Rpb1-TO or pFRT-S7A-TO plasmids using Fugene, as described in section 2.4. Transfected cells were selected using 100 μ g/ml hygromycin and 3 μ g/ml blasticidin. Clonal Flp-in TR-Rbp1 and Flp-in-TR-S7A lines were generated by expanding colonies from single cells in a 96-well plate. Cells sensitivity to zeocin was tested and inducibility of expression of the Rpb1 or S7A-Rbp1 was tested by Western blot.

2.18 Genotyping

Genomic DNA extraction was performed using DNeasy Blood and Tissue Kit (69506, Qiagen), according to the manufacturer's instructions. Genotyping PCR reactions were set up using BIOTAQ DNA polymerase (BIO-21040, Bioline) as follows: 100 ng genomic DNA, 0.2 μ M primer, 5 units BIOTAQ polymerase, 1X BIOTAQ buffer, 200 μ M dNTPs, 3 mM MgCl₂ in a total volume of 50 ul. For MRTF-A genotyping, primers GT5, GT6 and IacZ3-Q8 were used with following cycling conditions: 94°C 5 min - 30x (94°C 30 sec – 57°C 30 sec – 72°C 1 min) – 72°C 10 min – 4°C. For a wild-type MRTF-A allele a fragment of 600 bp is generated by primers GT5 and GT6, while a fragment of 350 bp is generated by primers GT5 and GT6, while a fragment of 350 bp is generated by primers GT5 and SAR were used with the following cycling conditions: 94°C 5 min - 30x (94°C 10 min – 4°C. For a wild-type MRTF-A allele. For MRTF-B primers LAF, EXR and SAR were used with the following cycling conditions: 94°C 5 min - 30x (94°C 30 sec – 70°C 30 sec – 72°C 1 min) – 72°C 10 min – 4°C. For a wild-type MRTF-B allele, a fragment of 460 bp is generated by primers LAF and EXR, a fragment of 570 bp is generated by primers LAF and EXR for the loxP allele and a fragment of 360 bp is generated by primers LAF and SAR for the knock-out allele.

2.19 List of primers

Genotyping primers	Sequence
GT5	GTTGCTCAGTCATGTGACACCTGTACAG
GT6	GGCTTCAGTACCTTCCTAAGCTCTGCAG
lacZ3-Q8	CATGGTGGATCCTGAGACTGGCGAATTC
EXR	GGCTTAGACAAGATGGTTGGTCTGGCACTGC
LAF	CCAGTGGTGTCCAGTCTTACTGAACAGCTCACTCAG
SAR	CATGGCGACTTCCTTCTCCTCTTCTCAAGGCTG

ChIP primersSequenceActa2(-1kb) FPCCTGCAAGCCAAGGTTCTGAActa2(-1kb) RPGCACTCCCAGAATCCATCCAActa2(-0.3kb) FPGAGGCCTGGGTCTCTTCCAActa2(-0.3kb) RPGCTGAGCTGCCTCCTGTTTCActa2(TSS) FPCATTCAGATTCCCACAGACAATGActa2(TSS) RPTCGAGTTTTCCCAGGCTCTTTActa2(2.8kb) FPCCCACGATGGATGGGAAAActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) RPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(-0.3kb) FPGAGGCCTGGGTCTCTTCCAActa2(-0.3kb) RPGCTGAGCTGCCTCCTGTTTCActa2(TSS) FPCATTCAGATTCCCACAGACAATGActa2(TSS) RPTCGAGTTTTCCCAGGCTCTTTActa2(2.8kb) FPCCCACGATGGATGGGAAAActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(-0.3kb) RPGCTGAGCTGCCTCCTGTTTCActa2(TSS) FPCATTCAGATTCCCACAGACAATGActa2(TSS) RPTCGAGTTTTCCCAGGCTCTTTActa2(2.8kb) FPCCCACGATGGATGGGAAAActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(-0.3kb) RPGCTGAGCTGCCTCCTGTTTCActa2(TSS) FPCATTCAGATTCCCACAGACAATGActa2(TSS) RPTCGAGTTTTCCCAGGCTCTTTActa2(2.8kb) FPCCCACGATGGATGGGAAAActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(TSS) RPTCGAGTTTTCCCAGGCTCTTTActa2(2.8kb) FPCCCACGATGGATGGGAAAActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(2.8kb) FPCCCACGATGGATGGGAAAActa2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(2.8kb) RPCGGCTTCGCTGGTGATGActa2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(6.6kb) FPAGAGGAGCGTGGTAATCTGTTCTTActa2(6.6kb) RPGAACATCCCTGTCCCTTTCCA	
Acta2(6.6kb) RP GAACATCCCTGTCCCTTTCCA	
Acta2(12.3kb) FP ACTGGACCCCTGAGTTTCACA	
Acta2(12.3kb) RP GGCAAGCCTCAATTCTCCAA	
Acta2(14.1kb) FP ATACGCAAGGCTTGATGCAA	
Acta2(14.1kb) RP AAGCATACACACGTGCATGGA	
Acta2(16.3kb) FP CCGTATTTGAATCTGCAACATTCT	
Acta2(16.3) RP TATAACACAAGAGCAAATGGCTGAA	
Actb (-1kb) FP TCCCCTCACCTAAGTACCAG	
Actb (-1kb) RP CTGACCCCGTGTGTAGCTC	
Actb FP GCCGCCGGGTTTTATAGG	
Actb RP CGTTCCGAAAGTTGCCTTTTA	
Actb (TSS) FP AGGAGCTGCAAAGAAGCTGT	
Actb (TSS) RP CCGCTGTGGCGTCCTATAAA	
Actb (1Kb) FP GGCTTTGCACATGCCGGA	
Actb (1Kb) RP CTTTTGTGTCTTGATAGTTCGCCA	
Actb (2Kb) FP CGGAGTCCATCACAATGCCT	
Actb (2Kb) RP GCCATGTACGTAGCCATCCA	
Actb (3.1kb) FP GCCTTCACCGTTCCAGTTTT	
Actb (3.1kb) RP TGAGCTGCGTTTTACACCCT	
Actb (4.1kb) FP GTCCAAGGATCACGACTGACA	
Actb (4.1kb) RP CATCCTGGAAATCAGCCCCT	
Actg1 FP AACGCGGTGCACGAGAAG	
Actg1 RP TCACACTGCCCAGTTGCAA	
Col1a1 FP CCAGGAGGGCATATGGAAGA	
Col1a1 RP GTCCTCAGCCCCTTATTTGGT	
Mir145-143 FP CCTTGCCCGTGGCTCTCT	
Mir145-143 RP AGGCTCGTTTCTTCAGCTCATATAA	
FilaminA FP TGAGCTCAGCGCTCTGTGAA	
FilaminA RP GCTCTGGAGGTGAGCCCTACT	
Zfp37 FP CCAGCAATGTGTGACTTGGATC	

Zfp37 RP	TATTTCGAGCGCTGTGGCA
Vcl (-1kb) FP	CGAGGTCCCCTCTCTGG
Vcl (-1kb) RP	TCCGCAGGATCACCTCAGTA
Vcl (TSS) FP	GAGGGAAGCCCGGACTCTA
Vcl (TSS) RP	AAAACTGGGATCCGTAGGGC
Vcl (40kb) FP	AGGTGCTACCAGGTTTCACTAA
Vcl (40kb) RP	ACCATTCACTGGCTTCGAGT
Vcl (104kb) FP	CGTGAACACTAGCCGGAAGC
Vcl (104kb) RP	AAAGGGAGTTGGTGAACCGT
Vcl (106kb) FP	ATTCCGAGGTTAGGCTTGGC
Vcl (106kb) RP	TTGGGCTTAGCCAGGAACTT

Expression primers	Sequence
Gadph FP	TCTTGTGCAGTGCCAGCCT
Gadph RP	CAATATGGCCAAATCCGTTCA
Ctgf Intron FP	GCTCCTCGCTCTCTGCAC
Ctgf Intron RP	TGTGATCGCAGCTCACTCTG
Ctgf Exon FP	GGAGGAAAACATTAAGAAGGGCAA
Ctgf Exon RP	AACTTGACAGGCTTGGCGAT
Vcl Intron FP	CGTCACTTGCGTTGAGTACC
Vcl Intron RP	GAAACCACCCACAGGTTGGA
Vcl Exon FP	ACGGCTCTAGGGGAATCCTT
Vcl Exon RP	TTACGAACCTCAGCCTCATCG
Srf Intron FP	TCAAGGCAGCAGCAGTTTCT
Srf Intron RP	CAGGCAGGGTTAGGAACCAG
Srf Exon FP	TGAAGAAGGCCTATGAGCTGTC
Srf Exon RP	ACACATGGCCTGTCTCACTG
Acta2 Intron FP	CCAGAAGCAATGCGTCCACT
Acta2 Intron RP	TGAGGTAGTTGCCTGCTCTC
Acta2 Exon FP	CTGTCAGGAACCCTGAGACGC
Acta2 Exon RP	GGCTGTGCTGTCTTCCTCTT
Cyr61 Intron FP	CGTAAACTGCCCTGAGCCTA
Cyr61 Intron RP	GACGCGATCGAGACACTTCT
Cyr61 Exon FP	ATCGCAATTGGAAAAGGCAGC
Cyr61 Exon RP	GGTGCCAAAGACAGGAAGCCT
Actb Intron FP	CGTAGCGTCTGGTTCCCAAT

A eth listres DD	0T0T0000ATTT0AT0A000
Actb Intron RP	GTGTGGGCATTTGATGAGCC
Actb Exon FP	CGCCACCAGTTCGCCAT
Actb Exon RP	CTTTGCACATGCCGGAGC
Egr1 Intron FP	TGATGTCTCCGCTGCAGATC
Egr1 Intron RP	GGTGGGTGAGTGAGGAAAGG
Egr1 Exon FP	ATTGATGTCTCCGCTGCAGATC
Egr1 Exon RP	TCAGCAGCATCATCTCCTCCA
Fos Intron FP	GCATGGGCTCTCCTGTCAA
Fos Intron RP	GACCTGGCGGCTACACAAA
Fos Exon FP	TTCCTACTACCATTCCCCAGCC
Fos Exon RP	GATCTGCGCAAAAGTCCTGTG
B2m Intron FP	TGGGCTGGAACAGAGAAACC
B2m Intron RP	CCTCAGGTGGCAGGTGTTAG
Pbgd Intron FP	CTGGCCAAGGAGGTTCTGAG
Pbgd Intron RP	ATCATTTTGCCCACCTGGCT
Hprt Intron FP	TTCAGCAGTAAGACGCAGCA
Hprt Intron RP	GCTACAAGAGGGTATGTAGAGCA
Rps16 Intron FP	CCCCGGGATGATAGGGAGTT
Rps16 Intron RP	GCCCAGGTTAAGGTCTACCG
Mtr4 Exon FP	GAAATGGAAGGGGCCACCAG
Mtr4 Exon RP	GTATCCAGTCGTTTCCCGGC
Ars2 Exon FP	CATCTTGGGCTATGGAGTCCC
Ars2 Exon RP	AGCATCATAGTTCCCACGGC
Dis3 Exon FP	GCACCAGATTGATGTCCTCG
Dis3 Exon RP	CGCTCCGGTTTCTCACTTCT
Zcchc8 Exon FP	CGCGCCGAGAATCAAGAACT
Zcchc8 Exon RP	ACCACTGGGTCTTGTCAGAA
Rmb7 Exon FP	CGGCAAGCAGTGATGAACAG
Rmb7 Exon RP	GATCCGCATGTGGAGAACCA
Ncbp1 Exon FP	GCTAGCAACTCAGATCGGCT
Ncbp1 Exon RP	TGTGAGGTTGTCCACCATCG
Zc3h18 Exon FP	TGAGGAGCGAAAAGGCTGAG
Zc3h18 Exon RP	CCCACAGATCTCAACGCGAA
Nrde2 Exon FP	CACCACCGCCAAGGAGTC
Nrde2 Exon RP	TCGCTAGTGTTGCTCTCACC
Zfc3h1 Exon FP	CAGTTCTCCAGCGCCTTCA
Zfc3h1 Exon RP	GCTGGTGGAGGCAAAGAAAC
Pabpn1 Exon FP	CCATCCCAAAGGGTTTGCAT
Pabpn1 Exon RP	GGGACGTCCTCACTGACTCT
· · ·	

2.20 List of siRNA

Target	Catalogue Number
Dis3	L-048884-01-0005
Dis3l	L-054584-01-0005
Dis3l2	L-054755-01-0005
Eri1	L-059530-02-0005
Eri2	L-059795-01-0005
Eri3	L-049763-01-0005
Exosc1	L-064024-01-0005
Exosc2	L-064407-01-0005
Exosc3	L-064537-01-0005
Exosc4	L-063925-01-0005
Exosc5	L-064420-01-0005
Exosc6	L-064503-01-0005
Exosc7	L-062387-00-0005
Exosc8	L-064119-01-0005
Exosc9	L-040354-01-0005
Exosc10	L-049286-00-0005
Xrn1	L-046621-01-0005
Xrn2	L-046490-01-0005
Nrd1	L-061245-01-0005
Setx	L-066634-00-0005
Smg6	L-066166-01-0005
Dcp1a	L-065144-01-0005
Dcp1b	L-056964-00-0005
Dcp2	L-040353-01-0005
Dcps	L-046656-01-0005
Nudt16	L-048777-01-0005
Zcchc7	L-056810-02-0005
Papd5	L-061333-01-0005
Mtr4	L-058707-01-0005
Zcchc8	L-057599-01-0005
Rmb7	L-055957-01-0005
Dom3z	L-050491-01-0005
Ncbp1	L-160309-00-0005
Ars2	L-045428-02-0005
Zc3h18	L-066066-01-0005
Srf	L-050116-01-0005

Scrambled	D-001810-10
Swt1	L-050799-01-0005
Zfc3h1	L-063190-01-0005
Pabpn1	L-045150-01-0005
Nrde2	L-066291-01-0005
Rpb1	D-011186-03-0020
Rpb1	D-011186-05-0020

2.21 List of antibodies

ChIP and IP antibodies	Catalogue Number	Concentration
MRTF-A	sc-21558, Santa Cruz	5 ug
SRF	16821-1-AP, Proteintech	3 ug
Rpb1	14958S, Cell Signalling	10 ug
phospho-Ser5 CTD	61085, Active Motif	10 ug
phospho-Ser2 CTD	61083, Active Motif	10 ug
phospho-Ser7 CTD	61087, Active Motif	10 ug
phospho-Thr4 CTD	61361, Active Motif	10 ug
phospho-Tyr1 CTD	61383, Active Motif	10 ug
CDK9	2316, Cell Signalling	10 ug
Spt5	sc-28678, Santa Cruz	10 ug
NELF-E	10705-1-AP, Proteintech	10 ug
Total H3	ab1791, Abcam	3 ug
H3K4me3	ab8580, Abcam	3 ug
H3K27Ac	ab4729, Abcam	3 ug
H3K36me3	ab9050, Abcam	3 ug
H3K79me3	ab2621, Abcam	3 ug
НА	11867431001, Roche	5 ug
lgG	ab6703, Abcam	3 ug
Mtr4	nb100-1574, Novus	10 ug

IF antibodies and dyes	Catalogue Number	Concentration
	MMS-101R-500, Cambridge	
НА	Bioscience	1/1000
Phalloidin	T7471, Life technologies	1/40
MRTF	sc-21558, Santa Cruz	1/50

WB antibodies	Catalogue Number	Concentration
HA	11867431001, Roche	1/1000
MRTF	sc-21558, Santa Cruz	1/1000
tubulin	T5162, Sigma	1/10000
Rpb1	14958S, Cell Signalling	1/1000
phospho-Ser5 CTD	Dirk Eick laboratory	1/5000
phospho-Ser2 CTD	Dirk Eick laboratory	1/5000
phospho-Ser7 CTD	Dirk Eick laboratory	1/2000
phospho-Thr4 CTD	Dirk Eick laboratory	1/500
phospho-Tyr1 CTD	Dirk Eick laboratory	1/500
SRF	16821-1-AP, Proteintech	1/1000
Mtr4	nb100-1574, Novus	1/1000
Gapdh	sc-25778, Santa Cruz	1/1000
α-actin	sc-56499, Santa Cruz	1/1000
β-actin	sc-47778, Santa Cruz	1/1000

Chapter 3. Nuclear MRTF induces non-productive RNA synthesis

MRTF responds to changes in actin dynamics to regulate cytoskeletal genes. In NIH3T3 fibroblasts, the majority of MRTF binding sites are bound by MRTF-A and MRTF-B homodimers or heterodimers, recruited in association with SRF. Even though at some loci SRF is constitutively bound, these are predominantly TCF-associated, whereas inducible SRF binding reflects MRTF recruitment. 683 SRF/MRTF target genes were identified as induced by serum, bound by SRF and MRTF and sensitive to CD or LatB treatment. These include the *Acta2*, *Actb* and *Actg1* genes, genes associated with F-actin, actomyocin, focal adhesion and extracellular matrix (Esnault et al., 2014).

MRTF directly interacts with monomeric G-actin through an RPEL domain located at the N-terminus of the protein and this interaction controls the localization of MRTF in the cell (Guettler et al., 2008; Hirano & Matsuura, 2011; Miralles et al., 2003; Mouilleron et al., 2011; Pawłowski et al., 2010; Vartiainen et al., 2007). While depletion of the G-actin pool promotes MRTF-importin interaction and nuclear import, G-actin binding to MRTF promotes its export through the Crm1 nuclear export receptor (Hirano & Matsuura, 2011; Mouilleron et al., 2008; Mouilleron et al., 2011; Panayiotou et al., 2016; Pawłowski et al., 2010; Vartiainen et al., 2007).

In addition to controlling MRTF subcellular localization, G-actin also regulates its nuclear activity. MRTF directly interacts with actin in the nucleus (Vartiainen et al., 2007) and MRTF activity is promoted by NLS-tagged mutant actins G15S and S14C, which promote F-actin formation, while over-expression of NLS-actin inhibits MRTF target genes (Kokai et al., 2014; Posern et al., 2004; Sharili et al., 2016). Similarly, the mDia formin and nucleoskeletal proteins such as the LINC complex, which mediate actin polymerization in the nucleus, stimulate MRTF activity (Baarlink et al., 2013; Plessner et al., 2015), and so does the monooxygenase MICAL2, which causes nuclear G-actin depletion (Lundquist et al., 2014).

In NIH3T3 mouse fibroblasts, even though the transcriptional activation following serum stimulation is transient, MRTF remains in the nucleus for hours (Vartiainen et al., 2007). Thus, nuclear accumulation of MRTF in the absence of an activating signal is not sufficient for target gene activation. Fusing MRTF with an additional NLS or blocking Crm1-mediated nuclear export by LMB does not elicit a transcriptional response. Nevertheless, nuclear MRTF is recruited to target genes (Vartiainen et al., 2007). In contrast, MRTF mutant protein harbouring point mutations in its RPEL motifs (MRTF-XXX), making it insensitive to G-actin, is not only constitutively nuclear, but also constitutively transcriptionally active (Miralles et al., 2003; Vartiainen et al., 2007).

This data demonstrates a repressive effect of nuclear actin on MRTF activity, however the exact mechanism is unclear. In this chapter, to investigate the nuclear regulation of MRTF, Crm1 inhibition by LMB was used to induce nuclear accumulation of MRTF in the absence of an activating signal.

Chapter 3 Results

3.1 Nuclear MRTF does not activate target gene expression

To study the inhibitory role of G-actin in the MRTF-mediated transcriptional response, recruitment of nuclear MRTF to target genes and its ability to activate transcription was examined in cells treated with the Crm1 inhibitor LMB.

First, the effect of actin-binding agents on MRTF subcellular localization was assessed by immunofluorescence in NIH3T3 cells. Cells were treated with serum, which activates Rho signaling and actin polymerization; CD, which directly disrupts the MRTF/G-actin interaction; LatB, which increases the cellular concentration of G-actin; or LMB, which does not affect the actin treadmilling cycle but prevents MRTF export from the nucleus. Following treatment, cells were fixed and an MRTF antibody was used to visualize the transcription factor. In addition, cells were stained with Phalloidin, to examine the effect of the treatment on F-actin, and DAPI, to visualize the nucleus. Results are shown in Figure 27.

In unstimulated cells, MRTF was found predominantly in the cytoplasm, whereas serum shock caused MRTF nuclear accumulation, consistent with previous studies (Miralles et al., 2003; Vartiainen et al., 2007). Both CD and LatB disrupted actin filaments, as visualized by Phalloidin staining, but had opposing effects on MRTF localization. While CD treatment caused nuclear translocation of MRTF, MRTF remained cytoplasmic upon LatB treatment. Following LMB treatment, MRTF was found predominantly in the nucleus. Subsequent stimulation of LMB-treated cells with FCS, CD or LatB did not alter MRTF subcellular localization.

As previously reported, inhibition of Crm1 causes nuclear accumulation of MRTF, without disrupting actin filaments (Vartiainen et al., 2007). Furthermore, subsequent stimulation of LMB pre-treated cells with CD or LatB disrupts actin filaments, without affecting MRTF localization, which would allow us to study the role of G-actin in regulation of MRTF activity in the nucleus.

Next, MRTF target gene expression was examined in the same conditions. To assess the relative transcription rate at endogenous MRTF-SRF target genes,

qPCR probes targeting the first intron of the gene were used to measure premRNA levels. The specificity of the treatments for MRTF target genes was tested by examining pre-mRNA levels at the *Egr1* gene. Although serum-inducible, *Egr1* is activated by ERK signalling to the TCF family of SRF co-factors (Esnault et al., 2014). Results are shown in Figure 28.

As previously reported, MRTF target genes were not expressed in untreated cells or in response to LatB treatment (Miralles et al., 2003; Vartiainen et al., 2007). Stimulation with serum or CD, which interfere with MRTF/G-actin interaction, either by directly disrupting it or by promoting F-actin assembly, induced gene expression. In LMB-treated cells, nuclear MRTF did not activate target genes. Nevertheless, treatment with LMB slightly increased baseline expression at MRTF target genes, as compared to this in untreated cells.

To test whether nuclear MRTF was responsive to changes in G-actin concentration, cells pre-treated with LMB were re-stimulated with FCS, CD or LatB. Subsequent stimulation of LMB-treated cells with CD or FCS induced gene expression, whereas subsequent LatB treatment reversed the increased baseline expression in cells treated with LMB alone. The *Egr1* gene was insensitive to LMB or CD treatment. It was only activated in response to serum stimulation (Figure 28B).

Taken together these results confirm that although LMB treatment induces MRTF nuclear accumulation, under this condition MRTF target genes remain inactive. Nuclear MRTF is nevertheless responsive to changes in G-actin concentration, since subsequent stimulation of LMB pre-treated cells with FCS or CD results in gene activation.






Figure 27 MRTF subcellular localization

Immunofluorescence microscopy of MRTF-A in NIH3T3 fibroblasts. Cells were serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D); 50nM LMB (Leptomycin B); 15% FCS; 0.5µM LatB (Latrunculin B); LMB->CD (30 min LMB followed by 30 min CD); LMB->LatB (30 min LMB followed by 30 min LatB); LMB->15% FCS (30 min LMB followed by 30 min 15% FCS). Phalloidin was used to stain actin filaments and DAPI to stain the nucleus. In the merged images, MRTF (sc-21558) is shown in magenta and DAPI in blue.





Pre-mRNA accumulation in response to stimulation at MRTF target genes (A) and the TCF target gene *Egr1* (B). NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); 15% FCS; 0.5 μ M LatB (Latrunculin B); LMB->CD (30 min LMB followed by 30 min CD); LMB->LatB (30 min LMB followed by 30 min LatB); LMB->15% FCS (30 min LMB followed by 30 min 15% FCS). qPCR probes are located within the first intron of each gene. Signal was normalized to *Gapdh*. Data is shown as mean \pm SEM and is representative of three independent experiments.

3.2 G-actin inhibits MRTF recruitment to target genes

To investigate how G-actin interferes with MRTF-dependent gene expression, MRTF and SRF recruitment to target gene promoters in response to stimulation was examined by ChIP-qPCR.

As shown in Figure 29A, MRTF was bound to target gene promoters in response to stimulation with CD and serum and absent in untreated and LatB-treated cells. As previously described even though LMB treatment did not activate MRTF target genes, in this condition MRTF was recruited to target promoters, while it was not detectable at the *Zfp37* control gene (Figure 29B)(Vartiainen et al., 2007). However, DNA binding was reduced as compared to this in CD-stimulated cells.

To test whether the LMB-induced recruitment of MRTF was subject to regulation by G-actin, ChIP assays in LMB pre-treated cells subsequently stimulated with CD, FCS or LatB were performed. Strikingly, while CD and FCS re-stimulation increased ChIP signal in LMB treated cells, treatment with LatB reduced it.

In addition, SRF recruitment to target gene promoters was examined by ChIPqPCR under the same conditions. Results are shown in Figure 30.

Like MRTF, SRF was bound to target gene promoters in response to serum stimulation and in CD-treated cells, while it was not recruited in untreated and LatB-treated cells. In response to LMB, SRF was recruited to target genes, albeit at reduced levels, relative to these in CD-stimulated cells. SRF was not detected at the *Zfp37* control gene in response to any of the treatments (Figure 30B).

As for MRTF, SRF recruitment upon LMB treatment was subject to regulation by Gactin. Re-stimulation of LMB pre-treated cells with CD or serum, which disrupt the interaction between MRTF and G-actin, increased SRF ChIP signal. In contrast, LatB addition, which increases the concentration of free G-actin, disrupted SRF recruitment to target gene promoters. Despite the low enrichment of MRTF-A in the ChIP assay (see Figure 29), MRTF ChIP levels were sensitive to treatement with LMB, CD, FCS and LatB at MRTF target genes specifically and not at the *Zfp37* control gene, which is not under the regulation of MRTF. Furthermore, the same pattern of recruitment to DNA was observed for SRF (see Figure 30). The low enrichment in MRTF-A ChIP could reflect efficiency of the MRTF-A antibody, low abundance of MRTF-A on DNA or less stable recruitment of the protein to DNA. Using an alternative ChIP protocol (Tian et al., 2012) did not increase the quality of the MRTF ChIP assay, as it increased background due to inefficient sonication and degradation of the protein.




Figure 29 MRTF recruitment to target gene promoters in response to stimulation

MRTF-A (sc-21558) ChIP at MRTF target gene promoters (A) and at the *Zfp37* promoter (B). NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); 15% FCS; 0.5 μ M LatB (Latrunculin B); LMB->CD (30 min LMB followed by 30 min CD); LMB->LatB (30 min LMB followed by 30 min LatB); LMB->15% FCS (30 min LMB followed by 30 min 15% FCS). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments.




Figure 30 SRF recruitment to target gene promoters in response to stimulation

SRF (16821-1-AP) ChIP at MRTF target gene promoters (A) and at the *Zfp37* promoter (B). NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); 15% FCS; 0.5 μ M LatB (Latrunculin B); LMB->CD (30 min LMB followed by 30 min CD); LMB->LatB (30 min LMB followed by 30 min LatB); LMB->15% FCS (30 min LMB followed by 30 min 15% FCS). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments.

The results presented above are consistent with a model in which G-actin interferes with ternary complex formation between SRF and MRTF on DNA. To exclude the possibility that the reduction in SRF and MRTF recruitment to target gene promoters observed upon LMB treatment reflects slower binding kinetics, SRF/MRTF recruitment and activation of the model gene *Acta2* was examined in a time-course over 90 min following stimulation with CD, FCS or LMB.


First, we used qPCR probes targeting the first intron of the *Acta2* gene to measure pre-mRNA levels, as an indication of the relative transcription rate. As shown in Figure 31A, prolonged treatment with LMB did not activate the *Acta2* gene. In response to CD or serum, precursor RNA started accumulating 15 min following stimulation and reached maximum at 30 min. The response to serum-shock was transient and pre-mRNA levels started decreasing 30 min after treatment, whereas the response to CD lasted throughout the time-course. Addition of LatB to cells prestimulated with CD or FCS for 30 min inhibited Acta2 pre-mRNA synthesis. Precursor RNA production stopped within 5-10 min following addition of LatB and was completely abolished by 30 min.

In addition, exonic qPCR probes, targeting sequences flanking intron 2, were used to measure mature RNA levels at the *Acta2* gene in response to stimulation. Results are shown in Figure 31B.

mRNA started accumulating 60 min following CD or FCS stimulation. Consistent with the inhibitory effect of LatB on pre-mRNA synthesis, addition of LatB to cells pre-stimulated with CD or FCS for 30 min prevented mRNA accumulation.

Next, SRF recruitment to the *Acta2* promoter was examined by ChIP at different time points following stimulation with CD or LMB. As shown in Figure 32, despite the lack of precursor RNA in LMB-treated cells, SRF bound to the *Acta2* promoter in response to LMB treatment. SRF recruitment was observed 15 min following LMB addition. ChIP levels did not increase with time. SRF recruitment to the *Acta2* promoter was sensitive to an increase in G-actin concentration. Addition of LatB to LMB-treated cells abolished DNA binding within 5 min. Similarly, SRF bound to DNA 15 min following LatB addition to cells pre-stimulated with CD (Figure 31A), SRF binding was reduced within 5 min after LatB addition and was completely abolished within 30 min (Figure 32).

As shown in Figure 32, SRF ChIP levels in cells treated with CD or LMB were comparable at 15 min following addition of the drug, a time point at which precursor



RNA was observed only in cells treated with CD and not in cells treated with LMB (see Figure 31A).

Figure 31 G-actin inhibits MRTF target gene activation

Pre-mRNA (A) and mRNA (B) accumulation at the inducible MRTF model gene *Acta2* in response to stimulation over the timeframe of 90 min. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); 15% FCS; CD->LatB (30 min CD followed by 30 min LatB); 15% FCS->LatB (30 min 15% FCS followed by 30 min LatB). To measure pre-mRNA qPCR probes targeting the first intron of the gene were used. To measure mRNA exonic qPCR probes targeting sequences flanking intron 2 of the gene were used. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments.




Figure 32 G-actin inhibits SRF/MRTF recruitment to target genes

SRF (16821-1-AP) ChIP in at the promoter of the MRTF model gene *Acta2* in response to stimulation over the timeframe of 90 min. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D); 50nM LMB (Leptomycin B); CD->LatB (30 min CD followed by 30 min LatB); LMB->LatB (30 min LMB followed by 30 min LatB). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments.

In LMB-treated cells, SRF binding levels at the *Acta2* promoter rapidly reach maximum and persist over time. This is consistent with less efficient binding, rather than slower recruitment of the transcription factor. Furthermore, SRF/MRTF recruitment at early timepoints is broadly comparable between LMB and CD stimulated cells, whereas only CD induces a transcriptional response, suggesting that reduced transcription factor recruitment alone does not cause the defective pre-mRNA accumulation in LMB-treated cells.

3.3 Nuclear MRTF induces transcription but not productive RNA synthesis


In the absence of G-actin depletion, nuclear MRTF is recruited to target gene promoters but does not induce pre-mRNA synthesis. This could potentially occur because Pol II fails to be recruited at target genes or due to increased stalling at the TSS. Alternatively, under this condition transcripts could be co-transcriptionally degraded. To characterize the transcriptional response to LMB and CD, both RNAseq and transient transcriptome sequencing (TTseq), a method that employs metabolic labelling of RNA with 4-thiouridine (4SU) to measure nascent Pol II-associated transcripts were performed (Gregersen et al., 2020; Gregersen et al., 2019; Schwalb et al., 2016; Tufegdžić Vidaković et al., 2020).

The transcriptional response to CD

For RNAseq, sequencing libraries were prepared from total RNA purified from NIH3T3 cells treated with CD for 30 min. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini. To increase sensitivity, read count within introns only (intronic reads) or exons only (exonic reads) were analysed. Differential gene expression analysis was performed, comparing each stimulus to untreated cells (for discussion of the processing analysis strategy see Chapter 2.12). Results are shown in Figure 33.

CD stimulation resulted in detectable upregulation of 2116 genes in intronic reads and 679 genes, as assessed by exonic reads. These were enriched in genes involved in cytoskeleton organization and actin-based processes, gene categories which are also significantly overrepresented in MRTF-SRF target genes (Esnault et al., 2014). For full list of significantly overrepresented GO terms see Figure 92. Genes downregulated in response to CD treatment were not enriched in gene categories associated with MRTF-SRF signalling (see Figure 93). This result is consistent with MRTF being the only transcription factor known to be directly activated by CD.

To examine nascent transcription, NIH3T3 cells were stimulated with CD for 30 min and, guided by the findings in Figure 31A, newly-synthesised RNA was pulselabelled with 4SU for the last 15 min. The 4SU-labelled RNA was then purified and sequenced. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini. As before, differential gene expression analysis was performed, comparing each stimulus to untreated cells. Results are shown in Figure 34.



В

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
CYTOSKELETON ORGANIZATION	247	2.14E-74	1.62E-70
CELL PROJECTION ORGANIZATION	256	1.54E-68	5.82E-65
POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS	278	2.96E-67	7.47E-64
CELL MORPHOGENESIS	200	4.19E-66	7.93E-63
ACTIN FILAMENT BASED PROCESS	173	1.01E-64	1.54E-61
NEUROGENESIS	256	8.58E-64	1.05E-60
POSITIVE REGULATION OF CELLULAR BIOSYNTHETIC PROCESS	281	9.67E-64	1.05E-60
REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION	268	3.05E-61	2.89E-58
POSITIVE REGULATION OF MOLECULAR FUNCTION	263	2.35E-60	1.98E-57
CELLULAR MACROMOLECULE LOCALIZATION	275	2.56E-59	1.94E-56

Figure 33 The response to CD stimulation by RNAseq

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by RNAseq. NIH3T3 cells were serum-starved overnight and subsequently stimulated with 3µM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.




Figure 34 The response to CD stimulation by TTseq

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by TTseq. NIH3T3 cells were serum-starved overnight and subsequently stimulated with 3µM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

As in the RNAseq experiment, by TTseq CD stimulation induced the expression of genes associated with actin-based processes. In addition, genes involved in apoptosis and cell differentiation were overrepresented (Figure 34B). For full list of significantly overrepresented GO terms see Figure 94. Genes downregulated in response to CD treatment were not enriched in gene categories associated with MRTF-SRF signalling. Genes involved in cell cycle control were overrepresented (see Figure 95).




Figure 35 Defining a stringent CD-induced gene set

CELL SUBSTRATE ADHESION

(A) Venn diagram representing the overlap between CD-induced genes in NIH3T3 cells by RNAseq and TTseq. Note that some genes where intronic reads were increased by CD stimulation, nevertheless showed a decrease on the exonic level (shown in black). (B) Scatter plot comparing fold change expression by RNAseq and TTseq at the stringent CD-induced gene set (n=312). The red lines represent the 95% confidence bands of the best-fit line (black). (C) Distance to the closest SRF binding site within CD-induced genes. Coordinates of SRF binding sites published in (Esnault et al., 2014) were used. (D) Proportion of genes overlapping with FCS-inducible LatB sensitive genes (n=1022), as defined in (Esnault et al., 2014). (E) Gene ontology analysis of the stringent CD-induced gene set (n=312). Shown are the top 10 GO categories. FDR<0.05. Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.

38

31

1.84E-17

7.07E-17

1.55E-14

5.35E-14

Next, to define a stringent set of CD-responsive genes, the overlap between CDinduced genes by TTseq and RNAseq in intronic or exonic reads was used. Results are shown in Figure 35.

512 genes were detectably induced by CD in both assays (Figure 35A). However, 200 of those were downregulated on the exonic level in CD-treated cells, probably reflecting indirect effects of the CD treatment on RNA stability. These genes were therefore excluded. Using this approach, 312 genes were identified as induced by CD both by RNAseq and TTseq and not downregulated in CD-treated cells in exonic reads. As presented in Figure 35B, expression of the stringent 312 gene set strongly correlated between the RNAseq and TTseq experiments. There was a weak correlation between expression changes in CD-treated cells in the RNAseq and TTseq experiments in the full dataset (see Figure 114A).

Next, a previously published dataset of SRF ChIP in NIH3T3 cells was used to examine the association of CD activated genes with SRF binding (Esnault, Stewart et al. 2014). It has been proposed that the maximum distance at which an SRF binding site influences transcription is 70kb (Esnault, Stewart et al. 2014). Therefore, SRF binding sites were classified into direct (within 5kb of the TSS of the nearest gene), near (between 5 and 70 kb away from the TSS of the nearest gene) and far (beyond 70kb of the TSS of the nearest gene).

Genes in the stringent CD-activated set were associated with direct SRF binding (Figure 35C). Using previously published coordinates of SRF binding sites, an SRF binding site was found within 5 kb of the TSS of 40% of the stringent CD-induced set (Esnault, Stewart et al. 2014). In contrast, less than 5% of inactive genes in CD-treated cells were located in close proximity to an SRF binding site. Genes upregulated in response to CD by TTseq only (n=467) were also associated with direct SRF binding: approximately 20% of these were with an SRF binding site within 5kb of their TSS (Figure 35C).

Furthermore, as shown in Figure 35D, the stringent CD-induced gene set was heavily enriched in previously defined FCS-inducible LatB-sensitive genes (Esnault et al., 2014). Whereas only approximately 10% of other CD-activated genes and

less than 5% of genes inactive in CD-stimulated cells were present in the FCSinducible LatB-sensitive gene set.

Finally, gene ontology analysis was performed on the stringent CD-induced gene set (Figure 35E). CD-activated genes were functionally related to MRTF-SRF targets. These were enriched in genes involved in actin-based processes, cell morphology, migration and adhesion, showing an overlap with signatures of MRTF-SRF target genes.

Overall, the stringent CD-induced gene set is enriched in serum-inducible genes, whose expression is sensitive to an increase in G-actin concentration by LatB, physically associated with SRF and functionally related to MRTF-SRF target genes. This is consistent with the transcriptional response to CD being MRTF-dependent.

The transcriptional response to LMB

The same approach was used to characterize the transcriptional response to LMB. As before, for RNAseq, sequencing libraries were prepared from total RNA purified from NIH3T3 cells treated with LMB for 30 min. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini. To increase sensitivity, read count within introns only (intronic reads) or exons only (exonic reads) were analysed. Differential gene expression analysis was performed, comparing each stimulus to untreated cells. Results are shown in Figure 36.

Consistent with previous studies and data presented above, no transcriptional response was detected by RNAseq following treatment with LMB (Vartiainen et al., 2007).

LMB-induced changes





Figure 36 LMB stimulation does not induce gene activation

Volcano plots representing LMB-induced changes in gene expression, as compared to untreated cells, by RNAseq. NIH3T3 cells were serum-starved overnight and subsequently stimulated with 50nM LMB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in blue. Significantly upregulated genes are shown in the yellow boxes. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.



5.42E-58 5.94E-53
5.94E-53
7.45E-53
1.16E-52
1.01E-49
3.65E-48
3.55E-44
4.67E-43
9.69E-43
4.87E-42

Figure 37 LMB induces nascent RNA synthesis

(A) Volcano plots representing LMB-induced changes in gene expression, as compared to untreated cells, by TTseq. NIH3T3 cells were serum-starved overnight and subsequently stimulated with 50nM LMB. Significant changes (fold change>1 and pvalue>0.01) are marked in blue. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by LMB treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq are marked with *. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

Next, to examine nascent transcription, NIH3T3 cells were stimulated with LMB for 30 min and newly-synthesised RNA was pulse-labelled with 4SU for the last 15 min. The 4SU-labelled RNA was then purified and sequenced. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini. As before, differential gene expression analysis was performed, comparing each stimulus to untreated cells. Results are shown in Figure 37.

Strikingly, although no transcriptional response to LMB treatment was detected by RNAseq, by TTseq LMB upregulated the expression of genes enriched in the same

GO categories as MRTF-SRF targets and CD-induced genes-cell morphology, migration and adhesion. As in CD-stimulated cells, genes associated with cell death and apoptosis were also upregulated (Figure 34B and Figure 37B). For full list of significantly overrepresented GO terms see Figure 96. Genes downregulated in response to LMB treatment were not enriched in gene categories associated with MRTF-SRF signalling (see Figure 97).

This data demonstrates that LMB treatment induces transcription but under this condition pre-mRNA accumulation is defective. The LMB-induced gene set is functionally related to MRTF-SRF target genes, suggesting that the transcriptional response to LMB is mediated by MRTF.

Even though no gene activation was detected in response to LMB by RNAseq, more than 90% of the stringent CD-induced gene set was activated on the nascent RNA level, as assessed by TTseq (Figure 38A). Moreover, as shown in Figure 38B, induction levels of these genes in response to LMB strongly correlated with those following CD stimulation, not only in the TTseq, but also in the RNAseq experiment.

At the 312 stringent CD-induced gene set, while no gene activation was detected in response to LMB by RNAseq, as assessed by TTseq gene expression was upregulated to levels comparable to these following CD stimulation (Figure 38C and D). Furthermore, as shown in Figure 38E, the TTseq read profiles at MRTF-SRF target genes in response to CD and LMB were very similar. No differences in Pol II processivity and elongation speed or termination were apparent.




Figure 38 Nuclear MRTF induces non-productive RNA synthesis

(A) Venn diagram representing the overlap between the stringent CD-induced gene set (n=312) and LMB-induced genes by TTseq. Pie chart representing percentage of CD-induced genes also upregulated by LMB on the nascent RNA level. (B) Scatter plots comparing fold change expression by CD TTseg and LMB TTseg and CD RNAseq and LMB TTseq at the stringent CD-induced gene set (n=312). The black lines represent the 95% confidence bands of the best-fit line (red). (C) Heatmap representing gene expression changes at the 312 genes in the stringent CD-induced gene set in untreated, LMB-stimulated and CD-stimulated cells by RNAseq and TTseq. Genes are separated by distance to their nearest SRF binding site, direct (within 5kb); near (within 70kb); far (>70kb). Overlap with FCS-induced LatB-sensitive genes (n=1022), as published in (Esnault et al., 2014), is shown. The red lines represent FCS-induced LatB-sensitive genes, the white lines represent genes not present in the FCS-induced LatB-sensitive gene set and the grey lines represent genes not identified in the analysis. (D) Violin plot representing gene expression changes at the 312 genes in the stringent CD-induced gene set in untreated, LMB-stimulated and CD-stimulated cells by RNAseg and TTseq. (E) TTseq plots in untreated, CD-stimulated and LMB-treated cells at the constitutive Idh1 and Pikfyve genes and the CD-inducible MRTF-SRF target genes Vcl and Acta2. Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.

These results suggest that in response to LMB, nuclear MRTF induces nonproductive transcription at target genes.

Finally, CD- and LMB-induced genes that were not present in the stringent CDinduced set were examined. As shown in Figure 39A, 592 genes were upregulated in response to CD and LMB stimulation as assessed by TTseq but were not detectably induced following CD-stimulation by RNAseq. To determine whether these were physically and functionally linked to SRF, as before, distance to the nearest SRF binding site, overlap with published FCS-controlled genes and gene ontology analyses were performed.

Approximately 20% of the 592 gene set was associated with direct SRF binding and present in the published FCS-controlled gene set (Figure 39B and C). Out of the 132 genes upregulated in response to CD but not LMB, approximately 20% were associated with direct SRF binding, induced by serum stimulation and sensitive to LatB treatment. In contrast, there was little enrichment for direct SRF binding sites in genes insensitive to CD. Approximately 10% of genes upregulated only by LMB were physically linked to SRF or present in the published FCS-controlled LatB-sensitive gene set.

The 592 gene set was mainly enriched in genes involved in apoptosis and cell differentiation. Nevertheless, cytoskeletal genes and genes associated with cell motility were also overrepresented (Figure 39D).

It appears that some SRF-controlled CD-inducible genes are detected by TTseq and not by RNAseq. This could be due to higher basal expression in untreated cells, lower inducibility by CD, impaired RNA stability or increased sensitivity of the TTseq method.

In conclusion, the transcriptional response to CD and LMB appears to be mediated by MRTF. While CD, which disrupts the MRTF/G-actin interaction, induces productive RNA synthesis, LMB-induced nuclear MRTF induces non-productive transcription. In response to LMB, Pol II is recruited and although it engages in elongation, no pre-mRNA accumulates, suggesting that under this condition, nascent transcripts might be co-transcriptionally degraded.




Figure 39 The transcriptional response to LMB and CD

(A) Venn diagram representing the overlap between CD- and LMB-induced genes by TTseq only. (B) Distance to the closest SRF binding site. Coordinates of SRF binding sites published in (Esnault et al., 2014) were used. (C) Proportion of FCSinducible LatB-sensitive genes (n=1022), as defined in (Esnault et al., 2014). (D) Gene ontology analysis of the 592 genes upregulated by CD and LMB treatment by TTseq, but not present in the stringent CD-induced gene set. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq are marked with *. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

Chapter 4. Constitutively nuclear MRTF does not induce productive RNA synthesis

The preceding results show that in LMB-treated NIH3T3 cells, unless the interaction between MRTF and G-actin is disrupted, nuclear accumulation of MRTF is not sufficient for productive RNA synthesis. Nevertheless, under this condition, MRTF is recruited at target promoters and induces transcription. To exclude the possibility that this transcriptional defect is a result of Crm1 inhibition by LMB, MRTF-A/MRTF-B null cells were reconstituted with an NLS-tagged MRTF and used to study the properties of nuclear MRTF in the absence of LMB. In this chapter, the recruitment of the constitutively nuclear MRTF to target genes, as well as its ability to induce transcription in the absence of stimulation were assessed.

4.1 Characterization of cells with constitutively nuclear MRTF

Even though MRTF isoforms are mostly redundant, in specific contexts they may have a unique function. While deletion of MRTF-A does not affect viability, it causes defects myofibroblast differentiation (Lei et al., 2015; Li et al., 2006; Sun et al., 2006). On the other hand, deletion of MRTF-B causes embryonic lethality due to defects in neural crest development (Li et al., 2005; Oh et al., 2005). Previous work in the laboratory has shown that MRTF-A ^{-/-} MRTF-B ^{flox/flox} MEF cells are viable, whereas following tamoxifen-induced deletion of MRTF-B, MRTF-A ^{-/-} MRTF-B ^{flox/flox} MEF cells (dKO) enter senescence (Bellamy S. (2019) MRTF-SRF signalling in migration, PhD thesis; Nielsen J., unpublished). This observation was exploited to generate cells expressing wild-type or mutant MRTF derivatives at levels sufficient to restore proliferation.

To generate MEF cells with constitutively nuclear MRTF, MRTF-A fused to an additional NLS (MRTF-NLS) was introduced in MRTF-A ^{-/-},MRTF-B ^{flox/flox} MEF cells, which were simultaneously treated with tamoxifen to delete MRTF-B. Since dKO MEFs are senescent, cells expressing MRTF-NLS at a level sufficient for normal growth were selected, generating dKO^{MRTF-NLS} cells (Figure 40A). In addition, cells reconstituted with a wild-type MRTF-A (dKO^{MRTF}) and an MRTF

Chapter 4 Results

RPEL domain mutant (dKO^{MRTF-XXX}) were generated in the same way. MRTF-XXX harbours a single amino acid substitution of arginine to alanine in each of the three RPEL motifs which prevent it from interacting with G-actin and make it constitutively active (Guettler et al., 2008; Miralles et al., 2003; Vartiainen et al., 2007). All ectopically expressed MRTFs were fused to a C-terminal HA tag.

We were unable to generate clonal cell lines from dKO^{MRTF}, dKO^{MRTF-NLS} or dKO^{MRTF-XXX} cells by single cell sorting. In addition, we attempted to generate pools of cells expressing MRTF at low/medium/high levels by FACS. However, MRTF protein levels fluctuated after sorting and over time returned to levels observed prior to sorting, suggesting that rescuing senescence of dKO cells selects for a particular level of MRTF activity. Consistent with levels of MRTF protein in the cell being tightly regulated, we were unable to over-express wild-type MRTF, MRTF-NLS or MRTF-XXX in NIH3T3 cells using the doxycycline-inducible pTRIPZ vector.

To characterize the reconstituted cell lines, their proliferation following MRTF reexpression was assessed. Results are shown in Figure 40B. Consistent with dKO MEF cells entering senescence, dKO MEFs stopped proliferating a week following treatment with tamoxifen. In contrast, re-expression of wild-type MRTF, the constitutively nuclear MRTF-NLS or the constitutively active MRTF-XXX prevented dKO MEFs from entering senescence. All the reconstituted cell lines proliferated at rates comparable to wild-type MEF cells.

As shown in Figure 40C, PCR on genomic DNA confirmed knock-out of the endogenous MRTF-A and MRTF-B in the reconstituted cell lines. As presented in Figure 40D, in the reconstituted cell lines, MRTF-NLS was expressed at a level comparable to that in cells reconstituted with the wild-type protein and wild-type MEF cells, whereas the constitutively active MRTF-XXX was present at a much lower level.




Figure 40 Reconstitution of MRTF-A/B null cells


(A) Stable cell line generation. MRTF-A ^{-/-} MRTF-B ^{flox/flox} MEF cells were treated with tamoxifen to generate MRTF-A/B null cells (dKO) and simultaneously infected with lentivirus expressing pMY-MRTF-A/MRTF-NLS/MRTF-XXX-IRES-GFP or vector alone. MRTF-A/B null cells enter senescence, while ectopic expression of MRTF prevents cells from entry into senescence. (B) Growth curves. Cells were counted daily (in triplicate) after addition of tamoxifen over the period of 14 days. Data is shown as mean ± SEM. (C) Genotyping. PCRs were set up with genomic DNA isolated from WT MEF, MRTF-A KO MEF, dKO^{MRTF}, dKO^{MRTF-NLS} and dKO^{MRTF-XXX} cells and primers SAF, EXR and LAR or GT5, GT6 and QB to test MRTF-A and MRTF-B knock-out, respectively. Expected PCR product size for the wild-type, the floxed and the knock-out alleles are indicated in red in the schematic. (D) Western blot. Protein lysates from WT MEF, MRTF-A KO MEF, dKO^{MRTF}, dKO^{MRTF}, dKO^{MRTF-NLS} and dKO^{MRTF-NLS} and dKO^{MRTF-NLS} and dKO^{MRTF-NLS} and dKO^{MRTF-XXX} cells were probed with antibodies against MRTF-A (sc-21558) or HA (11867431001). Tubulin (T5162) was used as a loading control.

Taken together these results suggest that rescuing senescence of dKO cells selects for a particular level of MRTF activity. The observation that MRTF-XXX expression is low indicates that regulation by G-actin is maintained in dKO^{MRTF} and dKO^{MRTF-NLS} cells, which express higher levels of MRTF.

dKO^{MRTF}, dKO^{MRTF-NLS} and dKO^{MRTF-XXX} were unresponsive to stimulation with FCS or CD following serum starvation, which presumably reflects changes arising during the selection process. Nevertheless, cells cultured in 10%FCS remained responsive to CD stimulation and were used to examine MRTF regulation.


First, MRTF subcellular localization in the reconstituted cell lines was examined. To test whether the ectopically expressed MRTF was responsive to changes in G-actin concentration, cells were treated with CD, which directly disrupts the MRTF/G-actin interaction, or LatB, which increases the concentration of G-actin. Following treatment, cells were fixed and an HA antibody was used to visualize MRTF. In addition, cells were stained with Phalloidin, to examine the effect of the treatment on F-actin, and DAPI, to visualize the nucleus. Results are shown in Figure 41.






В

dKO^{MRTF-NLS}





dKO^{MRTF-XXX}

Figure 41 MRTF subcellular localization

Immunofluorescence microscopy of MRTF-A in dKO^{MRTF} cells (A), dKO^{MRTF-NLS} cells (B), dKO^{MRTF-XXX} cells (C). Cells were stimulated for 30 min with 3 μ M CD (Cytochalasin D); 0.5 μ M LatB (Latrunculin B) or left untreated. Phalloidin was used to stain actin filaments and DAPI to stain the nucleus. In the merged images, MRTF (MMS-101R-500) is shown in magenta and DAPI in blue.

In cells reconstituted with wild-type protein (dKO^{MRTF}), MRTF was found predominantly in the cytoplasm in untreated cells and LatB-treated cells and translocated into the nucleus following stimulation with CD. In contrast, in dKO^{MRTF-NLS} and dKO^{MRTF-XXX} cells, MRTF was predominantly nuclear in untreated cells and its localization was not affected by treatment with LatB or CD. Nevertheless, CD and LatB disrupted F-actin, as visualized by Phalloidin staining. As in wild-type fibroblasts, MRTF subcellular localization in dKO^{MRTF} cells is controlled by G-actin. In contrast, MRTF-NLS and MRTF-XXX remain nuclear despite CD or LatB treatment, allowing us to study the effect of changes in G-actin concentration on MRTF activity in the nucleus.

Next, MRTF transcriptional activity in the reconstituted cell lines was assessed by qPCR at endogenous MRTF-SRF target genes under resting and stimulated conditions. As before, as an indication of relative transcription rates, qPCR probes targeting the first intron of the gene were used to measure pre-mRNA levels. Results are shown in Figure 42A.

As in wild-type fibroblasts, in dKO^{MRTF} cells, MRTF target genes were inactive in untreated cells, remained uninduced in LatB-treated cells and were activated in response to stimulation with CD. In untreated dKO^{MRTF-NLS} cells, even though MRTF was found in the nucleus, target genes were inactive. While target genes remained inactive in response to LatB, treatment with CD induced MRTF target gene expression. In dKO^{MRTF-XXX} cells, MRTF target genes were constitutively induced. Consistent with the inability of MRTF-XXX to interact with G-actin, MRTF target gene expression was not altered by CD or LatB treatment.

In addition, a gel contraction assay was used as a readout of MRTF activity. MRTF regulates the expression of contractility markers such as the αSMA (*Acta2*) and MLC2 (*Myl9*) genes and has been shown to control cell contractility and proinvasive behaviour of fibroblasts (Foster et al., 2017; Gualdrini et al., 2016). Wild-type MEF, dKO^{MRTF}, dKO^{MRTF-NLS} and dKO^{MRTF-XXX} cells were seeded in collagen gels. Two days later, gel area was measured and compared to its original size. As shown in Figure 42B, wild-type MEF cells did not contract collagen gels. Consistent with the gene expression data presented above, neither did dKO^{MRTF} or dKO^{MRTF-NLS} cells. In contrast, dKO^{MRTF-XXX} cells reduced their gel area to approximately half its original size.

148

The results presented above corroborate findings in LMB-treated NIH3T3 cells. Since both MRTF-NLS and MRTF-XXX are constitutively nuclear, these results demonstrate that that G-actin regulates MRTF activity in the nucleus.




Figure 42 Nuclear MRTF does not activate target genes

(A) Pre-mRNA accumulation at MRTF target genes in dKO^{MRTF} cells, dKO^{MRTF-NLS} cells and dKO^{MRTF-XXX} cells. Cells were stimulated for 30 min with 3µM CD (Cytochalasin D); 0.5μ M LatB (Latrunculin B); or left untreated. qPCR probes targeting the first intron of the gene were used to measure pre-mRNA levels. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. (D) Gel contraction assay. Cells were seeded in collagen gels and gel contraction was measured after 48h, expressed as percentage of the original gel area. Data is shown as mean ± SEM and is representative of three independent experiments.

4.2 Constitutively nuclear MRTF is recruited to target gene promoters

In dKO^{MRTF-NLS} cells, the constitutively nuclear MRTF does not induce target genes in the absence of G-actin depletion. To test whether the MRTF-NLS is nevertheless recruited to target gene promoters, MRTF and SRF ChIP assays were performed. Results are shown in Figure 43.

In dKO^{MRTF} cells, MRTF and SRF did not bind to target gene promoters in untreated or LatB-treated cells but were recruited in response to CD stimulation. In dKO^{MRTF-NLS} cells, under resting conditions, MRTF and SRF were bound to target gene promoters, but were not detected at the *Zfp37* control gene. CD stimulation only slightly increased ChIP signal at MRTF target genes. In contrast, addition of LatB reduced ChIP signal to background levels. Finally, in dKO^{MRTF-XXX} cells, MRTF and SRF were constitutively bound to target promoters and their recruitment was not altered by CD or LatB treatments.

As in LMB-treated NIH3T3 cells, in dKO^{MRTF-NLS} cells MRTF is recruited at target gene promoters, but it is unable to activate gene expression, unless its interaction with G-actin has been disrupted. As observed before, MRTF and SRF recruitment to target promoters is sensitive to an increase in G-actin concentration. The data presented above corroborates findings in NIH3T3 cells and is consistent with a model in which G-actin interferes with ternary complex formation between SRF and MRTF on DNA.

As was the case for MRTF ChIP (see Figure 29), despite the low enrichment of HA ChIP, ChIP levels were sensitive to treatement with CD and LatB at MRTF target genes specifically and not at the *Zfp37* control gene, which is not under the regulation of MRTF (Figure 43A). Furthermore, the same pattern of recruitment to DNA was observed for SRF (Figure 43B). The low enrichment in the HA ChIP assay could reflect efficiency of the HA antibody, low abundance of MRTF-A on DNA or less stable recruitment of the protein to DNA.




Figure 43 Nuclear MRTF is recruited to target gene promoters

HA (11867431001) ChIP (A) and SRF (16821-1-AP) ChIP (B) in dKO^{MRTF}, dKO^{MRTF-NLS} and dKO^{MRTF-XXX} cells at the MRTF-SRF target genes *Acta2*, *FilaminA*, *Mir145*, *Actb*, *Col1a1* and the *Zfp37* gene, which is not an MRTF-SRF target. Cells were stimulated for 30 min with 3μ M CD (Cytochalasin D); 0.5 μ M LatB (Latrunculin B) or left untreated. Signal was normalized to input. Data is shown as mean \pm SEM and is representative of three independent experiments.


4.3 Constitutively nuclear MRTF induces non-productive transcription

Under resting conditions, MRTF-NLS is recruited at target promoters but does not induce productive RNA synthesis. To characterize the transcriptional response to the constitutively nuclear MRTF-NLS genome-wide, RNAseq and TTseq experiments were performed in the dKO^{MRTF} and dKO^{MRTF-NLS} cell lines.

Defining a stringent CD-induced gene set in dKO^{MRTF} and dKO^{MRTF-NLS} cells

For RNAseq, sequencing libraries were prepared from total RNA purified from cells treated with CD or LatB for 30 min. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini. As in NIH3T3 cells, to increase sensitivity, read count within introns only (intronic reads) or exons only (exonic reads) were analysed. Differential gene expression analysis was performed, comparing each stimulus to untreated cells, and results were processed.

As presented in Figure 44, in dKO^{MRTF} cells, CD stimulation resulted in detectable upregulation of 334 genes in intronic reads and 2583 genes, as assessed by exonic reads. Gene ontology analysis showed that the CD-induced genes were enriched in genes involved in cytoskeleton organization and actin-based processes (Figure 44B). Consistent with MRTF being the only transcription factor known to be directly activated by CD, these gene categories are also significantly overrepresented in MRTF-SRF target genes in NIH3T3 cells (see Figure 35E and (Esnault et al., 2014)). For full list of significantly overrepresented GO terms see Figure 98. Genes downregulated in response to CD treatment also included gene categories associated with MRTF-SRF signalling, which could potentially reflect indirect effects of the CD treatment on RNA stability (see Figure 99). No



В

	GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
*	ACTIN FILAMENT BASED PROCESS	50	1.88E-30	1.42E-26
*	CYTOSKELETON ORGANIZATION	59	5.09E-27	1.93E-23
*	CELL MOTILITY	66	1.61E-26	4.07E-23
	RESPONSE TO CYTOKINE	54	1.39E-25	2.64E-22
*	ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS	51	1.99E-23	3.02E-20
*	SUPRAMOLECULAR FIBER ORGANIZATION	40	1.03E-22	1.31E-19
*	APOPTOTIC PROCESS	62	2.00E-21	2.17E-18
*	REGULATION OF CELLULAR COMPONENT MOVEMENT	47	4.47E-21	4.23E-18
*	BIOLOGICAL ADHESION	53	5.49E-21	4.62E-18
	POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS	58	3.60E-20	2.72E-17,

С

LatB-induced changes





Figure 44 dKO^{MRTF} RNAseq

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by RNAseq. dKO^{MRTF} cells were stimulated with 3µM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. (C) Volcano plots representing LatB-induced changes in gene expression, as compared to untreated cells, by RNAseq. dKO^{MRTF} cells were treated with 0.5µM LatB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in red. Significantly upregulated genes are shown in the yellow boxes. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

The same experiment was performed in dKO^{MRTF-NLS} cells. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini. Results are shown in Figure 45. CD stimulation resulted in fewer changes in intronic features than in dKO^{MRTF} cells (Figure 45A), perhaps reflecting higher basal transcription in dKO^{MRTF-NLS} cells under resting conditions. Nevertheless, genes within the union of intronic and exonic features upregulated in response to CD were enriched in GO categories which were also overrepresented in CD-induced genes in NIH3T3 cells (Figure 45B). For full list of significantly overrepresented GO terms see Figure 100. Genes downregulated in response to CD treatment were not enriched in gene categories associated with MRTF-SRF signalling (see Figure 101).



В

	GO BIOLOGOCAL PROCESS	# Genes	p-value	FDR q-value
*	REGULATION OF CELL DIFFERENTIATION	366	6.75E-134	5.11E-130
*	CYTOSKELETON ORGANIZATION	306	1.93E-129	7.32E-126
*	NEUROGENESIS	321	1.02E-118	2.56E-115
*	POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS	327	6.39E-110	1.21E-106
	POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS	321	5.06E-106	7.67E-103
	NEURON DIFFERENTIATION	277	1.44E-104	1.82E-101
	POSITIVE REGULATION OF DEVELOPMENTAL PROCESS	281	4.31E-103	4.66E-100
	POSITIVE REGULATION OF CELLULAR BIOSYNTHETIC PROCESS	325	1.31E-101	1.24E-98
	CELL CYCLE	317	2.67E-101	2.25E-98
*	CELL MOTILITY	311	5.92E-101	4.48E-98



LatB-induced changes




Figure 45 dKO^{MRTF-NLS} RNAseq

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by RNAseq. dKO^{MRTF-NLS} cells were stimulated with 3µM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. (C) Volcano plots representing LatB-induced changes in gene expression, as compared to untreated cells, by RNAseq. dKO^{MRTF-NLS} cells were treated with 0.5µM LatB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in red. Significantly upregulated genes are shown in the yellow boxes. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

To define a stringent set of CD-responsive genes, the overlap between CD-induced genes in dKO^{MRTF} and dKO^{MRTF-NLS} cells in intronic or exonic reads was used. Results are shown in Figure 46.

As was the case in NIH3T3 cells, some of the CD-induced genes were downregulated on the exonic level in CD-treated cells. Again, this is likely due to indirect effects of the CD treatment on RNA stability. These genes were therefore excluded. 180 genes were induced by CD both in dKO^{MRTF} and dKO^{MRTF-NLS} cells and not downregulated in CD-treated cells in exonic reads (Figure 46A). As shown in Figure 46B, induction in response to CD at the 180 gene set strongly correlated in dKO^{MRTF} and dKO^{MRTF-NLS} cells. However, global expression changes in response to CD did not correlate in dKO^{MRTF} and dKO^{MRTF-NLS} cells (see Figure 114B).

Next, to determine whether CD-induced genes were physically and functionally linked to SRF, gene ontology analysis, SRF binding and the overlap with published FCS-controlled genes were examined.

As presented in Figure 46C, CD-activated genes were functionally related to SRF-MRTF targets identified in NIH3T3 cells. The stringent CD-induced gene set was enriched in genes involved in cytoskeleton organization and cell migration, showing an overlap with signatures of MRTF-SRF target genes.

Because previously published SRF ChIPseq datasets do not include MRTF stimulus such as serum or CD stimulation, to assess whether CD-induced genes were associated with SRF recruitment, transcription factor binding motif search was performed. Genes within the stringent CD set were associated with SRF binding sites. These were enriched in genes with at least one SRF binding site found within 4kb of their TSS (Figure 46D).




Figure 46 Defining a stringent CD-induced gene set

(A) Venn diagram representing the overlap between CD-induced genes by RNAseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells. (B) Scatter plot comparing fold change expression by RNAseq at the 180 genes in the CD-induced gene set. The black lines represent the 95% confidence bands of the best-fit line (red). (C) Gene ontology analysis of the CD-induced gene set. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. (D) Transcription factor binding motif analysis of the CD-induced gene set. Shown are the top 5 transcription factor binding motifs. FDR<0.05. (E) Overlap of CD-induced genes in MEF and NIH3T3 cells (312 CD-induced gene set defined in Chapter 3.3). (F) Overlap of CD-induced genes in MEF and FCS-induced LatB-sensitive genes in NIH3T3 cells (n=1022), as defined in (Esnault et al., 2014). FCS-induced LatB-sensitive gene set are shown in red, genes not present in the FCS-induced LatB-sensitive gene set are shown in white and genes not identified in the analysis are shown in grey. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.


Next, the overlap between CD-induced genes in MEF and NIH3T3 cells was examined. As shown in Figure 46E, less than 20% of the CD-induced genes in MEFs were present within the stringent CD-induced gene set in NIH3T3 cells. Nevertheless, the CD-induced gene set was enriched in previously published FCSinducible LatB-sensitive genes (Figure 46F) (Esnault et al., 2014).

Overall, the stringent CD-induced gene set is enriched in serum-inducible genes, whose expression is sensitive to an increase in G-actin concentration by LatB, associated with SRF binding sites and functionally related to MRTF-SRF target genes. This data is consistent with the transcriptional response to CD being MRTF-dependent and corroborates results in NIH3T3 cells presented in Chapter 3.

MRTF-NLS induces non-productive transcription

To examine nascent transcription in dKO^{MRTF} and dKO^{MRTF-NLS} cells, TTseq was performed. Cells were stimulated with CD or LatB for 30 min and during treatment, newly-synthesised RNA was pulse-labelled with 4SU for 15 min. The 4SU-labelled RNA was then purified and sequenced. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini. As before, differential gene expression analysis was performed, comparing each stimulus to untreated cells.

First, gene expression changes in dKO^{MRTF} cells were examined. Results are shown in Figure 47. 2996 genes were upregulated in response to CD. As in the RNAseq experiment, by TTseq CD stimulation induced the expression of genes associated with actin-based processes. In addition, genes involved in apoptosis and cell differentiation were overrepresented (Figure 47C). For full list of significantly overrepresented GO terms see Figure 102. Genes downregulated in response to CD treatment were not enriched in gene categories associated with MRTF-SRF signalling (see Figure 103).



	GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
*	ACTIN FILAMENT BASED PROCESS	154	1.60E-65	1.21E-61
*	CYTOSKELETON ORGANIZATION	202	2.00E-64	7.56E-61
*	REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION	234	4.55E-63	1.15E-59
*	CELL MORPHOGENESIS	169	5.69E-61	1.08E-57
*	CELL MOTILITY	226	5.36E-60	8.12E-57
*	BIOLOGICAL ADHESION	199	4.46E-58	5.63E-55
*	CELLULAR MACROMOLECULE LOCALIZATION	234	8.07E-58	8.73E-55
*	REGULATION OF CELL DIFFERENTIATION	227	2.15E-55	2.04E-52
*	APOPTOTIC PROCESS	229	1.17E-54	9.84E-52
*	POSITIVE REGULATION OF MOLECULAR FUNCTION	216	1.05E-53	7.93E-51

Figure 47 dKO^{MRTF} TTseq

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by TTseq. dKO^{MRTF} cells were stimulated with 3μM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Volcano plots representing LatB-induced changes in gene expression, as compared to untreated cells, by TTseq. dKO^{MRTF} cells were stimulated with 0.5μM LatB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in red. Significantly upregulated genes are shown in the yellow boxes. (C) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.




Figure 48 dKO^{MRTF-NLS} TTseq

CELLULAR MACROMOLECULE LOCALIZATION

ESTABLISHMENT OF PROTEIN LOCALIZATION TO ENDOPLASMIC RETICULUM

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by TTseq. dKO^{MRTF-NLS} cells were stimulated with 3μM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes.
(B) Volcano plots representing LatB-induced changes in gene expression, as compared to untreated cells, by TTseq. dKO^{MRTF-NLS} cells were stimulated with 0.5μM LatB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in red. Significantly upregulated genes are shown in the yellow boxes.
(C) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

175

6.39E-78

62 9.46E-78

5 37E-75

7.16E-75

In contrast, as shown in Figure 48, CD-induced genes by TTseq in dKO^{MRTF-NLS} cells were depleted of cytoskeletal genes. In dKO^{MRTF-NLS} cells, CD stimulation caused fewer changes in gene expression than in dKO^{MRTF} cells (Figure 48A), perhaps reflecting higher basal transcription in dKO^{MRTF-NLS} cells under resting conditions. CD stimulation resulted in upregulated expression of genes associated with RNA metabolism processes (Figure 48C). For full list of significantly

overrepresented GO terms see Figure 104. Genes downregulated in response to CD treatment were not enriched in gene categories associated with MRTF-SRF signalling either (see Figure 105).

Next, gene expression changes by TTseq were examined at the 180 stringent CDinduced gene set. Results are shown in Figure 49.

In dKO^{MRTF} cells, as in the RNAseq experiment, by TTseq genes within the stringent CD set were inactive in untreated cells, remained uninduced in LatB-treated cells and were activated in response to stimulation with CD. In dKO^{MRTF-NLS} cells, even though no gene activation was detected under resting conditions by RNAseq, genes within the stringent CD set were induced in the absence of an activating signal as assessed by TTseq. Furthermore, their expression was sensitive to treatement with LatB and subsequent increase in G-actin concentration.

As shown in Figure 49C, in dKO^{MRTF} cells, Pol II was engaged in elongation only in response to stimulation with CD and was not recruited at MRTF target genes under resting conditions and in LatB-treated cells. In contrast, in dKO^{MRTF-NLS} cells, the TTseq profiles at MRTF-SRF target genes under resting conditions and in response to CD were very similar. Pol II was engaged in elongation in the absence of an activating signal and its recruitment was sensitive to LatB addition and subsequent increase in G-actin levels (Figure 49D).

Consistent with MRTF activity in the nucleus being under the regulation of G-actin, nuclear MRTF induces non-productive transcription at target genes, whereas disrupting the interaction between MRTF and G-actin is required for productive RNA synthesis. Under resting G-actin levels, despite the lack of pre-mRNA accumulation, Pol II is engaged in elongation at MRTF target genes, suggesting that nascent transcripts might be co-transcriptionally degraded. Even though MRTF-NLS differs from LMB-induced nuclear MRTF, in that the dKO^{MRTF-NLS} cells are subjected to chronic stimulation, rather than an acute stimulus like the LMB treatment, this data corroborates findings in NIH3T3 cells.




Figure 49 Constitutively nuclear MRTF induces non-productive transcription

(A) Heatmap representing gene expression changes at the 180 genes in the CDinduced gene set in untreated, CD-stimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells. Overlap with previously published FCS-induced LatB-sensitive genes (n=1022) is shown (Esnault et al., 2014). The red lines represent FCS-induced LatB-sensitive genes, the white lines represent genes not present in the FCS-induced LatB-sensitive gene set and the grey lines represent genes not identified in the analysis. Overlap with the 312 stringent CDinduced gene set in NIH3T3 cells is shown. The green lines represent CD-inducible genes, the white lines represent genes not present in the stringent CD-induced gene set in NIH3T3 cells. (B) Violin plot representing gene expression changes at the 180 genes in the CD-induced gene set in untreated, CD-stimulated and LatBtreated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells. (C) TTseq plots in untreated, CD-stimulated and LatB-treated dKO^{MRTF} cells at the constitutive Zmiz1 and Zcchc24 genes and the CD-inducible MRTF-SRF target genes Vcl and Acta2. (D) TTseq plots in untreated, CD-stimulated and LatB-treated dKO^{MRTF-NLS} cells at the constitutive Zmiz1 and Zcchc24 genes and the CDinducible MRTF-SRF target genes Vcl and Acta2. Bioinformatic analysis of RNAseg and TTseg data was performed by Francesco Gualdrini.

Chapter 5. The nuclear exosome regulates transcription at MRTF target genes

In the absence of G-actin depletion, nuclear MRTF is recruited to target gene promoters and induces transcription. Even though Pol II is actively transcribing MRTF target genes, pre-mRNA does not accumulate. These data suggest that under this condition, nascent MRTF-dependent transcripts might be cotranscriptionally degraded. In this chapter, the role of the nuclear exosome complex in regulating MRTF target gene expression was studied.

5.1 Inactivating the nuclear exosome rescues non-productive transcription in LMB-treated cells

In the nucleus, various complexes regulate co-transcriptional RNA processing and degradation (Schmid & Jensen, 2018). A small-scale RNAi screen was conducted in order to investigate the potential involvement of known RNA exonucleases and de-capping enzymes, the core nuclear exosome, its adapter complexes TRAMP, NEXT and PAXT and the CBCA complex, through which these are recruited to target RNAs.

Depletion of any protein involved should result in accumulation of MRTF target gene transcript in LMB-treated cells. Therefore, NIH3T3 cells were treated with siRNA for 48 hours and subsequently treated with LMB for 30 min. Pre-mRNA levels at the *Acta2* gene were measured by qPCR and compared to these in CD-stimulated cells. Depletion of SRF was used as a negative control. In addition, non-targeting scrambled siRNA control was used. Results are shown in Figure 50.

Depletion of Dis3l1 or Dis3l2 catalytic subunits of the cytoplasmic exosome, 5' RNA exonucleases or de-capping enzymes did not affect precursor RNA levels at the *Acta2* gene. In contrast, depletion of the catalytic subunit of the nuclear exosome, Dis3, as well as components of the core exosome Exosc 2,3,7,9 and 10, upregulated pre-mRNA levels in LMB-treated cells.




Figure 50 Inactivation of the nuclear exosome restores pre-mRNA accumulation

in LMB-treated cells

(A) siRNA screen in NIH3T3 fibroblasts. Pre-mRNA at the MRTF model gene *Acta2* was measured using qPCR probes targeting the first intron of the gene. Cells were treated with siRNA for 48h, serum-starved overnight and stimulated for 30 min with 50nM LMB (Leptomycin B) or 3µM CD (Cytochalasin D) (dark red bar). Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. The black dotted line represents pre-mRNA levels in cells treated with scrambled siRNA (siCtrl) and LMB. (B) Nuclear exosome adapter complexes. The NEXT (Mtr4, Zcchc8, Rmb7) and PAXT (Mtr4, Zfc3h1, Pabpn1) complexes share the Mtr4 RNA helicase, which interacts with the core exosome. The NEXT and PAXT are both recruited to target RNAs through Zc3h18 and the CBCA (CBC and Ars2) complex.

Depletion of the Mtr4 RNA helicase, which is responsible for the unwinding of the RNA substrate and mediating its access to the core exosome, upregulated premRNA levels at the *Acta2* gene in LMB-treated cells, to levels comparable to these in CD-stimulated cells. In addition, depletion of the Rmb7 RNA binding protein and the Zcchc8 protein, which together with Mtr4 form the NEXT complex, also increased precursor RNA levels. In contrast, depletion of Pabpn1 and Zfc3h1, components of the PAXT complex, or Papd5 and Zcchc7, components of the TRAMP complex, did not.

The NEXT complex is recruited to RNA via the cap-binding complex (CBC) in association with Ars2 and Zc3h18 co-factors (Figure 50B). Depletion of the nuclear cap binding protein (Ncbp1) and Ars2 (CBCA complex), as well as Zc3h18 also upregulated pre-mRNA levels at the *Acta2* gene in response to LMB treatment.

Overall, inactivating the nuclear exosome through depletion of individual components of the CBCA, NEXT or core exosome complexes rescues the *Acta2* pre-mRNA synthesis defect observed in LMB-treated NIH3T3 cells. To corroborate these findings, the involvement of these factors in the regulation of MRTF-dependent transcripts on additional MRTF target genes, including *Actb*, *Srf* and *Vcl*, was assessed (Figure 51).

As before, NIH3T3 cells were treated with siRNA for 48 hours and subsequently stimulated with LMB for 30 min. Baseline expression levels were assessed in untreated cells, when MRTF is in the cytoplasm and its target genes are inactive. As a control, non-targeting scrambled siRNA was used. To test whether the observed effects are MRTF-dependent, LMB-treated cells were subsequently stimulated with CD, which disrupts the MRTF/G-actin interaction and activates MRTF, or LatB, which increases the concentration of G-actin and inhibits MRTF-dependent transcription. In addition, the experiment was repeated in cells depleted of SRF, in which MRTF cannot be recruited to target genes. The specificity for MRTF target genes was tested by examining pre-mRNA levels at the *Egr1* gene, which is not under the regulation of MRTF. Although serum-inducible, *Egr1* is activated by ERK signalling to the TCF family of SRF co-factors (Esnault et al., 2014). Knock-down efficiency following siRNA treatment was assessed by


measuring target mRNA by qPCR using exonic probes and comparing their levels to these in cells treated with a non-targeting siCtrl. Results are presented in Figure 51.

Overall, depletion of Dis3, Zc3h18 and individual components of the NEXT (Zcchc8, Rmb7 and Mtr4) and CBCA (Ncbp1 and Ars2) complexes upregulated pre-mRNA levels in response to LMB treatment not only at the *Acta2* gene, but also at the *Actb*, *Vcl* and *Srf* genes, to variable degrees. The increased expression in response to LMB was MRTF-dependent, since it was inhibited by SRF depletion or LatB addition to LMB pre-treated cells, both of which prevent MRTF recruitment to targets.

Depletion of the Mtr4 helicase had a pronounced effect at MRTF-target genes in LMB-treated cells, in specific, without affecting pre-mRNA levels in untreated cells or expression of the *Egr1* gene. Despite having a milder effect, depletion of Dis3 and Rmb7 also specifically affected transcription at MRTF target genes in response to LMB.

In addition to its effect in LMB-treated cells, depletion of Zcchc8 also inhibited CD induction at MRTF target genes, as well as FCS stimulation at the *Egr1* gene. Similarly, depletion of Ncbp1 and Ars2 affected expression levels in response to CD and FCS stimulation at MRTF target genes and at the *Egr1* gene, respectively. Ars2 and Ncbp1 depletion also mildly upregulated *Egr1* pre-mRNA in LMB-treated cells.

Apart from increasing gene expression levels in response to LMB treatment, Zc3h18 depletion upregulated pre-mRNA levels in untreated and CD-stimulated cells at all MRTF target genes tested, except for the *Acta2* gene. Furthermore, its depletion also enhanced the expression of the *Egr1* gene in untreated cells, as well as in response to LMB and FCS stimulation.






Figure 51 Inactivation of Dis3, the NEXT or CBCA complexes restores pre-mRNA

accumulation in LMB-treated cells

Pre-mRNA accumulation at MRTF target genes in NIH3T3 fibroblasts (A) and SRF depleted NIH3T3 fibroblasts (B). Pre-mRNA accumulation at the TCF/SRF target gene Egr1 in NIH3T3 fibroblasts (C) and SRF depleted NIH3T3 fibroblasts (D). Cells were treated with siRNA for 48h, serum-starved overnight and stimulated for 30 min with 50nM LMB (Leptomycin B), LMB->CD (30 min LMB followed by 30 min 3µM CD (Cytochalasin D)), LMB->LatB (30 min LMB followed by 30 min 0.5µM LatB (Latrunculin B)), LMB->15% FCS (30 min LMB followed by 30 min 15% FCS) or left untreated. Pre-mRNA was measured using qPCR probes targeting the first intron of the gene. Signal was normalized to Gapdh. Data is shown as mean ± SEM and is representative of three independent experiments. The black dotted lines represent pre-mRNA levels in cells treated with scrambled control siRNA and LMB. (E) siRNA efficiency. NIH3T3 cells were treated with siRNA for 48h. mRNA was measured using exonic qPCR probes. mRNA levels following siRNA treatment are shown, relative to these in cells treated with non-targeting scrambled siRNA control. Signal was normalized to Gapdh. Data is shown as mean ± SEM and is representative of three independent experiments.

Taken together these results indicate that in LMB-treated cells MRTF-dependent transcripts are targeted for degradation by the CBCA-dependent NEXT exosome complex. The strongest rescue of the pre-mRNA accumulation defect in LMB-treated cells was observed in cells depleted of Mtr4.

Since Mtr4 is shared between the NEXT and the PAXT exosome adapter complexes (Ogami et al., 2018), its depletion inactivates both. Although depletion of the PAXT-specific components Pabpn1 and Zfc3h1 did not affect *Acta2* transcription in LMB-treated cells, next the effect of simultaneous depletion of PAXT- and NEXT-specific components was determined. Results are presented in Figure 52.

As shown above, depletion of Mtr4, as well as depletion of Zcchc8 and Rmb7 of the NEXT complex restored pre-mRNA accumulation at MRTF target genes in LMB-treated cells, whereas depletion of Pabpn1 and Zfc3h1 of the PAXT complex did not. Co-depleting a component from the NEXT and the PAXT complex (Rmb7 and Pabpn1; Rmb7 and Zfc3h1; Zcchc8 and Pabpn1; Zcchc8 and Zfc3h1) did not enhance the effect of individual depletion of Rmb7 or Zcchc8 in LMB-treated cells. Nevertheless, inactivating both PAXT and NEXT complexes resulted in upregulation of *Acta2* and *Vcl* pre-mRNA in CD re-stimulated cells.

Since inactivating both the NEXT and the PAXT nuclear exosome adapter complexes does not increase pre-mRNA levels in LMB-treated cells, relative to these in cells depleted of Zcchc8 or Rmb7 alone, it appears unlikely that the PAXT complex is involved in regulating MRTF-dependent transcript levels in LMB treated cells.




Figure 52 Inactivation of the NEXT but not the PAXT complex rescues pre-mRNA

accumulation in LMB-treated cells

Pre-mRNA accumulation at MRTF target genes in NIH3T3 fibroblasts. Cells were treated with siRNA for 48h, serum-starved overnight and stimulated for 30 min with 50nM LMB (Leptomycin B), LMB->CD (30 min LMB followed by 30 min 3μ M CD (Cytochalasin D)), LMB->LatB (30 min LMB followed by 30 min 0.5μ M LatB (Latrunculin B)) or left untreated. Pre-mRNA levels were measured using qPCR probes targeting the first intron of the gene. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. The black and green dotted lines represent pre-mRNA levels in cells treated with scrambled control siRNA and LMB or CD, respectively.


5.2 Genome-wide expression analysis in Mtr4-depleted cells

The results presented above show that inactivation of the nuclear exosome rescues the non-productive transcriptional state in LMB-treated cells at individual MRTF target genes. The most potent effect is observed in cells depleted of Mtr4. To examine the effect of Mtr4 depletion across the whole genome, RNAseq was performed in cells depleted of Mtr4.

CD- and LMB-induced changes in gene expression in Mtr4-depleted cells

Sequencing libraries were prepared from total RNA purified from NIH3T3 cells treated with siMtr4 for 48 hours and subsequently stimulated with LMB or CD for 30 min. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini. As before, to increase sensitivity, read count within introns only (intronic reads) or exons only (exonic reads) were analysed. Differential gene expression analysis was performed, comparing each stimulus to untreated cells. Results are shown in Figure 53.

CD-induced changes




В

С

Α

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
CELL CYCLE	152	4.49E-32	3.40E-28
CELL CYCLE PROCESS	120	5.72E-27	2.17E-23
MITOTIC CELL CYCLE	96	4.23E-24	1.07E-20
CELLULAR RESPONSE TO DNA DAMAGE STIMULUS	85	1.43E-23	2.71E-20
REGULATION OF INTRACELLULAR SIGNAL TRANSDUC	TION 131	4.21E-22	6.37E-19
CYTOSKELETON ORGANIZATION	107	6.71E-21	8.47E-18
PROTEIN CONTAINING COMPLEX SUBUNIT ORGANIZA	TION 130	1.80E-19	1.95E-16
CELLULAR MACROMOLECULE LOCALIZATION	128	1.94E-18	1.84E-15
REGULATION OF CELL CYCLE	93	5.53E-18	4.66E-15
REGULATION OF ORGANELLE ORGANIZATION	96	1.50E-17	1.14E-14

LMB-induced changes



D

	GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
*	ACTIN FILAMENT BASED PROCESS	85	3.13E-45	2.37E-41
*	CYTOSKELETON ORGANIZATION	105	4.22E-42	1.60E-38
*	BIOLOGICAL ADHESION	104	4.96E-39	1.25E-35
*	REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION	115	6.91E-38	1.31E-34
	REGULATION OF PHOSPHORUS METABOLIC PROCESS	114	4.19E-37	6.35E-34
*	REGULATION OF CELL DIFFERENTIATION	115	3.74E-36	4.68E-33
*	CELL MOTILITY	111	4.33E-36	4.68E-33
*	APOPTOTIC PROCESS	115	3.76E-35	3.56E-32
*	REGULATION OF CELL DEATH	105	1.53E-33	1.29E-30
	REGULATION OF PHOSPHORYLATION	102	3.66E-33	2.77E-30

Figure 53 CD- and LMB- induced gene expression changes in Mtr4-depleted cells

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by RNAseq. NIH3T3 cells were treated with siRNA against Mtr4 for 48h, serum-starved overnight and subsequently stimulated with 3µM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. (C) Volcano plots representing LMB-induced changes in gene expression, as compared to untreated cells, by RNAseq. NIH3T3 cells were treated with siRNA against Mtr4 for 48h, serum-starved overnight and subsequently stimulated with 50nM LMB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in blue. Significantly upregulated genes are shown in the yellow boxes. (D) Gene ontology analysis of genes upregulated by LMB treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. GO categories also enriched in LMB-induced genes by TTseq in NIH3T3 cells are marked with *. Bioinformatic analysis of RNAseg data was performed by Francesco Gualdrini.

In Mtr4-depleted cells, CD stimulation resulted in detectable upregulation of 2020 genes in intronic reads and 3301 genes in exonic reads (Figure 53A). Mtr4 depletion appeared to alter the profile of CD-induced gene expression. CD-induced gene were enriched in genes involved mainly in cell cycle regulation. While genes associated with actin-based processes were also upregulated, these were not as enriched as in CD-stimulated wild-type NIH3T3 cells (Figure 53B). For full list of significantly overrepresented GO terms see Figure 106. Genes downregulated in response to CD treatment were not enriched in gene categories associated with MRTF-SRF signalling or cell cycle regulation (see Figure 107).

Whereas in wild-type NIH3T3 cells LMB treatment did not elicit a transcriptional response detectable by RNAseq (see Figure 36), in cells depleted of Mtr4, induction of 760 genes in intronic and 1769 genes in exonic reads was detected by RNAseq (Figure 53C). LMB-stimulation induced expression of genes associated with actin cytoskeleton, cell adhesion and motility (Figure 53D). For full list of significantly overrepresented GO terms see Figure 108.




Figure 54 Mtr4 depletion restores productive RNA synthesis at MRTF target genes in LMB-treated cells

(A) Heatmap representing gene expression changes at the 312 stringent CDinduced gene set in untreated, LMB-stimulated and CD-stimulated cells by RNAseq and TTseq in wild-type NIH3T3 cells and by RNAseq in Mtr4-depleted NIH3T3 cells. Genes are separated by distance to their nearest SRF binding site, direct (within 5kb); near (within 70kb); far (>70kb). (B) Violin plot representing gene expression changes at the 312 stringent CD-induced gene set in untreated, LMBstimulated and CD-stimulated cells by RNAseq and TTseq in wild-type NIH3T3 cells and by RNAseq in Mtr4-depleted NIH3T3 cells. (C) Scatter plots comparing fold change expression at the 312 stringent CD-induced gene set between conditions. The black lines represent the 95% confidence bands of the best-fit line (red). Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini. This gene signature overlapped with the one of MRTF-SRF target genes, CDresponsive genes (see Figure 33B and Figure 34B) and the LMB-induced gene set from the TTseq experiment (see Figure 37B), indicating that Mtr4 depletion restores productive transcription at MRTF target genes in response to LMB. Genes downregulated in response to LMB treatment were not enriched in gene categories associated with MRTF-SRF signalling (see Figure 109).

First, the effect of Mtr4 depletion on MRTF-regulated genes was assessed. The behaviour of the 312 stringent CD-induced gene set defined in Chapter 3.3 were examined. Results are shown in Figure 54.

At these genes Mtr4 depletion led to elevated basal expression in untreated cells, as compared to that in wild-type NIH3T3 cells, and inducibility in response to CD was attenuated. Nevertheless, LMB stimulation stimulated gene expression, with a magnitude of induction comparable to that observed by TTseq (Figure 54A and B). Fold induction in LMB-treated cells correlated with that observed in LMB-treated and CD-treated wild-type cells by TTseq. There was a weaker correlation between fold induction in LMB treated Mtr4-depleted cells and CD-stimulated wild-type NIH3T3 cells by RNAseq (Figure 54C). There was no correlation in gene expression changes globally between LMB-treated Mtr4-depletedcells and LMB-treated cells by TTseq, CD-treated cells by TTseq or CD-treated cells by RNAseq. For correlation plots between full datasets see Figure 114C.

These results suggest that Mtr4-depetion rescues the RNA synthesis defect observed in the LMB-induced non-productive transcriptional state at MRTF target genes.




Figure 55 Mtr4 depletion supresses CD induction at MRTF target genes

(A) Venn diagram representing the subset of CD-induced genes which remain responsive to CD stimulation in the absence of Mtr4. (B) Heatmap representing gene expression changes at the subset of 111 CD-inducible genes in untreated, LMB-stimulated and CDstimulated cells by RNAseq and TTseq in wild-type NIH3T3 cells and by RNAseq in Mtr4depleted NIH3T3 cells. Genes are separated by distance to their nearest SRF binding site, direct (within 5kb); near (within 70kb); far (>70kb). Overlap with previously published FCSinduced LatB-sensitive genes (n=1022) is shown (Esnault et al., 2014). The red lines represent FCS-induced LatB-sensitive genes, the white lines represent genes not present in the FCS-induced LatB-sensitive gene set and the grey lines represent genes not identified in the analysis. (C) Violin plot representing gene expression changes at the subset of 111 CD-inducible genes in untreated, LMB-stimulated and CD-stimulated cells by RNAseg and TTseg in wild-type NIH3T3 cells and by RNAseg in Mtr4-depleted NIH3T3 cells. (D) Scatter plots comparing fold change induction at the subset of 111 CD-inducible genes between conditions. The black lines represent the 95% confidence bands of the best-fit line (red). Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.

CD stimulation is impaired in Mtr4 depleted cells, perhaps a result of the increased baseline expression in untreated cells. As shown in Figure 55A, 111 genes remained CD-inducible upon Mtr4 knock-down. These were heavily enriched in SRF direct target genes and FCS-inducible genes, sensitive to LatB treatment. Induction levels in response to CD in Mtr4-depleted cells strongly correlated with those in LMB-treated cells, as well as with those in CD-stimulated wild-type NIH3T3 cells (Figure 55C). There was no correlation in gene expression changes globally between CD-treated Mtr4-depleted cells and LMB-treated Mtr4-depleted cells by RNAseq, CD-treated cells by RNAseq or CD-treated cells by TTseq. For correlation plots between full datasets see Figure 114D.

Mtr4 depletion restores productive RNA synthesis at LMB-induced genes

As an alternative approach, the effect of Mtr4 depletion on LMB-induced transcripts, without pre-selecting for CD-inducibility, was examined. Results are shown in Figure 56.


Of the 2510 LMB-induced genes by TTseq, 455 were also detectably upregulated in Mtr4-depleted cells by RNAseq (Figure 56A). To determine whether these were physically and functionally linked to SRF, as before, distance to the nearest SRF binding site, overlap with published SRF-controlled genes and gene ontology analyses were performed.

More than 30% of the 455 LMB-induced Mtr4-controlled gene set was associated with direct SRF binding (Figure 56B). In contrast, approximately 5% of inactive genes and less than 10% of other LMB-responsive genes were located in close proximity to an SRF binding site. Furthermore, these were functionally related to MRTF-SRF targets. This gene set was heavily enriched in exactly the same gene classes as the stringent CD-induced gene set, genes involved in actin filament-based processes, cytoskeleton organization, biological adhesion, cell motility (Figure 56C). In addition, consistent with regulation by MRTF, these were strongly enriched in serum-inducible LatB-sensitive genes (Figure 56D).

Genes in the 455 gene set were inactive in untreated cells and expressed in response to CD in all experiments. Like at bona-fide MRTF target genes, in response to LMB, no gene activation was detectable by RNAseq, despite being upregulated by TTseq and in Mtr4-depleted cells (Figure 56D and E).

Fold induction in LMB-treated Mtr4-depleted cells strongly correlated with that in LMB-treated wild-type cells by TTseq. There was also a correlation with CD-induced fold change by TTseq and a weak correlation with CD-induction by RNAseq (Figure 56F).

The LMB-induced gene set regulated by Mtr4 is enriched in CD- and FCS-inducible genes, sensitive to an increase in G-actin concentration by LatB, physically associated with SRF and functionally related to MRTF-SRF target genes, strongly suggesting these are MRTF regulated.



С

	GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
*	ACTIN FILAMENT BASED PROCESS	69	2.04E-46	1.54E-42
*	CYTOSKELETON ORGANIZATION	81	7.33E-42	2.77E-38
*	BIOLOGICAL ADHESION	75	1.09E-34	2.75E-31
*	SUPRAMOLECULAR FIBER ORGANIZATION	51	2.52E-30	4.77E-27
*	CELL MOTILITY	76	1.12E-29	1.70E-26
*	ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS	60	2.52E-27	3.18E-24
*	ACTIN FILAMENT ORGANIZATION	39	4.16E-27	4.50E-24
*	REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION	72	5.09E-26	4.82E-23
*	REGULATION OF CELL DIFFERENTIATION	72	6.33E-25	5.33E-22
*	CELL SUBSTRATE ADHESION	34	1.84E-24	1.39E-21




Figure 56 Mtr4 depletion restores productive transcription at a subset of LMB-

inducible genes

(A) Venn diagram representing the subset of LMB-induced genes regulated by Mtr4. (B) Distance to SRF binding site. Coordinates of SRF binding sites published in (Esnault et al., 2014) were used. (C) GO analysis of LMB-induced genes regulated by Mtr4. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseg or TTseg in NIH3T3 cells are marked with *. (D) Heatmap representing gene expression changes at LMBinduced genes regulated by Mtr4 in untreated, LMB-stimulated and CD-stimulated cells by RNAseq and TTseq in wild-type NIH3T3 cells and by RNAseq in Mtr4depleted NIH3T3 cells. Genes are separated by distance to their nearest SRF binding site, direct (within 5kb); near (within 70kb); far (>70kb). Overlap with previously published FCS-induced LatB-sensitive genes (n=1022) is shown (Esnault et al., 2014). The red lines represent FCS-induced LatB-sensitive genes, the white lines represent genes not present in the FCS-induced LatB-sensitive gene set and the grey lines represent genes not identified in the analysis. (E) Violin plot representing gene expression changes at LMB-induced genes regulated by Mtr4 in untreated, LMB-stimulated and CD-stimulated cells by RNAseg and TTseg in wild-type NIH3T3 cells and by RNAseq in Mtr4-depleted NIH3T3 cells. (F) Scatter plots comparing fold change expression in response to CD and LMB between experiments. The black lines represent the 95% confidence bands of the best-fit line (red). Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.

Effect of Mtr4 depletion in resting cells

Finally, the effect of Mtr4 depletion on gene expression under resting conditions was examined. Differential gene expression analysis was performed comparing Mtr4-depleted untreated cells with wild-type untreated cells. Results are shown in Figure 57.

Mtr4 depletion resulted in a significant increase in RNA levels at 1894 genes in intronic reads and 2425 genes in exonic reads (Figure 57A). The Mtr4-sensitive genes were not associated with direct SRF binding or present in the FCS controlled set (Figure 57B). The majority of upregulated genes were protein-coding, enriched in genes involved in cell cycle control and the DNA damage repair response (Figure 57C and D). For full list of significantly overrepresented GO terms see Figure 110.

In addition to its characterized role in regulating non-coding transcripts, this data suggests that Mtr4 also controls the expression of specific subsets of protein-coding genes.

Overall, Mtr4 depletion restores productive RNA synthesis in response to LMB stimulation at MRTF controlled genes. This data is consistent with a model in which in the absence of G-actin depletion, LMB-induced recruitment of MRTF to target gene promoters induces production of nascent transcripts that are targeted for co-transcriptional degradation by Mtr4 and the nuclear exosome complex.




Figure 57 Transcriptional changes induced by Mtr4 depletion

(A) Volcano plots representing changes in gene expression induced by Mtr4 depletion in untreated cells. Significant changes (fold change>1 and pvalue>0.01) are marked in purple. Significantly upregulated genes are shown in the yellow boxes. (B) Distance to SRF binding sites. Coordinates of SRF binding sites published in (Esnault et al., 2014) were used. Overlap with previously published FCS-induced LatB-sensitive genes (n=1022) is shown (Esnault et al., 2014). (C) Fraction of protein-coding and non-coding transcripts upregulated in Mtr4-depleted cells. (D) Gene ontology analysis of genes upregulated by Mtr4 depletion. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseq or TTseq in NIH3T3 cells are marked with *. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

Chapter 5. Results

5.3 Mtr4 is recruited to transcripts of MRTF target genes

The results presented above show that Mtr4 depletion restores pre-mRNA accumulation at MRTF target genes in LMB-treated cells. To determine whether this effect reflects direct action of the nuclear exosome complex on MRTF-dependent transcripts, the association of Mtr4 with transcripts of MRTF target genes in response to stimulation was examined.

Following treatment, cells were UV-irradiated to induce RNA-protein cross-linking and Mtr4-associated RNA was recovered by immunoprecipitation (Ule et al., 2005). Recovered RNA was quantified by qPCR. Signal was normalized to IgG immunoprecipitates. To test the specificity for transcripts of MRTF target genes, the constitutively expressed *B2m* and *Rps16* genes, which are not SRF targets, and the serum-inducible TCF-SRF target gene *c-Fos* were used. Results are shown in Figure 58A.

In untreated cells, Mtr4 was not detectably associated with any of the transcripts tested. While CD and FCS stimulation had no effect on Mtr4 recruitment to *B2m*, *Rps16* or *c-Fos*, they caused a marginal increase in the association of Mtr4 with transcripts of MRTF target genes, which are strongly induced by CD and FCS. In contrast, LMB treatment, which does not induce transcript accumulation detectable by RNAseq, strongly induced Mtr4 association with MRTF-dependent transcripts.

Thus, the non-productive transcriptional state at MRTF targets in LMB-treated cells is associated with direct recruitment of Mtr4 to transcripts of MRTF target genes.

To determine whether the rescued transcripts in Mtr4-depleted LMB-treated cells generate functional RNA, mature RNA levels were assessed by qPCR using exonic probes. NIH3T3 cells were treated with a non-targeting scrambled siRNA or siRNA against Mtr4 for 48 hours and subsequently stimulated with LMB or CD for 1 hour. Results are presented in Figure 58B. Depletion of Mtr4 caused upregulation of *Acta2*, *Actb* and *Vcl* mRNA in response to LMB treatment, while it did not affect their levels in untreated cells.

To test whether the RNA rescued in Mtr4-depleted cells was competent for nuclear export and translation, α -actin and β -actin protein levels in cells depleted of Mtr4 were examined. NIH3T3 cells were treated with a non-targeting scrambled siRNA or siRNA against Mtr4 for 48 hours and subsequently stimulated with LMB or CD for 4 hours.




Figure 58 Mtr4 is recruited to MRTF-dependent transcripts in response to LMB

(A) Mtr4 UV-RIP. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 50nM LMB (Leptomycin B), 3μ M CD (Cytochalasin D), 15% FCS or left untreated. Signal was normalized to IgG IP. Pre-mRNA levels were measured using qPCR probes targeting the first intron of the gene. Data is shown as mean ± SEM and is representative of three independent experiments. (B) mRNA accumulation at MRTF target genes. NIH3T3 fibroblasts were treated with siRNA for 48h, serum-starved overnight and stimulated for 60 min with 50nM LMB (Leptomycin B), 3μ M CD (Cytochalasin D) or left untreated. mRNA levels were measured using exonic qPCR probes. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. (C) Western blot. Cells were treated with siMtr4 or scrambled control siRNA for 48h, serum-starved overnight and stimulated for 4 hours with 50nM LMB (Leptomycin B), 3μ M CD (Cytochalasin D) or left untreated. Protein lysates were probed with antibodies against Mtr4 (nb100-1574), α -actin (sc-56499), β -actin (sc-47778) and Gapdh (sc-25778).

In cells treated with control siRNA, CD stimulation upregulated α -actin and β -actin protein levels, as compared to these in untreated cells. Whereas LMB treatment did not affect α -actin and β -actin protein levels. In contrast, in cells depleted of Mtr4, α -actin and β -actin levels were upregulated not only in CD-stimulated cells but also in response to LMB treatment. The effect on α -actin protein level was more pronounced than the one on β -actin. Depletion of Mtr4 did not affect protein levels in the absence of stimulation, and Gapdh levels remained unchanged across conditions.

Overall, Mtr4 directly interacts specifically with MRTF-dependent transcripts and its depletion is sufficient to restore productive transcription at MRTF target genes in LMB-treated cells.

5.4 Nrde2 depletion inhibits activation of MRTF target genes

Recent studies show that Mtr4 activity is negatively regulated by Nrde2, which binds to Mtr4, inhibits its recruitment to RNA, as well as its interaction with the Dis3 exosome subunit (J. Wang et al., 2019). Depletion of Nrde2 thus potentially provides a route to increasing Mtr4-dependent RNA processing. The crosslinking data in Figure 58A suggests that Mtr4 might be weakly recruited to transcripts of MRTF targets under inducing conditions. Therefore, whether depletion of Nrde2 might potentiate Mtr4 activity to the point at which it would detectably inhibit productive transcription at MRTF target genes, even under inducing conditions, was tested.

As before, NIH3T3 cells were treated with siRNA for 48 hours and subsequently stimulated with CD or FCS, both of which activate MRTF, either by directly disrupting MRTF/G-actin interaction or by promoting F-actin assembly. Non-targeting scrambled siRNA was used as a control. Transcription at MRTF target genes was assessed by qPCR using probes targeting the first intron of the gene. Baseline expression levels were assessed in untreated cells, when MRTF is in the cytoplasm and its target genes are inactive. The specificity for MRTF target genes was tested by examining pre-mRNA levels at the *Egr1* and *c-Fos* genes. Although serum-inducible *Egr1* and *c-Fos* are activated by ERK signalling to the TCF family of SRF co-factors (Esnault et al., 2014). In addition, pre-mRNA levels at the constitutively active genes *B2m*, *Rps16*, *Pbgd* and *Hprt*, which are not SRF targets, were examined. To confirm that any potential effect of Nrde2 depletion reflects the activity of Mtr4, the experiment was repeated in cells depleted of Mtr4. Results are shown in Figure 59.

In cells treated with siCtrl, stimulation with CD induced expression of MRTF target genes and this was unaffected by depletion of Mtr4. In contrast, depletion of Nrde2 inhibited CD stimulation, while co-depletion of Nrde2 and Mtr4 restored pre-mRNA accumulation, to levels comparable to these in cells treated with siCtrl (Figure 59A). Pre-mRNA levels in untreated cells remained unaffected in all the conditions tested. In contrast, depletion of Nrde2 did not affect expression of the constitutively active *B2m*, *Rps16*, *Pbgd* and *Hprt* genes (Figure 59B).




Figure 59 Nrde2 depletion inhibits MRTF target gene expression in response to

stimulation

Pre-mRNA accumulation at MRTF target genes (A), constitutively expressed genes (B), TCF target genes in response to FCS stimulation (C) and MRTF target genes in response to serum stimulation (D). NIH3T3 fibroblasts were treated with siRNA for 48h, serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D), 15% FCS or left untreated. qPCR probes targeting the first intron of the gene were used to measure ore-mRNA levels. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments.

Next, the effect of Nrde2 depletion on FCS stimulation was examined. Depletion of Nrde2 or Mtr4 had no effect on serum induction of *Egr1* and *c-Fos*, whose activation is dependent on Ras-ERK-TCF signalling (Figure 59C). However, Nrde2 depletion reduced FCS induction of the *Acta2* and *Vcl* genes, which are activated via the Rho-actin-MRTF pathway. In this case the effect of Nrde2 depletion was relieved by simultaneous Mtr4 depletion (Figure 59D).

The data presented above demonstrates that Nrde2 depletion inhibits gene activation in response to stimulation at MRTF target genes, in specific, and its effect reflects Mtr4 activity. These findings suggest that Mtr4 recruitment to MRTF target genes might be a feature of their normal regulation.

Chapter 6. Evidence that the nuclear exosome regulates transcription in dKO^{MRTF-NLS} cells

Inactivating the nuclear exosome through depletion of individual components of the CBCA, NEXT and core exosome complexes rescues the pre-mRNA synthesis defect observed in LMB-treated NIH3T3 cells. To exclude the possibility that the rescue of RNA synthesis in LMB-treated cells reflects pleiotropic effects of Crm1 inhibition by LMB, the involvement of these factors in the regulation of MRTF-dependent transcripts in cells with constitutively nuclear MRTF was tested.

6.1 Inactivating the nuclear exosome rescues the pre-mRNA synthesis defect in dKO^{MRTF-NLS} cells

As presented in Chapter 4.3, in dKO^{MRTF-NLS} cells MRTF target genes exhibit elevated levels of transcription by TTseq that is not detectable by RNAseq. To test whether the defect in pre-mRNA accumulation reflects the activity of the nuclear exosome, siRNA depletions of exosome components were performed.

dKO^{MRTF-NLS} cells were treated with siRNA for 48 hours and transcription at MRTF target genes was assessed by qPCR using probes targeting the first intron of the gene. Non-targeting scrambled siRNA was used as a control. To test whether the observed effects are MRTF-dependent, cells were stimulated with CD, which disrupts the MRTF/G-actin interaction and activates MRTF, or LatB, which increases the concentration of G-actin and inhibits MRTF-dependent transcription. In addition, the experiment was repeated in cells depleted of SRF, in which MRTF cannot be recruited to target genes. The specificity for MRTF target genes was tested by examining pre-mRNA levels at the *Egr1* gene, whose activation is dependent on Ras-ERK-TCF signalling. To induce the *Egr1* gene, cells were stimulated with 12-O-tetradecanoyl phorbol-13-acetate (TPA), which activates ERK and the TCFs, but not Rho-actin signalling (Griner and Kazanietz, 2007). Knock-down efficiency following siRNA treatment was assessed by measuring target


mRNA by qPCR using exonic probes and comparing their levels to these in cells treated with a non-targeting siCtrl. Results are presented in Figure 60.

Transcription at MRTF target genes was induced by CD stimulation in siCtrl treated cells. In cells depleted of Dis3, Zc3h18 and individual components of the NEXT (Zcchc8, Rmb7 and Mtr4) and CBCA (Ncbp1 and Ars2) complexes pre-mRNA levels in the absence of stimulation were upregulated, to levels comparable to these in CD-stimulated cells. The increased expression was MRTF-dependent, since it was inhibited by SRF depletion or LatB addition, both of which prevent MRTF recruitment to targets. In contrast, the TCF-SRF controlled gene *Egr1* showed no change in baseline expression upon depletion of Dis3, Mtr4, Rmb7 or Zcchc8.

However, as in NIH3T3 cells, depletion of Zcchc8 also impaired stimulation with CD at MRTF target genes, as well as TPA stimulation of the *Egr1* gene. Similarly, depletion of Ncbp1 and Ars2 affected expression levels in response to CD and TPA at MRTF target genes and at the *Egr1* gene, respectively.

Apart from increasing gene expression levels under resting conditions, Zc3h18 depletion upregulated pre-mRNA levels in CD-stimulated cells at MRTF target genes. Furthermore, its depletion also enhanced the expression of the *Egr1* gene in untreated cells, as well as in response to TPA stimulation.

The results presented above are consistent with findings in LMB-treated NIH3T3 cells and further support a model in which under resting G-actin levels, MRTF-dependent transcripts are targeted for degradation by the CBCA-dependent NEXT exosome complex.



192




Figure 60 Inactivating the nuclear exosome restores pre-mRNA accumulation at MRTF target genes in dKO^{MRTF-NLS} cells.

Pre-mRNA accumulation at MRTF target genes in dKO^{MRTF-NLS} cells (A) and SRF depleted dKO^{MRTF-NLS} cells (B). Pre-mRNA accumulation at the TCF target gene *Egr1* in dKO^{MRTF-NLS} cells (C) and SRF depleted dKO^{MRTF-NLS} cells (D). Cells were treated with siRNA for 48h, serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D), 0.5µM LatB (Latrunculin B) or left untreated. Pre-mRNA levels were measured using qPCR probes targeting the first intron of the gene. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. The black dotted lines represent pre-mRNA levels in cells treated with scrambled control siRNA. (E) siRNA efficiency. dKO^{MRTF-NLS} cells were treated with siRNA for 48h. mRNA levels were measured using exonic qPCR probes. Signal was normalized to *Gapdh*. mRNA levels following siRNA treatment are shown, relative to these in cells treated with non-targeting scrambled siRNA control. Data is shown as mean ± SEM and is representative of three independent experiments.

6.2 Genome-wide expression analysis in dKO^{MRTF-NLS} cells depleted of Mtr4

Results presented in Chapter 5 demonstrate that the non-productive transcriptional state in LMB-treated NIH3T3 cells correlates with Mtr4 recruitment to MRTF-dependent transcripts and that its depletion is sufficient to restore productive transcription. Moreover, Mtr4 depletion rescues productive RNA synthesis at individual MRTF target genes in untreated dKO^{MRTF-NLS} cells, when nascent RNA synthesis is detected by TTseq. To generalize these findings, RNAseq in dKO^{MRTF-NLS} cells depleted of Mtr4 was performed.

Sequencing libraries were prepared from total RNA purified from dKO^{MRTF-NLS} cells treated with siMtr4 for 48 hours and subsequently stimulated with CD or LatB for 30 min. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini. To increase sensitivity, read count within introns only (intronic reads) or exons only (exonic reads) were analysed. Differential gene expression analysis was performed, comparing each stimulus to untreated cells.

As shown in Figure 61, virtually no gene expression changes in response to CD or LatB were detected by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Nevertheless, the effect of Mtr4 depletion on the expression of the stringent CD-induced gene set defined in Chapter 4.3 was examined. Results are presented in the appendix at the end of this chapter.




Figure 61 The transcriptional response to CD and LatB in Mtr4-depleted

dKO^{MRTF-NLS} cells

(A) Volcano plots representing CD-induced changes in gene expression, as compared to untreated cells, by RNAseq. dKO^{MRTF-NLS} cells were treated with siRNA against Mtr4 for 48h and subsequently stimulated with 3μM CD for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Volcano plots representing LatB-induced changes in gene expression, as compared to untreated cells, by RNAseq. dKO^{MRTF-NLS} cells were treated with siRNA against Mtr4 for 48h and subsequently stimulated with 0.5μM LatB for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in red. Significantly upregulated genes are shown in the yellow boxes. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

dKO^{MRTF-NLS} cells are subjected to chronic stimulation by the constitutively nuclear MRTF-NLS fusion. This in combination with the siRNA treatment might lead to elevated basal transcription and reduced sensitivity to signal. Therefore, we sought to identify genes regulated by MRTF using their sensitivity to LatB.


First, to identify genes whose expression under resting conditions in Mtr4-depleted cells was sensitive to LatB treatment, as an indication of MRTF activity, differential gene expression analysis was performed comparing expression levels in CD-stimulated and untreated cells to those in response to LatB. Results are shown in Figure 62.

In response to CD treatment 133 genes were upregulated in intronic reads and 253 in exonic reads, relative to LatB-treated cells (Figure 62A). Genes upregulated in response to CD were enriched in genes associated with cell proliferation and adhesion (Figure 62B). For full list of significantly overrepresented GO terms see Figure 111. 63 genes showed elevated expression in untreated cells, relative to LatB-treated cells, in intronic reads and 8 in exonic reads (Figure 62C). These were depleted of genes associated with MRTF-SRF signature (Figure 62D). For full list of significantly overrepresented CD terms see Figure 112.

Next, the same approach was applied to identify genes active in untreated dKO^{MRTF-NLS} cells as assessed by TTseq, whose expression was sensitive to LatB and subsequent increase in G-actin levels, as an indication of regulation by MRTF. Differential gene expression analysis was performed comparing expression levels in untreated cells to those in response to LatB. As shown in Figure 63A, 630 genes were active under resting conditions in dKO^{MRTF-NLS} cells and showed sensitivity to LatB treatment.

Α


<u>CD-induced changes/LatB</u>



GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
REGULATION OF CELL POPULATION PROLIFERATION	65	1.56E-24	1.18E-2
POSITIVE REGULATION OF CELL POPULATION PROLIFERATION	45	3.79E-24	1.44E-2
BIOLOGICAL ADHESION	55	1.14E-23	2.89E-2
RESPONSE TO CYTOKINE	47	1.43E-22	2.71E-1
POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS	47	5.68E-22	8.60E-1
POSITIVE REGULATION OF DEVELOPMENTAL PROCESS	28	5.28E-20	6.66E-1
POSITIVE REGULATION OF CELL ADHESION	53	3.58E-19	3.88E-1
REGULATION OF PHOSPHORUS METABOLIC PROCESS	52	2.72E-18	2.57E-1
POSITIVE REGULATION OF MOLECULAR FUNCTION	34	4.47E-18	3.76E-1
REGULATION OF PHOSPHORYLATION	46	1.18E-17	8.96E-1

С

untreated/LatB



D


GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
REGULATION OF CELL DEATH	23	4.04E-17	3.02E-13
APOPTOTIC PROCESS	23	1.06E-15	2.76E-12
RESPONSE TO WOUNDING	16	1.10E-15	2.76E-12
LOCOMOTION	23	1.72E-15	3.22E-12
MUSCLE STRUCTURE DEVELOPMENT	15	8.47E-15	1.27E-11
CELL POPULATION PROLIFERATION	22	1.72E-14	2.14E-11
WOUND HEALING	14	3.42E-14	3.66E-11
PROTEIN PHOSPHORYLATION	20	6.41E-14	5.99E-11
POSITIVE REGULATION OF MOLECULAR FUNCTION	20	2.66E-13	2.21E-10
CIRCULATORY SYSTEM DEVELOPMENT	17	3.82E-13	2.67E-10

Figure 62 Gene expression changes, relative to LatB-treated cells, in Mtr4-

depleted dKO^{MRTF-NLS} cells

(A) Volcano plots representing CD-induced changes in gene expression, as compared to LatB-treated cells, by RNAseq. dKO^{MRTF-NLS} cells were treated with siRNA against Mtr4 for 48h and subsequently stimulated with 3µM CD or 0.5µM LatB for 30 min for 30 min. Significant changes (fold change>1 and pvalue>0.01) are marked in green. Significantly upregulated genes are shown in the yellow boxes. (B) Gene ontology analysis of genes upregulated by CD treatement. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CDinduced genes by RNAseq or TTseq in dKO^{MRTF-NLS} cells are marked with *. (C) Volcano plots representing upregulated and downregulated genes under resting conditions, as compared to LatB-treated cells, by RNAseq. dKO^{MRTF-NLS} cells were treated with siMtr4 for 48h and subsequently stimulated with 0.5µM LatB for 30 min or left untreated. Significant changes (fold change>1 and pvalue>0.01) are marked in purple. Significantly upregulated genes are shown in the yellow boxes. (D) Gene ontology analysis of active genes under resting conditions. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseg or TTseg in dKO^{MRTF-NLS} cells are marked with *. Bioinformatic analysis of RNAseg data was performed by Francesco Gualdrini.

Of the 67 genes which were active under resting conditions and sensitive to LatB treatment in Mtr4-depleted dKO^{MRTF-NLS} cells, 55 fulfilled the same criteria as assessed by TTseq in dKO^{MRTF-NLS} cells (Figure 63B). In contrast, their expression under resting conditions was not detectable by RNAseq (Figure 63C and D). Nevertheless, these were induced in response to CD not only in the RNAseq experiment, but also by TTseq and in Mtr4-depleted cells. Finally, in dKO^{MRTF} cells these genes were inactive in untreated and LatB-treated cells and induced in response to CD in both the RNAseq and TTseq experiments. The same pattern of gene expression was observed at CD-inducible genes and is consistent with regulation by MRTF.



* ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 8.17E-15 16

Figure 63 Defining a Mtr4-controlled MRTF target gene set in dKO^{MRTF-NLS} cells

(A) Volcano plot representing genes active under resting conditions in dKO^{MRTF-} ^{NLS} cells, relative to LatB-treated cells, as assessed by TTseq. dKO^{MRTF-NLS} cells were treated with 0.5µM LatB for 30 min or left untreated. Significant changes (fold change>1 and pvalue>0.01) are marked in purple. Significantly upregulated genes are shown in the yellow boxes. (B) Venn diagram representing the subset of genes active under resting conditions by TTseq in dKO^{MRTF-NLS} cell and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. (C) Heatmap representing gene expression changes at the 55 Mtr4-controlled MRTF-NLS-induced genes in untreated, CDstimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseg in Mtr4-depleted dKO^{MRTF-NLS} cells. Overlap with previously published FCS-induced LatB-sensitive genes (n=1022) is shown (Esnault et al., 2014). The red lines represent FCS-induced LatB-sensitive genes, the white lines represent genes not present in the FCS-induced LatB-sensitive gene set and the grey lines represent genes not identified in the analysis. Overlap with the 180 stringent CD-induced gene set in MEF is shown. The blue lines represent CD-induced genes, the white lines represent genes not present in the gene set. Overlap with the 312 stringent CD-induced gene set in NIH3T3 is shown. The green lines represent CD-induced genes, the white lines represent genes not present in the gene set. (D) Violin plot representing gene expression changes at the 55 Mtr4-controlled MRTF-NLS-induced genes in untreated, CD-stimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. (E) Transcription factor binding motif analysis of the 55 Mtr4-controlled MRTF-NLS-induced genes. Shown are the top 5 TF binding motifs. FDR<0.05. (F) Gene ontology analysis of the 55 Mtr4controlled MRTF-NLS-induced genes. Shown are the top 10 GO categories. FDR<0.05. GO categories also enriched in CD-induced genes by RNAseg or TTseq in dKO^{MRTF-NLS} cells are marked with *. Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.

29 out of the 55 MRTF-NLS-induced Mtr4-sensitive genes were present in the stringent CD-induced gene set defined in MEFs (n=180) and 21 were also CD-inducible in NIH3T3 cells. In addition, 34 of the 55 genes overlapped with previously published FCS-inducible LatB-sensitive genes (Esnault et al., 2014). The 55 MRTF-NLS-induced Mtr4-sensitive genes were enriched in genes associated with SRF binding sites (Figure 63E). Gene ontology analysis showed that genes associated with cell proliferation were overrepresented. In addition, genes associated with apoptotic processes, cell proliferation and cell motility were

enriched in that group (Figure 63F). For full list of significantly overrepresented GO terms see Figure 113.


Taken together, these results and qPCR data on bona-fide MRTF-SRF target genes are consistent with the observation in NIH3T3 cells that nuclear MRTF generates unstable nascent transcripts that are degraded in a Mtr4-dependent manner. However, the chronic state of the dKO^{MRTF-NLS} cells in combination with the prolonged siRNA treatment complicated genome-wide analysis of transcriptional changes in Mtr4-depleted cells.


6.3 Appendix

Relative to untreated cells, no significant changes in gene expression were detected in response to CD or LatB in Mtr4-depleted cells (see Figure 61). Nevertheless, the effect of Mtr4 depletion on expression of genes in the stringent 180 CD-induced gene set defined in Chapter 4 was assessed (see Figure 46).

As described in Chapter 4.3, this gene set was expressed in response to stimulation with CD and inactive in untreated and LatB-treated dKO^{MRTF} cells by RNAseq and TTseq. In dKO^{MRTF-NLS} cells, while under resting conditions no gene expression was detected by RNAseq, genes within the stringent CD set were induced by TTseq in the absence of an activating signal. Their expression was sensitive to treatement with LatB and subsequent increase in G-actin concentration (see Figure 49). In contrast, in Mtr4-depleted dKO^{MRTF-NLS} cells, whereas these genes were induced in untreated cells, they were unresponsive to stimulation with CD and LatB (Figure 64).

This data suggests that Mtr4 depletion in dKO^{MRTF-NLS} cells disrupts signal regulation of the CD-inducible set.







Mtr4-depleted dKO^{MRTF-NLS} cells

(A) Heatmap representing gene expression changes at the 180 genes in the stringent CD-induced gene set defined in Chapter 4.3 (see Figure 46) in untreated, CD-stimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Data for dKO^{MRTF} and dKO^{MRTF-NLS} RNAseq and TTseq is from Figure 49. (B) Violin plot representing gene expression changes at the 180 genes in the CD-induced gene set in untreated, CD-stimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Data for dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Data for dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Data for dKO^{MRTF-NLS} cells and tTSeq in Mtr4-depleted dKO^{MRTF-NLS} cells. Data for dKO^{MRTF-NLS} cells and tTSeq in Mtr4-depleted dKO^{MRTF-NLS} cells. Data for dKO^{MRTF} and dKO^{MRTF-NLS} RNAseq and TTSeq is from Figure 49. Bioinformatic analysis of RNAseq and TTSeq data was performed by Francesco Gualdrini.

Next, gene expression at the 312 stringent CD-induced gene set in NIH3T3 cells defined in Chapter 3 was examined (see Figure 35). As described in Chapter 3.3, genes within this set were induced by CD stimulation and inactive in untreated and LMB-treated NIH3T3 cells by RNAseq. Nevertheless, they were induced in response to LMB as assessed by TTseq and by RNAseq in Mtr4-depleted cells.

As expected from the small overlap between CD-induced genes in MEF and NIH3T3 cells (see Figure 46), these were only weakly induced by CD in dKO^{MRTF} cells (Figure 65A and B). Genes within this set exhibited lack of sensitivity to LatB treatment not only in Mtr4-depleted dKO^{MRTF-NLS}, but also in dKO^{MRTF} and dKO^{MRTF-NLS} cells as assessed by RNAseq, further indicating their expression might not be MRTF-dependent. This might reflect differential regulation of these genes in NIH3T3 and MEF cells or changes arising during the generation of the reconstituted dKO^{MRTF} and dKO^{MRTF-NLS} cell lines. Nevertheless, in the TTseq experiment genes within this set were significantly upregulated in response to CD stimulation and sensitive to LatB treatment both in dKO^{MRTF} and dKO^{MRTF-NLS} cells, potentially due to higher sensitivity of the TTseq method.






from NIH3T3 cells in Mtr4-depleted dKO^{MRTF-NLS} cells

(A) Heatmap representing gene expression changes at the 312 genes in the CDinduced gene set in NIH3T3 cells defined in Chapter 3.3 in untreated, CDstimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. (B) Violin plot representing gene expression changes at the 312 genes in the CD-induced gene set defined in NIH3T3 cells in untreated, CD-stimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.

Chapter 6. Results

Finally, the expression of the 455 LMB-induced Mtr4-sensitive gene set in NIH3T3 cells defined in Chapter 5 was assessed. As described in Chapter 5.2, this gene set was inactive in untreated cells NIH3T3 cells and expressed in response to CD by TTseq and RNAseq. In response to LMB, no gene activation was detectable by RNAseq, despite being upregulated by TTseq and in Mtr4-depleted cells (see Figure 56).

The results from this analysis were similar to these at the 312 stringent CD-induced gene set. As presented in Figure 66, genes in the 455 LMB-induced Mtr4-controlled gene set exhibited elevated basal expression and lack of sensitivity to CD and LatB not only in Mtr4-depleted dKO^{MRTF-NLS} cells, but also in dKO^{MRTF} and dKO^{MRTF-NLS} cells as assessed by RNAseq, potentially reflecting differences arising during the reconstitution of MRTF-A/B null cells. In the TTseq experiment genes within this set were mostly sensitive to LatB treatment both in dKO^{MRTF} and dKO^{MRTF-NLS} cells, which might potentially be due to higher sensitivity of the TTseq method.





gene set from NIH3T3 cells in Mtr4-depleted dKO^{MRTF-NLS} cells

(A) Heatmap representing gene expression changes at the 455 genes in the LMBinduced Mtr4-controlled gene set in NIH3T3 cells defined in Chapter 5.2 in untreated, CD-stimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseg in Mtr4-depleted dKO^{MRTF-NLS} cells. (B) Violin plot representing gene expression changes at the 455 genes in the LMB-induced Mtr4-controlled gene set defined in NIH3T3 cells in untreated, CDstimulated and LatB-treated cells by RNAseq and TTseq in dKO^{MRTF} and dKO^{MRTF-NLS} cells and by RNAseq in Mtr4-depleted dKO^{MRTF-NLS} cells. Bioinformatic analysis of RNAseq and TTseq data was performed by Francesco Gualdrini.


Chapter 7. Recruitment of the exosome correlates with aberrant phosphorylation of the Pol II CTD at MRTF target genes

The data presented in the previous chapters demonstrates that in the absence of G-actin depletion, nuclear MRTF induces Pol II recruitment and nascent RNA synthesis but no pre-mRNA accumulates. In this setting, Mtr4 is recruited to transcripts of MRTF target genes and appears to target them for degradation by the nuclear exosome. In this chapter, to characterize the non-productive transcriptional state at MRTF-SRF targets in LMB-treated cells, chromatin remodeling, the recruitment of pausing and elongation factors, as well as the phosphorylation state of the Pol II CTD at MRTF target genes were examined.

7.1 Chromatin remodeling is not defective in LMB-treated cells

Dense nucleosome occupancy obstructs the elongating polymerase and inversely correlates with transcription rates (Gates et al., 2017). Various chromatin remodelers and histone modifiers associate with Pol II during elongation to promote its processivity though chromatin. Modifications of histones alter the physical and chemical properties of chromatin and influence its compaction and accessibility. Thus, actively transcribed and transcriptionally silenced regions of the genome have distinct chromatin signatures. H3K4me3 and H3K27Ac are canonical chromatin marks present at active gene promoters, whereas H3K36me3, H3K79me3 and H2Bub are found within gene bodies and associated with the elongating Pol II. Whether these chromatin marks are deposited normally at MRTF target genes in the non-productive transcriptional state was examined.

NIH3T3 cells were treated with CD, which activates MRTF target genes, or LMB, which induces non-productive transcription at MRTF targets. H3K4me3, H3K27Ac, H3K36me3 and H3K79me3 were examined by ChIP-qPCR. qPCR probes targeting regions along the length of the *Acta2* and *Actb* model genes were used. Results are shown in Figure 67.






Figure 67 Chromatin remodeling in LMB-treated cells

H3 (ab1791), H3K4me3 (ab8580), H3K27Ac (ab4729), H3K36me3 (ab9050) and H3K79me3 (ab2621) ChIP at the *Acta2* (A) and *Actb* (B) genes. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B) or left untreated. Signal was normalized to input or H3, as indicated in the figure. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics. In CD-stimulated cells, H3K4me3 and H3K27Ac were upregulated at the TSS of the *Acta2* and *Actb* genes. Within the gene body, H3K79me3 was detected towards the 5' end, whereas H3K36me3 started accumulating within the gene body, reaching maximum towards the 3' end of the gene. Similar results were seen in LMB-treated cells. Both H3K4me3 and H3K27Ac were present at the TSS of the *Acta2* and *Actb* genes, at levels similar to these in CD-stimulated cells. H3K79me3 and H3K36me3 were observed at the 5' and 3' end of the gene body, respectively, at levels comparable to these seen in CD-stimulated cells.

Consistent with the presence of elongating Pol II and active transcription, chromatin remodeling at the promoter region, as well as within the gene body of MRTF target genes appears to occur normally in response to LMB treatement.

7.2 Pol II pause-release occurs in LMB-treated cells

Prior to transitioning into elongation, Pol II undergoes promoter-proximal pausing (Chen et al., 2018). In addition to promoting 5' capping of the nascent transcript, pausing potentially represents a transcriptional checkpoint to ensure that Pol II is competent for elongation. To examine Pol II pausing in the LMB-induced non-productive transcriptional state, the recruitment of CDK9 and the positive and negative elongation factors DSIF and NELF, which regulate the transition of the paused Pol II into elongation (Figure 68A), was analysed at MRTF target genes.

As before, NIH3T3 cells were treated with CD or LMB and the recruitment of NELF and CDK9 to MRTF target gene promoters assessed by ChIP-qPCR. The *Zfp37* gene, which is not regulated by MRTF, was used as a control. To determine whether DSIF was properly associated with the elongating Pol II, ChIP for its Spt5 subunit was performed. Whereas CDK9 and NELF associate with paused Pol II at 5' ends of genes, Spt5 remains associated with the elongating form of the Pol II. Therefore, qPCR probes targeting regions along the whole transcriptional unit of the *Acta2* and *Actb* genes were used. Results are shown in Figure 68.




Figure 68 Pol II undergoes pause-release in LMB-treated cells

(A) Pol II pause-release is dependent on CDK9. CDK9 phosphorylates NELF, DSIF and Serine 2 of the Pol II CTD, allowing the Pol II to transition into elongation. (B) NELF-E (10705-1-AP), (C) CDK9 (2316) and (D) Spt5 (sc-28678) ChIP at MRTF target genes. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B) or left untreated. Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

In response to CD stimulation, CDK9, NELF-E and Spt5 were recruited to MRTF target gene promoters. The Spt5 profile along the gene resembled the one of the Pol II. Spt5 was present along the gene, with a pronounced peak at the TSS. LMB treatment also induced recruitment of NELF, CDK9 and Spt5 at MRTF target genes. Furthermore, the Spt5 ChIP profile was similar to that in CD-stimulated cells. Nevertheless, ChIP levels were somewhat reduced as compared to these in CD-stimulated cells.

These results indicate that promoter-proximal pausing occurs at MRTF targets in LMB-treated cells and that the released Pol II is accompanied by DSIF.

7.3 The non-productive transcriptional state in LMB-treated cells correlates with aberrant phosphorylation of the Pol II CTD

The phosphorylation state of the Pol II CTD orchestrates the recruitment of various factors that mediate transcription and RNA processing throughout the transcriptional cycle (Zaborowska et al., 2016). Therefore, whether the susceptibility of MRTF-dependent transcripts to degradation by the exosome correlates with defective phosphorylation of the Pol II CTD was investigated next.

In mammalian cells, the CTD of the Pol II consists of 52 heptad repeats of the consensus sequence Y¹S²P³T⁴S⁵P⁶S⁷ (Bartolomei et al., 1988; Corden et al., 1985). Dynamic phosphorylation of residues within the Pol II CTD is the best characterized CTD modification in transcription. Distinct CTD phosphorylation patterns correlate with different stages of the transcription cycle. Serine 5 phosphorylation is associated with initiation of transcription, whereas phospho-Ser2 and phospho-Thr4 are involved in elongation and termination (Gomes et al., 2006; Kim et al., 2002; Komarnitsky et al., 2000). Despite being present at all actively transcribed genes, phospho-Ser7 appears to play specific role in the transcription and RNA processing of snRNA genes (Egloff et al., 2007). Tyr1P is involved in the control of transcription directionality (Descostes et al., 2014).

To determine whether the different treatments affect Pol II CTD phosphorylation globally, the phosphorylation status of the Pol II CTD was examined by Western blot using phospho-specific antibodies. NIH3T3 cells were treated with CD, which induces productive RNA synthesis at MRTF target genes; LMB which induces non-productive transcription; or LatB, which inhibits MRTF-dependent transcription. Results are shown in Figure 69.

Rpb1 antibody detected two Pol II species, a higher molecular weight one which corresponds to the phosphorylated form of Pol II (Pol II0), and a lower molecular weight one which corresponds to unphosphorylated Pol II (Pol IIA). As compared to untreated cells, Pol II0 levels remained unchanged in cells treated with CD, LMB or LatB. None of the treatments affected Ser5P, Ser7P, Ser2P, Thr4P or Tyr1P levels, demonstrating that they have no general effect on Pol II phosphorylation.




Figure 69 Inhibition of Crm1 does not affect Pol II CTD phosphorylation globally

Western blot analysis of RNA polymerase II C-terminal domain phospho-activating marks. Cells were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); 0.5 μ M LatB (Latrunculin B) or left untreated. Samples were probed with antibodies targeting Rpb1 (D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12), Serine 2 (S2P, 3E10), Tyrosine 1 (Y1P, 3D12) or Threonine 4 (Thr4P, 6D7).

Next, potential differences in Pol II recruitment and phosphorylation status between conditions at MRTF target genes, specifically, were examined by ChIP. NIH3T3 cells were treated with CD or LMB and Pol II recruitment to target genes was assessed using antibodies against the Rpb1 subunit of the Pol II (D8L4Y), to measure total Pol II, and phospho-specific antibodies targeting Ser5P (3E8), Ser7P (4E12), Ser2P (3E10), Thr4P (6D7) and Tyr1P (3D12) of the Rpb1 CTD (Chapman et al., 2007). The model gene *Acta2* was used. As before, qPCR probes targeting regions along the length of the gene were used. Results are shown in Figure 70.




Figure 70 Pol II recruitment and CTD phosphorylation at the Acta2 gene

Rpb1 (D8L4Y), phospo-Ser5 (S5P, 3E8), phospho-Ser7 (S7P, 4E12), phospho-Ser2 (S2P, 3E10), phospho-Thr4 (T4P, 6D7) and phospho-Tyr1 (Y1P, 3D12) ChIP at the model gene *Acta2*. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); or left untreated. Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within the series and are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematic.

In response to CD stimulation, Pol II was recruited to the *Acta2* gene. Pol II ChIP signal was present across the *Acta2* gene, with a peak at the TSS. The ChIP profile of Ser5P and Ser7P followed the one of total Pol II, while Ser2P and Thr4P started accumulating within the gene body and reached maximum towards the poly(A) site at the 3' end of the gene. Tyr1P reached maximum near the TSS of the *Acta2* gene.

LMB treatment also induced Pol II recruitment. Pol II distribution along the gene was as in CD-stimulated cells. However, ChIP levels were reduced compared to these in CD-stimulated cells. The same result was observed for phospho-Ser5. LMB treatment did not induce Ser7P, Ser2P, Thr4P or Tyr1P accumulation.


These results suggest that the LMB-induced non-productive transcriptional state correlates with aberrant phosphorylation of the Pol II CTD. To determine whether this was generally true for MRTF target genes, we performed ChIPseq.


NIH3T3 cells were treated with CD or LMB, sequencing libraries were prepared following IPs using antibodies against the Rpb1 subunit of the Pol II (D8L4Y), to measure total Pol II, and phospho-specific antibodies targeting Ser5P (3E8), Ser7P (4E12) and Ser2P (3E10) (Chapman et al., 2007). Pol II recruitment and CTD phosphorylation was analysed at the 312 stringent CD-induced gene set defined in Chapter 3.3. Bioinformatic analysis of ChIPseq data was performed by Francesco Gualdrini. Metaprofiles of total Pol II and Ser5P, Ser7P and Ser2P forms of Pol II are shown in Figure 71A and metaprofiles of Ser5P, Ser7P and Ser2P forms of Pol II normalized to total Pol II signal are shown in Figure 71B, separately covering three gene regions: the TSS of MRTF target genes, defined as the region spanning 500bp upstream to 500bp downstream of the TSS; the gene body, defined as the region 500bp downstream of the TSS to 500bp upstream of the TTS, normalized to 100%; and the TTS- the region 500bp upstream of the TTS to 7000bp downstream of the TTS.

Like at the *Acta2* model gene, in response to CD stimulation, the fully phosphorylated form of Pol II was recruited at MRTF target genes. Pol II ChIP signal was present across the gene, with a peak at the TSS. The ChIP profile of

Ser5P and Ser7P followed the one of total Pol II, while Ser2P reached maximum towards the poly(A) site at the 3' end of genes. In response to LMB treatment, the Pol II was recruited to MRTF target genes, albeit at reduced levels. The Pol II ChIP profile was as in CD-stimulated cells. However, the CTD of the recruited Pol II was aberrantly phosphorylated. Ser5P and Ser7P levels were reduced, with the effect on Ser7P being more pronounced, while Ser2P was virtually absent. In contrast, Pol II recruitment and CTD phosphorylation was unaltered in CD- and LMB-treated cells at a control set of 160 constitutively expressed genes, which are not under the regulation of MRTF (Figure 72).

Overall, stimulation with CD, which activates productive RNA synthesis at MRTF target genes, induces the recruitment of the fully phosphorylated form of the RNA Pol II. On the other hand, the LMB-induced non-productive transcriptional state correlates with defective Pol II CTD phosphorylation. This data suggests that while hypo-phosphorylated Pol II is competent for elongation, additional phosphorylation events are required for productive RNA synthesis.








Figure 71 Pol II ChIPseq at the stringent 312 CD-inducible gene set

(A) Metaprofiles of Rpb1 (D8L4Y), phospo-Ser5 (Ser5P, 3E8), phospho-Ser7 (Ser7P, 4E12) and phospho-Ser2 (Ser2P, 3E10) ChIPseq at the 312 CD-inducible gene set defined in Chapter 3.3. NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D); 50nM LMB (Leptomycin B); or left untreated. Normalized average read counts are plotted at the TSS region (500bp upstream to 500bp downstream of the TSS (0)); the gene body (500bp downstream of the TSS to 500bp upstream of the TTS, normalized to 100%); the TTS (500bp upstream to 7000bp downstream of the TTS (0)). (B) Metaprofiles of phospo-Ser5 (Ser5P), phospho-Ser7 (Ser7P) and phospho-Ser2 (Ser2P) ChIPseq relative to total Pol II at the 312 CD-inducible gene set defined in Chapter 3.3. The untreated ChIP profile per base was substracted from each individual ChIP, the per-base ratio between CD/LMB for total Pol II was calculated and the obtained Pol II per-base ratio from CD/LMB was applied on the ChIP of Ser5P, Ser7P and Ser2P. Relative signal is plotted at the TSS region (500bp upstream to 500bp downstream of the TSS (0)); the gene body (500bp downstream of the TSS to 500bp upstream of the TTS, normalized to 100%); the TTS (500bp upstream to 7000bp downstream of the TTS (0)). (C) ChIPseq read plots in untreated, CDstimulated and LMB-treated cells at the CD-inducible MRTF-SRF target genes Actb, Acta2 and Vcl. Bioinformatic analysis of ChIPseq data was performed by Francesco Gualdrini.





Figure 72 Pol II ChIPseq at constitutively expressed genes

Metaprofiles of Rpb1 (D8L4Y), phospo-Ser5 (Ser5P, 3E8), phospho-Ser7 (Ser7P, 4E12) and phospho-Ser2 (Ser2P, 3E10) ChIPseq at a control set of constitutively expressed genes (n=160). NIH3T3 fibroblasts were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D); 50nM LMB (Leptomycin B); or left untreated. Normalized average read counts are plotted at the TSS region (500bp upstream to 500bp downstream of the TSS (0)); the gene body (500bp downstream of the TSS to 500bp upstream of the TTS, normalized to 100%); the TTS (500bp upstream to 7000bp downstream of the TTS (0)). Bioinformatic analysis of ChIPseq data was performed by Francesco Gualdrini.

7.4 Mtr4 and Nrde2 depletion does not affect Pol II recruitment at MRTF target genes

As described in Chapter 5, Mtr4 depletion restores productive RNA synthesis in LMB-treated NIH3T3 cells. Conversely, Nrde2 depletion can inhibit CD-stimulation of MRTF target genes. To exclude the possibility that rather than acting directly at the level of RNA turnover, depletion of Mtr4 and Nrde2 affect Pol II recruitment or CTD phosphorylation at MRTF target genes, ChIP assays in cells depleted of Mtr4 or Nrde2 were performed.

NIH3T3 cells were treated with siRNA against Mtr4, Nrde2 or a non-targeting scrambled siRNA for 48 hours and subsequently stimulated with LMB or CD. As before, Pol II recruitment and CTD phosphorylation at the *Acta2* model gene was assessed by qPCR. qPCR probes targeting regions along the length of the *Acta2* gene were used. Results are shown in Figure 73.



223




Figure 73 Depletion of Mtr4 and Nrde2 does not affect Pol II recruitment

Total RNA Polymerase (Pol II, D8L4Y), phospho-serine 5 (S5P, 3E8), phosphoserine 7 (S7P, 4E12) and phospho-serine 2 (S2P, 3E10) of the Pol II CTD ChIP at the *Acta2* gene. NIH3T3 fibroblasts were treated with non-targeting siRNA (A), siRNA against Mtr4 (B) or siRNA against Nrde2 (C) for 48h, serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D) or 50nM LMB (Leptomycin B). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematic.

In cells treated with siCtrl, CD stimulation induced the recruitment of the fully phosphorylated form of the Pol II to the *Acta2* gene. The ChIP profiles of total Pol II, Ser5P, Ser7P and Ser2P were as in wild-type NIH3T3 cells. LMB treatment also

induced Pol II recruitment. Pol II distribution along the gene and CTD phosphorylation was as in wild-type NIH3T3 cells (Figure 73A).

Next, Pol II recruitment and CTD phosphorylation was examined in cells depleted of Mtr4 (Figure 73B) or Nrde2 (Figure 73C). Mtr4 or Nrde2 depletion did not alter Pol II recruitment or distribution along the gene in response to CD or LMB treatment. Furthermore, levels of phospho-Ser5, phospho-Ser7 and phospho-Ser2 were not affected in cells depleted of Mtr4 or Nrde2.

These results show that depletion of Mtr4 restores productive RNA synthesis at MRTF target genes in LMB-treated cells, without affecting Pol II loading on the gene or Pol II CTD phosphorylation. Moreover, Nrde2 depletion, which inhibits RNA synthesis in response to CD stimulation, does not perturb Pol II recruitment or phosphorylation. This data is consistent with a model in which Mtr4 and its inhibitor Nrde2 act downstream of Pol II, to regulate the turn-over of transcripts of MRTF target genes.

7.5 The non-productive transcriptional state in dKO^{MRTF-NLS} cells correlates with aberrant phosphorylation of the Pol II CTD

The non-productive transcriptional state observed in LMB-treated NIH3T3 cells also occurs in dKO MEF cells expressing the constitutively nuclear MRTF-NLS derivative. Under resting conditions, the constitutively nuclear MRTF-NLS is recruited to target gene promoters and induces transcription, but not productive RNA synthesis. To test the correlation between the non-productive transcriptional state and the abnormal phosphorylation status of the Pol II CTD, Pol II recruitment and CTD phosphorylation at MRTF target genes in dKO^{MRTF-NLS} cells were examined.

Pol II recruitment and CTD phosphorylation were examined by ChIP-qPCR at the *Acta2* and *Actb* genes in dKO^{MRTF-NLS} under resting conditions, as well as in response to CD, which induces productive RNA synthesis, and LatB, which inhibits

transcription at MRTF target genes. As controls, the experiment was repeated in dKO^{MRTF} cells, in which in the absence of stimulation target genes are inactive, and in $dKO^{MRTF-XXX}$ cells, in which MRTF target genes are constitutively active.

In dKO^{MRTF} cells under resting conditions Pol II was not recruited to the *Acta2* and *Actb* genes (Figure 74). Pol II remained absent from MRTF target genes in LatB-treated cells. In response to stimulation with CD, Pol II was recruited to target genes. Pol II signal was present throughout the gene, with a distinct peak at the TSS. In CD-treated cells, Ser5P, Ser7P and Ser2P were upregulated. Ser5P and Ser7P ChIP profile resembled that of total Pol II, whereas Ser2P started accumulating within the gene body and reached maximum at the 3' end of genes.





Figure 74 Pol II recruitment and phosphorylation at MRTF target genes in dKO^{MRTF} cells

Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12) or Serine 2 (S2P, 3E10) ChIP in dKO^{MRTF} cells on the model genes *Acta2* (A) and *Actb* (B). Cells were stimulated for 30 min with 3 μ M CD (Cytochalasin D); 0.5 μ M LatB (Latrunculin B) or left untreated. Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

In contrast, in dKO^{MRTF-NLS} cells, Pol II was recruited at the *Acta2* and *Actb* genes under resting conditions, although at reduced levels, relative to these in CD-stimulated cells (Figure 75). Furthermore, Ser5P was present at the 5' end of the gene, albeit at reduced levels. In contrast, Ser7 and Ser2 were not phosphorylated at the 3' end of the genes tested. CD treatment induced Pol II recruitment and phosphorylation at Ser5P, Ser7P and Ser2P. The ChIP profiles of the total and phosphorylated forms of Pol II were as in CD-stimulated dKO^{MRTF} cells. LatB addition abolished Pol II recruitment.



229

Figure 75 Pol II recruitment and phosphorylation at MRTF target genes in dKO^{MRTF-NLS} cells

Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12) or Serine 2 (S2P, 3E10) ChIP in dKO^{MRTF-NLS} cells on the model genes *Acta2* (A) and *Actb* (B). Cells were stimulated for 30 min with 3 μ M CD (Cytochalasin D); 0.5 μ M LatB (Latrunculin B) or left untreated. Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

In dKO^{MRTF-XXX} cells, where MRTF is constitutively active, Pol II was recruited at MRTF target genes in the absence of treatment (Figure 76). Furthermore, its CTD was phosphorylated at Ser5, Ser7 and Ser2. The ChIP profiles of the total and phosphorylated forms of the Pol II were as in CD-stimulated dKO^{MRTF} cells. Consistent with the inability of MRTF-XXX to interact with G-actin, Pol II recruitment and phosphorylation remained unchanged in response to CD and LatB treatments.




Figure 76 Pol II recruitment and phosphorylation at MRTF target genes in dKO^{MRTF-XXX} cells

Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12) or Serine 2 (S2P, 3E10) ChIP in dKO^{MRTF-XXX} cells on the model genes *Acta2* (A) and *Actb* (B). Cells were stimulated for 30 min with 3 μ M CD (Cytochalasin D); 0.5 μ M LatB (Latrunculin B) or left untreated. Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

The data presented above demonstrates that Pol II recruitment to MRTF target genes is dependent on MRTF binding and that CTD phosphorylation is promoted by disrupting the interaction between MRTF and G-actin. Consistent with data in NIH3T3 cells, these results suggest that in the absence of an activating signal, nuclear MRTF recruits Pol II to targets in a non-productive state associated with aberrant CTD phosphorylation and Mtr4 recruitment.

Chapter 8. Phospho-Ser7 of the Pol II CTD is required for productive RNA synthesis at MRTF target genes

In the absence of an activating signal, nuclear MRTF is recruited to target gene promoters. Its binding induces Pol II recruitment and nascent RNA synthesis, but pre-mRNA does not accumulate. Instead, transcripts of MRTF target genes are bound by Mtr4, which appears to target them for degradation by the nuclear exosome. This non-productive transcriptional state correlates with aberrant phosphorylation of the Pol II CTD. To establish whether the relationship between low Ser5P, Ser7P and Ser2P levels and transcript destabilization is causal or correlative, in this chapter the effect of CTD phospho-marks on productive RNA synthesis at MRTF target genes was examined.


8.1 The effect of CDK inhibitors on MRTF target gene expression

A number of CTD kinases act during the transcription cycle to ensure appropriate regulation of Pol II during transcription. During initiation, CDK7 phosphorylates Ser5 and Ser7 of the Pol II CTD (Glover-Cutter et al., 2009; Ramanathan et al., 2001). During promoter-proximal pausing, CDK9 phosphorylates Ser2 of the Pol II CTD, along with DSIF and NELF, to induce pause release into elongation (Ramanathan et al., 2001). In addition, CDK12 and CDK13 have been shown to target Ser2 (Bartkowiak et al., 2010). Thr4P is deposited by Plk3, whereas the Tyr1P kinase in mouse is unknown (Hintermair et al., 2012; Tybulewicz et al., 1991).

To study the role of different CTD phospho-marks in transcription at MRTF target genes, CDK inhibitors were investigated, aiming to ascertain whether any could block RNA synthesis and recapitulate the defect in Pol II CTD phosphorylation observed in the non-productive transcriptional state. Cells were treated with CD to induce productive transcription and the effect of different CDKs assessed using

specific small molecule inhibitors. Alongside the effect on CD-induced RNA synthesis, recruitment of Pol II to the *Acta2* model gene was examined, together with the distribution of CTD phosphorylations.

NIH3T3 cells were simultaneously treated with CD and THZ1 to inhibit CDK7 (Kwiatkowski et al., 2014); Flavopiridol (FP) to inhibit CDK9 (Biglione et al., 2007; Chao & Price, 2001; Ni et al., 2004); THZ531 to inhibit CDK12 and CDK13 (Zhang et al., 2016); GW843682X to inhibit Plk3 (Pohl et al., 2017). Following treatment pre-mRNA levels at endogenous MRTF target genes were measured by qPCR using probes targeting the first intron of each gene.





Pre-mRNA accumulation in response to stimulation at MRTF target genes. NIH3T3 fibroblasts were serum-starved overnight and stimulated with 3μ M CD for 30 min; ; 0.5 μ M Flavopiridol (FP) for 1h and 3μ M CD for 30 min; 0.5 μ M THZ1 for 1h and 3μ M CD for 30 min; 1 μ M THZ531 for 1h and 3μ M CD for 30 min; 10 μ M GW843682X for 1h and 3μ M CD for 30 min; or left untreated. qPCR probes are located within the first intron of each gene. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments.

As shown in Figure 77, THZ1 and FP substantially blocked CD induction at all MRTF target genes tested, while THZ531 and GW843682X had no effect.

Chapter 8. Results

Next, the effect of the CDK inhibitors on Pol II CTD modifications the model gene *Acta2* was assessed by ChIP-qPCR using antibodies against the Rpb1 subunit of the Pol II (D8L4Y), to measure total Pol II, and phospho-specific antibodies targeting Ser5P (3E8), Ser7P (4E12), Ser2P (3E10), Thr4P (6D7) and Tyr1P (3D12) of the Rpb1 CTD (Chapman et al., 2007). NIH3T3 cells were simultaneously treated with CD and THZ1 to inhibit CDK7; Flavopiridol (FP) to inhibit CDK9; THZ531 to inhibit CDK12 and CDK13; GW843682X to inhibit Plk3. Background ChIP levels were assessed in untreated cells, when MRTF target genes are uninduced. qPCR probes targeting regions along the length of the *Acta2* gene were used.

First, the effect of inhibiting CDK7 was examined. Results are presented in Figure 78. As shown before, CD stimulation induced Pol II recruitment and phosphorylation at Ser5, Ser7, Ser2, Thr4 and Tyr1 of the Pol II CTD. Addition of the CDK7 inhibitor THZ1 to CD-stimulated cells inhibited Pol II loading on the gene.

Next, the effect of inhibiting Ser2 phosphorylation was examined. To this end, Flavopiridol (FP), a CKD9 inhibitor, as well as THZ531, an inhibitor of CDK12 and CDK13, were used. Of these inhibitors only FP inhibited CD-induced RNA synthesis (Figure 77). In CD-stimulated cells treated with FP, a peak of Pol II remained at the TSS of the *Acta2* gene, but no Pol II was detected along the gene body. The paused Pol II was phosphorylated on Ser5, Ser7 and Tyr1 (Figure 79). In contrast, treatment with THZ531 did not affect the profiles of total Pol II, Ser5P, Ser7P or Tyr1P, although levels of Ser2P and Thr4P were reduced at the 3' end of the gene (Figure 80).




Figure 78 THZ1 inhibits Pol II recruitment at MRTF target genes

(A) Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12), Serine 2 (S2P, 3E10), Tyrosine 1 (Y1P, 3D12) or Threonine 4 (T4P, 6D7) ChIP at the *Acta2* gene. NIH3T3 fibroblasts were serum-starved overnight, treated with 0.5μ M THZ1 for 1h and stimulated for 30 min with 3μ M CD (Cytochalasin D). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.




Figure 79 FP inhibits Pol II elongation at MRTF target genes

(A) Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12), Serine 2 (S2P, 3E10), Tyrosine 1 (Y1P, 3D12) or Threonine 4 (T4P, 6D7) ChIP at the *Acta2* gene. NIH3T3 fibroblasts were serum-starved overnight, treated with 0.5μ M Flavopiridol (FP) for 1h and stimulated for 30 min with 3μ M CD (Cytochalasin D). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.




Figure 80 THZ531 does not affect Pol II elongation at MRTF target genes

(A) Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12), Serine 2 (S2P, 3E10), Tyrosine 1 (Y1P, 3D12) or Threonine 4 (T4P, 6D7) ChIP at the *Acta2* gene. NIH3T3 fibroblasts were serum-starved overnight, treated with 1 μ M THZ531 for 1h and stimulated for 30 min with 3 μ M CD (Cytochalasin D). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

As shown in Figure 81, addition of the Plk3 inhibitor GW843682X in CD-stimulated cells reduced the accumulation of Thr4P at the 3' end of the gene. Apart from the reduction in Thr4P levels, GW843682X treatment also reduced S2P levels, whereas it did not have an effect on Pol II recruitment and elongation, Ser5P, Ser7P or Tyr1P levels.

We were unable to assess the effect of depleting Tyr1P, as the kinase responsible for depositing this mark in mouse cells remains unidentified (Tybulewicz et al., 1991).

Overall, none of the inhibitors tested reproduced the non-productive state observed in LMB-treated NIH3T3 cells and dKO^{MRTF-NLS} cells. Although Ser2P and Thr4P levels were reduced by THZ531 or GW843682X treatment, expression of MRTF target genes was unaffected. While inhibiting CDK7 perturbed CD stimulation of MRTF target genes, its effect was due to inhibition of Pol II recruitment, consistent with its role in TFIIH activity. Consistent with the role of CDK9 in pTEFb activity and Pol II pause-release, Flavopiridol addition prevented the transition of the Pol II into elongation. Thus, neither inhibitor that prevents RNA synthesis induces a Pol II CTD phospho-profile similar to that seen in the LMB-induced non-productive transcriptional state.




Figure 81 GW843682X does not affect Pol II elongation MRTF target genes

(A) Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12), Serine 2 (S2P, 3E10), Tyrosine 1 (Y1P, 3D12) or Threonine 4 (T4P, 6D7) ChIP at the *Acta2* gene. NIH3T3 fibroblasts were serum-starved overnight, treated with 10 μ M GW843682X for 1h and stimulated for 30 min with 3 μ M CD (Cytochalasin D). Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

8.2 Generation of NIH3T3 cells expressing Rpb1-S7A mutant

CDK7 phosphorylates both Ser5 and Ser7 of the Pol II CTD. While phosphorylation of Ser5 precedes that of Ser7 and is required for transcription initiation, little is known about the role of Ser7P in transcription at protein-coding genes. We were unable to study the role of Ser7P in transcription of MRTF target genes using CDK7 inhibition, as THZ1 blocked phosphorylation of Ser5 and Pol II recruitment. Therefore, to study the role of Ser7P, a Rpb1 mutant (Rpb1-S7A) was used. The Rpb1 and Rpb1-S7A plasmids were generated by Ana Tufegdzic Vidakovic. Both Rpb1 and Rpb1-S7A plasmids contain point mutations making them siRNA resistant (see Chapter 2.16). Rpb1-S7A harbours serine 7 to alanine substitutions in all 26 Ser7-containing repeats of the Rpb1 CTD (Figure 82A), preventing phosphorylation of the Pol II CTD at this position (Tufegdzic Vidakovic A., unpublished).

To study Rpb1-S7A a conditional depletion-expression strategy was used (Figure 82B). NIH3T3 FIp-In TREx cells were used to generate stable cell lines expressing doxycycline-inducible wild-type Rpb1 (WT) or Rpb1-S7A (S7A). WT and S7A cells were treated with siRNA against Rpb1 for 48 hours, to deplete the endogenous Rpb1 protein, and simultaneously treated with doxycycline, to reconstitute them with either wild-type Rpb1 or Rpb1-S7A, to generate "switch-over" cells expressing exogenous wild-type Rpb1 (WT-ON) or Rpb1-S7A (S7A-ON). WT and S7A cells grown in doxycycline-free medium and treated with scrambled siRNA for 48 hours are referred to as WT-off and S7A-off, respectively. As shown in Figure 82C, Rpb1 protein levels were comparable in WT-ON and S7A-ON cells, while phospho-Ser7 levels were lower in S7A-ON than in WT-ON cells. The remaining Ser7P signal in S7A-ON cells is likely due to incomplete depletion of the endogenous Rpb1 protein.




Figure 82 Generation of WT-ON and S7A-ON cells

(A) Human Rpb1 CTD. Ser7-containing repeats are highlighted in yellow. Nonconsensus repeats are shown in grey and amino acid substitutions at position 7 of each repeat are indicated. (B) Generation of WT-ON and S7A-ON cells. NIH3T3 Flp-In TREx cells were used to generate stable cell lines expressing doxycyclineinducible wild-type Rpb1 (WT) or Rpb1-S7A (S7A). WT and S7A cells were treated with siRNA against Rpb1 for 48 hours, to deplete the endogenous Rpb1 protein, and simultaneously treated with doxycycline, to reconstitute them with either wildtype Rpb1 or Rpb1-S7A, to generate "switch-over" cells expressing exogenous wild-type Rpb1 (WT-ON) or Rpb1-S7A (S7A-ON). WT and S7A cells grown in Tetfree medium and treated with scrambled siRNA for 48 hours are referred to as WToff and S7A-off, respectively. For gene expression and ChIP experiments, 24 hours following siRNA treatment, cells were starved overnight and subsequently stimulated with CD or FCS or left untreated. (C) Western blot showing Rpb1 (D8L4Y) and phospho-Ser7 (4E12) levels in WT-off, WT-ON, S7A-off and S7A-ON cells. Tubulin (T5162) was used as loading control.


8.3 Inhibition of phosphorylation at Ser7 of the Pol II CTD perturbs MRTF target gene activation

To examine the effect of inhibition of Ser7P on transcription at MRTF target genes, WT-ON and S7A-ON cells were stimulated with CD or FCS and pre-mRNA levels at endogenous MRTF target genes were measured by qPCR. Probes targeting the first intron of the gene were used. Baseline expression levels were assessed in untreated cells, when MRTF target genes are uninduced. The specificity for MRTF target genes was tested by examining pre-mRNA levels at the *Egr1* and *c-Fos* genes, which are not under the regulation of MRTF, but are serum-inducible TCF-SRF target genes. In addition, pre-mRNA levels at the constitutively active genes *B2m*, *Rps16*, *Pbgd* and *Hprt* were examined. Results are shown in Figure 83.

In WT-ON cells, MRTF target genes were inactive in untreated cells and induced in response to stimulation with CD (Figure 83A). In contrast, CD induction of MRTF target genes was defective in S7A-ON cells. As shown in Figure 83B, despite blocking activation of MRTF target genes, inhibition of phospho-Ser7 did not affect expression of the constitutively active genes *B2m*, *Rps16*, *Pbgd* and *Hprt* (Figure 83B). Inhibition of Ser7P did not affect serum-induced expression of the TCF-SRF target genes *c-Fos* and *Egr1*, which was comparable in WT-ON and S7A-ON cells (Figure 83C). Conversely, Ser7P inhibition blocked FCS stimulation at the MRTF target genes *Acta2* and *Vcl* (Figure 83D).


The same experiment was repeated in WT-off and S7A-off cells. As shown in Figure 84, expression levels in untreated cells or in response to CD or FCS stimulation at MRTF target genes, TCF targets or constitutively induced genes were comparable in WT-off and S7A-off cells.

Taken together, these results suggest that Ser7P of the Pol II CTD is required for productive RNA synthesis at MRTF target genes.





Pre-mRNA accumulation in response to CD at MRTF target genes (A), constitutively active genes (B) in response to FCS stimulation at TCF target genes (C) and in response to FCS stimulation at MRTF target genes (D). Cells were serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D), 15% FCS or left untreated. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments.







Pre-mRNA accumulation in response to CD at MRTF target genes (A), constitutively active genes (B) in response to FCS stimulation at TCF target genes (C) and in response to FCS stimulation at MRTF target genes (D). Cells were serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D), 15% FCS or left untreated. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments.

Next, the effect of Ser7P depletion on Pol II recruitment and CTD phosphorylation at MRTF target genes was examined by ChIP-qPCR. WT-ON and S7A-ON cells were stimulated with CD and Pol II recruitment to target genes was assessed using antibodies against the Rpb1 subunit of the Pol II (D8L4Y), to measure total Pol II, and phospho-specific antibodies targeting Ser5P (3E8), Ser7P (4E12) and Ser2P (3E10) of the Rpb1 CTD (Chapman et al., 2007). qPCR probes targeting regions along the length of the *Acta2*, *Actb* and *Vcl* genes were used. Results are shown in Figure 85.

In WT-ON cells, CD stimulation induced Pol II recruitment and phosphorylation of Ser5, Ser7 and Ser2 of the Pol II CTD. The ChIP profiles of total Pol II and the phosphorylated forms of Pol II were as in wild-type NIH3T3 cells (see Figure 70). In S7A-ON cells, Pol II ChIP levels were reduced in the TSS region, but remained comparable to those in WT-ON cells within the gene body and at the TTS region. Similar results were observed with Ser5P. As expected, Ser7P levels were reduced in S7A-ON cells. In addition, S7A-ON cells also exhibited reduced Ser2P levels at the 3' end of genes.

These results suggest that inability to induce phosphorylation of Ser7 of the Pol II CTD results in reduced Pol II pausing at MRTF target genes. In addition, depletion of Ser7P is associated with greatly reduced phospho-Ser2 levels, a profile reminiscent of that seen in the non-productive transcriptional state. This data is consistent with phosphorylation of Ser7 preceding that of Ser2 and suggests that Ser7P might be a prerequisite for phosphorylation of Ser2 of the Pol II CTD.








Figure 85 Ser7P inhibition alters the Pol II profile at MRTF target genes

Total RNA Polymerase (Pol II, D8L4Y), RNA Polymerase II C-terminal domain phosphorylated at Serine 5 (S5P, 3E8), Serine 7 (S7P, 4E12) or Serine 2 (S2P, 3E10) ChIP at the *Acta2* (A), *Actb* (B) and *Vcl* (C) genes in WT-ON and S7A-ON cells. Cells were serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D) or left untreated. Signal was normalized to input. Data is shown as mean ± SEM and is representative of three independent experiments. The lines connecting individual points within data series are not necessarily representative of ChIP levels between data points. The location of the qPCR probes, relative to the TSS (0), is indicated by the red lines in the gene schematics.

8.4 Depletion of Mtr4 restores productive RNA synthesis at MRTF target genes in Ser7P-depleted cells

In cells expressing the Rpb1-S7A mutant, phospho-Ser7 and phospho-Ser2 levels are reduced and expression of MRTF target genes is perturbed, resembling the non-productive transcriptional state observed in LMB-treated NIH3T3 cells and dKO^{MRTF-NLS} cells. Therefore, whether inactivating the nuclear exosome would restore pre-mRNA synthesis at MRTF target genes in S7A-ON cells was tested next.

To deplete Mtr4 in WT-ON and S7A-ON cells, the parental WT and S7A cells were treated with doxycycline, siRpb1 and siMtr4 for 48 hours. Subsequently cells were stimulated with CD or FCS and pre-mRNA levels at endogenous MRTF target genes were measured by qPCR using probes targeting the first intron of the gene. Baseline expression levels were assessed in untreated cells, when MRTF target genes are uninduced. Results are shown in Figure 86.





Figure 86 Mtr4 depletion restores MRTF target gene expression in S7A-ON cells

Pre-mRNA accumulation at MRTF target genes in response to CD stimulation (A) or FCS stimulation (B). Cells were treated with siMtr4 for 48 hours, serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D), 15% FCS or left untreated. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. Data for WT-ON and S7A-ON is from Figure 83.

In WT-ON cells, CD stimulation induced MRTF target genes, while MRTF target gene activation in response to CD was inhibited in S7A-ON cells. Mtr4 depletion restored pre-mRNA synthesis at MRTF target genes in S7A-ON cells, but did not affect expression levels in WT-ON cells (Figure 86A). Similar results were seen upon serum stimulation of MRTF-SRF target genes (Figure 86B).

To confirm that the effect of depleting Mtr4 is specific for the Rpb1-S7A mutant, the experiment was repeated in WT-off and S7A-off cells, where transcription is

controlled by the endogenous Rpb1. As shown in Figure 87, Mtr4 depletion did not affect MRTF target gene expression in cells expressing the endogenous Rpb1 protein.





and S7A-off cells

Pre-mRNA accumulation at MRTF target genes in response to CD stimulation (A) or FCS stimulation (B). Cells were treated with siMtr4 for 48 hours, serum-starved overnight and stimulated for 30 min with 3μ M CD (Cytochalasin D), 15% FCS or left untreated. Signal was normalized to *Gapdh*. Data is shown as mean ± SEM and is representative of three independent experiments. Data for WT-off and S7A-off cells is from Figure 84.

Taken together these results show that the defective induction of MRTF target genes seen in S7A-ON cells is dependent on Mtr4. This is consistent with a model in which Ser7P protects the nascent RNA from being targeted by the nuclear exosome.

8.5 Depletion of Nrde2 does not exacerbate the transcriptional defect in Ser7P-depleted cells

As presented in Chapter 5.4, depletion of the Mtr4 negative regulator Nrde2 inhibits CD induction of MRTF target genes. Given that Rpb1-S7A exhibits an Mtr4dependent defect in CD-induced transcription, whether Nrde2 depletion could enhance the transcriptional defect seen in S7A-ON cells was tested next.

WT-ON and S7A-ON cells were treated with siRNA for 48 hours and subsequently stimulated with CD. As before, transcription at MRTF target genes was assessed by qPCR using probes targeting the first intron of the gene. Baseline expression levels were assessed in untreated cells, when MRTF target genes are inactive. To confirm that any effect of Nrde2 depletion reflects the activity of Mtr4, the experiment was repeated in cells depleted of Mtr4. Results are presented in Figure 88.

Consistent with results presented in Chapter 5.4, in WT-ON cells, CD-induced MRTF target gene expression was inhibited by Nrde2 depletion, but not by Mtr4 depletion, and co-depletion of Mtr4 and Nrde2 restored pre-mRNA synthesis, to levels comparable to these in WT-ON cells (Figure 88A).




Figure 88 Nrde2 depletion does not affect MRTF target gene expression in S7A-

ON cells

Cells were treated with siMtr4, siNrde2 or both for 48 hours, serum-starved overnight and stimulated for 30 min with 3µM CD (Cytochalasin D) or left untreated. Pre-mRNA was measured using qPCR probes targeting the first intron of the gene. Signal was normalized to Gapdh. Data is shown as mean ± SEM and is representative of three independent experiments. Data for Mtr4-depleted WT-ON and S7A-ON is from Figure 86.

In S7A-ON cells, CD-stimulation at MRTF target genes was defective and depletion of Mtr4 rescued the pre-mRNA synthesis defect. Depletion of Nrde2 alone did not affect MRTF target gene expression, whereas co-depletion of Mtr4 and Nrde2 upregulated pre-mRNA synthesis (Figure 88B).

As in wild-type NIH3T3 cells, in WT-ON cells Nrde2 depletion inhibits stimulation of MRTF target genes and its effect is dependent on Mtr4. Nrde2 depletion does not exacerbate the transcriptional defect observed in S7A-ON cells, suggesting that it is unlikely that Nrde2 and Ser7P cooperate to regulate exosome recruitment at transcripts of MRTF target genes.

Chapter 9. Discussion

The data presented in this thesis demonstrates that G-actin regulates MRTF activity in the nucleus at two levels. First, G-actin binding to MRTF interferes with ternary complex formation between SRF and MRTF on DNA and inhibits MRTF-dependent transcription. In response to G-actin depletion, MRTF is recruited to target gene promoters and induces the recruitment of the fully phosphorylated form of Pol II, resulting in productive RNA synthesis. In contrast, in high G-actin concentrations, MRTF recruitment to target promoters is impaired. Second, under resting G-actin levels, nuclear MRTF is recruited to target promoters, but at reduced levels, and it induces non-productive transcription. While Pol II is engaged in elongation, no pre-mRNA accumulates. This inhibited transcriptional state correlates with aberrant Pol II CTD phosphorylation, Mtr4 recruitment and degradation of the nascent transcripts by the nuclear exosome. Phosphorylation of Ser7 of the Pol II CTD is required to inhibit Mtr4-mediated degradation of MRTF-dependent transcripts under induced conditions.

9.1 Regulation of MRTF activity in the nucleus

In the nucleus, actin also exists in both monomeric and filamentous form. Nuclear F-actin is formed in response to extracellular stimuli and during cell adhesion and spreading and appears to play a role in maintaining nuclear structure, chromatin organization, as well as in DNA damage repair (Baarlink et al., 2017; Belin et al., 2013; Belin et al., 2015; Bohnsack et al., 2006; Caridi et al., 2018; Kiseleva et al., 2004; Ohkawa & Welch, 2018; Plessner et al., 2015; Schrank et al., 2018; Y. Wang et al., 2019; Yamazaki et al., 2020).

G-actin inhibits ternary complex formation between MRTF and SRF on DNA

Like actin assembly in the cytoplasm, serum stimulation results in a rapid and transient F-actin assembly in the nucleus. Furthermore, nuclear F-actin formation, which is sensitive to treatment with LatB, and subsequent depletion of the nuclear G-actin pool, is sufficient for MRTF activation (Baarlink et al., 2013). Consistent with this data and previous publications from the lab, CD or serum stimulation was required for gene activation by the constitutively nuclear MRTF-NLS and in LMB-

treated cells, when MRTF export from the nucleus is inhibited (Miralles et al., 2003; Vartiainen et al., 2007). In contrast, MRTF-XXX, which is unable to interact with Gactin, was constitutively active, demonstrating that disrupting the interaction between MRTF and G-actin is essential for gene activation.

Crm1 inhibition by LMB or expression of an MRTF-NLS fusion protein, which result in nuclear accumulation of MRTF, without affecting the cellular F- to G-actin ratio or the interaction between MRTF and G-actin, induced MRTF recruitment to target genes, consistent with previous work (Vartiainen et al., 2007). Under these conditions, recruitment of MRTF and SRF to target promoters was sensitive to addition of LatB, which increases G-actin concentration. In contrast, recruitment of MRTF-XXX, which is unable to interact with G-actin, was unaffected by LatB. This data demonstrates that G-actin binding to the MRTF RPEL domain interferes with ternary complex formation between MRTF and SRF on DNA. The exact mechanism by which G-actin inhibits MRTF recruitment is unclear.

Although MRTF contacts DNA in the ternary complex, it is unable to bind to DNA independently of SRF (Miralles et al., 2003; Pellegrini et al., 1995; Zaromytidou et al., 2006). One possibility is that G-actin binding physically inhibits MRTF/SRF complex formation through mediating a conformational change in the protein that occludes the B1 box, through which MRTF/SRF interaction is mediated (Miralles et al., 2003; Zaromytidou et al., 2006). This might occur either by interaction of the actin-bound RPEL domain with the B1 box or through recruitment of additional actin to the B1 box region (Figure 89A). To understand which sequences are required for this inhibition, MRTF mutant proteins lacking the entire N-terminal domain (Δ N-MRTF), with point mutations within the RPEL domain (MRTF-XXX) and B1 box mutants could be used in *in vitro* assays to study the interaction between SRF, MRTF and DNA in the presence of increasing concentrations of G-actin.




Figure 89 G-actin inhibits the interaction between MRTF and SRF on DNA

(A) G-actin binding to MRTF could inhibit its interaction with SRF directly, through interaction of the RPEL domain with the B1 box or through recruitment of additional actin to the B1 box region. (B) G-actin binding to MRTF could inhibit its interaction with SRF indirectly, by preventing MRTF phosphorylation. G-actin could inhibit the recruitment of the kinase that targets MRTF or it could occlude MRTF phosphorylation sites. (C) Reduced MRTF recruitment to targets under resting G-actin levels could reflect lower efficiency of binding, dependent on how many molecules of G-actin interact with MRTF or more transient interaction of MRTF with target promoters. Under resting G-actin levels, nuclear MRTF would form a trimeric complex with G-actin, which might bind DNA weakly. An increase in the G-actin concentration in the nucleus by treatment with LatB would abolish DNA binding completely by stimulating pentameric complex formation. On the other hand, inhibiting MRTF/G-actin interaction by CD or serum would increase the abundance of free MRTF, which would efficiently associate with DNA.

Alternatively, G-actin might perturb the interaction between MRTF and SRF indirectly, by preventing MRTF phosphorylation (Figure 89B). G-actin binding inhibits MRTF phosphorylation, which normally occurs in response to stimulation with CD or serum and is required for MRTF transcriptional activity (Panayiotou et al., 2016). G-actin might inhibit the recruitment of the kinase that targets MRTF or it could occlude MRTF phosphorylation sites.

It has been shown that phosphorylation of serine 98 of MRTF inhibits G-actin binding (Panayiotou et al., 2016). Apart from Ser98, phosphorylation at Ser231, Ser663 and Ser744 of MRTF also increase substantially in response to serum stimulation (Panayiotou et al., 2016). The role of these phospho-marks on MRTF recruitment to target gene promoters and its ability to activate transcription could be tested by reconstitution of dKO MEFs with S98A, S231A, S663A and S744A MRTF mutants.

Under resting G-actin levels, nuclear MRTF is recruited to target genes at reduced levels

Even though MRTF and SRF were recruited to target gene promoters under resting G-actin levels, their DNA binding was reduced, relative to this in cells stimulated with CD or serum, which deplete free G-actin. One possibility is that any actin binding to MRTF blocks its interaction with SRF and the interaction between MRTF and DNA or G-actin is mutually exclusive. In this case, MRTF recruitment to DNA under resting G-actin levels would reflect the lower effective concentration of free MRTF. Alternatively, reduced recruitment of MRTF to DNA could reflect lower efficiency of binding, dependent on how many molecules of G-actin interact with MRTF (Figure 89C).

The MRTF/G-actin complex exists as a trimer, where each RPEL motif is bound by one actin molecule, or as a pentamer, where in addition to the three RPELs, each of the two spacer regions in between are bound by one actin molecule. It has been proposed that the trimer complex is readily assembled under resting conditions, while the recruitment of additional actin molecules is sensitive to cellular actin concentration (Mouilleron et al., 2008; Mouilleron et al., 2011). According to this

view, the trimer complex is competent for nuclear import, whereas the pentameric complex, in which both of MRTF's NLS elements are occluded, is not. The ability of the different MRTF-actin complexes to interact with SRF and DNA has not been evaluated directly.

Thus, it is conceivable that under resting G-actin levels, nuclear MRTF would form a trimeric complex with G-actin, which might bind DNA weakly. An increase in the G-actin concentration in the nucleus by treatment with LatB would abolish DNA binding completely by stimulating pentameric complex formation. On the other hand, inhibiting MRTF/G-actin interaction by CD or serum would increase the abundance of free MRTF, which would efficiently associate with DNA. Whether actin is at all found with MRTF at target promoters under resting conditions could be studied by ChIP.

Does LMB induce an unstable MRTF-SRF-DNA complex?

ChIP is a global method of studying transcription factor recruitment at target genes, averaging over whole populations of cells. An alternative view of the reduced ChIP signal is that rather than representing weaker binding of the trimeric complex, it reflects a more transient interaction between MRTF and its binding sites. MRTF/G-actin interaction and its effect on MRTF phosphorylation and SRF binding might ultimately impact on the residence time of MRTF at target gene promoters.

In the nucleus many transcription factors exist in three different states, a diffusing state, as transiently bound and as stably bound. Longer residence time of the transcription factor at the target promoter reflects a more stable interaction and correlates with productive output (Gorski et al., 2006; Hager et al., 2009; Misteli, 2001). Slower transcription factor dynamics at a specific promoter have been shown to correlate with more mRNA synthesis for the heat-shock transcription factor (HSF) (Yao et al., 2006), the glucocorticoid receptor and the mineralocorticoid receptor (Stavreva et al., 2004) (Groeneweg et al., 2014), STAT1 (Tietjen et al., 2010), Sox2 (White et al., 2016), p53 (Morisaki et al., 2014) and SRF (Hipp et al., 2019).

Serum stimulation increases not only the fraction of SRF bound to chromatin, but also the residence time of SRF at promoters, in a LatB-sensitive manner, in both fibroblasts and neuronal cells (Hipp et al., 2019). To determine whether LMB treatment impacts on MRTF residence time at target promoters, an MRTF HaloTag could be used to study MRTF dynamics in response to stimulation. If the decreased ChIP signal in LMB-treated cells reflects a more transient interaction of MRTF with target promoters, MRTF should have short residence time at targets in response to LMB. Addition of LatB, which abolishes MRTF binding by ChIP, should further decrease its residence time, while subsequent re-stimulation of LMB-treated cells with CD should increase MRTF residence time, to reflect stable binding of MRTF to target promoters.

Biological significance of regulated MRTF-SRF interaction

Many transcription factors which regulate inducible genes, such as MRTF, p53, NFkB and steroid receptors, are controlled via regulating their concentration in the nucleus (Hager et al., 2009; Levine et al., 2013; Stavreva et al., 2004). However, the cellular environment is noisy and stochastic signalling could inadvertently lead to activation of the system which could then have deleterious effects (Aoki et al., 2013; Elowitz et al., 2002; Fang et al., 2013; Hsu et al., 2012; Ozbudak et al., 2002). Hence, additional layers of regulation are needed to modulate transcription factor activity while in the nucleus and discriminate signal from noise.

Residence time at promoters is an example of such a mechanism. In the case of MRTF, since it constantly shuttles between the nucleus and the cytoplasm, it could transiently interact with genomic loci while in the nucleus, even though the system has not been activated. In order to avoid the deleterious effect of overexpressing its target genes, such short-lived interactions would be insufficient to result in engaging a transcriptionally competent form of Pol II.

Under resting G-actin levels, MRTF interacts with actin while in the nucleus (Vartiainen et al., 2007). This interaction results in less DNA binding, which might reflect either decreased residence time at promoters or weaker binding of the actinbound complex, and is insufficient for target gene activation.

9.2 Nuclear MRTF induces non-productive transcription

RNAseq and TTseq experiments were performed to study the effect of nuclear MRTF on transcription genome-wide, in response to acute stimulation with CD or LMB or chronic stimulation as in dKO^{MRTF-NLS} cells, when MRTF is constitutively nuclear.

The transcriptional response to CD

Genes significantly upregulated in response to CD by RNAseq and TTseq in NIH3T3 cells were enriched in serum-inducible genes, whose expression is sensitive to an increase in G-actin concentration by LatB, physically associated with SRF and functionally related to MRTF-SRF target genes. These results are consistent with MRTF being the only transcription factor known to be directly activated by CD.

As in NIH3T3 cells, in dKO^{MRTF} and dKO^{MRTF-NLS} MEF cells CD stimulation induced genes functionally related to MRTF-SRF targets and associated with SRF binding sites. Nevertheless, there was little overlap between these and CD-induced genes in NIH3T3 cells. While this could represent cell-type specific effects, it might also reflect differences arising during the reconstitution of the MRTF-A/B null MEF cells.

The non-productive transcriptional state at MRTF target genes

Under resting G-actin levels, nuclear MRTF was recruited to target gene promoters but did not activate gene expression. There are three potential explanations for this. First, it might be that in the absence of G-actin depletion, MRTF fails to recruit Pol II. Alternatively, this could potentially be due to increased stalling of Pol II at the TSS or co-transcriptional degradation of the nascent transcript.

In NIH3T3 cells, even though no transcriptional changes were detected in response to LMB by RNAseq, more than 90% CD-controlled genes were activated in LMBtreated cells, as assessed by TTseq. TTseq data demonstrated that in response to LMB, Pol II was recruited to MRTF target genes and engaged in elongation. The TTseq read profiles at MRTF-SRF target genes in response to CD and LMB were very similar. No apparent differences in Pol II processivity and elongation speed or termination were detected.

Genome-wide experiments in dKO^{MRTF-NLS} MEF cells corroborated these findings, showing that they do not reflect pleiotropic effects of the LMB treatment. As in LMB-treated NIH3T3 cells, in dKO^{MRTF-NLS} cells, even though no gene activation was detected in the absence of G-actin depletion by RNAseq, CD-regulated genes were induced, as assessed by TTseq. Under resting G-actin levels, Pol II was recruited and engaged in elongation. Gene expression was sensitive to treatement with LatB and subsequent increase in G-actin concentration, indicating this effect is MRTF-dependent.

These results are consistent with a model in which nascent transcripts of MRTF target genes are co-transcriptionally degraded in the non-productive transcriptional state.

9.3 Mtr4 regulates MRTF target gene expression

Inactivation of the NEXT and CBCA complexes restores productive transcription at MRTF target genes

A small-scale RNAi screen identified the RNA helicase Mtr4, as well components of the core nuclear exosome and the NEXT and the CBCA complexes as factors whose depletion can restore productive RNA synthesis in the LMB-induced non-productive transcriptional state. Their depletion also rescued productive transcription under resting conditions in dKO^{MRTF-NLS} cells.

The RNA exosome consists of a barrel-shaped core of nine subunits and the catalytically active subunit Dis3 (Greimann & Lima, 2008; Lebreton et al., 2008; Schaeffer et al., 2009). To achieve its function, the exosome associates with a variety of co-factors, including the Mtr4 RNA helicase, which is responsible for the threading of the RNA into the exosome (Gerlach et al., 2018; Weick et al., 2018). Mtr4 is part of three nuclear exosome adapter complexes: TRAMP, which is

Chapter 9. Discussion

restricted to the nucleolus, and the nuclear PAXT (Pabpn1, Zfc3h1, Mtr4) and NEXT (Rmb7, Zcchc8, Mtr4) complexes.

Exosomal degradation is mediated in a 3'->5' direction, following cleavage of the transcript by the CPA or the Integrator complex (Kamieniarz-Gdula & Proudfoot, 2019). All exosome adapter complexes are recruited to RNA through the capbinding complex (CBC) (Andersen et al., 2013; Falk et al., 2016; Giacometti et al., 2017; Hrossova et al., 2015; Meola et al., 2016; Wu et al., 2020). The CBC interacts with the Ars2 adapter protein, forming the CBCA complex (Giacometti et al., 2017; Gruber et al., 2009; Schulze et al., 2018). Subsequently, the CBCA forms higher order complexes with distinct RNA processing factors (Schulze et al., 2018). Recruitment of Zc3h18 to the CBCA marks the transcript for degradation and it is involved in both NEXT and PAXT complex recruitment (Andersen et al., 2013; Falk et al., 2016; Meola et al., 2016).

In addition to rescuing pre-mRNA synthesis in the inhibited transcriptional state at MRTF targets, depletion of Zc3h18 also upregulated the expression of TCF target genes and MRTF targets under induced conditions. This might be due to its more general role in RNA decay. Conversely, CBCA inactivation also attenuated the response to CD stimulation, likely as a result of exposing the 5' cap to de-capping enzymes and 5' exonucleases. Depletion of Zcchc8 and Rmb7 also negatively impacted on CD-induction at some genes. This is perhaps because apart from their role in NEXT-mediated RNA decay, they are also involved in pre-mRNA splicing. The interaction of Rmb7 with components of the spliceosome and the NEXT complex is mutually exclusive (Falk et al., 2016).

Is the NEXT or the PAXT complex involved in MRTF target gene regulation?

Out of the factors tested, Mtr4 showed the strongest effect on MRTF-dependent transcription in the inhibited state, specifically. This could be due to technical issues, such as knock-down efficiency or protein stability, or reflect the involvement of multiple exosome complexes that share Mtr4.

The NEXT complex targets immature RNA such as PROMPTs and eRNAs, while the PAXT complex is recruited to polyadenylated RNA (Meola et al., 2016; Silla et al., 2020; Wu et al., 2020). The preference of PAXT for mature transcripts is consistent with Pabpn1 being a canonical poly(A) binding protein (Banerjee et al., 2013). On the other hand, Rmb7 binds RNA in a promiscuous manner, with some preference for U-rich pyrimidine stretches (Lubas et al., 2015; Vanácová et al., 2005). It is found in association with newly synthesised RNA is general (Andersen et al., 2013; Andersson et al., 2014; Lubas et al., 2015) and preferentially bound to introns (Giacometti et al., 2017; Lubas et al., 2015).

Data presented in Chapter 5.1 suggests that the NEXT and not the PAXT complex is involved in regulating transcription in the LMB-induced non-productive state. First, depletion of Pabpn1 and Zfc3h1 of PAXT did not upregulate pre-mRNA levels at MRTF target genes in response to LMB. Furthermore, simultaneous depletion of the RNA binding proteins Rmb7 and Pabpn1 or the adapter proteins Zcchc8 and Zfc3h1 did not exacerbate the effect of individual depletion of Zcchc8 or Rmb7 of NEXT.

However, interpreting these results is difficult because of the potential involvement of multiple complexes which share Mtr4. The essential functions of exosome components make knock-downs difficult. Furthermore, long siRNA treatments could trigger compensatory mechanisms. Since generating knockouts is not possible, an auxin-based degron system would be useful to study the role of each of these exosome components in regulating RNA turn-over and defining their substrates. RNA IPs with PAXT- and NEXT-specific components could determine which complex is associated with transcripts of MRTF target genes in the nonproductive transcriptional state.

Mtr4 is recruited to transcripts of MRTF target genes

Mtr4 depletion did not affect Pol II recruitment or CTD phosphorylation at MRTF target genes, indicating that Mtr4 functions downstream of Pol II, consistent with previous publications (Fan et al., 2017). Furthermore, Mtr4 directly associated with MRTF-dependent transcripts in LMB-treated cells, specifically, demonstrating a

direct effect on RNA turn-over. Others have also observed that apart from its well characterized role in regulating PROMPTs and eRNAs, Mtr4 controls the expression of protein-coding genes (Fan et al., 2017; Ogami et al., 2017; Silla et al., 2018; J. Wang et al., 2019; Yu et al., 2020).

In addition to upregulating pre-mRNA levels, Mtr4 depletion also caused an increase in α -actin and ß-actin messenger RNA and protein levels. This is in line with increased expression of full-length mature RNAs upon exosome inactivation and Mtr4 depletion promoting accumulation of mature RNA in the cytoplasm and its association with polysomes (Ogami et al., 2017; Silla et al., 2018).

Depletion of Mtr4 rescues the defect in the non-productive transcriptional state

To examine the effect of Mtr4 depletion genome-wide, RNAseq was performed. At CD-inducible genes, Mtr4-depetion restored productive RNA synthesis in response to LMB, with a magnitude of induction comparable to that observed by TTseq. In addition, a set of 455 LMB-induced Mtr4-controlled genes was identified, without pre-selecting for CD-inducibility. These were enriched in CD- and FCS-inducible genes, sensitive to an increase in G-actin concentration by LatB, physically associated with SRF and functionally related to MRTF-SRF target genes, strongly suggesting they are MRTF regulated. These results are consistent with a model in which in the non-productive transcriptional state MRTF-dependent transcripts are targeted for exosomal degradation by Mtr4.

In dKO^{MRTF-NLS} cells, following Mtr4 depletion, no gene expression changes in response to CD or LatB were detected by RNAseq. The prolonged siRNA treatment in combination with the chronic stimulation by the constitutively nuclear MRTF-NLS fusion might lead to elevated basal transcription and decreased sensitivity to signal. Therefore, we attempted to identify genes whose expression under resting conditions was sensitive to LatB, as an indication of MRTF activity, and tested whether these are also induced in the absence of stimulation by TTseq.

Approximately 80% of the 67 genes which were active under resting conditions and sensitive to LatB treatment in Mtr4-depleted dKO^{MRTF-NLS} cells were also active in resting dKO^{MRTF-NLS} cells as assessed by TTseq but not detectably upregulated as assessed by RNAseq. This gene set was enriched in genes associated with SRF binding sites and FCS-inducible genes, consistent with regulation by MRTF.

The nuclear MRTF in dKO^{MRTF-NLS} cells differs from LMB-induced nuclear MRTF, in that the dKO^{MRTF-NLS} cells are subjected to chronic stimulation, rather than an acute stimulus like the LMB treatment. The chronic state of the dKO^{MRTF-NLS} cells in combination with the prolonged siRNA treatment impeded the genome-wide analysis of transcriptional changes in Mtr4-depleted cells. Nevertheless, data on the small MRTF-NLS induced Mtr4-controlled gene set and qPCR data on bonafide MRTF-SRF target genes is consistent with Mtr4 targeting MRTF-dependent transcripts for degradation under uninduced conditions.

Mtr4 regulates DNA repair and cell cycle genes

In NIH3T3 cells under resting conditions Mtr4 depletion alone caused the upregulation of genes associated with cell cycle control and DNA repair. Mtr4 and its negative regulator Nrde2 have been implicated in the response to DNA damage through resolving DNA-RNA hybrids and promoting double-strand break repair (Blasius et al., 2014; Domingo-Prim et al., 2019; Lim et al., 2017; Puno & Lima, 2018; Richard et al., 2018). Data presented in Chapter 5.2 suggests that they might also be involved in the transcriptional regulation of factors involved in the DNA damage response. That Mtr4 depletion upregulated genes involved in cell cycle control is in line with previous publications (Yu et al., 2020).

How is the exosome recruited to its substrates?

How different exosome complexes recognize specific sets of RNA targets remains unclear. It has been proposed that exosome complexes have specificity for a particular structure or sequence within RNAs (Torchet et al., 2002). However, given the wide variety of exosome substrates, a requirement for common structural or sequence features seems unlikely.

Chapter 9. Discussion

Alternatively, RNAs could be recognized based on their functionality. The role of the nuclear exosome in regulating PROMPTs, eRNAs and lincRNAs, aberrantly processed snRNA, snoRNA and histone RNA, as well as CUTs in yeast, has been well-characterized (Giacometti et al., 2017; Lubas et al., 2015; Lubas et al., 2011). Nevertheless, in addition to regulating the expression of non-coding transcripts, exosome complexes are also found at protein-coding genes (lasillo et al., 2017; Lloret-Llinares et al., 2018; Silla et al., 2018; Wu et al., 2020) and have been found to interact with the elongating Pol II in Drosophila (Andrulis et al., 2002).

Several lines of evidence suggest that whether an RNA molecule is an exosome target is determined by kinetic competition between maturation and degradation processes. The RNA processing factors DROSHA, PHAX, FLASH and Zc3h18 all compete for binding to the CBCA (Giacometti et al., 2017; Gruber et al., 2012; Gruber et al., 2009; Hallais et al., 2013; Schulze & Cusack, 2017; Schulze et al., 2018). Furthermore, the TRAMP, PAXT and NEXT complexes bind to Zc3h18 in a mutually exclusive manner (Giacometti et al., 2017; Meola et al., 2016; Schulze et al., 2018; Silla et al., 2018). Dynamic exchange of RNA processing complexes at the CBC further supports the competition model. While the CBC is stably associated to RNA with the interaction lasting for minutes, recruitment of Zc3h18 and PAXT is very transient, lasting only several seconds (Giacometti et al., 2017).

In addition to exosome complexes, the RNA export machinery is also recruited through the CBCA and competes with the exosome for binding to RNA (Figure 90). Mtr4 and ALYREF are recruited to CBCA in a mutually exclusive manner (Fan et al., 2017). ALYREF is approximately five times more abundant than Mtr4 and it has been proposed that its high concentration is important to prevent promiscuous recruitment of Mtr4 (Fan et al., 2017). On the other hand, ALYREF recruitment to CBCA is stabilized by the recruitment of additional TREX components, efficient splicing and polyadenylation, ensuring appropriate sorting of the RNA substrate for export or degradation (Chi et al., 2013; Luo et al., 2001). Consistently, in RNA export mutants RNAs are targeted for degradation (Fan et al., 2017; Gudipati et al., 2012; Hilleren et al., 2001; Jensen et al., 2001; Libri et al., 2002) and pre-mRNAs

268

with splicing and polyadenylation defects are also exosome substrates (Bousquet-Antonelli et al., 2000; Milligan et al., 2005)




Figure 90 Kinetic competition between the exosome and the export machinery

The TREX RNA export complex and the NEXT and PAXT exosome complexes compete for binding to CBCA. Their recruitment is influenced by additional factors-Nrde2 negatively regulates Mtr4 by preventing its association with transcripts and TREX recruitment is dependent on efficient splicing and polyadenylation. It is conceivable that transcripts unable to efficiently recruit the TREX complex associate with Mtr4 and are degraded by the nuclear exosome. Signal-induced MRTF favours TREX recruitment and nuclear export of transcripts whereas the non-productive transcriptional state at MRTF targets correlates with Mtr4 recruitment and degradation of the nascent transcript by the nuclear exosome. Consistent with a model of kinetic competition between the exosome and the export machinery, depletion of Nrde2 could potentiate Mtr4 activity on MRTF-dependent transcripts, even under induced conditions, when normally Mtr4 is only weakly associated. This result suggests that Mtr4 association with MRTF target transcripts occurs as part of the normal initiation process, not just in the inhibited state. Nevertheless, Nrde2 depletion did not affect the expression of TCF target genes and control genes, suggesting that regulation by Mtr4 might not be a general feature of Pol II regulated protein-coding genes.

Taken together, these observations suggest that the inhibited transcriptional state reflects an imbalance in the competition between the RNA export machinery and the exosome for the nascent transcripts of MRTF target genes.

9.4 Pol II CTD phosphorylation and transcription at MRTF target genes

The inhibited transcriptional state at MRTF target genes correlates with aberrant Pol II CTD phosphorylation

In response to stimulation, MRTF induced the recruitment of the fully phosphorylated form of Pol II to its target genes, resulting in productive transcription. In contrast, in the inhibited transcriptional state the Pol II CTD lacked phospho-Ser2 and only low levels of Ser5P and Ser7P were detected at MRTF target genes. LMB did not affect the phosphorylation status of the Pol II CTD globally and the defective phosphorylation of the Pol II CTD was also observed in dKO^{MRTF-NLS} cells, demonstrating that this phenotype is MRTF-dependent.

Subpopulations of Pol II which is differentially phosphorylated have previously been described in the literature. At Toll-like receptor-inducible genes, in the absence of an activating signal, Pol II phosphorylated at Ser5 but not at Ser2 of its CTD is associated with short-lived full-length transcripts, albeit at reduced levels. Stimulation causes phosphorylation of Ser2 of the Pol II CTD and increased levels of mature full-length transcripts (Hargreaves et al., 2009). Pol II phosphorylated at Ser5 but lacking Ser2P has been observed at PRC repressed genes (Brookes et

al., 2012), as well during embryo development (Bellier et al., 1997; Palancade et al., 2001). Generally, high Ser5P to Ser2P ratio correlates with reduced transcription genome-wide (Odawara et al., 2011).

Chromatin remodeling at MRTF target genes is not impaired in the inhibited state

Despite the aberrant phosphorylation of the Pol II CTD, chromatin remodeling at MRTF target genes did not appear to be defective in the non-productive transcriptional state. Presence of H3K4me3 and H3K27Ac at TSSs of MRTF target genes is in line with MRTF binding and Pol II recruitment. In addition, consistent with Pol II elongation, histone marks typically found within the body of actively transcribed genes, including H3K36me3 and H3K79me3, were upregulated at MRTF target genes in response to LMB.

Although chromatin de-condensation within the gene body is thought to be dependent on Ser2P (Kizer et al., 2005; Li et al., 2003; Xiao et al., 2003), others have also observed that Pol II lacking Ser2P is engaged in elongation (Ahn et al., 2004; Blazek et al., 2011; Liang et al., 2015; Zhang et al., 2016). It appears that the necessity for Ser2P might vary between different genes. Genes with stably paused Pol II have more accessible chromatin structure (Gilchrist et al., 2010; Gilchrist et al., 2012; Gilchrist et al., 2008; Muse et al., 2007; Zeitlinger et al., 2007) and chromatin marks associated with active genes are co-dependent (Dover et al., 2002; Lee et al., 2007; Ng, Ciccone, et al., 2003; Sun & Allis, 2002), suggesting that early open-chromatin marks might contribute to the recruitment of additional chromatin remodelers.

Pol II pause-release into elongation is not defective in the inhibited transcriptional state

Pol II enters the pre-initiation complex in an unphosphorylated form and its transition into initiation is dependent on CDK7-mediated phosphorylation of Ser5 of the Pol II CTD (Hengartner et al., 1998; Lu et al., 1992). The Pol II pauses 20-120 nucleotides downstream of the TSS (Plet et al., 1995; Schwartz et al., 2003). The paused Pol II is bound by NELF and DSIF, which function cooperatively to inhibit

Pol II elongation (Muse et al., 2007). In addition to Ser5, CDK7 also phosphorylates Ser7 of the Pol II CTD and Ser7P has been proposed to promote Pol II promoter-proximal pausing (Glover-Cutter et al., 2009).

The transition of the paused Pol II into elongation is mediated by CDK9, which phosphorylates Ser2 of the Pol II CTD, Spt5 of DSIF and NELF. The phosphorylated NELF dissociates from the Pol II, whereas phospho-Spt5 functions as a positive elongation factor associated with the elongating Pol II (Fujinaga et al., 2004; Ping & Rana, 2001; Yamada et al., 2006).

NELF, DSIF and CDK9 were recruited in LMB-treated cells, suggesting pauserelease into elongation is not impaired in LMB-treated cells. Furthermore, Spt5, which is known to regulate Pol II transcription rate (Baluapuri et al., 2019; Cortazar et al., 2019), was found associated with the elongating Pol II. This is in line with TTseq data, which did not indicate pre-mature termination or reduced Pol II processivity in the non-productive transcriptional state.

The inhibited transcriptional state does not reflect defective activity of CDK7 or CDK9

In an attempt to recapitulate the non-productive transcriptional state observed in LMB-treated NIH3T3 cells and dKO^{MRTF-NLS} MEFs, CTD kinase inhibitors were used in combination with CD stimulation and the Pol II profile was assessed by ChIP. Both CDK7 and CDK9 inhibitors blocked induction of MRTF target genes by CD. However, neither inhibitor gave rise to a Pol II profile like the one in the non-productive state.

Inhibition of CDK7 blocked Pol II loading on the *Acta2* model gene upon CD stimulation. Since the Pol II enters the PIC unphosphorylated and Ser5P is required for its transition into initiation, loss of Pol II ChIP signal is probably a result of rapid turn-over of Pol II which is unable to initiate transcription.

Consistent with its role in alleviating Pol II promoter-proximal pausing, CDK9 inhibition in CD-stimulated cells impaired Pol II elongation, but not Pol II

recruitment. A characteristic paused Pol II peak at the TSS of the *Acta2* gene was observed. Unlike the Pol II recruited at MRTF target genes in the non-productive transcriptional state, under this condition, the Pol II CTD was phosphorylated at Ser5, Ser7 and Tyr1.

In addition to CDK9, CDK12 and CDK13 have also been shown to phosphorylate Ser2 of the Pol II CTD. In contrast to CDK9, CDK12 and CDK13 are only found within gene bodies and do not bind near transcription start sites. It has been proposed that they phosphorylate Ser2 only during elongation (Bartkowiak et al., 2010; Blazek et al., 2011; Bowman et al., 2013).

Inhibition of CDK12/13 did not affect MRTF target genes expression, even though levels of Ser2P of the Pol II CTD were reduced at the 3' end of the *Acta2* gene. Although this could be due to incomplete inhibition of phosphorylation, these results suggest that Ser2P is not limiting for activation of MRTF targets.

Similar results were observed when Plk3 was inhibited. While Thr4P levels at the 3' end of the *Acta2* gene were reduced, MRTF target gene expression was unaffected, indicating that Thr4 phosphorylation is not essential for gene expression at MRTF targets.

Pol II lacking Ser2P displays a normal transcriptional profile

While Pol II is phosphorylated on Ser5 and Ser7 along the gene, with a distinct peak at the TSS, Ser2P starts accumulating in the gene body and reaches maximum at the 3' region of the gene. The association of Ser2P with 3' ends of genes has led to the idea that this modification is required for promoter escape and transition into elongation. However, evidence for this stems from experiments done in cells treated with the CDK9 inhibitors DRB and FP, which block not only Ser2 phosphorylation, but also Pol II release into elongation, therefore inhibiting transcription (Biglione et al., 2007; Chao & Price, 2001; Gomes et al., 2006; Komarnitsky et al., 2000; Ni et al., 2004). Targeting Ser2P and not CDK9, by genetic approaches or by inactivating CDK12 and CDK13 shows that Ser2P is not necessary for Pol II pause-release and elongation. For instance, analysis of a Rpb1-S2A mutant also shows that Ser2P is not necessary for transcription elongation. However, S2P depletion slows down the rate of transcription and the mutant exhibits impaired splicing and 3' end processing (Gu et al., 2013). Furthermore, a reduction in Ser2P levels in cells treated with the CDK12/CDK13 inhibitor THZ531 does not cause global transcriptional shutdown, but affects only a subset of genes involved in DNA replication, recombination and repair (Blazek et al., 2011; Liang et al., 2015; Zhang et al., 2016). In yeast Ctk1 deletion and subsequent depletion of Ser2P does not affect Pol II elongation, but results in inefficient 3' end processing (Ahn et al., 2004).

Ser2P and transcription termination

Despite the aberrant phosphorylation of Ser2 of the Pol II CTD in the nonproductive transcriptional state, termination did not appear defective, as no transcription read-through or early termination was detected by TTseq. These observations indicate that loss of Ser2P might not be the main defect underlying the inhibited state.

Previous studies have shown that Ser2P of the Pol II CTD is involved in transcription termination. Pol II becomes competent for termination after transcribing the poly(A) signal, which is then recognised and bound by the 3' processing machinery. Ser2P facilitates recruitment of Pcf11 (Meinhart & Cramer, 2004), a component of the cleavage and polyadenylation complex (CPA), which is involved in poly(A) site recognition (Kamieniarz-Gdula et al., 2019; West & Proudfoot, 2008).

Nevertheless, several lines of evidence suggest that termination can occur in the absence of Ser2P. The CPA complex assembles directly onto the pre-mRNA poly(A) site as it emerges from the exit channel of the Pol II and cap-proximal poly(A) sites terminate transcription of PROMPTs, when Ser2P levels are low (Andersen et al., 2013; Ntini et al., 2013). This data suggests that the presence of

Ser2P increases the efficiency of CPA complex recruitment, but it is not absolutely essential for termination. In addition, phospho-Ser2 is not required for termination in *C.elegans* (Cassart et al., 2020). In yeast, whereas Pcf11 deletion is lethal, cells expressing the Rpb1-S2A mutant are viable (Cassart et al., 2012; Coudreuse et al., 2010).

Ser7P of the Pol II CTD is required for productive transcription at MRTF target genes

In addition to low Ser2P levels, Pol II exhibited severely impaired phosphorylation of Ser7 and reduced phosphorylation of Ser5 in the inhibited transcriptional state. As the only kinase inhibitor that prevents Ser7P also blocked Ser5P and transcription initiation, depletion of endogenous Rpb1 and reconstitution with a Rpb1-S7A mutant was used to study the functional significance of Ser7 phosphorylation.

Expression of Rpb1-S7A was associated with defective MRTF-dependent gene expression. This effect was specific for MRTF targets and dependent on Mtr4. S7A-ON cells exhibited normal regulation of TCF targets and control genes. This result suggests that Ser7P is specifically required for productive transcription of MRTF target genes, consistent with genome-wide analysis of a Rpb1-S7A mutant, whose expression has no global effect on transcription (Chapman et al., 2007; Egloff et al., 2007). Inhibition of the Ser7 targeting kinase CDK7 does not affect transcription globally either (Chapman et al., 2007; Kanin et al., 2007; Lee et al., 2005). However, it perturbs expression of inducible p-53 target genes (Glover-Cutter et al., 2009), snRNA genes (Egloff et al., 2007) and cell-cycle genes (Lee et al., 2005).

In cells reconstituted with the Rpb1-S7A mutant, Pol II levels in the gene body of MRTF targets were normal, although the Pol II peak at the TSS, associated with promoter-proximal pausing, was reduced. Phospho-serine 5 levels at the TSS were also reduced, while occupancy at downstream regions of the gene was unaffected. These results are consistent with a defect in establishment of Pol II promoter-proximal pausing. It has been shown that CDK7 inhibition reduces Pol II occupancy specifically at the TSS, relative to downstream regions of the gene (Glover-Cutter

et al., 2009; Schwartz et al., 2003), a phenotype also observed in NELF-depleted cells (Gilchrist et al., 2012), suggesting that Ser7P is involved in establishing promoter-proximal pausing. Furthermore, the profile of Ser7P along the gene is in line with a role of Ser7P in Pol II pausing. The two peaks of Ser7P correlate with Pol II paused at TSSs and at 3' end pause sites near the poly(A) site of genes (Chapman et al., 2007).

In addition, in S7A-ON cells the recruited Pol II exhibited impaired phosphorylation at Ser2 of its CTD. This is consistent with CTD modifications being deposited in succession: Ser7P primes phosphorylation of Ser2 (Akhtar et al., 2009; Boeing et al., 2010; Bösken et al., 2014; Chapman et al., 2007), while Ser2P is required for phosphorylation of Thr4 (Hintermair et al., 2012; Krajewska et al., 2019). Thus, lack of Ser7 phosphorylation would impact on downstream phosphorylation events.

These results largely recapitulate the non-productive transcriptional state observed in LMB-treated NIH3T3 cells and dKO^{MRTF-NLS} MEFs, suggesting that loss of Ser7P of the Pol II CTD might cause the pre-mRNA accumulation defect in the non-productive transcriptional state.

How might defective Ser7P arise in the non-productive transcriptional state?

The reduced levels of Ser5P and Ser7P of the Pol II CTD at MRTF target genes in the non-productive transcriptional state suggest that the defect in Pol II phosphorylation occurs early on in the transcription cycle. One possibility is that under resting G-actin levels, actin directly inhibits the recruitment of CTD kinases at the TSS. It is also possible that reduced residence time of the Pol II complex at promoters might be insufficient for efficient phosphorylation of Ser5 and Ser7 or that the unstable formation of the Pol II complex might lead to their rapid dephosphorylation.

Phosphorylation of Ser5 of the Pol II CTD is required for transcription initiation and capping of the nascent transcript (Komarnitsky et al., 2000). In addition, inhibition of CDK7, the only kinase known to phosphorylate Ser5 and Ser7 of the Pol II CTD *in vivo*, inhibited Pol II loading on genes. Thus, it seems unlikely that the reduced

levels of Ser5P and Ser7P in the non-productive transcriptional state reflect failure to recruit CDK7.

Even though the inhibited transcriptional state does not appear to reflect impaired recruitment CDK7, it is possible that defective phosphorylation at Ser7 of the Pol II CTD might be a result of failure to recruit another kinase. Several lines of evidence suggest that Ser7 might be targeted by other kinases. First, inhibition of CDK7 does not completely abolish Ser7P (Boeing et al., 2010; Tietjen et al., 2010) and at snRNA genes, where Ser7P is essential for transcription, CDK7 is not required (Kuhlman et al., 1999). Moreover, because of its position within the heptad, Ser7 is not a good TFIIH substrate (Songyang et al., 1996). In addition, CDK7 is found in association with the Pol II at gene promoters, but not within gene bodies (Eyboulet et al., 2013; Eyboulet et al., 2015), while Ser7P is present along genes (Chapman et al., 2007). Finally, *in vitro* Ser7 is also a substrate for DNAPK (Egloff et al., 2010; Trigon et al., 1998).

Low Ser5P and Ser7P levels might also arise from de-phosphorylation. The Ssu72 phosphatase targets Ser5P and Ser7P of the Pol II CTD. it is recruited at TSSs and associates with the PIC (Chen et al., 2014; Spector et al., 2019). Ssu72 has been proposed to regulate the transition from initiation into elongation following promoter escape and dissociation of CDK7, possibly by facilitating subsequent phosphorylation of Ser2 of the Pol II CTD and exchange of initiation and elongation factors.

Dephosphorylation would explain how Pol II with low Ser5P and Ser7P levels is able to initiate. Moreover, ChIP experiments in cells reconstituted with the Rpb1-S7A mutant suggest a role of Ser7P in maintaining Pol II promoter-proximal pausing. Yet, unlike S7A-ON cells, LMB-treated NIH3T3 cells and dKO^{MRTF-NLS} cells do not exhibit a defect in pausing. This observation suggests that Ser5P and Ser7P are likely dephosphorylated.

In addition to its role in early elongation, Ssu72 is also required for efficient transcription termination at snoRNA genes, some protein-coding genes and

277

promoter-proximal termination of CUTs in yeast (Ansari & Hampsey, 2005; Krishnamurthy et al., 2004; Tan-Wong et al., 2012; Zhang et al., 2012). Analogously to termination of CUTs and PROMPTs, which, like transcripts of MRTF target genes, are associated with aberrantly phosphorylated Pol II and susceptible to degradation by the exosome, it might be that Ssu72-mediated dephosphorylation of Ser5 and Ser7 is an attempt to terminate transcription prematurely as a result of unstable PIC complex formation (Chiu et al., 2018; Kamieniarz-Gdula et al., 2019). The potential involvement of Ssu72 could be tested by assessing the Pol II CTD phosphorylation status by ChIP in LMB-treated cells depleted of Ssu72.

9.5 A model for the non-productive transcriptional state

Transition into productive elongation might involve exchange of Mtr4 for the RNA export machinery

The non-productive transcriptional state at MRTF target genes correlates with aberrant phosphorylation of Ser5, Ser7 and Ser2 of the Pol II CTD, as well as Mtr4 recruitment to transcripts of MRTF target genes and their degradation by the nuclear exosome. Our data indicates that loss of Ser7P results in Mtr4 recruitment. As discussed in the previous sections, it is conceivable that the weaker or more transient interaction of MRTF with target promoters in the absence of G-actin depletion might impact on the stability of the Pol II complex and result in defective Pol II phosphorylation, possibly reflecting Ssu72 activity.

We favour a "checkpoint" model in which even during the normal initiation process Pol II passes through a state in which it is possible to recruit Mtr4 to the newly capped transcript, potentially targeting it to the NEXT complex (Figure 91). Transition to the productive state would involve exchange of Mtr4 for the nuclear export machinery and this process would be regulated by the phosphorylation status of the Pol II CTD. In this model, MRTF has two functions in target gene activation: recruitment of Pol II, which occurs both in the induced state and in the non-productive transcriptional state, and facilitation of the exchange of exosome and RNA export complexes, a step that is inhibited at resting G-actin levels. Under induced conditions, G-actin depletion allows stable association of MRTF with target gene promoters. Pol II is recruited and phosphorylation of Ser5 of the Pol II CTD promotes capping of the nascent transcript. At this point, the NEXT complex could be recruited at the CBCA. Subsequent phosphorylation of Ser7 and Ser2 of the Pol II CTD during promoter-proximal pausing and early elongation promote the exchange of the NEXT complex for the TREX complex and nuclear export of the transcript for translation in the cytoplasm. In the non-productive transcriptional state, reduced phosphorylation of Ser7 of the Pol II CTD makes the RNA susceptible to degradation by the nuclear exosome, probably as a result of failure to exchange the NEXT complex for the RNA export machinery, resulting in co-transcriptional degradation of the nascent transcript (Figure 91).

That depletion of Nrde2 could potentiate Mtr4 activity on MRTF-dependent transcripts, even under induced conditions, when Mtr4 is only weakly associated, is consistent with a model of kinetic competition between the exosome and the export machinery. Consistent with an Mtr4 checkpoint prior to release into elongation, low levels of MRTF-dependent transcripts were found associated with Mtr4 in cells stimulated with CD and FCS.

In addition, Mtr4 binding has been observed in a window of 150bp from the TSS where the Pol II solely phosphorylated at Ser5, while Ser7, Ser2, Tyr1 and Thr4 phosphorylations were depleted (Milligan et al., 2016). Moreover, NEXT substrates such as CUTs in yeast lack Ser2, Ser7 and Thr4 phosphorylations of the Pol II CTD (Milligan et al., 2016). In agreement, Mtr4 and Zcchc8 interact specifically with Ser5P of the Pol II CTD (Ebmeier et al., 2017), suggesting that exosome recruitment might be influenced by the phosphorylation status of the Pol II CTD.

Phosphorylation of Ser7 of the Pol II CTD protects MRTF-dependent transcripts from degradation

As in the inhibited transcriptional state, S7A-ON cells exhibited impaired activation of MRTF target genes in response to signal and productive transcription was rescued by Mtr4 depletion, suggesting that Ser7P is important for protecting the transcript from exosomal degradation. This might be due to Ser7P directly inhibiting exosome recruitment. However, as depletion of the Mtr4 inhibitor Nrde2 perturbs stimulation of MRTF target genes, without affecting Pol II loading or CTD phosphorylation, this seems unlikely. Moreover, the effects of depleting Nrde2 and Ser7P appear to be independent, since Nrde2 depletion does not exacerbate the transcriptional defect in cells reconstituted with Rpb1-S7A.

Because LMB-treated NIH3T3 cells and dKO^{MRTF-NLS} cells do not exhibit the defect in Pol II promoter-proximal pausing observed in S7A-ON cells, it appears unlikely that exosome recruitment is a consequence of reduced pausing.

Since reduced Ser7P of the Pol II CTD also inhibited phosphorylation of Ser2, it is possible that Mtr4 recruitment is a result of lack of Ser2P. However, inhibiting phosphorylation of Ser2 of the Pol II CTD using the CDK12/13 inhibitor THZ531 did not block gene expression at MRTF target genes.

Alternatively, Ser7 phosphorylation of the Pol II CTD might favour recruitment of the TREX complex, similar to how recruitment of the CPA complex is promoted by Ser2 phosphorylation. The potential interaction of the TREX complex with Pol II CTD phosphorylated at Ser7 could be tested by IP.

It appears that various RNA processing complexes compete for binding to the CBC and continuously exchange during transcription until transcript fate is decided by locking a particular complex at the CBC at a specific stage during the transcription cycle. One such point is the 3' end processing signal emerging from the Pol II exit channel. It has been shown that cap-proximal poly(A) sites recruit the NEXT complex at the CBCA of PROMPTs (Andersen et al., 2013; Ntini et al., 2013) and 3' end processing signal at snRNAs recruit the PHAX complex (Hallais et al., 2013).

Another potential checkpoint could be during promoter-proximal pausing. Association with a degradation complex early on during transcription would prevent the dynamic exchange of factors at the CBC and ensure degradation of the transcript. Aberrant Pol II CTD phosphorylation could be a signal for degradation.




Figure 91 Regulation of transcription at MRTF target genes

G-actin depletion allows stable association of MRTF with target gene promoters. Pol II is recruited and phosphorylation at Ser5 of the Pol II CTD by CDK7 promotes capping of the nascent transcript. At this point, the NEXT complex could be recruited at the CBCA. Subsequent phosphorylation of Ser7 and Ser2 of the Pol II CTD during promoter-proximal pausing and early elongation promotes the exchange of the NEXT complex for the TREX complex and nuclear export of the transcript for translation in the cytoplasm. On the other hand, in the absence of Gactin depletion, G-actin prevents stable association of nuclear MRTF with genomic loci. Pol II is recruited and phosphorylated at Ser5 of the Pol II CTD. The nascent transcript is capped and could be bound by the NEXT complex. The inefficient MRTF recruitment results in a defect in Pol II CTD phosphorylation, possibly due to rapid dephosphorylation of Ser5P and Ser7P, potentially as a result of Ssu72 activity. Reduced phosphorylation of Ser7 of the Pol II CTD makes the RNA susceptible to degradation by the nuclear exosome, probably as a result of failure to exchange the NEXT complex for the RNA export machinery, resulting in cotranscriptional degradation of the nascent transcript.

It is possible that Mtr4 exchange for the export machinery at a checkpoint during transcription occurs at all protein-coding genes. This idea is in line with pre-mRNAs with structural, splicing and polyadenylation defects being exosome substrates (Bousquet-Antonelli et al., 2000; Hilleren et al., 2001; Houseley et al., 2006; Jensen et al., 2001; Lebreton & Séraphin, 2008; Libri et al., 2002; Milligan et al., 2005; Moore et al., 2006; Torchet et al., 2002) and consistent with transcripts being targeted for degradation in RNA export mutants (Fan et al., 2017; Gudipati et al., 2012; Hilleren et al., 2001; Jensen et al., 2001; Libri et al., 2002). Nevertheless, experiments in Nrde2-depleted cells suggest that this checkpoint is not a general feature of Pol II regulated protein-coding genes and might be MRTF-specific. This is line with experiments in S7A-ON cells, which demonstrate that reconstitution with the Rpb1-S7A mutant affected MRTF target gene expression, specifically.

Genome-wide studies in S7A-ON cells in combination with Mtr4 depletion would help understand the potential relationship between phosphorylation of Ser7 of the Pol II CTD and Mtr4 recruitment at additional sets of genes.

Chapter 10. Appendix

GO BIOLOGICAL PROCESS	# Genes		
GOBP_CYTOSKELETON_ORGANIZATION GOBP_CELL_PROJECTION_ORGANIZATION	247 256	2.14E-74 1.54E-68	1.62E-70 5.82E-65
GOBP CELL PROJECTION OR ANIZATION	256	2.96E-67	7.47E-64
GOBP_CELL_MORPHOGENESIS	200	4.19E-66	7.93E-63
GOBP_ACTIN_FILAMENT_BASED_PROCESS	173	1.01E-64	1.54E-61
GOBP_NEUROGENESIS	256	8.58E-64	1.05E-60
GOBP_POSITIVE_REGULATION_OF_CELLULAR_BIOSYNTHETIC_PROCESS	281	9.67E-64	1.05E-60
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	268	3.05E-61	2.89E-58
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION	263 275	2.35E-60 2.56E-59	1.98E-57 1.94E-56
GOBP_CELL_MIGRATION	213	1.68E-56	9.70E-54
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	195	1.01E-54	
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	216	2.19E-54	1.09E-51
GOBP_NEURON_DIFFERENTIATION	211	8.90E-54	4.16E-51
GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION	263	2.09E-53	9.19E-51
GOBP_INTRACELLULAR_TRANSPORT	242	3.59E-53	1.49E-50
GOBP_MACROMOLECULE_CATABOLIC_PROCESS	215	2.27E-52	8.92E-50
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	186	9.20E-52 1.05E-50	3.44E-49 3.73E-48
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS GOBP_CELL_CYCLE	229	1.17E-50	3.73E-48 3.99E-48
GOBP_NEURON_DEVELOPMENT	182	9.39E-50	3.05E-47
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	166	1.13E-48	3.52E-46
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	213	2.06E-46	6.15E-44
GOBP_POSITIVE_REGULATION_OF_SIGNALING	229	2.46E-46	7.09E-44
GOBP_APOPTOTIC_PROCESS	244	1.24E-45	3.44E-43
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_DIFFERENTIATION	138	2.11E-45	5.63E-43
GOBP_REGULATION_OF_GTPASE_ACTIVITY	112	2.38E-45	6.13E-43
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	136	7.33E-45	1.83E-42
GOBP_BIOLOGICAL_ADHESION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	206	1.02E-44	2.46E-42 4.10E-42
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	190	1.76E-44 1.96E-44	
GOBP_REGULATION_OF_ANATOMICAL_STRUCTORE_MORPHOGENESIS	187	3.79E-44	
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	172		9.33E-42
GOBP_CELLULAR_COMPONENT_MORPHOGENESIS	140		1.85E-41
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	220	2.88E-43	
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	173	1.47E-42	2.89E-40
GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS	178	2.07E-42	3.97E-40
GOBP_REGULATION_OF_CELL_DIFFERENTIATION	211	1.99E-41	
GOBP_CHROMOSOME_ORGANIZATION	180	2.20E-41	4.01E-39
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	210	3.04E-41	5.42E-39
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	174	4.15E-41 5.88E-41	7.22E-39 9.99E-39
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION_OR_REMOVAL GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS			1.12E-38
GOBP_NEGATIVE_REGULATION_OF_NOCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	159	2.52E-40	4.11E-38
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY	162	1.25E-39	2.00E-37
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	207	3.80E-39	5.92E-37
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	190	4.40E-39	6.72E-37
GOBP_REGULATION_OF_CATABOLIC_PROCESS	155	5.90E-39	8.83E-37
GOBP_CELL_PART_MORPHOGENESIS	124	8.34E-39	1.22E-36
GOBP_CHROMATIN_ORGANIZATION	136	1.62E-38	2.33E-36
GOBP_ACTIN_FILAMENT_ORGANIZATION	97	4.05E-38	5.72E-36
GOBP_POSITIVE_REGULATION_OF_GTPASE_ACTIVITY	94	4.95E-38	
GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	157	8.50E-38 9.85E-38	1.16E-35 1.32E-35
GOBP_CELL_POPULATION_PROLIFERATION	200	1.78E-37	2.34E-35
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION	229	2.46E-37	3.17E-35
GOBP_POSITIVE_REGULATION_OF_HYDROLASE_ACTIVITY	131	2.52E-37	3.20E-35
GOBP_HEAD_DEVELOPMENT	128	7.20E-37	8.98E-35
GOBP_CELL_CYCLE_PROCESS	185	1.94E-36	2.38E-34
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	168	2.69E-36	3.25E-34
GOBP_PROTEOLYSIS	214	4.89E-36	5.80E-34
GOBP_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELL_DEATH	144 202	1.42E-35 2.39E-35	1.66E-33 2.74E-33
GOBP_REGULATION_OF_CELL_DEATH GOBP_REGULATION_OF_CELL_CYCLE	166	3.20E-35	3.63E-33
GOBP_REGULATION_OF_CELLULAR_CATABOLIC_PROCESS	134	6.44E-35	7.19E-33
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION	108	9.28E-35	1.02E-32
GOBP_TUBE_DEVELOPMENT	154	1.88E-34	2.04E-32
GOBP_CELL_JUNCTION_ORGANIZATION	119	3.17E-34	3.39E-32
GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT	144	6.62E-34	6.98E-32
GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION	107	8.41E-34	8.74E-32
GOBP_EMBRYO_DEVELOPMENT	144	2.55E-33	2.61E-31
GOBP_NEGATIVE_REGULATION_OF_SIGNALING GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	178	3.73E-33 1.03E-32	3.77E-31 1.03E-30
GOBP_ORGANONTROGEN_COMPOUND_CATABOLIC_PROCESS GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY	1/1	1.03E-32 1.32E-32	1.03E-30 1.30E-30
SSEL_TOTIONENDINAL_RECEITOR_FROTEIN_TROUBLE_RINASE_SIGNALING_FATHWAT	120	3.80E-32	3.69E-30
GOBP POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION		3.95E-32	3.79E-30
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	166		5.26E-30
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION		5.56E-32	8.73E-30
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS	166	9.34E-32	
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS	166 96 124 115	9.34E-32 1.05E-31	9.71E-30
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_HEART_DEVELOPMENT GOBP_HEART_DEVELOPMENT	166 96 124 115 101	9.34E-32 1.05E-31 1.20E-31	1.10E-29
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REART_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION	166 96 124 115 101 108	9.34E-32 1.05E-31 1.20E-31 1.54E-31	1.10E-29 1.38E-29
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROFIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_HEART_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_COVALENT_CHROMATIN_MODIFICATION	166 96 124 115 101 108 91	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31	1.10E-29 1.38E-29 1.88E-29
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_ARATON_IDEVELOPMENT GOBP_CAULENT_CHROMATIN_MODIFICATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	166 96 124 115 101 108 91 153	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31	1.10E-29 1.38E-29 1.88E-29 2.00E-29
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP SIGNAL_TRANSDUCTION GOBP_CELLULAR_REOTEIN_CATABOLIC_PROCESS GOBP REGULATION, OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION, OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION, OF_CELL_PROJECTION_ORGANIZATION GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_ROTEIN_CHROMATIN_MODIFICATION GOBP_ROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION	166 96 124 115 101 108 91 153 137	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 4.23E-31	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_CELL_PROJECTION_ORGANIZATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	166 96 124 115 101 108 91 153	9.34E-32 1.05E-31 1.20E-31 2.12E-31 2.27E-31 4.23E-31 7.94E-31	1.10E-29 1.38E-29 1.88E-29 2.00E-29
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROFIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_ROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT	166 96 124 115 101 108 91 153 137 141 95	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 4.23E-31 7.94E-31 2.24E-30	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_CELL_PROJECTION_ORGANIZATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	166 96 124 115 101 108 91 153 137 141	9.34E-32 1.05E-31 1.20E-31 2.12E-31 2.27E-31 4.23E-31 7.94E-31	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_HEART_DEVELOPMENT GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_CSTIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	166 96 124 115 101 108 91 153 137 141 95 128	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 4.23E-31 7.94E-31 2.24E-30 2.55E-30	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP SMALL GTPASE MEDIATED_SIGNAL_TRANSDUCTION GOBP CELULAR PROTEIN CATABOLIC PROCESS GOBP REGULATION OF CELULAR RESPONSE_TO_STRESS GOBP GOBLATION OF CELULAR RESPONSE_TO_STRESS GOBP COVALENT DEVELOPMENT GOBP COVALENT CHOMENT GOBP COVALENT CHOMENT GOBP COVALENT CHONOMICAL GOBP COVALENT CHOMENT GOBP COVALENT CHOMENT GOBP COVALENT CHOMENT GOBP COVALENT CHOMENT GOBP REGULATION OF TRANSFERASE GOBP REGULATION OF TRANSFERASE GOBP CELLULAR RESPONSE TO GOBP CELLULAR RESPONSE TO GOBP CELLULAR NT GOBP GOBP GOBP REGULATION OF MUL GOBP	166 96 124 115 101 108 91 153 137 141 95 128 171	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 4.23E-31 7.94E-31 2.24E-30 2.55E-30 3.27E-30 4.22E-30 5.44E-30	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28 2.72E-28 3.47E-28 4.43E-28
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_UNOLVED_IN_MORPHOGENESIS GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	166 96 124 115 101 108 91 153 137 141 95 128 171 95 229 94	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 4.23E-31 7.94E-31 2.24E-30 2.55E-30 3.27E-30 3.27E-30 5.44E-30 5.68E-30	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28 2.14E-28 3.47E-28 4.43E-28 4.57E-28
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_HEART_DEVELOPMENT GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS GOBP_REGULATION_OF_MULTICELLULAR_COGANISMAL_DEVELOPMENT GOBP_OSTITVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_HOMEOSTATIC_PROCESS GOBP_MADEOSTATIC_PROCESS GOBP_MADEOSTATIC_PROCESS GOBP_MAPK_CASCADE	166 96 124 115 101 153 137 141 95 128 171 96 209 94 131	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.27E-31 4.23E-31 7.94E-31 2.24E-30 2.55E-30 3.27E-30 4.22E-30 5.68E-30 6.44E-30	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28 2.72E-28 3.47E-28 3.47E-28 4.43E-28 4.57E-28 5.13E-28
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP GOBP GOBLALLAR_PROTEIN_CATABOLIC_PROCESS GOBP REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP GOBLATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_RCOVALENT_CHROMATIN_MODIFICATION BY SMALL_PROTEIN_CONJUGATION GOBP_ROTEIN_MODIFICATION_BY SMALL_PROTEIN_CONJUGATION GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_CTOSES GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_RECL_CELL_SIGNALING GOBP_CELL_CELL_SIGNALING GOBP_MAPK_CASCADE	166 96 124 115 101 108 91 153 137 141 95 5128 171 96 209 94 4131 191	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 4.23E-31 2.24E-30 2.55E-30 4.22E-30 5.44E-30 5.44E-30 5.68E-30 8.23E-30	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28 2.14E-28 3.47E-28 4.43E-28 4.57E-28 5.13E-28 6.48E-28
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROFENTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_UNOLVED_IN_MORPHOGENESIS GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_MODIFICATION_BEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS	166 96 124 115 101 108 91 153 137 141 95 128 171 96 209 94 131 191	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 2.27E-31 2.24E-30 2.55E-30 3.27E-30 3.27E-30 4.42E-30 5.44E-30 5.64E-30 6.44E-30 8.23E-30 2.67E-29	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28 2.72E-28 3.47E-28 4.43E-28 4.43E-28 5.13E-28 5.13E-28 5.13E-28
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_INVOLVED_IN_MORPHOGENESIS GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WANT GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS GOBP_OSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_MULTICELLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION GOBP_MAPK_CASCADE GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION GOBP_MAPK_CASCADE GOBP_REGULATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS GOBP_TISSUE_MORPHOGENESIS	166 96 124 115 101 108 91 153 137 141 95 128 171 96 209 94 131 191 107 105	9.34E-32 1.05E-31 1.20E-31 1.20E-31 2.27E-31 4.23E-31 2.27E-31 4.23E-31 7.94E-31 2.24E-30 3.27E-30 3.27E-30 3.27E-30 4.22E-30 5.44E-30 5.44E-30 6.44E-30 6.267E-29 2.80E-29	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 1.90E-28 2.14E-28 2.14E-28 3.47E-28 4.43E-28 4.43E-28 6.48E-28 6.48E-28 2.08E-27 2.16E-27
GOBP POSITIVE REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP SIGNAL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION GOBP CELLULAR_PROTEIN_CATABOLIC_PROCESS GOBP REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_ROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_CELL_CELL_SIGNALING_BY_WNT GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_MULTICELLULAR_COMPONENT_BIOGENESIS GOBP_POSITIVE_REGULATION_OF_CCLULAR_COMPONENT_BIOGENESIS GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS	166 96 124 115 101 108 91 153 137 141 95 128 171 96 209 94 131 191	9.34E-32 1.05E-31 1.20E-31 1.54E-31 2.12E-31 2.27E-31 2.27E-31 2.24E-30 2.55E-30 3.27E-30 3.27E-30 4.42E-30 5.44E-30 5.64E-30 6.44E-30 8.23E-30 2.67E-29	1.10E-29 1.38E-29 1.88E-29 2.00E-29 3.68E-29 6.82E-29 1.90E-28 2.14E-28 2.72E-28 3.47E-28 4.43E-28 4.43E-28 5.13E-28 5.13E-28 5.13E-28

Figure 92 Gene ontology analysis of genes upregulated in response to CD in

NIH3T3 cells by RNAseq

Gene ontology analysis of genes upregulated by CD treatment in NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 33B. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

Cold Deck North Section 2011 Cold Deck North Section 2011 0.100000000000000000000000000000000000	GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
Deep EstRUBANEET OF PROTE 1.000000000000000000000000000000000000	GOBP_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE	65	1.30E-85	9.74E-82
SEGP PARTING (6) 196.00 196.00 206.00	GOBP_NUCLEAR_TRANSCRIBED_MRNA_CATABOLIC_PROCESS_NONSENSE_MEDIATED_DECAY			
SCRP BALCOLOGAL PROCESS 115 3886-77 9525-74 SCRP BALCORDAL SPROSERSON 3346-75 4526-74 4347-72 SCRP BALCOLOGAL PROCESS 16 7766-66 5976-66 SCRP BALCOLOGAL SPROSERSON MINIC CARADOLO, PROCESS 16 7766-66 5976-66 SCRP BALCOLOGAL SPROSERSON MINIC CARADOLO, PROCESS 16 7766-66 5976-66 SCRP BALCOLOGAL SPROSERSON MINIC CARADOLO, PROCESS 16 5456-60 1756-56 SCRP BALCOLOGAL SPROSERSON MINIC CARADOLO, PROCESS 16 5456-60 1756-56 SCRP BALCOLOGAL SPROSES 16 5456-60 1756-56 SCRP CARADOLOG COMPOUND EQUIVATION DO CARADOLOGINO COMPARIEL 16 5466-60 1566-56 SCRP PROTEIN LOCALDATION TO MEMBRANE 16 5466-60 1566-56 166 5466-60 1566-56 166 5466-60 1566-56 166 5466-60 1566-66 1266-50 166 5466-60 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66 1566-66				
GOP TARGE 2276-80 2226-80 DOP TARGE 2276-80 2276-80 2276-80 DOP TARGE 1000 2276-80 2276-80 2276-80 DOP TARGE 1000 2266-80 2276-80	GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION			
DORP INTRACLULUAL TRANSPORT 118 7015-66 5975-83 DORP INCLEAR TRANSPORT OF PROTEN LOCAL ZATION 06 7985-86 5972-83 DORP INCLEAR TRANSPORT OF PROTEN LOCAL ZATION TO MEMBRANE 07 2814-64 1785-86 DORP ISTALLISHEME OF PROTEN LOCAL ZATION TO MEMBRANE 08 2814-64 1785-86 DORP ISTALLISHEME OF PROTEN LOCAL ZATION TO MEMBRANE 08 1825-87 1416-86 DORP ISTALLISHEME CONCLUSTICUE PROCESS 10 1584-57 1776-86 DORP ISTALLISHEME CONCLUSTICUE PROCESS 10 1584-56 1276-85 10 3846-54 1276-85 DORP ISTALLISHEME CONCLUSTICUE PROCESS 118 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 3846-54 1276-85 10 1384-54 1276-85 10 1286-54 1276-85 10 1286-54 1276-85 <	GOBP_VIRAL_GENE_EXPRESSION			
SORP MULLAR, TRANSCREED, MENA CATABOLO, PROCESS 66 7.996-66 5.976-03 SORP MOTEN TARGETING TO MERRAME 67 5.976-03 5.976-03 SORP MOTEN TARGETING TO MERRAME 67 5.976-03 5.976-03 SORP MOTEN LOCAL ADDA TO, MERRAME 67 5.866-03 1.956-55 SORP MOTEN LOCAL ADDA TO, MERRAME 68 1.966-66 1.956-56 SORP MOTEN LOCAL ADDA TO, MERRAME 68 1.966-66 2.976-53 SORP MOTEN LOCAL ADDA TO, MERRAME 68 3.976-53 1.966-66 2.976-53 SORP MOTENCIC E ADARADIC PROCESS 1.66 3.976-53 3.986-54 <td></td> <td></td> <td></td> <td></td>				
SGAP BOTTEN TARGETING TO MEMBRANE 66 9.976-66 5.976-51 SGAP BOTTEN TARGETING TO MEDIC LOCALIZATION 16 5.456-51 3.726-51 SGAP BOTTEN TARGETING TO MEDIC LOCALIZATION 17 5.456-51 3.726-51 SGAP BOTTEN TARGETING TO MEDIC LOCALIZATION 17 5.456-51 175-53 4.865-55 175-53 4.865-55				
GGRP_ESTALLISHEAT_OF_PROTEN_LOCAUZATION TO_INSTREAME 79 281-62 1756-56 GGRP_ENTEN_LOCAUZATION TO_INSTREAMENT 106<	GOBP_PROTEIN_TARGETING_TO_MEMBRANE			
GGP PROTEN LOCALZATION TO MEMBRANE 96 18.85:69 11.85:69 1	GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION			
DBP CELLUAR MACROMOLOUE CATABOLC PROCESS 128 835-69 4416-53 DBP MACRANCELE CATABOLC PROCESS 138 1078-89 1078-89 DBP CREAL CATABOLC PROCESS 148 516-56 2275-58 DBP CREAL CATABOLC PROCESS 148 516-56 2275-58 DBP CREAL CATABOLC PROCESS 148 516-56 2275-58 DBP CREAL CALLENC CONCARLLE 183-55-31 151-55-53 <				
GBP_MACRAMELECULE_CATABOLC_PROCESS 198 279:68 108:628 GBP_MACATABOLC_PROCESS 161 151:67 1717:65 GBP_CALADARONITOCER_COMPUND_BONTHETO_PROCESS 161 161:67 227:67 GBP_CALADARONITOCER_COMPUND_BONTHETO_PROCESS 161 144:63 151:62 GBP_CELLULAR_ANDM_CPROCESS 103 33:64:31 127:65 GBP_MACE_TADAGUE_PROCESS 103 33:64:31 127:65 GBP_MADE_GROWENTERO_EPROCESS 103 34:64:31 127:65 GBP_MADE_GROWENTERO_EPROCESS 103 34:64:30 127:65 GBP_MADE_GROWENTERO_EPROCESS 110 84:64:51 157:64 GBP_MADE_GROWENTERO_EPROCESS 110 84:64:51 157:64 GBP_MEDATER_REQUARDANC_OF REPRESSON 151 157:64 157:64 GBP_MODELIDOROFINITALOCALIZATION 144 152:64 157:64 GBP_MODELIDOROFINITALOCALIZATION 146 32:64:31 156:74 GBP_MODELIDOR_ALIZATION 146:43 157:65 157:65 GBP_MODELIDOR_ALIZATION 146:43 157:65 157				
GBP PROTE 146 5166 50 2276-23 GBP PETRUE URACUC, PROCESS 108 336-64 336-64 GBP PETRUE URACUC, PROCESS 108 336-64 336-64 GBP SABLESA 108 336-64 1216-65 GBP CELLUAR ANDE WERKICK PROCESS 108 336-64 1226-65 GBP PETRUE GURANDE WERKICK PROCESS 109 436-63 7276-61 GBP PETRUE GURANDE WERKICK PROCESS 109 436-63 7266-61 GBP PETRUE GURANDE WERKICK PROCESS 109 436-63 736-64 GBP PERCENC CONTINUE CONCENT TANARCONTINC 146 536-64 1196-64 GBP PROTEIN CONTINUE CONCENT TANARCONTINC 146 536-64 1196-63 GBP PROTEIN CONTINUE CONCENT TANARCONTINC 1196-53 126-63 1196-53 GBP PROTEIN CONTINUE CONCENTRICANARCONTINC 1196-53 126-63 1196-53 GBP PROTEIN CONTINUE CONCENTRICANARCONTINC 109-63 126-63 126-63 126-63 <td>GOBP_MACROMOLECULE_CATABOLIC_PROCESS</td> <td></td> <td></td> <td></td>	GOBP_MACROMOLECULE_CATABOLIC_PROCESS			
360P PEPTOE METABOLC, PROCESS 110 6.386-60 3.496-53 300P PESTABLISHING OF PROTEIN TO ORGANELLE 112 4.846-80 1112-52 300P PESTABLISHING OF PROTEIN TO ORGANELLE 112 4.846-80 1112-52 300P PESTABLISHING OF PROTEIN TO ORGANELLE 112 4.846-80 1112-53 300P PESTABLISHING OF PROTEIN TARGETING 122 746-53 3.966-51 300P PESTABLISHING OF PROTEIN TARGETING 122 746-53 3.966-51 300P PESTABLISHING OF PROTEIN TARGETING 123 7466-53 3.966-51 300P PESTABLISHING OF PROTEIN TARGETING 133 3.466-50 3.866-51 300P PESTABLISHING OF PROTEIN CONTAINING COMPLEX ASSEMPLY 130 3.846-50 3.566-51 300P PESTABLISHING OF PROTEIN CONTAINING COMPLEX ASSEMPLY 130 3.846-51 3.156-52 300P PESTABLISHING AND FORDER 130 3.246-51 3.156-52 300P PESTABLISHING AND FORDER 130 3.246-51 3.156-52 300P PE	GOBP_RNA_CATABOLIC_PROCESS			
DBP PCOTEN COAL ADTON TO ORGANELLE 98 2.376-58 9.386-53 DBP PCOTEN COARNELLE 12 4.464-64 116-15-64 DBP DESTINGTON ADTON TO PROCESS 10 3.462-64 116-15-63 3.462-64 116-15-63 DBP PETPLED DESTINGTON ADTON TO PROCESS 104 2.446-63 7.765-61 DBP DESTINGTON ADTON TO PROCESS 104 2.446-63 7.976-61 DBP PROTEIN TARGETING 115 3.066-63 3.066-63 DBP PROTEIN TARGETING 116 3.066-63 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73 3.066-73				
SDP. PROTEN LOCALIZION TO GRANELLE 1112 444-68 1314-52 SDP. CELLUAR ANDE METAGUIC, PROCESS 103 3384-64 1324-51 SDP. MOLE INSONTHETIC PROCESS 104 1345-44 7374-51 SDP. MOLE INSONTHETIC PROCESS 104 1345-44 7374-51 SDP. MOLE INSONTHETIC PROCESS 104 1345-44 7374-51 SDP. PROTEIN TARGETING 116 9466-50 2474-58 8464-51 SDP. PROTEIN TARGETING 116 9466-50 2474-58 8464-51 SDP. PROTEIN, CONTINNIC CONTRUING CONTREX, SUBMUT ORGANIZATION 114 4324-48 1378-45 SDP. PROTEIN, CONTINNIC CONTRUES, CONTREX, SUBMUT ORGANIZATION 114 4324-48 1378-45 SDP. PROTEIN, CONTINNIC CONTRUES, SUBMUT ORGANIZATION 114 4324-48 1378-53 SDP. PROTEIN, CONTINNIC CONTRUES, CONTREX, SESSIMELY 106 5384-52 1272-53 SDP. PROTEIN, CONTRINUC, CONTRUES, CONTREX, SESSIMELY 106 1652-1 1212-53 SDP. PROTEIN, CONTRINUC, CONTRUES, SESSIMELY 106 1652-2 1226-52 SDP. PROTEIN, CONTRINUC, CONTRUES, SESSIMELY<				
0369 LELLARA_AMDE_METABOLC_PROCESS 120 338-64 1212-65 0369 MINA_LEXACU_PROCESS 00 138-63 338-64 1212-65 0369 MINA_LEXACU_PROCESS 00 138-63 338-64 1212-65 0369 PORTIN_TARCETMO 152 306-64 346-61 0369 PORTIN_TARCETMO 152 306-64 346-61 0369 PORTIN_TARCETMO 152 306-64 346-61 0369 PORTIN_TARCETMO 152 306-64 356-64 0369 PORTIN_TARCELLAR PORTER_DALLATION CAMPLEX SUBLITY 16 327-53 327-53 0369 PORTING_TARCELLOPATH 115 138-63 327-53 326-54 326-52 327-53 326-52 327-53 326-52 327-53 326-52 327-53 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 326-52 <t< td=""><td></td><td></td><td></td><td></td></t<>				
SORP_PERDE BIGSYNTHETIC_PROCESS 97 1138-83 3986-51 SORP_MODE_BIGSYNTHETIC_PROCESS 104 2446-53 756-51 SORP_MODE_BIGSYNTHETIC_PROCESS 164 2446-53 546-51 SORP_MODE_BIGSYNTHETIC_PROCESS 164 2446-50 356-56 SORP_PROTIN_TARGETING 768-56 1516-57 SORP_PROTIN_TARGETING 768-56 1516-57 SORP_PROTIN_TARGETING 768-56 1516-57 SORP_PROTIN_CONTAINING_COMPLEX_SUBURY ORGANIZATION 114 4526-49 1275-53 SORP_PROTING_TOR_CONTAINING_COMPLEX_ASSEMILY 68 528-53 1266-27 SORP_PROTING_TOR_CONTAINING_COMPLEX_ASSEMILY 68 126-27 1276-25 SORP_PROTING_TOR_CONTAINING_COMPLICARDOCESS 168 126-27 1276-25 SORP_PROTING_TOR_CONTAINING_COMPLICARDOCESS 168 126-28 1276-25 SORP_DECLL_MODUTION PROLETING TONON 106 1166-28 1276-25 SORP_DECLL_MODUTION OF_RECORSS TAMULIS 101 1166-28 1276-25 SORP_DECLLATION OF_RECORSTAINLUS 101 1166-28	GOBP_CELLULAR_AMIDE_METABOLIC_PROCESS	120	3.39E-54	1.21E-51
SORP_ADDLE_BOSYNTHETC. PROCESS 1104 2.448-63 7.976-51 SORP_ADDLE_BOSYNTHETC. PROCESS 1162 3.066-63 8.984-51 SORP_ADDLE_MARCHING_FORCES 1162 3.066-63 8.944-51 SORP_ADDLE_MARCHING_FORCESS 116 9.042-64 3.946-43 SORP_ADDLE_MORTANCE_CONTRAINS_CONTRAI				
300P PROTEIN TARGETING 176 2.24E-53 8.49E-51 300P PSTALEJNENT OF PROTEIN LOCALIZATION 152 8.44E-51 3.44E-51 300P PSTALEJNENT OF PROTEIN TRANSPORT 116 9.49E-53 3.44E-51 3.				
DORP_ESTABLISHMENT_G_PROTEN_LOCALZATION 152 3.006-53 8.046-51 DORP_INTRACELLIAR, PROTEN_TANARSPORT 156 3.006-53 3.061-54 3.061-54 DORP_INTRACELLIAR, PROTEN_TANARSPORT 151 3.061-54 3.061-54 3.061-54 SORP_ACQUART, CAULAR, PROTEN_CANARSPORT 151 3.061-54 3.061-54 3.061-54 SORP_ACQUART, CAULAR, PROTEN_CONTANING COMPLEX, ASSEMBLY 163 3.061-54 3.278-53 SORP_ACQUART, ADMISSION 107 1.064-54 2.296-53 SORP_ACQUART, ADMISSION 107 1.064-54 2.296-53 SORP_ACQUART, ADMISSION 107 1.064-54 2.296-53 SORP_ACQUART, ADMISSION 108 1.696-26 2.006-23 SORP_ACQUART, RESULTION, OF DECIMARING COMPOUND 108 1.696-26 2.206-22 SORP_ACQUART, RESULTION, OF DECIMARTIC, PROCESS 100 1.496-24 7.146-23 SORP_ACQUART, RESULTION, OF DECIMARTIC, PROCESS 101 1.466-24 7.246-23 SORP_ACQUART, RESULTION, OF DECIMARTIC, PROCESS 101 1.466-24 7.466-23 SORP_ACQUART, RESULTION, OF D	GOBP_PROTEIN_TARGETING			
SOBP_ORANIC_CYCLIC_COMPOUND_CATABOLIC_PROCESS 88 142E-50 386E-48 SOBP_NEGATIVE_REGULATION_OF COMPLEX_SUSSION 137 586E-50 315E-45 SOBP_NEGATIVE_REGULATION_OF COMPLEX_ASSEMBLY 181 545E-50 172E-53 SOBP_PROTIN_CONTAINING_COMPLEX_ASSEMBLY 181 542E-50 172E-53 SOBP_DECLOCIDE_ADDESS 180 142E-50 172E-53 SOBP_DECLOCIDE_ADDESS 180 142E-50 172E-53 SOBP_DECLOCIDE_ADDESS 181 102E-27 272E-25 SOBP_DECLID_ADR_ADDESS 181 102E-27 272E-25 SOBP_DECLID_ADR_ADDLY ON_OF PROTEIN METABOLIC_PROCESS 181 112E-25 274E-25 SOBP_DECLID_ADR_ADDLY OF PROTEIN METABOLIC_PROCESS 181 112E-25 274E-25 SOBP_DEGATIVE_REGULATION OF PROTEIN METABOLIC_PROCESS 181 112E-25 274E-25 274E-25 SOBP_DEGATIVE_REGULATION OF PROTEIN METABOLIC_PROCESS 181 117E-25 274E-27	GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION			8.64E-51
SDBP_INCENTUC_REGULTATION_OF_REVERSION 137 5.68E-50 1.51E-47 SDBP_INCENTUC_ONTAINING_COMPLEX_ASSEMULY 146 4.52E-51 1.22E-53 SDBP_APORTINC_OPROCESS 130 5.48E-50 1.22E-53 SDBP_APORTINC_ORTAINING_COMPLEX_ASSEMULY 146 5.22E-33 1.22E-53 SDBP_APORTINC_ORTAINING_COMPLEX_ASSEMULY 146 5.42E-33 1.22E-53 SDBP_APORTINC_DEVOCIMATIONING_COMPLEX_ASSEMULY 146 5.42E-33 1.22E-53 SDBP_APORTINC_REQULATION_OF PORTEM METABOLIC_PROCESS 166 5.41E-53 1.21E-27 SDBP_APORTINC_REQULATION_OF PORTEM METABOLIC_PROCESS 101 1.47E-54 2.20E-23 SDBP_APORTINC_REGULATION_OF PORTEM METABOLIC_PROCESS 101 1.47E-54 2.20E-23 SDBP_APORTINC_REGULATION_OF PROCENS METABOLICES 101 1.47E-54 2.20E-23 SDBP_APORTINC_REGULATION_OF PROCENS METABOLICERS 101 1.47E-52 2.20E-23 SDBP_APORTINC_REGULATION_OF PROCENS METABOLICERS 101 1.47E-52 2.20E-23 2.20E-23 2.20E-23 2.20E-23 2.20E-23 2.20E-23 2.20E-23 2.20E-23 2.20E-23	GOBP_INTRACELLULAR_PROTEIN_TRANSPORT			
SORP PROTIN CONTAINING COMPLEX SUBUNT ORGANIZATION 1141 4.9524-80 9.2725-37 SORP APOPTION CONTAINING COMPLEX ASSEMBLY 96 5.285-80 9.2765-37 SORP REGULTATION OF CELL DEPTH 1151-158-35 2.276-32 SORP REGULTATION OF CELL DEPTH 1151-158-35 2.276-32 SORP SOLUTION CONC, TRANSLING COMPONID 32 7.465-31 1.696-32 SORP POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 96 1.0222-32 2.076-23 SORP DECLINOPTIVE REGULATION OF PROTEIN METABOLIC PROCESS 101 1.195-25 2.246-23 SORP DEGLINATION OF PROTEIN METABOLIC PROCESS 11 1.185-24 2.246-23 SORP DEGLINATION OF PROTEIN METABOLIC PROCESS 11 1.185-24 2.246-23 SORP DEGLINATION OF PROTEIN METABOLICE AND ENERGY 1.54 4.496-24 2.366-23 SORP DEGLINATION OF PROTEIN METABOLICE AND ENERGY 1.54 4.496-24 2.366-23 SORP TUBE DEVELOPMENT 7.6 4.496-24 2.366-23 3.366-23 3.366-23 3.366-23 3.366-23 3.366-23 3.366-23 3.366-23 3.366-23 3.366-23 3.366-23				
SORP APPTOTIC PROCESS 130 344E-39 347E-37 SORP CELLULAR PROTEIN CONTINUE COMPLIX, ASSEMBLY 191 532E-39 122E-35 SORP RECULATION OF, CELL DEATH 115 118E-34 22E-53 SORP RECULATION OF, CELL DEATH 107 14AE-34 22E-53 SORP AREADINES 107 14AE-34 22E-53 SORP AREADINES 100 14E-24 22E-53 SORP AREADINES 100 14E-24 22E-27 SORP AREADINES 101 14E-24 22E-27 SORP AREADINES 101 14E-24 22E-22 SORP AREADINES 101 14E-24 22E-22 SORP AREADINES TO AND OR INTRACLUAR SIGNAL TRANSDUCTION 100 74E-24 74E-22 SORP GELLAGEL ADHESION 101 74E-24 74E-25 74E-22 SORP CELLAGEL ADHESION 101 74E-24 <td>GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION</td> <td></td> <td></td> <td></td>	GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION			
SOBP_REGULATIÓN, OF_CELL_DEATH 115 1158 2267 SOBP_RISCICACA_DATESION 107 104E-34 2295-32 SOBP_RESPONSE TO AVIGEN CONTAINING COMPOUND 106 681E-30 121E-27 SOBP_RESPONSE TO AVIGEN CONTAINING COMPOUND 106 681E-30 121E-27 SOBP_RESPONSE TO AVIGEN CONTAINING COMPOUND 106 681E-30 121E-27 SOBP_RESPONSE TO AVIGEN CONTAINING COMPOUND 106 868E-26 1.71E-23 SOBP_RESPONSE TO AVIGEN CONTAINING COMPOUND 681E-30 1.21E-27 2.27E-23 SOBP_RESPONSE TO AVIGEN CONTONNE 97 141E-24 2.26E-22 SOBP_RESPONSE TO ENDOCENDING METABOLICE PROCESS 76 141E-24 2.26E-23 SOBP_RESPONSE TO ENDOCENDING STIMULUS 94 170E-22 2.86E-24 1.26E-24 SOBP_RESPONSE TO ENDOCENDING STIMULUS 94 170E-22 2.86E-22 1.46E-19 SOBP_RELL_ACTIVATION 68 5.86E-22 1.46E-19 2.26E-21 1.35E-19 SOBP_RELL_ACTIVATION 68 5.86E-22 1.46E-19 2.86E-21 1.75E-19 <td< td=""><td>GOBP_APOPTOTIC_PROCESS</td><td>130</td><td>3.84E-39</td><td>9.27E-37</td></td<>	GOBP_APOPTOTIC_PROCESS	130	3.84E-39	9.27E-37
SORP_BIOLOGICA_ADHESION 107 1016-30 2264-231 1556-28 SORP_CTOTULASING TRANSLATION 22 7448-31 1556-28 SORP_RESTINES TO_OXYGEN_CONTAINING COMPOUND 106 681-33 1216-27 SORP_RESTINE REQUILATION_OF PROTEIN_METABOLIC_PROCESS 109 680-27 2.07E-25 SORP_NEGATINE_REQUILATION_OF PROTEIN_METABOLIC_PROCESS 101 118E-28 2.20E-23 SORP_NEGATINE_REQUILATION_OF PROTEIN_METABOLIC_PROCESS 101 118E-24 2.20E-23 SORP_REGULATION OF PROTEIN_METABOLIC_PROCESS 101 141E-24 2.20E-23 SORP_REGULATION OF PROTEIN_METABOLIC_PROCESS 101 141E-24 2.20E-23 SORP_REGULATION OF PROTEIN_METABOLIC_PROCESS 104 120E-24 7.18E-24 SORP_TOLE_DEVELOPMENT 100 7.81E-24 7.18E-24 7.20E-22 SORP_REGULATION OF REGULATION OF RESONSE TO_STIMULUS 94 120E-24 1.46E-14 7.19E-19 SORP_CELL_CATANTAN 66 6.74E-22 1.46E-19 3.08E-21 4.42E-14 3.08E-21 4.42E-14 3.08E-21 4.32E-19 3.08E-12 4.	GOBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY		5.23E-39	
SORP CYTOPLASHIC TRANSLATION 122 748-53 156-52 SORP RESPONSE TO CAYCER CONTAINING COMPOUND 166 681-63 1216-27 SORP PROSTIVE, REGULATION OF PROTEIN METABOLIC PROCESS 160 1626-27 2076-28 SORP CELL POPULATION POLEPRATON 169 686-26 1716-23 SORP SESTORSE, TO CAYCEN CONTAINING COMPOUND 161 186-26 1716-23 SORP MERTATION OF BROTHERTIC PROCESS 101 1186-28 216-22 SORP MERTATION OF PROTEIN METABOLIC PROCESS 101 146-24 216-22 SORP MERTATION OF PROTEIN METABOLIC PROCESS 101 146-24 216-22 SORP MERTATION OF PROTEIN METABOLIC PROCESS 101 146-24 216-22 SORP TUBE DEVICE DEVICENT 73 600-22 296-22 206-22 296-22 SORP TUBE DEVICE DEVICENT 73 600-22 296-22 146-51 SORP CELL CART ANDINO 68 577-22 286-22 146-51 SORP CELL CART ANDINO 68 586-22 145-51 220-22 286-22 SORP CELL CART ANDINO 780				
SORP RESPONSE TO OXYGEN CONTAINING COMPOUND 166 6816.20 1216.27 SORP POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 169 1026.27 2.2076.25 SORP CELL POPULATION PROLFERATION 169 1666.27 2.2076.25 SORP CELL POPULATION PROLFERATION 1716.25 2.206.23 SORP CELL MIGRATION 1716.25 2.216.23 SORP CELL MIGRATION OF PROTEIN METABOLIC PROCESS 161 184.24 7.417.25 SORP CENTRATION OF PROTEINS METABOLITES AND ENERGY 163 4.446.24 2.166.22 SORP CELL ACTION OF PROTEINS METABOLITES AND ENERGY 164 1.216.22 2.266.23 SORP CELL ACTION OF METABOLITES AND ENERGY 163 4.446.24 7.416.22 2.266.23 SORP CELL ACTION OF METABOLITES AND ENERGY 163 6.746.22 9.466.13 2.266.23 SORP CELL ACTION OF REGULATION OF RESPONSE TO OXYGEN CONTAINING COMPOUND 176 1.206.21 1.466.14 2.266.23 SORP SECULATION OF NUCLEOBASE CONTAINING COMPOUND 176 1.206.21 1.456.12 2.466.13 SORP SECULATION OF NUCLEOBASE CONTAINING COMPOUND 176 1.206.21 <t< td=""><td></td><td></td><td></td><td></td></t<>				
SORP - CELL, POPULATION, PROLIFERATION 109 6.892-66 1.71E-23 SORP - REGULATION OF BOSYNTHETIC, PROCESS 100 1.15E-26 2.24E-23 SORP - RESPUES, TO, CYTOKINE 811 1.15E-26 2.74E-23 SORP - RESPUES, TO, CYTOKINE 811 1.15E-26 2.15E-22 SORP - RESPUES, TO, CYTOKINE 801 1.15E-26 2.15E-22 SORP - RESPUES, TO, CYTOKINE 801 1.15E-24 2.15E-22 SORP - REGULATION OF PROCEINS, STIMULUS 94 1.26E-24 2.16E-24 SORP - REGULATION OF RECORDUS STIMULUS 94 1.26E-22 2.86E-20 SORP - RELOCIVATION 66 9.74E-22 2.86E-20 SORP - RELOCIVATION 66 9.74E-22 2.86E-20 SORP - RELOCIVATION 66 9.74E-22 2.86E-20 SORP - REGULATION OF NUCLEORASE CONTAINING COMPOUND 76 1.22E-21 1.45E-19 SORP - REGULATION OF CELL DIFFERENTIATION 90 3.06E-21 4.33E-19 SORP - REGULATION OF CELL DIFFERENTIATION 90 4.32E-21 3.3E-19 SORP - REGULATION OF CELL DIFFEREN	GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND			
DOP PIELL MIGRATION OF BIOSYNTHETIC PROCESS 100 118-25 2206-23 DOP CELL MIGRATION 97 147E-25 2206-23 DOP CELL MIGRATION 97 147E-25 2206-23 DOP NEGATIVE, REGULATION OF PROTEIN METABOLIC PROCESS 78 141E-24 2156-22 DOP REGURE REGULATION OF INTRACULLUAR, SIGNAL TRANSDUCTION 100 7.61E-24 1.236-21 DOP REGURE REGULATION OF RESPONSE TO STMULUS 94 1.76E-22 3.686-21 DOP CELL CARL ARESONSE TO ENDOGENOUS STMULUS 94 1.76E-23 3.686-21 DOP CELL CARL ARESONSE TO ENDOGENOUS STMULUS 96 7.47E-23 3.686-21 DOP CELL CARL ARESONSE TO ENDOGENOUS STMULUS 96 7.47E-23 3.68E-21 DOP CELL CARL ARESONSE TO ENTATION CONTAINING COMPOUND 65 9.67E-23 3.41E-54 DOP CELL CARL ARESONSE TO ENTATION OF ARESONSE TO ENTATION 96 3.00E-21 3.41E-54 DOP REGULATION OF CARL DEATH 66 3.66E-21 3.55E-3 DOP REGULATION OF CONTAINING COMPOUND 7.46E-21 3.55E-3 DOP REGULATION OF PROTEIN MODIFICATION PROCESS 90 4.26E-11	GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	98	1.02E-27	2.07E-25
308P CELL MIGRATION 97 1.47E-25 2.74E-25 308P RESPONSE TO, CYTOKINE 81 1.18E-24 2.515-22 308P RESPONSE TO, CYTOKINE 83 4.49E-24 7.512-23 308P RESPONSE TO, CYTOKINE 84 4.49E-24 7.512-24 308P CENERATION OF, PRECURDUS STIMULUS 94 2.20E-23 3.66E-21 308P TUBE DEVELOPMENT 73 6.00E-22 2.86E-20 308P CELL CATUATION OF, RESPONSE TO STIMULUS 94 7.87E-22 2.86E-20 308P CELL CATUATION 76 6.00E-22 2.86E-20 308P CELL CATUATION 76 6.00E-22 2.86E-20 308P CELL CATUATION 66 3.46E-21 1.46E-19 308P CELL CATUATION 60 3.00E-21 4.31E-19 308P REGULATION OF NOLLEOBASE CONTAINING COMPOUND METABOLIC PROC 2.28E-21 3.31E-19 308P REGULATION OF CILL DIFFERENTIATION 60 3.80E-21 4.30E-19 308P REGULATION OF CONTON PROCESS 60 3.80E-21 4.30E-19 308P REGULATION OF PROTEIN MODIFICATION PROCESS 60 7.66E-21				
SORP RESPONSE TO CYTOKINE 81 118:244 2165:22 SORP NEGATVE, REGULATION OF PROTEIN METABOLIC PROCESS 78 1411:24 2506:22 SORP REGULATION OF INTECLUARS, SIGNAL TRANSDUCTION 100 7.611:24 1285:21 SORP REGULATION OF, INTECLUARS, SIGNAL, TRANSDUCTION 94 1.762:23 3.666:21 SORP NEGATVE, REGULATION OF, RESPONSE, TO, STMULUS 94 1.762:24 3.666:21 SORP CELL, CATURATION 66 6.742:22 1.656:19 SORP CELL, CATURATION 66 6.742:22 1.466:19 SORP CELL, CATURATION OF NUCLEOBASE CONTAINING COMPOUND 76 1.205:21 1.436:19 SORP SCELCTON 66 5.287:21 3.316:19 3.316:21 4.336:19 SORP REGULATION OF CELL DIFFERENTIATION 90 3.006:21 4.236:19 3.006:21 4.236:19 SORP REGULATION OF CELL DIFFERENTIATION 90 4.306:19 3.006:21 4.236:19 3.006:21 4.236:16 3.066:21 4.236:16 3.066:21 4.236:16 3.066:21 4.366:19 3.066:21 4.366:17 3.066:21 3.066:21				
308P. NEGATIVE, REGULATION, OF_RROTEIN, METABOLIC, PROCESS 76 141F244 2.506-22 308P. GENERATION, OF_RETROUTISS, AND ENERGY 53 4.496-24 1.296-21 308P. RESPONSE, TO_ENDGENOUS STIMULUS 94 1.206-21 2.306-21 308P. RESPONSE, TO_ENDGENOUS STIMULUS 94 2.007-21 2.306-21 308P. TUBE, DEVELOPMENT 73 6.006-22 2.806-20 308P. TUBE, DEVELOPMENT 73 6.006-22 2.806-20 308P. CELL, CLIL, ADHESION 86 9.446-21 1.036-11 308P. CELL, LAL, ADHESION 60 3.006-21 2.316-11 308P. SCHETION 60 3.006-21 4.316-19 308P. REGULATION OF OUCLEOBASE CONTAINING COMPOUND METABOLIC PROC 2.286-21 3.776-11 308P. REGULATION OF OCTON 60 3.006-21 4.306-19 308P. REGULATION OF CRUEIN MODIFICATION PROCESS 06 3.426-21 6.764-19 308P. REGULATION OF FROTEOL SEGUTION 7.662-61 3.962-19 3.962-19 308P. REGULATION OF FROTEOL SEGUTION 60 3.486-21 3.966-19 308P. AD CONTON O				
500P REGULATION, OF, INTRACELLULAR, SIGNAL, TRANSDUCTION 100 7 215-24 1.216-21 500P RESONASTE TO, ENDOCONUS, STIMULUS 94 1.766-22 2.866-23 500P REGOLATION, OF, RESPONSE, TO, STIMULUS 94 1.766-22 2.866-23 500P CELL, ACTIVATION 86 5.956-22 1.466-19 500P CELL, CALL, ADHESION 66 5.956-22 1.466-19 500P CELL, ACINESION 66 5.956-22 1.466-19 500P CELL, ADHESION 66 5.956-22 1.466-19 500P SECRETION 67 1.206-21 1.316-19 500P REGULATION, OF, CILL, DIFFERENTIATION 93 3.06-21 4.238-19 500P REGULATION, OF, PROTEIN, MODIFICATION, PROCESS 90 4.266-21 9.356-19 500P REGULATION, OF, PHOSEN-MORAUS, METABOLIC, PROCESS 90 1.366-21 9.356-19 500P REGULATION, OF, SIGNALING 70 1.366-21 9.356-19 500P REGULATION, OF, SIGNALING 70 1.366-19	GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS			
300P RESPONSE TO ENDOGENOUS STIMULUS 94 126E-23 3366E-21 300P NEGATIVE, REGULATION OF RESPONSE TO STIMULUS 94 126E-22 236E-23 300P TUBE DEVELOPMENT 78 500E-22 236E-21 135E-19 300P CELL, ACHERSION 86 574E-22 145E-19 300P CELL, ADRESION 68 574E-22 145E-19 300P CELL, CELL, ADRESION 76 120E-21 123E-19 300P SECATIVATION 76 120E-21 433E-19 300P SECATIVE REGULATION, OF NOCELL DIFFERENTIATION 90 300E-21 433E-19 300P SECATIVE 98 300E-21 432E-11 517E-19 300P SECATIVE 98 300E-21 432E-11 52E-12 52E-12<	GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY			
DORP NEGATIVE, REGULATION OF, RESPONSE TO, STIMULUS 94 1.76E-22 2.86E-20 DORP TUBE DEVELOPMENT 76 6.00E-22 9.56E-20 1.36E-13 9.50E-21 1.75E-13 3.56E-31 3.31E-13 3.31E-21 3.31E-13 3.31E-21 3.31E-13 3.30E-21 4.32E-21 3.31E-13 3.30E-21 4.32E-21 3.31E-13 3.30E-21 4.32E-13 3.31E-13 3.30E-21 4.32E-21 5.77E-19 3.30E-21 4.32E-21 5.77E-19 3.30E-21 5.37E-19 3.30E-21 5.37E-19 3.30E-21 5.37E-19 3.30E-21 5.37E-19 3.30E-21 5.37E-19 3.30E-21 5.37E-19 3.30E-21 5.35E-19 3.30E-21 5.35E-19 </td <td></td> <td></td> <td></td> <td></td>				
300P TUBE_DEVELOPMENT 75 600E-22 9.54E-20 300P CELL_ADRESION 86 6.74E-22 1.05E-10 300P CELL_ADRESION 86 9.54E-20 1.05E-10 300P CELL_ADRESION 86 9.54E-20 1.35E-11 300P CELL_ADRESION 86 2.45E-21 1.35E-13 300P SELL_ADRESION 88 2.45E-21 4.13E-19 300P SELL_ADRESION 88 3.05E-21 4.23E-19 300P SELL_ADRESION 900E 3.05E-21 4.33E-19 300P SELL_OCELL_ADRESION 900 4.32E-21 6.17E-19 300P SELL_ADRESION 90 4.32E-21 6.77E-19 300P REGULATION, OP FOREIN_MODIFICATION_PROCESS 90 4.32E-21 6.58E-21 300P REGULATION, OP FOREINALING 90E-11 9.55E-10 9.35E-19 300P REGULATION, OP FOREINALING 90E-11 9.55E-21 9.35E-19 300P REGULATION, OP FOREINALING 9.55E-10 <td></td> <td></td> <td></td> <td></td>				
308P CELL CELL COLLAGEL ADEL 308P CELLUAR RESPONSE TO XYGEN CONTAINING COMPOUND 76 120521 1785-19 308P SECRETON 85 2875-21 4135-19 308P SECRETON 85 2875-21 4235-19 308P SECRETON 86 3005-21 4235-19 308P SEL COLL BIS 3005-21 4235-19 308P SEC CVCIE 88 3105-21 4235-19 308P SEC CVCIE 88 3105-21 4235-19 308P REGULATION OF PROTEIN MODIFICATION PROCESS 80 4.325-21 5.7754-19 308P SUFRAMOLCOLLAR, FIBER ORGANAZION 77 7.452-19 5.385-29 308P NEGATIVE REGULATION OF COLL DEATH 68 5.855-19 1.615-17 308P SUFRAMOLCOLLAR, FIBER ORGANAZION 77 1.332-20 6.432-19 308P REGULATION OF PHOSPHORUS METABOLIC PROCESS 69 7.665-19 9.555-19 308P REGULATION OF PROTEIN MEDICIDAR INFORMENT 71 1.532-20 6.432-19 308P REGULATION OF SIGNALING 22 2.55	GOBP_TUBE_DEVELOPMENT			
DORP CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND METABOLIC PROC 17.26-21 17.96-19 DORP NEGATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROC 87 22.85-21 3.15-19 DORP SECRETION 061 005.21 4.236-19 005 005.21 4.236-19 DORP ACCULAR DESCRETION 101 38.005-21 4.306-11 1.306-21 5.175-19 DORP ACCULATION OF CELL DIFFERENTATION 101 38.005-21 4.306-19 5.776-19 DORP REGULATION OF PROTEIN MODIFICATION PROCESS 00 4.326-21 5.756-19 5.756-21 5.926-11 5.966-21 9.366-11 5.966-21 9.366-11 5.966-21 9.366-11 5.966-21 9.366-11 9.366-21 9.366-21 9.366-21 9.366-21 9.366-21 9.366-21 9.366-21 9.366-21 9.366-21 9.366-2	GOBP_CELL_ACTIVATION			
303P NECATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROC 37 225E-21 4.13E-19 303P SECRETION 452 287E-21 4.13E-19 303P SECRETION 423E-19 4.23E-19 4.23E-19 303P CELL CYCLE 98 3.00E-21 4.23E-11 303P RECULATION OF PROTEIN MODIFICATION PROCESS 90 4.23E-21 5.77E-19 303P REGULATION OF PROTEIN MODIFICATION PROCESS 90 4.76E-21 6.25E-21 5.75E-19 303P SECRETION 57 7.40E-21 9.39E-19 5.75E-19 5.75E-19 303P REGULATION OF PROTEIN MODIFICATION PROCESS 68 5.85E-21 7.54E-19 5.95E-19 5.95E-19 <td></td> <td></td> <td></td> <td></td>				
SORP SECRETION 66 247E-21 4.13E-10 SORP REGULATION OF CELL DIFFERENTATION 90 300E-21 4.30E-11 SORP CEUL CYCLE 98 310E-21 4.30E-11 SORP REGULATION OF PROTEIN MODIFICATION PROCESS 90 4.32E-21 5.77E-19 SORP REGULATION OF PROTEIN MODIFICATION PROCESS 90 4.32E-21 5.77E-19 SORP REGULATION OF CELL DEATH 66 5.86E-21 7.74E-21 6.32E-11 5.75E-19 SORP REGULATION OF CELLOPATH 66 5.86E-21 7.74E-21 6.33E-11 6.55E-11 7.74E-21 6.33E-11 5.5EE-11 5.5EE-11 <t< td=""><td></td><td></td><td></td><td></td></t<>				
DOP CELL CYCLE 96 310E-21 4.30E-19 SOBP LOCOMOTION 101 3062-21 5.77E-19 SOBP REGULATION OF FROTEIN MODIFICATION PROCESS 90 4.32E-21 6.77E-19 SOBP REGULATION OF FROTEIN MODIFICATION PROCESS 90 4.32E-21 6.72E-19 SOBP REGULATION OF FROTEIN MODIFICATION 76 7.40E-21 6.32E-21 6.72E-19 SOBP REGULATION OF FROTEIN MEDICAL PROCESS 68 6.6E-21 6.52E-19 7.40E-21 9.3BE-19 SOBP REGUNATION OF FROTEOLYSIS 68 1.34E-20 1.66E-11 6.53E-19 1.6EE-11 1.6EE-19 1.6EE-11 1.6EE-19 1.6EE-11 1.6EE-19 1.6EE-1	GOBP_SECRETION	85	2.87E-21	4.13E-19
SOBP LOCOMOTION 101 3.80E-21 5.17E-19 SOBP REGULATION OF PROTEIN MODIFICATION PROCESS 90 4.32E-21 6.22E-19 SOBP REGULATION OF PROTEIN MODIFICATION PROCESS 90 4.32E-21 6.22E-19 SOBP SURRANOLECULAR FIBER ORGANIZATION 66 5.86E-21 7.54E-19 SOBP SURRANOLECULAR FIBER ORGANIZATION 67 7.46E-21 9.39E-10 SOBP MEGATIVE REGULATION, OF SIGNALING 62 1.34E-20 1.64E-10 SOBP REGULATION, OF PROSPHORUS METABOLIC PROCESS 69 7.66E-21 9.55E-19 SOBP REGULATION, OF SIGNALING 62 1.34E-20 1.43E-19 1.16E-11 SOBP REGULATION, OF SIGNALING 50 1.35E-19 1.30E-17 1.30E-19 1.31E-17 SOBP REGULATION, OF MORPHOGENESIS 62 2.33E-10 2.31E-17 3.30E-17	GOBP_REGULATION_OF_CELL_DIFFERENTIATION			
SOBP, REGULATION, OF, PROCIENS, MODIFICATION, PROCESS 90 4.32E-21 5.77E-19 SOBP, REGULATION, OF, PROCLASE, ACTIVITY 79 4.76E-21 6.28E-10 6.28E-10 6.28E-10 6.28E-10 6.28E-10 6.28E-10 6.28E-10 9.39E-19 5.30B SOBP, REGULATION, OF, CELL, DEATH 66 5.68E-21 7.54E-10 9.39E-19 5.30E-10 9.56E-10 9.39E-19 5.30E-10 9.50E-10 9.50E-10 9.56E-10 1.64E-18 5.30E-10 1.90E-17 1.93E-10 1.90E-17 1.93E-19 1.21E-17 5.30E-20 2.83E-10 2.83E-10 2.83E-10 2.83E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 3.85E-10 <td< td=""><td></td><td></td><td></td><td></td></td<>				
SOBP REGULATION OF HYDROLASE ACTIVITY 79 476:21 625E-19 SOBP NEGATIVE REGULATION OF CELL DEATH 66 585:21 7.56E-10 SOBP SUPRAMOLECULAR FIBER ORGANIZATION 57 7.40E-21 9.39E-19 SOBP NEGATIVE REGULATION OF PICOSPHORUS METABOLIC PROCESS 89 7.66E-21 9.55E-19 SOBP NEGATION OF PICOSPHORUS METABOLIC PROCESS 68 1.56E-19 1.61E-17 SOBP REGULATION OF SIGNALING 62 1.38E-20 6.43E-18 SOBP REGULATION OF PROTEOLYSIS 566 1.35E-19 1.61E-17 SOBP REGULATION OF ROMONATION 79 1.88E-19 2.81E-17 SOBP REGULATION OF MORENESIS 62 2.83E-19 2.81E-17 SOBP REGULATION OF MUTCHCELLULAR ORGANISMAL DEVELOPMENT 79 3.87E-17 SOBP POSITIVE REGULATION OF GUENE EXPRESSION 68 4.43E-19 4.80E-17 SOBP REGULATION OF GUENE EXPRESSION 68 6.43E-19 6.88E-17 SOBP REGULATION OF MUTCHCELLULAR ORGANIZATION 69 4.32E-18 1.33E-16 SOBP REGULATION OF MUTCHCELLULAR COMPONENT 79 0.56E-19 8.37E-17 </td <td></td> <td></td> <td></td> <td></td>				
308P SUPRAMOLECULAR, FIER, ORGANIZATION 57 7.40E-21 9.38E-19 308P REGULATION OF PROFENCIS. 89 7.66E-21 9.55E-10 308P NEGATIVE, REGULATION, OF SIGNALING 82 1.34E-20 1.64E-18 308P NEGATIVE, REGULATION, OF SIGNALING 71 5.33E-20 6.43E-10 308P REGULATION, OF FUEOLYSIS 531E-20 1.64E-18 1.61E-17 308P REGULATION, OF SIGNALING 71 1.62E-19 1.161E-17 308P CIRCULATORY, SYSTEM, DEVELOPMENT 71 1.62E-19 3.15E-17 308P REGULATION, OF MULTICELLULAR ORGANISMAL_DEVELOPMENT 73 3.75E-19 4.22E-17 308P RESPONSE TO, GROWTH, FACTOR 66 6.53E-19 6.84E-17 5.655E-19 9.89E-10 308P REGULATION, OF, SIGNALING 88 6.40E-19 6.84E-17 5.655E-19 9.89E-10 2.83E-19 3.82E-16 3.82E-16 <td< td=""><td>GOBP_REGULATION_OF_HYDROLASE_ACTIVITY</td><td>79</td><td></td><td></td></td<>	GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	79		
308P_REGULATION OF_PHOSPHORUS_METABOLIC_PROCESS 88 7.66E-21 9.55E-19 308P_REGULATION OF_SIGNALING 82 1.34E-20 1.64E-18 308P_REGULATION OF_SIGNALING 53 1.35E-19 1.64E-18 308P_REGULATION OF_SIGNALING 56 1.35E-19 1.61E-17 308P_REGULATION_OF_PROTEOLYSIS 56 1.35E-19 2.18E-17 308P_TUBE_MORPHOGENESIS 62 2.83E-19 3.15E-17 308P_TUBE_MORPHOGENESIS 62 2.83E-19 3.15E-17 308P_REGULATION_OF_MULTCELLULAR ORGANISMAL_DEVELOPMENT 79 3.87E-19 4.25E-17 308P_REGULATION_OF_MULTCELLULAR ORGANISMAL_DEVELOPMENT 79 8.842-19 4.30E-17 308P_REGULATION_OF_MOLTECELOPMENT 79 8.87E-19 4.25E-17 308P_VASCULATURE_REGULATION_OF_SIGNALING 86 4.43E-19 4.30E-19 308P_VASCULATURE_REGULATION_OF_SIGNALING 85 6.53E-19 6.88E-17 308P_REGULATION_OF_ANTOMICAL_STRUCTURE_MORPHOGENESIS 65 6.53E-19 6.88E-17 308P_REGULATION_OF_ANTOMICAL_STRUCTURE_MORPHOGENESIS 66 6.55E-19 9.88E-17 </td <td>GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH</td> <td></td> <td></td> <td></td>	GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH			
308P NEGATIVE RÉGULATION OF SIGNALING 82 134E-20 164E-18 308P RESPONSE TO NITROGEN COMPOUND 71 538E-20 643E-18 308P RESPONSE TO NITROGEN COMPOUND 71 163E-19 161E-17 308P REGULATION OF PROTEOLYSIS 61 138E-19 161E-17 308P CROULATIONY SYSTEM DEVELOPMENT 71 188E-19 2.18E-17 308P REGULATION OF GANIZATION 71 182E-19 2.47E-17 308P REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 79 3.87E-19 4.25E-17 308P REGULATION OF GENE EXPRESSION 66 4.43E-19 4.80E-17 308P RESPONSE TO GROWTH FACTOR 86 6.44E-17 6.84E-17 308P RESPONSE TO GROWTH FACTOR 56 6.53E-19 6.84E-17 308P REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 66 9.65E-19 9.89E-17 308P PORTICE REGULATION OF MOLECULAR FUNCTION 89 1.32E-18 1.33E-16 308P ACPOTOTIC SIGNALING PATHWAY 48 2.71E-16 2.66E-16 308P ACPOTOTIC SIGNALING PATHWAY 48 2.71E-18 2.66E-16 <				
308P RESPONSE TO_NITROGEN_COMPOUND 71 5.38E-20 6.43E-18 308P REGULATION OF PROTEOLYSIS 56 1.35E-19 1.80E-17 308P REGULATION, SYSTEM DEVELOPMENT 71 1.82E-19 1.80E-17 308P REGULATION, SYSTEM DEVELOPMENT 79 1.88E-19 2.83E-19 2.82E-17 308P REGULATION, OF MULTCELLULAR ORGANISMAL DEVELOPMENT 79 3.87E-19 4.26E-17 308P REGULATION, OF MULTCELLULAR ORGANISMAL DEVELOPMENT 79 3.87E-19 4.26E-17 308P POSITIVE REGULATION OF SIGNALING 86 6.40E-19 6.44E-19 308P RESPONSE TO, GROWTH FACTOR 56 6.53E-19 6.38E-17 308P REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 66 9.65E-19 9.89E-17 308P REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 65 9.65E-19 9.89E-17 308P REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 66 9.65E-19 9.89E-17 308P REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 66 9.65E-19 9.89E-				
GOBP CIRCULATORY_SYSTEM_DEVELOPMENT 71 1.62E-19 1.90E-17 GOBP CIRCULATORY_SYSTEM_DEVELOPMENT 79 1.89E-19 2.81E-17 GOBP PROTECLYSIS 92 2.33E-19 3.15E-17 GOBP PROTECLYSIS 92 2.33E-19 3.15E-17 GOBP PROSITIVE_REGULATION_OF_GENE_EXPRESSION 68 4.43E-19 4.26E-17 GOBP_ROSTIVE_REGULATION_OF_SIGNALING 89 6.40E-19 6.84E-17 GOBP_ROSTIVE_REGULATION_OF_GENE_EXPRESSION 68 4.43E-19 4.80E-17 GOBP_ROSTIVE_REGULATION_OF_GONTH_FACTOR 55 6.53E-19 6.83E-19 6.84E-17 GOBP_POSITIVE_REGULATION_OF_AUXOLOCIN 89 1.32E-16 1.33E-16 1.33E-16 GOBP_ATP_METABOLIC_PROCESS 36 1.50E-18 1.33E-16 1.33E-16 GOBP_PATP_INTE_REGULATION_OF_AUXON_OF GOLOCULAR_FUNCTION 48 2.71E-18 2.66E-16 GOBP_PATP_INTERSUBULTI ORGANIZATION 48 2.71E-18 2.66E-16 GOBP_PATP_INTERSUBULTION_OF_CELLULAR_COMPONENT_ORGANIZATION 48 2.71E-18 2.26E-16 <td>GOBP_RESPONSE_TO_NITROGEN_COMPOUND</td> <td></td> <td>5.33E-20</td> <td></td>	GOBP_RESPONSE_TO_NITROGEN_COMPOUND		5.33E-20	
30BP_CYTOSKELETON_ORGANIZATION 79 1.88E-19 2.18E-17 30BP_TUBE_MORPHOGENESIS 62 2.83E-19 3.15E-17 30BP_TUBE_MORPHOGENESIS 62 2.83E-19 3.15E-17 30BP_TUBE_MORPHOGENESIS 62 2.83E-19 3.15E-17 30BP_OSITIVE_REGULATION_OF_GENE_EXPRESSION 68 4.343E-19 4.36E-17 30BP_POSITIVE_REGULATION_OF_SIGNALING 89 6.40E-19 6.84E-17 30BP_NCLUATURE_DEVELOPMENT 57 6.35E-19 9.837E-17 30BP_AREGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 66 9.85E-18 1.33E-16 30BP_ARTP_METABOLIC_PROCESS 36 1.06E-18 1.38E-18 1.33E-16 30BP_APOPTOTIC_SIGNALING_PATHWAY 448 2.71E-18 2.26E-16 3.10E-16 30BP_REQULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 34 2.79E-18 3.10E-16 30BP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 60 3.23E-18 3.10E-16 30BP_REDULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 60 3.23E-18 3.10E-16 30BP_REDULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 61	GOBP_REGULATION_OF_PROTEOLYSIS			
GOBP PROTEOLYSIS 92 2.53E-19 2.47E-17 GOBP TUBE MORPHOGENESIS 62 2.83F-19 3.15E-17 GOBP REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 79 3.87E-19 4.25E-17 GOBP REGULATION_OF_GENE EXPRESSION 68 4.43E-19 4.80E-17 GOBP RESULATION_OF_GENE EXPRESSION 68 6.40E-19 6.84E-17 JOBP RESULATION_OF_GROWTH FACTOR 55 6.53E-19 6.83E-17 JOBP RESULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 66 6.65E-19 9.89E-17 JOBP POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 89 1.32E-18 1.33E-16 JOBP APOSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 88 2.71E-16 2.66E-16 JOBP POTICL SIGNALING PATHWAY 448 2.71E-16 2.66E-16 JOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 34 2.79E-18 2.21E-16 JOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 66 3.24E-18 3.10E-16 JOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 68 3.40E-16 3.22E-18 3.10E-16 JOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 68				
308P TUBE_MORPHOGENESIS 62 2.83E-19 3.15E-17 308P REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 79 3.87E-19 4.25E-17 308P POSITIVE_REGULATION_OF_GENE_EXPRESSION 68 4.43E-19 4.80E-17 308P POSITIVE_REGULATION_OF_SIGNALING 65 6.53E-19 6.84E-17 308P RESULATION_OF_ANATOR 55 6.55E-19 6.83E-17 308P POSITIVE_REQULATION_OF_ANATORICAL_STRUCTURE_MORPHOGENESIS 66 9.65E-19 9.89E-17 308P POSITIVE_REGULATION_OF_ANATONICAL_STRUCTURE_MORPHOGENESIS 66 9.65E-18 1.149E-16 308P APOPTOTIC_SIGNALING_PATHWAY 36 1.50E-18 1.43E-16 308P PAOPTOTIC_SIGNALING_PATHWAY 48 2.71E-18 2.68E-16 308P REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 340E-18 3.12E-16 308P REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 440E-18 3.22E-16 308P REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.85E-18 7.23E-17				
30BP POSITIVE REGULATION OF GENE EXPRESSION 68 4.43E-19 4.80E-17 30BP POSITIVE REGULATION OF SIGNALING 89 6.40E-19 6.84E-17 30BP RESPONSE TO GROWTH FACTOR 55 6.53E-19 6.83E-17 30BP RESPONSE TO GROWTH FACTOR 57 8.05E-19 6.83E-17 30BP RESULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 65 9.65E-19 9.83FE-17 30BP POSITIVE REGULATION OF MOLECULAR FUNCTION 89 1.32E-18 1.33E-16 30BP APT. METABOLIC PROCESS 36 1.50E-18 1.49E-16 30BP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 34 2.79E-18 2.271E-16 30BP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 66 3.23E-18 3.10E-16 30BP REGULATION OF CELLULAR COMPONENT MOVEMENT 67 6.67E-18 5.31E-16 30BP REGULATION OF CELLULAR COMPONENT MOVEMENT 67 5.67E-18 5.31E-16 30BP REGULATION OF CELLULAR COMPONENT BIOGENESIS 51 1.22E-17 1.10E-15 30BP REGULATION OF CELLULAR COMPONENT BIOGENESIS 51 1.22E-17 1.06E-15 30BP REGULATION OF CELLULAR COMP	GOBP_TUBE_MORPHOGENESIS			
GOBP POSITIVE REGULATION OF SIGNALING 68 6.40E-19 6.44E-17 GOBP RESPONSE_TO_GROWTH_FACTOR 55 6.53E-19 6.83E-19 6.83E-19 6.83E-17 GOBP RESULATION OF ANATOMICAL_STRUCTURE_MORPHOGENESIS 65 9.65E-19 9.837E-17 GOBP POSITIVE_REGULATION OF MOLECULAR_FUNCTION 89 1.32E-18 1.33E-16 GOBP ATP_METABOLIC_PROCESS 36 1.50E-18 1.49E-16 GOBP APOPTOTIC_SIGNALING PATHWAY 48 2.71E-18 2.66E-16 GOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 34 2.79E-18 2.71E-16 GOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 68 3.40E-18 3.32E-16 GOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 68 3.40E-18 3.22E-16 GOBP REGULATION OF_CELLULAR COMPONENT_ORGANIZATION 68 4.40E-18 3.22E-16 GOBP REGULATION OF_CELLULAR COMPONENT MOVEMENT 67 567E-18 5.31E-16 GOBP REGULATION OF_CELLULAR COMPONENT BIOGENESIS 51 1.22E-17 1.10E-15 GOBP REGULATION OF_CELLUVAR RESPONSE TO_STRESS 51	GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT			
SOBP_RESPONSE TO_GROWTH_FACTOR 55 6.53E-19 6.88E-17 SOBP_RESPONSE TO_GROWTH_FACTOR 56 6.53E-19 6.83E-17 SOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 66 9.65E-19 9.89E-17 SOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 66 9.65E-19 9.89E-17 SOBP_APOPTOTIC_SIGNALING_PATHWAY 48 1.33E-16 1.33E-16 SOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 34 2.71E-18 2.66E-16 SOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 34 2.71E-18 2.66E-16 SOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 60 3.23E-18 3.10E-16 SOBP_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 3.40E-18 3.22E-16 SOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.85E-18 5.31E-16 SOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 51 1.22E-17 1.10E-15 SOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP_REGULATION_OF_CELLULAR_COMPO				4.80E-17
30BP VASCULATURE DEVELOPMENT 57 8.05E-19 9.87E-17 30BP REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 65 9.65E-19 9.89E-17 30BP POSITIVE REGULATION OF MOLECULAR FUNCTION 89 1.32E-18 1.33E-16 30BP POSITIVE REGULATION OF MOLECULAR FUNCTION 89 1.32E-18 1.33E-16 30BP ATP_METABOLIC_PROCESS 36 1.50E-18 1.49E-16 30BP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 48 2.71E-18 2.66E-16 30BP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 66 3.40E-18 3.22E-18 30BP REGULATION OF CELLULAR COMPONENT ORGANIZATION 66 3.40E-18 5.31E-16 30BP REGULATION OF CELLULAR COMPONENT MOVEMENT 67 5.67E-18 5.31E-16 30BP REGULATION OF CELLULAR COMPONENT MOVEMENT 60 7.85E-18 7.25E-16 30BP REGULATION OF CELLULAR COMPONENT BIOGENESIS 51 1.22E-17 1.10E-15 30BP REGULATION OF CELLULAR COMPONENT BIOGENESIS 61 2.27E-17 2.00E-15 30BP REGULATION OF CELLULAR COMPONENT BIOGENESIS 61 2.27E-17 2.00E-17 30B				
30BP REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 66 9.69E-19 9.89E-17 30BP ATP. METABOLIC PROCESS 36 1.32E-18 1.32E-18 1.32E-18 30BP ATP. METABOLIC PROCESS 36 1.50E-18 1.49E-16 2.66E-19 9.89E-17 30BP ATP. METABOLIC PROCESS 36 1.50E-18 1.49E-16 2.66E-16 2.66E-16 30BP ATP. METABOLIC PROCESS 36 1.50E-18 2.71E-18 2.66E-16 30BP ATP. MAX COMPLEX SUBUNIT ORGANIZATION 34 2.79E-18 2.71E-16 3.22E-16 30BP REGULATION OF CELLULAR COMPONENT ORGANIZATION 68 3.40E-18 3.22E-16 3.22E-16 30BP REGULATION OF_CELLULAR COMPONENT MOVEMENT 67 5.67E-18 5.31E-16 30BP REGULATION OF_CELLULAR COMPONENT MOVEMENT 67 5.67E-18 5.32E-17 30BP REGULATION OF_CELLUKAR COMPONENT BIOGENESIS 51 1.22E-17 1.10E-15 30BP REGULATION OF CELLULAR COMPONENT BIOGENESIS 61 2.27E-17 2.00E-15 30BP REGULATION OF_CELLULAR RESPONSE TO STRESS 61 4.59E-17 3.94E-15 30BP REGULATION OF_C	GOBP_VASCULATURE_DEVELOPMENT			8.37E-17
30BP ATP_METABOLIC_PROCESS 36 1.50E-18 1.49E-16 30BP APOPTOTIC_SIGNALING_PATHWAY 48 2.71E-18 2.66E-16 30BP PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 34 2.79E-18 2.71E-16 30BP PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 34 2.79E-18 2.71E-16 30BP PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 60 3.22E-18 3.10E-16 30BP REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 340E-18 3.22E-16 30BP REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.85E-18 7.25E-16 30BP REDUD_LEUKOCYTE_MEDIATED_IMMUNITY 46 9.28E-18 8.47E-16 30BP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 51 1.22E-17 1.10E-15 30BP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 30BP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.04E-15 30BP REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.46E-15 30BP REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 6.03E-17 30BP REGULATION_OF_CATABOLIC_PROCESS	GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	65	9.65E-19	9.89E-17
GOBP_APOPTOTIC_SIGNALING PATHWAY 48 2.71E-18 2.66E-16 GOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 34 2.79E-18 2.71E-16 GOBP_EXOCYTOSIS 60 3.23E-18 3.10E-16 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 3.40E-18 3.22E-16 GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 67 5.67E-18 5.31E-16 GOBP_MYELOID_LEUKOCYTE_MEDIATED_IMMUNITY 46 9.28E-18 8.47E-16 GOBP_REGULATION_OF_CELL_UXAR_COMPONENT_BIOGENESIS 51 1.22E-17 1.10E-15 GOBP_REGULATION_OF_CELL_OYCLE 70 1.53E-17 1.36E-15 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.02E-15 GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 61 4.59E-17 3.94E-15 GOBP_REGULATION_OF_CALABOLIC_PROCESS 62 6.05E-17 5.03E-17 GOBP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-17 GOBP_REGULATION_OF_CATABOLIC_PROCESS 64 8.84E-17 7.11E-15 GOBP_REGULATION_OF_CATABOLIC_PROCESS 64 8.84E-17				1.33E-16
GOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 34 2.79E-18 2.71E-16 GOBP PROTEIN DNA COMPLEX SUBUNIT ORGANIZATION 60 3.24E-18 3.10E-16 GOBP POSTIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 3.40E-16 3.22E-18 SOBP REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 67 5.67E-18 5.31E-16 SOBP REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.85E-18 7.25E-16 SOBP MELOID_LEUKOCYTE_MEDIATED_IMMUNITY 46 9.28E-18 8.47E-16 SOBP REGULATION_OF_CELLUKAR_COMPONENT_BIOGENESIS 51 1.22E-17 1.10E-15 SOBP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-16 SOBP REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-17 SOBP REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-15 SOBP ACTIN_FLIAMM				
SOBP_EXOCYTOSIS 60 3.23E-18 3.10E-16 SOBP_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 3.40E-18 3.22E-16 SOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.657E-18 5.31E-16 SOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.657E-18 5.31E-16 SOBP_NEGULATION_OF_CELLUKAR_COMPONENT_MOVEMENT 60 7.85E-18 7.25E-16 SOBP_NEOD_VESSEL_MORPHOGENESIS 51 1.22E-17 1.10E-15 SOBP_REGULATION_OF_CELL_CYCLE 70 1.53E-17 1.36E-15 SOBP_REGULATION_OF_CELLUAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 SOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 SOBP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 6.03E-15 SOBP_REGULATION_OF_CATABOLIC_PROCESS 64 8.44E-17 7.11E-15 SOBP_RESPONSE_TO_ABIOTIC_STIMULUS 68 6.78E-17 5.59E-17 SOBP_REGULATION_OF_CATABOLIC_PROCESS 54 8.44E-17 <t< td=""><td>GOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION</td><td></td><td></td><td>2.71E-16</td></t<>	GOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION			2.71E-16
30BP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 3.40E-18 3.22E-16 30BP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 67 5.67E-18 5.31E-16 30BP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 67 5.67E-18 5.31E-16 30BP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT 60 7.85E-18 7.25E-16 30BP_REGULATION_OF_CELL_QUCCLE 51 1.22E-17 1.10E-15 30BP_REGULATION_OF_CELL_QUCLE 70 1.53E-17 1.36E-15 30BP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 30BP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 61 4.59E-17 3.94E-15 30BP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 61 4.59E-17 3.94E-15 30BP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 6.36E-17 30BP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.93E-15 30BP_REGULATION_OF_CATABOLIC_PROCESS 54 8.84E-17 7.11E-15 30BP_REGULATION_OF_TRANSFERASE ACTIVITY 62 7.30E-17 5.36E-17 30BP_ACTIN_FILAMENT_BASED PROCESS 54	GOBP_EXOCYTOSIS	60	3.23E-18	3.10E-16
GOBP GROWTH 60 7.85E-18 7.25E-16 GOBP MYELOID_LEUKOCYTE_MEDIATED_IMMUNITY 46 9.28E-18 8.47E-16 GOBP BLOOD_VESSEL_MORPHOGENESIS 51 1.22E-17 1.10E-15 GOBP REGULATION OF CELL_CYCLE 70 1.53E-17 1.36E-15 GOBP REGULATION OF CELL_UXAR COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 GOBP REGULATION OF CELLULAR RESPONSE TO_STRESS 42 2.58E-17 2.24E-15 GOBP REGULATION OF CELLULAR RESPONSE TO_STRESS 51 4.59E-17 3.94E-15 GOBP REGULATION OF CELLULAR RESPONSE TO_STRESS 51 4.59E-17 3.94E-15 GOBP REGULATION OF CALABOLIC PROCESS 62 6.05E-17 6.03E-15 GOBP REGULATION OF_CATABOLIC PROCESS 62 6.05E-17 5.03E-15 GOBP REGULATION OF_CATABOLIC PROCESS 64 8.84E-17 7.11E-15 GOBP ACTIN FILAMENT BASED PROCESS 54 8.84E-17 7.11E-15 GOBP CELLULAR COMPONENT DISASEMBLY 65 9.33E-17 7.55E-16 GOBP CELLUATION OF_DEVELOPMENTAL_PROCESS 51 1.73E-16 1.35E-14 <	GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION			3.22E-16
SOBP MYELOID LEUKOCYTE_MEDIATED_IMMUNITY 46 9.28E-18 8.47E-16 SOBP BLOOD_VESSEL_MORPHOENESIS 51 1.22E-17 1.10E-15 SOBP REGULATION_OF_CELL_CYCLE 70 1.53E-17 1.36E-15 SOBP REGULATION_OF_CELL_UCR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 42 2.58E-17 2.24E-15 SOBP REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 SOBP NUCLEOSOME_ORGANIZATION 27 5.42E-17 4.61E-15 SOBP REBULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-15 SOBP RESULATION_OF_TRANSFERASE ACTIVITY 62 7.30E-17 5.93E-15 SOBP REGULATION_OF_TRANSFERASE ACTIVITY 62 7.30E-17 5.35E-17 SOBP_ACTIN_FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 SOBP_CELL_ACTIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 54 8.84E-17 7.11E-15 SOBP_CELL_ACTIVATION_INVOLVED IN IMMUNE_RES				
SOBP BLOOD_VESSEL_MORPHOGENESIS 51 1.22E-17 1.10E-15 SOBP REGULATION_OF_CELL_CYCLE 70 1.53E-17 1.30E-15 SOBP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 SOBP REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 62 2.27E-17 2.20E-17 SOBP REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 SOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 4.61E-15 SOBP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 4.62E-17 SOBP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.57E-15 SOBP_REGULATION OF_TRANSFERASE ACTIVITY 62 7.30E-17 5.57E-15 SOBP_REGULATION OF_TRANSFERASE ACTIVITY 62 7.30E-17 5.57E-15 SOBP_REGULATION OF_TRANSFERASE ACTIVITY 62 7.30E-17 5.57E-15 SOBP_ACTIVITY 62 7.30E-17 7.11E-16 SOBP_CELLULAR_COMPONENTAL_PROCESS 54 8.84E-17 7.11E-16 SOBP_CELLULAR_COMPONENT_D_ISASEMBLY	GOBP_GROWTH GOBP_MYELOID_LEUKOCYTE_MEDIATED_IMMUNITY			8.47E-16
30BP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 61 2.27E-17 2.00E-15 30BP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 42 2.58E-17 2.24E-15 30BP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 30BP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 30BP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-17 30BP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-17 30BP_REGULATION_OF_CATABOLIC_PROCESS 62 7.30E-17 5.57E-15 30BP_REGULATION_OF_TRANSFERASE_ACTIVITY 62 7.30E-17 5.37E-15 30BP_ACTIN_FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 30BP_CELL_ACTIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 71 8.93E-17 7.51E-15 30BP_CELL_ACTIVATION_INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.55E-14 30BP_CELL_ACTIVATION_INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.55E-14 30BP_DOSTIVE_REGULATION_OF_CATABOLIC_PROCESS 59 2.14E-16 1.65E-14 30BP_DELL_ACTIVATION_INVOLVED IN IMMUNE RESPON	GOBP_BLOOD_VESSEL_MORPHOGENESIS	51	1.22E-17	1.10E-15
30BP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 42 2.24E-17 2.24E-17 30BP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 30BP_NUCLEOSOME_ORGANIZATION 27 5.42E-17 4.61E-15 30BP_RIBOSOME_ASSEMBLY 18 5.50E-17 4.61E-15 30BP_REQULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.37E-17 30BP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.57E-15 30BP_REQULATION OF TRANSFERASE ACTIVITY 62 7.30E-17 5.57E-15 30BP_REQULATION OF TRANSFERASE ACTIVITY 62 7.30E-17 7.11E-15 30BP_OSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 54 8.84E-17 7.11E-15 30BP_CELLULAR_COMPONENT DISASSEMBLY 45 9.58E-17 7.55E-15 30BP_CELLULAR_COMPONENT DISASSEMBLY 45 9.58E-17 7.11E-15 30BP_CELLULAR_COMPONENT DISASSEMBLY 56 1.73E-16 1.35E-14 30BP_TISSUE_MIGRATION 36 2.14E-16 1.58E-14 30BP_PORTIN_CATABOLIC_PROCESS 59 2.19E-16 1.67E-14 30BP_PORTI	GOBP_REGULATION_OF_CELL_CYCLE			1.36E-15
GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 51 4.59E-17 3.94E-15 GOBP_NUCLEOSOME_ORGANIZATION 27 5.42E-17 4.61E-15 GOBP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 4.62E-15 GOBP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-15 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.57E-15 GOBP_REQULATION_OF_CATABOLIC_PROCESS 62 7.30E-17 5.39E-17 GOBP_REQUATION_OF_DEVELOPMENTAL_PROCESS 54 8.84E-17 7.11E-15 GOBP_CELLUAR_COMPONENT DISASSEMBLY 45 9.58E-17 7.55E-16 GOBP_CELLUAR_COMPONENT DISASSEMBLY 45 9.58E-17 7.55E-16 GOBP_CELL ACTIVATION_INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.35E-14 GOBP_POSTINE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.67E-14				
30BP_NUCLEOSOME_ORGANIZATION 27 5 42E-17 4 61E-15 30BP_RIBOSOME_ASSEMBLY 18 5.0E-17 4.61E-15 30BP_RESPONSE_TO_ABIOTIC_PROCESS 62 6.05E-17 5.03E-15 30BP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.57E-15 30BP_REGULATION_OF_TRANSFERASE_ACTIVITY 62 7.30E-17 5.37E-15 30BP_ACTIN_FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 30BP_CELLUAR_COMPONENT_DISASSEMBLY 45 9.58E-17 7.55E-15 30BP_CELL_ACTIVATION_INVOLVED IN IMMUNE_RESPONSE 51 1.73E-16 1.55E-14 30BP_POSTITUS_REGRATION 36 2.14E-16 1.65E-14 30BP_ROTEIN_CATABOLIC_PROCESS 59 2.19E-16 1.65E-14 30BP_DOSTITUS_REGULATION_OF_CATLYTIC_ACTIVITY 36 2.14E-16 1.55E-14				
SOBP_REGULATION_OF_CATABOLIC_PROCESS 62 6.05E-17 5.03E-15 SOBP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.57E-15 SOBP_RESURATION_OF_TRANSFERASE_ACTIVITY 62 7.30E-17 5.93E-15 SOBP_ACTIN_FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 SOBP_CELLUAR_COMPONENT DISASSEMBLY 45 9.58E-17 7.55E-15 SOBP_CELLUAR_COMPONENT DISASSEMBLY 45 9.58E-17 7.55E-15 SOBP_CELL ACTIVATION_INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.35E-14 SOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 36 2.14E-16 1.65E-14 SOBP_CELL_ACTIVATION_INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.65E-14 SOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 36 2.14E-16 1.65E-14 SOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14	GOBP_NUCLEOSOME_ORGANIZATION			4.61E-15
SOBP_RESPONSE_TO_ABIOTIC_STIMULUS 69 6.78E-17 5.57E-15 SOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 62 7.30E-17 5.93E-15 SOBP_ACTIN_FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 SOBP_CELLUAR_COMPONENT_DISASSEMBLY 45 9.58E-17 7.15E-15 SOBP_CELL ACTIVATION_INVOLVED IN IMMUNE_RESPONSE 51 1.73E-16 1.53E-14 SOBP_POSITIVE_REGULATION 36 2.14E-16 1.65E-14 SOBP_POSITIVE_REGULATION_O_OCATALYTIC_ACTIVITY 74 2.27E-16 1.72E-16	GOBP_RIBOSOME_ASSEMBLY			4.62E-15
GOBP REGULATION OF TRANSFERASE ACTIV 62 7.30E-17 5.93E-15 30BP ACTIN FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 30BP_OSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 71 8.93E-17 7.11E-15 30BP_CELLULAR_COMPONENT_DISASSEMBLY 45 9.58E-17 7.55E-15 30BP_CELL ACTIVATION_INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.35E-14 30BP_DETEIN_CATABOLIC_PROCESS 59 2.14E-16 1.65E-14 30BP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-16				5.03E-15
SOBP_ACTIN_FILAMENT_BASED_PROCESS 54 8.84E-17 7.11E-15 SOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 71 8.93E-17 7.11E-15 SOBP_CELLUAR_COMPONENT_DISASSEMBLY 45 9.58E-17 7.55E-15 SOBP_CELL ACTIVATION_INVOLVED IN IMMUNE_RESPONSE 51 1.73E-16 1.35E-14 SOBP_DELL_ACTIVATION_INVOLVED IN IMMUNE_RESPONSE 51 1.73E-16 1.65E-14 SOBP_PROTEIN_CATABOLIC_PROCESS 59 2.19E-16 1.67E-14 SOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14				
30BP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 71 8.93E-17 7.11E-15 30BP_CELLULAR_COMPONENT_DISASSEMBLY 45 9.58E-17 7.55E-15 30BP_CELL ACTIVATION_INVOLVED IN_IMMUNE_RESPONSE 51 1.73E-16 1.35E-14 30BP_TISSUE_MIGRATION 36 2.14E-16 1.65E-14 30BP_PORTEIN_CATABOLIC_PROCESS 59 2.19E-16 1.67E-14 30BP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14	GOBP_ACTIN_FILAMENT_BASED_PROCESS			7.11E-15
GOBP CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE 51 1.73E-16 1.35E-14 JOBP_TISSUE_MIGRATION 36 2.14E-16 1.65E-14 JOBP_PROFIN_CATABOLIC_PROCESS 59 2.19E-16 1.67E-14 JOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14	GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	71	8.93E-17	7.11E-15
GOBP_TISSUE_MIGRATION 36 2.14E-16 1.65E-14 GOBP_PROTEIN_CATABOLIC_PROCESS 59 2.19E-16 1.67E-14 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14				7.55E-15
GOBP_PROTEIN_CATABOLIC_PROCESS 59 2.19E-16 1.67E-14 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14				
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 74 2.27E-16 1.72E-14	GOBP_PROTEIN_CATABOLIC_PROCESS			1.67E-14
	GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	74	2.27E-16	1.72E-14
SUBP_RIBUNUGLEUPKUTEIN_GUMPLEX_SUBUNIT_ORGANIZATION 29 2.53E-16 1.89E-14	GOBP_RIBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION	29	2.53E-16	1.89E-14

Figure 93 Gene ontology analysis of genes downregulated in response to CD in

NIH3T3 cells by RNAseq

Gene ontology analysis of genes downregulated by CD treatment in NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 17. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

	# Genes	p-value	EDR g-valu
GO BIOLOGICAL PROCESS GOBP_ACTIN_FILAMENT_BASED_PROCESS	# Genes 114		2.56E-52
GOBP_CYTOSKELETON_ORGANIZATION	145		
GOBP_CELL_MOTILITY	153	1.68E-45	4.24E-42
GOBP_BIOLOGICAL_ADHESION	134	3.78E-43	7.16E-40
GOBP_APOPTOTIC_PROCESS	156	1.65E-42	2.17E-39
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	93		
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	150	2.90E-42	3.14E-39
GOBP_REGULATION_OF_CELL_DEATH	140		
GOBP_REGULATION_OF_CELL_DIFFERENTIATION	147	3.02E-38	2.54E-35
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	109		
GOBP_ACTIN_FILAMENT_ORGANIZATION GOBP_PROTEIN_PHOSPHORYLATION	68 126	1.61E-36 3.84E-34	1.10E-33 2.21E-31
	110	2.40E-34	1.28E-30
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	103		
GOBP_CELL_SUBSTRATE_ADHESION	59	5.55E-33	2.59E-30
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	101		
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	136	1.05E-31	4.36E-29
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	120		1.13E-27
GOBP_POSITIVE_REGULATION_OF_SIGNALING	124	3.10E-30	1.16E-27
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	102		1.25E-27
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	119	4.25E-30	1.45E-27
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY	95		1.91E-27
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	119	9.31E-30	2.90E-27
GOBP_REGULATION_OF_TRANSPORT	122		1.66E-26
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	127	6.37E-29	1.83E-26
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	122		
GOBP_MUSCLE_STRUCTURE_DEVELOPMENT	69	2.99E-28	7.99E-26
GOBP_CELL_MORPHOGENESIS	88		
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	95		8.19E-25
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	97	3.51E-27	8.47E-25
GOBP_RESPONSE_TO_WOUNDING	70	4.65E-27	1.09E-24
GOBP_WOUND_HEALING	63		
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	92	1.18E-26	2.60E-24
GOBP POSITIVE REGULATION OF CELL DIFFERENTIATION	79	1.50E-26	
GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS	54	1.50E-26	3.12E-24
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	104		
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	114		6.06E-24
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	103		1.06E-23
GOBP_CELL_POPULATION_PROLIFERATION	125	8.20E-26	1.53E-23
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	108		1.76E-23
GOBP_TUBE_DEVELOPMENT	89	1.05E-25	1.87E-23
GOBP_HOMEOSTATIC_PROCESS	123		
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	83	1.28E-25	2.18E-23
GOBP_TUBE_MORPHOGENESIS	80		
GOBP_VASCULATURE_DEVELOPMENT	74	4.45E-25	7.24E-23
GOBP_REGULATION_OF_CELL_ADHESION	71		1.17E-22
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	101	7.75E-25	1.21E-22
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	83		
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	63	1.35E-24	2.02E-22
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	83		
GOBP_CELL_CELL_ADHESION	76	2.06E-23	2.96E-21
GOBP_CELL_ACTIVATION	101		
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	99	2.51E-23	3.48E-21
GOBP_RESPONSE_TO_GROWTH_FACTOR	68		
GOBP_EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	50	8.48E-23	1.13E-20
GOBP_CELL_MATRIX_ADHESION	39	1.00E-22	1.31E-20
GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS		1.16E-22	1.49E-20
GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION	56		
GOBP_PROTEOLYSIS	112		3.63E-20
GOBP EMBRYO DEVELOPMENT	79		
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	92		5.06E-20
GOBP_EPITHELIUM_DEVELOPMENT	91		
GOBP_BLOOD_VESSEL_MORPHOGENESIS	64	6.47E-22	7.56E-20
GOBP_ANIMAL_ORGAN_MORPHOGENESIS	80		9.00E-20
GOBP_NEGATIVE_REGULATION_OF_SIGNALING	96	8.40E-22	9.52E-20
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	79		
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	106		2.50E-19
GOBP_RESPONSE_TO_CYTOKINE	86		
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	77		3.65E-19
GOBP_CELL_JUNCTION_ORGANIZATION	64		
GOBP_REGULATION_OF_ION_TRANSPORT	91	3.58E-21	3.68E-19
GOBP_SECRETION	97		3.68E-19
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	105	4.07E-21	4.11E-19
GOBP_POSITIVE_REGULATION_OF_CELL_DEATH	61		1.03E-18
GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION	36		1.09E-18
	49		1.16E-18
GOBP_CELL_JUNCTION_ASSEMBLY			1.16E-18
	84		1.20E-18
GOBP_DEGLTIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE	73		2.73E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE			
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION	73	2.92E-20	3.47E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS	73 101	2.92E-20	3.47E-18 3.52E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND	73 101 72	2.92E-20 3.76E-20 3.85E-20	3.52E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND GOBP_CELL_PROJECTION_ORGANIZATION GOOPP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	73 101 72 99 76	2.92E-20 3.76E-20 3.85E-20 5.80E-20	3.52E-18 5.23E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND GOBP_CELL_PROJECTION_ORGANIZATION	73 101 72 99	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20	3.52E-18 5.23E-18 5.54E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_REUROGENESIS GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_ORGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_CYCLE	73 101 72 99 76 110	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20	3.52E-18 5.23E-18 5.54E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_RESURGENESIS GOBP_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_OBLL_CYCLE GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	73 101 72 99 76 110 83	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MERCASCADE GOBP_REVROGENESIS GOBP_RESPONSE_TO_ORGANIC CYCLIC_COMPOUND GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_RESULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_RESPONSE_TO_HORMONE	73 101 72 99 76 110 83 70	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_NEUROGENESIS GOBP_NEUROGENESIS GOBP_REUROBECTON_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_RESPONSE_TO_HORMONE GOBP_CELL_CELL_SIGNALING GOBP_CELL_CELL_SIGNALING	73 101 72 99 76 110 83 70 102	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.16E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_MAPK_CASCADE GOBP_REUROGENESIS GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_RESULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_RESPONSE_TO_HORMONE GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY	73 101 72 99 76 110 83 70 102 66	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.16E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_REVOCENT GOBP_RESPONSE_TO_ORGANIC CYCLIC_COMPOUND GOBP_CELL_PROJECTION_ORGANIZATION GOBP_RESULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_CYCLE GOBP_RESPONSE_TO_HORMONE GOBP_CELL_CYCLE GOBP_CELL_SYGENCE GOBP_MUSCLE_SYSTEM_PROCESS	73 101 72 99 76 110 83 70 102 66 49	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19 1.80E-19 2.35E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.16E-17 1.51E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_REUROGENESIS GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_MUSCLE_SYSTEM_PROCESS GOBP_ITANUSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY	73 101 72 99 76 110 83 70 102 66 49 63	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19 1.80E-19 2.35E-19 2.80E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.16E-17 1.51E-17 1.95E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_REVOCENESIS GOBP_RESPONSE_TO_ORGANIZATION GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_OYCLE GOBP_CELL_CYCLE GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_CELL_SYSTEM_PROCESS GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_CELL_SYSTEM_PROCESS GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_CELLUCATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_CELLONG_TRANSCRIPTION_BY_RNA_POLYMERASE_II	73 101 72 99 76 110 83 70 102 66 49 63 69	2.92E-20 3.76E-20 3.85E-20 5.80E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19 2.35E-19 2.35E-19 3.35E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.51E-17 1.51E-17 2.30E-17 2.30E-17 2.73E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_REUROGENESIS GOBP_REUROGENESIS GOBP_REUROJECTION_ORGANIZATION GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_CYCLE GOBP_CELL_CYCLE GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_CELLLAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND GOBP_CELLLAR GOBP_CELLLAR	73 101 72 99 76 110 83 70 102 66 49 63 69 82 82 44	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19 1.80E-19 2.35E-19 3.35E-19 3.41E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.51E-17 1.51E-17 2.30E-17 2.30E-17 2.73E-17 2.74E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND GOBP_REQULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_CYCLE GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_RESULATION_OF_RANTOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_ROCESS GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY GOBP_CLLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND GOBP_CELULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_CSTRUE_REGULATION_OF_CELL_ADHESION	73 101 72 99 76 110 83 70 102 66 63 69 63 69 82 44	2.92E-20 3.76E-20 3.85E-20 6.22E-20 8.62E-20 8.62E-20 1.18E-19 1.37E-19 1.80E-19 2.35E-19 3.35E-19 3.35E-19 3.35E-19	3.52E-18 5.23E-18 5.54E-18 7.57E-18 7.77E-18 1.02E-17 1.51E-17 1.95E-17 2.73E-17 2.73E-17 2.74E-17 3.23E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_REVOCENSIS GOBP_RESPONSE_TO_ORGANIZATION GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_PROJECTION_ORGANIZATION GOBP_RESULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_HORMONE GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_REGULATION_OF_CELL_ADHESION GOBP_REGULATION_OF_CELLAR_FIBER_ORGANIZATION	73 101 72 99 97 6 110 102 66 6 6 9 9 9 9 0 3 3 0 0 9 9 9 9 9 9 9 9 9 9 9	2.92E-20 3.76E-20 5.80E-20 6.22E-20 8.93E-20 1.18E-19 1.37E-19 1.37E-19 2.35E-19 3.35E-19 3.35E-19 3.41E-19 4.06E-19	3.52E-18 5.23E-18 5.54E-18 7.57E-18 7.77E-18 1.02E-17 1.16E-17 1.95E-17 2.30E-17 2.73E-17 2.74E-17 3.23E-17 3.32E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_REUROGENESIS GOBP_RESPONSE_TO_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION GOBP_POSITIVE_REGULATION_OF_TRANSPORT	73 101 72 99 76 110 83 37 70 102 66 66 66 9 82 82 82 44 44 47 38 89 9	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.93E-20 1.18E-19 1.37E-19 1.37E-19 1.37E-19 3.36E-19 3.36E-19 3.36E-19 3.36E-19 3.41E-19 4.06E-19 4.21E-19 5.13E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.16E-17 1.95E-17 2.30E-17 2.73E-17 2.73E-17 3.23E-17 3.32E-17 4.00E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_REVOCENTIST GOBP_RESPONSE_TO_ORGANIZ_CYCLIC_COMPOUND GOBP_RESPONSE_TO_ORGANIZATION GOBP_CELL_PROJECTION_ORGANIZATION GOBP_CELL_CYCLE GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_RESULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEN_KINASE_ACTIVITY GOBP_REGULATION_OF_ROTEN_ROTEN_KINASE_SIGNALING_PATHWAY GOBP_REGULATION_OF_COLLATION_F_CONTAINING_COMPOUND GOBP_REGULATION_OF_COLLATION_GOC GOBP_REGULATION_OF_COLL_ADHESION GOBP_REGULATION_OF_COLL_ADHESION GOBP_REGULATION	73 101 722 99 76 1100 833 70 1022 66 66 49 63 69 82 82 82 84 44 47 7 38 89 97 66	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19 1.37E-19 1.37E-19 1.36E-19 2.36E-19 3.36E-19 3.36E-19 3.36E-19 4.06E-19 4.21E-19 5.13E-19 7.10E-19	3.52E-18 5.23E-18 5.54E-18 7.59E-18 7.77E-18 1.02E-17 1.51E-17 1.51E-17 2.73E-17 2.73E-17 3.23E-17 3.23E-17 3.22E-17 4.00E-17 5.48E-17
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_MAPK_CASCADE GOBP_NEUROGENESIS GOBP_REUROGENESIS GOBP_RESPONSE_TO_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_HORMONE GOBP_RESPONSE_TO_HORMONE GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION GOBP_POSITIVE_REGULATION_OF_TRANSPORT	73 101 72 99 76 110 83 37 70 102 66 66 66 9 82 82 82 44 44 47 38 89 9	2.92E-20 3.76E-20 3.85E-20 5.80E-20 6.22E-20 8.62E-20 8.93E-20 1.18E-19 1.37E-19 1.37E-19 1.37E-19 2.35E-19 3.35E-19 3.35E-19 3.35E-19 5.13E-19 5.13E-19 7.10E-19 1.10E-18	3.52E-18 5.23E-18 5.54E-18 7.75E-18 7.77E-18 1.02E-17 1.51E-17 2.30E-17 2.30E-17 2.73E-17 3.23E-17 3.22E-17 4.00E-17 5.48E-17 8.39E-17

Figure 94 Gene ontology analysis of genes upregulated in response to CD in

NIH3T3 cells by TTseq

Gene ontology analysis of genes upregulated by CD treatment in NIH3T3 cells by TTseq. FDR<0.05. Relates to Figure 34B. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

0008 3.001 111 115.50 0.0025 0009 UPU MERSULE PROCESS 112 2.015.05 0.026 0009 UPU MERSULE PROCESS 112 2.015.05 0.026 0009 UPU MERSULE AND ARRAY REPORTS 112 1.015.05 0.026 0009 UPU MERSULE AND ARRAY REPORTS 112 1.015.05 0.026 0009 UPU MERSULE AND ARRAY REPORTS 112 1.015.05 0.026 0009 UPU MERSULE AND ARRAY REPORTS 112 1.015.05 0.026 0009 UPU MERSULE AND ARRAY REPORTS 112 1.015.05 0.026 0.026 0009 UPU MERSULE AND ARRAY REPORTS 112 1.015.05 0.026 <t< th=""><th>GO BIOLOGICAL PROCESS</th><th># Genes</th><th>p-value</th><th>FDR q-value</th></t<>	GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
OBMP_COLL_PYCLE 182 278-68 868-73 OBMP_NELLANE, REGULATINA OF BOOSTINEED PROCESS 12 246-53 52-52 ORP_NELLANE, REGULATINA OF BOOSTINEED PROCESS 12 246-53 52-52 ORP_NELLANE, REGULATINA OF BOOSTINEED PROCESS 10 745-53 657-53 ORP_NELLANE, REGULATINA OF NUCLEOASE, CONTAINING COMPOND METADOL PROCESS 10 745-53 657-53 ORP_NELLANE, REGULATINA OF NUCLEOASE, CONTAINING COMPOND METADOL PROCESS 12 145-52 145-52 ORP_CARLED, PORTARE REGULATION OF NUCLEOASE, CONTAINING COMPOND METADOL PROCESS 12 145-52 145-52 ORP_DELLANE, REGULATION, OF NUCLEOASE, CONTAINING COMPOND, METADOL PROCESS 10 245-53 325-56 ORP_DERING, REGULATION, OF CULL OCULAR CRANINGUA, DEFLEXISTATION 10 324-56 325-56 ORP_REGULATION, OF CULL OCULAR CRANINGUA, DEFLEXISTATION 10 324-56 325-56 ORP_REGULATION, OF CULL OCULAR CRANINGUA, DEFLEXISTATION 10 345-57 325-56 ORP_REGULATION, OF CULL OCULAR CRANINGUA, DEFLEXISTATION 10 345-57 325-56 ORP_REGULATION, OF CULL OCULAR CRANINGUA, DEFLEXISTATION 10				
COUP INCENTING FURGUARDAY OF BIOSYNTHETIC PROCESS 121 206 - 25 3232 - 21 COUP CELLULAR COURT AND CONFORMED				
CORP. ECILLIAM. LIPR. METABOLC, PROCESS 98 128-24 128-24 128-24 CORP. SELLUAM. LIPR. METABOLC, PROCESS 100 728-23 647-23 CORP. MEGNUTZ, MEGNUTZ, MULCEGAASE CONTAINING, COMPUND, METABOLE, PROCESS 100 728-23 647-23 CORP. SELL, OTCA. MILLION, PRULETABOLE, PROCESS 101 728-23 647-23 CORP. CELL, OTCA. MILLION, PRULETABOLE, PROCESS 102 728-23 647-23 CORP. DESUGATION, PRULETABOLE, PROCESS 102 728-23 647-23 CORP. DEGULATION, PRULETABOLE, PROCESS 102 728-73 728-74 728-74 CORP. DEGULATION, PRULETABOLE, PROCESS 102 728-74 <				
GORP EGULARY, ALCADOUD SCIE LOCAL DATION [13] [16] 24 2045-21 GORP ADDITION OF MIRAGELLUARY BANKL TRANSDURTON [13] 25 [13] 26 2145-22 1255-22 GORP CATELONYMER DERVATIVE MARCLE MONCE CONTAINING COMPOND METABOLE, PROCESS [16] 124-52 1255-22 1255-13 GORP CATELONYMER DERVATIVE METAGOLE PROCESS [16] 124-52 1265-11 6415-53 GORP CATELONYMER DERVATIVE METAGOLE PROCESS [16] 126-21 6415-53 GORP PORTIVE REGULATION OF MULCIONEL CONTAINING COMPOND METABOLE PROCESS [16] 126-21 6415-53 GORP PORTIVE REGULATION OF MULCIONEL CONTAINING COMPOND [16] 126-21 6415-53 GORP PORTIVE REGULATION OF MULCIONEL CONTAINING COMPONENT [0] 576-63 3255-63 GORP MEGULATION OF MULTICELLUAR ORGANISMA, DEVELOPMENT [0] 576-64 3255-64 GORP MEGULATION OF CLU DETREMITION [0] 576-65 [0] 586-67 3255-64 GORP MEGULATION OF MULTICELLUAR ORGANISMA, DEVELOPMENT [0] 586-67 3255-64 GORP MEGULATION OF MULTICELLUAR ORGANISMA, DEVELOPMENT [0] 586-67 3255-64 GORP MEGULATION OF MULTICELLUAR ORGANISMA, DEVELOPMENT [0] 586-57 3255-64 GORP MEGULATION OF MU				
CBRP REQUARTION OF INTRODUCTION 112 1106-23 1106-23 1106-23 1106-23 1106-23 1106-23 1106-23 1062-24 1062-10 1062-10 106				
0500P CELL, CYCLE, PROCESS 1005 1265-22 1025-12 0500P CAMBLENTRINE DERVINITIVE METABLICLE PROCESS 1105<				
GREP - CARBONNERIATE DERIVATIVE METABOLIC PROCESS 92 1146-22 1166-12 GREP - PARTINE REGULATION OF AUCONSINC COMPACING METABOLIC PROCESS 118 1125-11 6.455-10 GREP - PARTINE REGULATION OF AUCONSINC COMPACING METABOLIC PROCESS 118 1025-11 6.455-10 GREP - CORRING REGULATION OF AUCONSINC COMPACING PROCESS 118 1025-11 6.455-10 GREP - CORRING REGULATION OF CELL DIFFERENTIATION 100 755-16 3.125-11 GREP - CORRING REGULATION OF CELL DIFFERENTIATION 100 755-16 3.125-17 GREP - CORRING REGULATION OF CELL DIFFERENTIATION 100 1305-16 3.125-17 GREP - CORRING REGULATION OF CELL DEATH 1305-16 100 4.006-16 2.225-16 GREP - CORRING REGULATION OF CELL DEATH 1305-16 1305-16 2.225-16 2.225-16 GREP - CORRING REGULATION OF CELL DEATH 1305-16 1305-16 2.226-16 2.226-16 GREP - REGULATION OF CELL DEATH 1205-16 1305-16 2.226-16 2.226-16 GREP - REGULATION OF CELL DEATH 1205-16 1305-16 2.226-16 2.226-16 GREP - REG				
GREP_POSITVE_RESULATION OF NUCLEORASE_CONTAINING COMPOUND_METABOLIC_PROCESS 122 1022-21 64/16-19 GORD_CONTOURN TROUTENTION CONTOURNAME 111 40/66-10 44/16-19 GORD_CONTOURNAME CONTOURNAME 111 40/66-10 44/16-19 GORD_CONTOURNAME CONTOURNAME 111 40/66-10 23/26-16 GORD_REGULATION OF CELL CYCLE 011 30/66-10 23/26-16 33/26-16 <				
GBBP CELL, POPULATION, PROLIFENTION [126 1026-21 6445-19 GBBP PORTINE CREATION OF BOUNDEMENT PROCESS [126 1026-21 6365-19 GORD PROSING REQUEATION OF BOUNDEMENT PROCESS [126 4265-19 2365-16 GORD FREGULATION OF SMLL TOPELLIAR ORGANISMA, DEVELOPMENT [126 335-16 2365-16 GORD FREGULATION OF MULTIPELLULAR ORGANISMA, DEVELOPMENT [126 335-16 2365-16 GORD FREGULATION OF MULTIPELLULAR ORGANISMA, DEVELOPMENT [126 335-16 2365-16 GORD FREGULATION OF MULTIPELLULAR ORGANISMA, DEVELOPMENT [126 335-16 2365-16 GORD FREGULATION OF MULTIPELLULAR ORGANISMA, DEVELOPMENT [126 335-16 335-16 GORD FREGULAR DEVELOPMENT [126 336-16 335-17 236-16 336-16 336-16 336-17 336-16				
ODEP POSITIVE_REGULATION OF_BIOSYNTHETIC PROCESS 118 112.5-21 6.468-19 ODEP POSITIVE_REGULATION OF_BIOL_CYTLE 118 6.025-01 4.282-11 ODEP REGULATION OF_GIALL_CYTLEL 118 6.025-01 4.282-11 ODEP REGULATION OF_GIALL_CYTLELAR GRAMINAMA_DEVELOPMENT 17 5.325-11 3.122-11 ODEP REGULATION OF_GIALL_DEFERENTIATION 106 7.552-11 3.122-11 ODEP REGULATION OF_COLLE_OPTICENTIATION 106 1.242-17 4.022-11 ODEP REGROMENT FERODENTIATION 106 1.242-17 4.022-17 ODEP REGROMENT REGROMENT 1.012-17 2.022-17 1.012-17 2.022-17 ODEP REGROMENT REGROMENT 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17 1.012-17 2.022-17				
GOBP - GRAMONTROGEN COMPOUND BOSYNTHETC PROCESS 115 4.246.17 GOBP - MANGENT, PROCESS 119 2.426.17 GOBP - REGULATION OF JAILITCELLUAR, ORANISMAL DEVELOPHINT 07 5.516.19 2.226.16 GOBP - REGULATION OF ALLITCELLUAR, ORANISMAL DEVELOPHINT 07 5.516.19 2.226.16 GOBP - REGULATION OF CLELL OFFERENTATION 106 7.507.19 3.126.14 14.467.15 GOBP - REGULATION OF ALLITAR, ORANISMAL DEVELOPHINT 06 9.007.19 3.226.14 14.467.15 GOBP - REGULATION OF CLELL DEFENDATION 100 100.07.19 127.14 14.467.15 GOBP - REGULATION OF CLELL DEFENDATION 101 102.14 127.14 124.14 127.14 124.14 <td< td=""><td></td><td></td><td></td><td></td></td<>				
GRDP_MOMEOSTATIC_PROCESS 119 248-19 2.238-19 GRDP_REGULATION OF CELL_VETERNITATION 100 100 125-19 2.238-19 GORP_REGULATION OF CELL_VETERNITATION 100 125-19 2.238-19 125-16 GORP_REGULATION OF CELL_OFFERENTIATION 100 125-16 2.238-16 126-16 GORP_ARGONDENTE_METRADUCE PROCESS 117 3.288-16 3.288-16 3.288-16 GORP_RESPONSE 100 1.248-17 2.448-16 3.287-17 2.446-17 GORP_RESPONSE 0.00 1.248-17 2.446-17 2.246-17 2.446-17 GORP_RESPONSE 0.00 1.062-17 2.446-17 2.246-17 2.246-17 GORP_RESPONSE 0.004-17 2.046-17 2.246-17 2.246-17 2.246-17 GORP_RESPONSE 0.004-17 2.046-17 2.046-17 2.046-17 2.046-17 GORP_REGULATION OF GENERATION CONTRATUS 0.048-17 2.046-17 2.046-17 2.046-17 GORP_REGULATION OF GENERATION PROCESS 0.046-17 2.046-17 2.046-17 2.046-17				
GOBP REGULATION 07 5.51-19 2.425-16 GOBP REGULATION 06 7.651-19 2.425-16 GOBP REGULATION C. REDUCTERSENTATION 107 2.525-16 2.125-16 GOBP REGULATION C. REDUCTERSENTATION 107 2.525-18 2.255-18 GOBP RESIGNATION C. RELLOPERCENTATION 107 2.257-18 2.256-18 GOBP RESIGNATION C. CELLOPERCENTATION 107 2.425-18 2.425-18 GOBP RESIGNATION C. CELLOPERCENTATION 107 2.425-18 2.425-18 GOBP RESIGNATION C. CELLOPERCENTATION 107 2.425-16 2.425-16 GOBP RESIGNATION C. CELLOPERCENTATION 101 2.425-16 2.425-16 GOBP RESIGNATION C. CELLOPERCENTATION 101 2.425-16 3.425-13 GOBP RESIGNATION 101 2.425-16 3.425-13 3.45-13 GOBP RESIGNATION 101 2.425-13 3.45-13 3.456		119		
GOBP REGULATION OF CHELL DEFERSIVITATION 1100 7.560-10 3.128-10 GOBP AGRAMOPHATE LEFEADOL FRACESS 113 3.886-10 1142-15 GOBP AGRAMOPHATE LEFEADOL FRACESS 113 3.886-10 1142-15 GOBP AGRAMOPHATE LEFEADOL FRACESS 113 3.886-10 1142-17 GOBP RESPORES TO AVECEN CONTAINING COMPOUND 107 7.374-7 2.426-10 GOBP RESPORES TO AVECEN CONTAINING COMPOUND 107 7.374-7 2.426-10 GOBP RESPORES TO AVECEN CONTAINING COMPOUND 107 115 8.866-16 4.966-16 GOBP RESPORES TO ABLEMENT OF PROTEIN CONTAINING COMPOUND 112 1286-16 3.966-16 3.966-16 GOBP RESPORTER CONTAINING COMPOUND 112 1286-16 3.966-16 3.9				
DGBP DGBP GERAUDFINGERIA 171 3.32-18 1.315-15 DGBP ADGRAUDTINGORIA COMOUND CATABOLIC, PROCESS 172 3.92-18 1.315-15 DGBP ADGRAUDTINGORIA COMOUND CATABOLIC, PROCESS 172 3.92-17				
CodP Applortion C. PROCESS 117 3.88-10 1.48-15 CodP DeGAGNATINECRAL COMPOUND CATABOLIC PROCESS 26.46-18 2.272-15 CodP DEGAGNATINE CONTAINING COMPOUND 100 1.272-17 2.46-16 CODP RESPONSE TO DATABOLIC PROCESS 60 9.44-17 2.972-16 CODP CREAPING-ED OWTRAIN DURING COMPOUND 101 1.272-17 2.46-16 CODP CREAPING-ED MERSION DURING COMPOUND 101 1.276-18 3.184-13 CODP CREAPING-ED MERSION DURING COMPOUND 101 1.276-18 3.184-13 CODP CREAPING-ED CONTAINING COMPOUND 101 1.276-18 3.184-13 3.184-13 CODP CREAPING-ED CONTAINING COMPOUND 101 1.276-18 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 3.184-13 <td></td> <td></td> <td></td> <td></td>				
OGDE GOBE GEAUARINEGOEN 02 644-19 2.375-16 OGDE RESPONSE 104 8.002-11 2.325-16 OGDE RESPONSE 104 8.002-11 2.325-16 OGDE RESPONSE 109 1.324-17 2.025-16 OGDE RESPONSE 100 1.324-17 2.025-16 OGDE RESPONSE 100 1.324-18 2.025-16 OGDE RESPONSE TO ANDIC CHARLING 101 1.326-15 3.136-16 3.136-15 OGDE RECURLINAR RESPONSE TO ANDIC STIMULUS 67 1.326-15 3.136-15				
CODP RESPONSE TO ENDOGENOUS STMULUS 1041 6.006-18 2726-15 CODP REGULATION OF CELL DERNM 105 1246-17 4026-15 CODP RESPONSE TO OXYOPI CONTAINING COMPOUND 103 1736-17 4476-14 CODP RESPONSE TO ADVICENCE PROCESS 781 1356-16 2356-14 CODP RESPONSE TO ADVICENCE PROCESS 781 1366-16 2356-14 CODP RESPONSE TO ADVICE STMULUS 104 4716-16 2356-14 CODP RESPONSE TO ADVICE STMULUS 104 4716-16 2356-15 CODP RESPONSE TO ADVICE STMULUS 103 1366-15 3366-15 CODP REGULATION OF CALLARA TRANSPORT 103 1366-15 3366-15 CODP REGULATION OF CALLARA TRANSPORT 103 1366-15 3366-15 CODP REGULATION OF CALLARA TRANSPORT 106 1366-15 3366-15 1066-15 CODP REGULATION OF CHULGANDIN REGULATION OF CHULGANDIN REGULATION OF CHULGANDIN 1066-15 1066-11 1066-15 1066-15 <				
CORP RESPONSE TO, GAVGEL CONTAINING COMPOUND 103 773E-17 247E-14 CORP AND MARKE DERNAMES BOSYNTHETO DROCESS 60 9481-17 237E-14 CORP REGULATION OF STREMUND 114 145E-16 42E-14 CORP POSITIVE, FREQULATION OF SIGNALING 114 47TE-16 31E-13 CORP POSITIVE, FREQULATION OF SIGNALING 114 47TE-16 31E-13 CORP POSITIVE, FREQULATION OF SIGNALING 114 47TE-16 31E-13 CORP POSITIVE, CONTAINING, COMPLEX, SUBURITI GRANKZATON 112 12E-16 31E-13 CORP POSITIVE, CONTAINING, COMPLEX, SUBURITI GRANKZATON 115 12E-16 31E-15 CORP POSITIVE, CONTAINING, COMPLEX, SUBURITI GRANKZATON 115 12E-16 31E-15 CORP POSITIVE, REGULATION, OF RESPONSE TO STAULUIS 100 312E-15 31E-15 CORP REGULATION, OF RESPONSE TO STAULUIS 106 532E-15 11E-165 CORP REGULATION, OF RESPONSE TO STAULUIS 106 532E-15 11E-165 CORP		104		
060P CARBONYDRATE DERNATIVE BIOSYNTHETIC PROCESS 60 9.94E-17 2.32E-14 060P ORGANC, CAD METAGOLE PROCESS 76 1.36E-16 2.32E-14 060P ORGANC, CAD METAGOLE PROCESS 76 1.36E-16 2.32E-14 060P STALLS, RESULTATO, G. SOMANING 114 1.36E-16 3.18E-13 060P CIELLUAR, RESOLUTATO, G. SOMANING 112 1.32E-15 3.18E-13 060P CIELLUAR, RESOLUTATO, G. SOMANING 67 1.33E-15 3.18E-13 060P CIELLUAR, RESOLUTATO, G. SOMANING 67 1.33E-15 3.18E-13 060P CIELLUAR, RESOLUTATO, G. TONADULOS 67 1.33E-15 5.36E-15 3.32E-15 060P FEGULATON, OF PROCESS 53 2.29E-16 3.42E-15 1.46E-12 060P REGULATON, OF PROCESS 66 3.37E-15 1.46E-12 060P REGULATON, OF TRANSCRIPTON, PROCESS 61 3.92E-15 1.46E-12 060P REGULATON, OF CHARSCRIPTON, PROADULARS, ILLUAR, AND YARACARE, I 79 1.46E-12 060P REGULATON, OF CHARSCRIPTON, PROADULAR, STAL, PALVMERAS, I 79 1.46E-14 4.46E-14 060P REGULATON, OF CHARSCRIPTON, PROADULAR, PROADULARS	GOBP_REGULATION_OF_CELL_DEATH	105	1.24E-17	4.02E-15
0G8P COG8P				
GORP ESTABLISHMENT OF PROTEIN LOCALZATION 115 1967-16 5258-17 GORP RESONANT OF SIGNALING 644 1977-16 5258-14 GORP PORTINE REQUILATION OF SIGNALING 104 471E-16 538-14 GORP PORTINE REQUILATION OF SIGNALING 114 471E-16 538-14 GORP ADDITION CONTAINING COMPARTS 1146-15 538-15 338-15 GORP ADDITION OF CATABOLIC PROCESS 73 1566-15 338-15 GORP CREAMPORDENTIETICS PROCESS 632 2392-15 4306-15 GORP MEGATION OF RESIDENTIETICS PROCESS 632 338-15 1166-15 GORP MEGATION ERGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 106 338-15 1166-12 GORP MEGATION ERGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 78 3676-15 1166-12 GORP MEGATION ERGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 78 308-15 1166-12 GORP MEGATION ERGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 78 308-16-14 496-14 GORP MEGATION ERGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 78 308-16-14 496-14 GORP MEGATION ERGULATION OF TRANSCRIPT				
GOBP RESPONSE TO ABJORC STIMULUS 841 197E-16 525E-14 GOBP POTEIN, CONTAINIG COMPLEX SUBUNT ORGANIZATION 112 129E-15 319E-13 GOBP MOTEIN, CONTAINIG COMPLEX SUBUNT ORGANIZATION 112 129E-15 319E-13 GOBP MOTEIN, CENTRANSPORT 103 130E-15 319E-13 GOBP MITACELLUCIAR, TRANSPORT 103 130E-15 329E-13 GOBP REGULATION OF CATABOLIC PROCESS 53 229E-15 430E-13 GOBP MEGATICE, REGULATION OF PROTEIN MODELSCHART 66 532E-15 105E-15 GOBP MEGATICE, REGULATION OF TRANSCRIPTION BY RNA, POLYMERASE II 66 33EE-15 106E-16 106E-16 GOBP MEGATICE, REGULATION OF TRANSCRIPTION BY RNA, POLYMERASE II 79 87EE-15 166E-12 GOBP MEGATICE, REGULATION OF TRANSCRIPTION BY RNA, POLYMERASE II 79 87EE-15 166E-12 166E-				
GOBP PORTUTE REGULATION OF SIGNALING 104 471E-19 121E-19 GOBP PORTUTE NOTING OF SIGNALING 171 128E-15 31EE-13 GOBP CALLULAR RESPONSE TO DNA DAMAGE STMULUS 67 138E-15 31EE-13 GOBP CALLULAR RESPONSE TO DNA DAMAGE STMULUS 67 138E-15 31EE-15 GOBP CREAUTORY SYSTEM DEVELOMENT 73 138E-15 31EE-15 GOBP RECOLLATION OF CATABOLIC PROCESS 59 228E-15 490E-13 GOBP RECOLLATION OF CATABOLIC PROCESS 99 37EE-15 751E-13 GOBP RECOLLATION OF CREATORNER TO STIMULUS 000 31EE-15 11EE-15 GOBP RECOLLATION OF TRANSCRIPTION BY RNA POLYMERASE II 73 04E-15 11EE-15 GOBP MICHTE CREGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 73 04E-15 11EE-15 GOBP TUBE DEVELOPMENT 74 258E-14 435E-14 435E-14 GOBP MICHTE CREGULATION OF CREL CYCLE PROCESS 68 28E-14 435E-14 GOBP TUBE DEVELOPMENT 74 258E-14 435E-14 435E-14 GOBP TUBE DEVELOPMENT 74 258E-14				
GOBP PROTEIN CONTAINING COMPLEX JUBUIT ORGANIZATION 112 1226-15 3.186-13 GOBP CELLUAR RESPONSE TO ONL DAMAGE STMULUS 67 1386-15 3.186-13 GOBP CEQUATORY SYSTEM DEVELOPMENT 70 1386-16 3.186-13 GOBP CEQUATORY SYSTEM DEVELOPMENT 70 1386-16 3.027-11 GOBP CEQUATORY SYSTEM DEVELOPMENT 70 1386-16 3.027-11 GOBP CEQUATOR OF CATACOLE PROCESS 71 1386-16 5.067-13 GOBP REGULATION OF CRESS 93 3.026-15 7.166-15 GOBP NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I 70 6.386-15 1.166-12 GOBP NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE I 70 6.386-16 1.166-12 GOBP NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 60 946-16 1.166-12 GOBP INDE DEVELOPMENT 72 2.382-14 4.036-12 GOBP INDE DEVELOPMENT 72 2.382-14 4.066-14 1.966-14 GOBP INDE DEVELOPMENT 72 2.382-14 4.306-12 2.362-14 GOBP INDE DEVELOPMENT 72 2.382-14				
OODE CRCULATORY_SYSTEM DEVELOPMENT 19 136E-15 339E-13 OODE MITAGELULAR, TRANSPORT 100 150E-15 339E-13 OODE MITAGELULAR, TRANSPORT 100 115E-15 332E-13 OODE MITAGELULAR, TRANSPORT TRANSPORT 100 115E-15 535E-15 OODE MEDATIVE REGULATION OF RESPONSE TO STIMULUD 00 115E-15 535E-15 116E-15 OODE MEDATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 97 545E-15 116E-15 OODE POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 78 776E-15 116E-12 OODE POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 78 776E-14 435E-14 445E-14 445E-14 446E-11 446E-11 446E-14 446E-14 446E-14 446E-14	GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION			3.19E-13
ODBP INTRACELLULAR TRANSPORT 00 150E-16 33E-13 OOBP REQUIATION OF CATABOLIC PROCESS 73 165E-16 33E-13 OOBP REQUIATION OF CATABOLIC PROCESS 93 23E-15 6.50E-13 OOBP REQUIATION OF MOTEEN INCORFICIAN PROCESS 98 77E-15 7.65E-15 OOBP RECONTROL 77 6.56E-15 1.1EE-12 OOBP RECONTROL 77 6.56E-15 1.1EE-12 OOBP RECONTROL 77 6.56E-15 1.1EE-12 OOBP RECONTROL OF CELL CYCLE 77 6.56E-16 1.7EE-15 OOBP RECONTROL OF CELL CYCLE PROCESS 61 2.33E-14 4.05E-12 OOBP LINE DEVELOPMENT 72 2.55E-14 4.65E-14 4.6EE-14				
ODEP_RECULATION OF CATABOLIC_PROCESS 57 168-71 362-75 OOBP_ORGANOPORSHATE_IDSPONTHENC_PROCESS 52 226-75 490E-13 OOBP_RECATURO OF PROTEIN MODIFECTION PROCESS 99 370E-15 7.01E-13 OOBP_MECATURO OF PROTEIN MODIFECTION PAY PRA POLYMERASE II 06 384E-15 1.11E-12 OOBP_MEUROPERSID 97 6.81E-15 1.11E-12 0.000 1.000 0.000 1.000 1.000 1.000 1.000 1.000 0.000 0.000 0.000 0.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 <				
GOBP ORGANOPHOSPHATE_BIOS/WITHETIC_PROCESS 53 228-16 400E-13 GOBP MEGATIVE REGULATION OF RESPONSE TO STMULUS 100 3132-16 65.06-13 GOBP MEGATIVE, REGULATION OF TRANSCRIPTION BY RNA POLYMERASE 66 6382-15 7.01E-13 GOBP MEGATIVE, REGULATION OF TRANSCRIPTION BY RNA POLYMERASE 70 63.72E-16 1.11E-12 GOBP MEGATIVE, REGULATION OF TRANSCRIPTION BY RNA POLYMERASE 70 63.72E-16 1.11E-12 GOBP MEGATIVE, REGULATION OF TRANSCRIPTION BY RNA POLYMERASE 70 63.72E-16 1.71E-16 GOBP MEGATIVE, REGULATION OF TRANSCRIPTION BY RNA POLYMERASE 70 63.72E-16 1.71E-16 GOBP MEGATIVE, REGULATION OF GLELOPMENTAL, PROCESS 64 238E-14 4.30E-12 GOBP MEGATIVE, REGULATION OF MULTICELLULAR ORGANISMAL_PROCESS 74 6685-14 4.96E-12 GOBP MEGATIVE, REGULATION OF MULTICELLULAR ORGANISMAL_PROCESS 77 1.46E-14 1.22E-11 GOBP MEGATIVE, REGULATION OF MULTICELLULAR ORGANISMAL_PROCESS 71 1.46E-14 1.42E-13 GOBP MEGATIVE, REGULATION OF ORLIGIC PROCESS 71 1.46E-14 1.42E-14 GOBP MEGATIVE, REGULATION OF ORLIGIC				
CORP NECATIVE RECULATION OF RESPONSE TO STIMULUS 100 3126-15 6.500-5 CORP RECULATION OF FRESTOR MODIFICATION PY RNA POLYMERASE II 66 5386-15 1.006-11 CORP MECATIVE, RECULATION OF TRANSCRIPTION BY RNA POLYMERASE II 73 6386-15 1.106-12 CORP MECATIVE, RECULATION OF TRANSCRIPTION BY RNA POLYMERASE II 73 6386-15 1.106-12 CORP MECATIVE, RECULATION OF DEPELORMENTAL PROCESS 66 2.356-14 4.056-11 CORP MECATIVE, RECULATION OF DEPELORMENTAL PROCESS 74 2.356-14 4.056-12 CORP MECATIVE, RECULATION OF MULTICELLULAR ORGANISMAL PROCESS 74 6.056-14 4.036-12 CORP MECATIVE, RECULATION OF MULTICELLULAR ORGANISMAL PROCESS 74 6.056-14 1.046-11 CORP MECATIVE, RECULATION OF MULTICELLULAR ORGANISMAL PROCESS 78 8.146 4.146-12 CORP MECATIVE, RECULATION OF MULTICELLULAR CORGANISMAL PROCESS 78 8.146 1.046-13 CORP MECATIVE, RECULATION OF MULTICELLULAR CORGANISMAL PROCESS 78 8.146 1.046-13 CORP MECATIVE, RECULATION OF MULTICELLULAR CORGANISMAL PROCESS 78 8.146 1.046-13 CORP MECATIVE, RECULATION OF				
GOBP_RECOLUTION_OF_PROTEIN_MODIFICATION_PROCESS 98 378:15 7816-13 GOBP_NECENTE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 97 5818-15 1.116-12 GOBP_MECENTE_REGULATION_OF_DEVELOPMENTAL_PROCESS 68 9318-16 1.116-12 GOBP_MEDITIC_REGULATION_OF_DEVELOPMENTAL_PROCESS 64 9318-16 1.126-12 GOBP_MEDITIC_REGULATION_OF_DEVELOPMENTAL_PROCESS 64 938-14 4.905-12 GOBP_MEDITIC_REGULATION_OF_DEVELOPMENTAL_PROCESS 64 938-14 4.905-12 GOBP_MEDITIC_REGULATION_OF_DEVELOPMENT 69 6.958-12 528-854 4.905-14 4.965-12 GOBP_MINITEC FORCESS 74 6.965-14 4.965-12 528-54 4.968-14 1.968-16 1.				
GOBP_NECATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 66 5.881-51 1.008-12 GOBP_NECROSCHNSIS 75 5.811-51 1.116-12 GOBP_NECROSCHNSIS 75 5.811-51 1.116-12 GOBP_NECROSCHNSIS 75 5.811-51 1.166-12 GOBP_NECROSCHNSIS 66 9.911-51 1.766-17 GOBP_NECROSCHNSTERCE_DOMERTAL_PROCESS 66 9.912-16 1.766-17 GOBP_NECROSCHNTERCE_DOMERTAL PROCESS 52 2.886-14 4.306-12 GOBP_NECRONCE_RECOMENT 69 5.926-14 4.956-12 GOBP_NECRONCE_RECOLLATION_OF_MILTOFELULAR_ORGANISMAL_PROCESS 64 6.956-14 4.956-12 GOBP_NECRONCE_CLUE_CATABOLIC_PROCESS 43 8.966-14 1.966-11 GOBP_NELTO_NORACTIVE STRESS 43 9.966-14 1.966-14 GOBP_CONSUME_CONSUME_CONSUME CONSUME CONSUM				
GOBP_MEUROCENESIS 97 5.81E-15 1.116-12 GOBP_MICTOC CELL CYCLE 73 6.08E-15 1.60E-12 GOBP_MICTOC CELL CYCLE 76 76 76 76 76 76 GOBP_MICTOC F, EGULATION, OF TRANSCRIPTION BY RNA, PROCESS 61 2.33E-14 4.09E-12 GOBP_MICTOC, CELL CYCLE_PROCESS 61 2.33E-14 4.09E-12 GOBP_MICTOC, CADD METADOLC, PROCESS 61 2.33E-14 4.09E-12 COBP_MICTOC, ACD METADOLC, PROCESS 74 6.09E-14 4.09E-12 COBP_MICTOC, ACD METADOLC, PROCESS 74 6.09E-14 4.09E-12 COBP_MICTOC, ACD DEVELOPMENT 60 7.73E-14 1.19E-11 COBP_MICTOC, DEVELOPMENT 60 7.73E-14 1.09E-13 1.59E-11 COBP_MICTOC, NOB 101 1.05E-13 1.59E-11 1.05E-13 1.59E-11 COBP_MICTOC, NOB 101 1.05E-13 1.59E-11 1.05E-13 2.29E-13 COBP_MICTOC, NOB 101 1.05E-13 1.59E-11 1.05E-13 2.29E-13 2.29E-13 2.29E-13	GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II		5.38E-15	1.06E-12
CODE POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 79 8.76E-15 1.60E-12 CORP NEGUTATION OF CELL_CYCLE_PROCESS 61 9.91E-15 1.76E-12 CORP NEGUTATION OF CELL_CYCLE_PROCESS 61 9.91E-16 1.43E-12 CORP TUBE DESVINTHETC PROCESS 56 2.36E-14 4.76E-12 CORP MEGATIVE REGULATION OF MULTICELLULAR_ORGANISMA_PROCESS 76 6.06E-14 9.06E-12 CORP MEGATIVE ACOLOPMENT 68 6.06E-14 1.94E-11 CORP MEGATIVE ACOLOPMENT 68 6.06E-14 1.94E-11 CORP MEGATIVE ACOLOPMENT 68 9.06E-14 1.94E-11 CORP MEGATIVE ACOLOPMENT 68 9.06E-14 1.94E-11 CORP MEGATIVE ACOLOPMENT 68 9.06E-14 1.94E-13 1.94E		97	5.81E-15	1.11E-12
GORP NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 661 238-14 4.065-12 GORP REGULATION OF CELL LOYCLE PROCESS 74 238-14 4.065-12 GORP JUED DEVELOPMENT 74 238-14 4.065-12 GORP MUNCARBOXYLIC, ACID, METABOLIC, PROCESS 74 0.052-14 4.965-12 GORP MUNCE, SVITHETIC, PROCESS 74 0.052-14 1.966-14 GORP MUNCE, SVITHETIC, PROCESS 74 0.052-14 1.966-14 GORP MUNCE, SVITHETIC, PROCESS 74 0.052-14 1.966-14 GORP MUNCE, SVITHETIC, PROCESS 87 3.966-14 1.966-14 GORP MUNCE, SVITHETIC, PROCESS 87 3.146-14 1.226-11 GORP MUNCE, SVITHETIC, PROCESS 87 3.146-14 1.226-11 GORP MUNCE, SVITHETIC, PROCESS 87 3.146-14 1.926-11 GORP MUNCE, POLSHORYLATION 94 1.122-151 1.966-11 3.966-14 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 1.966-13 <td></td> <td></td> <td></td> <td></td>				
GOBP REGULATION OF CELL_OYCLE PROCESS 61 238E-14 406E-12 GOBP JUBE DOSYNTHETC PROCESS 58 236E-14 476E-12 GOBP MOLECARDAVIL C, ADID, METABOLIC PROCESS 58 236E-14 496E-12 GOBP MOLECARDAVIL C, ADID, METABOLIC PROCESS 74 636E-12 636E-14 946E-12 GOBP MOLECALE CATABOLIC PROCESS 74 646 636E-14 146E-11 GOBP MOLECALE CATABOLIC PROCESS 78 8144 142E-11 126E-11 GOBP MOLECALE CATABOLIC PROCESS 48 946E-14 122E-11 136E-11 GOBP REGULATION OF ANATORIN 91 136E-11 136E-11 136E-11 GOBP REGULATION OF CATABOLIC PROCESS 69 946E-14 142E-13 138E-11 GOBP REGULATION OF ANATORIAL STRUCTURE MORPHOGENESIS 76 225E-13 236E-11				
GOBP_TUBE_DEVELOPMENT 74 2.53E-14 4.30E-12 CORP_LIPID_BIOSVITHETC_PROCESS 58 2.66E-14 4.96E-12 CORP_MICATOROSVITHETC_PROCESS 74 6.05E-14 4.96E-12 CORP_MICATOR ERGULATION OF MULTICELLULAR_ORGANISMA_PROCESS 74 6.05E-14 1.96E-11 CORP_MINUNE_SYSTEM DEVELOPMENT 69 7.73E-14 1.96E-11 CORP_MINUNE_SYSTEM DEVELOPMENT 69 7.73E-14 1.96E-11 CORP_MICATORO 91 1.22E-11 6.05E-14 1.96E-13 CORP_RESTOND OF ANATONCAL, STRUCTURE MORPHOGENESIS 61 1.05E-13 1.5E-11 CORP REGULATION OF ANATONCAL, STRUCTURE MORPHOGENESIS 62 1.05E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-14 2.96E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-13 2.26E-14 2.96E-13 2.26E-13				
GOBP LIPID BIOSYNTHETIC PROCESS 58 2.86E-14 4.96E-12 CORP MONCORROVYLIC ACTO METABOLIC PROCESS 74 6.05E-14 963E-12 CORP MONCORROVYLIC ACTO METABOLIC PROCESS 74 6.05E-14 963E-12 CORP MAUNCRE SYSTEM DEVELOPMENT 69 6.05E-14 1.04E-11 CORP MACRONOLECULE, CATABOLIC PROCESS 47 8.14E-14 1.22E-11 CORP MACRONOLECULE, CATABOLIC PROCESS 47 8.14E-14 1.22E-11 CORP ACTORNOLECULE, CATABOLIC PROCESS 101 1.05E-13 1.51E-11 CORP ACTORNOLECULE, CATABOLIC PROCESS 101 1.05E-13 1.51E-11 CORP ACTORNOLECULE, CATABOLIC, PROCESS 102 1.05E-13 1.54E-11 CORP ACEULAR, CATABONSE TO, OXIDATIVE, STRUCTURE MORPHOGENESIS 102 1.05E-13 2.04E-11 CORP ACEULAR, RESPONSE TO, OXIDATIVE, CONTAINING, COMPOUND 76 2.25E-13 2.95E-11 CORP ACEULAR, RESPONSE TO, OXIDATIVE, STRUCTURE MORPHOGENESIS 68 3.17E-13 2.95E-11 CORP ACEULAR, RESPONSE TO, OXIDATIVE, CONTAINING, COMPOUND 76 2.25E-13 2.46E-13 2.24E-13 CORP ACEU				
COEP MONOCARBOXYLIC. ACID. METABOLIC. PROCESS 4 4.96E-12 COEP NEGATIVE REGULATION OF MULTICELLUAR, ORGANISMAL_PROCESS 74 6.05E-14 9.63E-12 COEP MAURE SYSTEM DEVELOPMENT 69 7.352-14 1.18E-11 COEP MARCHONCLECULE_CATABOLIC_PROCESS 43 9.96E-14 1.44E-11 COEP, PROTEOLYSIS 43 9.96E-14 1.44E-11 1.51E-11 COEP, PROTEOLYSIS 69 1.05E-13 1.95E-11 1.95E-11 COEP, PROTEIN, PHOSPHORYLATION 94 1.25E-13 2.99E-11 COEP, PROTEIN, PHOSPHORYLATION 94 1.25E-13 2.99E-11 COEP, PROTEIN, CO, CALLZATION, TO, ORGANELLE 68 3.08E-13 3.98E-11 COEP, PROTEIN, LOCALLZATION, TO, ORGANELLE 68 3.08E-13 3.98E-11 COEP, PROTEIN, LOCALLZATION, TO, CORGANELLE 68 3.05E-13 2.94E-13 COEP, PROTEIN, LOCALLZATION, TO, CORGANELLE 68 3.05E-13 3.98E-11 COEP, PROTEIN, LOCALLZATION, TO, CORGANELLE 68 3.05E-13 3.98E-11 COEP, PROTEIN, LOCALLZATION, OF,		· · · · ·		
GOBP, NEGATINE, REGULATION, OF, MULTICELLULAR, ORGANISMAL, PROCESS 74 6.05E-14 96.35E-14 96.35E-14 104E-11 GOBP, MUNUNE, SYSTEM, DEVELOPMENT 69 7.73E-14 11.8EE-11 104E-11 GOBP, MURUNG LECULE, CATABOLIC, PROCESS 47 8.14E-14 122E-11 GOBP, RESPONSE, TO, OXIDATIVE, STRESS 43 9.96E-14 1.46E-11 GOBP, PROTEIN, PHOSPHORYLATION 94 1.12E-13 1.56E-11 GOBP, REGULATION, OF, CALLUAR, CATABOLIC, PROCESS 62 1.70E-13 2.24E-11 GOBP, REGULATION, OF, CALLUAR, CATABOLIC, PROCESS 62 1.70E-13 2.24E-11 GOBP, CELLULAR, RESPONSE, TO, OXYGEN, CONTAINING, COMPOUND 76 2.25E-13 2.94E-11 GOBP, DECLULAR, RESPONSE, TO, OXYGEN, CONTAINING, COMPOUND 66 3.7E-13 4.40E-11 GOBP, DECLULAR, RESPONSE, TO, OXYGEN, CONTAINING, COMPOUND 66 3.52E-11 4.40E-13 GOBP, DECLULAR, REGULATION, OF, CELLULAR, COMPONENT, ORGANIZATION 61 4.42E-13 5.22E-11 GOBP, CELLULAR, RESPONSE, TO, STRESS 52 52E-13 4.46E-11 5.22E-13 GOBP, REGULATION, OF, MIDTOTO, CELL,				
GOBP_EMBRYO_DEVELOPMENT 69 7.78E-14 118E-11 GOEP_MACRONCLECULE_CATAGULE_PROCESS 87 814E-14 122E-11 GOEP_PROTEN_PHOSPHORYLATION 94 112E-13 158E-11 GOEP_ROTEN_PHOSPHORYLATION 79 140E-13 158E-11 GOEP_CHENCONCOME_ORGANIZATION 79 140E-13 158E-11 GOEP_CELLULAR_DOF_OREDUCAR CATABOLIC_PROCESS 62 170E-13 224E-11 GOEP_CELLULAR_DOF_OREDUCAR CONTAINING_COMPOUND 76 228E-13 295E-11 GOEP_REGULATION_OF_OREDUCAR CONTAINING_COMPOUND 76 228E-13 295E-11 GOEP_DECLULAR_RESPONSE_TO_XIVEEN_COMPONENT_ORGANIZATION 66 37E-13 402E-11 GOEP_DECLULAR_RESPONSE_TO_XIVEEN_COMPONENT_ORGANIZATION 66 37E-13 402E-11 GOEP_CELL_MIGRATION 67 228E-13 528E-11 651E-11 GOEP_DECLUMER REGULATION OF_CELL_DIFFERENTIATION 61 442E-13 528E-11 GOEP_LOCOMOTION 614 442E-13 528E-11 651E-11 GOEP_ACOLINE MERGULATION OF_CELL_DIFFERENTIATION 64 54E-13 77E		74	6.05E-14	9.63E-12
CORP MACROMOLECULE_CATABOLIC_PROCESS 67 8.14E-14 122E-11 CORP RESPONSE TO XDRAYE STRESS 43 99E-14 146E-11 CORP RESPONSE TO XDRAYE STRESS 94 140E-13 151E-11 CORP RESPONSE TO XDRAYE ATRUCTURE MORPHOGENESIS 69 140E-13 195E-11 CORP REGULATION OF CALULAR CATABOLIC_PROCESS 62 170E-13 224E-11 CORP REGULATION OF CALULAR CATABOLIC_PROCESS 62 170E-13 29E-11 CORP REGULATION OF CELLULAR CONTAINING COMPOUND 76 224E-13 29E-11 CORP REGULATION OF CELLULAR COMPONENT ORGANIZATION 66 3.57E-13 4.02E-11 CORP REGULATION OF CELLULAR COMPONENT ORGANIZATION 66 3.57E-13 4.02E-11 CORP REGULATION OF CELLULAR COMPONENT ORGANIZATION 61 4.42E-13 5.25E-11 CORP REGULATION OF MITOTO, CELL CYCLE 50 4.50E-13 5.26E-11 CORP REGULATION OF PHOSPHORUS, METABOLIC PROCESS 92 5.68E-13 6.51E-11 CORP REGULATION OF CHILOPOHORUS, METABOLIC PROCESS 79 7.09E-13 7.72E-11 CORP REGULATION OF CHILOPOHORUS, METABOLIC PROCESS				
GOBP RESPONSE TO OXIDATIVE STRESS 43 998E-14 146E-11 GOBP PROTEN, PHOSPHORYLATION 94 112E-13 158E-11 GOBP REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 69 150E-13 204E-11 GOBP REGULATION OF CELLULAR, CATABOLIC, PROCESS 622 170E-13 298E-11 GOBP REGULATION OF CELLULAR, CONTAINING COMPOUND 76 228E-13 298E-11 GOBP REGULATION OF CELLULAR, COMPONENT ORGANIZATION 66 308E-13 308E-13 GOBP REGULATION OF CELLULAR, COMPONENT ORGANIZATION 62 228E-13 242E-13 GOBP REGULATION OF GELLULAR, COMPONENT ORGANIZATION 62 357E-13 440E-11 GOBP REGULATION OF MITOTIC CELL DIFFERENTIATION 61 440E-13 52EE-11 GOBP REGULATION OF MITOTIC CELL CYCLE 50 450E-13 52EE-11 GOBP REGULATION OF OF DEVELOPMENTAL, PROCESS 92 568E-13 651E-11 GOBP PROSITIVE REGULATION OF DEVELOPMENTAL, PROCESS 97 709E-13 777E-11 GOBP PROSITIVE REGULATION OF CELL POPULATION, PROLIFERATION 56 177E-13 778E-11 GOBP POSITIVE REGULATION OF CEL				
GOBP_PROTECLYSIS 1011 105E-13 151E-11 GOBP_PROTECLYSIS 94 112E-13 158E-11 GOBP_REGULATION_OF_CARLATION 94 112E-13 159E-11 GOBP_REGULATION_OF_CELLULAR_CATABOLIC_PROCESS 69 150E-13 227E-11 GOBP_REGULATION_OF_CELLULAR_CONTAINING_COMPOUND 76 222E-33 239E-11 GOBP_REGULATION_OF_CELLULAR_CONTAINING_COMPOIND 76 22E-33 239E-11 GOBP_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 68 357E-13 448E-11 GOBP_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 61 440E-13 528E-11 GOBP_REGULATION_OF_FROSPONSE TO_STRESS 85 357E-13 649E-13 528E-11 GOBP_REGULATION_OF_FROSPONSE TO_STRESS 80 442E-13 528E-11 649E-13 528E-11 GOBP_REGULATION_OF_FROSPHORUS_METABOLIC_PROCESS 80 456E-13 651E-11 GOBP_ROTEIN_MODIFICATION_S PS_MANLL_PROTEIN_CONJUGATION_OR_REMOVAL 74 622E-13 772E-11 GOBP_ROTEIN_MODIFICATION_OF_CELL_POPULATION_PROLIFERATION 51 751E-13 777F-11 GOBP_ROTEIN				
GOBP_PROTEN_PHOSPHORYLATION 94 1.12E-13 1.58E-11 COPP_CHRONGSOME_ORGANIZATION 71 1.40E-13 2.94E-11 COPP_REGULATION OF CAULUAR, CATABOLIC_PROCESS 69 1.50E-13 2.24E-11 COPP_REGULATION OF CAULUAR, CATABOLIC_PROCESS 68 3.07E-13 2.92E-13 2.99E-11 COPP_PROTEIN_LOCALIZATION TO, ORGANIZATION 66 3.57E-13 4.40E-11 GOBP_REGULATION, OF CELLULAR, CAMPONENT_ORGANIZATION 56 3.17E-13 4.40E-13 5.23E-11 GOBP_PROTEIN_PHOSPHORE CORD_CELL_MIGRATION 92 4.29E-13 5.23E-11 GOBP_REGULATION OF_OCLL_OTC CELL_OFCLE 06 4.30E-13 5.23E-11 GOBP_REGULATION OF_MOTOC CELL_OFCLE 06 4.30E-13 5.23E-11 GOBP_REGULATION OF_OFDHORUS_MERADOLIC_PROCESS 92 5.88E-13 6.51E-111 GOBP_REGULATION OF_DEPHORUS_MERADOLIC_PROCESS 92 5.88E-13 6.51E-111 GOBP_ROGULATION OF_DELPOMENTAL_PROCESS 92 5.78E-13 6.51E-111 GOBP_ROGULATION OF_CELLOPMENT 50 1.22E-12 1.44B-10 GOBP_NEGATIVE_REGULATION OF CELLOPMENTAL_P				
COEP_CHRONOSOME_ORGANIZATION 79 1.40E-13 1.95E-11 COEP_REGULATION OF CELLULAR_CATABOLIC_PROCESS 62 1.70E-13 2.24E-11 COEP_REGULATION OF CELLULAR_CATABOLIC_PROCESS 62 1.70E-13 2.25E-11 COEP_REGULATION OF CELLULAR CATABOLIC_PROCESS 68 3.08E-13 3.98E-11 GOEP_REGULATION OF CELLULAR_COMPONENT_ORGANIZATION 76 2.25E-13 5.25E-11 GOEP_CELL_MIGRATION 66 3.77E-13 4.20E-13 5.25E-11 GOEP_CELL_MIGRATION 61 4.40E-13 5.25E-11 GOEP_CELL_MIGRATION 61 4.40E-13 5.25E-11 GOEP_REGULATION OF_CELL DIFFERENTIATION 61 4.40E-13 5.25E-11 GOEP_REGULATION OF_PORTOR 64.50E-13 5.25E-11 5.25E-11 GOEP_REGULATION OF_PORTOR 7.77E-11 5.75E-13 5.75E-13 5.75E-13 5.25E-11 GOEP_NEGULATION OF_PORTORUS_METAOLIC_PROCESS 79 7.72E-11 5.65E-11 1.52E-11 1.52E-11 1.52E-11 1.52E-11 1.52E-11 1.52E-11 1.52E-11 1.52E-12 1.77E-11 5.77E-				
GOBP REGULATION, OF_CELLULAR, CATABOLIC, PROCESS 62 1.70E-131 2.27E-111 GOBP CELLULAR, RESPONSE TO OXYGANIC, COMPONID 76 2.55E-13 2.95E-11 GOBP PROTEIN, LOCALIZATION, TO ORGANELLE 68 3.08E-13 3.98E-11 GOBP REQUIATION, OF_CELLULAR, COMPONENT, ORGANIZATION 56 3.57E-13 4.46E-11 GOBP, CELL, MIGRATION 62 4.29E-13 5.28E-11 GOBP, CELL, MIGRATION 62 4.29E-13 5.28E-11 GOBP, CELL, MIGRATION 62 4.29E-13 5.28E-11 GOBP, REQUILATION, OF_CHEL, CYCLE 50 4.50E-13 5.26E-11 GOBP, REQUILATION, OF_UMOTIC, CELL, CYCLE 50 4.50E-13 5.26E-11 GOBP, REQUILATION, OF_UMOTIC, METABOLIC, PROCESS 92 5.68E-13 6.51E-11 GOBP, PROTEIN, MODIFICATION, BY, SMALL, PROTEIN, CONJUGATION, OR, REMOVAL 74 6.92E-13 7.77E-11 GOBP, PROTEIN, MODIFICATION, OF CELL POPULATION, PROCESS 97 7.09E-13 7.77E-11 GOBP, NEGATIVE, REGULATION, OF, CELL, POPULATION, PROLIFERATION 56 1.25E-12 1.38E-10 GOBP, NEGATIVE, REGULATION, OF, CELL, POP	GOBP_CHROMOSOME_ORGANIZATION	79	1.40E-13	1.95E-11
GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 76 2.25E-13 2.95E-11 GOBP_PROFIN_LOCAL/ZATION_TO_RORANELLE 68 3.08E-11 3.98E-11 GOBP_REGULATION_OF_RESPONSE_TO_STRESS 85 3.17E-13 4.40E-11 GOBP_REGULATION_OF_CELL_ULAR_COMPONENT_ORGANIZATION 56 3.57E-13 4.46E-11 GOBP_COMOTION 92 4.29E-13 5.25E-11 GOBP_REGULATION_OF_CELL_DIFFERENTIATION 61 4.40E-13 5.25E-11 GOBP_REGULATION_OF_MITOTC_CELL_CYCLE 50 4.50E-13 5.25E-11 GOBP_REGULATION_OF_MOSPHORUS_METABOLIC_PROCESS 26 6.8E-13 6.51E-11 GOBP_VACONTON_MOPINATION_DEVELOPMENTAL_PROCESS 79 7.02E-13 7.72E-11 GOBP_VACOLIATURE_DEVELOPMENT 58 7.17E-13 7.17E-11 GOBP_NEGATIVE_REGULATION OF CELL LOPOPULATION PROLIFERATION 61 1.25E-12 1.32E-10 GOBP_NEGATIVE_REGULATION OF CELL LOPOPULATION ROLIFERATION 61 1.25E-12 1.32E-10 GOBP_NEGATIVE_REGULATION OF CELL LOVCLE 50 1.42E-12 1.34E-11 GOBP_NEGATIVE_REGULATION OF CELLUXAR_COMPONENT_GRANIZATION				
GOBP_PROTEN_LOCALIZATION_TO_ORGANELLE 68 3.08E-13 3.98E-13 3.98E-13 3.98E-13 COPP REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 56 3.57E-13 4.40E-11 GOBP_REGULATION_OF_CELL_DIFFERENTIATION 61 4.40E-13 5.25E-13 5.28E-13 5.25E-13 GOBP_DOSITIVE_REGULATION_OF_CELL_OYCLE 06 4.50E-13 5.25E-11 5.25E-13 5.25E-13 5.25E-13 5.25E-13 5.25E-13 5.25E-11 5.25E-13 5.25E-12 5.25E-12				
GOBP REGULATION OF RESPONSE TO STRESS 86 3.17E-13 4.02E-11 GOBP NEGATIVE REGULATION OF CELLULAR_COMPONENT_ORGANIZATION 56 3.57E-13 4.46E-11 GOBP NEGATIVE REGULATION OF CELL DIFFERENTIATION 61 4.40E-13 5.25E-11 GOBP NEGULATION OF MITOTIC CELL_CYCLE 50 4.50E-13 5.26E-11 GOBP REGULATION OF MITOTIC CELL_CYCLE 50 4.50E-13 5.51E-11 GOBP REGULATION OF MOSPHORUS METABOLIC PROCESS 92 5.68E-13 6.51E-11 GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROTEIN CONJUGATION OR REMOVAL 74 6.92E-13 7.77E-11 GOBP REGULATION OF CELLULAR RESPONSE TO STRESS 54 7.61E-13 8.13E-11 GOBP NEGATIVE REGULATION OF CELL POPULATION PROLIFERATION 56 1.22E-12 1.32E-10 GOBP NEGATIVE REGULATION OF CELL POPULATION PROLIFERATION 56 1.22E-12 1.32E-11 GOBP PROTEIN CATABOLIC PROCESS 54 7.61E-13 8.13E-11 GOBP PROTEIN CATABOLIC PROCESS 54 7.61E-13 8.13E-11 GOBP PROTEIN CATABOLIC PROCESS 54 7.61E-13 8.13E-11 GOBP PROTEIN CATABOL				
GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION \$61 3.57E-13 4.46E-11 GOBP_CELL_MIGRATION \$22 4.28E-13 5.25E-11 GOBP_LOCOMOTION \$61 4.40E-13 5.25E-11 GOBP_REGULATION_OF_MITOTC_CELL_CYCLE \$50 4.50E-13 5.25E-11 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS \$92 5.68E-13 5.51E-11 GOBP_REDULATION_OF_PHOSPHORUS_METABOLIC_PROCESS \$92 5.68E-13 7.57E-13 6.51E-11 GOBP_PROTEIN_MODIFICATION_DOF_CELLOPMENT_CONJUGATION_OR_REMOVAL 74 6.92E-13 7.77E-11 GOBP_REGULATION_OF_CELLUPMENT 58 7.17E-13 7.77E-11 GOBP_REGULATION_OF_CELLOPMENT 58 7.17E-13 7.77E-11 GOBP_NEGATIVE_REGULATION_OF_CELL_OPOLLATION PROLIFERATION 56 1.25E-12 1.32E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_OPOLLATION PROLIFERATION 56 1.42E-12 2.48E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_OPOLLATION 50 1.42E-12 2.48E-10 GOBP_POSITIVE_REGULATION_OF_CELL_OPOLESS 58 2.28E-12 2.48E-10 GOBP_POSITIVE_REGULATION_OF_CELL_				
GOBP CELL MIGRATION 92 429E-13 5.25E-11 GOBP COCOMOTION 61 440E-13 5.25E-11 GOBP REGULATION OF, MITOTIC CELL CYCLE 50 4.50E-13 5.25E-11 GOBP REQUATION OF, MITOTIC CELL CYCLE 50 4.50E-13 5.25E-11 GOBP REQUATION OF, MOTOR CELL CYCLE 50 4.50E-13 5.51E-11 GOBP ALCOHOL METABOLIC PROCESS 38 5.75E-13 6.51E-11 GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROTEIN CONJUGATION OR REMOVAL 74 6.92E-13 7.77E-11 GOBP NEGATIVE, REGULATION OF CELL POPULATION PROLIFERATION 56 1.25E-12 1.32E-10 GOBP NEGATIVE, REGULATION OF CELL POPULATION PROLIFERATION 56 1.25E-12 1.32E-10 GOBP NEGATIVE, REGULATION OF CELL LYCLE 501 1.42E-12 1.48E-10 GOBP POSITIVE, REGULATION OF CELL LYCLE 501 1.42E-12 1.48E-10 GOBP POSITIVE, REGULATION OF CELLUYCLE PROLECTON 56 1.25E-12 2.37E-10 GOBP POSITIVE, REGULATION OF CELLUYCLE 501 1.42E-12 1.48E-10 GOBP POSITIVE, REGULATION OF CELLUYCLE 501 3.				
GOBP_LOCOMOTION 106 4.42E-13 5.25E-11 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 92 5.68E-13 6.51E-11 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 92 5.68E-13 6.51E-11 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 92 5.68E-13 6.51E-11 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 79 7.09E-13 7.77E-11 GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 54 7.61E-13 8.13E-11 GOBP_NEGATIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION 56 1.22E-10 1.22E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 50 1.42E-12 2.29E-10 GOBP_PROTEIN_CATABOLIC_PROCESS 64 2.24E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.34E-12 GOBP_ORGANIC_HYDROXY_COMPOUND_METABOLIC_PROCESS 62 2.89E-12 2.34E-12 3.48E-10 GOBP_CELL_PROJECTION_ORGANIZATION 71 2.54E-12 2.34E-12 3.48E-12 3.48E-12 3.48E-12 3.48E-12 3.48E-12 3.48E-12 3.48E-12 3.48E				
GOBP REGULATION OF MITOTIC CELL CYCLE 60 4.50E-13 6.26E-11 GOBP REGULATION OF PHOSPHORUS METABOLIC PROCESS 92 6.68E-13 6.51E-11 GOBP RACCHOL METABOLIC PROCESS 38 5.75E-13 6.51E-11 GOBP PROTEIN_MODIFICATION BY SMALL_PROTEIN_CONJUGATION_OR_REMOVAL 74 6.92E-13 7.72E-11 GOBP PROSTIVE_REGULATION OF DEVELOPMENT 58 7.17E-13 7.77E-11 GOBP REGULATION OF CELLULAR RESPONSE TO_STRESS 54 7.61E-13 8.13E-11 GOBP NEGATIVE_REGULATION_OF CELL_POPULATION_PROLIFERATION 56 1.22E-12 1.32E-10 GOBP PROSTIVE_REGULATION_OF CELL_OVOLE 50 1.42E-12 1.48E-10 GOBP POSITIVE_REGULATION_OF CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.57E-10 GOBP GOBP_ORGINC_HYDROXY_COMPOUND_METABOLIC_PROCESS 82 2.89E-12 2.88E-10 GOBP COMON OF CELLULAR_COMPONENT_ORGANIZATION 61 5.45E-12 3.48E-12 GOBP COMON OF CELLULAR_COMPONENT_ORGANIZATION 61 3.44E-12 <		1 1		
GOBP_REGULATION_OF_PHOSPHÖRUS_METABOLIC_PROCESS 92 6.68E-13 6.51E-11 GOBP_ALCOHOL_METABOLIC PROCESS 38 5.75E-13 6.51E-11 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 79 7.09E-13 7.77E-11 GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 54 7.61E-13 8.13E-11 GOBP_NEGATIVE_REGULATION_OF_CELL_COULTANC 70 1.24E-12 1.44E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 50 1.42E-12 1.44E-10 GOBP_PROTEIN_CATABOLIC_PROCESS 64 2.24E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_CELL_CYCLE 50 1.42E-12 2.48E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.28E-10 GOBP_POSITIVE_REGULATION_OF_ORULTICELLULAR_CORGANISMAL PROCESS 82 2.89E-12 2.88E-10 GOBP_CELL_PROJECTION_ORGANIZATION 50 3.82E-12 3.71E-10 GOBP_CELL_PROJECTION_ORGANIZATION 68 4.74E-12 4.53E-10 GOBP_CELL_PROJECTION_ORGANIZATION 68 4.74E-12 4.53E-10 GOBP_CELL_PROJECTION_ORGANIZATION 68				
GOBP FALCOHOL. METABOLIC PROCESS 38 5.75E-13 6.51E-11 GOBP PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 74 6.92E-13 7.72E-11 GOBP PROTEIN MODIFICATION OF DEVELOPMENTAL PROCESS 79 7.09E-13 7.77E-11 GOBP PROTEIN REGULATION OF CELLULAR RESPONSE TO STRESS 54 7.117E-13 8.13E-11 GOBP NEGATIVE REGULATION OF CELLUCYCLE 50 1.42E-12 1.32E-10 GOBP PROTEIN CATABOLIC PROCESS 64 2.24E-12 2.29E-10 GOBP POSITIVE REGULATION OF CELLUCYCLE 50 1.42E-12 2.29E-10 GOBP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 71 2.54E-12 2.29E-10 GOBP POSITIVE REGULATION OF CULULAR COMPONENT ORGANIZATION 71 2.54E-12 3.48E-10 GOBP COLL CYCLE PHASE TRANSITION 60 3.62E-12 3.48E-10 GOBP CELL CYCLE PHASE TRANSITION 88 4.74E-12 4.53E-10 GOBP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 88 4.74E-12 4.53E-10 GOBP CELL CYCLE PHASE TRANSITION 61 6.60E-12 6.17E-10 GOBP CELL CYCLE PHASE TRAN				
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION_OR_REMOVAL 74 6.92E-13 7.72E-11 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 79 7.09E-13 7.77E-11 GOBP_REGULATION_OF_CELLUAR_RESPONSE_TO_STRESS 54 7.61E-13 8.13E-11 GOBP_NEGATIVE_REGULATION_OF_CELL_OPOLATION_PROLIFERATION 56 1.25E-12 1.32E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_OPOLES 64 2.24E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.38E-10 GOBP_OSITIVE_REGULATION_OF_MULTICELULAR_ORGANISMAL_PROCESS 82 2.89E-12 3.48E-10 GOBP_CRELL_PROJECTION_OF_MULTICELULAR_ORGANISMAL_PROCESS 66 3.54E-12 3.48E-10 GOBP_CRELL_PROJECTION_OF_GUMPUND_METABOLIC_PROCESS 46 3.24E-12 4.53E-10 GOBP_CELL_PROJECTION_ORGANIZATION 42 4.78E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 41 6.60E-12 6.1				
GOBP POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 79 7.09E-13 7.77E-11 GOBP_VASCULATURE_DEVELOPMENT 58 7.17E-13 7.77E-11 GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 54 7.61E-13 8.13E-11 GOBP_NEGATIVE_REGULATION_OF_CELL_OPOPULATION_PROLIFERATION 56 1.25E-12 1.32E-10 GOBP_PROTEIN_CATABOLIC_PROCESS 64 2.24E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.57E-10 GOBP_ORGANIC_HYDROXY_COMPOUND_METABOLIC_PROCESS 48 3.54E-12 3.48E-10 GOBP_ORGANIC_HYDROXY_COMPOUND_METABOLIC_PROCESS 48 3.54E-12 3.48E-10 GOBP_CELL_CYCLE_PHASE_TRANSITION 50 3.82E-12 3.48E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 44 4.78E-12 4.53E-10 GOBP_REGUNE_TRONS				
GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 54 7.61E-13 &.13E-11 GOBP_NEGATIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION 56 1.25E-12 1.32E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 50 1.42E-12 1.42E-12 1.42E-12 1.42E-12 1.42E-12 1.42E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.57E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.37E-10 GOBP_POSITIVE_REGULATION_OF_CULLUAR_COMPONENT_ORGANIZATION 71 2.54E-12 3.48E-10 GOBP_COLL_CYCLE_PHASE_TRANSITION 50 3.82E-12 3.71E-10 GOBP_CELL_CYCLE_PHASE_TRANSITION 68 4.74E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 7.29E-10 GOBP_RESTURE_REGULATION_OF_CORTOR_SIS 61 6.06E-12 6.17E-10 GOBP_TUBE_MORPHOGENESIS 66 1.02E-12 7.29E-10 GOBP_RESTURE_REGULATION_OF_INTRACELULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_FATTY_ACID_METABOLIC_PROCESS 39		79		
GOBP_NEGATIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION 56 1.25E-12 1.32E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 50 1.42E-12 1.48E-10 GOBP_PROTEIN_CATABOLIC_PROCESS 64 2.24E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.57E-10 GOBP_POSITIVE_REGULATION_OF_CULLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.37E-10 GOBP_CELL_CYCLE_PHASE_TRANSITION 50 3.82E-12 3.71E-10 GOBP_CELL_PROJECTION_ORGANIZATION 68 4.74E-12 4.53E-10 GOBP_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_TUBE_MORPHOGENESIS 61 6.60E-12 6.17E-10 GOBP_RESPONSE_TO_RADIATION 42 4.78E-12 7.46E-10 GOBP_CLULULAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_CRELULARA_MACROMOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_SONSE_TO_RADIATION 65 1.01E-11 9.01E-10 GOBP_SONSUTE REGULATION_OF_CELLULAR_SIGNAL_TRANSDUCTION 65		58	7.17E-13	
GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 50 1.42E-12 1.48E-10 GOBP_PROTEIN_CATABOLIC_PROCESS 64 2.24E-12 2.29E-10 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.57E-10 GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_COMPONENT_ORGANIZATION 71 2.54E-12 2.38E-10 GOBP_ORANIC_HYDRAXY_COMPOUND_METABOLIC_PROCESS 46 3.54E-12 3.48E-10 GOBP_CELL_PROJECTION_ORGANIZATION 50 3.82E-12 3.71E-10 GOBP_REGULATION_OF_CELL_CLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_REDULATION_OF_CELL_PROSENS 61 6.60E-12 6.17E-10 GOBP_REDULATION_OF_CELL_PROSENS 61 6.60E-12 6.17E-10 GOBP_RESPONSE_TO_RADIATION 40 8.17E-12 7.49E-10 GOBP_RESPONSE_TO_RADIATION OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_DROSES 37 1.12E-11 9.88E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_DROSES 37				
GOBP PROTEIN CATABOLIC PROCESS 64 224E-12 229E-10 GOBP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 71 2.54E-12 2.57E-10 GOBP POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 82 2.89E-12 2.57E-10 GOBP CACUC PHASE TRANSITION 50 3.82E-12 3.48E-10 GOBP CELL CYCLE PHASE TRANSITION 68 4.74E-12 4.53E-10 GOBP REGULATION OF CELL CYCLE PHASE TRANSITION 42 4.78E-12 4.53E-10 GOBP REGULATION OF CELL CYCLE PHASE TRANSITION 42 4.78E-12 4.53E-10 GOBP RESPONSE TO RADIATION 68 7.47E-12 7.46E-10 GOBP RESPONSE TO RADIATION 68 7.89E-12 7.46E-10 GOBP FATTY ACID METABOLIC PROCESS 73 9.32E-12 8.40E-10 GOBP FATTY ACID METABOLIC PROCESS 33 1.14E-11 9.01E-10 GOBP SMALL MOLECULE CATABOLIC PROCESS 39 1.14E-11 9.88E-10 GOBP NEGATIVE REGULATION OF CELL DIFFERENTIATION 50 1.30E-11 1.00E-09 GOBP NEGATIVE REGULATION OF CELL DIFFERENTIATION 50 1.30E-11				
GOBP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 71 2.54E-12 2.57E-10 GOBP POSITIVE REGULATION OF MULTICELULAR COMPONENT ORGANIZATION 71 2.54E-12 2.89E-12 2.88E-10 GOBP ORGANIC HYDROXY COMPOUND METABOLIC PROCESS 82 2.89E-12 3.48E-10 GOBP CELL CYCLE PHASE TRANSITION 50 3.82E-12 3.71E-10 GOBP CELL CYCLE PHASE TRANSITION 42 4.78E-12 4.53E-10 GOBP TUBE MORPHOGENESIS 61 6.60E-12 6.17E-10 GOBP TUBE MORPHOGENESIS 61 6.60E-12 6.17E-10 GOBP CELLULAR MACROMOLECULE CATABOLIC PROCESS 73 9.32E-12 7.46E-10 GOBP CELLULAR MACROMOLECULE CATABOLIC PROCESS 73 9.32E-12 8.40E-10 GOBP SINTUR ERGULATION OF CELLULAR SIGNAL TRANSDUCTION 66 1.01E-11 9.01E-10 GOBP SMALL MOLECULE CATABOLIC PROCESS 37 1.12E-11 9.88E-10 GOBP NEGATIVE REGULATION OF CELL DIFFERENTIATION 50 1.30E-11 1.00E-09 GOBP NEGATIVE REGULATION OF CELL DEATH 54 1.58E-10 90BP NEGATIVE REGULATION OF CELL DEATH 54 1.5				
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 82 2.89E-12 2.88E-10 GOBP_ORGANIC_HYDROXY_COMPOUND_METABOLIC_PROCESS 46 3.54E-12 3.48E-10 GOBP_CELL_CYCLE_PHASE_TRANSITION 50 3.82E-12 3.71E-10 GOBP_CELL_PROJECTION_ORGANIZATION 88 4.74E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 6.17E-10 GOBP_TUBE_MORPHOGENESIS 61 6.00E-12 6.17E-10 GOBP_REDULATION_OF_CELL_CYCLE_PHASE_TRANSITION 40 8.17E-12 7.49E-10 GOBP_RESPONSE_TO_RADIATION 40 8.17E-12 7.49E-10 GOBP_RESPONSE_TO_RADIATION 40 8.17E-12 7.49E-10 GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_FOSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.01E-09 GOBP_INTRACELULAR_PROTEIN_TRANSPORT 71 1.4				
GOBP_ORGANIC_HYDROXY_COMPOUND_METABOLIC_PROCESS 46 3.54E-12 3.48E-10 GOBP_CELL_CYCLE_PHASE_TRANSITION 50 3.82E-12 3.71E-10 GOBP_CELL_PROJECTION_ORGANIZATION 88 4.74E-12 4.53E-10 GOBP_REGULATION_OR_COLL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_TUBE_MORPHOGENESIS 61 6.60E-12 6.17E-10 GOBP_RESPONSE_TO_RADIATION 42 4.78E-12 7.29E-10 GOBP_RESPONSE_TO_RADIATION 68 7.89E-12 7.29E-10 GOBP_CELLUAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_FATTY_ACID_METABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.10E-09 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_REGULATION_OF_ORGANIZLATION 71 1.47E-11 1.37E-09 GOBP_				
GOBP_CELL_PROJECTION_ORGANIZATION 88 4.74E-12 4.53E-10 GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_TUBE_MORPHOGENESIS 61 6.60E-12 6.0E-12 7.29E-10 GOBP_TUBE_MORPHOGENESIS 61 6.60E-12 7.29E-10 GOBP_CELLUAR_MACGMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 7.29E-10 GOBP_COSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_MEDAL_MOLECULE_CATABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_INEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.00E-09 GOBP_INEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.20E-09 GOBP_INEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_COLL_ORANIZATION 71 1.67E-11 1.37E-09 GOBP_NEGATIVE_REGULATION_OF_MOLECUL		46	3.54E-12	3.48E-10
GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION 42 4.78E-12 4.53E-10 GOBP_TUBE_MORPHOGENESIS 61 6.00E-12 6.17E-10 GOBP_REXTME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 68 7.89E-12 7.49E-10 GOBP_RESPONSE_TO_RADIATION 40 8.17E-12 7.46E-10 GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_FATTY_ACID_METABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_MED_TEXPECTOR_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 9.88E-10 GOBP_INTRACELLULAR_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.00E-09 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_REGULATION_OF_CREANELE_ORGANIZATION 71 1.67E-11 1.30E-09 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 71 1.67E-11 1.30E-09 GOBP_POSITIVE_REGULATION_OF_COLL_DEATH 64 1.56E-11 1.59E-09 GOBP_RESONSE_TO_UV 22 2.37E-11				
GOBP_TUBE_MORPHOGENESIS 61 6.60E-12 6.17E-10 GOBP_ENZTME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY 68 7.89E-12 7.29E-10 GOBP_RESPONSE_TO_RADIATION 40 8.17E-12 7.49E-10 GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_INTRACELLULAR_REGULATION_OF_CELL_DIFFERENTIATION 54 1.15E-11 1.988E-10 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_REGULATION_OF_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_RESONTWE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_RESPONSE_TO_UVID 64 1.56E-11 1.59E-09 GOBP_RESPONSE_TO_UVID 93 1.97E-11 1.59E-09 <td></td> <td></td> <td></td> <td></td>				
GOBP ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 68 7.89E-12 7.29E-10 GOBP RESPONSE_TO_RADIATION 40 8.17E-12 7.46E-10 GOBP GOBP CELULAR_MACGMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP GOBP_COSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP GOBP_FATTY_ACID_METABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_SCATTY_ACID_METABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.10E-09 GOBP_INEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.10E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION <				
GOBP_RESPONSE_TO_RADIATION 40 8.17E-12 7.46E-10 GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_POSITIVE_REGULATION_OF_INTRACELULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_MEDATIVY_ACID_METABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_MEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.00E-09 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_REGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_PHOSITIVE_REGULATION_OF_CORGANIZATION 71 1.67E-11 1.37E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 <				
GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS 73 9.32E-12 8.40E-10 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 65 1.01E-11 9.01E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_MEAD_DEVELOPMENT 54 1.15E-11 9.88E-10 GOBP_IEAD_DEVELOPMENT 54 1.15E-11 9.88E-10 GOBP_INTRACELULAR_PROTEIN_TRANSPORT 50 1.30E-11 1.20E-09 GOBP_REGULATION_OF_CELL_DATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DATH 64 1.56E-11 1.30E-09 GOBP_PHOSPHOLIPID_INETABOLIC_PROCESS 38 1.95E-11 1.39E-09 GOBP_PHOSPHOLIPID_INETABOLIC_PROCESS 38 1.95E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.88E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.88E-09 GOBP_RESPONSE_TO_UPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-08 GOBP_RES				
GOBP_FATTY_ACID_METABOLIC_PROCESS 37 1.12E-11 9.88E-10 GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_MEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 54 1.15E-11 9.88E-10 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_REGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 64 1.56E-11 1.30E-09 GOBP_REGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_PHOSPHOLIPID ORANIZATION 71 1.67E-11 1.37E-09 GOBP_PHOSPHOLIPID METABOLIC_PROCESS 38 1.95E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.59E-09 GOBP_ROBIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_RESPONSE_TO_UPENT 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09		73		
GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS 39 1.14E-11 9.88E-10 GOBP_HEAD_DEVELOPMENT 54 1.15E-11 9.88E-10 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.10E-09 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_REGULATION_OF_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_POSHOLIPID_METABOLIC_PROCESS 38 1.95E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.88E-08 GOBP_MEDIPICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 1.28E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 3.36E-11 2.48E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 3.36E-11 2.48E-09 3.36E-11 2.48E-09 <td></td> <td></td> <td></td> <td></td>				
GOBP_HEAD_DEVELOPMENT 54 1.15E-11 9.88E-10 GOOP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.10E-09 GOBP_INEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.20E-09 GOBP_INEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_NEDSPHOLIPID_METABOLIC_PROCESS 38 195E-11 1.37E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_NOSPHOLIPID_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 1.88E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 4.32E-09				
GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 50 1.30E-11 1.10E-09 GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_REGULATION_OF_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_PHOSPHOLIPID METABOLIC_PROCESS 38 1.95E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 1.88E-09 GOBP_RESPONSE_TO_LIPID GOBP_ARESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 3.64E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 3.64E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 4.32E-09 3.64E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09 3.64E-09 </td <td></td> <td></td> <td></td> <td></td>				
GOBP_INTRACELLULAR_PROTEIN_TRANSPORT 71 1.43E-11 1.20E-09 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_POSULATION_OF_ORGANELLE_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_RESULATION_OF_GRAGANELL_ORGANIZATION 71 1.67E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.88E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_RESPONSE_TO_LIPID 56 3.38E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 56 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 66 4.77E-11 3.64E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 64 1.56E-11 1.30E-09 GOBP_REGULATION_OF_RORANELLE_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_POSITIVE_REGULATION_OF_MOLECUL_ORGANIZATION 38 1.95E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_MOLPIPID_PERDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 1.88E-09 GOBP_MOLPIPID_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_MOLPIPID_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 GOBP_NETAROULC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_REGULATION_OF_ORGANIZATION 71 1.67E-11 1.37E-09 GOBP_PHOSPHOLIPID_IMETABOLIC_PROCESS 38 1.95E-11 1.59E-09 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.88E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_RESPONSE_TO_LIPID 58 3.38E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.48E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 4.36E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 93 1.97E-11 1.59E-09 GOBP_RESPONSE_TO_UV 22 2.37E-11 1.89E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_EMBRYO_DEVELOPMENT_ENDING IN BIRTH_OR_EGG_HATCHING 46 3.18E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.58E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 GOBP_NA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09	GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	71		
GOBP_RESPONSE_TO_UV 22 2.37E-11 1.88E-09 GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_RESPONSE_TO_LIPID 46 3.18E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.58E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 4.36E-09 GOBP_NA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 49 2.76E-11 2.17E-09 GOBP_EMBRYD_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING 46 3.18E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.58E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 66 4.77E-11 3.64E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 46 3.18E-11 2.48E-09 GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.58E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_RESPONSE_TO_LIPID 58 3.35E-11 2.58E-09 GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_RESPONSE_TO_NITROGEN_COMPOUND 68 4.77E-11 3.64E-09 GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_DNA_METABOLIC_PROCESS 61 5.71E-11 4.32E-09				
GOBP_REGULATION_OF_TRANSPORT 91 6.54E-11 4.89E-09	GOBP_DNA_METABOLIC_PROCESS		5.71E-11	4.32E-09
	GOBP_REGULATION_OF_TRANSPORT	91	6.54E-11	4.89E-09

Figure 95 Gene ontology analysis of genes downregulated in response to CD in

NIH3T3 cells by TTseq

Gene ontology analysis of genes downregulated by CD treatment in NIH3T3 cells by TTseq. FDR<0.05. Relates to Figure 34. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP_CYTOSKELETON_ORGANIZATION	203	7.16E-62	5.42E-58
GOBP_ACTIN_FILAMENT_BASED_PROCESS	146	1.57E-56	5.94E-53
GOBP_BIOLOGICAL_ADHESION GOBP_CELL_MOTILITY	201 225	2.95E-56 6.15E-56	7.45E-53 1.16E-52
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	223	6.69E-53	1.01E-49
GOBP_APOPTOTIC_PROCESS	229	2.89E-51	3.65E-48
GOBP_REGULATION_OF_CELL_DEATH	205	3.29E-47	3.55E-44
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS GOBP_CELL_MORPHOGENESIS	164 151	4.93E-46 1.15E-45	4.67E-43 9.69E-43
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	123		4.87E-42
GOBP_HOMEOSTATIC_PROCESS	211	1.16E-44	8.67E-42
GOBP_PROTEIN_PHOSPHORYLATION	191	1.31E-44	8.88E-42
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	191 155	2.69E-44 1.53E-43	1.67E-41 8.17E-41
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY	148	2.27E-42	1.13E-39
GOBP_CELL_POPULATION_PROLIFERATION	208	1.39E-41	6.50E-39
GOBP_RESPONSE_TO_WOUNDING	112	4.66E-41	2.05E-38
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_SIGNALING	184 191	6.58E-41 1.56E-40	2.73E-38 6.15E-38
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	182	3.43E-39	1.28E-36
GOBP_CELL_SUBSTRATE_ADHESION	81	6.41E-39	2.28E-36
	143	1.30E-38	4.22E-36
GOBP_WOUND_HEALING GOBP_REGULATION_OF_CELL_DIFFERENTIATION	98 179	1.40E-38 6.72E-38	4.37E-36 1.94E-35
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	151	6.74E-38	1.94E-35
GOBP_ACTIN_FILAMENT_ORGANIZATION	87	1.76E-37	4.89E-35
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	142	2.51E-37	6.70E-35
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	193	4.21E-37	1.08E-34
GOBP_REGULATION_OF_TRANSPORT GOBP_CELL_PROJECTION_ORGANIZATION	184 173	1.13E-36 1.68E-36	2.83E-34 4.05E-34
GOBP_MUSCLE_STRUCTURE_DEVELOPMENT	101	5.48E-36	1.28E-33
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	197	5.98E-36	1.36E-33
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	177	1.33E-35	2.93E-33
GOBP_NEGATIVE_REGULATION_OF_SIGNALING GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	160 177	3.38E-35 5.73E-35	7.23E-33 1.19E-32
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	180	3.76E-34	7.61E-32
GOBP_EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	79	5.62E-34	1.11E-31
GOBP_ANIMAL_ORGAN_MORPHOGENESIS	130	2.04E-33	3.91E-31
GOBP_TUBE_MORPHOGENESIS	120	5.94E-33	1.11E-30
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	155 147	6.09E-33 9.79E-33	1.11E-30 1.74E-30
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	154	2.06E-32	3.58E-30
GOBP_EPITHELIUM_DEVELOPMENT	144	1.93E-31	3.28E-29
GOBP_NEUROGENESIS	166	2.30E-31	3.82E-29
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	125 160	2.51E-31 4.36E-31	4.09E-29 6.93E-29
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	92	6.47E-31	1.01E-28
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	151	1.13E-30	1.72E-28
GOBP_RESPONSE_TO_GROWTH_FACTOR	103	2.16E-30	3.24E-28
GOBP_CELL_CELL_ADHESION GOBP_CELL_CELL_SIGNALING	113 165	1.32E-29 4.45E-29	1.93E-27 6.40E-27
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	132	5.39E-29	7.61E-27
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_DIFFERENTIATION	100	7.08E-29	9.82E-27
GOBP_CELL_ACTIVATION	151	9.63E-29	1.31E-26
GOBP_REGULATION_OF_RESPONSE_TO_STRESS GOBP_NEURON_DIFFERENTIATION	147 143	2.96E-28 4.28E-28	3.96E-26 5.62E-26
GOBP CELL CYCLE	145	4.75E-28	6.13E-26
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	117	9.95E-28	1.26E-25
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY	99	1.39E-27	1.73E-25
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION GOBP_CELL_MATRIX_ADHESION	126 54	1.73E-27 2.88E-27	2.12E-25 3.43E-25
GOBP_TRANSMEMBRANE_TRANSPORT	157	2.89E-27	3.43E-25
GOBP_VASCULATURE_DEVELOPMENT	102	3.55E-27	4.15E-25
GOBP_RESPONSE_TO_HORMONE	108	7.55E-27	8.69E-25
GOBP_EMBRYO_DEVELOPMENT GOBP_POSITIVE_REGULATION_OF_PROTEIN_PHOSPHORYLATION	116 104	9.52E-27 1.04E-26	1.08E-24 1.17E-24
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	113	1.95E-26	2.15E-24
GOBP_SECRETION	146	3.20E-26	3.46E-24
GOBP_REGULATION_OF_CELL_ADHESION	96		5.92E-24
GOBP_LIPID_METABOLIC_PROCESS	143		6.59E-24
GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	68 127	7.19E-26 8.80E-26	7.47E-24 9.02E-24
GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	118	1.20E-25	1.22E-23
GOBP_PROTEOLYSIS	165	1.33E-25	1.33E-23
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	134	1.52E-25	1.50E-23
GOBP_REGULATION_OF_ION_TRANSPORT GOBP_CELL_JUNCTION_ORGANIZATION	135 92	1.68E-25 4.67E-25	1.63E-23 4.46E-23
GOBP_SMALL_MOLECULE_METABOLIC_PROCESS	169	4.71E-25	4.46E-23
GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION	50	7.46E-25	6.98E-23
GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION	76	1.00E-24	9.26E-23
GOBP_NEURON_DEVELOPMENT GOBP_HEART_DEVELOPMENT	120 80	1.15E-24 1.73E-24	1.05E-22 1.56E-22
GOBP_COAGULATION	62	3.17E-24	2.82E-22
GOBP_POSITIVE_REGULATION_OF_CELL_DEATH	87	3.63E-24	3.19E-22
GOBP_MUSCLE_TISSUE_DEVELOPMENT	64	4.25E-24	3.70E-22
GOBP_RESPONSE_TO_CYTOKINE GOBP_TISSUE_MORPHOGENESIS	124	4.45E-24 8.90E-24	3.83E-22 7.57E-22
GOBP_TISSUE_MORPHOGENESIS GOBP_CATION_TRANSPORT	121	8.90E-24 1.19E-23	1.00E-21
GOBP_BLOOD_VESSEL_MORPHOGENESIS	88	1.22E-23	1.02E-21
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	111	2.01E-23	1.66E-21
GOBP_RESPONSE_TO_NITROGEN_COMPOUND	118	2.18E-23	1.77E-21
GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_CELLULAR_COMPONENT_MORPHOGENESIS	96 94	2.38E-23 2.38E-23	1.90E-21 1.90E-21
GOBP_CELLOLAR_COMPONENT_MORPHOGENESIS	74		2.18E-21
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION	121	2.87E-23	2.24E-21
GOBP_MAPK_CASCADE	104		2.43E-21
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	124	3.38E-23 4.80E-23	2.58E-21 3.63E-21
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	109		5.92E-21
	.52		

Figure 96 Gene ontology analysis of genes upregulated in response to LMB in

NIH3T3 cells by TTseq

Gene ontology analysis of genes upregulated by LMB treatment in NIH3T3 cells by TTseq. FDR<0.05. Relates to Figure 37B. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION	# Genes 300	-	6.61E-70
GOBP_CELEDEAR_MACROMOLECUEE_LOCALIZATION	264		1.15E-61
GOBP_MACROMOLECULE_CATABOLIC_PROCESS	231		4.33E-58
GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION	275		6.18E-56
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION_OR_REMOVAL	198	1	3.23E-53
GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS	198		6.93E-51
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	244		4.57E-48
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION	258		4.57E-48 3.03E-45
GOBP_PROTEIN_CATABOLIC_PROCESS GOBP_CELL_CYCLE	165	1	1.68E-44
GOBP_CELL_CICLE GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	196		8.06E-44
GOBP_REGULATION_OF_CATABOLIC_PROCESS	166		2.03E-42
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION	161		3.33E-42
GOBP_INTRACELLULAR_PROTEIN_TRANSPORT	179	1	8.78E-42
GOBP_LIPID_METABOLIC_PROCESS	200		1.05E-40
GOBP_SMALL_MOLECULE_METABOLIC_PROCESS	237		1.35E-40
GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS	142		4.59E-40
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	237		5.74E-38
GOBP POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS	3 227	1.76E-39	6.94E-37
GOBP PROTEIN LOCALIZATION TO ORGANELLE	154	2.33E-38	8.60E-36
GOBP_PROTEOLYSIS	220	2.41E-38	8.60E-36
GOBP_REGULATION_OF_CELLULAR_CATABOLIC_PROCESS	140	3.30E-38	1.12E-35
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	209	3.39E-37	1.10E-34
GOBP_CHROMOSOME_ORGANIZATION	173	4.78E-37	1.49E-34
GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCES			2.58E-34
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	215	1.78E-36	5.02E-34
GOBP_CELL_CYCLE_PROCESS	186	1.81E-36	5.02E-34
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	165		6.68E-34
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	202		1.26E-33
GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS	152		1.82E-33
GOBP_CELLULAR_LIPID_METABOLIC_PROCESS	155		1.88E-33
GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS	116		2.45E-32
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	197		6.50E-32
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	189		3.74E-31
GOBP_APOPTOTIC_PROCESS	219		6.97E-31
GOBP_PEPTIDYL_AMINO_ACID_MODIFICATION	167		1.67E-30
GOBP_PROTEIN_PHOSPHORYLATION	194		2.49E-30
	132		1.06E-29
GOBP_REGULATION_OF_CELLULAR_LOCALIZATION	126	1	1.87E-29
GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS	131		2.10E-29
GOBP_MITOTIC_CELL_CYCLE	145		2.43E-29
GOBP_REGULATION_OF_CELLULAR_PROTEIN_LOCALIZATION	100		5.66E-29
GOBP_CELLULAR_AMIDE_METABOLIC_PROCESS	157		5.66E-29
GOBP_REGULATION_OF_CELL_CYCLE	159		6.36E-29
GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION	141		7.92E-29
GOBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY	149		3.83E-28
GOBP_NCRNA_METABOLIC_PROCESS	93	1	4.59E-28
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	198		7.54E-28
GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS	91		2.04E-27
GOBP_AMIDE_BIOSYNTHETIC_PROCESS	128		2.08E-27
GOBP REGULATION OF TRANSFERASE ACTIVITY GOBP_CELL_PROJECTION_ORGANIZATION	139		3.18E-27
GOBP_CELL_FROMECTION_ORGANIZATION GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	146		1.07E-26 2.94E-26
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	140	1	7.18E-26
GOBP LIPID BIOSYNTHETIC PROCESS	112		7.49E-26
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	184		9.99E-26
GOBP REGULATION OF CELL DIFFERENTIATION	183		1.71E-25
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	131	1	2.08E-25
GOBP_PHOSPHOLIPID_METABOLIC_PROCESS	81		4.26E-25
GOBP_CHROMATIN_ORGANIZATION	117		9.13E-25
GOBP_MEMBRANE_ORGANIZATION	129		9.82E-25
GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS	96	1	3.81E-24
GOBP_MITOCHONDRION_ORGANIZATION	92		6.57E-24
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	164		6.57E-24
GOBP_REGULATION_OF_CELL_DEATH	182		7.78E-24
GOBP REGULATION OF PROTEIN PHOSPHORYLATION	148	1	9.88E-24
GOBP_REGULATION_OF_TRANSPORT	186	2.03E-25	2.26E-23
GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS	141		2.72E-23
GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	139	2.76E-25	2.99E-23
GOBP_CELL_POPULATION_PROLIFERATION	201		5.45E-23
GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS	104		7.25E-23
GOBP_MRNA_METABOLIC_PROCESS	119		1.20E-22
GOBP_NCRNA_PROCESSING	75	2.01E-24	2.06E-22
GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY	87		2.76E-22
GOBP_CYTOSKELETON_ORGANIZATION	157	5.03E-24	5.02E-22
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	158		9.36E-22
GOBP_NEGATIVE_REGULATION_OF_SIGNALING	157		4.11E-21
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	148		7.80E-21
GOBP_DNA_METABOLIC_PROCESS	121	1	8.07E-21
GOBP_NEUROGENESIS	171		8.79E-21
GOBP_HOMEOSTATIC_PROCESS	192		9.27E-21
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	173		2.00E-20
GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	102	1	2.04E-20
GOBP_REGULATION_OF_CELL_CYCLE_PROCESS	107		2.16E-20
GOBP_NUCLEAR_TRANSPORT GOBP_NEGATIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	66		2.39E-20
		5.73E-22	4.99E-20
	86		5.48E-20
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	113	6.37E-22	7007
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	113	6.37E-22 8.54E-22	
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION	113 153 92	6.37E-22 8.54E-22 1.12E-21	9.38E-20
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	113 153 92 123	6.37E-22 8.54E-22 1.12E-21 1.35E-21	9.38E-20 1.12E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	113 153 92 123 139	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21	9.38E-20 1.12E-19 1.23E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CALLSTRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_COVALENT_CHROMATIN_MODIFICATION	113 153 92 123 139 76	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.41E-21	9.38E-20 1.12E-19 1.23E-19 2.77E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_ORGANELLE_LOCALIZATION	113 153 92 123 139 76 93	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.41E-21 3.53E-21	9.38E-20 1.12E-19 1.23E-19 2.77E-19 2.84E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_COVALENT_CHROMATIN_MODIFICATION GOBP_ORGANELLE_LOCALIZATION GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY	113 153 92 123 139 76 93 105	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.41E-21 3.53E-21 4.12E-21	9.38E-20 1.12E-19 1.23E-19 2.77E-19 2.84E-19 3.28E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_RESOUNSE_TO_ABIOTIC_STIMULUS GOBP_ORGANELLE_LOCALIZATION GOBP_REGULATION_OF_FROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY	113 153 92 123 139 76 93 105 153	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.41E-21 3.53E-21 4.12E-21 5.45E-21	9.38E-20 1.12E-19 1.23E-19 2.77E-19 2.84E-19 3.28E-19 4.29E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_ORGANELLE_LOCALIZATION GOBP_ORGANELLE_LOCALIZATION GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REQULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_CATABOLIC PROCESS	113 153 92 123 139 76 93 105 153 68	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.41E-21 3.53E-21 4.12E-21 5.45E-21 6.63E-21	7.26E-20 9.38E-20 1.12E-19 2.77E-19 2.84E-19 3.28E-19 4.29E-19 5.15E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION GOBP_RESULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RNA_PROCESSING GOBP_ALCOHOL_METABOLIC_PROCESS	113 153 92 123 138 76 93 105 153 66 67	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.41E-21 3.41E-21 4.12E-21 5.45E-21 6.63E-21 6.68E-21	9.38E-20 1.12E-19 1.23E-19 2.77E-19 2.84E-19 3.28E-19 4.29E-19 5.15E-19 5.15E-19
GOBP NEGATIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II GOBP REGULATION OF MULTICELLULAR ORGANIZATION ORGANIZATION GOBP REGULATION OF CELL PROCECTION ORGANIZATION GOBP REGULATION OF ANTOMICAL STRUCTURE MORPHOGENESIS GOBP REGULATION OF ANTOMICAL STRUCTURE MORPHOGENESIS GOBP REGULATION OF ANTOMICAL STRUCTURE MORPHOGENESIS GOBP REGULATION OF ANTIN MODIFICATION GOBP GOBP ORGANELLE LOCALIZATION GOBP REGULATION OF PROTEIN KINASE ACTIVITY GOBP REGULATION OF PROTEIN CATABOLIC PROCESS GOBP REGULATION OF PROTEIN CATABOLIC PROCESS GOBP REGULATION OF PROTEIN CATABOLIC PROCESS GOBP RIGANELLE LOSENSE GOBP GOBOL METABOLIC	1113 155 92 122 135 93 93 93 100 155 66 67 111	6.37E-22 8.54E-22 1.12E-21 1.35E-21 1.50E-21 3.53E-21 3.53E-21 4.12E-21 5.45E-21 6.63E-21 6.68E-21 7.92E-21	9.38E-20 1.12E-19 1.23E-19 2.77E-19 2.84E-19 3.28E-19 4.29E-19 5.15E-19 5.15E-19 6.04E-19
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT GOBP_REGULATION_OF_CELL_PROLECTION_ORGANIZATION GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP_RNA_PROCESSING GOBP_RALCHULATION_OF_PROTEIN_CATABOLIC_PROCESS	113 153 92 123 138 76 93 105 153 66 67	6.37E-22 8.54E-22 1.12E-21 1.35E-21 3.41E-21 3.41E-21 4.12E-21 5.45E-21 6.63E-21 6.63E-21 7.92E-21 1.27E-20	9.38E-20 1.12E-19 1.23E-19 2.77E-19 2.84E-19 3.28E-19 3.28E-19 5.15E-19 5.15E-19

Figure 97 Gene ontology analysis of genes downregulated in response to LMB

treatment in NIH3T3 cells by TTseq

Gene ontology analysis of genes downregulated by LMB treatment in NIH3T3 cells by TTseq. FDR<0.05. Relates to Figure 37. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Canaa	e uslus	
GOBP ACTIN FILAMENT_BASED PROCESS	# Genes 50	1.88E-30	FDR q-value 1.42E-26
GOBP_CYTOSKELETON_ORGANIZATION	59		1.93E-23
GOBP_CELL_MOTILITY	66	1.61E-26	4.07E-23
GOBP_RESPONSE_TO_CYTOKINE	54		2.64E-22
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	51	1.99E-23	3.02E-20
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	40	1.03E-22	1.31E-19
GOBP_APOPTOTIC_PROCESS	62	2.00E-21	2.17E-18
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	47	4.47E-21	4.23E-18
GOBP_BIOLOGICAL_ADHESION	53	5.49E-21	4.62E-18
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	58	3.60E-20	2.72E-17
GOBP_REGULATION_OF_CELL_DEATH	54	1.40E-19	8.03E-17
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	45	1.53E-19	8.19E-17
GOBP_PROTEIN_PHOSPHORYLATION	53	2.29E-19	1.07E-16
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	49		2.97E-16
GOBP_POSITIVE_REGULATION_OF_SIGNALING	54	7.78E-19	3.23E-16
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	52	1.46E-18	5.74E-16
GOBP_WOUND_HEALING	31	2.70E-18	1.01E-15
GOBP_VASCULATURE_DEVELOPMENT	36		3.04E-15
GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION	40	1.10E-17	3.74E-15
GOBP_RESPONSE_TO_WOUNDING	33		4.16E-15
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	40	1.49E-17	4.66E-15
GOBP_REGULATION_OF_ACTIN_FILAMENT_ORGANIZATION	23		6.73E-15
GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS	26	5.21E-17	1.50E-14
GOBP_RESPONSE_TO_BIOTIC_STIMULUS	49		3.05E-14
GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION	40	1.42E-16	3.79E-14
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	54		4.56E-14
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	30	2.67E-16	6.52E-14
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	42		6.52E-14
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	38	3.31E-16	7.74E-14
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	38		1.18E-13
GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION	19	6.05E-16	1.33E-13
GOBP_MUSCLE_STRUCTURE_DEVELOPMENT	30	7.17E-16	1.53E-13
GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND	36	7.38E-16	1.53E-13
GOBP_CYTOKINE_MEDIATED_SIGNALING_PATHWAY	34		1.53E-13
GOBP_RESPONSE_TO_VIRUS	24	8.05E-16	1.58E-13
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	48	8.54E-16	1.64E-13
GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION	24	1.68E-15	3.14E-13
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	46	1.75E-15	3.20E-13
GOBP_POSITIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION	36	2.27E-15	4.05E-13
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	47	2.63E-15	4.57E-13
GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION	27	4.08E-15	6.94E-13
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_MET	50	7.08E-15	1.18E-12
GOBP_CELL_SUBSTRATE_ADHESION	23	8.62E-15	1.40E-12
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	39	1.08E-14	1.68E-12
GOBP CELL CELL ADHESION	34	1.08E-14	1.68E-12
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	48		1.83E-12
GOBP_RESPONSE_TO_GROWTH_FACTOR	31	1.47E-14	2.20E-12
GOBP_CELL_MORPHOGENESIS	36	1.61E-14	2.36E-12
GOBP_TUBE_DEVELOPMENT	37	3.13E-14	4.50E-12
GOBP_CELL_ACTIVATION	43	3.49E-14	4.88E-12
GOBP_REGULATION_OF_TRANSPORT	47	3.68E-14	5.01E-12
GOBP_CELLULAR_COMPONENT_MORPHOGENESIS	31	5.11E-14	6.83E-12
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION	50	5.47E-14	7.18E-12
GOBP BLOOD VESSEL MORPHOGENESIS	29	8.46E-14	1.09E-11
GOBP ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY	36	1.13E-13	1.43E-11
GOBP REGULATION OF ANATOMICAL STRUCTURE SIZE	25	1.16E-13	1.43E-11
GOBP_TUBE_MORPHOGENESIS	33	1.17E-13	1.43E-11
GOBP RESPONSE TO OXYGEN CONTAINING COMPOUND	45	1.31E-13	1.58E-11
GOBP_EPITHELIUM_DEVELOPMENT	39	1.85E-13	2.20E-11
GOBP NEGATIVE REGULATION OF RESPONSE TO STIMULUS	45	1.95E-13	2.28E-11
GOBP_IMMUNE_EFFECTOR_PROCESS	39	3.07E-13	3.53E-11
GOBP AMEBOIDAL TYPE CELL MIGRATION	24	3.59E-13	4.07E-11
GOBP_CELL_PROJECTION_ORGANIZATION	43	3.68E-13	4.11E-11
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	37	3.90E-13	4.29E-11
GOBP_DEFENSE_RESPONSE	46	5.04E-13	5.47E-11
GOBP_REGULATION_OF_CELL_ADHESION	29		6.30E-11
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	33		6.59E-11
GOBP_TISSUE_MORPHOGENESIS	27	7.24E-13	7.52E-11
GOBP_NEGATIVE_REGULATION_OF_SIGNALING	40	9.28E-13	9.51E-11
GOBP_CELL_JUNCTION_ORGANIZATION	28		1.17E-10
GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION	48	1.22E-12	1.21E-10
GOBP_REGULATION_OF_CELLULAR_COMPONENT_SIZE	21		1.32E-10
GOBP_ACTIN_FILAMENT_BUNDLE_ORGANIZATION	15	1.44E-12	1.40E-10
GOBP_POSITIVE_REGULATION_OF_CYTOSKELETON_ORGANIZATION	17	1.46E-12	1.40E-10
GOBP_NEURON_DEVELOPMENT	34	6.95E-12	6.58E-10
GOBP POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION	34		
GOBP_RESPONSE_TO_HORMONE	30	8.86E-12	8.18E-10
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_DIFFERENTIATION	27		1.35E-09
GOBP_NEUROGENESIS	41	1.51E-11	1.36E-09
GOBP_HOMEOSTATIC_PROCESS	45		1.58E-09
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	35	1.90E-11	1.67E-09
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS	36		1.74E-09
	30	2.37E-11	2.04E-09
GOBP_MAPK_CASCADE	43		2.19E-09
GOBP_MAPK_CASCADE GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS			3.20E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	33		3.28E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND	33		
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS	33 40	3.95E-11	
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE	33 40 25	3.95E-11 6.02E-11	4.95E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_PROFILN_LOCALIZATION_TO_MEMBRANE GOBP_REGULATION_OF_CELL_DIFFERENTIATION	33 40 25 40	3.95E-11 6.02E-11 6.28E-11	4.95E-09 5.11E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_ROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_TISSUE_MIGRATION	33 40 25 40 19	3.95E-11 6.02E-11 6.28E-11 7.08E-11	4.95E-09 5.11E-09 5.69E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_TISSUE_MIGRATION GOBP_CELL_CELL_JUNCTION_ORGANIZATION	33 40 25 40 19 15	3.95E-11 6.02E-11 6.28E-11 7.08E-11 8.79E-11	4.95E-09 5.11E-09 5.69E-09 7.00E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_RROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_TISSUE_MIGRATION GOBP_TIL CELL_JUNCTION_ORGANIZATION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	33 40 25 40 19 15 35	3.95E-11 6.02E-11 6.28E-11 7.08E-11 8.79E-11 1.09E-10	4.95E-09 5.11E-09 5.69E-09 7.00E-09 8.58E-09
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_RROTEIN_LOCALIZATION TO_MEMBRANE GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_TISSUE_MIGRATION GOBP_CELL_CELL_JUNCTION_ORGANIZATION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_ACTIN_POLYMERIZATION_OR_DEPOLYMERIZATION	33 40 25 40 19 15 35 15	3.95E-11 6.02E-11 6.28E-11 7.08E-11 8.79E-11 1.09E-10 1.31E-10	4.95E-09 5.11E-09 5.69E-09 7.00E-09 8.58E-09 1.02E-08
COBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_RESUL_MICRATION GOBP_CELL_CELL_JUFFERENTIATION GOBP_CELL_CELL_JUNCTION_ORGANIZATION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_REGULATION_OF_CELL_ADHERIZATION GOBP_REGULATION_OF_CELL_ADHERION	33 40 25 40 19 15 35 15 20	3.95E-11 6.02E-11 6.28E-11 7.08E-11 8.79E-11 1.09E-10 1.31E-10 1.32E-10	4.95E-09 5.11E-09 5.69E-09 7.00E-09 8.58E-09 1.02E-08 1.02E-08
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_TISSUE_MIGRATION GOBP_CELL_CELL_JUNCTION_ORGANIZATION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_ACTIN_POLYMERIZATION_OR_DEPOLYMERIZATION GOBP_ACTIN_FOLYMERIZATION_OF_CELL_ADHESION GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION	33 40 25 40 19 15 35 15 20 15	3.95E-11 6.02E-11 6.28E-11 7.08E-11 8.79E-11 1.09E-10 1.31E-10 1.32E-10 1.59E-10	4.95E-09 5.11E-09 5.69E-09 7.00E-09 8.58E-09 1.02E-08 1.02E-08 1.21E-08
COBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_IMMUNE_SYSTEM_PROCESS GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_RESUL_MICRATION GOBP_CELL_CELL_JUFFERENTIATION GOBP_CELL_CELL_JUNCTION_ORGANIZATION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_REGULATION_OF_CELL_ADHERIZATION GOBP_REGULATION_OF_CELL_ADHERION	33 40 25 40 19 15 35 15 20	3.95E-11 6.02E-11 6.28E-11 7.08E-11 8.79E-11 1.09E-10 1.31E-10 1.32E-10 1.59E-10 1.64E-10	4.95E-09 5.11E-09 5.69E-09 7.00E-09 8.58E-09 1.02E-08 1.02E-08

Figure 98 Gene ontology analysis of genes upregulated in response to CD

treatment in dKO^{MRTF} cells by RNAseq

Gene ontology analysis of genes upregulated by CD treatment in dKO^{MRTF} cells by RNAseq. FDR<0.05. Relates to Figure 44. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP_LOCOMOTION	120	1.04E-49	7.75E-46
GOBP_CELL_MIGRATION	104		9.05E-42
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT GOBP_NEUROGENESIS	82 97	7.38E-40 2.31E-39	1.84E-36 4.32E-36
GOBP_REGULATION_OF_CELL_DIFFERENTIATION	93	4.02E-36	6.02E-33
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	82		6.91E-32
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	83	3.60E-33	3.85E-30
	81	1.69E-32	1.58E-29
GOBP_ANIMAL_ORGAN_MORPHOGENESIS GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	70 87	1.29E-31 1.71E-31	1.07E-28 1.28E-28
GOBP_CELL_POPULATION_PROLIFERATION	95	3.77E-31	2.56E-28
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	71	1.36E-29	8.50E-27
GOBP_TUBE_DEVELOPMENT	69	2.66E-29	1.53E-26
GOBP_BIOLOGICAL_ADHESION	80	3.66E-29	1.85E-26
GOBP_CELL_CELL_SIGNALING	85	3.71E-29	1.85E-26
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY GOBP_CELL_PROJECTION_ORGANIZATION	67 80	5.07E-28 1.53E-27	2.37E-25 6.73E-25
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	74		7.93E-24
GOBP_RESPONSE_TO_GROWTH_FACTOR	54	4.10E-26	1.62E-23
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	80	1.07E-25	4.02E-23
GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION	57	1.44E-25	5.12E-23
GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS GOBP_NEURON_DEVELOPMENT	75 64	6.28E-25 6.82E-25	2.14E-22 2.22E-22
GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	63	2.98E-24	9.29E-22
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	78	3.72E-24	1.11E-21
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	60	4.30E-24	1.24E-21
GOBP_GROWTH	57	5.31E-24	1.47E-21
GOBP_EMBRYO_DEVELOPMENT	59	1.22E-23	3.25E-21
GOBP_POSITIVE_REGULATION_OF_SIGNALING GOBP_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_INVOLVED_IN_CELL_CELL_SIGNALING	78	1.53E-23 1.64E-23	3.94E-21 4.10E-21
GOBP_TUBE_MORPHOGENESIS	56	2.09E-23	5.04E-21
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	79	2.69E-23	6.29E-21
GOBP_CELL_CELL_SIGNALING_BY_WNT	43	4.61E-23	1.05E-20
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	74		2.06E-20
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II GOBP_HEART_DEVELOPMENT	63	9.79E-23	2.09E-20 2.51E-20
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	44 54	1.21E-22 1.68E-22	2.51E-20 3.40E-20
GOBP REGULATION OF PROTEIN MODIFICATION PROCESS	74	1.73E-22	3.41E-20
GOBP_SKELETAL_SYSTEM_DEVELOPMENT	41	3.31E-22	6.34E-20
GOBP_ACTIN_FILAMENT_BASED_PROCESS	51		8.17E-20
GOBP_DEVELOPMENTAL_GROWTH	45	5.08E-22	9.27E-20
GOBP_CELL_MORPHOGENESIS	57	6.85E-22	1.22E-19
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	78 80	1.34E-21 1.98E-21	2.34E-19
GOBP_NEGATIVE_REGULATION_OF_LICOMOTION	36		3.36E-19 3.60E-19
GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION	45	2.25E-21	3.66E-19
GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	54	2.91E-21	4.64E-19
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	54	1.17E-20	1.83E-18
GOBP_VASCULATURE_DEVELOPMENT	49	1.29E-20	1.97E-18
GOBP_CELLULAR_COMPONENT_MORPHOGENESIS GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	48		3.95E-18
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	71	3.40E-20 4.02E-20	4.98E-18 5.79E-18
GOBP_CELL_PART_MORPHOGENESIS	45	4.87E-20	6.87E-18
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	58		8.29E-18
GOBP_OSSIFICATION	35	1.23E-19	1.68E-17
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	72	1.58E-19	2.11E-17
GOBP_PROTEIN_PHOSPHORYLATION GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY	69 33	1.63E-19 3.09E-19	2.14E-17 3.98E-17
GOBP CELL GROWTH	37	4.13E-19	5.23E-17
GOBP_EPITHELIUM_DEVELOPMENT	60		6.34E-17
GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM	39	5.61E-19	6.88E-17
GOBP_APOPTOTIC_PROCESS	75		9.02E-17
GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION GOBP_NEGATIVE_REGULATION_OF_SIGNALING	43	7.62E-19	9.02E-17
GOBP_NEGATIVE_REGULATION_OF_SIGNALING GOBP_APPENDAGE_DEVELOPMENT	63 24	7.71E-19 8.59E-19	9.02E-17 9.88E-17
GOBP TISSUE MORPHOGENESIS		9.16E-19	1.04E-16
GOBP_APPENDAGE_MORPHOGENESIS	22	1.28E-18	1.43E-16
GOBP_CIRCULATORY_SYSTEM_PROCESS	41		1.59E-16
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION	40	1.48E-18	1.60E-16
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION GOBP_HEAD_DEVELOPMENT	40		2.26E-16 2.37E-16
GOBP_READ_DEVELOPMENT GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_DIFFERENTIATION	45		3.35E-16
GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT	51	4.46E-18	4.57E-16
GOBP_EMBRYONIC_MORPHOGENESIS	39	5.28E-18	5.33E-16
GOBP_UROGENITAL_SYSTEM_DEVELOPMENT	30		8.34E-16
	34		8.76E-16
GOBP_BLOOD_VESSEL_MORPHOGENESIS GOBP_REGULATION_OF_GROWTH	42		9.44E-16 9.44E-16
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	61	1.06E-17	1.00E-15
GOBP_NEGATIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION	44		1.30E-15
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	56	1.82E-17	1.69E-15
	31		1.91E-15
GOBP_AMEBOIDAL_TYPE_CELL_MIGRATION GOBP_CELL_JUNCTION_ORGANIZATION	35	2.67E-17	2.40E-15 2.73E-15
GOBP_CELL_JUNCTION_ORGANIZATION GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT	42		2.73E-15 3.84E-15
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	53		4.37E-15
GOBP_CYTOSKELETON_ORGANIZATION	59		7.28E-15
GOBP_EMBRYONIC_APPENDAGE_MORPHOGENESIS	19	1.54E-16	1.31E-14
	25		1.36E-14
GOBP_AXON_DEVELOPMENT	35		1.88E-14
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	49 56		2.27E-14 2.94E-14
GOBP EXTERNAL ENCAPSULATING STRUCTURE ORGANIZATION	31	3.86E-16	3.11E-14
GOBP_RESPONSE_TO_LIPID	45		3.70E-14
GOBP_REGULATION_OF_CELL_DEATH	64	5.15E-16	4.05E-14
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	61		4.45E-14
GOBP_DEVELOPMENTAL_GROWTH_INVOLVED_IN_MORPHOGENESIS	24	9.12E-16	7.03E-14
GOBP_SYNAPSE_ORGANIZATION GOBP_NEURON_PROJECTION_GUIDANCE	31 26	1.16E-15 1.41E-15	8.83E-14 1.07E-13
GOBP_CANONICAL_WNT_SIGNALING_PATHWAY	28	1.41E-15 1.74E-15	1.30E-13

Figure 99 Gene ontology analysis of genes downregulated in response to CD

treatment in dKO^{MRTF} cells by RNAseq

Gene ontology analysis of genes downregulated by CD treatment in dKO^{MRTF} cells by RNAseq. FDR<0.05. Relates to Figure 44. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GODE ACC PERSIANTIAN Site 197 7.252-10 GODE CONTROL FOR CALLATION OF AUGLE FORMAL CONTROL OF CAMPAGE AUGLE PROCESS 227 5.851-10 7.252-10 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 227 5.852-10 7.252-10 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 227 5.852-10 7.252-10 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 227 5.852-10 7.252-10 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 277 7.852-80 7.252-80 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 278 7.852-80 7.252-80 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 278 7.852-80 7.252-80 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 278 7.852-80 7.252-80 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 278 7.452-80 7.252-80 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS 278 7.452-80 7.452-80 GODE POSITIVE SEGULATION OF AUGLE FORMAL TARGETS FORMAL TARGETS 278 7	GO BIOLOGOCAL PROCESS	# Genes	n-value	DR g-value
Goop P. CONSELETON, DEPARAMONINO 100 100.1 <				5.11E-130
GORP _ DOTATE_ RESOLUTION_OF_NUCLEORAGE_CONTINUNG_COMPONED_RETABLE_PROCESS 27 0.987 0.	GOBP_CYTOSKELETON_ORGANIZATION	306	1.93E-129	7.32E-126
OODP, PORTWE, REGULATION, OF MULTICELLURA, ORGANISMAL, PROCESS 321 5.086-108 7.77 1.46 1.126	GOBP_NEUROGENESIS	321	1.02E-118	2.56E-115
CORP_NEDRING_PERSIMATION OF DESIGNMENTIA_PROCESS 277 1.44-10.1 1.45-10.1 1.45-10.1 1.45-10.1 1.45-10.1 255-10.				1.21E-106
CORP_PORTNE_REQUARTNO, PD EXELOPMENTAL_PROCESS 281 315 13155 1315 1315 13				7.67E-103
CORP. POSITIVE, REGULATION, OF, BIOSYNTHETC, PROCESS 325 1316-101 1246-9 CORP. CELL, CIVIL 337 2375-30 2385-8 CORP. REGULATION DIMUTCELLUAR, ORGANISMAL, DEVELOPMENT 246 456-65 2385-8 CORP. REGULATION DIMUTCELLUAR, ORGANISMAL, DEVELOPMENT 276 436-55 2385-8 CORP. REGULATION DIMUTCELLUAR, ORGANISMAL, DEVELOPMENT 276 2485-80 436-55 CORP. REGULATION DIMUTCELLUAR, ORGANISMAL, DEVELOPMENT 276 2485-80 436-55 CORP. REGULATION OF MILCITCELLUAR, ORGANISMAL, DEVELOPMENT 247 2485-80 2385-80 246 466-76 2385-80 246 466-76 2385-80 246 466-76 2385-80 246 466-76 2385-80 246 466-76 2385-80 246 466-76 2385-76 2385-76 2385-76 2385-76 2385-76 2385-76 2385-76 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-77 2385-				
068P_CELL_VICLE 317 228F-101 2285-01 058P_CELL_VICLE 315 3267-01 4486-8 058P_ESEL_PROJECTION, GRANUEDALO P/ELOPMENT 244 4386-85 2386-8 058P_ESEL_PROJECTION, GRANUEDALO P/ELOPMENT 226 4386-85 2386-8 058P_ESEL_PROJECTION, GRANUEDALO P/ELOPMENT 226 4386-87 2386-8 058P_ESEL_PROJECTION, GRANUEDALO P/ELOPMENT 220 446-56 446-56 058P_ESEL_PROJECTION, GRANUEL GRANUEDATION 221 446-56 446-56 058P_ESEL_PROJECTION, GRANUEL GRANUEDATION 221 446-56 446-56 058P_ESEL_ADMON CONCENCIA STIMULIS 241 446-56 446-56 058P_ESEL_ADMON CONCENCIA STIMULIS 241 446-57 436-57 058P_ESEL_ADMON CONCENCIA STIMULIS 445-57 436-57 436-57 058P_ESEL_ADMON CONCENCIA STIMULIS				
060P CELL MORTANO 311<558-101				
060P. CELL MIGRATION 287 7915 98 7386 98				
GORP_REGULATION OF MULTICALLULAR_ORGANISMA_DEVELOPMENT 284 4.366.69 328.69 GORP_REGULATION OF MULTICALUNAR_ORGANISMA_DEVELOPMENT 265 338.66 338.66 GORP_REGULATION OF MULTICALUNAR_ORGANISMA 276 438.66 338.66 GORP_RESTORE, TO_REDOCENSIS 276 438.66 338.67 GORP_RESTORE, TO_REDOCENSIS 276 438.66 328.67 GORP_RESTORE, TO_REDOCENSIS 276 438.66 328.67 GORP_RESTORE, TO_REDOCENSIS 276 438.67 338.77 GORP_RESTORE, REQUIREDOCENSIS 276 338.77 338.77 GORP_RESTORE, SCHARDAN, OF INTRA SCHARDAN, DEVELOPMENT 276 338.77 338.77 GORP_REGULATION, OF INTRA SCHARDAN, DEVELOPMENT 276 338.77 338.77 338.77 338.77 338.77 338.77 338.77 338.77 338.77 338.77 <				7.39E-95
GORP_ ECL, PROJECTION, DERMANZATION 276 30672 29584 GORP_ NELIG, DARLE CAMENT 201 776 4116 GORP_ CLL, MORPHOORNESIS 271 2065-00 4116 GORP_ CLL, MORPHOORNESIS 271 2065-00 2958-00 GORP_ RESIGNES 271 2065-00 2958-00 GORP_ RESIGNES 270 2065-00 2069-00 GORP_ RESIGNES 270 2065-00 2069-00 GORP_ RESIGNES 270 3016-7 3016-7 GORP_ REGULATION CF FORDER RESIGNES 270 3016-7 GORP_ REGULATION CF FORDER RESIGNES 281				3.26E-92
GORP NULLION DEVILOPMENT 220 57.65-21 421.65 GORP BILLIONAL ADHESION 227 420.67 55.65 GORP DESCRIPTION ENDOGRNOUS STATULUS 221 420.67 55.65 GORP TREE LAND OF CREALATION 221 54.62 51.65 GORP TREE LAND OF CREALATION 221 54.62 51.65 GORP TREE LAND OF CREALATION 221 54.62 51.65 GORP TREE LAND OF CREALATION OF CREALURAR COMPONENT CREANAGATION 221 54.62 51.65 GORP TREE LAND OF CREANAGATION OF CREANAGATION 221 54.62 51.65 51.65 GORP CREALLAND OF PROCESS 221 55.67 51.65 51.67 51.65 GORP CRELLAND OF MARCHERANCE DEPROCESS 220 55.67 71.67 51.67 GORP RELLAND OF MARCHERANCE SOLE OF CREAL AND ADD OF TREAL COMPONENT 220 55.67 71.67 71.67 GORP RELLAND OF CRELLAND ADD EXCLOPMENT 220 57.67 71.67 71.67 71.67 71.67 71.67 71.67 71.67 71.67 71.67 71.67 71.67				2.93E-89
GRP_BIOLOGICAL_ADDESION 287 7.024-00 4.025.8 GORD_CELL_ADDECOGENESS 217 1.024-07 4.025.8 GORD_FECLLANTOLOF_DORABELE_CREATESTON 218 4.025.8 1.025.6 GORD_FECLLANTOLOF_DORABELE_CREATESTON 218 4.025.8 1.025.6 GORD_FEGULATECOLORABELE_CREATESTON 221 4.026.9 1.055.7 GORD_FEGULATECOLORABELE_CREATESTON 221 4.026.9 1.055.7 GORD_FEGULATECOLORABELE_CREATESTON 221 4.026.9 1.057.7 GORD_FEGULATECOLORABELE_CREATESTON 221 4.026.9 1.057.7 GORD_FEGULATECOLORADESTON 221 4.027.7 1.057.7 GORD_FEGULATECOLORADESTON 224 3.027.7 1.057.7 GORD_FEGULATECOLORADESTON 224 3.027.7 1.057.7 GORD_FEGULATECOLORADESTON 221 3.027.7 1.057.7				4.21E-88
GOBP 221 4.628-67 232.6 GOBP REQUIATOR COMPACT 221 5.627.6 0.184.2 GOBP REQUIATOR CREQUIATOR CREQUIATOR 221 5.627.6 0.184.2 GOBP REQUIATOR CREQUIATOR CREQUIATOR 221 5.627.6 0.184.7 GORP REQUIATOR CREQUIATOR CREQUIATOR 226.7 0.185.7 GORP CREQUIATOR CREQUIATOR CREQUIATOR 221 5.627.7 3.185.7 GORP CREQUIATOR CREQUIATOR CREQUIATOR 221 5.916.7 1.816.7 GORP CREQUIATOR CREQUIATOR 220 3.136.77 1.816.7 GORP CREQUIATOR CREQUIATOR 220 3.136.77 1.816.7 GORP CREQUIATOR CREQUIATOR 220 3.136.77 1.816.7 GORP CREQUIATOR CREQUIATOR 221 1.416.7 1.816.7 GORP CREQUIATOR CREQUIATOR CREQUIATOR 1.816.7				4.02E-87
OGP RESPONSE TO, ENDOCRAUG, STIMULUS 224 4.284-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-58 6.184-59 6.185-79 6.087-78 6.087-78 6.087-78 6.087-78 6.087-78 7.187-79 3.182-77 3.182-7	GOBP_CELL_MORPHOGENESIS	217	2.98E-89	1.49E-86
GORP PODE DUPK REGULATION C. CELLULAR, COMPONENT, ORGANIZATION 221 5.428-83 2288-85 GORP TUDE DUPK REGULATION C.F. INSTRUME DE MONTANIS	GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	274	6.26E-87	2.93E-84
GORP TUBE, DEVELOPMENT 144 4.00-800 1455-75 GORP MEGNINE, DEROLIATION, OF BIOWNINETIC, PROCESS 280 10.852-79 3.012-75 GORP MEGNINE, DEROLIATION, OF BIOWNINETIC, PROCESS 240 2447-74 1242-75 GORP CELL, ONC, EPROCESS 243 2447-74 1242-75 GORP CELL, ONC, DENOLFINO, EPROCESS 224 4262-76 1355-77 GORP CELL, ONC, DENOLFINO, EPROCESS 226 4262-76 1355-77 GORP CELL, ONC, DENTERT, LAURA, SIGNIT, TRANSDUCTION 226 3354-77 145-75 GORP MEGNITE, GELL, DERULATION, ENCLEDRA, FUNCTION 226 3354-77 145-75 GORP MOTION, CELL, ONCLE 200 3354-77 145-75 GORP ANTE, REGULATION, OF FORDERS 217 146-75 1365-76 GORP ANTE, REGULATION, OF FORDERS 216 2352-74 1365-76 GORP ANTE, REGULATION, OF FORDERS 217 1464-75 1365-76 GORP ANTE, REGULATION, OF FORDERS 217 1474-73 1365-76 GORP ANTE, REGULATION, OF FORDERS 217 1474-73 1456-77 GORP	GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	229	1.40E-85	6.18E-83
GORP INCREMENT OF DISCHATTER PROCESS 280 108E-79 407E-7 GORP EXAMEL INCRE DECEPTOR POTENTS SIGNALIDO PROCESS 281 9.71E-29 31E-7 GORP EXEMPLE LINE DECEPTOR POTENTS SIGNALIDO PROCESS 281 9.71E-29 31E-7 GORP ERELLATION C.P. INCLECOASE CONTAINING COMPOUND METABOLIC PROCESS 224 40E-78 14E-77 GORP INEGATIVE, REGULTION, C.P. INCLECOASE CONTAINING COMPOUND METABOLIC PROCESS 224 40E-78 14E-77 GORP INEGATIVE, REGULTION, C.P. INCLECOASE CONTAINING COMPOUND METABOLIC PROCESS 226 44E-78 15E-77 14E-77 14				2.25E-80
GORP BLYME, LINED, RECEPTOR, FROTEN, SONALING, PATHWAY 211 6.857-70 316-7. GORP REGULTION OF PHOSPHORESIS 241 2.447-70 316-7. GORP CELL, OYGE, PROCESS 241 2.447-70 316-7. GORP CELL, OYGE, PROCESS 242 2.447-70 316-7. GORP CELL, OYGE, PROCESS 226 346-70 136-7. GORP CELL, POPULATION, PROLIEERATION 276 436-7.7 446-7. GORP CELL, POPULATION, PROLIEERATION 276 326-7.6 176-7. GORP CENTRUE, CANCECULAR, RUNCINN, TANUSCUETON 271 326-7.6 136-7. GORP ACTIN, FLAMENT, BASED, PROCESS 266 266-7.6 136-7. GORP ACTIN, FLAMENT, MOSENTH, TOYONKINT 210 326-7.6 136-7. GORP ACTIN, FLAMENT, MOSENTH, MOVENTY 210 346-7.0 146-7.7 GORP ACTIN, PLANENT, MORPHORENSIS 267 118-7.5 146-7.7 GORP ACTIN, PLANENT, MORPHORENSIS 267 118-7.6 146-7.7 GORP ACTIN, PLANENT, MORPHORENSIS 267 118-7.6 146-7.7 GORP ACTIN, PLANENT, MORPHORENSIS<				
GORP RECULATION OF PROCESS 261 9.716-79 3.266-7 GORP CELL CYCLE PROCESS 243 2.466-78 8.226-7 GORP CELL CYCLE PROCESS 243 2.466-78 8.226-7 GORP CELL CYCLE PROCESS 243 2.466-78 9.262-7 GORP REQUATION OF INTRACELULAR SCIANL_TRANSDUCTON 274 1.686-77 4.716-7 GORP REQUATION OF INTRACELULAR SCIANL_TRANSDUCTON 200 3.186-77 4.716-7 GORP ACCULATOR SYSTEM DEVELOPMENT 216 3.186-77 4.716-7 GORP ACCULATOR OF INTRACELULAR SCIANL_TRANSDUCTON 200 3.186-77 4.716-7 GORP ACCULATOR OF INTRACELULAR SCIANL TRANSDUCTON 200 3.186-77 4.716-7 GORP ACCULATOR OF INTRACELULAR SCIANL TRANSDUCTON 200 3.186-77 4.716-7 GORP ACCULATOR OF INTRONON CONCENT WOVEMENT 201 7.866-70 1.936-7 GORP ACCULATOR OF INCONTON NOVECES 210 7.416-71 5.346-70 GORP ACCULATOR OF ORDICONTON PROCENSIS 212 4.666-70 2.586-70 GORP ACCULATOR OF ORDICONTON PROCENSIS 218 4.666-70 2.586-70				4.07E-77
0GPP CELL CYCLE PROCESS 241 244.7.8 9582-7. 0GPP CELL CYCLE PROCESS 178 9582-7. 9582-7. 0GPP CELL CYCLE PROCESS 221 4.02.7.8 9582-7. 0GPP REQUITION OF INTROCTINUA SIGNAL TRANSUCTION 221 4.02.7.8 9582-7. 0GPP REQUITION OF INTROCTINUA SIGNAL TRANSUCTION 228 4.02.7.8 158-7.7 0GPP REQUITION OF INTROCTINUA SIGNAL TRANSUCTION 228 2.44.7.8 158-7.7 0GPP REQUITION OF INTROCTION OF MOLECULAR LINKTION 228 2.44.7.8 158-7.7 158-7.7 0GPP REQUITION OF MOLECULAR LINKTION 228 2.44.7.8 158-7.7 158-7.7 0GPP ADDETIN ADDISTION OF MODERATION PROCESS 271 2.415.4 4.885-7.7 158-7.7 0GPP REQUITION OF ANOTHADING MORPHOLENESIS 272 2.415.4 4.885-7.7 158-7.8 158-7.8 158-7.7 158-7.8 158-7.7 158-7.8 158-7.7 158-7.8 158-7.7 158-7.8 158-7.7 158-7.7 158-7.7 158-7.7 158-7.7 158-7.7 158-7.7 158-7.7 158-7.7 158-7.7				
GORP COLUMAR COMPONENT MORPHOGENESIS 178 3025-78 3025-78 1325-77 GORP MEGATINE REQUILATION PROLIEPENTION 2211 6425-78 1325-77 4485-77 GORP MEGATINE REQUILATION PROLIEPENTION 2211 6425-77 4485-77 GORP MEGATINE REQUILATION PROLIEPENTION 2201 6425-77 4485-77 GORP METOTIC CELL CYCLE 6008-77 7415-75 6008-76 6135-77 GORP PROTINE REQUILATION OF MOLECULAR FUNCTION 220 5456-76 6135-75 GORP PROTINE REQUILATION OF CELL CARCUPANTINO MOVEMENT 210 7416-73 4362-75 GORP PROTINE REQUILATION OF CELL CARCUPANTINO 2007 7416-73 4362-72 1466-60 GORP PROTINE REQUILATION OF AMATOMINIA PROCEESIS 227 7416-73 4362-72 1466-60 2356-70 4326-72 1466-60 2356-70 4326-82 2466-64 1356-66 2356-70 4326-82 2466-64 1356-66 2466-64 1356-66 2366-65 2366-67 2366-65 2366-65				
CORP MICRATURE REGULATION OF MUCLEORARS CONTAINING COMPOUND METABOLIC, PROCESS 222 4.627.47 138.77 CORP CELL DARVIATION INCO MITTAGE.LULAR, SANAL, TRANSDUCTION 226 138.77 741.57 CORP MICTIO, COLL, OYCLE 200 31.87.77 741.57 CORP MICTIO, COLL, OYCLE 200 31.87.77 741.57 CORP MICTIO, COLL, OYCLE 200 31.87.77 741.57 CORP MICTIO, CONCOLL, OYCLE 200 35.87.76 138.57 CORP MICTIO, CONCORTIN, OF MICLEULAR, COMPONINT, MOVEMENT 201 35.87.76 136.57 CORP PROTEIN, FREQUENTION, OF MOLECULAR, COMPONINT, MOVEMENT 217 2416.74 146.57 CORP ANATOMICAL, STINUCTURE FORMATION, NIVOLVED, IN MORPHOGENESIS 272 2416.74 144.54 CORP ANATOMICAL, STINUCTURE FORMATION, NIVOLVED, IN MORPHOGENESIS 149 344.57 145.56 CORP ANOTION, OF CORCESS 247 145.64 242.67 144.64 CORP ANOTION, OF CORCESS 149 344.57 146.64 242.64 344.64 CORP ANOTION, OF CORCESS 149 344.57 144.54 344.64 <t< td=""><td></td><td></td><td></td><td></td></t<>				
GORP CELL, POPULATION PROLIFERATION 286 6.915.73 1485.77 CORP REGULATION C PRITACCELLUR, RIXINAL TRANSDUCTION 274 1885.77 4485.7 CORP REGULATION C PRITACCELLUR, RIXINAL TRANSDUCTION 283 5245.76 715.7 CORP ACTUM, TRANSPORTED BEVELOPMENT 210 5826.76 715.7 CORP ACTUM, FLANDERU DEVELOPMENT 210 5826.76 1565.7 CORP REGULATION C PROTEIN MODIFICATION PROCESS 265 256.74 4885.7 CORP REGULATION C PROTEIN MODIFICATION PROCESS 262 284.67.4 4885.7 CORP REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESS 151.2 281.67.1 428.7 CORP REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESS 159.2 282.67.0 428.67 CORP TUBE, MORPHOGENESS 159.2 282.67.0 128.66 286.66 CORP CELL PARK MACREMONCENESS 159.2 286.67.0 128.68 286.66 CORP TUBE, MORPHOGENESS 159.2 286.67.0 128.68 286.66 CORP TUBE, MARCHMONCENESS 159.2 286.64 286.66 286.66 CORP TUBE, MARCHMON				
OGEP RECULATION OF NITRACELLULAR, SIGNAL, TRANSDUCTION 274 1686-77 4716-7 OGEP CRICULATORY SYSTEE DEVELOPMENT 216 1826-77 4716-7 OGEP POSITINE GELLATOR DE MONSCILLAR FUNCTION 205 3116-77 4716-7 OGEP POSITINE GELLATOR OF DECOMENT MOVEMENT 210 7086-76 1086-77 OGEP REGULATION OF CELLULAR, COMPONENT MOVEMENT 220 7086-76 2506-76 OGEP REGULATION OF ORTONI MOVEMENT 220 7186-76 2506-76 OGEP ANTONICAL STRUCTURE FORMATION INVALVED IN MORPHOGENESIS 2212 7416-73 1506-75 OGEP ANTONICAL STRUCTURE FORMATION INVALVED IN MORPHOGENESIS 192 256-70 1036-75 OGEP ANTONICAL STRUCTURE FORMATION 163 566-70 1036-76 OGEP REGULATION OF ANTONICAL STRUCTURE MORPHOGENESIS 193 256-70 1036-76 OGEP REGULATION OF CELL COCLUATION 266 266-70 1036-76 OGEP REGULATION OF CELL COCLUATION 261 456-70 1036-76 OGEP REGULATION OF CELL COCLUATION 260 266-70 1036-76 OGEP REGULATION OF CELL COCLUATION 260				
GOBP CORDUCTORY \$157ETM PERCED 206 158E-77 7.15E-77 7.15E-		1		
GOBP 206 1317 7415-71 7415-71 7415-71 7415-71 7415-71 7415-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 1385-71 2385-71 3385-71<				
GOBP POSITIVE REGULATION OF MALECULAR FUNCTION 209 2454-76 6.136-7 6.136-7 GOBP ACTIN FUNCHINT ISSED PROCESS 176 5.88-76 1.136-7 206-7 GOBP REGULATION OF CELLULAR COMPORENT MOVEMENT 210 7.082-76 1.136-76 206-7 GOBP ADDETION OF CELLULAR COMPORENT MOVEMENT 210 7.082-76 1.136-76 206-76 GOBP ADATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 212 2.162-77 1.136-76 GOBP ADATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 119 2.525-77 1.256-77 GOBP ADDETION OF ADATOMICAL STRUCTURE MORPHOGENESIS 119 2.525-77 1.256-77 1.256-77 GOBP CELLUDAR OF ANATOMICAL STRUCTURE MORPHOGENESIS 118 5.822-70 1.256-76 1.				
GOBP ACTIN, FLAMENT BASED, PROCESS 176 5382-76 1362-76 GOBP REGULTATION OF CRELLUAR COMPONENT INVOVEMENT 227 1157-72 2506-77 GOBP ROTEN, PHOSPHORVATION 227 1157-72 2506-77 GOBP ROTEN, NHOSPHORVATION 227 1157-72 2506-77 GOBP ANATOWICAL, STRUCTURE FORMATION INVOLVED IN MCRPHOGENESIS 212 2167-74 4382-72 GOBP ANATOWICAL, STRUCTURE FORMATION 144 2482-71 5346-70 GOBP CELL CAND OF ROTENTING 128 2562-70 1356-67 GOBP CELL CAND MACROMACEUL CLOCALIZION 278 9456-70 1366-69 GOBP CELL CANDING ANATOMICAL, STRUCTURE MORPHOGENESIS 135 1566-69 2566-60 GOBP REGULATION OF CELL CANLED IN DIFFERINTRY 121 1366-69 2566-60 GOBP REGULATION OF CELL CANLE LOCALIZION 121 1366-69 2566-60 GOBP REGULATION OF CELL CANLED IN DIFFERINTRY 121 1366-60 2466-60 GOBP REGULATION OF CELL CANLED IN DIFFERINTRY 121 1366-60 2466-60 GOBP REGULATION OF CELL CANLED IN DIFFERENTRY 121 1366-60 </td <td></td> <td></td> <td></td> <td></td>				
GOBP RECULTION OF CELLULAR COMPONENT MOVEMENT 210 7.082-76 158-76 158-76 158-76 258-77 GOBP PROTEIN MOSHICATION PROTEIN MODIFICATION PROCESS 226 228-74 438-77 GOBP ARAUNOL, STRUCTURE COMMATION INVOLVED IN MORPHOGENESIS 212 216-74 554-22-77 GOBP ANAUNOL, STRUCTURE COMMATION INVOLVED IN MORPHOGENESIS 212 216-74 554-22-77 GOBP ALLATION OF PROTEIN MODIFICATION PROCESS 219 748-77 154-67 GOBP CELL, PART MORPHOGENESIS 159 528-70 158-66 GOBP CELL, MART MORPHOGENESIS 128 548-70 158-66 GOBP CELL, MART MORPHOGENESIS 128 148-68 258-66 GOBP REGULATION OF CELL, CYCLE 2148-68 248-68 248-68 GOBP REGULATION OF CELL, CONTAINING COMPOUND 224 148-68 248-68 GOBP REGULATION OF CELLULAR COMPONENT BIOGENESIS 129 148-68 248-68 GOBP REGULATION OF CELLULAR COMPONENT BIOGENESIS 120 148-68 248-68 GOBP REGULATION OF CELLULAR COMPONENT BIOGENESIS 120 148-68 248-68				
GORP PROTEN_PHOSPHORYLATION 297 1118-72 2.50E-74 4.38E-75 2.50E-74 4.38E-75 5.26E 228E-74 4.38E-75 5.26E 2.78E-74 5.26E-74				
GOBP REGULATION OF PROTEIN MODIFICATION PROCESS 296 296-74 4.486-7 GOBP ANADOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 212 216-73 1.542-7 GOBP ANADOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 217 2141-73 1.546-6 GOBP ANADOMICAL STRUCTURE MORPHOGENESIS 118 2.542-71 5.346-0 GOBP TOBLE MORPHOGENESIS 128 2.542-71 5.346-0 GOBP TOBLE MORPHOGENESIS 128 2.542-71 1.586-0 GOBP TOBLE MORPHOGENESIS 121 1.486-0 2.586-0 GOBP FEGULATION OF CELLULAR COMPONENT BIOGENESIS 180 2.245-0 2.586-0 GOBP FEGULATION OF CELLULAR COMPONENT BIOGENESIS 180 2.436-0 3.346-0 GOBP FEGULATION OF CELLULAR COMPONENT BIOGENESIS 180 2.436-0 3.346-0 GOBP FEGULATION OF CELLULAR COMPONENT BIOGENESIS 180 2.436-0 3.346-0 GOBP FEGULATION OF CELLULAR COMPONENT BIOGENESIS 180 3.346-0 1.136-0 GOBP FEGULATION OF CELLULAR COMPONENT BIOGENESIS 180 3.346-0 1.136-0 GOBP FEGULATION OF CELLUCAR COMPONENT BIOGENESIS </td <td></td> <td></td> <td></td> <td></td>				
CORP ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 212 216:74 6.942-72 CORP APOPTOR: FROCESS 217 741E-73 136E-73 CORP TUBE MORPHOGENESIS 119 2282-70 472E-73 CORP TUBE MORPHOGENESIS 119 2282-70 472E-73 CORP TEUE MORPHOGENESIS 119 2282-70 472E-73 CORP TEUE MORPHOGENESIS 119 5282-70 103E-65 CORP TEUE MORPHOGENESIS 119 5282-70 103E-65 CORP TEUE MORPHOGENESIS 119 5282-70 103E-65 CORP TEUE MORPHOGENESIS 118 129E-23 245E-6 CORP ECULATION OF CELLUARD. COMPONENT BIOGENESIS 118 243E-63 33E-6 CORP RECOMPTOR OF CELLUAR COMPONENT BIOGENESIS 118 243E-63 33E-6 CORP RESPONSE TO CONTAINING COMPOUND 244 156E-65 33E-6 CORP RESPONSE TO CONTAINING COMPOUND 244 156E-65 33E-6 CORP RESPONSE TO CONTAINING COMPOUND 244 157E-65 2286-1 13E-6 CORP RESPONSE TO CONTAINING COMPOUND <td< td=""><td></td><td></td><td></td><td></td></td<>				
COBP_APOPTOTIC_PROCESS 279 7.41E-73 1.98E-76 COBP_ENDERVOD_DEVELOPMENT 194 3.44E-73 1.98E-76 COBP_ENDERVOD_DEVELOPMENT 194 2.42E-74 5.44E-6 COBP_ENDERVOD_NENSIS 195 2.52E-77 1.03E-6 COBP_ENDERVOD_NEARCONCEL_COLLE_LOCALIZATION 271 9.45E-77 1.03E-6 COBP_ENDERVOD_NACCEL_COLLE_LOCALIZATION 271 9.45E-77 1.03E-6 COBP_ENDERTIC_REGULATION_OF_CRESIS_INVOLVED_IN_DIFFERENTIATION 271 1.94E-63 2.94E-76 COBP_ENDERTIC_REGULATION_OF_CRESIS_INVOLVED_IN_DIFFERENTIATION 271 1.94E-63 2.94E-65 COBP_ENDERTIC_ROCAL_CONTAINING_COMPOUND 271 1.94E-63 2.94E-65 COBP_ENDERTIC_ROCAL_CONTAINING_COMPOUND 274 4.15E-65 5.33E-65 COBP_ENDERTIC_ROCAL_CONTAINING_COMPOUND 276 6.33E-65 1.95E-65 1.15E-64 COBP_ENDERTIC_ROCAL_CONTAINING_COMPOUND 271 1.94E-63 1.94E-63 <td></td> <td></td> <td></td> <td></td>				
CORP_EUBERNO_DEVELOPMENT 1948 348-672 10.44-62 CORP_TUBE_MORPHOGENESIS 195 2282-70 4.726-6 CORP_CELL_PART_MORPHOGENESIS 195 5.622-70 4.726-6 CORP_CELL_NART_MORPHOGENESIS 195 5.622-70 1.866-6 CORP_CELL_NART_MORPHOGENESIS 195 5.622-70 1.866-6 CORP_CELL_NART_MORPHOGENESIS 196 5.622-70 1.866-6 CORP_CELL_NART_MOR_OF_CELL_COLLE_LOCALIZATION 161 1.466-6 2.866-6 CORP_CELL_NARTH COLLELLOCAC/TONENT_BIOGENESIS 180 1.466-66 3.866-0 CORP_EPILLATION_OF_CELL_DEATH 177 3.406-56 3.386-0 CORP_EREQUARTION_OF_CELL_DEATH 177 3.406-56 3.386-0 CORP_EREQUARTION_OF_CELL_DEATH 1244 7.586-66 3.386-0 CORP_EREQUARTION_OF_CELL_DEATH 1244 7.586-66 3.386-0 CORP_EREQUARTION_OF_CELL_DEATH 1244 7.586-66 3.386-0 CORP_EREQUARTION_OF_CELL_DEATH 1245 3.386-63 1.386-0 CORP_EREQUARTION_OF_CELLATION 1244 <				
GOBP TUBE_INGREMOGENESIS 184 2282-70 4282-60 GOBP FEGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 193 5282-70 1038-60 GOBP REGULATION_OF_CELL_COLLE_LOCALIZATION 271 9485-70 1038-60 GODP REGULATION_OF_CELL_OVICLE_ 271 9485-70 1038-60 GODP REGULATION_OF_CELL_OVICLE_ 271 1486-60 2286-60 GODP REGULATION_OF_CELL_OVICLE_ 271 1486-60 2286-60 GODP REGULATION_OF_CELL_OVICLE_ 271 1486-60 2386-60 GODP REGULATION_OF_CELL_OVICLE_ONNET_BIOGENESIS 1616 2436-60 3386-60 GODP REGULATION_OF_OVICLE_LOBATIMING_COMPOUND 244 7366-60 3386-60 GODP REGULATION_OF_OVICLE_DEATIMINIZION 1071 3406-61 1386-60 GODP RESPONSE_TO_GROWTH FACTOR 1071 3406-61 1386-60 GODP RESPONSE_TO_GROWTH FACTOR 1071 3406-61 1386-60 GODP RESPONSE_TO_GROWTH FACTOR 10716-61				
GOBP CELL PART MORPHOGENESIS 199 252E-70 4.72E-8 GOBP REGULTAR, MACRONOLECULE, LOCALLZATION 270 4.96E-70 1.08E-6 GOBP REGULTAR, MACRONOLECULE, LOCALLZATION 271 1.46E-70 1.28E-60 GOBP REGULTARO, OF CELL, CYCLE 212 1.46E-60 2.28E-70 1.28E-60 GOBP REGULTARO, OF CELLULAR, COMPONENT, BIOGENESIS 1.80E-60 2.28E-70 1.28E-60 2.38E-70 GOBP REGULTARO, OF CELLULAR, COMPONENT, BIOGENESIS 1.80E-60 2.38E-60 3.38E-60 2.38E-60 3.38E-60 GOBP RESPONSE TO, OXYCEN, CONTAINING COMPOUND 244 7.58E-61 3.38E-60 1.33E-64 3.38E-60 1.33E-64 3.38E-60 1.33E-64 3.38E-64				
COBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 19.8 5.82E-70 1.03E-6 COBP_CELL_MARACRONOLCULE_LOCALZENTON 212 1.44E-69 2.55E-6 COBP_CELL_MORPHOGENESIS 211 1.44E-69 2.55E-6 COBP_REGULATION_OF_RESPONSE_TO_STIMULUS 251 1.44E-68 2.34E-6 COBP_REGULATION_OF_RESPONSE_TO_STIMULUS 251 1.44E-68 2.34E-6 COBP_REGULATION_OF_CELL_DENTH 1.21 1.80E-65 5.30E-6 COBP_REGULATION_OF_CELL_DENTH 1.24 1.55E-65 5.30E-6 COBP_REGULATION_OF_CELL_DENTH 1.24 1.55E-65 1.13E-6 COBP_REGULATION_OF_CELL_DENTH 1.24 1.55E-65 1.13E-6 COBP_REGULATION_OF_CELL_DENTH 1.24 1.55E-65 1.13E-6 COBP_RESPONSE_TO_CONTRINTON 1.26 4.38E-64 1.13E-6 COBP_RESPONSE_TO_CONTRINTON 1.26 4.38E-64 1.15E-6 COBP_RESPONSE_TO_CONTRINTON 1.26 4.38E-64 1.15E-6 COBP_RESPONSE_TO_CONTRINTANCING 1.26 4.38E-64 1.15E-6 COBP_RESPONSE_TO_CONTRINTANCING				
GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION 278 9.455-70 1.565-60 GOBP_RECULATION OF CELL CYCLE 212 1484-60 2.565-66 GOBP_RECULATION OF CELLUCAR_COMPONENT_BIOGENESIS 168 2.475-66 2.475-66 GOBP_REGULATION OF CELLULAR_COMPONENT_BIOGENESIS 128 2.435-66 2.475-66 GOBP_REGULATION_OF CELLULAR_COMPONENT_BIOGENESIS 128 2.425-66 3.335-66 GOBP_REGULATION_OF CELLULAR_COMPONENT_BIOGENESIS 128 2.444 1.555-65 1.375-66 GOBP_REGULATION_OF CELL_DEATH 2.44 1.555-65 1.375-66 5.356-66 GOBP_COMPONENCECULAR_REG REGULAZION 2.60 6.61 1.656-66 1.375-66 GOBP_CONCOMPONECULAR_REG REGULAZION 2.60 6.61 1.656-66 1.375-66 GOBP_CONCOMPONECULAR_REGULAZION 2.61 6.632-66 1.675-66 0.626-66 1.675-66 GOBP_CONCOMPONECULAR_REGULAZION 1.66 6.352-66 1.675-66 0.600-66 0.675-66 0.600-66 0.675-66 0.600-66 0.675-66 0.600-66 0.675-66 0.600-66 0.675-66 0				
GOBP REGULATION OF CELL_CYCLE 221 48E-69 2.58E-6 COOP CELL MORPHOGENESS INVOLVED N. DIFFERENTIATION 163 156E-69 2.58E-6 COOP REGATIVE REGULATION OF RESPONSE TO STIMULUS 251 149E-68 3.48E-68 3.48E-68 3.48E-68 3.48E-68 3.48E-68 3.48E-68 3.48E-66 5.35E-66 5.35				
GORP CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 161 156E-69 2.265E-6 GORP MEGATIVE, REGULATION OF CRESPONSE TO STIMULUS 251 149E-68 2.37E-68 GORP PERTIFICATION OF CELLULAR_COMPONENT_BIOGENESIS 168 2.21E 80E-65 2.25E-66 GORP PERTIFICATIVE, DEVELOPMENT 212 80E-66 3.38E-66 3.38E-66 GORP CORDINALING_DEVELOPMENT 2244 4.15E-66 3.33E-66 3.37E-66 GORP CORDINALING_EVELOPMENT 2244 4.15E-66 3.33E-66 1.37E-66 GORP MICROTUBLE BASED PROCESS 196 3.32E-46 3.32E-64 3.32E-64 GORP CHROMOSOME_GORGANIZATION 196 6.32E-64 3.32E-64 3.32E-64 GORP CHROMOSOME_GORGANIZATION 196 3.32E-64 1.32E-64 1.32E-64 GORP CHROMOSOME_GORGANIZATION 197 1.32E-64 1.32E-64 1.32E-64 GORP CHROMOSOME_GORGANIZATION 196 3.32E-64 1.32E-64 1.32E-64 GORP COSTING_REGULATION OF PROTEIN METABOLIC PROCESS 2.215 1.32E-64 1.32E-64 1.32E-64 GORP ALLINING				
GOBP, NEGATINE, REGULATION, OF, RESPONSE, TO, STIMULUS 261 1445-68 2476-60 GOBP, REGULATION, OF, CELLULAR, COMPONENT BIOGENESIS 166 2486-60 2486-60 GOBP, RESPONSE, TO, CAYGEN, CONTAINING, COMPOUND 244 1565-65 5386-60 GOBP, RESPONSE, TO, CAYGEN, CONTAINING, COMPOUND 244 1556-65 1376-60 GOBP, REGULAR, FIBER, ORGANIZATION 266 8.886-66 1276-60 GOBP, MURCIULAR, FIBER, ORGANIZATION 207 6.116-441 8.686-66 GOBP, MURCIULUAR, FIBER, ORGANIZATION 207 6.116-441 8.686-66 GOBP, MURCIULUAR, FIBER, ORGANIZATION 157 7.116-41 1.076-6 GOBP, NURCIULUAR, FIBER, ORGANIZATION 167 148 4.392-631 GOBP, POSITIVE, REGULATION, OF, TRANSCRIPTION BY RNA, POLYMERASE II 108 1.432-631 4.332-631 GOBP, ANIMAL, ORGAN, MORPHOGENESIS 228 1.306-611 1.672-55 GOBP, ANIMAL, ORGAN, MORPHOGENESIS 128 1.442-69 1.432-63 GOBP, CELL, JUNCTION, OF, CYROSKELETON, ORGANIZATION 128 2.426-60 2.466-5 GOBP, CELL, LINCH, REGULATION, OF				
GORP PREGULATION, OF CELLULAR, COMPONENT BLOGENESIS 1616 2.438-681 3.946-65 GORP PARTHELIM, DEVELOPMENT 1212 1806-65 2.986-66 GORP PARSULUM, DEVELOPMENT 1244 7.556-65 5.036-6 GORP RESULATION, OF CELL DEATH 2444 7.556-65 1.138-6 GORP SUPRAMOLECULAR FIBER ORGANIZATION 156 6.866-55 1.138-6 GORP CHROMOSOME CONG RIGANIZATION 156 6.866-55 1.138-6 GORP CHROMOSOME CONG RIGANIZATION 156 6.866-55 1.138-6 GORP MICROTIBULE BASED PROCESS 169 3.226-64 8.925-6 GORP POSITIVE REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 161 1.146-62 1.146-62 GORP POSITIVE REGULATION OF PROTEIN, METABOLIC, PROCESS 228 1.306-61 4.925-65 GORP MICROTIBULE OYTOSKELETION, ORGANIZATION 138 4.796-61 6.076-5 GORP MICROTIBULE OYTOSKELETON, ORGANIZATION 138 4.336-60 4.996-5 GORP MICROTIBULE OYTOSKELETON, ORGANIZATION 138 4.336-5 1.996-5 GORP MICROTIBULE OYTOSKELETON, ORGANIZATION 138 4.				
GORD PRIVIL 212 180E-66 286E-6 GORD PROVTH 177 340E-66 535E-6 GORD PRESPONSE TO CONYDEN CONTAINING COMPOUND 244 155E-65 113E-6 GORD PREQUARTION OF CELL DEATH 244 155E-65 113E-6 GORD PREQUARTION OF CELL DEATH 244 155E-65 113E-6 GORD PREQUARSE TO GROWTH FACTOR 207 601E-641 835E-6 GORD PRESPONSE TO GROWTH FACTOR 197 771E-641 107E-6 GORD PRESPONSE TO GROWTH FACTOR 197 771E-641 107E-6 GORD PRESPONSE TO GROWTH FACTOR 198 518E-632 128E GORD POSITIVE REGULATION OF CRANSCRIPTION BY RNA POLYMERASE II 1218 338E-631 433E-6 GORD POSITIVE REGULATION OF CRANSCRIPTION BY RNA POLYMERASE II 1080E-611 107E-64 107E-64 GORD POSITIVE REGULATION OF CRANSCRIPTION BY RNA POLYMERASE II 1080E-64 138E-67 248E-6 GORD POSITIVE REGULATION OF SIGNALINO 2161 448E-5 34E-67 34E-67 34E-67 34E-67 34E-67 34E-67 34E-67 34E-67		1		
GOBP GROWTH 177 340E-66 530E-6 GORP RESCRADES TO XYEEN CONTAINING COMPOUND 244 15E-65 633E-6 GORP RESCRADUCEULAR FIBER ORGANIZATION 168 686E-65 113E-6 GORP MICRONUCEULAR FIBER ORGANIZATION 156 686E-65 113E-6 GORP MICROTIBULE BASED PROCESS 169 632E-64 885E-6 GORP ANDRUBULE BASED PROCESS 169 532E-64 832E-64 GORP VIASCULATURE DEVELOPMENT 1612 339E-63 433E-64 GORP POSITIVE, REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 228 130E-61 167E-65 GORP MICROTIDUEL CYTOSKELETON, ORGANIZATION 138 428E-64 167E-65 GORP MICROTIDUEL CYTOSKELETON, ORGANIZATION 138 438E-64 167E-65 GORP MICROTIDUEL CYTOSKELETON, ORGANIZATION 138 438E-64 113E-62 GORP MICROTINE, REGULATION OF, STANALINATION 138 438E-64 113E-62 GORP MICROTINE, REGULATION OF, TRANSCRIPTION BY RNA, POLYMERASE II 165 65E-59 GORP MICROTINE, REGULATION OF, STANALINATION 138 35E-56 113E-56				
GOBP, RESPONSE_TO_QXYGEN_CONTAINING_COMPOUND 244 4.15E-65 6.33E-64 GOBP, REGULATON, OF_CELL DEATH 244 7.55E-65 1.37E-6 GORD P. REGULAR, FIBER, ORGANIZATION 207 6.01E-641 8.65E-6 GORD P. MICROTUBULE, BASED, PROCESS 169 6.32E-64 8.52E-6 GORD P. DESPONSE_TO_GROWTH_FACTOR 157 7.71E-641 1.07E-6 GORD P. DOSTIVE REGULATION OF TRANSCRIPTION BY RNA. POLYMERASE. II 108 3.39E-63 4.53E-6 GORD P. NESTOLE REGULATION, OF PROTEIN METABOLIC_PROCESS 128 1.14E-62 1.45E-62 GORD P. NEGATURE, REGULATION, OF PROTEIN METABOLIC_PROCESS 128 4.29E-61 6.07E-5 GORD P. CELL JUNCTION, OF CONSULETON, ORGANIZATION 128 2.23E-60 4.95E-65 GORD P. DEGATIVE, REGULATION, OF STRANSCRIPTION BY RNA, POLYMERASE_II 168 8.05E-59 9.85E-59 GORD P. DEGATIVE, REGULATION, OF STRANSCRIPTION BY RNA, POLYMERASE_II 1137 4.98E-65 1.98E-64 1.9				
GOBP_REGULATION_OF_CELL_DEATH 244 7.55E-665 1.13E-64 GOBP_SUPRANDLECULAR_PIBER ORGANIZATION 156 8.88E-65 1.27E-64 GOBP_MICROTUBULE_BASE_D_PROCESS 169 6.22E-64 8.52E-64 GOBP_MICROTUBULE_BASE_D_PROCESS 169 5.22E-64 8.52E-64 GOBP_NERSPONSE_TO_GROWTH_FACTOR 157 7.71E-64 1.15E-64 GOBP_VASCULATURE_REGULATION OF TRANSCRIPTION BY RNA POLYMERASE II 201 8.43E-64 4.53E-63 GOBP_MICROTUBULE_CYCOSKELETON_ORGANIZATION 128 2.32E-63 2.38E-63 4.53E-63 GOBP_MICROTUBULE_CYCOSKELETON_ORGANIZATION 128 2.22E-60 2.29E-63 2.38E-63 5.35E-63				
GOBP SUPRAMOLECULAR, FIBER ORGANIZATION 156 8.88E-65 127E-6 GORP CHRONOSOME, ORGANIZATION 207 6.01E-641 8.65E-6 GORP MCROTUBULE, BASED, PROCESS 169 5.22E-64 8.92E-64 GORP DESPONSE TO, GROWTH, FACTOR 157 7.71E-641 107E-6 GORP POSITIVE, REGULATION OF, TRANSCRIPTION BY RNA POLYMERASE II 201 8.43E-64 1.15E-6 GORP AUXITURE, DEVELOPMENT 168 1.34E-61 1.67E-5 GORP NEGOLUATION, OF, PROTEIN, METABOLC, PROCESS 228 1.34E-61 1.67E-5 GORP NEGATIVE, REGULATION, OF, CARONIZATION 124 2.24E-60 2.89E-5 GORP NEGATIVE, REGULATION, OF, CARONIZATION 149 4.33E-63 1.27E-58 GORP NEGATIVE, REGULATION, OF, GRANIZATION 133 1.15E-58 1.35E-56 GORP NEGATIVE, REGULATION, OF, GRANIZATION 133 1.15E-58 1.35E-56 GORP NEGATIVE, REGULATION, OF, GRANIZATION 133 1.15E-58 1.35E-56 GORP DEVELOPMENTAL, GROWTH 133 1.15E-58 1.35E-56 1.35E-56 GORP DEVELOPMENTAL, GROWTH 133 1.				1.13E-62
GOBP_CHROMOSOME_ORGANIZATION 207 6.01E-64(8.65E-64 GORP_MICROTUBULE_BASED_PROCESS 169 5.22E-64 8.92E-65 GORP_DISCRIPTUBULE_BASED_PROCESS 169 7.71E-64(1.07E-64 GORP_DISCRIPTUBUE_BASED_DEVELOPMENT 162 3.93E-63(4.53E-64 GORP_DISCRIPTUBUE_EXCLOPMENT 162 3.93E-63(4.53E-64 GORP_DISCRIPTUBUE_EXCLOPMENT 162 2.32E-63(4.53E-64 GORP_DISCRIPTUBUE_EXCLOSARLETON_ORGANIZATION 128 2.22E-60(2.29E-64) GORP_DISCRIPTUBUE_EXCLOSARLETON_ORGANIZATION 128 2.32E-60(2.29E-64) 2.29E-64) GORP_DISCRIPTUBUE_EXCLOSARLETON_ORGANIZATION 128 2.32E-64) 2.29E-64 2.39E-63 GORP_DISCRIPTUBUE_BASED_AND/OF SIGNALING 137 1.56E-66 9.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-56 0.35E-57 0.35E-57 0.35E-57 0.35E-57 0.35E-56 0.36E-56 0.35E-57 0.35E-56 0.36E-56 0.35E-57 0.35E-56 0.36E-				1.27E-62
GOBP_RESPONSE_TO_GROWTH_FACTOR 117 7.71E-64 1107E-6 GOBP_DOSITIVE_REGULATION OF TRANSCRIPTION_BY RNA POLYMERASE II 121 8.43E-64 115E-64 GOBP_VASCULATURE REQUENDMO FORTERIN_METABOLIC_PROCESS 228 130E-61 167E-75 GOBP_MIGNICURAL_ORGAN_MORPHOGENESIS 128 2.32E-60 2.89E-63 GOBP_REGULATION_OF_OTTON_ORGANIZATION 128 2.32E-60 2.89E-76 GOBP_REGULATION_OF_OTTON_ORGANIZATION 128 2.32E-60 2.89E-76 GOBP_NEGATIVE_REGULATION_OF_SIGNALING 2.181E-76 1.98E-76 1.98E-76 GOBP_DECLI_MORPHOTIVE_REGULATION_OF_SIGNALING 1.91E-76 1.93E-76 1.93E-76 GOBP_DECLI_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 133 9.58E-56 1.93E-76 GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 173 1.95E-76 4.94E-56 3.95E-56 GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 133 9.58E-56 3.95E-56 5.07E-76 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON 1.98E-77 4.98E-56 3.98E-56 3.98E-56 3.98E-56 3.98E-56 5.07E-75 GOBP_CELL_MORPHOGENE				8.65E-62
GOBP_RESPONSE_TO_GROWTH_FACTOR 117 7.71E-64 1107E-6 GOBP_DOSITIVE_REGULATION OF TRANSCRIPTION_BY RNA POLYMERASE II 121 8.43E-64 115E-64 GOBP_VASCULATURE REQUENDMO FORTERIN_METABOLIC_PROCESS 228 130E-61 167E-75 GOBP_MIGNICURAL_ORGAN_MORPHOGENESIS 128 2.32E-60 2.89E-63 GOBP_REGULATION_OF_OTTON_ORGANIZATION 128 2.32E-60 2.89E-76 GOBP_REGULATION_OF_OTTON_ORGANIZATION 128 2.32E-60 2.89E-76 GOBP_NEGATIVE_REGULATION_OF_SIGNALING 2.181E-76 1.98E-76 1.98E-76 GOBP_DECLI_MORPHOTIVE_REGULATION_OF_SIGNALING 1.91E-76 1.93E-76 1.93E-76 GOBP_DECLI_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 133 9.58E-56 1.93E-76 GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 173 1.95E-76 4.94E-56 3.95E-56 GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 133 9.58E-56 3.95E-56 5.07E-76 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON 1.98E-77 4.98E-56 3.98E-56 3.98E-56 3.98E-56 3.98E-56 5.07E-75 GOBP_CELL_MORPHOGENE	GOBP MICROTUBULE BASED PROCESS	169	6.32E-64	8.92E-62
GOBP_VASCULATURE, DEVELOPMENT 162 3.95E-63 4.53E-6 COBP_ANIMAL, ORGAN, MORPHOGENESIS 168 1.14E-62 1.49E-63 COBP_DOSITVE_REGULATION OF_PROTEIN_METABOLIC_PROCESS 228 1.30E-61 1.07E-55 GOBP_REGULATION OF_CYTOSKELETON, ORGANIZATION 128 2.32E-60 2.39E-55 GOBP_REGULATION_ORGANIZATION 128 2.32E-60 2.39E-55 GOBP_NEGATIVE_REGULATION OF_SIGNALING 1165 1.30E-56 9.55E-5 GOBP_DECLI_DMORENTAL_OROVTH 133 9.58E-58 1.10E-5 GOBP_DEVELOPMENTAL_OROVTH 133 9.58E-58 1.10E-5 GOBP_DEVELOPMENTAL_OROVTH 133 9.58E-56 2.01E-7 GOBP_DEVELVE_REGULATION OF CELL DIFFERENTIATION 108 1.83E-56 2.01E-7 GOBP_DOSITIVE_REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP_DOSITIVE_REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 3.12E-5 GOBP_CELL_DIVISION 133 3.08E-56 3.08E-5 3.12E-5 GOBP_CELL_DIVISION 131 3.08E-56 3.08E-5 <td></td> <td>157</td> <td></td> <td>1.07E-61</td>		157		1.07E-61
GOBP_ANIMAL_ORGAN_MORPHOGENESIS 185 1.14E-62 1.48E-60 GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 228 1.30E-61 6.76E-5 GOBP_MICROTUBULE_CYTOSKELETON_ORGANIZATION 128 2.32E-60 2.89E-5 GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION 128 2.32E-60 2.89E-5 GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 165 8.06E-59 9.55E-5 GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 137 1.15E-58 1.35E-50 GOBP_DEVELOPMENTAL_GROWTH 137 1.15E-58 1.35E-56 1.14E-57 4.34E-5 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 160 3.83E-57 4.34E-5 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 209 2.84E-56 5.97E-5 GOBP_POSITIVE_REGULATION_OF_SIGNALING 238 5.59E-55 5.97E-5 GOBP_ROSITIVE_REGULATION_OF_SIGNALING 131 3.80E-54 4.01E-53 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-53 1.22E-55 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-53 1.22E-55	GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	201	8.43E-64	1.15E-61
CORP POSITIVE REGULATION OF PROTEIN, METABOLIC PROCESS 228 1.30E-61 6.07E-5 CORP MICROTUBULE CYTOSKELETON, ORGANIZATION 128 2.32E-60 2.89E-5 GOBP, CELL JUNCTION, ORGANIZATION 128 2.32E-60 2.89E-5 GOBP, NEGATIVE REGULATION OF SIGNALING 126 1.46E-59 1.26E-5 GOBP, NEGATIVE REGULATION OF SIGNALING 137 1.15E-58 1.35E-5 GOBP, CELL MORPHOGENESIS, INVOLVED, IN NEURON, DIFFERENTATION 133 9.58E-58 1.10E-5 GOBP, CELL MORPHOGENESIS, INVOLVED, IN NEURON, DIFFERENTATION 160 3.88E-57 4.34E-5 GOBP, POSITIVE REGULATION OF CILL DIFFERENTIATION 160 3.88E-57 4.34E-5 GOBP, POSITIVE REGULATION, OF SIGNALING 160 3.85E-58 5.97E-5 GOBP, POSITIVE REGULATION, OF SIGNALING 2.33 5.59E-55 5.97E-5 GOBP, POSITIVE REGULATION, OF SIGNALING 2.33 5.59E-55 5.97E-5 GOBP, CELL DIVISION 3.38E-54 4.01E-5 5.97E-5 GOBP, CELL ADHESION 131 3.86E-54 4.97E-53 GOBP, CELLATION, OF, SIGNALING 2.09E-54	GOBP_VASCULATURE_DEVELOPMENT	162	3.39E-63	4.53E-61
GOBP MICROTUBULE CYTOSKELETON, ORGANIZATION 138 4.79E-61 6.07E-5 GOBP REGULATION, OF CYTOSKELETON, ORGANIZATION 128 2.23E-60 2.89E-5 GOBP NEGATIVE REGULATION, ORGANIZATION 149 4.03E-60 4.95E-5 GOBP NEGATIVE REGULATION OF SIGNALING 215 1.04E-59 1.26E-5 GOBP DEVELOPMENTAL GROWTH 137 1.15E-58 1.35E-5 GOBP POSITIVE REGULATION OF CELL DIFFERENTIATION 130 3.85E-58 1.10E-5 GOBP POSITIVE REGULATION OF CELL DIFFERENTIATION 160 3.83E-57 4.34E-5 GOBP POSITIVE REGULATION OF CELL DIFFERENTIATION 168 1.83E-56 2.01E-5 GOBP POSITIVE REGULATION OF CELLOPMENT 173 4.98E-57 4.68E-5 GOBP POSITIVE REGULATION OF CATALITIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP POSITIVE REGULATION OF SIGNALING 131 3.08E-54 4.01E-5 GOBP CELL DIVISION 131 3.08E-54 4.01E-5 GOBP CELL QUMENT 124E-53 1.32E-52 3.59E-55 5.97E-5 GOBP CELL LAR RESPONSE, TO DAYGEN CONTAINING COMPOUND 166	GOBP_ANIMAL_ORGAN_MORPHOGENESIS	185	1.14E-62	1.49E-60
COEP RECULATION OF, CYTOSKELETÓN ORGANIZATION 128 2.32E-60 2.89E-5 COOP CELL JUNCTION ORGANIZATION 149 403E-60 495E-55 COEP NEGATIVE, REGULATION, OF, SIGNALING 215 1.04E-59 1.26E-55 GOBP, NEGATIVE, REGULATION, OF, TRANSORIPTION, BY, RNA, POLYMERASE, II 165 8.05E-59 9.55E-55 GOBP, DECLEL, MORPHOGENESIS, INVOLVED, IN, NEURON, DIFFERENTIATION 133 1.58E-56 1.16E-56 GOBP, CELL, MORPHOGENESIS, INVOLVED, IN, NEURON, DIFFERENTIATION 160 3.38E-57 4.34E-5 GOBP, CENTRAL, NERVOUS, SYSTEM, DEVELOPMENT 173 4.19E-57 4.68E-5 COOP, PEOTIVE, REGULATION, OF, CATALYTIC, ACTIVITY 209 2.84E-56 3.08E-5 GOBP, POSITIVE, REGULATION, OF, CATALYTIC, ACTIVITY 209 2.84E-56 3.08E-5 GOBP, REGULATION, OF, HYDROLASE, ACTIVITY 196 1.20E-53 1.22E-55 GOBP, REGULATION, OF, HYDROLASE, ACTIVITY 196 1.20E-53 1.22E-55 COEP, TISSUE, MORPHOGENESIS 133 3.08E-54 3.12E-55 GOBP, REGULATION, OF, DEVELOPMENTAL, PROCESS 163 1.80E-53 1.77E-55	GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	228	1.30E-61	1.67E-59
GOBP_CELL_JUNCTION_ORGANIZATION 149 4.03E-60 4.98E-5 GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 165 8.05E-59 9.55E-5 GOBP_DEVELOPMENTAL_GROWTH 137 1.15E-88 1.35E-5 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 133 9.58E-58 1.10E-5 GOBP_OPSITIVE_REGULATION_OF_CELL_DIFFERENTIATION 160 3.33E-57 4.34E-5 GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION 198 1.83E-66 2.01E-5 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 209 2.44E-56 3.08E-5 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 209 2.44E-56 3.08E-5 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-5 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-5 GOBP_CELL_DIVISION 133 3.80E-54 4.01E-5 GOBP_CELL_DIVISION 134 1.28E-53 1.28E-5 GOBP_CELL_DIVISION 134 1.28E-53 1.28E-53 1.28E-53 GOBP_TISSUE_MORPHOGENESIS 134 1.28E-53 1.28E-53 1.28E-53<			4.79E-61	6.07E-59
COBP NEGATIVE_REGULATION_OF_SIGNALING 215 10.4E-59 126E-5 GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BU_RNA_POLYMERASE_II 165 8.05E-59 9.55E-5 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 133 9.58E-58 1.10E-5 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 160 3.83E-57 4.34E-5 COBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 173 4.19E-57 4.68E-5 GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 198 1.83E-56 2.01E-5 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 209 2.84E-56 3.08E-56 GOBP_CELLUATION_OF_HYDROLASE_ACTIVITY 106 1.20E-53 1.25E-5 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 106 1.20E-53 1.25E-5 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 106 1.20E-53 1.27E-5 GOBP_REGULATION_OF_EVELOPMENT 120 1.24E-53 1.30E-54 4.01E-53 GOBP_REGULATION_OF_EVELOPMENTA_PROCESS 163 1.47E-55 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 186 1.48E-53 1.37E-52 GOBP_REGULATION_OF_CEVELOPMENTA_PROC		128	2.32E-60	2.89E-58
COBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 165 8.05E-59 9.55E-5 COBP_DEVELOPMENTAL_GROWTH 137 1.15E-68 1.35E-5 COBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTATION 133 9.58E-58 1.10E-5 COBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 173 4.15E-56 1.30E-5 COBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 173 4.15E-56 2.01E-5 COBP_PEPTIDYL_AMINO_ACID_MODIFICATION 198 1.83E-56 2.01E-5 COBP_POSITIVE_REGULATION_OF_SIGNALING 233 5.59E-55 5.97E-55 GOBP_CELL_DIVISION 131 3.00E-54 4.01E-5 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-55 GOBP_CELL_DIVISION 131 3.00E-54 4.01E-5 GOBP_CELL_DIVISION 134 1.28E-53 1.22E-55 GOBP_CELL_DIVISION 134 1.28E-53 1.22E-52 1.32E-52 GOBP_CELL_DIVISION 134 1.28E-53 1.32E-52 1.32E-52 1.32E-52 1.32E-52 1.32E-52 1.32E-52 1.32E-52 1.32E-52			4.03E-60	4.95E-58
GOBP DEVELOPMENTAL GROWTH 137 115E-58 113E-56 GOBP CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTATION 133 9.58E-58 1.10E-5 GOBP POSITIVE REGULATION OF CELL DIFFERENTIATION 160 3.83E-57 4.34E-5 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP REGULATION OF LANDO OF SIGNALING 131 3.80E-54 4.01E-5 GOBP REGULATION OF HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-5 GOBP REGULATION OF DEVELOPMENTAL PROCESS 163 1.80E-53 1.77E-5 GOBP CELL LORINE REGULATION OF DEVELOPMENTAL PROCESS 163 1.80E-53 1.77E-5 GOBP REGULATION OF CELL ADHESION 143 9.74E-53 9.46E-5 GOBP CELL CELL SIGNALING COMPONIC MORPHOGENESIS 1.34E-53 9.46E-5 GOBP REGULATION OF CELL ADHESION 14				1.26E-57
COBP_CELL_MORPHOGENESIS INVOLVED_IN_NEURON_DIFFERENTIATION 133 9.58E-58 1.10E-5 GOBP_POSITIVE_REGULATION OF CELL DIFFERENTIATION 160 3.83E-57 4.34E-5 GOBP_CENTRAL_NERVOUS_SYSTEM DEVELOPMENT 173 4.19E-57 4.68E-5 GOBP_POSITIVE_REGULATION_OF_CATLYTIC_ACTIVITY 200 2.84E-56 3.08E-56 GOBP_POSITIVE_REGULATION_OF_SIGNALING 131 3.80E-54 4.01E-53 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-53 GOBP_CELLUDIVISION 131 3.80E-54 4.01E-53 GOBP_AXON_DEVELOPMENT 120 1.24E-53 1.22E-5 GOBP_AXON_DEVELOPMENT 120 1.24E-53 1.30E-53 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-5 GOBP_REGULATION_OF_DROTE_TO_CAYGEN_CONTAINING_COMPOUND 186 1.48E-53 1.47E-5 GOBP_REGULATION_OF_ROTEIN 143 9.74E-53 9.46E-5 GOBP_REGULATION_OF_ROTEIN 144 3.92E-52 1.67E-5 GOBP_CELL_CELL_SIGNALING 125 5.35E-52 4.94E-5 GOBP_CELL_CELL_SIGNALI				9.55E-57
COBP POSITIVE REGULATION OF CELL DIFFERENTIATION 160 383E-57 434E-5 GOBP CENTRAL NERVOUS SYSTEM DEVELOPMENT 173 4.19E-57 4.68E-5 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 209 2.84E-56 3.08E-5 GOBP POSITIVE REGULATION OF SIGNALING 131 3.80E-54 4.01E-5 GOBP REGULATION OF HYDROLASE ACTIVITY 196 1.20E-53 1.22E-5 GOBP ACSILULAR RESPONSE TO COXYGEN CONTAINING COMPOUND 186 1.48E-53 1.47E-5 GOBP REGULATION OF CELL DHESION 134 1.28E-52 1.34E-5 GOBP REGULATION OF CELL OPMENTAL PROCESS 163 1.60E-53 1.77E-5 GOBP REGULATION OF CELL OPMENTAL PROCESS 163 1.60E-53 1.47E-5 GOBP REGULATION OF CELLOPMENTAL PROCESS 163 1.60E-53 1.47E-5 GOBP REGULATION OF CENTOR 144 3.92E-52 3.38E-5 GOBP REGULATION OF CENTOR 144 3.92E-52 3.38E-5 GOBP REGULATION OF CENTOR 144 3.92E-52 3.38E-5 <td></td> <td></td> <td></td> <td></td>				
GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT 173 4.19E-57 4.68E-5 GOBP_PEPTIDYL_ANINO_ACID_MODIFICATION 198 1.33E-56 2.01E-5 GOBP_POSITIVE_REGULATION_OF_SIGNALING 209 2.84E-56 3.08E-5 GOBP_POSITIVE_REGULATION_OF_SIGNALING 233 5.59E-55 5.97E-5 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-53 GOBP_AXON_DEVELOPMENT 120 1.24E-53 1.22E-53 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 186 1.48E-53 1.47E-5 GOBP_REGULATION_OF_DEVELOPMENT 120 1.24E-53 1.27E-5 GOBP_REGULATION_OF_DEVELOPMENT 124 1.28E-53 1.47E-5 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 186 1.48E-53 1.47E-5 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 163 1.80E-54 3.46E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 184 3.27E-52 3.38E-55 GOBP_CELL_CELL_SIGNALING 224 3.57E-52 3.67E-55 GOBP_CELL_CELL_SIGNALING 124 5.35E-52 4.94E-55 GOBP_CELL				
GOBP PEPTIDYL_AMINO_ACID_MODIFICATION 198 183E-56 201E-5 GOBP POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 209 284E-56 308E-5 GOBP CELL_DINISION 233 559E-55 557E-5 GOBP CELL_DINISION 131 380E-54 401E-53 GOBP REGULATION_OF_HYDROLASE_ACTIVITY 196 120E-53 125E-55 GOBP_TISSUE_MORPHOGENESIS 134 128E-53 1.30E-54 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 120 124E-53 1.30E-54 GOBP_REGULATION_OF_DEVELOPMENT 120 124E-53 1.30E-54 GOBP_REGULATION_OF_DEVELOPMENT 120 124E-53 1.30E-52 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 186 1.48E-53 1.47E-55 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.39E-52 1.34E-55 GOBP_MORPHOGENESIS 124 3.57E-52 3.38E-5 GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM 121 5.59E-52 5.10E-55 GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM 121 5.59E-52 5.10E-55 GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM <t< td=""><td></td><td></td><td>0.000</td><td></td></t<>			0.000	
GOBP POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 209 244E-56 308E-5 GOBP_POSITIVE_REGULATION_OF_SIGNALING 233 5.59E-55 5.97E-5 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-53 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-53 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-53 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-53 GOBP_TELULULAR_RESPONSE_TO_XYGEN_CONTAINING_COMPOUND 184 1.28E-53 1.47E-55 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 183 9.46E-55 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.39E-52 1.34E-52 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.39E-52 3.67E-52 3.67E-52 GOBP_MEDALCELL SCHLADHESION 184 3.92E-52 3.67E-52 GOBP_MERONIC_MORPHOGENESIS 124 5.56E-52 5.10E-55 GOBP_MEROPHOSENESIS 124 3.256E-52 1.92E-52 3.67E-52 GOBP_CELL_CELL_SICHADHESION 126 1.46E-51 <td< td=""><td></td><td></td><td></td><td></td></td<>				
GOBP_POSITIVE_REGULATION_OF_SIGNALING 233 5.59E-55 5.97E-55 GOBP_CELL_DIVISION 131 3.80E-54 4.01E-55 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.22E-55 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 120 1.24E-53 1.22E-55 GOBP_TISSUE_MORPHOGENESIS 134 1.28E-53 1.30E-55 GOBP_REGULATION_OF_DEVELOPMENT 120 1.24E-53 1.37E-55 GOBP_REGULATION_OF_DEVELOPMENT_L_PROCESS 163 1.80E-53 1.77E-55 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 127 1.34E-52 1.34E-55 GOBP_CELL_CELL_SIGNALING 224 3.57E-52 3.38E-55 GOBP_CELL_CELL_SIGNALING 121 5.59E-52 4.94E-55 GOBP_MORPHOGENESIS 124 3.92E-52 3.10E-54 GOBP_MORPHOGENESIS 124 3.98E-55 5.9E-52 4.94E-55 GOBP_CELL_CELL_SIGNALING 121 5.59E-52 5.10E-55 GOBP_CELL_CELL_ADHESION 156 1.04E-51 9.38E-55 GOBP_HOMEOSTATIC_PROCESS 246 <t< td=""><td></td><td></td><td></td><td></td></t<>				
GOBP_CELL_DIVISION 131 380E-54 4.01E-5 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.25E-5 GOBP_ACON_DEVELOPMENT 120 1.24E-53 1.32E-5 GOBP_TISSUE_MORPHOGENESIS 134 1.28E-53 1.30E-5 GOBP_ACON_DEVELOPMENT 126 1.24E-53 1.30E-5 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 163 1.80E-53 1.47E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.39E-52 1.34E-55 GOBP_ECLL_CELL_SIGNALING 224 3.57E-52 3.38E-5 GOBP_MEAD_DEVELOPMENT 144 3.22E-52 3.67E-52 GOBP_ECLL_CELL_ADHESION 125 5.35E-52 4.94E-53 GOBP_MEAD_DEVELOPMENT 144 3.22E-52 3.67E-52 GOBP_ECLL_CELL_ADHESION 121 5.59E-52 5.10E-5 GOBP_ECLL_CELL_ADHESION 126 1.44E-51 9.38E-5 GOBP_ECL_CELL_ADHESION 166 1.04E-51 9.38E-51 2.65E-41 GOBP_ECLL_CELL_ADHESION 126 3.46E-51 2.56E-41				
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 196 1.20E-53 1.25E-5 GOBP_AXON_DEVELOPMENT 120 1.24E-53 1.27E-5 GOBP_TISUE_MORPHOGENESIS 134 1.28E-53 1.30E-5 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 166 1.44E-53 1.47E-5 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 163 1.80E-53 1.77E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 143 9.74E-53 9.46E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.38E-52 1.34E-52 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.39E-52 3.36E-50 GOBP_MED_DEVELOPMENT 144 3.92E-52 3.36E-50 GOBP_MED_OPLOSENESIS 125 5.35E-52 4.94E-51 GOBP_MORPHOGENESIS 126 5.05E-51 6.05E-42 GOBP_CELL_CELL_SCHUMENT 126 1.04E-51 9.38E-50 GOBP_MORPHOGENESIS 240 7.55E-51 6.65E-44 GOBP_INTRACELULAR_TRANSPORT 226 9.46E-51 8.23E-44 GOBP_REGULATION_OF_CEL_PROCESS 134				
GOBP AXON DEVELOPMENT 120 124E-53 127E-5 GOBP TISSUE_MORPHOGENESIS 134 128E-53 1.30E-5 GOBP CELLULAR RESPONSE TO OXYGEN_CONTAINING_COMPOUND 148E-53 1.47E-5 GOBP NEGATIVE_REGULATION OF DEVELOPMENTAL_PROCESS 163 1.80E-53 1.77E-5 GOBP REGULATION OF CELL ADHESION 143 9.74E-53 9.46E-5 GOBP REGULATION OF CELL ADHESION 143 9.74E-52 3.38E-5 GOBP CELL_CELL_SIGNALING 224 3.67E-52 3.38E-5 GOBP MERDIVATION ORPHOGENESIS 125 5.35E-52 4.94E-51 GOBP MORPHOGENESIS OF AN EPITHELIUM 121 5.59E-52 5.10E-50 GOBP CELL_CELL_ADHESION 156 1.04E-51 9.38E-51 GOBP MORPHOGENESIS OF AN EPITHELIUM 121 5.59E-52 5.10E-50 GOBP FORTIC_PROCESS 240 7.55E-16 6.65E-4 GOBP HOMEOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP INTRACELLULAR TRANSPORT 226 9.46E-51 8.28E-51 2.92E-51 GOBP REGULATION_OF CRELCYCLE PROCESS 134		1		
GOBP_TISSUE_MORPHOGENESIS 134 1.28E-53 1.30E-5 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 186 1.48E-53 1.47E-5 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 163 1.80E-53 1.47E-5 GOBP_REGULATION_OF_ROTEIN_PHOSPHORYLATION 167 1.39E-52 1.34E-55 GOBP_REGULATION_OF_ROTEIN_PHOSPHORYLATION 167 1.39E-52 1.34E-55 GOBP_ECLL_CELL_SIGNALING 224 3.57E-52 3.38E-5 GOBP_MEAD_DEVELOPMENT 144 3.92E-52 3.67E-52 GOBP_EDEL_CELL_ADHESION 125 5.35E-52 4.94E-55 GOBP_CELL_CELL_ADHESION 125 5.35E-52 4.94E-55 GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 246 2.88E-51 2.56E-4 GOBP_ENTRACELULUAR_TRANSPORT 226 9.46E-51 9.38E-5 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_TRANSPORT 226 9.46E-51 8.23E-4 GOBP_REGULATION_OF_RORDENSIS 124 4.03E-50 3.39E-4 GOBP_REGULATION_OF_RORDENSIS 12				
GOBP_CELLULAR, RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 186 1.44E-53 1.47E-53 GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 163 1.80E-53 1.77E-55 GOBP_REGULATION_OF_CELL_ADHESION 143 9.74E-53 9.46E-55 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.33E-52 1.34E-55 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.33E-52 3.36E-55 GOBP_MERD_DEVELOPMENT 144 3.92E-52 3.36E-55 GOBP_MEMPHOGENESIS 125 5.35E-52 4.94E-51 GOBP_CELL_CELL_SCH_ADHESION 156 1.04E-51 9.38E-50 GOBP_CELL_CELL_ADHESION 156 1.04E-51 9.38E-50 GOBP_MEGOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP_INTRACELULAR_TRANSPORT 226 9.46E-51 8.23E-44 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-50 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-44 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-44 GOBP_ROTEIN_CONT				
GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 163 1.80E-53 1.77E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 143 9.74E-53 9.46E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 147 1.39E-52 1.34E-5 GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 144 3.92E-52 3.38E-5 GOBP_MEDULATION_OF_PROTEIN_PHOSPHORYLATION 144 3.92E-52 3.38E-5 GOBP_MERDULOWENT 144 3.92E-52 3.67E-52 4.94E-5 GOBP_MORPHOGENESIS 125 5.35E-52 4.94E-5 5.01E-5 GOBP_CELL_CELL_ADHESION 126 5.35E-52 4.94E-5 3.98E-5 GOBP_CELL_CELL_ADHESION 156 1.04E-50 3.98E-4 GOBP_ECEL_CELL_ADHESION 156 1.04E-50 1.25E-47 GOBP_INTRACELULAR_TRANSPORT 226 9.46E-51 8.23E-41 GOBP_REGULATION_OF_TRANSPORT 226 3.45E-50 2.93E-41 GOBP_REGULATION_OF_CLL_CYCLE_PROCESS 144 4.03E-50 3.39E-41 GOBP_REGULATION_OF_CLL_CACALIZATION 144 4.03E-50 3.99E-41				
GOBP REGULATION OF CELL ADHESION 143 9.74E-53 9.46E-51 GOBP REGULATION OF PROTEIN PHOSPHORYLATION 187 1.39E-52 1.34E-55 GOBP REGULATION OF PROTEIN PHOSPHORYLATION 224 3.57E-52 3.38E-55 GOBP CELL CELL SIGNALING 224 3.57E-52 3.38E-55 GOBP MEAD DEVELOPMENT 144 3.92E-52 4.94E-55 GOBP MEND MORPHOGENESIS 125 5.55E-52 4.94E-55 GOBP CELL CELL ADHESION 121 5.58E-52 5.10E-5 GOBP CELL OP AD EVELOPMENT 124 5.58E-52 4.94E-51 GOBP CELL OP AD EVELOPMENT 124 5.58E-52 4.94E-51 GOBP CELL OP AD ADVEXTOR 166 1.04E-51 9.38E-51 GOBP INTRACELULAR TRANSPORT 226 9.46E-51 8.23E-41 GOBP REGULATION OF TRANSPORT 225 3.45E-50 2.93E-41 GOBP REGULATION OF CELL COLL PROCESS 134 4.03E-50 3.39E-41 GOBP REGULATION OF CELL COLLA RUCALIZATION 144 4.77E-50 3.39E-41 GOBP REGULATION OF CELLOPATION OF ORDEINCATION PROCESS				
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION 187 1.38E-52 1.34E-52 GOBP_CELL_CELL_SIGNALING 224 3.57E-52 3.38E-5 GOBP_MEAD_DEVELOPMENT 1144 3.32E-52 3.36E-5 GOBP_MORPHOGENESIS 125 5.35E-52 4.94E-50 GOBP_MORPHOGENESIS_OR_AN_EPITHELIUM 121 5.59E-52 4.94E-50 GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 126 2.48E-51 2.56E-42 GOBP_HOMEOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP_REGULATION_OF_PROTEIN_LOCALIZATION 246 2.88E-51 2.56E-44 GOBP_NORRACELLULAR_TRANSPORT 226 9.44E-51 9.36E-55 GOBP_REGULATION_OF_TRANSPORT 226 3.45E-50 2.93E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.99E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_ROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 242 4.93E-50 4.06E-4 GOBP_POSITIVE_REGULATION_OF_CELLLCYCLE_PROCESS 168 2.81E-49 2.62E-4 GOBP_POSITIVE_REGU				
GOBP_CELL_SIGNALING 224 3.57E-52 3.38E-5 GOBP_HEAD_DEVELOPMENT 144 3.92E-52 3.67E-52 GOBP_MERTONIC_MORPHOGENESIS 125 5.35E-52 4.94E-55 GOBP_MORPHOGENESIS OF_AN_EPITHELIUM 121 5.55E-52 5.10E-55 GOBP_CELL_CELL_ADHESION 126 5.35E-52 4.94E-55 GOBP_ENDEVELOPMENTO 126 3.48E-51 9.38E-51 GOBP_ESTABLISHMENT OF_PROTEIN_LOCALIZATION 246 2.88E-51 2.55E-4 GOBP_HOMEOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP_INTRACELLULAR_TRANSPORT 226 9.46E-51 8.28E-41 GOBP_REGULATION_OF_TRANSPORT 226 3.46E-50 2.93E-4 GOBP_REGULATION_OF_CLL_CYCLE_PROCESS 134 4.03E-50 3.99E-4 GOBP_REGULATION_OF_CLL_CYCLE_PROCESS 145 4.77E-50 3.99E-4 GOBP_REGULATION_OF_CLLUAR_LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_REGULATION_OF_CLLUAR_LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170				
GOBP HEAD_DEVELOPMENT 144 392E-52 367E-5 GOBP EMBRYONIC_MORPHOGENESIS 125 5.35E-52 4.94E-5 GOBP CENTROPHOGENESIS 121 5.55E-52 5.10E-5 GOBP CELL_CELL_ADHESION 166 1.04E-51 9.38E-5 GOBP SOBP 246 2.88E-51 2.56E-42 GOBP INTRACELULAR TRANSPORT 226 9.46E-51 8.28E-41 GOBP RESPONSE_TO_HORMONE 154 1.46E-50 1.28E-45 0.29E-42 GOBP REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-44 0.39E-4 GOBP REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-4 GOBP REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.39E-4 GOBP REGULATION_OF_CELL_CYCLE_PROCESS 168 2.81E-49 2.26E-4 GOBP ROBULATION_OF_CENTUR_REGULATION_OF_GENESION 170 3.29E-49 2.62E-4 GOBP POSITIVE_REGULATION_OF_CROTEIN_NODCESS 168 2.				
GOBP EMBRYONIC MORPHOGENESIS 125 5.35E-52 4.94E-5 GOBP MORPHOGENESIS 121 5.59E-52 5.10E-5 GOBP CELL_CELL_ADHESION 126 1.04E-51 9.38E-5 GOBP FOTEIN_LOCALIZATION 246 2.88E-51 2.56E-4 GOBP FOTEIN_LOCALIZATION 246 2.88E-51 2.56E-4 GOBP FRACELLULAR, TRANSPORT 226 9.46E-51 8.23E-4 GOBP_REGULATION_OF_TRANSPORT 226 9.46E-51 8.23E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.99E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_ROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 242 4.93E-50 4.06E-4 GOBP_ROSTIVE_REGULATION_OF_CELLUCAR LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_POSITIVE_REGULATION_OF_ROTEIN_MODIFICATION_PROCESS 168				
GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM 121 5.59E-52 5.10E-52 GOBP_CELL_CAL_ADHESION 166 1.04E-51 9.38E-51 GOBP_ESTABLISHMENT OF_PROTEIN_LOCALIZATION 246 2.38E-51 2.56E-4 GOBP_INTRACELULAR_TRANSPORT 226 9.48E-51 8.23E-41 GOBP_RESPONSE_TO_HORMONE 154 1.46E-50 1.28E-41 GOBP_REGULATION_OF_TRANSPORT 226 3.45E-50 2.93E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.39E-4 GOBP_REGULATION_OF_CELL_LOCALIZATION 242 4.93E-50 4.08E-4 GOBP_REGULATION_OF_CELLUAR LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_POSITIVE_REGULATION_OF_ROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.62E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MOSCIE_CARABOLIC_PROCESS 199 7.93E-49 2.62E-4 GO				4.94E-50
GOBP_CELL_OLL_ADHESION 166 1.04E-51 9.38E-50 GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 246 2.88E-51 2.56E-4 GOBP_HOMEOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP_INTRACELLULAR_TRANSPORT 226 9.46E-51 8.23E-4 GOBP_BLOOD_VESSE_TO_HORMONE 125 1.46E-50 1.26E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.52E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 166 2.81E-49 2.26E-4 GOBP_REGULATION_OF_CENTLE_NODEICATION_PROCESS 166 2.81E-49 2.62E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECUELC_CATABOLIC_PROCESS 199 7.93E-49 6.24E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 162 2.27E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_				5.10E-50
GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION 246 2.88E-51 2.56E-41 GOBP_HOMEOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP_REGULATIC_ROCESS 226 9.46E-51 8.23E-4 GOBP_RESPONSE_TO_HORMONE 154 1.46E-50 1.26E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.99E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELLLACN LOCALIZATION 242 4.93E-50 4.06E-4 GOBP_REGULATION_OF_CELLLACN LOCALIZATION 147 6.79E-50 5.25E-4 GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.62E-4 GOBP_POSITIVE_REGULATION_OF_CENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 2.62E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 163 2.27E-48 1.77E-44 GOBP_M				9.38E-50
GOBP HOMEOSTATIC_PROCESS 240 7.55E-51 6.65E-4 GOBP INTRACELLULAR_TRANSPORT 226 9.46E-51 8.23E-4 GOBP_RESPONSE_TO_HORMONE 154 1.46E-50 1.28E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELLUAR_LOCALIZATION 242 4.93E-50 4.06E-4 GOBP_REGULATION_OF_CELLUAR_LOCALIZATION 147 6.77E-50 5.52E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 116 2.28E-49 2.62E-4 GOBP_MOSCLE_OLUATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MOSCLE_ULTION_OF_TRANSPERASE_ACTIVITY 163 2.27E-48 1.77E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_PROSHORUS_METABOLIC_PROCESS 159 1.98E-47 1.				2.56E-49
GOBP_INTRACELLULAR_TRANSPORT 226 9.46E-51 8.23E-4 GOBP_RESPONSE_TO_HORMONE 154 1.46E-50 1.26E-4 GOBP_RESPONSE_TO_HORMONE 225 3.45E-50 2.93E-4 GOBP_BLOOD_VESSEL_MORPHOGENESIS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELL_QALIZATION 242 4.33E-50 4.06E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 6.24E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 163 2.27E-48 1.77E-4 GOBP_NOSITIVE_REGULATION_OF_OPHOSHMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_OPHOSHMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_OPHOSHMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGUL				6.65E-49
GOBP_RESPONSE_TO_HORMONE 154 1.46E-50 1.26E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 134 4.03E-50 3.96E-4 GOBP_ROOD_VESSEL_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 242 4.93E-50 4.06E-4 GOBP_ROULATION_OF_CELLULAR_LOCALIZATION 242 4.93E-50 4.06E-4 GOBP_ROULATION_OF_CELLULAR_LOCALIZATION 242 4.93E-50 4.06E-4 GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 163 2.27E-48 1.77E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_PROSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-4 GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS 159 1.98E-47 1.51E-4				8.23E-49
GOBP_REGULATION_OF_TRANSPORT 225 3.45E-50 2.93E-4 GOBP_BLOOD_VESSEL_MORPHOGENESIS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELLUCRE_PROCESS 145 4.77E-50 3.96E-4 GOBP_REGULATION_OF_CELLULAR_LOCALIZATION 242 4.93E-50 4.06E-4 GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 2.62E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 163 2.27E-48 1.77E-47 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-47 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-477 1.51E-47 GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS 161 2.76E-47 2.08E-47				1.26E-48
GOBP_BLOOD_VESSEL_MORPHOGENESIS 134 4.03E-50 3.39E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.99E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.99E-4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 145 4.77E-50 3.99E-4 GOBP_REGULATION_OF_CELLULAR_LOCALIZATION 242 4.93E-50 4.06E-4 GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_REGULATION_OF_TRANSFERASE ACTIVITY 163 2.27E-48 1.77E-4 GOBP_REGULATION_OF_TRANSFERASE ACTIVITY 163 2.27E-48 1.77E-47 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-47 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-47 GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-47		225		2.93E-48
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 242 4.93E-50 4.06E-4 GOBP_REGULATION_OF_CELLULAR_LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_ROSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 6.24E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 163 2.27E-48 1.77E-4 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-44 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-44 GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS 161 2.76E-47 2.08E-44		134		3.39E-48
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 242 4.93E-50 4.06E-4 GOBP_REGULATION_OF_CELLULAR_LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_ROSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 6.24E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 163 2.27E-48 1.77E-4 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-44 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-44 GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS 161 2.76E-47 2.08E-44	GOBP_REGULATION_OF_CELL_CYCLE_PROCESS	145	4.77E-50	3.96E-48
GOBP REGULATION OF CELLULAR LOCALIZATION 147 6.79E-50 5.52E-4 GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 168 2.81E-49 2.26E-4 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MOSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_REGULATION OF_TRANSFERASE ACTIVITY 163 2.27E-48 1.77E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.66E-48 4.52E-4 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-4 GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-44				4.06E-48
GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 170 3.29E-49 2.62E-4 GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 6.24E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 163 2.27E-48 1.77E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-44 GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.76E-47 2.08E-44		147	6.79E-50	5.52E-48
GOBP_MACROMOLECULE_CATABOLIC_PROCESS 199 7.93E-49 6.24E-4 GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 163 2.27E-48 1.77E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-4 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-4 GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-44				2.26E-47
GOBP_REGULATION OF TRANSFERASE ACTIVITY 163 2.27E-48 1.77E-4 GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-4 GOBP_COSITIVE_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-4		170	3.29E-49	2.62E-47
GOBP_MUSCLE_STRUCTURE_DEVELOPMENT 124 5.86E-48 4.52E-4 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-44 GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-44		199	7.93E-49	6.24E-47
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 159 1.98E-47 1.51E-4 GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-4				1.77E-46
GOBP_REGULATION_OF_CATABOLIC_PROCESS 161 2.75E-47 2.08E-4				4.52E-46
				1.51E-45
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION 120 1.26E-46 9.43E-44				2.08E-45
	GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	120	1.26E-46	9.43E-45

Figure 100 Gene ontology analysis of genes upregulated in response to CD in $dKO^{MRTF-NLS}$ cells by RNAseq

Gene ontology analysis of genes upregulated by CD treatment in dKO^{MRTF-NLS} cells by RNAseq. FDR<0.05. Relates to Figure 45. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GO BIOLOGOCAL PROCESS	# Genes	p-value	FDR q-value
GOBP NEGATIVE REGULATION OF BIOSYNTHETIC PROCESS	45		2.36E-13
GOBP_BIOLOGICAL_ADHESION	42	6.32E-17	2.36E-13
GOBP_RESPONSE_TO_VIRUS	22		1.65E-12
GOBP_EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	22		9.92E-12
GOBP_RESPONSE_TO_CYTOKINE GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	35	1.07E-14 2.29E-14	1.60E-11 2.86E-11
GOBP_NEGATIVE_REGULATION_OF_NOCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	40		4.18E-11
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	37	4.50E-14	4.21E-11
GOBP_RESPONSE_TO_TYPE_I_INTERFERON	13		4.26E-11
GOBP REGULATION OF CELL ADHESION	27		6.14E-11
GOBP_CYTOKINE_MEDIATED_SIGNALING_PATHWAY	28	1.09E-13	7.40E-11
GOBP_REGULATION_OF_CELL_DIFFERENTIATION	39		1.04E-10
GOBP_INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY	12		2.09E-10
GOBP_CELL_POPULATION_PROLIFERATION GOBP_RESPONSE_TO_INTERFERON_GAMMA	42	7.68E-13 1.33E-12	4.10E-10 6.62E-10
GOBP_RESPONSE_TO_INTERFERON_GAMMA	15		1.33E-09
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	31	3.35E-12	1.44E-09
GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	28		1.44E-09
GOBP_TUBE_DEVELOPMENT	30	4.89E-12	1.93E-09
GOBP_DEFENSE_RESPONSE_TO_VIRUS	16	1 1 1	2.38E-09
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	37		2.38E-09
	11		2.43E-09
GOBP_REGULATION_OF_VIRAL_LIFE_CYCLE GOBP_CELL_SUBSTRATE_ADHESION	13		2.43E-09
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	39	9.44E-12 1.12E-11	2.94E-09 3.36E-09
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	40		3.87E-09
GOBP_DEFENSE_RESPONSE	38		4.33E-09
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	30		4.41E-09
GOBP_REGULATION_OF_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION	14	2.05E-11	5.29E-09
GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION	23		5.33E-09
GOBP_BLOOD_VESSEL_MORPHOGENESIS	23		7.81E-09
GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	29		9.00E-09
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	31	6.31E-11	1.43E-08
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY GOBP_VASCULATURE_DEVELOPMENT	28	9.77E-11 1.05E-10	2.15E-08 2.24E-08
GOBP_VASCOLATORE_DEVELOPMENT GOBP_NEGATIVE_REGULATION_OF_SIGNALING	32		2.24E-08 2.93E-08
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	25	1.56E-10	3.15E-08
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	35		3.18E-08
GOBP_CELL_MIGRATION	34		4.02E-08
GOBP_TUBE_MORPHOGENESIS	25		5.60E-08
GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION	24		7.95E-08
GOBP_VIRAL_LIFE_CYCLE	16		8.56E-08
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	31	4.92E-10	8.56E-08
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION	26		1.01E-07
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	13		1.57E-07 3.02E-07
GOBP_APOPTOTIC_PROCESS	36	1.90E-09	3.02E-07
GOBP_REGULATION_OF_VIRAL_GENOME_REPLICATION	9		3.15E-07
GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION	25		3.58E-07
GOBP_INNATE_IMMUNE_RESPONSE	25	2.39E-09	3.58E-07
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION	27	2.94E-09	4.32E-07
GOBP_LOCOMOTION	36		4.92E-07
GOBP_RESPONSE_TO_LIPID	23	3.64E-09	5.14E-07
GOBP_CELL_CELL_ADHESION	23		6.95E-07
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_SIGNALING_PATHWAY GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM	15		8.13E-07 8.13E-07
GOBP_IMMUNE_EFFECTOR_PROCESS	28	6.49E-09	8.51E-07
GOBP_RESPONSE_TO_TRANSFORMING_GROWTH_FACTOR_BETA	13		8.91E-07
GOBP_CYTOKINE_PRODUCTION	22	7.36E-09	9.33E-07
GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION	16	8.50E-09	1.06E-06
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	31	1.37E-08	1.68E-06
GOBP_PROTEIN_PHOSPHORYLATION	31		1.80E-06
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	26	1.58E-08	1.88E-06
	24		2.19E-06
GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	25	2.25E-08 2.35E-08	2.58E-06 2.66E-06
GOBP RESPONSE TO GROWTH FACTOR	20		2.79E-06
GOBP_OSSIFICATION	15		2.81E-06
GOBP_NEGATIVE_REGULATION_OF_VIRAL_GENOME_REPLICATION	7	3.69E-08	4.00E-06
GOBP_NEGATIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION	20		4.23E-06
GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND	22		4.32E-06
GOBP_TRANSFORMING_GROWTH_FACTOR_BETA_RECEPTOR_SIGNALING_PATHWAY	11		4.99E-06
GOBP_REGULATION_OF_CELL_DEVELOPMENT	16		5.28E-06
GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION GOBP_CELL_MORPHOGENESIS	31		5.32E-06 5.57E-06
GOBP_CELL_MORPHOGENESIS	30		6.09E-06
GOBP_REGULATION_OF_CELL_CELL_ADHESION	15		8.13E-06
GOBP_VIRAL_GENOME_REPLICATION	9		9.50E-06
GOBP_RESPONSE_TO_HORMONE	21	1.03E-07	9.72E-06
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	25		9.83E-06
GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	26		1.57E-05
	11		1.63E-05
	12		1.90E-05
GOBP_AMEBOIDAL_TYPE_CELL_MIGRATION GOBP_REGULATION_OF_CELL_DEATH	15		2.06E-05 2.78E-05
GOBP_REGULATION_OF_CELL_DEATH GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	29		2.76E-05 2.85E-05
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	25		3.24E-05
GOBP_ACTIN_FILAMENT_BASED_PROCESS	19		3.45E-05
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	30		3.64E-05
GOBP_POSITIVE_REGULATION_OF_CELL_DEATH	17		4.66E-05
GOBP_EMBRYO_IMPLANTATION	6		4.72E-05
GOBP_NEUROGENESIS	28		4.79E-05
	12		5.38E-05
GOBP_RESPONSE_TO_OXYGEN_LEVELS	13		5.75E-05
GOBP_IMMUNE_SYSTEM_DEVELOPMENT GOBP_POSITIVE_REGULATION_OF_CELL_SUBSTRATE_ADHESION	21		5.82E-05
GOBP_POSITIVE_REGULATION_OF_CELL_SUBSTRATE_ADHESION GOBP_RESPONSE_TO_PEPTIDE	15		6.00E-05 6.00E-05
GOBP_NEURON_DIFFERENTIATION	25		6.54E-05
GOBP_RESPONSE_TO_INTERFERON_BETA	5	9.62E-07	7.27E-05
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	21		7.73E-05

Figure 101 Gene ontology analysis of genes downregulated in response to CD in $dKO^{MRTF-NLS}$ cells by RNAseq

Gene ontology analysis of genes downregulated by CD treatment in dKO^{MRTF-NLS} cells by RNAseq. FDR<0.05. Relates to Figure 45. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GOP_ACTIN_LAURENT ANSID_PROCESS 141 156.66 151.6 GOP_ACTINE_LINE VARIANTIANE 200 4.0 166.6 151.6 GOP_CONSTRUCTION 200 4.0 166.6 151.6 GOP_COLLAL MORPOGENISS 100 4.00 4.00 4.00 GOP_COLLAL MORPOGENISS 100 4.00 4				
CORP_CONDERCY_TON OF NUMELATION 202 2005-41 7.585-4 CORP_RECULTION OF NUMELATION 203 4.655-6 1.155-5 CORP_RECULTION_CONTRINCT 203 4.655-6 4.555-6 CORP_RECULTION_CONTRIPUT 204 4.655-6 4.555-6 CORP_RECULTION_CONTRIPUT 204 4.655-6 4.555-6 CORP_RECULTION_CONTRUE 204 1.655-3 7.855-6 CORP_RECULTION_CONTRUE 204 1.655-3 7.855-6 CORP_RECULTION_CONTRUE 202 2.456-4 3.856-6 CORP_RECULTION_CONTRUE 202 2.456-4 3.856-6 CORP_RECULTION_CONTRUE 2.256-4 3.856-6 3.856-6 CORP_RECULTION_CONTRUE 2.856-6 3.856-6 3.856-6 CORP_RECULTION_CONTRECULINGU	GO BIOLOGICAL PROCESS			
GARP_REGULATION, OF_PUTRACELLULAR, SISNAL, TRANSDUCTION 204 4.866-63 1156-55 GORP_RELLULATION, OF_PUTRACELLULAR, SISNAL, TRANSDUCTION 204 4.667-65 6.855-65 GORP_BELLULATION, OF_CELLULAR, SISNAL, TRANSDUCTION 204 4.675-65 6.855-65 GORP_BELLULATION, OF_CELLULAR, SISNAL, TRANSDUCTION 214 4.675-65 2.245-62 GORP_DEDUCTION, ENCREMENTATION 204 4.675-65 2.245-62 4.664-65 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 214 4.675-65 7.815-65 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 214 4.676-65 7.815-65 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 214 4.666-65 7.825-66 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 215 2.466-65 7.825-66 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 216 2.826-66 7.825-66 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 217 2.826-66 7.825-66 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 217 2.826-66 7.825-66 GORP_DEDUCTION, CONCENCILLAR, FUNCTION 217 2.826-66 7.825-66 GORP_DEDUCTION, CONCE				
order Detta Luorit.INY 226 6.026-00 8.126-00 <td></td> <td></td> <td></td> <td>1.15E-59</td>				1.15E-59
0499 BLOCICAL ADDRESON 199 4485-89 6585-89 0499 CRELLIGAN MARCHARLECLE (DAMIDNON 220 1775-64 9845-09 0499 APPORTIO, FROGESS 221 1775-64 9845-09 0499 APPORTIO, FROGESS 222 2245-52 1845-49 0499 APPORTIO, FROGESS 222 2245-52 1845-49 0499 APPORTIO, FROGESS 221 2245-52 1845-49 0499 SERIEL, MARIN, OF BLOCHAR, FUNCTION 190 2145-44 3245-44 0499 SERIEL, REDURTION, OF SCHLARD, OF SCHLA		169	5.69E-61	1.08E-57
GORP - ECILLUAR INCORONOLOGUE LOCALIZATION 214 8.07E-58 8.27E-58 2.24E-56				8.12E-57
060P. JESCULATÓN, OF, CELL, DEFERENTIATION 227 2165-65 2045-8 060P. ADSTITOT PROCESS 221 2175-64 8455- 060P. MORCANGE LOCATABLE LOCATAS FUNCTION 222 2245-62 1464- 060P. MORCANGE LOCATABLE LOCATAS FUNCTION 272 245-64 1474- 060P. MORCANGE LOCATABLE LOCATAS FUNCTION 272 245-64 1274-44 060P. MORCANGE LOCATABLE LOCATAS FUNCTION 120 2476-44 1274-44 060P. REQUATION OF PROTEN MORDACINE PROCESS 111 494-67 2174-44 1284-44 1284-44 060P. REQUATION OF CELLULAR CONCOMENT MORDACINE 22 2184-44 1284-44				
OddP ACTIVITIC PROCESS 228 1775-54 9465.53 ODDP POSITIC ACQUILTION C& MACEULIA FUNCTIONS 121 1215-13 1215-13 ODDP POSITIC ACQUILTION C& MACEULIA FUNCTIONS 120 7245-50 1715-14 ODDP NOTTIC ACQUILTION C& MACEURAS CONTRAINC COMPUND, METABOLIC, PROCESS 121 7445-50 1715-14 ODDP ACTIVITIC ACQUILTION C& MACEURAS CONTRAINC COMPUND, METABOLIC, PROCESS 120 2464-47 3525-47 ODDP RECOLLATION C & MACEURAS CONTRAINC COMPUND 120 2464-47 3525-47 ODDP RECOLLATION C & PROTEIN MACEURAND PROCESS 120 2464-47 3526-44 ODDP RECOLLATION C & PROTEIN MACEURAND PROCESS 120 2464-47 3526-44 ODDP RECOLLATION C & PROTEIN MACEURAND 120 2464-44 464-44				
0dBP_DRITME_REGULATION_OF_MACECULAR_PUNCTION 216 1058-53 7.855-5 0dBP_DRITME_REGULATION_OF_MACECOMES 22 245.64 1022 0dBP_DRITME_REGULATION_OF_MACECOMES 211 24 1024 0dBP_DRITME_REGULATION_OF_MACECOMES 101 245.64 1024 0dBP_DRITME_REGULATION_OF_MACECOMES 102 406.74 1024 0dBP_DRITME_REGULATION_OF_MACECOMENT 102 406.74 1024 0dBP_DRITME_REGULATION_OF_CONCINCIN_MACES 102 406.74 1024 0dBP_REGULATION_OF_CELLUDATION 102 405.64 406.74 0dBP_REGULATION_OF_CELLUDATION 103 406.74				9.84E-52
OGP P. MACHWARLEQUE E. CARGOLESS 118 7.24-501 4.176-4 OGP P. SORTINE REVOLUTION OF SUPARINE COMPAGENESS 119 4.127-45 3.226-45 OGP P. SORTINE REVOLUTION OF SUPARINE COMPAGENESS 119 4.127-45 3.226-45 OGP P. SORTINE REVOLUTION OF SUPARINE COMPAGENESS 119 4.427-47 3.176-47 OGP P. SORTINE REVOLUTION OF SUPARINE COMPAGENESS 119 4.424-47 3.176-47 OGP P. SORTINE REVOLUTION OF SUPARINE COMPAGENESS 110 4.426-47 2.176-46 OGP P. SORTING REVOLUTION OF SUPARINE COMPAGENESS 110 4.464-47 2.176-46 2.264-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.176-46 2.126-46 2.126-46 2.126-46 2.126-46 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 2.126-47 <td></td> <td>216</td> <td></td> <td>7.93E-51</td>		216		7.93E-51
GORP POSITVE REQUILATION OF JULIE ECONAGE 201 3.21E-49 1.72E-44 3.00E-40 GORP RESPICACE 101 4.40E-47 3.00E-44 3.00E-44 GORP RESULATION OF POSTONE INCOMPACTION PROCESS 101 4.40E-47 3.00E-46				1.40E-49
GORP DESINCE.TO_ENDODENOS_STIMULUS 114 5154-40 3264-40 GORP POSITIVE REQUIATION_GORMALING 116 5154-40 3264-40 GORP POSITIVE REQUIATION_GORMALING 112 2.474-47 3154-40 GORP SEQUENCESS 112 2.474-47 3154-40 GORP REQUIATION_GOT_CELLULAR COMPONENT MOVEMENT 112 2.574-40 3264-40 GORP REQUIATION_GOT_CELLUPART 112 2.574-40 3264-40 GORP REQUIATION OF CELLUPART.COMPONENT MOVEMENT 120 1.544-41 4.644-4 GORP REQUIATION OF REDEPONDENT DO STREESS 117 2.474-44 6.954-4 GORP REQUIATION OF RESPONSE TO STREESS 117 2.446-44 6.954-4 GORP REQUIATION OF RESPONSE TO STREESS 117 6.466-44 2.644-4 GORP REQUIATION OF RESPONSE TO STREEM RETABOLING.PROCESS 116 6.464-4 2.164-4 GORP CELL PORUMENT STREEM RETABOLING.PROCESS 119 6.462-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-4 2.164-				4.17E-47
GORP TORING REQUIATION OF SIGNALING 198 5.824-84 3.844-44 GORP REQUIATION OF FROTEN HODORCATION PROCESS 191 4.844-47 2.174-44 GORP REQUIATION OF CELL LARA COMPONENT MOVEMENT 192 5.844-44 3.844-44 GORP REQUIATION OF CELL LARA COMPONENT MOVEMENT 192 5.844-44 3.844-44 GORP REQUIATION OF CELL LARA COMPONENT MOVEMENT 192 6.844-44 3.844-44 GORP REQUIATION OF CELL LARA COMPONENT MOVEMENT 192 6.844-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118 3.842-44 3.844-44 GORP REQUIATION OF RESPONSE TO STRESS 118				
GORP BERGULATION OF PROTEIN MODIFICATION PROCESS 191 4.948-47 2174-4 GORP SUPPORTLICATE REP CONSTRUCTION 120 2.9116-46 2165-47 GORP FEGULATION OF CELLUAR CONSTRUCTION 120 2.9116-46 2165-46 GORP FEGULATION OF CELLUAR CONSTRUCTION 221 7.982-46 2.164-4 GORP FEGULATION OF CELLUAR CONSTRUCTION 221 7.982-46 2.164-4 GORP CELL PORTUNE INCOLUZION 221 7.982-46 2.164-4 GORP SEGULATION OF FORSPHORE METADOL PROCESS 120 7.972-44 3.984-4 GORP REGULATION OF FORSPHORE IN METADOL PROCESS 121 3.924-4 1.944-4 3.944-4 GORP DOSTINE REGULATION OF FORSPHORE IN METADOL PROCESS 121 1.942-4 3.944-4 GORP DOSTINE REGULATION OF RESINES TO STULLUS 146 3.944-4 1.944-4 GORP DOSTINE REGULATION OF RESINES TO STULLUS 121 1.942-4 3.944-4 GORP DOSTINE REGULATION OF RESINES TO STULLUS 121 1.942-4 3.944-4 GORP DOSTINE REGULATION OF RESINES TO STULLUS 121 1.942-4 3.944-4 GORP DOSTINE REGULATION OF CREAU				
GORP_SUPPANDLECULAR_PERP_ORCANZATION 192 8.784-87 3.884-40 GORP_NEURGENTS 190 2.0574-40 2.264 GORP_SEGULATION, OF CELLULAR, COMPONENT 190 2.0574-40 2.764-40 GORP_SEGULATION, OF CELLULAR, COMPONENT 120 3.957-40 2.764-40 GORP_SEGULATION, OF CELLURAR, COMPONENT 120 3.957-44 3.564-40 GORP_CELLUROPULATION PROLIFERATION 120 3.764-40 3.564-40 GORP_SEGULATION, OF RESPONSE, TO STRESS 170 6.464-40 4.164-40 GORP_DEDITION_REGULATION 100 1.772-44 3.564-40 GORP_DEDITION_REGULATION 100 1.772-44 3.564-40 GORP_DEDITION_REGULATION 100 1.082-42 3.164-40 GORP_DEDITION_REGULATION OF CONTRINITION 100 <				
GORP REQUIATION OF CELLUAR CONTONENT MOVEMENT 12 23.78-46 8.484-4 CORP REQUIATION OF CELLUAR CONTONENT MOVEMENT 12 7.98-86 2.71-84 CORP SEGLIATION OF CELLUAR CONTONENT MOVEMENT 12 7.98-86 2.71-84 CORP SEGLIATION OF CELLUAR CONTONENT MOVEMENT 12 7.98-86 2.71-84 CORP SEGLIATION OF RESPONSE, TO STRESS 172 2.41-84 0.98-84 CORP REQUIATION OF PROSENSE TO STRESS 172 2.41-84 0.98-44 CORP REQUIATION OF PROSENSE TO STRESS 163 3.94-44 0.98-44 CORP REQUIATION OF PROSENSE TO STRUESS 163 3.94-44 0.98-44 CORP REQUIATION OF PROSENSE TO STRUEST OF STMULUS 163 5.92-43 3.94-44 CORP REQUIATION OF RESPONSE TO STMULUS 163 5.92-43 3.94-44 CORP CELLUAR CONTRON OF RESPONSE TO STMULUS 163 5.92-43 3.94-44 CORP CELLUAR CONTRON OF RESPONSE TO STMULUS 163 5.92-42 3.98-44 CORP CELLUAR CONTRON OF RESPONSE TO STMULUS 164 4.94-42 3.94-44 CORP CELLUAR CONTRON OF RESPONSE TO STMULUS 164				3.63E-44
CORP. PECULATION OF CELLULAR. COMPONENT MOVEMENT 152 6.655-46 2.765-4 CORP. ESTABLISHNET OF PROTEIN LOCAL ZATOM 223 7485-46 2.765-4 CORP. SELL, POPLATION PECLETRATION 223 7485-46 2.765-4 CORP. RESULATION OF PROSPICATE IN STRESS 155 3435-44 4.964-4 CORP. RESULATION OF PROSPICATES IN STRESS 155 3435-44 1.956-4 CORP. RESULATION OF PROSPICATES IN STRESS 156 3458-44 1.956-4 CORP. RESULATION OF PROSPICATES INFORME PATHWAY 147 6.866-44 2.776-4 CORP. DECIDIN, CORALIZATION INTERACTION 116 5.926-43 1.346-44 CORP. CREATING CORON ORGANIZATION 160 5.926-43 1.346-44 3.996-44 CORP. CREATING CORON ORGANIZATION 160 1.926-64 2.986-44 3.986-44 CORP. CREATING CORON ORGANIZATION 161 2.926-44 3.986-44 3.986-44 CORP. CREATING CORONAND ORGANIZATION 161 2.986-44 3.986-44 3.986-44 CORP. CREATING CORONAND ORGANIZATION 162 2.986-44 3.986-34 3			2.08E-46	8.20E-44
OGP ESTABLISHMENT OF, PROTEIN, LOCALATON 212 7.988-64 2.482-44 2.482-44 OGP CELL, DORPHICOENESS, AVIOLED M, SEPRENTIATION 100 1.784-44 2.684-44 OGP CELL, DORPHICOENESS, AVIOLED M, SEPRENTIATION 100 1.784-44 9.684-44 OGP REQUILATION FROSTENES, MICRUED M, SEPRENTIATION 141 8.584-44 9.581-44 OGP REQUILATION, CP PROSTEND, METABOLE, PROCESS 176 8.684-44 1.784-44 OGP REQUILATION, CP PROSTEND, METABOLE, CPROCESS 176 8.684-44 1.784-44 OGP REQUILATION, CP PROSTEND, STADAUE, CPROCESS 161 9.584-43 2.144-42 OGP CRICULTONY, SYSTEM, DEVEMMENT 159 9.562-42 2.264-44 OGP CRICULTONY, SYSTEM, DEVEMMENT 159 9.562-42 2.264-44 OGP CRICULATION, OR CRIAUZITON 115 2.986-44 3.0164-43 OGP CRICULATION, OR CRIAUZITON 115 2.986-44 1.015-366 OGP CRICULATION, OR CRIAUZITON 115 2.986-44 1.015-366 OGP CRICULATION, OR CRIAUZITON 115 2.986-44 1.015-366 OGP CRICULATION, OR CRIAUZITON <t< td=""><td></td><td></td><td></td><td>8.64E-44</td></t<>				8.64E-44
CGBP CELL POPULATION PROJERTEATION 120 143E-44 4.446-4 CORP CELL POPULATION POP RESERVATE TO STRESS 117 2.41E-44 5.05E-4 CORP REQUERTOR OF RESONANCE TO STRESS 117 2.41E-44 5.05E-4 CORP REVENCE TO STRESS 117 2.41E-44 5.05E-4 CORP DEVICE REGULATION OF PROTEIN SCIENCE INTERACTION 141 6.56E-4 2.44E-4 CORP PROTIN REGULATION OF PROTEIN SCIENCE INTERACTION 141 6.56E-4 2.44E-4 CORP PROTIN REGULATION OF RESPONSE TO STIMULUS 167 6.56E-4 2.44E-4 2.46E-4 CORP CELLUAR, TRANSPORT 169 6.6E-4 2.46E-4 2.56E-4 CORP CELLUAR, CONTONENT MONOLICULE CATABOLIC, PROCESS 161 1.44E-4 3.96E-4 CORP CELLUAR, CONTON REGARGINAL STRUCTURE MONPHOENESIS 2.01 2.98E-4 3.98E-4 CORP CELLUAR, CONTON REGARGINAL STRUCTURE MONPHOENESIS 2.01 2.98E-4 3.98E-4 CORP DESTRUCTURE CONTON REGARGINAL STRUCTURE MONPHOENESIS 101 2.98E-4 3.98E-4 CORP DESTRUCTURE CONTON REGARGINAL STRUCTURE MONPHOENESIS 101 2.98E-4 3.98E-4				
GORP COLL MORPHOGENESS, INVOLVED M, DPFERENTIATION 120 1786.44 6.556.44 GORP REGULATION OF PROSPHORUS, METABOLL PROCESS 122 2416.44 6.556.44 GORP REGULATION OF PROSPHORUS, METABOLL PROCESS 126 3.436.44 1776.44 GORP BOLING, CAPPROCESS, NVOLVED, M. SYNBOITC, INTERACTION 141 6.566.44 1776.45 GORP BOLING, CAPPROCESS, NVOLVED, M. SYNBOITC, INTERACTION 147 6.566.44 1776.45 GORP BOLING, CAPPROCESS, NVOLVED, M. SYNBOITC, INTERACTION 146 6.566.42 1584.44 GORP CELL, LINCOLTION, OF RESPONSE TO STIMULUS 147 6.566.42 1584.44 GORP CELLUAR, MACROMOLICUEL, CATASOLL, PROCESS 159.1 1464.42 3.416.44 GORP CELLUAR, MACROMOLICUEL, CATASOLL, PROCESS 121 1464.42 3.416.44 GORP POSITIVE, REGULATION OF CELLULAR COMPONENT IORPHORENESS 120 2.266.41 1476.34 GORP POSITIVE, REGULATION OF CELLULAR COMPONENT ORPHORENESS 120 2.466.44 1476.34 GORP POSITIVE, REGULATION OF CELLULAR COMPONENT ORPHORENESS 120 2.466.41 1476.34 GORP POSITIVE, REGULATION OF CELLULAR COMPONENT ORPHORENESS 12				
CORP. REGULATION. OF PRESPONSE TO, STRESS 171 2 411E-44 9.51E-4 CORP. REGULATION. OF PRESPONSE TO, STRESS 183 44 9.51E-4 CORP. REGULATION. OF PROFINES MICROALLE, PROCESS 143 6.07E-4 9.15E-4 CORP. DECORDER, PROCESS 143 6.07E-4 9.15E-4 CORP. INTRACELLULAR, TRANSPORT 192 0.07E-4 2.35E-4 CORP. INTRACELLULAR, TRANSPORT 160 0.27E-4 2.35E-4 CORP. CRUCITAC CONCRAMINGTON 160 0.27E-4 2.35E-4 CORP. CRUCITAC CONCRAMINGTON 161 1.45E-4 2.85E-4 CORP. CRUCITACING, CORGANIZATION 161 1.45E-4 2.85E-4 CORP. CRUCITACING, CORGANIZATION 161 1.45E-4 2.85E-4 CORP. CRUCITACING, CORGANIZATION 161 2.85E-4 1.85E-4 CORP. CRUCITACING, OR ANATOMICAL STRUCTURE MORPHOCENESIS 161 2.85E-4 1.85E-4 CORP. POSITICE, REGULATION, OF CRULULAR, COMPONINTI, ORGANIZATION 162 2.86E-4 1.85E-4 CORP. DOSTITICE, REGULATION, OF CRULULAR, COMPONINTIC ORGANIZATION 162 2.86E-4 1.85E-				
OGBP REQUILITION OF PHOSPHORUS METABOLIC PROCESS 186 3.43E-44 1.55E-44 OGBP EXATURE LINER DEFECTION PROTEIN SIGNAL NETRACTION 147 6.88E-44 1.55E-44 OGBP EXATURE LINER TRANSPORT 147 6.88E-44 1.55E-44 OGBP EXATURE LINER TRANSPORT 147 6.88E-44 1.55E-44 OGBP INTER ACCOUNT OF PROTEIN SIGNAL NETRACTION 148 6.89E-43 1.34E-44 OGBP INTER ACCOUNT OF RESPONSE TO STIMULUS 148 6.89E-43 1.34E-44 OGBP CELL PROCETON OF REPORTSICS 121 1.48E-42 3.98E-44 OGBP CELL PROCETON OF ANATOMICAL PROCESS 121 1.48E-42 3.98E-44 OGBP COLL PROCEDING COMPONITING COMPRIDGENESIS 129 2.98E-41 3.98E-44 OGBP POSITINE FROCESS 121 2.98E-41 3.98E-34 OGBP POSITINE FROCESS 122 2.98E-41 3.98E-34 OGBP POSITINE FROCENS 120 2.98E-41 3.98E-34 OGBP POSITINE FROCENS 120 2.98E-41 3.98E-34 OGBP POSITINE FROCENS 120 2.98E-41 3.98E-34 OGBP POSITINE				
GORP EXYME LINED ACCEPTOR H701 6.075-4.0 1.356-4 GORP DOSING AREALIATION, OF PORTISM. METAACACI, PROCESS 176 6.886-4.4 1.756-4 GORP DOSING, AREALIATION, PROFINE, METAACAC, PROCESS 176 0.886-4.4 1.756-4 GORP CELL, PROLECTION, ORGANIZATION 196 0.526-4.3 2.886-4 GORP CELL, ARCHECTION, ORGANIZATION 196 0.526-4.3 3.986-4 GORP CELLULAR, COMPONENT MORPHOGENESIS 201 2.986-4.4 3.886-4 GORP CELLULAR, COMPONENT MORPHOGENESIS 201 2.986-4.4 3.886-4 GORP DOSTITIVE, REGULATION CELLULAR, COMPONENT MORPHOGENESIS 201 2.986-4.4 3.886-4 GORP DOSTITIVE, REGULATION CELLULAR, COMPONENT, METHOLIPIK, COMPONENT ORGANIZATION 101 2.246-4.1 3.986-3 GORP DOSTITIVE, REGULATION OF CATALYTIC, ACTIVITY 106.6 3.486-4 1.986-3 GORP DOSTITIVE, REGULATION, OF CATALYTIC, ACTIVITY 106.6 3.486-4 1.986-3 GORP <td< td=""><td></td><td></td><td></td><td>9.51E-42</td></td<>				9.51E-42
GORP BILCOGCAL, PROCESS, INVOLVED JN, SYMBIOTC, NTERACTION 141 1898-44 2.164-4 GORP INTRACELLURAR TRANSPORT 192 1988-43 2.884-4 1.844-1 GORP INTRACELLURAR TRANSPORT 193 5.894-43 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 1.944-1 2.944-1 1.944-1 2.944-1 1.945-1 1.946-1 1.946-1 1.945-1 1.945-1 1.945-1 1.945-1 1.945-1 1.945-1 1.946-1 1.944-1 1.9		147		1.35E-41
OGP PIRACELULIAR TRANSFORT 192 1082 2.854-3 OGP NEATHE REQULATION OF RESPONSE TO STIMULUS 197 5.806-43 1.346-44 OGP CELL, PROCECTION, ORGANIZATION 100 526-43 1.346-44 OGP CELL, DRANGECTINE, ORGANIZATION 100 1024-42 2.256-44 OGP CELLUAR MACROMALECULE CATABOLIC PROCESS 101 126-42 2.856-44 OGP CELLUAR MACROMALECULE CATABOLIC PROCESS 101 2.956-42 5.866-44 OGP CELLUARD MACROMAL STRUCTURE MORPHOGENESIS 101 2.956-42 5.866-44 OGP REGULATION OF ANTOMICAL STRUCTURE MORPHOGENESIS 101 2.956-42 5.866-44 OGP REGULATION OF CALLUAR COMPONENT ORGANIZATION 117 7.996-42 1.666-44 1.666-33 OGP REGULATION OF CALLUTE CATORYTY 106 2.966-441 5.066-44 1.666-34 1		179		1.77E-41
GORP ADDRESS 197 5080-2014 1.456-41 GORP CELL PROLECTION, OF ANEPHOENER TO 190 1022-42 2.256-43 GORP CELL PROCENTON, OF ANEPHOENER TO 190 1022-42 2.256-43 GORP CELLUAR COMPONENT MORPHOENERSIS 191 1464-42 3.164-44 GORP CELLUAR COMPONENT MORPHOENERSIS 191 2.964-42 3.066-44 GORP REGULATION, OF ANATONICAL, STRUCTURE, MORPHOENERSIS 199 2.986-42 5.086-44 GORP REGULATION, OF CULLUAR, COMPONENT ORGANIZATION 147 7.986-42 1.465-34 GORP REGULATION, OF CULLUAR, COMPONENT ORGANIZATION 193 2.986-44 3.985-34 GORP REGULATION, OF CATALYTIC ACTIVITY 196 2.986-44 3.985-34 GORP REGULATION OF COMPLICATION 6.296-44 3.486-34 3.486-34 GORP REGULATION OF COMPLICATION 192 1.986-44 3.486-34 GORP REGULATION OF CONTRUTICE CONTRUMENT 1.986-44 3.486-34 3.486-34 GORP REGULATION OF CONTRUMICE CONTRUMENT 1.986-44 3.486-34 3.486-34 GORP REGULATION OF CONTRUMICE CONTRUMENT 3.986-34 <td< td=""><td></td><td></td><td></td><td>2.14E-41</td></td<>				2.14E-41
GORP CELL, PROJECTON, ORGANIZATION 100 522:43 1.54:4-3 1.54:4-3 1.52:4-3 2.52:4-4 3.62:4-4 4.62:3-4 4.62:4-4 4.62:5-4 4.62:4-4 4.62:5-4 4.62:4-4 4.62:5-4 4.62:4-4 4.62:5-4 4.				2.63E-41
GORP CIRCULATORY SYSTEM DEVELOPMENT 160 10224 22.824 GORP CILLUAR COMPONET MORPHOGENESIS 121 146.42 3.814 GORP CILLUAR COMPONET MORPHOGENESIS 121 2.984.42 3.814 GORP CILLUAR COMPONET MORPHOGENESIS 121 2.984.42 3.884.41 GORP MOREOSTATIC PROCESS 121 2.984.42 3.884.41 GORP REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 133 5.984.41 1.985.31 GORP REGINATION OF COMPACITURE MORPHOGENESIS 131 2.984.41 1.985.31 GORP REURON, DIFFECENTATION 132 2.984.41 1.985.31 GORP REURON, DIFFECENTATION 132 2.987.41 1.455.31 GORP REULARINO, OF CATALYTIC, ACTIVITY 166 2.986.41 1.765.31 GORP REGULATION OF CATALYTIC, ACTIVITY 166 2.986.41 1.765.31 GORP REGULATION, OF CATALYTIC, ACTIVITY 166 2.986.41 1.765.31 GORP ACTIVE, REGULATION, OF CATALYTIC, ACTIVITY 166 2.986.41 1.765.31 GORP ACTIVE, REGULATION, OF CATALYTIC, ACTIVITY 166 2.986.41 1.765.31				
GORP CELLUAR COMPONENT MORPHODENESIS 121 145E-42 3.09E-42 GORP CELLUAR MACRONOLCUE CATABOLIC PROCESS 115 145E-42 3.09E-42 GORP CELLUAR MACRONOLCUE CATABOLIC PROCESS 121 2.99E-42 5.88E-44 GORP MEDILATION OF ANATOMICAL STRUCTURE MORPHODENESIS 131 5.98E-44 1.01E-33 GORP MEDILATION OF ANATOMICAL STRUCTURE MORPHODENESIS 131 2.99E-42 3.98E-44 GORP MELON DIFFERENTIATION 162 2.99E-44 3.99E-44 3.99E-44 GORP MELON DIFFERENTIATION 162 2.99E-44 3.99E-44 3.99E-44 GORP MELON DIFFERENTIATION 163 2.99E-44 3.99E-44 3.99E-44 GORP MELON DIFFERENTIATION 163 2.99E-44 3.99E-44				2.25E-40
GOBP CELLUAR, MACRONOLECULE, CATADOLIC, PROCESS 154 154 295 231 GOBP CELLUAR, MACRONOLECULE, CATADOLIC, PROCESS 201 296 2 5885 4 602 5885 4 5885 4 5885 4 5885 1015 3 5295 2 5885 1015 3 5295 2 5885 1015 3 5295 1015 3 5295 1015 3 1015 3 1015 3 1015 3 1015 3 1015 4 6805 7 4 6805 7 4 6805 7 4 6805 7 4 6805 7 4 1015 3 115 4 6805 7 4 1015 3 115 4 115 4 115 4 115 4 115 4 115 4 115 4 115 4 115 4 115 4 115 4 115 <td< td=""><td></td><td></td><td></td><td>3.09E-40</td></td<>				3.09E-40
GOBP GELL JUNCTION GRANTCR PROCESS 201 296 296 297 298				3.41E-40
GOBP RECULATION OF ANATOMICAL STRUCTURE, MORPHOCENESIS 139 539E-42 10.1653 GOBP POSITIVE RECULATION OF CELLULAR, COMPONENT ORGANIZATION 147 799E-42 1.48E-31 GOBP CORDING ECOLLULAR, COMPONENT ORGANIZATION 161 2.44E-41 1.39E-33 GOBP INTERCENT ON CONTROLOGENESIS 192 1.44E-34 3.99E-33 GOBP INTERCENTATION 162 2.49E-41 4.88E-33 GOBP CONTROLER, REGULATION OF CATALYTIC, ACTIVITY 168 2.49E-41 4.88E-33 GOBP CONTROLER, REGULATION OF CATALYTIC, ACTIVITY 168 2.49E-41 1.82E-30 GOBP CONTRE, DEVELOPMENT 169E-40 1.79E-40 1.42E-40 GOBP CONTRE, DEVELOPMENT 169E-40 1.79E-40 1.42E-40 GOBP CONTRE, DEVELOPMENT 1.42E-40 3.24E-30 3.24E-30 GOBP CONTRE, DEVELOPMENT 1.42E-40 3.24E-30 3.24E-30 GOBP CONTRE, DEVELOPMENT 1.42E-40 3.24E-30 3.24E-30 GOBP CONTRE, DEVELOPMENT 1.42E-30E-30 3.24E-30 3.24E-30 GOBP CONTRE, DEVELOPMENT 1.42E-30E-30 3.24E-30 3.24E-30 <td>GOBP_CELL_JUNCTION_ORGANIZATION</td> <td>115</td> <td>2.95E-42</td> <td>5.88E-40</td>	GOBP_CELL_JUNCTION_ORGANIZATION	115	2.95E-42	5.88E-40
GOBP_DOSITIVE_REGULATION_OF_DELLULAR_COMPONENT_ORGANIZATION 147 790E-42 1.496-33 GOBP_ORGANONUND_BIOSYNTHETC_PROCESS 110 2.406-41 1.575-33 GOBP_RESPONSE_TO_WOUNDING 110 2.406-41 4.066-33 GOBP_RESPONSE_TO_WOUNDING 110 2.406-41 4.066-33 GOBP_CELL_OVCLE 116 2.406-41 4.066-33 GOBP_COLL_OVCLE 116 4.062-35 1.126-41 1.075-33 GOBP_COLL_OVCLE STRUTURE_DEVELOPMENT 106 4.426-41 1.075-33 GOBP_MICATIVE_DEVELOPMENT 106 5.426-41 1.075-33 1.126-40 1.326-33 GOBP_MICATIVE_DEVELOPMENT 106 2.466-43 3.246-33 3.066-33 GOBP_MICATIVE_CONVENTION_INVOLVED_IN_MORPHOSENESIS 146 3.266-33 3.066-33 3.066-33 3.066-33 3.066-33 3.067-33 3.066-33 3.067-33 3.066-33 3.067-33 3.066-33 3.067-33 3.067-33 3.067-33 3.066-33 3.067-33 3.067-33 3.067-33 3.067-33 3.067-33 3.067-33 3.067-33				5.88E-40
GOBP_DORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS 192 108E-41 3.956-33 GOBP_RESPONSE TO_WOUNDING 110 224E-41 3.956-33 GOBP_RESPONSE TO_WOUNDING 126 2.06E-41 5.06E-33 GOBP_COSTINE_REGULATION OF CATALYTIC_ACTIVITY 166 2.06E-41 1.05E-33 GOBP_COSTINE_REGULATION OF DEVELOPMENTAL PROCESS 157 1.02E-40 1.02E-33 GOBP_COSTINE_REGULATION OF DEVELOPMENTAL PROCESS 1.05 1.16E-40 1.02E-33 GOBP_COSTINE_REGULATION_OF_SIGNALING 1.05 1.16E-40 3.04E-33 GOBP_MICHINE_ROLATION_INVOLVED_IN_MORPHOGENESIS 1.02 4.02E-40 3.04E-33 GOBP_MICHINE_CONTREL FORMATION_INVOLVED_IN_MORPHOGENESIS 1.02 4.02E-40 3.04E-33 GOBP_MICHINE_CONTREL 2.02E-33 2.02E-37 1.05E-31 2.02E-37 GOBP_MICHINE_CONTREL 3.04E-31 3.04E-31 3.04E-31 3.04E-31 GOBP_MICHINE_CONTREL 3.04E-31 3.04E				1.01E-39
GOBP. RESPONSE, TO. WOUNDING 110 2.44-11 3.965-33 GOBP. DECRUD, DIFFERENTIATION 116 2.608-14 4.686-33 GOBP. CELL, CYCLE 116 2.496-41 10.755-33 GOBP. CELL, CYCLE 116 6.435-41 10.755-33 GOBP. REGULATION OF PROTEIN PHOSPHORYLATION 112 8.77E-41 1.435-33 GOBP. MUSCLE, STRUCTURE, DEVELOPMENT 1105 1.10E-40 1.10E-40 1.10E-40 1.10E-40 1.056-33 GOBP. MUSCLE, STRUCTURE, DEVELOPMENT 112 3.61E-40 3.045-33 GOBP. AUXIN, FLAMENT, ORGANIZATION 1142 3.61E-40 5.005-33 GOBP. MUSCLE, STRUCTURE, FORMATION, INVOLVED, IN, MORPHOGENESIS 1142 4.42E-30 6.016-33 GOBP. MUSCLE, DEVELOPMENT 124 4.42E-30 6.016-33 GOBP. AUXIN, FLAMENT, GRANIZATION 1162 4.42E-30 6.016-33 GOBP. MUSCLE, DEVELOPMENT 124 4.42E-30 6.016-33 GOBP. AUXIN, FLAMENT, GRANIZATION 1162 4.42E-30 6.016-33 GOBP. 3.026-33 GOBP. 3.026-33 GOBP. 3.026-33 GOBP. 3.026-33 GOBP. 3.026-33 GOBP.3				
GORP NEURON DIFFERENTATION 163 2.69E-41 5.46E-31 GORP DESTIVE, REGULTION OF CATALYTIC, ACTVITY 166 2.99E-41 5.43E-34 GORP CELL, CYCLE 196 6.43E-41 5.04E-33 GORP DOSTIVE, REGULTION OF DEVELOPMENTAL, PROCESS 157 1.02E-40 1.75E-33 GORP ACTIVE, REGULTION, OF, SIGNALING 195 1.16E-40 1.36E-33 GORP ACTIVE, REGULTION, OF, SIGNALING 195 2.16E-40 3.26E-33 GORP ACTIVE, REGULTION, OF, SIGNALING 196 3.26E-33 2.30E-33 GORP ACTIVE, REGULTION, OF, SIGNALING 198 3.86E-33 2.30E-33 GORP ANTAMICAL, STRUCTURE, FORMATION, INVOLVED, IN MORPHOGENESIS 164 2.20E-33 2.30E-33 GORP MUND, HEALING 071 2.06E-39 2.30E-33 2.06E-39 2.30E-33 GORP MUND, MERADIC, PROCESS 114 2.00E-33 2.20F-33 2.20F-33 GORP MELRON, DEVELOPMENT 1.26E-37 6.36E-37 6.36E-37 GORP RELINCH, REGULTION OF MUNTCELLILAR, ORGANISMAL, PROCESS 116 6.39E-37 6.36E-37 6.36E-37 6.36E-37				
GORP DOSITIVE REGULATION OF CATALYTIC ACTIVITY 166 (2967) 169 (2967) <td< td=""><td></td><td></td><td></td><td></td></td<>				
GOBP CELL CYCLE 106 642E-41 107E-33 GORP REGULATION OF PROTEIN PHOSPHORYLATION 152 877E-41 11.43E-33 GORP POSITIVE REGULATION OF DEVELOPMENT 105 115E-40 1.78E-33 GORP AUXINE REGULATION OF DEVELOPMENT 105 115E-40 1.78E-33 GORP AUXINE REGULATION OF SIGNALING 165 216E-40 3.24E-33 GORP AUXINE REGULATION OF SIGNALING 165 216E-40 3.24E-33 GORP AUXINE REGULATION OF SIGNALING 186 246-40 6.05E-33 GORP AUXING COMPLEX SUBUNIT ORGANIZATION 196 398E-39 5.40E-33 GORP RELIGION DEVELOPMENT 142 442E-39 6.01E-37 GORP RELIGION DEVELOPMENT 144 651E-37 6.86E-37 GORP RELIGUENTION OF FUNCTIONELULAR ORGANISMAL PROCESS 199 211E-37 1.27E-38 GORP REGULATION OF CHANDRORT 179 12E-36 1.38E-39 5.40E-37 GORP REGULATION OF CHANDRORT 179 12E-36 1.38E-39 5.60E-37				
GORP POSITIVE REGULATION OF DEVELOPMENT 1052 1052 GORP MUSCLE STRUCTURE DEVELOPMENT 1051 1152-401 1352-30 GORP ACTIN FLAMENT ORGANIZATION 1051 1152-401 1362-30 GORP ACTIN FLAMENT ORGANIZATION 1055 1152-401 3345-31 GORP ACTIN FLEREGULATION OF SIGNALING 1055 1164 2365-39 GORP ANTONICAL, STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 1461 2260-39 2065-39 GORP PORTINE CONTAINING COMPLEX SUBUNIT ORGANIZATION 1981 398-59 5-406-33 GORP PORTINE REQUILATION OF MULTICELULAR ORGANISMAL PROCESS 1591 2116-37 2265-39 GORP PORTINE REQUILATION OF MULTICELULAR ORGANISMAL PROCESS 1591 2116-37 226-38 GORP PRESIDENCE TO CYTOKINE 106 658-37 636-35 606-37 636-37 636-37 636				1.07E-38
GORP MUSCLE STRUCTURE DEVELOPMENT 119E-40 119E-40 GORP ACTIN FLAMENT ORGANIZATION 89 118E-40 136E-30 GORP MICRATIVE REGULATION, OF, SIGNALING 142 316E-40 5.36E-30 GORP MUED (PUELOPMENT 142 316E-30 5.36E-30 GORP, MOLED (PAILING 000000000000000000000000000000000000	GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	152	8.77E-41	1.43E-38
GORP ACTIN, FILAMENT, ORGANIZATION 89 1.86E-30 1.80E-30 GORP NEGATIVE, REGULATION, OF, SIGNALING 165 2.16E-40 5.34E-31 GORP NUED, REVELOPMENT 142 3.81E-40 5.30E-33 GORP MUCINCAL, STRUCTURE, FORMATION, INVOLVED, IN, MORPHOGENESIS 144 4.20E-401 6.05E-31 GORP MICHAN, METABOLIC, FORMATION, INVOLVED, IN, MORPHOGENESIS 142 4.22E-39 6.01E-33 GORP NEURON, DEVELOPMENT 142 4.24E-39 6.01E-37 1.86E-37 2.96E-37 1.96E-37 1.86E-37 2.96E-37 1.96E-37 1.86E-37 2.96E-37 1.96E-37				1.62E-38
GOBP, NEGATIVE, REGULATION, OF, SIGNALING 166 2.16E-40 3.24E-31 GOBP, TUBE, DEVELOPMENT 142 3.01E-40 6.05E-31 GOBP, MANTONICAL, STRUCTURE, FORMATION, INVOLVED, IN, MORPHOGENESIS 146 4.02E-401 6.05E-31 GOBP, MEURO, DEVELOPMENT 142 2.06E-30 5.40E-31 GOBP, DEURO, DEVELOPMENT 142 2.06E-30 5.40E-31 GOBP, DEURO, DEVELOPMENT 142 2.00E-30 2.07E-30 GOBP, DEURO, DEVELOPMENT 142 2.00E-30 2.07E-30 GOBP, DEURO, DEVELOPMENT 142 2.00E-30 2.07E-30 GOBP, CELL, DUBRTRATE, ADHESION 706 2.07E-30 2.07E-30 GOBP, CELL, DUBRTRATE, ADHESION 110 1.08E-36 1.33E-30 GOBP, CELL, GELL, ADHESION 1179 1.25E-36 2.31E-30 GOBP, CELL, MER, ADHESION 1179 1.25E-36 2.35E-31 GOBP, CELL, MEL, SIGNALING 127 1.25E-36 2.35E-31 GOBP, CELL, CELL, SIGNALING, OF, PROTEN, TRANSPORT 142 7.07E-36 2.45E-33 GOBP, CELL, MEL, ADHESION <				1.79E-38
GORP TUBE DEVELOPMENT 142 3.01E-40 5.00E-30 GORP ANATONCAL, STRUCTURE FORMATION_INVOLVED_IN_MORPHOGENESIS 146 4.20E-40 6.05E-31 GORP PROTEINCAL, STRUCTURE FORMATION_INVOLVED_IN_MORPHOGENESIS 142 4.20E-30 6.05E-31 GORP PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 198 3.89E-39 6.01E-31 GORP CELL_SUBSTRATE_ADHESION 142 4.24E-39 6.01E-31 GORP CELL_SUBSTRATE_ADHESION 70 126E-37 1.66E-30 GORP CELL_SUBSTRATE_ADHESION 70 126E-37 1.66E-30 GORP CELL_DART_MORPHOGENESIS 144 6.11E-37 2.72E-38 GORP CELL_DART_MORPHOGENESIS 144 6.11E-37 2.72E-38 GORP REGULATION OF CELL SIGNALITANSPORT 170 1.25E-38 1.51E-3 GORP CELL_USIONALINON 71 1.25E-35 1.42E-31E-3 5.05E-3 GORP CELL_USIONALINON 718 3.65E-31 5.05E-3 1.22E-34E-35 5.05E-3 GORP POSTIVE REGULATION OF, TRANSPORT 173 3.42E-35 5.04E-3 5.05E-3 GORP POSTIVE REGULATION OF, TRANSPORT </td <td></td> <td></td> <td></td> <td></td>				
COBP ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 146 4.026-401 6.055-30 CORP WOUND IFALING 97 2.065-30 5.005-30 CORP PROTEIN CONTAINING COMPLEX, SUBUNIT_ORGANIZATION 198 3.985-391 5.405-30 CORP NEURON DEVELOPMENT 142 2.005-30 2.075-30 CORP DEULOND DEVELOPMENT 142 2.005-30 2.075-30 2.075-30 CORP DESITIVE REGULATION OF MULTICELLULAR_ORGANISMAL_PROCESS 159 2.115-37 2.272-30 CORP DESITIVE REGULATION OF CELL ADHESION 110 1085-36 1.335-30 CORP CELL CARL SIGNALING 179 1.255-36 1.515-3 CORP CELL CELL SIGNALING 179 1.255-36 3.595-3 CORP CELL CELL SIGNALING 121 1.225-36 3.595-3 CORP CELL CELL SIGNALING OF INTRANSPORT 141 3.075-36 3.595-3 CORP REGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 132 2.275-35 2.535-35 CORP REGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 120 2.275-34 2.536-33 CORP R				
GOBP WOUND HEALING 97 206E-39 2.90E-33 GORP PROTEN CONTAINING_COMPLEX_SUBUNT_ORGANIZATION 149 3.80E-30 5.00E-30 GORP NEURON, DEVELOPMENT 142 4.20E-30 6.01E-33 GORP CELL_SUBSTRATE_ADHESION 174 2.00E-30 2.87E-37 1.66E-33 GORP CELL_SUBSTRATE_ADHESION 178 1.20E-37 1.66E-33 GORP RESPONSE TO_CYTOKINE 144 6.51E-37 8.25E-33 GORP RESPONSE TO_CYTOKINE 110 1.00E-36 1.35E-34 GORP REGULATION_OF_CELL_ADHESION 110 1.00E-36 1.35E-34 GORP REGULATION_OF_TRANSPORT 179 1.25E-36 1.35E-34 GORP PLOLL_SKOMALING 177 1.94E-36 3.59E-34 GORP CELL_USKOMALING 178TAGELLULAR_SIGNAL_TRANSDUCTION 129 1.23E-35 1.40E-33 GORP PLOSTIVE REGULATION OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 129 1.23E-36 1.40E-33 GORP PLOSTIVE REGULATION OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 129 1.22E-36 1.50E-32 GORP PLOSTIVE REGULATION OF_INTRACELLULAR_ORGANISMAL_DEVEND 120E-35				
GOBP NEURON DEVELOPMENT 142 42E-39 601E-33 GOBP MICHA METABOLIC PROCESS 124 200E-38 227E-33 GOBP CELL_SUBSTRATE_ADHESION 78 126E-37 166E-33 GOBP CELL_SUBSTRATE_ADHESION 78 126E-37 167E-33 GOBP CELL_PART_MORPHOGENESIS 106 639E-33 639E-33 GOBP REGULATION OF CELL_ADHESION 101 108E-36 151E-3- GOBP REGULATION OF CELL_ADHESION 107 129E-36 151E-3- GOBP CELL_USIGNALING 177 194E-36 231E-33 GOBP CELLUAR_AMIDE METABOLIC PROCESS 142 751E-36 635E-35 GOBP POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 129 123E-35 140E-35 GOBP NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 120 122E-34 132E-33 GOBP POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 120 122E-34 132E-33 GOBP RESPONSE TO OXYGEN CONTAINING COMPOUND 130 820E-35 9.86E-33 GOBP REGULATION OF INTRAINSE CATIVITY 147 235E-33 136E-33				2.90E-37
GOBP_MRNA_MÉTABOLIC_PROCESS 247 2005-38 2675-3 GOBP_CELL_UBSTRATE_ADHESION 78 2262-3 1.665-3 GOBP_RESPONSE_TO_CYTOKINE 144 6.515-37 8.255-3 GOBP_RESULTION, OF_MULTICELLULAR_ORGANISMAL_PROCESS 159 2.115-37 2.726-3 GOBP_RESULTION, OF_CELL_ADHESION 106 6.396-37 8.595-3 GOBP_REGULATION, OF_CELL ADHESION 10 1.086-36 1.315-3 GOBP_CELL_CALLSIGNALING 175 1.946-36 2.316-3 GOBP_INTACACLULULAR_PROTEIN_TRANSPORT 1141 3.076-36 3.595-3 GOBP_CELLULAR_ANDE_METABOLIC_PROCESS 142 7.516-36 8.656-35 GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 120 8.806-35 9.686-35 GOBP_REFORDE_REGULATION_OF_LORGOMOTION 1212-34 1.326-3 1.326-3 GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 170 2.076-34 2.186-3 GOBP_REGULATION OF_LORGOMOTION 126 2.486-34 3.576-3 GOBP_REGULATION OF_MUSE_EACTIVITY 147 2.286-34 2.386-3 GOBP_REGU	GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION	198	3.89E-39	5.40E-37
GOBP CELL_SUBSTRATE_ADHESION 78 126E-37 166E-33 GOBP POSTRVE REGULATION OF MULTICELLULAR_ORGANISMAL_PROCESS 159 2.11E-37 2.72E-33 GOBP RESPONSE TO CYTOKINE 144 6.51E-37 8.25E-33 GOBP REQUATION OF CELL ADHESION 101 1.68E-37 8.55E-33 GOBP REQUATION OF TRANSPORT 179 1.25E-36 1.51E-3 GOBP CELL CELL SIGNALING 177 1.94E-36 2.31E-3 GOBP CELLUAR AMDE METABOLIC PROCESS 164 3.55E-3 GOBP POSITIVE REGULATION OF INTRACELLULAR, SIGNAL_TRANSDUCTION 129 1.22E-35 1.41E-3 GOBP POSITIVE REGULATION OF INTRACELLULAR, SIGNAL_TRANSDUCTION 120 8.80E-33 1.96E-34 1.32E-35 GOBP POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 120 8.80E-35 120 8.80E-35 GOBP POSITIVE REGULATION OF PROCESS 120 8.80E-35 1.96E-34 1.32E-34 GOBP REGULATION OF PROCESS 120 8.80E-35 1.96E-34 1.32E-34 GOBP REGULATION OF PROCESS 120 8.80E-35 1.96E-34 1.32E-34 GOBP REG				6.01E-37
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 159 2.11E-37 2.72E-33 GOBP_CEDU_PART_MORPHOGENESIS 106 6.89E-37 8.59E-33 GOBP_REGULATION_OF_CELL_ADHESION 101 1.08E-36 1.51E-37 GOBP_REGULATION_OF_CENANSPORT 110 1.08E-36 1.51E-37 GOBP_CELLULAR_REDUCTION_TRANSPORT 111 1.08E-36 1.51E-37 GOBP_CELLULAR_REDUC_PROTEIN_TRANSPORT 1141 3.07E-36 3.59E-37 GOBP_DECLULUAR_REGULATION_OF_INTRACELULUAR_SIGNAL_TRANSDUCTION 129 122E-35 1.40E-36 GOBP_PETIDE_MERGULATION_OF_PROTEIN_UNETABOLIC_PROCESS 120 1.22E-34 1.32E-33 GOBP_PETIDE_MERGULATION_OF_PROTEIN_METABOLIC_PROCESS 120 1.22E-34 1.32E-33 GOBP_REGULATION_OF_PROTEIN_UNETABOLIC_PROCESS 120 1.22E-34 1.32E-33 GOBP_REGULATION_OF_PROTEIN_CONTINING_COMPOUND 170 1.47E-34 1.57E-33 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 147 2.25E-34 2.34E-33 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 147 2.42E-33 1.66E-32 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY				
GOBP_RESPONSE_TO_CYTOKINE 144 6.5HE-37 6.22553 GOBP_CELL_PART_MORPHOCENESIS 106 6.89E-37 6.59E-31 GOBP_REGULATION_OF_TRANSPORT 119 1.25E-36 1.51E-3 GOBP_REGULATION_OF_TRANSPORT 117 1.25E-36 1.51E-3 GOBP_INTRACELLULAR_NOG 175 1.94E-36 2.31E-3 GOBP_INTRACELLULAR_AMDE_METABOLIC_PROCESS 142 7.51E-36 6.85E-3 GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 136 2.27E-35 2.53E-33 GOBP_POSITIVE_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP_POSITIVE_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP_RESOULATION_OF_UNDROLASE_ACTIVITY 147 2.07E-34 2.18E-33 GOBP_REGULATION_OF_MURRANE 100 7.87E-34 3.57E-33 GOBP_REGULATION_OF_TRANSPERASE_ACTIVITY 147 2.34E-34 3.57E-33 GOBP_REGULATION_OF_MURRANE 100 7.87E-34 3.36E-33 GOBP_REGULATION_OF_MURRANEA 107 2.07E-34 2.18E-33 GOBP_REGULATION_OF_MURRANEA				
GOBP_CELL_PART_MORPHOGENESIS 106 6.89E-37 6.59E-3 GOBP_REGULATION_OF_CELL_ADHESION 110 108E-36 151E-3 GOBP_REGULATION_OF_TRANSPORT 117 128E-36 151E-3 GOBP_CELL_CELL_SIGNALING 117 194E-36 2.31E-3 GOBP_CELL_ULAR_AMDE_METABOLIC_PROCESS 141 3.07E-36 8.65E-3 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 122 2.345-3 1.41E-3 GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 136 2.27E-35 2.53E-3 GOBP_PEPTDE_METABOLIC_PROCESS 120 8.30E-35 9.64E-3 GOBP_REGULATION_OF_INTRANSECASE_ACTIVITY 147 2.27E-34 2.34E-3 GOBP_REGULATION_OF_MONOF_LOCOMOTION 170 2.07E-34 2.34E-3 GOBP_REGULATION_OF_INTANSECASE_ACTIVITY 147 2.25E-34 2.34E-3 GOBP_REGULATION_OF_MONESA COTIVITY 127 3.48E-34 3.57E-3 GOBP_REGULATION_OF_MONESA COTIVITY 127 3.48E-34 1.56E-33 GOBP_REGULATION_OF_MONESA COTIVITY 128 1.68E-33				
GOBP REGULATION, OF CELL ADHESION 110 108E-36 133E-3 GOBP REGULATION, OF TRANSPORT 176 128E-36 151E-3 GOBP_CELL CELL SIGNALING 175 194E-36 2.31E-3 GOBP_CELLUAR, AMDE METABOLIC, PROCESS 141 3.07E-36 3.59E-3 GOBP_DOSITIVE, REGULATION, OF, PROTEIN, METABOLIC, PROCESS 132 2.27E-35 2.53E-35 GOBP_TUBE_MORPHOGENESIS 120 8.80E-35 9.68E-33 GOBP_PETITUE REGULATION, OF, PROTEIN, METABOLIC, PROCESS 120 8.80E-35 9.68E-33 GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 120 1.22E-34 1.32E-34 GOBP_REGULATION, OF, PROTEINS, ECONTAINING COMPOUND 170 2.07E-34 2.18E-33 GOBP_REGULATION, OF, THANSPERASE ACTIVITY 147 2.25E-34 2.32E-33 GOBP_REGULATION, OF, THANSPERASE ACTIVITY 127 3.48E-34 3.57E-33 GOBP_REGULATION, OF, MEMBRANE 100 7.67E-34 7.78E-33 GOBP_REGULATION, OF, MULTOELLULAR, ORGANISMAL, DEVELOPMENT 122 1.82E-33 1.06E-33 GOBP_RESPONSE_TO, GROWTH, FACTOR 168 <e-32< td=""> 2.4</e-32<>				8.59E-35
GOBP CELL CELL SIGNALING 175 194E-36 2.31E-3- GOBP MITRACELLULAR MODE METABOLIC PROCESS 141 307E-36 3.59E-3- GOBP CELLULAR AMIDE METABOLIC PROCESS 142 7.51E-36 8.65E-3- GOBP NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 129 1.23E-35 1.40E-33 GOBP NEGATIVE REGULATION OF FORTEIN METABOLIC PROCESS 130 8.27E-35 9.68E-33 GOBP POSITIVE REGULATION OF LOCOMOTION 95 1.47E-34 1.57E-33 GOBP RESPONSE TO OXYGEN CONTAINING COMPOUND 170 2.07E-34 2.34E-34 GOBP REQULATION OF TRANSFERASE ACTIVITY 147 2.48E-34 3.57E-33 GOBP REQULATION OF TRANSFERASE ACTIVITY 147 3.48E-34 3.57E-33 GOBP REQULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 1.36E-33 1.36E-33 GOBP REQULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 1.26E-33 1.06E-33 GOBP RESPONSE TO GROWTH FACTOR 105 2.56E-33 2.46E-33 GOBP NEGATIVE REGULATION OF GENE EXPRESSION 129 1.17E-32 1.15E-33 GOBP NEGATIVE REGULATION OF GENE EXPRESSION 129 <t< td=""><td></td><td></td><td>1.08E-36</td><td>1.33E-34</td></t<>			1.08E-36	1.33E-34
GOBP_INITRACELLULAR_PROTEIN_TRANSPORT 141 307E-36 359E-35 GOBP_CELLULAR_AMIDE_METABOLIC_PROCESS 142 7.51E-36 8.65E-3 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 129 123E-35 1.40E-33 GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 136 2.27E-35 2.53E-35 GOBP_PEPTIDE_METABOLIC_PROCESS 120 8.80E-35 9.68E-33 GOBP_PEPTIDE_METABOLIC_PROCESS 120 1.22E-34 1.32E-35 GOBP_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP_REGULATION_OF_MORENCONTAINING_COMPOUND 170 2.07E-34 2.18E-33 GOBP_REGULATION_OF_MURASE_ACTIVITY 127 3.48E-34 3.57E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL DEVELOPMENT 152 1.62E-33 1.60E-33 GOBP_RUSCLE_SYSTEM_PROCESS 82 2.06E-33 2.01E-33 1.60E-32 GOBP_MUSCLE_SYSTEM_PROCESS 129 1.17E-32 1.11E-33 GOBP_NUSCLE_SYSTEM_PROCESS 82 2.06E-33 2.01E-33 GOBP_NUSCLE_SYSTEM_PROCESS 129 1.17E-32				1.51E-34
COBP CELLULAR, ANIDE METAGOLIC, PROCESS 142 7.51E-36 8.65E-33 GOBP POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 129 1.23E-35 1.40E-33 GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 120 8.80E-35 9.68E-33 GOBP_TUBE_MORPHOCENESIS 120 1.22E-34 1.32E-33 GOBP_RESPONSE_TO_OXYGEN_CONTAINING COMPOUND 95 1.47E-34 1.57E-33 GOBP_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP_REGULATION_OF_UNDROLASE_ACTIVITY 127 2.48E-34 3.57E-33 GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 127 3.48E-34 3.57E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 120 1.62E-33 1.60E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 1.62E-33 2.46E-33 2.04E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 1.62E-33 2.46E-33 2.04E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 1.62E-33 2.46E-33 2.04E-33 GOBP_REGULATION_OF_MULTICELLULAR_FUNCTION 1.62E-33 2.46E-33 2				
GOBP POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 129 1282-36 140E-35 GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 120 8.80E-35 9.68E-35 GOBP_TUBE_MORPHOCENESIS 120 8.80E-35 9.68E-35 GOBP_PEPTIDE_METABOLIC_PROCESS 120 1.22E-34 1.32E-35 GOBP_RESULATION_OF_LOCOMOTION 96 1.47E-34 1.57E-33 GOBP_REGULATION_OF_LOCOMOTION 147 2.07E-34 2.18E-33 GOBP_REGULATION_OF_LOCOMOTION 100 7.67E-34 2.34E-33 GOBP_REGULATION_OF_MULTICALLULAR_COMPOUND 100 7.67E-34 7.76E-34 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 119 1.36E-3 1.36E-3 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.62E-33 1.60E-32 2.01E-33 1.60E-32 2.01E-33 1.60E-32 2.01E-33 1.60E-32 1.02E-33 1.60E-32 2.01E-33 1.60E-32 2.01E-33 1.60E-32 1.02E-33 1.60E-32 2.01E-33 1.60E-32 1.01E-33 1.60E-32 2.01E-33 1.60E-32 1.01E				
COBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 136 2.27E-35 2.53E-33 GOBP_TUBE_MORPHOGENESIS 120 8.80E-35 9.68E-33 GOBP_POSITIVE_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP_POSITIVE_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 170 2.07E-34 2.34E-33 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 147 2.48E-33 3.67E-33 GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 127 3.48E-33 3.76E-33 GOBP_REGULATION_OF_HYDROLASE ACTIVITY 127 3.48E-33 1.36E-33 GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 127 3.48E-33 1.36E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.62E-33 2.01E-33 GOBP_RESULS_SYSTEM_PROCESS 60B-POSITIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.11E-33 GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 138 1.68E-32 1.56E-33 2.46E-33 GOBP_AMIDE_BIOSYNTHETIC_PROCESS 114 4.68E-32 4.25E-34 1.56E-32 <				
GOBP TUBE_MORPHOGENESIS 120 8.00E-35 9.68E-33 GOBP PEPTIDE_METABOLIC_PROCESS 120 1.22E-34 1.32E-33 GOBP RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 95 1.47E-34 1.57E-33 GOBP RESULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-33 GOBP REGULATION_OF_MUDASE_ACTIVITY 147 2.25E-34 2.34E-33 GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE 100 7.67E-34 7.76E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.62E-33 1.66E-33 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 100 7.67E-34 7.76E-33 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.11E-33 GOBP_VASCULATURE_DEVELOPMENT 106 2.66E-33 2.46E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.60E-32 1.55E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.66E-32 1.55E-33 GOBP_VASCULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.11E-33 GOBP_VASCULATION_OF_MOLECULAR_FUNCTION 135 1.66E-32 1.55E-33				
GOBP_PEPTIDE_METABOLIC_PROCESS 120 122E-34 1.32E-35 GOBP_POSITIVE_REGULATION_OF_LOCOMOTION 95 1.47E-34 1.57E-35 GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 170 2.07E-34 2.18E-35 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 147 2.25E-34 2.34E-35 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 127 3.48E-34 3.57E-35 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 100 7.67E-33 1.36E-33 GOBP_RESULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.82E-33 2.01E-33 GOBP_RESULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.62E-33 2.01E-33 GOBP_RESPONSE_TO_GROWTH_FACTOR 105 2.56E-33 2.01E-33 GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.15E-34 GOBP_VASCULATURE_DEVELOPMENT 108 1.60E-32 1.50E-34 GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.56E-34 GOBP_CELL_JUNCTION_ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_CELL_JUNCTION_ASSEMBLY 78 1.68E-32 </td <td></td> <td></td> <td></td> <td>9.68E-33</td>				9.68E-33
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 170 2.07E-34 2.18E-33 GOBP_REGULATION_OF_HYDROLASE_ACTIVITY 147 2.25E-34 2.34E-33 GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 127 3.48E-34 3.57E-33 GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 119 1.36E-33 1.66E-33 GOBP_MUSCLE_SYSTEM_PROCESS 82 2.06E-33 2.01E-33 GOBP_NEGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.62E-33 1.06E-33 GOBP_RESPONSE_TO_GROWTH_FACTOR 105 2.56E-33 2.06E-33 2.01E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.00E-32 1.11E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.06E-32 1.55E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.06E-32 1.55E-33 GOBP_AMIDE_BIOSYNTHETIC_PROCESS 114 4.88E-32 4.22E-33 GOBP_RESDUATION_OF_MOLECULAR_FUNCTION 135 1.88E-32 7.71E-33 GOBP_REGULATION_OF_CELL_UNCTION_ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_REGULATION_OF_CENESIS 1.06U-ECULAR 1.35E	GOBP_PEPTIDE_METABOLIC_PROCESS			1.32E-32
GOBP REGULATION OF HYDROLASE ACTIVITY 147 225E-34 234E-33 GOBP REGULATION OF TRANSFERASE ACTIVITY 127 3.48E-34 3.57E-33 GOBP REGULATION OF TRANSFERASE ACTIVITY 127 3.48E-34 3.57E-33 GOBP MAPK_CASCADE 119 1.36E-33 1.36E-33 GOBP REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 152 1.62E-33 1.60E-33 GOBP RESPONSE_TO_GROWTH_FACTOR 105 2.56E-33 2.46E-33 GOBP POSITIVE REGULATION OF MULTICELLULAR FUNCTION 105 2.56E-33 2.46E-33 GOBP_NEGATIVE_REGULATION OF_MOLECULAR FUNCTION 135 1.68E-32 1.55E-34 GOBP_NEGATIVE_REGULATION OF_MOLECULAR FUNCTION 135 1.68E-32 1.55E-34 GOBP_ADE_BIOSYNTHETIC_PROCESS 114 4.88E-32 2.67E-34 GOBP_CELL_JUNCTION ASSEMBLY 77E-33 60E-31 1.77E-32 GOBP_CELL_MORPHOGENESIS_INVOLVED IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.55E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-32 <				1.57E-32
COBP REGULATION OF_TRANSFERASE ACTIVITY 127 3.48E-34 3.57E-33 GOBP PROTEIN LOCALIZATION TO_MEMBRANE 100 7.67E-34 7.76E-33 GOBP REGULATION_OF_MULTCELLULAR_ORGANISMAL_DEVELOPMENT 152 1.42E-33 1.60E-33 GOBP MUSCLE_SYSTEM_PROCESS 82 2.06E-33 2.40E-33 2.40E-33 GOBP POSITIVE_REGULATION_OF_GENE_EXPRESSION 109 1.17E-32 1.11E-33 GOBP VASCULATURE_DEVELOPMENT 108 1.60E-32 1.50E-33 GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 108 1.60E-32 1.50E-33 GOBP_ADMIDE BIOSYNTHETIC_PROCESS 114 4.68E-32 2.42E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_VOLE 136 2.06E-31				2.18E-32
GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE 100 7.67E-34 7.76E-33 GOBP_MAPK_CASCADE 119 1.36E-33 1.36E-33 GOBP_MUSCLE_SYSTEM_PROCESS 82 2.06E-33 2.01E-33 GOBP_RESPONSE_TO_GROWTH_FACTOR 105 2.56E-33 2.01E-33 GOBP_NOSCLE_SYSTEM_PROCESS 82 2.06E-33 2.01E-33 GOBP_NOSTIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.11E-33 GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.11E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.60E-32 1.55E-33 GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 135 1.88E-32 2.57E-33 GOBP_AMIDE_BIOSYNTHETIC_PROCESS 114 4.88E-32 4.22E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_RESULATION_OF_PHORYENE_KINASE_SIGNALING_PATHWAY 103 1.58E-31 1.37E-22 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 2.68E-31 2.68E-31 <tr< td=""><td></td><td></td><td></td><td></td></tr<>				
GOBP MAPK_CASCADE 119 1.36E-33 1.36E-33 GOBP REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 1.52 1.62E-33 1.60E-33 GOBP RESOULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 1.52 1.62E-33 2.01E-33 GOBP RESPONSE_TO_GROWTH_FACTOR 105 2.56E-33 2.46E-33 GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 1.29 1.17E-32 1.11E-32 GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 135 1.68E-32 1.55E-33 GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 135 1.68E-32 1.55E-33 GOBP_CELL_JUNCTION_ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_CELL_BORYNTHETIC_PROCESS 114 4.68E-32 7.71E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-22 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 103 3.39E-31 2.85E-23 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-23 GOBP_REGULATION_OF				
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 152 1.62E-33 1.60E-33 GOBP_MUSCLE_SYSTEM_PROCESS 82 2.06E-33 2.01E-33 GOBP_RESPONSE_TO_GROWTH_FACTOR 105 2.66E-33 2.46E-33 GOBP_NOSTIVE_REGULATION_OF_GENE_EXPRESSION 129 1.17E-32 1.11E-33 GOBP_NASCULATURE_DEVELOPMENT 108 1.60E-32 1.50E-33 GOBP_CELL_JUNCTION_ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.55E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-22 GOBP_SECRETION 131 2.58E-23 2.66E-31 1.77E-22 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 103 1.58E-31 1.77E-22 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.58E-23 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 5.66E-31				1.36E-31
GOBP MUSCLE SYSTEM_PROCESS 82 2.06E-33 2.01E-33 GOBP RESPONSE TO GROWTH FACTOR 105 2.56E-33 2.46E-33 GOBP RESPONSE TO GROWTH FACTOR 109 2.56E-33 2.46E-33 GOBP NEGATIVE, REGULATION OF_GENE_EXPRESSION 129 1.1TE-32 1.50E-33 GOBP_NEGATIVE, REGULATION, OF_MOLECULAR_FUNCTION 135 1.68E-32 1.55E-33 GOBP_CELL_JUNCTION, ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_CELL_JUNCTION, ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.55E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.37E-22 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 2.72E-23 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.86E-23 GOBP_REGULATION_OF_ROTEIN_CRONZINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP_REGULATION_OF_RORANELLE ORGANIZATIO	GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT			1.60E-31
GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 129 1.71E-32 1.11E-33 GOBP_VASCULATURE_DEVELOPMENT 108 1.60E-32 1.50E-33 GOBP_NEGULATION_OF_MOLECULAR_FUNCTION 135 1.88E-32 1.55E-33 GOBP_CELL_JUNCTION_ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_AMIDE_BIOSYNTHETIC_PROCESS 114 4.68E-32 4.22E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-23 GOBP_SECRETION 152 3.03E-31 2.56E-23 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.56E-23 GOBP_REGULATION_OF_PROTEIN_TVROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_COCESS 75 1.12E-30 8.91E-23	GOBP_MUSCLE_SYSTEM_PROCESS		2.06E-33	2.01E-31
GOBP_VASCULATURE_DEVELOPMENT 108 1.60E-32 1.50E-30 GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 135 1.68E-32 1.55E-33 GOBP_CELL_JUNCTION_ASSEMBLY 78 2.93E-32 2.67E-33 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.55E-33 GOBP_REPTIDE_BIOSYNTHETIC_PROCESS 103 1.58E-31 1.37E-32 GOBP_REPTIDE_BIOSYNTHETIC_PROCESS 103 1.58E-31 1.37E-32 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-32 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-32 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 2.78E-32 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.88E-22 GOBP_REGULATION_OF_PROTEIN_TOROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-22 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.22E-22 GOBP_REGULATION_OF_PROTEIN_COMPLEX_BIOGENESIS 75 1.12E-30 8.91E-22 GOBP_REGULATION_OF_PROTEIN_COMPLEX_BIOGENESIS 75 1.12E-3				2.46E-31
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION 135 1.68E-32 1.55E-30 GOBP_CELL_JUNCTION_ASSEMBLY 78 2.93E-32 2.67E-30 GOBP_ADDE_BIOSYNTHETIC_PROCESS 114 4.68E-32 4.25E-30 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-30 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-30 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-22 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-22 GOBP_REGULATION_OF_PROSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-23 GOBP_REGULATION_OF_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_CELL_ACTIVATION 151 7.99E-31				1.11E-30
COBP_CELL_JUNCTION_ASSEMBLY 78 293E-32 2.67E-33 GOBP_AMIDE_BIOSYNTHETIC_PROCESS 114 4.68E-32 4.22E-33 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.25E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-23 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-23 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-23 GOBP_REGULATION_OF_PROTEIN_TVROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_CELL_COMPLEX_BIOGENESIS 75 1.12E-30 8.91E-23 GOBP_REGULATION_OF_CELL_COMPLEX_BIOGENESIS 75 1.1				
GOBP_AMIDE_BIOSYNTHETIC_PROCESS 114 4.68E-32 4.22E-30 GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.55E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-22 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.86E-23 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.86E-24 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 132 6.96E-31 4.27E-23 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 132 6.96E-31 6.27E-23 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 112				
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION 91 5.11E-32 4.55E-30 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-30 GOBP_RESPONSE_TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-30 GOBP_REDIDE_BIOSYNTHETIC_PROCESS 103 1.58E-31 1.37E-22 GOBP_SECRETION 136 2.06E-31 1.77E-22 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-22 GOBP_REGULATION_OF_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 6.12E-22 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-22 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-22 GOBP_REQUATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-22 GOBP_REQUATION_OF_CELLUACTOREX 105 7.39E-31 6.42E-22 GOBP_REDULATION_OF_CELL_DROCESS 75 1.12E-30 8.91E-22 GOBP_REDULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 80 1.23E-30 8.96E-22 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS <				4.22E-30
COBP RESPONSE TO_ABIOTIC_STIMULUS 137 8.76E-32 7.71E-33 GOBP PEPTIDE_BIOSYNTHETIC_PROCESS 103 1.58E-31 1.37E-23 GOBP REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-23 GOBP SECRETION 152 3.03E-31 2.56E-23 GOBP PREGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.56E-23 GOBP REGULATION_OF_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE 151 7.99E-31 6.42E-23 GOBP_REGULATION_OF_CENCESS 75 1.12E-30 8.91E-23 GOBP_REGULATION_OF_CELL_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-23				4.55E-30
GOBP_REGULATION_OF_CELL_CYCLE 136 2.06E-31 1.77E-25 GOBP_SECRETION 132 3.03E-31 2.56E-25 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-25 GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-25 GOBP_REGULATION_OF_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-25 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-25 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.42E-25 GOBP_REGULATION_OF_PROTEIN_COMPLEX_BIOGENESIS 75 1.12E-30 8.91E-25 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 80 1.23E-30 8.91E-25 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-20 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-20 GOBP_REGULATION_OF_CELLULATION_OF_CELL_DEATH 52 2.44E-30 1.88E-20 GOBP_REGULATION_OF_CELL_DEATH 119 3.39E-30 3.29E-20	GOBP_RESPONSE_TO_ABIOTIC_STIMULUS			7.71E-30
GOBP_SECRETION 152 3.03E-31 2.58E-21 GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-23 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP_REGULATION_OF_ORGANIZATION 132 6.96E-31 5.72E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 151 7.99E-31 6.42E-23 GOBP_REGULATION_OF_ORGANIZATION 151 7.99E-31 6.42E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 151 7.99E-31 6.42E-23 GOBP_RIB_COLL_ACTIVATION 151 7.99E-31 6.42E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 75 1.12E-30 8.91E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_REGULATION_INITIATION 52 2.44E-30 1.88E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.				1.37E-29
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 120 3.39E-31 2.85E-25 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 6.06E-31 4.21E-25 GOBP_REGULATION_OF_PROTEIN_ENTROSINE_KINASE_SIGNALING_PATHWAY 112 6.06E-31 4.21E-25 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 112 6.06E-31 6.12E-25 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-25 GOBP_REGULATION_OF_PROTEIN_COMPLEX_BIOGENESIS 75 1.12E-30 8.91E-25 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-25 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-25 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-25 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-25 GOBP_REGULATION_OF_CELLULATION 52 2.44E-30 1.86E-21 GOBP_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-22 GOBP_REGULATION_OF_CELL_DEATH 96 4.35E-30 3.29E-24				1.77E-29
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 102 5.06E-31 4.21E-23 GOBP_REGULATION_OF_ORGANIZATION 132 6.96E-31 5.72E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.42E-23 GOBP_REGULATION_OF_PROTEIN_COMPLEX_BIOGENESIS 75 1.12E-30 8.91E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 80 1.23E-30 9.96B-22 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_REGULATION_OF_CELLULATION_OF_CELL 2.44E-30 1.88E-23 0.28E-30 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24				2.58E-29
COBP_REGULATION OF_ORGANIELLE_ORGANIZATION 132 6.96E-31 5.72E-21 GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-23 GOBP_CELL_ACTIVATION 151 7.99E-31 6.42E-23 GOBP_RIA_CATABOLIC_PROCESS 75 1.12E-30 8.91E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_TRANSLATIONAL_INITIATION 52 2.44E-30 1.88E-23 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-23 GOBP_IEGONO_VESEL_MORPHOGENESIS 96 4.35E-30 3.29E-23				
GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 106 7.53E-31 6.12E-24 GOBP_CELL_ACTIVATION 151 7.99E-31 6.42E-24 GOBP_RNA_CATABOLIC_PROCESS 75 1.12E-30 8.91E-24 GOBP_REGULATION_OF_CELLUAR_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-24 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-24 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-24 GOBP_REGULATION_OF_CELLUAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-24 GOBP_IREADILATIONA_INITIATION 52 2.44E-30 1.88E-24 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-24 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24				
GOBP_CELL_ACTIVATION 151 7.99E-31 6.42E-24 GOBP_RNA_CATABOLIC_PROCESS 75 1.12E-30 8.91E-24 GOBP_REDUVCLEOPROTEIN_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-24 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-24 GOBP_REGULATION_OF_CELLULARINON 52 2.44E-30 1.88E-24 GOBP_INCERTIVE_REGULATION OF_CELL_DEATH 119 3.39E-30 2.59E-22 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24				6.12E-29
GOBP_RNA_CATABOLIC_PROCESS 75 1.12E-30 8.91E-23 GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS 80 1.23E-30 9.69E-23 GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-23 GOBP_TRANSLATIONAL_INITIATION 52 2.44E-30 1.88E-23 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-23 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24				6.42E-29
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS 117 2.07E-30 1.61E-21 GOBP_TRANSLATIONAL_INITIATION 52 2.44E-30 1.88E-21 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-22 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24	GOBP_RNA_CATABOLIC_PROCESS		1.12E-30	8.91E-29
GOBP_TRANSLATIONAL_INITIATION 52 2.44E-30 1.88E-24 GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-24 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24				9.69E-29
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH 119 3.39E-30 2.59E-24 GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-24				1.61E-28
GOBP_BLOOD_VESSEL_MORPHOGENESIS 96 4.35E-30 3.29E-20				
				3.99E-28

Figure 102 Gene ontology analysis of genes upregulated in response to CD in

dKO^{MRTF} cells by TTseq

Gene ontology analysis of genes upregulated by CD treatment in dKO^{MRTF} cells by TTseq. FDR<0.05. Relates to Figure 47. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP_SMALL_MOLECULE_METABOLIC_PROCESS	183	7.44E-35	5.57E-31
GOBP_LIPID_METABOLIC_PROCESS	136	3.33E-25	1.24E-21
GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS	100	1.09E-24	2.72E-21
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION GOBP_CELLULAR_LIPID_METABOLIC_PROCESS	158 106	1.28E-21 2.24E-21	2.39E-18 3.35E-18
GOBP_ORGANIC_ACID_CATABOLIC_PROCESS	45	1.42E-18	1.77E-15
GOBP_CELL_CYCLE	144	6.06E-18	6.48E-15
GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	114	1.17E-17	1.09E-14
GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS	57	2.64E-17	2.20E-14
GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS	100 89	1.84E-16	1.38E-13
GOBP_DNA_METABOLIC_PROCESS GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS	73	2.29E-16 2.83E-16	1.56E-13 1.76E-13
GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	120	6.30E-16	3.63E-13
GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION	144	7.02E-16	3.75E-13
GOBP_REGULATION_OF_CELL_DIFFERENTIATION	125		4.00E-13
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	133	1.57E-15	7.35E-13
	121		1.10E-12
GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION GOBP_ORGANIC_ACID_METABOLIC_PROCESS	142 93	3.63E-15 4.43E-15	1.51E-12 1.74E-12
GOBP CELL CYCLE PROCESS	112		2.05E-12
GOBP_DNA_REPAIR	62	1.16E-14	4.14E-12
GOBP_MONOCARBOXYLIC_ACID_CATABOLIC_PROCESS	28	2.15E-14	7.32E-12
GOBP_REGULATION_OF_CELL_CYCLE	99	3.15E-14	1.02E-11
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	124	3.73E-14	1.16E-11
	49	4.12E-14	1.23E-11
GOBP_FATTY_ACID_CATABOLIC_PROCESS GOBP_CILIUM_ORGANIZATION	25 50	4.80E-14 4.94E-14	1.37E-11 1.37E-11
GOBP_CELLULAR_LIPID_CATABOLIC_PROCESS	36	1.18E-13	3.08E-11
GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION	66	1.19E-13	3.08E-11
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	127	1.77E-13	4.41E-11
GOBP_REPRODUCTION	109	2.56E-13	6.19E-11
GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS	64	3.26E-13	7.62E-11
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	118 58	3.63E-13	8.24E-11
GOBP_ORGANIC_HYDROXY_COMPOUND_METABOLIC_PROCESS GOBP_SULFUR_COMPOUND_METABOLIC_PROCESS	58 46	4.93E-13 6.50E-13	1.09E-10 1.39E-10
GOBP_SOLFOR_COMPOUND_METABOLIC_PROCESS	24		1.39E-10 1.97E-10
GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS	85	9.76E-13	1.97E-10
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	128	1.40E-12	2.75E-10
GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	79	1.79E-12	3.43E-10
GOBP_MICROTUBULE_BASED_PROCESS	74		4.42E-10
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	118	2.56E-12	4.67E-10
GOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION	38	2.64E-12	4.70E-10
GOBP_LIPID_BIOSYNTHETIC_PROCESS GOBP_ORGANELLE_ASSEMBLY	67 75	2.90E-12 4.74E-12	5.04E-10 8.06E-10
GOBP_CIGARLELE_ASSEMBLT	103		8.78E-10
GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION	79		1.35E-09
GOBP_HOMEOSTATIC_PROCESS	128	1.01E-11	1.61E-09
GOBP_NUCLEOSOME_ASSEMBLY	26	1.28E-11	2.00E-09
GOBP_PEROXISOME_ORGANIZATION	20	1.33E-11	2.03E-09
GOBP_NUCLEOSOME_ORGANIZATION	29		3.07E-09
GOBP_MITOTIC_CELL_CYCLE GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	82 129	2.26E-11 2.34E-11	3.31E-09 3.36E-09
GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	73	2.74E-11	3.86E-09
GOBP_SKELETAL_SYSTEM_DEVELOPMENT	50	3.25E-11	4.50E-09
GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS	58	3.68E-11	5.01E-09
GOBP_INTRACELLULAR_TRANSPORT	117	4.46E-11	5.96E-09
GOBP_NEUROGENESIS	111	5.20E-11	6.83E-09
GOBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY GOBP_CYTOSKELETON_ORGANIZATION	85 99	5.74E-11 6.39E-11	7.40E-09 7.97E-09
GOBP_REGULATION_OF_CELL_DEATH	113		7.97E-09
GOBP_APOPTOTIC_PROCESS	126	7.78E-11	9.55E-09
GOBP_PROTEOLYSIS	119	1.11E-10	1.34E-08
GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS	55	1.25E-10	1.48E-08
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION	76	1.26E-10	1.48E-08
GOBP_CHROMOSOME_ORGANIZATION	91	1.44E-10	1.65E-08
GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE GOBP_CELL_POPULATION_PROLIFERATION	78 126	1.52E-10 1.70E-10	1.72E-08 1.90E-08
GOBP_COULT FOR BREAK REPAIR	34		2.29E-08
GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS	60	2.13E-10	2.29E-08
GOBP_LIPID_CATABOLIC_PROCESS	39	2.15E-10	2.29E-08
GOBP_STEROL_METABOLIC_PROCESS	26		2.65E-08
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	86	2.99E-10	3.11E-08
GOBP_EMBRYONIC_MORPHOGENESIS	53		3.65E-08
GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE	43 56		3.90E-08 4.43E-08
GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE GOBP_CHROMATIN_ASSEMBLY_OR_DISASSEMBLY	30		4.43E-08
GOBP_CHROMATIN_ASSEMBLIT_ON_DISASSEMBLIT GOBP_REGULATION_OF_RESPONSE_TO_DNA_DAMAGE_STIMULUS	30		4.43E-08
GOBP_SEX_DIFFERENTIATION	33		4.43E-08
GOBP_GAMETE_GENERATION	60		4.43E-08
GOBP_APPENDAGE_MORPHOGENESIS	23		4.43E-08
	17		4.77E-08
GOBP_EMBRYONIC_ORGAN_DEVELOPMENT GOBP_CARTILAGE_DEVELOPMENT	43		4.77E-08 5.34E-08
GOBP_DNA_PACKAGING	31		7.46E-08
GOBP_ALCOHOL_METABOLIC_PROCESS	40		8.29E-08
GOBP_FATTY_ACID_BETA_OXIDATION	17	1.03E-09	8.94E-08
GOBP_STEROID_METABOLIC_PROCESS	37	1.07E-09	9.24E-08
GOBP_NUCLEOSIDE_BISPHOSPHATE_METABOLIC_PROCESS	23		9.84E-08
GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	61 84	1.20E-09	9.85E-08
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION_OR_REMOVAL GOBP_MULTICELLULAR_ORGANISM_REPRODUCTION	84 67	1.20E-09 1.21E-09	9.85E-08 9.85E-08
GOBP_MULTCELLULAR_ORGANISM_REPRODUCTION GOBP_MICROTUBULE_CYTOSKELETON_ORGANIZATION	53		9.85E-08
GOBP_DEVELOPMENT_OF_PRIMARY_SEXUAL_CHARACTERISTICS	29	1.31E-09	1.05E-07
GOBP_RESPONSE_TO_GROWTH_FACTOR	61		1.06E-07
GOBP EMBRYO DEVELOPMENT	75	1.49E-09	1.17E-07
	0.4	1.62E-09	1.25E-07
GOBP_REGULATION_OF_CELL_CYCLE_PROCESS	64		
GOBP REGULATION OF CELL CYCLE PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS	59	1.62E-09	
GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS GOBP_DNA_CONFORMATION_CHANGE	59 38	1.62E-09 2.04E-09	1.25E-07 1.56E-07
GOBP REGULATION OF CELL CYCLE PROCESS GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS	59	1.62E-09	

Figure 103 Gene ontology analysis of genes downregulated in response to CD in dKO^{MRTF} cells by TTseq

Gene ontology analysis of genes downregulated by CD treatment in dKO^{MRTF} cells by TTseq. FDR<0.05. Relates to Figure 47. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

ORDER MUNAL METACOLIC, PROCESS 143 148.6.28 1.38.6.29 2.48.2 OPER TRANSCILLAR, TRANSFORT 10 7.44.5.2 3.38.6.20 <th>GO BIOLOGICAL PROCESS</th> <th># Genes</th> <th>p-value</th> <th>EDR g-value</th>	GO BIOLOGICAL PROCESS	# Genes	p-value	EDR g-value
ORP TANIS, ALTONAL, INTATION 76 138-71 5.28 ORP TELLULAR, MARCRADIC, CLIC, LATABOLC, PROCESS 16 5.775+11 5.775+11 ORP TANK, CARADULC, PROCESS 16 5.775+11 5.775+11 5.775+11 ORP TANK, CARADULC, PROCESS 16 5.775+11 </td <td></td> <td></td> <td></td> <td>1.12E-94</td>				1.12E-94
000P CELULAR. MACRIMOLECULE, CATABOLI, PROCESS 144 400-82 1.00 000P NTURGELINA, TRANSFORM TANOEL PROCESS 10 1.444 1.444 000P COTTANIA, TRANSFORM, TANOEL PROCESS 10 1.00				5.28E-84
GOBP_INTACCELLUAR_TRANSPORT 170 7.44-62 1.41 GOBP_RINC_CALUAR_TRANSPORT 187 377.65 377.65 GORP_RINC_CALUAR_TRANSCRED_URANS_CALUAR_CIPCOCES 147 315.76 377.65 GORP_RINC_CALUAR_TRANSCRED_URANSCRED_URANSCRETCULUM 170 34.87 357.77 750 GORP_EDUCICIE_CALUAR_TRANSCRED_URANSCRETCULUM 130 146.77 750 GORP_EDUCICIE_CALUAR_TRANSCRET_URANSCRETCULUM 130 146.77 750 GORP_MICACELLUAR_PORTS_TRANSCRET 130 146.77 750 GORP_MICACELLUAR_PORTS_TRANSCRET 130 146.77 750 GORP_MICACELLUAR_PORTS_TRANSCRET 130 146.77 750 GORP_MICACELLUAR_PORTS_TRANSCRET 140 146.70 750 GORP_MICACELLUAR_PORTS_TRANSCRET 140 146.70 750 155 350 346.71 155 350 355.71 155 350 355.71 155 350 355.71 155 355.71 155 350 355.71 155.75 155.75 155.75 155.75 155.7				1.03E-78
ODEP FIAL, CATABOLIC PROCESS 96 5772-81 8.46 OPE CONTANCE, MONTE TARGETING, O. DERBERME 61 7383-81 1000 OODP AND, LEAR, TRANSCREDE, MINA, CATABOLIC, PROCESS, NOSHES, LEDATED, DECK 12 4.864-78 7.86 OPE FILLIGAR, MARCONALECULE, LOCALIZATION 10 4.864-78 7.86 5.37 OUDP STALLSHARM, OF PROTEN LOCALIZATION 10 4.864-78 7.86 5.37 OUDP STALLSHARM, OF PROTEN LOCALIZATION 10 2.166-74 3.26 7.17 7.16 OUDP STALLSHARM, OF OF ROTEN LOCALIZATION 10 2.366-74 3.26 7.17 7.16		170		1.41E-78
GOBP CONTINUEL CATAGOL PROCESS 0.001 0.002 <				8.74E-78
GBEP MACEGAWINELGUE CATABOLC PROCESS 114 3106-80 328 GDEP MACEGAWINENT OF PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 20 4485-70 7.00 GDEP STAULESAWENT OF PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 20 4685-77 7.00 GDEP STAULESAWENT OF PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 20 4685-77 7.00 GDEP MOREL ALLAR, PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 26 5.845-77 7.00 GDEP MOREL ALLAR, PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 26 5.845-77 7.00 GDEP MOREL ALLAR, PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 26 4.845-70 1.00 GDEP MOREL ALLAR, PROTEX LOCALIZATION TO ENDORLAND. RETICULUM 26 4.845-70 1.00 GDEP MOREL ALLAR, PROTEX LOCALIZATION TO MEMBRANE 16 3.256-63 1.00 GDEP MOREL ALLAR, NARCING PROCESS 16 3.256-63 1.00 2.356-63 1.00 GDEP MOREL ALLAR, NARCING PROCESS 16 3.256-63 1.00 2.356-63 1.00 2.356-63 1.00 2.356-63 1.00 2.356-63 1.00 2.356-63 1.00 2.356-63				1.00E-77
GOBP ADDLEAR, TRANSCREDD, MENA CATABOLC, PROCESS, NORSING, MEDATED, DECAY 62 486-77 4.36 4.37 GOBP DEGLILLAR, MARCONDE, COLL, CARUZATON 63 4.37 5.37 GORP ERGO, COLL, PROCESS, MON VED, A. SYNKORTE, NTERACTON 63 4.36 5.37 GORP ERGO, COLL, PROCESS, MON VED, A. SYNKORTE, NTERACTON 64 5.46 7.37 GORP ERGN, LOCAL, ZATON, TO, ENDORA SAME, RETUCLUM 64 5.46 7.37 GORP ESTAL, BARRENT, OF FROTER, LOCALZATON 61 3.36 7.47 7.85 GORP MORAL, COLL, CANDON, NO, CATABOLC, PROCESS 100 3.36 7.45 7.45 GORP MORAL, CARLE, COLL, COMPOND, OCALZATON 1.38 7.45 7.45 7.45 GORP MORE, COLL, COMPOND, OCALZATON 1.38 7.45 7.45 7.45 7.45 GORP MORE, TOCAL, ZATON TO, ORAMELE 13 1.385 1.38 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45 7.45				3.35E-77
00PP CELLULAR, MACREMOLECUE, LOCALZYON O ENDORLASMO ENTOLUUM 176 6.385-78 5-77 00PP ESTABLISHINGT OF PROTEN DEALOZITANI O ENDORLASMO, ENTOLUUM 6.464-76 1.395 00PP STRALESIMENT OF PROTEN TRANSPORT VIENDETAIL 6.464-76 3.395 00PP STRALESIMENT OF PROTEN TRANSPORT VIENDETAIL 6.464-76 3.395 00PP STRALESIMENT OF PROTEN LOCALZYON 167 1245-71 0.74 00PP STRALESIMENT OF PROTEN LOCALZYON 167 1245-71 0.74 00PP STRALESIMENT OF PROTEN LOCALZYON 168 7.455-71 1.57 00PP MORE LOCALZYON CAMPACTOR STRALESIMENT OF PROTEN LOCALZYON TO MEMBRANE 16 3.75-62 00PP MORE LOCALZYON TO DEMERANE 17 7.556-62 108 3.85-61 4.52 00PP MORE LOCALZYON TO DEMERANE 17 7.556-62 108 4.52 2.70 00PP MORE LOCALZYON TO DEMERANE 18 1.26-63 1.32 4.55 4.52 2.70 00PP MORE LOCALZYON TO MEMBRANE 18 1.26-64 3.22 4.56 3.22 4.56 3.22 4.56 4				4.43E-75
GORP ESTABLISHMENT OF PROTEIN LOCALZYTON TO ENDORLAND (EFCULUM) 62 946E-78 7.16E GORP BIOLOGIAC MODESS AVAILABLE IN SYMBOLING INTERACTION 63 944E-77 7.10E GORP FROTES LLOCALLZYTON TO ENDOPLASMIC RETULUM 63 944E-74 1.9E GORP FROTES LLOCALLZYTON TO ENDOPLASMIC RETULUM 64 1.9E 7.10E GORP FROTES LLOCALLZYTON TO ENDOPLASMIC RETULUM 64 7.10E 7.10E GORP FROTES LLOCALLZYTON TO CARACTERIC PROCESS 60 2.47E 7.12E GORP FROTES LLOCALLZYTON TO ORGANELE 61 2.25E 7.12E 7.12E <td></td> <td></td> <td></td> <td>5.37E-75</td>				5.37E-75
GRDP BIOLOGICAL PROCESS NUCLARE DLS NUMBORE, RETROLUM 194 194.7.7 7.7.6 GRDP NUTRACLIAR PROTEN INCENDOL TO EDEORLANGE, RETROLUM 64 64.7.1 3.27 GRDP NUTRACLIAR PROTEN INCENDOL TO EDEORLANGE, RETROLUM 64 64.7.1 3.27 GRDP NUTLAC, RELEXPRESSION 64 161.7.6 8.7.6 GRDP NUCLEAR, TRANSCREED, UNIX, CATADOLC, PROCESS 69 2.465.70 1.16 GRDP NOTAN, CATADOLC, PROCESS 61 2.266.60 3.326.71 GRDP PROTEN, LARGE TING, TO LEMBRANE 76 556.62 2.700 GRDP PROTEN, LARGE TING, TO LEMBRANE 77 1.35.66 4.100 GRDP PROTEN, LARGE TING, CONSINTLE 77 1.36.56 5.100 GRDP PROTEN, LARGE TING, CONSINTLE 77 1.36.56 5.100 GRDP PROTEN, LARGE TING, CONSINTLE 78 1.36.56 5.22.56 5.22.56				7.16E-75
GOBP TRACELLULAR, PROFEN, TRANSPORT [19] 2185-75 1.37 GOBP PROFINE, LOLARIZINO, TO ENDOLASINO, ERTICULUM 64 64.64.7 3.28 GOBP TRANSPORTED, TRANSPORTED, TRANSPORTE, TRANSPORTED, TRANSPORT				7.10E-75
GOBP PROTEN_LOCALIZATION TO ENDOLLASIDO, RETICULUM 64 646-74 326 GODP ESTALLISMENT OF PROTEN LOCALIZATION 61 126-71 674 GODP ESTALLISMENT OF PROTEN LOCALIZATION 64 126-71 674 GODP ESTALLISMENT OF PROTEN LOCALIZATION 64 126-71 675 GODP ESTALLISMENT OF PROTEN LOCALIZATION 64 226-67 1375 GODP ESTALLISMENT OF PROTEN LOCALIZATION 68 226-67 1375 GODP PROTEN LOCALIZATION TO ORGANELLE 10 136-66 426-66 GODP PROTEN LOCALIZATION TO ORGANELLE 11 126-66 4406 GODP PROTEN LOCALIZATION TO ORGANELLE 17 133-66 426 GODP PROTEN LOCALIZATION TO ORGANELLE 17 23-67 126 53-11 GODP PROTEN LOCALIZATION TO ORGANELLE 17 23-16 34-16 52-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 126-12 1				
GODP ESTALLISHUENT OF PROTEIN LOCALZINON 167 1286-71 6.74 GODP WIRA, GONE ED MERS, ALTADOL C, PROCESS 68 2466-70 155 GODP MIRA, GONE ED MERS, ALTADOL C, PROCESS 68 2466-70 155 GODP PROTEN, TANGETMOLO, MENDRANE 68 2466-70 155 GODP PROTEN, TARGETMOLO, MENDRANE 68 2466-70 157 GODP PROTEN, TARGETMOLO, MENDRANE 68 2466-70 157 GODP PROTEN, TARGETMOLO, MENDRANE 68 2456-70 158 GODP PROTEN, TARGETMOLO, COLLEXION, TO MEMBRANE 78 138-56 4.10 GODP PROTEN, TARGETMOLO PROCESS 116 1275-56 5.13 GODP PROTEN, TARGETMOLO PROCESS 116 1275-56 5.13 GODP PROTEN, TARGET CONCOLLER DESCHILLE 718 138-56 5.22 GODP PROTEN, TARGET CONCOLLER DESCHILLE 718 1275-56 5.22 5.22 GODP RANGE, MERSANGLE PROCESS 16 1775-38 3.276 5.22 5.22 5.22 5.22 5.22 5.22 5.22 5.26 5.26 <t< td=""><td></td><td></td><td></td><td></td></t<>				
OBB PMRAL_CENE_EXPRESSION 66 1465-70 80.01 OBB MULCER_FINISCREEE_DINILA CATABULE_PROCESS 60 2465-77 145 OBB PMRALE_RINSCREEE_DINILA CATABULE_PROCESS 60 2465-77 145 OBB PMRALE_NERSINGREE_INILA CATABULE_PROCESS 60 2465-77 256 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 77 556-66 255 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 78 556-66 257 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 78 556-66 122 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 71 1316-66 122 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 71 1316-66 122 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 71 1316-66 122 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 717 660-67 1356 132 OBB ESTABLISHENT OF PROTENT LOALEZTON TO MEMBRANE 717 536-53 716 2372				
GREP NUCLÉAR, TRANSCRIEDE, JARNA CATABOLIC, PROCESS 60 2465-70 116 ORDP GRADEL, CYULE, COMPOUND, CATABOLIC, PROCESS 100 3375-37 145 ORDP FERTIDE, BUSYNTHETIC, PROCESS 100 3375-37 145 ORDP FERTIDE, LICAL/ZATION, TO, MEMBRANE 77 756-62 276 ORDP FERTIDE, LICAL/ZATION, TO, MEMBRANE 77 756-62 276 ORDP FORTEN, LICAL/ZATION, TO, MEMBRANE 101 124-63 426 ORDP FORTEN, LICAL/ZATION, TO, MEMBRANE 101 124-63 426 ORDP FRILIN, TAGETRIN, DIO, LICAL/ZATION, TO, ORGANELLE 171 246-64 322 ORDP FRILIN, TAGETRIN, DIO, LICAL/ZATION, TO, ORGANELLE 77 261-64 322 ORDP FRILIN, TAGETRIN, DIO, LICAL/ZATION, TO, ORGANELLE 77 261-64 322 ORDP FRILIN, TAGETRIN, DIO, LICAL/ZATION, TO, ORGANELLE 77 261-64 322 ORDP FRILIN, TAGETRIN, MICRIA, DIO, CALVELS, SUBJUIT, ORGANIZATION 116 782-78 318 ORDP FRILIN, CALVEL, MICRIA,				
GORP ADDRAME (10) 336E-67 14.56 GORP PETRIDE SONTHETC, FORCESS (10) 377E-63 100 GORP PETRIDE TARGETMIC TO MEMBRANE (10) 377E-63 100 GORP PETRIDE TARGETMIC TO MEMBRANE (10) 377E-63 100 GORP PETRIDE TRAGETMIC TO MEMBRANE (11) 235E-63 110 GORP ADDE DOCYNTHETC, PROCESS (11) 235E-64 420 GORP ADDE DOCYNTHETC, PROCESS (11) 235E-64 420 GORP ADDE DOCYNTHETC, PROCESS (11) 235E-64 420 GORP ADDE DOCYNTHETC, PROCESS (11) 245E-64 420 GORP ADDE DOCYNTHETC, PROCESS (12) 14E-64 527 GORP ADDE DOCYNTHETC, PROCESS (12) 14E-64 527 GORP MERATE, LANDET OF PROTENT, LOCALZIONTO NO CORANELLE (12) 14E-64 527 GORP MERATE, LOCALZIONTO NO CORANELLE, SUBURT, CRAMITER, PROCESS (12) 14E-64 527 GORP MERATE, LOCALZIONTO NO CORANELLE, SUBURT, CRAMITER, MANA PROCESSNO (12) 14E-64 528 GORP MERATE, LOCALZIONTO NO CORANELLE, SUBURT, CRAMITER, MANA PROCESSNO (12) 14E-64 524 GORP REGULATION OF MANA METABOLIC PROCESS (12) 14E-64 528 <td< td=""><td></td><td></td><td></td><td>8.01E-68</td></td<>				8.01E-68
000P PEPTIDE_BOGYNTHETIC_PROCESS 197 000P PROTEN_INGETING, ON MERRANE 68.2526.66 3352 000P PROTEN_INGETING, ON MERRANE 111 2384.41 110 000P PROTEN_INGETING, ON COSESS 111 2384.41 110 000P PROTEN_INCCALZATION TO ORGANELE 113 1286.64 4.200 000P PROTEN_INCCALZATION TO ORGANELE 114 115.46 4.16 000P PROTEN_INCCALZATION TO ORGANELE 114 115.76 3.17 000P PROTEN_INCCALZATION TO ORGANELE 119 116.46 124 2.01 000P PROTEN_INCCALZATION TO ORGANELE 119 116.76 3.17 3.17 000P PROTEN_INCONTANUS COMPLEX_SUBJINT ORGANIZATION 116 7.628-31 158 000P PROTEN_INCONTANUS COMPLEX_SUBJINT ORGANIZATION 116 7.628-31 158 000P PROTEN_INCONTANUS COMPLEX_SUBJINT ORGANIZATION 116 7.628-31 158 000P PROTEN_INCONTANUS COMPLEX_SUBJINT ORGANIZATION 116 7.628-31				1.15E-67
000P PROTEN TARGETING, TO, MEMBRANE 5265 3265 020P PROTEN LEALDATION, TO, MEMBRANE 76 7584-63 1205 020P PROTEN LOGALIZATION, TO, MEMBRANE 76 7584-63 1205 020P PROTEN, LANDEL METADOLC, PROCESS 116 1275 568-53 1275 020P PROTEN, MARDEL METADOLC, PROCESS 116 1276 568 1272 020P PROTEN, MARDEL METADOLC, PROCESS 116 1272 668 1272 669 661, 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 669 1272 1272 138 378 669 1222 1372 378 669 1222 1272 128 1272 128 1272 128 1272 128 1272 128 1276 128				1.45E-64
000P PEPTIDE_METABOLIC_PROCESS 1111 2.538-63 1112 000P ESTABLISHENT OF PROCESS 100 1.386-64 4.596 000P ANDEL SOLVITTERIC PROCESS 100 1.386-54 4.596 000P FORTEN LARGETING DOMAINELE 101 1.785-56 5.135 000P FORTEN LANGETING OMAINELE 101 1.785-56 5.135 000P FORTEN LOCALIZATION TO MEMBRANE 90 4.236-56 1.222 1.065-56 3.222 000P ESTABLISHENT OF PROTEIN LOCALIZATION TO MEMBRANE 102 1.785-58 3.786 2.616 000P ESTABLISHENT OF PROTEIN LOCALIZATION 116 7.425-58 3.786 2.616 000P ENTERLINGTON OF MENA MERCESSION 102 3.125-58 3.786	GOBP_PEPTIDE_BIOSYNTHETIC_PROCESS	106	3.77E-67	1.57E-64
GOBP ESTABLISHMENT OF PROTEIN LOCALIZATION TO MEMBRANE 76 7.568-62 2705 GOBP ANDE DISVITHEIC PROCESS 108 1.388-64 4.095 GOBP PROTEIN LOCALIZATION TO ORGANELLE 113 1.388-64 4.095 GOBP PROTEIN LOCALIZATION TO ORGANELLE 19 4.285-65 1.225 GOBP PROTEIN LOCALIZATION TO ORGANELLE 19 2.016-64 3.255 GOBP FROTEIN LOCALIZATION TO ORGANELLE 172 2.016-64 3.255 GOBP FROTEIN LOCALIZATION TO ORGANELLE 172 2.016-64 3.255 GOBP FROTEIN LOCALIZATION TO ORGANELLE 172 2.016-64 3.255 GOBP FROTEIN LOCALIZATION TO ORGANELLE 178 2.016-64 3.255 GOBP FROTEIN LOCALIZATION TO ORGANELLE 178 2.016-64 3.255 GOBP FROTEIN LOCALIZATION TO ORGANELLE 178 2.026-24 3.256 GOBP FROSTEIN COMPLEX SUBJOINT FROTEIN LOCALIZATION TO ORGANELLE 178 3.026-34 3.158 GOBP FROSTEIN ESCHANDING	GOBP_PROTEIN_TARGETING_TO_MEMBRANE	66	8.25E-66	3.25E-63
GOBP AMDE BLOSYNTHEITC, PROCESS 108 1.386-01 4686 GOBP PROTEN, TANGETING 0780-0164 116 1.286-01 4686 GOBP PROTEN, TANGETING 0780-0164 116 1.186-05 116 1.116-05 </td <td>GOBP_PEPTIDE_METABOLIC_PROCESS</td> <td>111</td> <td>2.93E-63</td> <td>1.10E-60</td>	GOBP_PEPTIDE_METABOLIC_PROCESS	111	2.93E-63	1.10E-60
GOBP ANDRE, BLOSYNTHEITC, PROCESS 108 1.386-01 4686 GOBP MORTER, TARGETING 778 1.336-04 466 GOBP MORTER, TARGETING 778 1.336-04 4166 GOBP MORTER, TARGETING 778 1.336-04 4166 GOBP CELLULAR, ANDER, MELANDUR PROCESS 108 1.186-04 3222 GOBP STABLISHMENT OF PROFENE LOCALIZATION 128 2.766-04 7.722 GOBP MORTER, COMPANNET OF PROFENE LOCALIZATION 120 1277-38 3787 GOBP MORTER, CONTAINUS, COMPEX, SUBUNT ORGANIZATION 120 1277-38 3787 GOBP MORTER, CONTAINUS, COMPEX, SUBUNT ORGANIZATION 120 1277-38 3787 GOBP MORTER, CONTAINUS, COMPEX, SUBUNT ORGANIZATION 121 1277-38 3787 GOBP RESOLUCTON OF INTAIN METABOLIC PROCESS 679 1228-30 691 GOBP RESULATION OF ANA SPLICING REACTONS 46 6.504-20 1248 GOBP RESULATION OF CHARAGEN, PROCESS 170 1282-24 3385 GOBP PORTINE, REGULATION OF CHARAGEN, PROCESS 170 1282-24 3385 GOBP PO	GOBP ESTABLISHMENT OF PROTEIN LOCALIZATION TO MEMBRANE	76	7.59E-62	2.70E-59
ORDEP PROTEIN_LOCALLIZATION_TO_ORGANELLE 113 128E-60 4.20E ORDEP PROTEIN_LOCALLIZATION_TO_ORGANELLE 116 177E-58 5.15E ORDEP ADDIENT LOCALLIZATION TO_ORGANELE 109 2.01E-48 5.15E ORDEP ROTEIN_LOCALLIZATION TO_ORGANELE 109 2.01E-48 5.15E ORDEP ROTEIN_LOCALLIZATION TO_ORGANELE 109 2.01E-48 5.12E ORDEP ROTEIN_COMTANUS_COMPLEX_SUBJINT_ORGANIZATION 108 1.75E-58 3.79E ORDEP ROTEIN_COMTANUS_COMPLEX_SUBJINT_ORGANIZATION 106 7.62E-34 1.35E ORDEP ROTEIN_COMTANUS_COMPLEX_SUBJINT_ORGANIZATION 106 7.62E-34 1.35E ORDEP ROTEIN_COMTANES CONCENSIS 103 2.11E-27 4.20E ORDEP ROTEIN_COMTANESTREPERCATION REACTONS 103 2.11E-27 4.20E ORDEP ROTEIN_COM_TANISESTERFIFCATION REACTONS 101 3.12E-24 3.35E ORDEP ROTEIN_EEGULATION_OF BIOSINTHETIC_PROCESS 101 3.12E-24 3.35E ORDEP ROTEINE REGULATION_OF BIOSINTHETIC_PROCESS 101 3.12E-24 3.35E ORDEP ROTEINE REGULATION OF BIOSINTHETIC PROCESS 101		108		4.69E-59
CORP PROTEN_TARGETING 719 1.33E-66 4.46E CORP CIELULAR ANDE METABOLIC PROCESS 116 171E-85 5.13E CORP CIELULAR ANDE METABOLIC PROCESS 110 171E-85 5.13E CORP CONTINUED CONTINUED CONTINUED PROCESS 110 171E-86 5.13E CORP CONTINUED CONTINUED CONTINUED CONCOMPLE 172E 278E-48 7.12E CORP CONTINUES CONTINUED CONTINU		113	1.29E-60	4.20E-58
ODEP COLULAR AMIDE METABOLIC PROCESS 116 171/E55 1.22 OORP PROTEIN LOCALIZATION TO, MEMBRANE 900 4.235-55 1.22 OORP CONTENCINE COMPOUND BIOSYNTHETIC PROCESS 139 1.165-55 1.22 OORP CONTENSING CONFOLUCALIZATION TO CREANELLE 71 2.915-44 5.37 OORP CYTORLASMIC TRANSLATION 105 1.955-83 3.78 CORP FORTEN CONTAINING COMPLEX SUBURIT ORGANIZATION 116 7.825-83 3.78 CORP FRONENCECHONGESSION 50 1.925-83 3.81 CORP FRONENCECHONGE 50 1.925-83 3.81 CORP FRONENCECHONGENCE 50 2.245-30 6.91 CORP FRONENCECHONG VERTANSSTERFERCATION REACTIONS 4.6 6.906-27 1.288 CORP FORTEN LEGULATION OF BIOSYNTHETIC PROCESS 10 1.916-24 3.916 CORP FORTEN REGULATION OF BIOSYNTHETIC PROCESS 10 3.916-24 3.916 CORP FORTEN REGULATION OF CORPOLICE PROCESS 10 3.916-24 3.916 CORP FORTEN REGULATION OF COLLERAGOLIC PROCESS 10 3.916-24 3.916		78		4.16E-54
OORP PROTEN_LOCALIZATION_TO_MEMBRANE 90 4/28:65 1228 OORP PROTEN_LOCALIZATION_TO_ORCAVELLE 79 2016-48 3/22 OORP MEGATIKEGEL_COMPUTEN_LOCALIZATION TO_ORCAVELLE 79 2016-48 7/22 OORP MEGATIKE REGULATION OF CENE_EXPRESION 35 1055-50 2016 OORP FORTEN LOCALIZATION 35 1055-50 2016 2016-48 7/22 OORP FORTEN LOCALIZATION 56 7985-51 315 505-50 2085 2016 2016-50 2086 OORP FINA SPLICING COMPLEX_BIODENESS 50 3235-50 2086 5097 2285-50 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-30 2086 5097 2285-40 3316 5009 5001 500 3285-20 2385 500 2285-41 3316 5006				5.13E-53
GOBP CORANONITROCEN COMPACTURE 719 1185-53 3.221 GOBP ESTABLISHMENT OF PROTEIN LOCALZATION 128 2.705-44 5.372 GOBP MANARMC, TRANSLATION 138 1.055-35 2.515 GOBP MANARMC, TRANSLATION 138 1.055-35 2.515 GOBP MANARMC, TRANSLATION 101 1.325-35 2.515 GOBP MINA PROCESSING 59 3.235-30 6.915 GOBP MENA PROCESSING 59 3.215-22 2.665 GOBP PRINA PRICUME COMPLEX, BIOGENESIS 103 2.115-22 2.486 GOBP PRINA PRICUME COMPLEX, BIOGENESIS 101 9.712-23 1.386 GOBP PROSITIVE, REGULATION OF DROTEINE PROCESS 101 9.712-23 1.386 GOBP PROSITIVE, REGULATION OF PROTEIN, METABOLIC, PROCESS 401 4.952-42 7.918 GOBP POSITIVE, REGULATION OF PROTEIN, METABOLIC, PROCESS 401 4.952-42 7.938 GOBP POSITIVE,				1.22E-52
CORP ESTABLISHMENT OF PROTEIN LÖCZUZATION TO ORGANELLE 79 2015-68 3.77 CORP NEGATINE REGULATION OF GENE EXPRESSION 135 1.055-88 3.77 CORP FORTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 116 7.82-88 3.78 CORP FORTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 116 7.82-88 3.78 CORP FORTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 116 7.82-83 3.78 CORP FRONTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 116 7.82-82 2.86 CORP FRONTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 103 2.115-22 2.86 CORP FORTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 103 2.115-22 2.86 CORP FORTERN CONTAINING COMPLEX SUBJUNIT ORGANIZATION 103 2.115-23 3.84 CORP FORTERN CONTAINING CONTAINING CONCESS 103 1.865-26 1.386 CORP FORTERN ERGULATION OF CREADEL (PROCESS 103 2.345 3.44 CORP FROSTINA ARTABUSTING CONCESS 103 2.345 3.456				
OBDE NECATIVE REGULATION OF GÈNE EXPRESSIÓN 128 2.762.40 OBDE VICTORAMIC, TRANSLATION 36.1055.83 2.015 OBDE VICTORAMIC, TRANSLATION 102 1.752.63 3.765 OBDE PRIAL ROCTRANING, COMPLEX, SUBUNIT, ORGANIZATION 102 1.725.63 3.765 OBDE PRIAL SECONTAINING, COMPLEX, SUBUNIT, ORGANIZATION 66 7.425.43 1.835 OBDE PRICEL, CONTRAINING, COMPLEX, BIOGENESS 67 3.215.27 4.266 OORP PROTEIN, CATAGOLO, PRIVA, TRANSESTERFICATION, REACTIONS 46 6.505.29 1.285 0.81 1.325.24 3.315 OORP POSITIVE, REGULATION, OF POTEIN, BIOSVITHETIC, PROCESS 68 1.305.24 3.315 0.305 3.245.24 3.315 0.005 5.365.24 3.315 0.006 9.005.24 3.315 0.006 9.005.24 3.315 0.006 9.005.24 3.315 0.006 0.006.24 3.315 0.006 0.006.24 3.315 0.006 0.006.24 3.315 0.006 0.006.24 3.316 0.006 </td <td></td> <td></td> <td></td> <td>5.37E-46</td>				5.37E-46
OGBP CYTOPLASMC_TRANSLATION 35 105:25 241E OGBP FINA_PROTEN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 116 7.825-33 3.78E OGBP FINA_SPLCIAG 53 7.89E 3.18E 3.83E OGBP FINA_SPLCIAG 53 2.42E 3.24E 3.56 3.57E OGBP FINA_SPLCIAG 53 2.42E 3.56 3.57E				5.37E-46 7.12E-46
OOBE PROTEN CONTAINUS COMPLEX SUBUNT ORGANIZATION 110 1975-33 3785 OOBP PROTEN CONTAINUS COMPLEX SUBUNT ORGANIZATION 116 7385-33 1385 OOBP MINA PROCESSING 66 7385-33 1385 OOBP MINA PROCESSING 55 3278-30 2086 OOBP REQUIZION OF MIRAN ARTAGUIC PROCESS 471 1385-29 2486 OOBP REQUIZION OF MIRAN ARTAGUIC PROCESS 471 1385-29 2486 OOBP REQUIZION OF MINA SPECIFICATION REACTONS 40 4592-25 3585 OOBP POTEN CATAGUAC PROCESS 68 1302-24 3316 OOBP REQUIZION OF CATABOLIC PROCESS 67 2225-24 3356 OOBP REQUIZION OF CATABOLIC PROCESS 67 3452-24 3356 OOBP REQUIZION OF CATABOLIC PROCESS 67 3452-24 3576 OOBP REQUIZING MERGULATION OF NULLEOBASE CONTRINING COMPOUND METABOLIC PROCESS 60 4564-25 3464 OOBP COLL CYNON OF CULLUAR AMDE METABOLIC PROCESS 60 4564-25 3464 OOBP COLL CYNON OF CULLUAR AMDE METABOLIC PROCESS 60 4564-25 3464				
CORP PROTEN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 116 7.82-41 1.838 CORP PRIAS_PLICING 56 7.98E-31 1.818 CORP RISOLUCING 56 7.98E-31 1.818 CORP RISOLUCING COMPLEX_BIOGENESIS 56 3.23E-30 2.688 CORP REGULATION OF MRINA METABOLIC_PROCESS 47 3.38E-29 2.686 CORP REGULATION OF MRINA METABOLIC_PROCESS 46 5.62-26 1.388 CORP REGULATION OF MRINA METABOLIC_PROCESS 46 5.62-26 1.388 CORP REGULATION OF LASSULC PROCESS 60 1.971-25 1.866 CORP REGULATION OF CRATAGUL PROCESS 70 2.22E-24 3.958 CORP REGULATION OF CRATAGUL PROCESS 70 2.22E-24 3.958 CORP POSITIVE REGULATION OF FROTEIN_METABOLIC_PROCESS 70 2.82E-23 8.484 CORP POSITIVE REGULATION OF FROTEIN_METABOLIC_PROCESS 60 9.65E-23 5.646 CORP POSITIVE REGULATION OF CRATAGUL PROCESS 60 9.65E-23 5.646 CORP COLLULAR, PROTEIN MODERICATION CORE DEVENDES 61 3.96E-21 5.056				2.61E-34
GOBP_RNA_SPLICING 66 7982-11 611 GOBP_MINA_PROCESSING 268E 661 228-30 651 GOBP_REGULATION OF MIRNA CMETABOLC PROCESS 67 138E-20 268E GOBP_REGULATION OF MIRNA CMETABOLC PROCESS 163 218E-27 488 GOBP_REGULATION OF MIRNA CONTENCTONS 164 615E-27 488 GOBP_REGULATION OF ANATON FANCTONS 164 615E-27 488 GOBP_REGULATION OF CALASOLIC PROCESS 161 182E-24 316 GOBP_REGULATION OF CATASOLIC PROCESS 70 222E-41 356 GOBP_REGULATION OF CATASOLIC PROCESS 70 222E-41 356 GOBP_REGULATION OF CHULLAR AMOLE PROCESS 46 542E-32 548 GOBP_REGULATION OF CHULLAR AMOLE PROCESS 46 542E-22 244 GOBP_ROTINE REGULATION OF MUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS 60 868E-23 548 GOBP_ROTINE REGULATION OF CILLURA AMOLE PROCESS 60 868E-23 548 568 60 868E-23 548 568 569 558 60 222E-22 <t< td=""><td></td><td></td><td></td><td>3.79E-34</td></t<>				3.79E-34
GORP JIRKIN, PROCESSING 96 122-00 268 GORP JIRGOULDEPROTEIN, COMPLEX BLOGENESIS 55 3228-30 654E GORP JIRGOULDEPROTEIN, COMPLEX BLOGENESIS 47 1342-20 268E GORP CELL CYCLE 103 2.11E-27 428E GORP FINA SPLCING VIA, TRANSESTERIFICATION REACTONS 46 5.052-61 136E GORP FINA SPLCING VIA, TRANSESTERIFICATION REACTONS 66 100-22-62 136E GORP FORTINE CALLADLO FRACESS 66 100-22-62 136E GORP FROJENCING OF MAX SPLCING CERCESS 67 327E-24 335E GORP FROJENCING OF CRUCIDES 67 327E-24 335E GORP FROJENCING REGULATION OF FUCIDEOASE CONTAINING COMPOUND METABOLIC PROCESS 68 364E-23 348E GORP POSITIVE REGULATION OF CRUCIDECATAOLIC PROCESS 69 335E-21 245E 305E 200 335E-21 245E 346E 346E-22 224E 326E 346E 345E-22 346E 346E 346E-22 346E 346E 346E-22 346E 346E 346E-26 346E				1.83E-31
GORP RIBCUNCLEOPROTEN COMPLEX BIOGENESIS 55 3232-30 691 GORP RECULATION OF MIRNA METABOLC PROCESS 47 138E-29 286E GORP CELL CYCLE 103 211E-27 426E GORP COLL CYCLE 103 211E-27 426E GORP POSITIVE REGULATION OF ENDSYNTHETIC PROCESS 101 871E-28 166E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 101 871E-28 166E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 101 871E-28 166E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 101 871E-24 571E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 10 895E-23 548E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 40 846E-23 846E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 40 845E-22 642E GORP POSITIVE REGULATION OF CATABOLIC PROCESS 60 856E-22 640E GORP POSITIVE ROPONAL, REGULATION OF CATABOLIC PROCESS 60 856E-22 640E GORP POSITIVE ROPONAL REGULATION OF CATABOLIC PROCESS 60 846E-22 646E				1.81E-28
GORP REGULATION OF MRNA METABOLIC PROCESS 471 138-29 268 GORP CELL CYCLE 163 2.11E-27 4266 GORP POTEN CATABOLIC PROCESS 161 8.71E-25 168 GORP POTEN CATABOLIC PROCESS 161 8.71E-25 168 GORP PROTEN CATABOLIC PROCESS 161 8.71E-25 168 GORP REGULATION OF CATABOLIC PROCESS 170 222-41 356 GORP REGULATION OF CATABOLIC PROCESS 170 222-41 356 GORP REGULATION OF CATABOLIC PROCESS 163 8.72-24 356 GORP REGULATION OF CATABOLIC PROCESS 46 542-4 7.11 GORP REGULATION OF CLILULAR AMOLE PROCESS 46 542-4 7.11 GORP PROTEIN MODIFICATION PERSON 71 1552-2 2.454 GORP PROTEIN MODIFICATION PERSON 71 1552-2 2.452	GOBP_MRNA_PROCESSING	59		2.68E-28
GORP REGULATION OF MRNA METABOLIC PROCESS 471 138-29 268 GORP CELL CYCLE 163 2.11E-27 4266 GORP POTEN CATABOLIC PROCESS 161 8.71E-25 168 GORP POTEN CATABOLIC PROCESS 161 8.71E-25 168 GORP PROTEN CATABOLIC PROCESS 161 8.71E-25 168 GORP REGULATION OF CATABOLIC PROCESS 170 222-41 356 GORP REGULATION OF CATABOLIC PROCESS 170 222-41 356 GORP REGULATION OF CATABOLIC PROCESS 163 8.72-24 356 GORP REGULATION OF CATABOLIC PROCESS 46 542-4 7.11 GORP REGULATION OF CLILULAR AMOLE PROCESS 46 542-4 7.11 GORP PROTEIN MODIFICATION PERSON 71 1552-2 2.454 GORP PROTEIN MODIFICATION PERSON 71 1552-2 2.452	GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS	55	3.23E-30	6.91E-28
GOBP_CELL_CYCLE 103 2111-27 428 GORP_INA_SPLCING_VIA_TRANSESTERIFICATION_REACTIONS 46 650E-28 128 GORP_POSITIVE_REGULATION_OF_BIOSTWHETIC_PROCESS 101 8711-22 1316 GORP_POSITIVE_REGULATION_OF_BIOSTWHETIC_PROCESS 30 1822-44 3316 GORP_REGULATION_OF_CATABOLIC_PROCESS 70 222E-24 3356 GORP_POSITIVE_REGULATION_OF_POSITIVE_METABOLIC_PROCESS 70 222E-24 3585 GORP_POSITIVE_REGULATION_OF_POSITIVE_METABOLIC_PROCESS 67 3872-24 6738 GORP_POSITIVE_REGULATION_OF_POSITIVE_REGULATION_OF_GENE_EXPRESSION 71 1512-22 2462 GORP_POSITIVE_REGULATION_OF_CELLUAR_ADULE_PROCESS 60 9622-23 1546 GORP_POSITINE_NOOP_CELLUAR_REGULATION_OF_GENE_EXPRESSION 71 1512-22 2462 GORP_POSITINE_NOOP_CELLUAR_ACTABOLIC_PROCESS 60 2426-21 349 GORP_POSITINE_NOOP_CELLUAR_CATABOLIC_PROCESS 61 342-22 620 GORP_POSITINE_NOOP_CELLUAR_CATABOLIC_PROCESS 61 342-21 620 GORP_BOLICLONO_OF_CELLUE_CATABOLIC_PROCESS 61	GOBP REGULATION OF MRNA METABOLIC PROCESS	47		2.86E-27
GOBP_RNA_SPLCING_VUA_TRANSESTER/IRCATION_REACTIONS 466 6.506-26 1288 GOBP_POSTINC_REQUILATION_OF_BIOSYNTHETIC_PROCESS 661 1306-24 3311 GOBP_REGULATION_OF_RNA_SPLCING 301 1282-24 3365 GOBP_REGULATION_OF_ROTEN_SPLCING 301 1282-24 3365 GOBP_REGULATION_OF_ROTEN_METABOLIC_PROCESS 67 3672-34 746 GOBP_REGULATION_OF_ROTEN_METABOLIC_PROCESS 60 5386-23 844 GOBP_ROSTINER REGULATION_OF_NUCLEORASE_ONTAINING_COMPOUND_METABOLIC_PROCESS 60 9686-23 844 GOBP_ROSTINER_REGULATION_OF_RULAR_DADUC_PROCESS 60 9686-23 844 23 844 GOBP_ROSTINE_ROPORTH_ROSTINE_CONJUGATION_CONJUGATION_CONJUGATION 73 1362-22 207 GOBP_ROSTINE_ROSTINE_RESPIRATION 61 1362-22 207 GOBP_ROSTINE_ROSTINE_ROSTINE_CONJUGATION_CONJUGATION_CONJUGATION 73 1362-22 207 GOBP_ROSTINE_ROSTINE_ROSTINE_ROSTINE_SON 73 1362-22 207 GOBP_ROSTINE_ROSTINE_ROSTINE_ROSTINE_ROSTINE_ROSTINE 61 1362-22 207 GOBP_ROSTINE_ROS				4.26E-25
COBP. POSITIVE, REGULATION, OF, BIOSYNTHETIC, PROCESS 101 9716-25 1386 COBP. PREGULATION, OF, RIA, SPLICINO 301 1382-24 3315 COBP. REGULATION, OF, CATABOLIC, PROCESS 70 2225-44 3755 GOBP, REGULATION, OF, CATABOLIC, PROCESS 87 3475-24 6735 GOBP, POSITIVE, REGULATION, OF, PROTEIN, METABOLIC, PROCESS 87 3475-24 6735 GOBP, REGURATION, OF, CATABOLIC, PROCESS 68 5446-23 1846 GOBP, POSITIVE, REGULATION, OF, NUCLEORASE, CONTAINING, COMPOUND, METABOLIC, PROCESS 68 5446-23 1846 GOBP, POSITIVE, REGULATION, OF, CATABOLIC, PROCESS 60 5466-23 154 5442 622 622 GOBP, POSITIN, MADRICHARTIMA, CATABOLIC, PROCESS 60 2286-21 620 600 600 2286-21 620 600 621 2246 620 620 621 7426-63 746 630 646 630 646 626 621 620 620 621 7426-43 740 640 646 6406 6406 6406				1.28E-23
CORP PROTEIN CATABOLIC PROCESS 68 1805-24 331E CORP REGULATION, OF, RNA SPUCING 30 1825-24 335E CORP REGULATION, OF, RNA SPUCING 30 1825-24 335E CORP, REGULATION, OF, ROTEN, METABOLIC, PROCESS 67 3775-24 737E CORP, REGULATION, OF, CELLULAR, AMDE, METABOLIC, PROCESS 60 536E-23 846 CORP, POSTITRANSCRIPTIONAL, REGULATION, OF, CENE, EXPRESSION 73 153E-22 2546 CORP POSTITRANSCRIPTIONAL, REGULATION, OF, CENE, EXPRESSION 63 34E-22 2542 CORP POSTITRANSCRIPTIONAL, REGULATION, OF, CENE, EXPRESSION 63 34E-22 2546 CORP POSTITRANSCRIPTIONAL, REGULATION, OR, CENED, CONJUGATION OR REMOVAL 71 157E-21 2567 CORP POSTITRANSCRIPTIONAL, REGULATION OR CREMOVAL 71 157E-21 2567 CORP PROTEIN, MODIFICATION, DE FNA LOCALIZATION 77 296E-20 4006 CORP PROTEIN, REGULATION, OF, RUCLEQUES 73 268E-19 3566 CORP RICELLAR, REGULATION, OF, RUCLEQUES 73 268E-19 3566 CORP RICELLAR, REGULATION, OF, RUCLEQUES				1.86E-22
GORP REGULATION OF RNA SPLICING 30 132E-24 331E GORP REGULATION OF CATABOLIC PROCESS 70 222E-24 637E GORP POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 87 347E-24 678E GORP POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 40 459E-24 84E GORP POSITIVE REGULATION OF OF CLUCEORASE CONTAINING COMPOUND METABOLIC PROCESS 46 544E-23 844 GORP POSITIVE REGULATION OF CENE LEPRESSION 71 163E-22 620 GORP PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION 65 394E-22 620E GORP PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 71 163E-24 640E GORP PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL 71 136E-24 620E GORP CELLULAR PROTEIN CONTAINING COMPLEX ASSEMBLY 68 103E-24 640E GORP CELLUCAR PROTEIN CONTAINING COMPLEX ASSEMBLY 68 138E-19 246E-19 246E 620E		1		
CORP. PREGULATION. OF_CATABOLIC_PROCESS 70 222E-24 336E CORP. POSITIVE, REGULATION. OF_NUCLEORASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 40 459E-24 731E CORP. PROSITIVE, REGULATION. OF_NUCLEORASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 60 966E-23 854E CORP. PROSITIVE, REGULATION. OF_CELLULAR_AMIDE_METABOLIC_PROCESS 60 966E-23 854E GORP POSITIVE, REGULATION. OF_CELLULAR_AMIDE_METABOLIC_PROCESS 60 966E-23 652E				
CODEP POSITIVE REGULATION OF PROTEIN, METABOLIC, PROCESS 87 3.87E-24 678 COOPP, RIGSONGE BIOGENESIS 401 4.99E-24 7.81 COOPP, RIGSONGE BIOGENESIS 401 4.99E-24 7.81 COOPP, REGULATION, OF, CULLURA, ANDE METABOLIC, PROCESS 461 5.44E-23 8.84E COOPP, CELLULAR, NOTEN, CATABOLIC, PROCESS 60 9.66E-23 1.54E COOPP, PROTEIN, MODIFICATION BY, SMALL, PROTEIN, CONJUGATION 65 3.94E-22 6.02E COOPP, PROTEIN, MODIFICATION BY, SMALL, PROTEIN, CONJUGATION OR, REMOVAL 771 1.57E-21 2.21E COOPP, PROTEIN, MODIFICATION BY, SMALL, PROTEIN, CONJUGATION OR, REMOVAL 771 1.97E-21 2.31E COOPP, CELLULAR, PROTEIN, CONTAINING, COMPLEX, ASSEMBLY 68 1.03E-20 1.49E COOPP, CELLUCAR, PROTEIN, CONTAINING, COMPLEX, ASSEMBLY 68 1.03E-20 1.49E COOPP, CELLUCAR, PROTEIN, CONTAINING, COMPLEX, ASSEMBLY 68 1.03E-20 1.49E COOPP, CELLUCAR, PROTEIN, CONTAINING, COMPLIAN, PROCESS 61 2.44E-19 3.66E-20 5.92E COOPP, RAL, LOCALIZATION CELLUCAR, CONCESS 61 <t< td=""><td></td><td></td><td></td><td></td></t<>				
GOBP RIBOSONE BIOGENESIS 171E CORP POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND_METABOLIC PROCE 95 5.362-23 8.84E CORP PAGULATION OF CELLULAR AMDE METABOLIC PROCESS 60 9.662-33 1.54E-23 1.54E-23 1.54E-23 1.54E-23 1.54E-23 1.54E-24 6.22 6.22 CORP POSITICANASCRIPTIONAL REGULATION OF GENE EXPRESSION 65 3.45E-22 6.22 6.22 CORP POSITICANSCRIPTIONAL REGULATION OF GENE CANDUCATION 65 3.45E-22 6.22 6.22 CORP POSITICANTON DEPENDENT MACROMOLECULE CATABOLIC PROCESS 68 1.33E-21 2.27E CORP PAGULATION OF CELLUAR CATABOLIC, PROCESS 68 1.36E-20 5.26E CORP CELLUAR, PROTEN CONTAINING COMPLEX ASSEMBLY 68 1.33E-20 1.46E CORP REGULATION OF CILL CYCLE 7.208E-20 5.26E 7.208E-20 5.26E CORP REGULATION OF CONTAINING COMPOUND TRANSPORT 3.232E-19 2.21E 1.32E-19 3.42E-19 3.48E-19 5.44E-19 5.45E-10 5.44E-19 5.45E-10 5.44E-19 5.45E-10 5.44E-19 5.45E-10 5.45E-10 <				
GORP POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND, METABOLIC PROCE 5.36E-23 8.84E GORP REGULATION OF CELLURA, MODE METABOLIC, PROCESS 46 5.44E-23 8.84E GORP DESILULAR, NOTEN CATABOLIC, PROCESS 60 9.66E-23 1.54E GORP POSITIN, MODIFICATION BY, SMALL, PROTEIN, CONJUGATION 65 3.94E-22 6.02E GORP PROTEIN, MODIFICATION BY, SMALL, PROTEIN, CONJUGATION OR REMOVAL 71 1.57E-21 2.21F GORP PROTEIN, MODIFICATION BY, SMALL, PROTEIN, CONJUGATION OR REMOVAL 71 1.57E-21 2.31E GORP CELLUAR, PROTEIN, CONTAINING, COMPLEX, ASSEMBLY 68 1.03E-20 1.48E GORP CELLUAR, PROTEIN, CONTAINING, COMPLEX, ASSEMBLY 68 1.03E-20 5.35E GORP CELLUAR, COMPOUND, CATABOLIC, PROCESS 72 2.04E-19 3.05E GORP, CELLUAR, COMPOUND, CATABOLIC, PROCESS 73 3.04E-19 3.45E 3.62E GORP REGULATION OF, CULL, CYCLE 669 2.04E-19 3.05E 3.05E 3.05E 3.05E 3.05E 3.05E 3.05E 3.05E 3.05E 3.05E-19 2.44E-19 5.35E GORP REGULAT				6.73E-22
GOBP, REGULATION. OF, CELLULAR, AMIDE, METABOLIC, PROCESS 648 5.44E-23 5.44E GOBP, OSTITAANSCRIPTIONAL, REGULATION. OF, GENE, EXPRESSION 73 1.53E-22 5.24E GOBP, POSTTRANSCRIPTIONAL, REGULATION. OF, GENE, EXPRESSION 65 3.49E-22 5.25E GOBP, MODIFICATION. DEPENDENT, MACROMOLECULE, CATABOLIC, PROCESS 653 1.39E-21 2.27E GOBP, REGULATION. OF, CELLULAR, CATABOLIC, PROCESS 661 0.28E-21 3.29E GOBP, CELL, LARLA, PROTEIN. CONJUGATION OR REMOVAL 71 1.57E-21 2.31E GOBP, CELL, CYCLE, PROCESS 661 0.28E-20 5.48E 0.49E GOBP, CELL, CYCLE, PROCESS 73 2.08E-20 5.26E 0.29E 9.24E-19 3.48E 0.54E-21 3.52E 0.29E 0.29E 0.29E-19 2.74E 0.00P 0.60P 0.60P <td></td> <td></td> <td></td> <td>7.81E-22</td>				7.81E-22
GOBP CELLULAR, PROTEIN CATABOLIC, PROCESS 60 6.68E-23 1.54E GOBP, PROTEIN, MODIFICATION, BY, SMALL, PROTEIN, CONJUGATION 65 3.94E-22 6.02E GOBP, PROTEIN, MODIFICATION, BY, SMALL, PROTEIN, CONJUGATION, OR REMOVAL 71 1.57E-21 2.31E GOBP, PROTEIN, MODIFICATION, BY, SMALL, PROTEIN, CONJUGATION, OR REMOVAL 71 1.57E-21 2.31E GOBP, CELLULAR, CATABOLIC, PROCESS 60 2.98E-21 3.32E GOBP, CELLULAR, CRADUCL, DROCESS 61 0.326E-20 5.35E GOBP, CELLULAR, PROTEIN, CONTAINING, COMPLEX, ASSEMBLY 63 0.386E-20 5.35E GOBP, CELLULAR, PROTEIN CONTAINING, COMPLEX, ASSEMBLY 77 2.96E-20 5.35E GOBP, RIA, LOCALIZATION 30 3.85E-20 5.35E 73 2.08E-19 2.94E GOBP, RIGALTROY, OF, CLUL, CYCLE 66 2.94E-18 3.05E 3.32E-18 4.21E GOBP, RIGALTRON, OF, CALLZATION 3.32E-18 4.21E 5.33E 73 2.08E-19 2.94E-19 5.93E GOBP, RIGULTRON, OF, COLLZATION, OF, MONDUND, TRANSPORT 21 3.42E-18 5.02E	GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCE	95	5.36E-23	8.84E-21
GOBP POSITIANISCRIPTIONAL REGULATION OF GENE EXPRESSION 73 1.63E-22 2.54E GOBP PROTEIN MODIFICATION DIS YSMALL PROTEIN CONJUGATION 65 3.94E-22 6.52E GOBP PROTEIN MODIFICATION DIS YSMALL PROTEIN CONJUGATION OR REMOVAL 71 1.57E-21 2.31E GOBP PROFLUAR PROTEIN CONTINING COMPLEX ASSEMBLY 661 2.28E-21 3.29E GOBP CELL UNAR PROTEIN CONTINING COMPLEX ASSEMBLY 661 3.08E-20 4.59E GOBP CELL CYCLE PROCESS 77 2.96E-20 4.99E GOBP CELL CYCLE PROCESS 78 0.38E-20 6.39E GOBP CREDULTAR PROTEIN CONTAINING COMPLEX ASSEMBLY 661 2.86E-20 4.99E GOBP CELL CYCLE PROCESS 78 0.88E-20 4.99E GOBP CELL CYCLE PROCESS 28 7.02E-20 4.99E GOBP CELL CYCLE PROCESS 28 6.92 2.84E-19 3.85E GOBP CREDULATION OF CULTOR 671 2.84E-19 3.85E 9.75E 7.32EE-19 7.85E GOBP NEGATIVE, REGULATION OF MUCLEOBASC CONTAINING COMPOUND METABOLIC PROCESS 29 4.91E-19 5.83E GOB	GOBP_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS	48	5.44E-23	8.84E-21
COBP_PROTEIN_MODIFICATION 65 3.94E-22 6.022 COOPP_MODIFICATION FROTEIN_MODIFICATION 71 1.57E-21 2.07E COOPP_ROTEIN_MODIFICATION SMALL PROTEIN CONDUCTABLY 71 1.57E-21 2.31E COOPP_REGULATION OF CLULAR CATABOLIC PROCESS 60 2.28E-21 3.29E COOP_CELL_CYCLE_PROCESS 72 0.46E-20 4.39E GOOP_CELL_CYCLE_PROCESS 73 0.38E-20 5.25E GOOP_REGULATION OF CLUCALZATION 30 3.84E-19 3.86E GOOP_REGULATION OF CLUCYCLE 60 2.44E-19 3.66E GOOP_REGULATION OF CLUCYCLE 61 3.24E-19 3.66E GOOP_NEGATIVE_REGULATION OF ADDUID_TANSPORT 31 3.24E-19 5.50E GOOP_NEGATIVE_REGULATION OF ADDUID_TANSPORT 22 3.44E-19 5.50E GOOP_NEGATIVE_REGULATION OF ADDUST 31 5.23E-18 5.20E GOOP_NEGATIVE_REGULATION OF ADDUST 31 5.23E-18 5.20E GOOP_NEGATIVE_REGULATION OF ADDUST 31 5.23E-18 5.20E GOOPP_REGU	GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS	60	9.66E-23	1.54E-20
CORP PROTEIN, MODIFICATION BY SMALL PROTEIN, CÔNJUGATION 65 3.94E-22 6.022 CORP MODIFICATION, DEY SMALL PROTEIN, CONJUGATION OR REMOVAL 71 1.57E-21 2.31E CORP PROTEIN, MODIFICATION, BY SMALL PROTEIN, CONJUGATION OR REMOVAL 71 1.57E-21 2.31E CORP REGULATION OF CLULAR, CATABOLIC, PROCESS 60 2.28E-21 3.29E GORP, CELLULAR, CATABOLIC, PROCESS 61 0.38E-20 4.90E GORP, CELL, CYCLE, PROCESS 73 2.08E-19 3.86E-20 5.25E GORP, REGULATION, OF, CALL, OXOLE 60 2.44E-19 3.86E-20 5.38E GORP, REGULATION, OF, CALL, OYOLE 60 2.44E-19 3.66E 5.25E 73 2.08E-19 2.74E GORP, RAL, COALIZATION GOMPOUND_TANSPORT 31 3.22E-19 4.25E 5.02E 5.0	GOBP POSTTRANSCRIPTIONAL REGULATION OF GENE EXPRESSION	73	1.63E-22	2.54E-20
GOBP_MODIFICATION_DEPENDENT_MACROMOLECULE_CATABOLIC_PROCESS 53 1.39E-21 2.07E GOBP_PREDULATION_OF_CELLULAR_CATABOLIC_PROCESS 60 2.28E-21 3.29E GOBP_CELLULAR_ROTION_OF_MALLOCATABOLIC_PROCESS 60 2.28E-21 3.29E GOBP_CELL_CYCLE_PROCESS 61 3.08E-20 4.08E GOBP_CELL_CYCLE_PROCESS 71 2.96E-20 4.08E GOBP_RIA_EXPORT_FROM_NUCLEUS 69 2.68E-19 2.74E GOBP_RIA_EXPORT_FROM_NUCLEUS 69 2.84E-19 3.68E-20 3.98E GOBP_RIA_EXPORT_FROM_NUCLEUS 69 2.84E-19 3.68E-20 3.98E GOBP_ROGANONTROGEN_COMPOUND_CATABOLIC PROCESS 73 3.68E-19 3.64E-19 3.68E 3.68E-19 4.21E GOBP_NEGATIVE_REGULATION OF_DUCLEOBASE_CONTAINING_COMPOUND_METABOLIC PROC 78 4.39E-19 5.23E 5.35 5.35 5.35 6.36 5.25E 6.36 5.25E 6.36 5.25E 6.36 3.99E-19 5.25E 6.36 5.25E 5.36 5.36 5.36 5.36 5.36 5.36 5.35E </td <td>GOBP PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION</td> <td>65</td> <td>3.94E-22</td> <td>6.02E-20</td>	GOBP PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION	65	3.94E-22	6.02E-20
COBP PROTEIN_MODIFICATION BY SMALL PROTEIN_CONJUGATION_OR_REMOVAL 71 157E-21 231E COBP REGULATION OF_CELULUAR_CATABOLIC_PROCESS 60 228E-21 326E COBP CELLULAR_PATROLIC_PROCESS 67 298E-20 406E COBP CELL CYCLE_PROTEN_CONTAINING_COMPLEX_ASSEMBLY 68 103E-20 409E COBP CELL CYCLE_PROTEN_COMPOUND_CATABOLIC_PROCESS 73 208E-19 366E-20 525E GOBP_REGULATION OF_CELL CYCLE 69 284E-19 366E 366E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 83 408E-19 582E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 83 408E-19 583E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 73 544E-18 583E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 73 544E-18 583E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 73 544E-18 583E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 73 544E-18 526E GOBP_NEGATIVE_REGULATION_OF_DISONTHETIC_PROCESS 73 544E-18 526E GOBP_NOCLEAR_EXPONT				2.07E-19
GOBP_REGULATION_OF_CELLULAR_CATABOLIC_PROCESS 60 228E-21 329E GOBP_CELLUCAR_PROTEINC_COMPLEX_ASSEMBLY 68 103E-20 406E GOBP_CELLUCYCLE_PROCESS 26 702E-20 938E GOBP_CELLONCE_PROCESS 26 702E-20 938E GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS 73 208E-19 2.744 GOBP_RINA_LOCALIZATION CALL_OTCLE 69 2.84E-19 3.64E GOBP_NICOLEGASE_CONTAINING_COMPOUND_TRANSPORT 32 3.84E-19 5.82E GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.83E-19 5.82E GOBP_NUCLEAR_EXPORT 29 4.91E-19 5.83E 6.92E 6.92E-16 6.83E GOBP_REGULATION_OF_ROTEIN_MODIFICATION_PROCESS 73 5.44E-18 6.28E 6.90E 7.93E-18 7.85E 7.854E-18 6.28E GOBP_REGULATION_OF_RRANG_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.32E-17 <t< td=""><td></td><td></td><td></td><td>2.31E-19</td></t<>				2.31E-19
GOBP CELLULAR, PROTEIN CONTAINING COMPLEX, ASSEMBLY 68 103E-20 146E GOBP CELL CYCLE PROCESS 77 296E-20 525E GOBP, RIA, EXPORT FROM, NUCLEUS 30 386E-20 525E GOBP, RIA, EXPORT FROM, NUCLEUS 61 702E-20 9.36E GOBP, REGULATION, OF, CELL CYCLE 69 284E-19 36E GOBP, NUCLEOBASE, CONTAINING, COMPOUND, TRANSPORT 32 364E-19 454E GOBP, NUCLEOBASE, CONTAINING, COMPOUND, TRANSPORT 32 364E-19 528E GOBP, NUCLEOBASE, CONTAINING, COMPOUND, TRANSPORT 32 364E-19 528E GOBP, NEGATIVE, REGULATION, OF, INSYNTHETIC, PROCESS 831 628E-19 583E GOBP, NEGATIVE, REGULATION, OF, INSYNTHETIC, PROCESS 31 622E-19 583E GOBP, REGULATION, OF, INSYNTHETIC, PROCESS 31 622E-19 728E GOBP, REGULATION, OF, INSYNTHETIC, PROCESS 31 622E-17 728E GOBP, REGULATION, OF, INSYNTHETIC, PROCESS 31 622E-17 728E GOBP, REGULATION, OF, INSYNTHETIC, PROCESS 33 624E-18 535E-16				
GOBP CELL CYCLE PROCESS 77 296E-20 400E GOBP ESTABLISHMENT OF RNA LOCALIZATION 30 386E-20 386 GOBP RIAL EXPORT FROM NUCLEUS 26 702E-20 386 GOBP RIAL EXPORT FROM NUCLEUS 69 284E-19 274E GOBP REGULATION OF CELL CYCLE 69 284E-19 284E-19 GOBP NUCCEARSE CONTAINING COMPOUND TRANSPORT 32 326E-19 582E GOBP NEGATIVE REGULATION OF DIDON TRANSPORT 32 342E-19 583E GOBP NEGATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROC 78 483E-19 583E GOBP REGULATION OF RUCLEORASE TO STRESS 31 622E-19 583E 626E GOBP REGULATION OF ROTEIN MODIFICATION PROCESS 79 703E-18 626E GOBP REGULATION OF RUCLEAR EXPORT 51 51 622E 622E 621 327 GOBP REGULATION OF RUCLEAR EXPORT 51 522E1 73 544E-18 626E GOBP REGULATION OF RUCLEY 51 522E1 73 544E-18 626E 600P 703E-18				
GOBP ESTABLISHMENT OF RNA LOCALIZATION 30 366E-20 525E GOBP RNA EXPORT, FROM NUCLEUS 26 7022-20 338E GOBP RASULATION, OF, CELL, CYCLE 66 244E-19 3.66E GOBP NUCLEOBASE CONTAINING_COMPOUND_TRANSPORT 32 3.44E-19 4.54E GOBP NUCLEOBASE CONTAINING_COMPOUND_TRANSPORT 32 3.44E-19 4.54E GOBP NEGATIVE, REGULATION, OF SIOSYNTHETIC, PROCESS 33 4.90E-19 5.83E GOBP NEGATIVE, REGULATION, OF SIOSYNTHETIC, PROCESS 34 4.98E-19 5.83E GOBP NEGATIVE, REGULATION, OF NUCLEOBASE CONTAINING COMPOUND_METABOLIC PROC 78 4.43E-19 5.83E GOBP NEGATIVE, REGULATION, OF RUSCESS 73 5.44E-18 6.26E GOBP REGULATION, OF, RESPONSE TO_STRESS 73 5.44E-18 6.26E GOBP REGULATION, OF, PROTEIN, MODIFICATION PROCESS 79 7.03E-18 7.85E GOBP REGULATION, OF, MINA, SPLICING, VIA, SPLICEOSOME 21 1.32E-17 1.43E GOBP REGULATION, OF, MINA, CATABOLIC, PROCESS 21 1.62E-16 1.66E GOBP REGULATION, OF, MINA, CATABOLIC, PROCESS <				
GOBP RNA EXPORT_FROM NUCLEUS 26 7.02E-20 9.36E GOBP ORGAUNTROGEN_COMPOUND_CATABOLIC_PROCESS 73 2.08E-19 3.62 GOBP RAL_LOCALZATION 60 2.84E-19 3.60 GOBP NILCEARSE_CONTAINING_COMPOUND_TRANSPORT 31 3.32E-19 4.51E GOBP NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 83 4.09E-19 5.02E GOBP NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 83 4.09E-19 5.83E GOBP NUCLEAR_EXPORT 29 4.91E-19 5.83E GOBP REGULATION_OF_RESPONSE TO_STRESS 73 5.44E-18 6.20E GOBP ROTECLYSIS 84 6.53E-18 6.26E GOBP ROTECLYSIS 74 7.03E-18 1.02E GOBP REGULATION_OF_RORT 35 9.23E-18 1.02E GOBP REGULATION_OF_RANG, SPLICING_VALSPLICEOSOME 21 1.22E-17 2.3FE GOBP REGULATION_OF_MARA SPLICING_VALSPLICEOSOME 1.112E-17 1.438E GOBP REGULATION_OF_MARA SPLICING_VALSPLICEOSOME 21 1.22E-17 2.3FE GOBP REGULATION_OF_MARA SPLICING_VALSPLICEOSOME 1.132E-11 </td <td></td> <td></td> <td></td> <td></td>				
GOBP ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS 73 208E-19 2.74E GOBP REGULATION OF CELL_CYCLE 69 284E-19 3.62E-19 5.62E GOBP NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.43E-19 5.83E GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.43E-19 5.83E GOBP_NEGLEAR_EXPORT 31 6.23E-19 7.28E 6.26E GOBP_REQULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-18 7.85E 6.26E GOBP_REGULATION_OF_MENA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.37E 6.36E-17 3.84E 1.02E GOBP_REGULATION_OF_MENA_SIGNAL_TRANSDUCTION 82 3.68E-17 3.84E 0.26E 0.02P 1.62E-16 1.66E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E 0.34E-16 3.36E 0.39E 0.11E-16 1.16E				5.25E-18
GOBP REGULATION OF CELL CYCLE 69 2.44E-19 3.66E GOBP RNA LOCALIZATION 31 3.32E-19 4.21E GOBP NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT 32 3.64E-19 4.54E GOBP NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 83 4.09E-19 5.83E GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.38E-19 5.83E GOBP_NUCLEAR_EXPORT 29 4.91E-19 5.83E 5.36E-18 6.26E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 73 5.44E-18 6.26E 6.26DP 7.03E-18 7.85E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-18 7.85E 6.26E-17 2.37E GOBP_REGULATION_OF_RINA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E 6.06P 8.68E-17 3.86E 7.38E 7.64E-18 1.66E 6.06P 8.00P 1.11E-16 1.16E 6.06P 6.06P 7.132E-17 1.43E 6.06P 6.06P 7.14E-16 1.66E 6.06P 6.06P 7.16E-16 6.172E 6.06P 6				9.38E-18
GOBP_RNA_LOCALIZATION 31 3.22E-19 4.21E GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT 32 3.64E-19 4.54E GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 83 4.09E-19 5.02E GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.83E-19 5.83E GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.83E-19 5.83E GOBP_REGULATION_OF_ROTES 31 6.23E-19 7.28E 29 4.91E-19 5.83E GOBP_REGULATION_OF_ROTEN_MODIFICATION_PROCESS 73 5.44E-18 6.26E GOBP_REGULATION_OF_ROTEN_MODIFICATION_PROCESS 79 7.03E-18 1.02E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 3.68E-17 3.88E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 3.68E-17 3.89E 1.60E-16 1.02E 1.60E		73	2.08E-19	2.74E-17
GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT 12: 3.44E-19 4.54E GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 83: 4.09E-19 5.83E GOBP_NUCLEAR_EXPORT 29: 4.91E-19 5.83E GOBP_NUCLEAR_EXPORT 29: 4.91E-19 5.83E GOBP_REGULATION_OF_ROCESS 31: 6.23E-19 7.28E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 73: 5.44E-18: 6.26E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 73: 5.44E-18: 6.26E GOBP_REGULATION_OF_RONAL_SPLICING_VIA_SPLICEOSOME 21: 1.32E-17: 1.43E GOBP_REGULATION_OF_INRNA_SPLICING_VIA_SPLICEOSOME 21: 3.28E-17: 2.37E GOBP_REGULATION_OF_INRNA_SPLICING_VIA_SPLICEOSOME 21: 3.28E-17: 2.37E GOBP_REGULATION_OF_INRNA_SPLICING_VIA_SPLICEOSOME 21: 1.28E-17: 2.37E GOBP_REGULATION_OF_INRNA_SPLICING_VIA_SPLICEOSOME 21: 3.28E-16: 1.46E GOBP_REGULATION_OF_INRNA_CATABOLIC_PROCESS 27: 1.28E-16: 1.46E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58: 1.70E-16:	GOBP_REGULATION_OF_CELL_CYCLE	69	2.84E-19	3.66E-17
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 83 4.09E-19 5.022 GORP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 78 4.83E-19 5.832 GOBP_RECLEAR_EXPORT 29 4.91E-19 5.832 GOBP_REQULATION_OF_RESPONSE_TO_STRESS 31 6.23E-19 7.23E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 84 5.53E-18 6.26E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-18 7.85E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_MINA_CATABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_MINA_CATABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_MINA_CATABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_REGULATION_OF_MINA_CATABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_REGULATION_OF_TRANSPERASE_ACTIVITY 58 1.70E-16 1.72E-16 GOBP_PROSTITVE_REGULATION_OF_TRANSLATION 22 4.70E-16 3.39E GOBP_ROSTITVE_REGULATION_OF_TRANSLATION 22 4.70E-16	GOBP_RNA_LOCALIZATION	31	3.32E-19	4.21E-17
GOBP_NEGATIVE_REGULATION, OF_BIOSYNTHETIC_PROCESS 83 4.09E-19 5.020 GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 76 4.83E-19 5.83E GOBP_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROC 76 4.83E-19 5.83E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 31 6.23E-19 7.28E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 73 5.44E-18 6.20E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-16 7.85E GOBP_REGULATION_OF_MENA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_MENA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_INTRACELULAR_SIGNAL_TRANSDUCTION 82 3.68E-17 3.86E GOBP_REGULATION_OF_MENA_CATABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_MANA_CATABOLIC_PROCESS 24 3.41E-16 1.70E GOBP_PROTEX 58 1.70E-16 1.72E 58 1.70E-16 3.39E GOBP_REGULATION_OF_TRANSPERASE_ACTIVITY 58 1.70E-16 3.39E 3.39E-16<	GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT	32	3.64E-19	4.54E-17
GOBP NEGATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROC 78 4.83E-19 5.835 GOBP NUCLEAR EXPORT 29 4.91E-19 5.835 GOBP REGULATION OF RESPONSE TO STRESS 31 6.23E-19 7.28E GOBP REGULATION OF RESPONSE TO STRESS 33 5.44E-18 6.26E GOBP REGULATION OF RESPONSE TO STRESS 79 7.03E-18 7.85E GOBP NUCLEAR TRANSPORT 35 9.23E-18 1.02E GOBP REGULATION OF PROTEIN MODIFICATION PROCESS 79 7.03E-18 7.85E GOBP REGULATION OF MRNA SPLICING VIA SPLICEOSOME 21 1.32E-17 1.43E GOBP REGULATION OF MRNA CATABOLIC PROCESS 27 1.62E-16 1.66E GOBP REGULATION OF MRNA CATABOLIC PROCESS 27 1.62E-16 1.62E GOBP POSITIVE REGULATION OF CELLULAR AMIDE METABOLIC PROCESS 24 3.41E-16 3.39E GOBP PROTEIN EXEGULATION OF CELLULAR AMIDE METABOLIC PROCESS 24 3.41E-16 3.39E GOBP PROTEIN EXEGULATION OF CELLULAR AMIDE METABOLIC PROCESS 39 3.45E-16 3.39E GOBP PROTENE REGULATION OF PROTEIN METABOLIC PROCESS		83	4.09E-19	5.02E-17
GOBP_NUCLEAR_EXPORT 29 491E-19 538E GOBP_RRNA_METABOLIC_PROCESS 31 623E-19 728E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 73 544E-18 626E GOBP_REGULATION_OF_ROTEN_MODIFICATION_PROCESS 79 703E-18 763E GOBP_REGULATION_OF_ROTEN_MODIFICATION_PROCESS 79 703E-18 763E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 132E-17 1.43E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 82 368E-17 388E GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_CREGULATION_OF_COLLAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_REGULATION_OF_CREGULATION_OF_COLLAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_ROTIC CELL CYCLE 58 84 3.69E-16 3.39E GOBP_NOTIC CELL CYCLE 58 4.42E-16 4.35E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.42E GOBP_ROTOTIC_CELL_CYCLE 58 4.34E-16 5.39E <tr< td=""><td></td><td>78</td><td>4.83E-19</td><td>5.83E-17</td></tr<>		78	4.83E-19	5.83E-17
GOBP_RENA_METABOLIC_PROCESS 31 6.23E-19 7.28E GOBP_REGULATION_OF_RESPONSE_TO_STRESS 73 5.44E-18 6.26E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 74 7.03E-18 7.35E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-18 7.35E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_MRNA_CATABOLIC PROCESS 27 1.62E-16 1.66E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 3.76E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.42E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.42E GOBP_NOTITIC_REAGULATION_OF_CELLUAR_AMIDE_METABOLIC_PROCESS				5.83E-17
GOBP_REGULATION_OF_RESPONSE_TO_STRESS 73 5.44E-18 6.26E GOBP_ROTEOLYSIS 84 5.53E-18 6.26E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 77 7.03E-18 7.03E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 82 3.68E-17 3.88E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_INTRACELLULAR_AMIDE_METABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.32E GOBP_NEGULATION_OF_PHORUS_METABOLIC_PROCESS 34 4.81E-16 4.29E GOBP_REGULATION_OF_PHORUS_METABOLIC_PROCESS 36 4.42E-16 4.42E GOBP_REGULATION_OF_REGULATION_OF_REGUS 39				7.28E-17
GOBP_PROTEOLYSIS 84 5.53E-18 6.26E GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-18 7.85E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 3.68E-17 3.88E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 82 3.68E-17 3.88E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS 27 1.62E-16 1.62E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS 24 3.41E-16 3.99E GOBP_PROTEINCEREGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 39 3.45E-16 3.99E GOBP_PROTEINCEREGULATION_OF_TRANSFERASE_ACTIVITY 58 4.369E-16 3.58E GOBP_PROTEINCEREGULATION_OF_TRANSFERASE_ACTIVITY 58 4.369E-16 3.99E GOBP_PROTEINCERCESS 39 3.45E-16 3.99E GOBP_PROTEINCEREGULATION_OF_TRANSFERASE 5.10.10E-16				
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 79 7.03E-18 7.85E GOBP_NUCLEAR_TRANSPORT 35 9.23E-18 1.02E GOBP_REGULATION_OF_MENA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_MENA_SPLICING_VIA_SPLICEOSOME 22.217 2.37E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_MOLECULAR_FUNCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 39 3.45E-16 3.58E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 24 4.70E-16 6.29E GOBP_NORNA METABOLIC_PROCESS 75 4.78E-16 4.47E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 30 7.30E-16 6.29E<				6.26E-16
GOBP_NUCLEAR_TRANSPORT 35 9.23E-18 1.02E GOBP_REGULATION_OF_MRNA_SPLICING_VIA_SPLICEOSOME 21 1.32E-17 1.43E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 82 3.68E-17 3.88 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 80 1.11E-16 1.66E GOBP_REGULATION_OF_INTRACELLULAR_MOLECULAR FUNCTION 80 1.11E-16 1.66E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.70E GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 3.39E GOBP_PONTOTIC_CELL_CYCLE 56 4.42E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 29 6.81E-16 6.29E GOBP_ROTINE_REGULATION_OF_GENE EXPRESSION 59 7.32E-16 6.40E GOBP_POSITIVE_REGULATION_OF_CONTAUNING_COMPLEX_LOCALIZATION 30 7.30E-16 6.424E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 <t< td=""><td></td><td></td><td></td><td></td></t<>				
GOBP REGULATION OF MENA SPLICING VIA SPLICEOSOME 21 1.32E-17 1.43E GORP ORGANELLE ASSEMBLY 65 2.22E-17 2.37E GOBP REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 82 3.88E-17 3.88E GOBP POSITIVE REGULATION OF MOLECULAR FUNCTION 80 1.11E-16 1.16E GOBP REGULATION OF TRANSFERASE ACTIVITY 58 1.70E-16 1.72E GOBP POSITIVE REGULATION OF CELLULAR AMIDE METABOLIC PROCESS 24 3.41E-16 3.39E GOBP PROTEASOMAL PROTEIN CATABOLIC PROCESS 39 3.45E-16 3.39E GOBP PROTEASOMAL PROTEIN CATABOLIC PROCESS 84 3.69E-16 3.58E GOBP PROTEASOMAL PROTEIN CATABOLIC PROCESS 39 3.45E-16 4.34E GOBP POSITIVE REGULATION OF TRANSFERASE ACTIVITY 56 4.70E-16 4.47E GOBP PROTEIN CROCESS 39 3.45E-16 3.39E GOBP PROTEINCE REGULATION OF TRANSLATION 22 4.70E-16 4.47E GOBP POSITIVE REGULATION OF TRANSLATION 30 7.30E-16 6.49E GOBP PROTEIN_CONTAINING COMPLEX_LOCALIZATION 30 7.30E-16				7.85E-16
GOBP_ORGANELLE_ASSEMBLY 55 2.22E-17 2.37E GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 82 3.68E-17 3.88E GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_IRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 34 3.68E-16 3.58E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 34 3.69E-16 3.58E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 34 3.69E-16 3.58E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.24E GOBP_NORINA_METABOLIC_PROCESS 75 4.78E-16 4.47E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 30 7.30E-16 6.29E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 59 7.02E-16 6.40E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 30 7.30E-16 6.59E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION				1.02E-15
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 82 3.68E-17 3.88E GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_MINA_CATABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.42E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_POSITIVE_REGULATION_OF_GENE EXPRESSION 39 6.81E-16 6.29E GOBP_POSITIVE_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.30E-16 6.40E GOBP_ROTEIN_CONTAINING_COMPLEX_LOCALIZATION 39 6.81E-16 6.29E GOBP_REGULATION_OF_TRANSLATIONAL_INITATION 18 7.46E-16 6.40E GOBP_REGULATION_OF_ROTEIN_METABOLIC_PROCESS <t< td=""><td></td><td></td><td></td><td>1.43E-15</td></t<>				1.43E-15
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 80 1.11E-16 1.16E GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS 27 1.62E-16 1.66E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 658 1.70E-16 1.72E GOBP_PROTEIN_CATABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_PROTECREGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 345E-16 3.39E GOBP_PROTECREGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 345E-16 3.39E GOBP_PROTOTIC_PROCESS 88 4.42E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.47E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 39 7.02E-16 6.40E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 59 7.02E-16 6.40E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.44E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.44E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.49E <				2.37E-15
GOBP_REGULATION_OF_MENA_CATABOLIC_PROCESS 27 1.62E-16 1.62E GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 39 3.45E-16 3.58E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 24 3.41E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.42E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 6.29E GOBP_REGULATION_OF_PHORUS_METABOLIC_PROCESS 75 4.78E-16 6.29E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 59 7.32E-16 6.40E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 30 7.30E-16 6.59E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 30 7.30E-16 6.59E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 30 7.30E-16 6.37E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.48E GOBP_REGULATION_OF_CELLIZAR 22 1.30E				3.88E-15
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY 58 1.70E-16 1.72E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_MOTOTIC_CELL_CYCLE 58 4.42E-16 4.24E GOBP_REGULATION_OF_PROSPHORUS_METABOLIC_PROCESS 75 4.78E-16 4.45E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 29 6.81E-16 6.29E GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.44E GOBP_REGULATION_OF_TRANSLATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.30E-16 6.49E GOBP_REGULATION_OF_TRANSLATIONAL_INITATION 18 7.46E-16 6.49E GOBP_REGULATION_OF_TRANSLATIONAL_INITATION 18 7.46E-16 6.49E GOBP_REGULATION_OF_TRANSLATIONAL_INTATION 18 7.46E-16 6.49E GOBP_REGULATION_OF_CREASING 35 1.10E-15 9.54E GOBP_REGULATION_OF_CRANEAPROCESSING 22 1.23				1.16E-14
GOBP_POSITIVE_REGULATION_OF_CELLULAR_AMIDE_METABOLIC_PROCESS 24 3.41E-16 3.39E GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_POSITIVE_REGULATION_OF_CROCESS 84 3.69E-16 3.58E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.47E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 59 7.02E-16 6.40E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 59 7.02E-16 6.40E GOBP_ROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.58E GOBP_REGULATION_OF_TRANSLATIONAL, INITIATION 18 7.46E-16 6.47E GOBP_REGULATION_OF_RADSLATIONAL_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 1.05E GOBP_REGULATION_OF_CELLULAR RESPONSE_TO_STRESS <td< td=""><td></td><td></td><td></td><td>1.66E-14</td></td<>				1.66E-14
GOBP PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS 39 3.45E-16 3.39E GOBP_APOPTOTIC_PROCESS 84 3.69E-16 3.58E GOBP_MITOTIC_CELL_CYCLE 58 4.42E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.42E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.47E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 29 6.81E-16 6.29E GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.40E GOBP_REGULATION_OF_CONTENT_METABOLIC_PROCESS 60 7.80E-16 6.40E GOBP_REGULATION_OF_TRANSLATIONAL INITIATION 18 7.46E-16 6.58E GOBP_NEGATIVE_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_TRANSLATIONAL INITATION 18 7.46E-16 6.44E GOBP_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_CENSING 22 1.23E-15 1.55E GOBP_REGULATION_OF_ORGANIZATION 42 1.23E-15 1.55E				
GOBP APOPTOTIC PROCESS 84 3.69E-16 3.58E GOBP MITOTIC CELL CYCLE 58 4.42E-16 4.24E GOBP POSTIVE REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP POSTIVE REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 75 4.78E-16 4.47E GOBP POSTIVE REGULATION_OF_CENCESS 39 6.81E-16 6.40E GOBP_POSTIVE REGULATION_OF_CENE CORNELSCONTON 59 7.02E-16 6.40E GOBP_ROTINE_REGULATION_OF_CENE CORNELSCONTON 30 7.30E-16 6.58E GOBP_NCRNA_PROCESSING 30 7.30E-16 6.87E 6.07E-16 6.47E GOBP_NCRNA_PROCESSING 35 1.10E-15 9.54E 6.087E 6.07E-16 6.87E GOBP_REGULATION_OF_RENAPROCESSING 22 1.23E-15 1.05E 6.00F R60E-15 1.05E GOBP_REGULATION_OF_CELLULAR RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_REGULATION_OF_CELLULAR				3.39E-14
GOBP APOPTOTIC PROCESS 84 3.69E-16 3.68E GOBP_MITOTIC CELL CYCLE 58 4.42E-16 4.24E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 75 4.78E-16 4.47E GOBP_NORNA_METABOLIC_PROCESS 39 6.81E-16 6.29E GOBP_POSITIVE_REGULATION_OF_DENCE COENE_EXPRESSION 50 7.02E-16 6.40E GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.58E 6.09E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.47E GOBP_NORNA_PROCESSING 057.80E-16 6.87E 6.07E-16 6.87E GOBP_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E 6.09E 1.10E-15 9.54E GOBP_REGULATION_OF_RENTWAY 42 1.23E-15 1.05E 60BP 1.88E-15 1.58E GOBP_REGULATION_OF_CELLULAR RESPONSE_TO_STRESS 46 1.88E-15 1.58E 60BP 1.88E-15 3.69E 1.58E-14 </td <td></td> <td>39</td> <td>3.45E-16</td> <td>3.39E-14</td>		39	3.45E-16	3.39E-14
GOBP_MITOTIC_CELL_CYCLE 58 4.42E-16 4.44E GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 75 4.78E-16 6.47E GOBP_NCRNA_METABOLIC_PROCESS 39 6.81E-16 6.29E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 39 7.02E-16 6.40E GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.58E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.44E GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_CELLULAR RESPONSE_TO_STRESS 40 1.88E-15 1.05E GOBP_REGULATION_OF_CELLULAR RESPONSE_TO_STRESS 46 1.88E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E		84	3.69E-16	3.58E-14
GOBP_POSITIVE_REGULATION_OF_TRANSLATION 22 4.70E-16 4.45E GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 75 4.78E-16 4.75E GOBP_NCRNA_METABOLIC_PROCESS 39 6.81E-16 6.29E GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 59 7.30E-16 6.40E GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.58E GOBP_NEGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.64E GOBP_NEGATIVE_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NEGATIVE_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NEGULATION_OF_CRESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_ORMA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLLICAR_RESPONSE TO_STRESS 46 1.88E-15 1.58E GOBP_REGULATION_OF_CREGNALIZENON 40 4.58E-15 3.46E GOBP_REGULATION_OF_CREGNALIZENON 40 4.58E-15 3.46E GOBP_REGULATION_OF_CREGNALIZENON 40 4.58E-15 3.46E				
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS 75 4.78E-16 4.47E GOBP_NCRNA_METABOLIC_PROCESS 39 6.81E-16 6.29E GOBP_ROTINE_REGULATION_OF_GENE_EXPRESSION 59 7.02E-16 6.40E GOBP_ROTINE_REGULATION_OF_GENE_EXPRESSION 30 7.30E-16 6.58E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.84E GOBP_NCRNA_PROCESSING 35 1.10E-15 9.54E GOBP_NCRNA_PROCESSING 35 1.10E-15 9.54E GOBP_NCRNA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_MENA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION <t< td=""><td></td><td></td><td></td><td>4.45E-14</td></t<>				4.45E-14
GOBP NCRNA METABOLIC PROCESS 39 6.81E-16 6.29E GOBP POSITIVE REGULATION OF GENE_EXPRESSION 59 7.02E-16 6.49E GOBP PROTEIN_CONTAINING COMPLEX_LOCALIZATION 30 7.30E-16 6.58E GOBP REGULATION OF TRANSLATIONAL INITIATION 18 7.46E-16 6.64E GOBP NEGATIVE REGULATION OF TRANSLATIONAL INITIATION 18 7.46E-16 6.64F GOBP NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 60 7.80E-16 6.87E GOBP APOPTOTIC SIGNALING PATHWAY 42 1.23E-15 1.05E GOBP REGULATION OF CELLULAR RESPONSE TO STRESS 46 1.88E-15 1.58E GOBP REGULATION OF CELLULAR RESPONSE TO STRESS 46 1.88E-15 3.76E GOBP REGULATION OF ORGANIZATION 40 4.58E-15 3.76E GOBP REGULATION OF ORGANIZATION 40 4.58E-15 3.76E GOBP REGULATION OF ORGANIZATION 60 6.72E-15 5.41E GOBP REGULATION OF ORGANIZATION 60 6.72E-15 5.41E GOBP REGULATION OF ORGANELLE ORGANIZATION 60 6.72E-15 5.85E				4.47E-14
GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION 59 7.02E-16 6.40E GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.58E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.64E GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NCGNA_PROCESSING 35 1.10E-15 9.54E GOBP_REGULATION_OF_MENA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE TO_STRESS 64 1.88E-15 1.58E GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.46E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_RIBONOLLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 22 7.35E-15 5.85E GOBP_REDUL				6.29E-14
GOBP_PROTEIN_CONTAINING_COMPLEX_LOCALIZATION 30 7.30E-16 6.58E GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.64E GOBP_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NCRNA_PROCESSING 35 1.10E-15 9.54E GOBP_REGULATION_OF_ROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_ON_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_REGULATION_OF_MENA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 3.46E GOBP_REGULATION_OF_CORDANZATION 40 4.58E-15 3.76E GOBP_POSITIVE REGULATION_OF_SIGNALING 76 5.66E-15 4.60E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.45E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.85E GOBP_REBON				6.40E-14
GOBP_REGULATION_OF_TRANSLATIONAL_INITIATION 18 7.46E-16 6.64E GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NCRAL_PROCESSING 35 1.10E-15 9.54E GOBP_APOPTOTIC_SIGNALING_PATHWAY 42 1.23E-15 1.05E GOBP_REGULATION_OF_MRNA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_RIBOSOMAL_SMALL_SUBUNT_BIOGENESIS 17 4.17E-15 3.46E GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_NETOLINO_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_RESOLUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_VIRAL_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.24E				
GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 60 7.80E-16 6.87E GOBP_NCRNA_PROCESSING 35 1.10E-15 9.54E GOBP_REGULATION_OF_MENA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_MENA_PROCESSING 22 1.23E-15 1.58E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_REGULATION_OF_CELLULAR 9.56MAL 3.76E 6.68E-15 GOBP_REGULATION_OF_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 22 7.35E-15 5.85E GOBP_REDUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 22 7.35E-15 5.85E GOBP_RESONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E <t< td=""><td></td><td></td><td></td><td>6.58E-14</td></t<>				6.58E-14
GOBP_NCRNA_PROCESSING 35 1.10E-15 9.54E GOBP_APOPTOTIC_SIGNALING_PATHWAY 42 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 42 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_RECOCHONDRION_ORGANIZATION 4.17E-15 3.45E 3.76E GOBP_POSITIVE_REGULATION_OF_SIGNALING 76 5.66E-15 4.60E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.45E GOBP_RESPONSE_TO_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE_TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.24E GOBP_VIRAL_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.24E				6.64E-14
GOBP_APOPTOTIC_SIGNALING_PATHWAY 42 123E-15 1.05E GOBP_REGULATION_OF_MRNA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 47 4.17E-15 3.46E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 47 4.17E-15 3.46E GOBP_NITOCHONDRION_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.45E GOBP_REBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.24E GOBP_VIRAL_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.26E				6.87E-14
GOBP_REGULATION_OF_MRNA_PROCESSING 22 1.23E-15 1.05E GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_RISOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_RISOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_RISOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_NITOCHONDRION_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_OF_SIGNALING 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANIZATION 22 7.35E-15 5.85E GOBP_RIBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE_TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				9.54E-14
GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS 46 1.88E-15 1.58E GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_MITOCHONDRION_ORGANIZATION 40 4.58E-15 3.76E GOBP_OSITIVE_REGULATION_OF_SIGNALING 76 5.66E-15 4.60E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_RIBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE_TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.24E GOBP_WIRAL_EXPOR_FROM_NUCLEUS 19 3.46E-14 2.24E				1.05E-13
GOBP_RIBOSOMAL_SMALL_SUBUNIT_BIOGENESIS 17 4.17E-15 3.46E GOBP_MITOCHONDRION_ORGANIZATION 40 4.58E-15 3.76E GOBP_REGULATION_ORGANIZATION 60 6.56E-15 4.60D GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.45E GOBP_REBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23B GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_NRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.26E				1.05E-13
GOBP_MITOCHONDRION_ORGANIZATION 40 4.58E-15 3.76E GOBP_POSITIVE_REGULATION OF SIGNALING 76 5.66E-15 4.60 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 22 7.35E-15 5.85E GOBP_RESONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E		46	1.88E-15	1.58E-13
GOBP_MITOCHONDRION_ORGANIZATION 40 4.58E-15 3.76E GOBP_POSITIVE_REGULATION OF SIGNALING 76 5.66E-15 4.60 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 22 7.35E-15 5.85E GOBP_RESONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E		17	4.17E-15	3.46E-13
GOBP POSITIVE REGULATION OF SIGNALING 76 5.66E-15 4.60E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.85E GOBP_REBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23B GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.24E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.24E		40	4.58E-15	3.76E-13
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 60 6.72E-15 5.41E GOBP_MRNA_TRANSPORT 22 7.35E-15 5.85E GOBP_REDONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.26E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				
GOBP_MRNA_TRANSPORT 22 7.35E-15 5.85E GOBP_RIBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE_TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				5.41E-13
GOBP_RIBONUCLEOPROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 26 1.22E-14 9.60E GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23E GOBP_URAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				5.85E-13
GOBP_RESPONSE TO_CYTOKINE 60 1.58E-14 1.23E GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				
GOBP_VIRAL_LIFE_CYCLE 31 2.96E-14 2.28E GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				
GOBP_MRNA_EXPORT_FROM_NUCLEUS 19 3.46E-14 2.64E				1.23E-12
				2.28E-12
IGOBP INTRINSIC APOPTOTIC SIGNALING PATHWAY 28 3.89E-14 2.94E				2.64E-12
	GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY			2.94E-12
GOBP_MEMBRANE_ORGANIZATION 52 4.27E-14 3.19E	GOBP_MEMBRANE_ORGANIZATION	52	4.27E-14	3.19E-12

Figure 104 Gene ontology analysis of genes upregulated in response to CD in $dKO^{MRTF-NLS}$ cells by TTseq

Gene ontology analysis of genes upregulated by CD treatment in dKO^{MRTF-NLS} cells by TTseq. FDR<0.05. Relates to Figure 48. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

GOBP CELL CYCLE 82 4262-31 1 GOBP NEGATIVE, FREGULATION, OF, PUCLEOBASE, CONTAINING, COMPOUND, METABOLIC, PROCESS 73 432E-30 1 GOBP CELL DOPULATION, PROLIFERATION 61 1016-28 1 GOBP NEGATIVE, REGULATION, OF, BUCJENATION 61 1016-28 1 GOBP REGULATION, OF, MULTERLIULAR, ORGANISMAL DEVELOPMENT 68 252E-28 2 GOBP, MITOTIC, CLUCLE 62 252E-28 2 6 GOBP, CELL, CYCLE, PROCESS 74 4.87E-28 4 GOBP, CELL, CYCLE, PROCESS 74 1.26E-26 7 GOBP, CELL, CYCLE, PROCESS 66 1.22E-25 7 GOBP, CELL, CYCLE, PROCESS 74 4.28E-24 1 GOBP, REGULATION, OF, CULLORANZATION 42 2.04E-25 1 GOBP, REGULATION, OF, CULL, OYCLE CONTAINING, COMPOUND, METABOLIC, PROCESS 7	80E-28 50E-27 62E-26 62E-26 50E-25 50E-25 50E-25 50E-25 50E-25 70E-24 70E-22 93E-21 70E-22 93E-21 70E-22 93E-21 70E-21
GOOP, NEGATIVE, REGULATION, OF, NUCLEOBASE, CONTAINING, COMPOUND_METABOLIC_PROCESS 73 4.22E-30 1 GOOP CIELL_POPULATORY, SYSTEM DEVELOPMENT 61 1.01E-23 1 GOOP TIGE DEVELOPMENT 61 1.01E-23 1 GOOP TUBE DEVELOPMENT 61 1.01E-23 1 GOOP TUBE DEVELOPMENT 68 2.52E-28 2 GOOP TUBE CREGULATION OF BIOSYNTHETIC_PROCESS 74 4.87E-28 4 GOOP CIELL OYCLE 66 1.28E-26 9 GOOP CIELL OYCLE PROCESS 76 1.28E-26 7 GOOP CIELL OYCLE PROCESS 76 1.28E-25 7 GOOP CIELL MORATION 69 1.28E-26 7 GOOP CIELL MORATION 61 1.28E-26 7 GOOP CIELL MORATION OF DIOSONTHETIC PROCESS 56 1.18E-24 1 GOOP CIELL DIVIER REGULATION OF DIOSONTHETIC PROCESS 72 4.31E-24 1 GOOP ASCULATION OF CIELL DIFFERENTIATION 60 1.98E-24 2 GOOP NEGULATION OF CIELL DIFFERENTIATION 67 5.98E-24 2 <t< td=""><td>08E-26 62E-26 62E-26 63E-25 63E-25 55E-25 18E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-21 19E-21 13E-20 43E-21 45</td></t<>	08E-26 62E-26 62E-26 63E-25 63E-25 55E-25 18E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-24 43E-21 19E-21 13E-20 43E-21 45
COOP CIRCULATORY SYSTEM DEVELOPMENT 63 300E-29 5 COOP CEL POPULATORY PROLFERATION 81 454E-29 6 COOP TUBE DEVELOPMENT 68 252E-28 2 GOOP RELATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 68 252E-28 2 GOOP REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 68 252E-28 1 GOOP CELL CYCLE PROCESS 74 487E-28 4 GOOP CELL CYCLE PROCESS 74 128E-26 1 GOOP CELL CYCLE PROCESS 74 128E-25 7 GOOP CELL OVICLE ORGANIZATION 44 200E-25 1 GOOP REGULATION OF CORANELLE ORGANIZATION 58 119E-24 5 GOOP REGULATION OF CULL OVICLE ORGANEZ 74 4128E-24 1 GOOP REGULATION OF CULL OFFERENTIATION 60 128E-24 1 GOOP REGULATION OF CULL OFFERENTIATION 60 128E-24 1 GOOP REGULATION OF CUL	62E-26 79E-26 69E-25 56E-25 56E-25 56E-26 72E-24 43E-24 43E-24 77E-23 77E-23 77E-23 97E-21 48E-21 70E-21 48E-21 70E-21 48E-21 70E-21 48E-21 70E-21 48E-21 70E-21 48E-21 70E-21 70E-21 48E-21 70
GOBP CELL POPULATION, PROLIFERATION 81 4.54E-29 6 GOBP TUBE DEVELOPMENT 61 1015-281 1 GOBP REQULATION, OF MULTICELLULAR, ORGANISMAL DEVELOPMENT 68 2.52E-28 2 GOBP NEGATIVE, REGULATION, OF BIOSYNTHETIC_PROCESS 74 4.87E-28 4 GOBP LOCOMOTIN 78 1.26E-26 9 2.82E-27 2 GOBP CELL CYCLE 50 2.82E-27 2 6 1.26E-26 1 GOBP CELL MIGRATION 69 1.26E-25 7 6 1.26E-25 7 GOBP CELL DIVISION 44 2.00E-25 1 1 1.26E-25 7 GOBP REQULATION OF DROGRAMELE ORGANIZATION 51 1.16E-24 5 1.26E-25 7 GOBP POSITIVE, REGULATION OF DIOSYNTHETIC PROCESS 74 4.23E-24 1 1 GOBP POSITIVE, REGULATION OF DIOLEORASE CONTINING COMPOUND_METABOLIC_PROCESS 74 2.44E-24 8 GOBP PUBLE MORPHOGENESIS 60 1.22E-22 4 60BP VASULATION, OF CELL DEVELOPMENT 2.42E-24 8	79E-26 26E-25 56E-25 18E-24 43E-24 30E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-24 28E-21 19E-21 19E-21 19E-21 19E-21 19E-21 19E-21 19E-21 28E-28E-28 28E-28E-28 28E-28E-28E-28E-28E-28E-28E-28E-28E-28E-
GORP TUBE_DEVELOPMENT 61 101E-28 1 GORP REGULATION, OF MULTCELLULAR, ORGANISMAL DEVELOPMENT 62 252:25 2 GORP REGULATION, OF BIOSYNTHETIC_PROCESS 74 437:528 2 GORP REGULATION, OF BIOSYNTHETIC_PROCESS 74 437:528 2 GORP CELL CYCLE PROCESS 66 126:25 7 GORP CELL CYCLE PROCESS 66 126:25 7 GORP CELL DYCLOPMENT 55 126:25 7 GORP REGULATION OF CORGANELLE ORGANIZATION 58 126:25 1 GORP REGULATION OF CORGANELLE ORGANIZATION 58 119:24 5 GORP REGULATION OF CICL DIFFERENTATION 61 226:23 8 GORP REGULATION OF CELL CYCLE 58 810E:24 3 GORP NUER REGULATION OF DISYNTHETIC PROCESS 58 122:22 4 GORP NUERCHAURTON OF CELL DIFFERENTATION 60 22:32:23 8 GORP NEGULATION OF CELL DIFFERENTATION 61 122:22 4 GORP NEGULATION OF CELL DIFFERENTATION 62 23:52:3 8	26E-25 60E-26 50E-25 18E-24 43E-24 43E-24 43E-24 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-24 298E-21 19E-21 13E-20 48E-20 63E-20 13E-20 74E-19 20E-18 43E-18 20E-18 43E-18 20E-18 43E-18 20E-18 43E-18 20E-18 43E-18 20E-18 2
GOOP REGULATION, OF, MULTICELLULAR ORGANISMAL DEVELOPMENT 68 2.52E-28 2 GOOP NEGATIVE REGULATION OF BIOSYNTHETIC_PROCESS 74 4.87E-28 4 GOBP LOCOMOTION 78 1.28E-28 9 GOBP CLL CYCLE 76 1.28E-26 9 GOBP CELL WIGRATION 69 1.20E-26 1 GOBP CELL DYNSION 69 1.20E-25 7 GOBP CELL DIVISION 64 1.20E-25 7 GOBP CELL DIVISION 64 1.20E-25 7 GOBP REQULATION, OF ORGANELLE_ORGANIZATION 64 1.20E-25 1 GOBP POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 74 4.31E-24 5 GOBP POSITIVE REGULATION OF DUCLOBASE CONTINING COMPOUND_METABOLIC_PROCESS 74 5.45E-24 2 GOBP VABULATION, OF CELL DIFFERENTATION 67 5.46E-24 3 8 1.20E-23 8 8 1.20E-23 8 8 1.20E-24 4 60BP VASULATION, OF OLEL DEASE CONTINUNC COMPOUND_METABOLIC_PROCESS 66 1.22E-24 4 60BP ACHOROGENESIS 66 1.24E-24 <td>60E-25 56E-26 56E-26 43E-24 43E-24 43E-24 43E-24 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-24 48E-20 13E-20 12</td>	60E-25 56E-26 56E-26 43E-24 43E-24 43E-24 43E-24 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-23 27E-24 48E-20 13E-20 12
GOBP NEGATIVE REGULATION OF BIOSYNTHETIC PROCESS 74 4.97E-28 4 GOBP MITOTIC CELL CYCLE 58 2.82E-27 2 GOBP CELL CYCLE PROCESS 66 1.92E-26 9 GOBP CELL CYCLE PROCESS 66 1.92E-26 1 GOBP CELL CYCLE PROCESS 66 1.92E-26 7 GOBP REGULATION OF DOSVNTHETIC PROCESS 74 4.32E-24 1 GOBP REGULATION OF DIOSVNTHETIC PROCESS 74 4.32E-24 1 GOBP REGULATION OF CELL DIFFERENTIATION 68 8.105-24 2 GOBP REGULATION OF CELL DIFFERENTIATION 67 5.96E-24 2 GOBP REGULATION OF CELL DIFFERENTIATION 67 5.96E-24 2 GOBP REGULATION OF CELL DIFFERENTIATION 67 5.96E-24 2 GOBP NEUROGENESIS 50 2.23E-23 8 GOBP NEUROGENESIS 50 2.23E-23 8 GOBP REGULATION OF CELL DEATH 47 2.44E-23 8 GOBP REGULATION OF CELL DEATH 65 5.132E-22 4 GOBP REGULATION OF CELL DEA	56E-25 18E-24 33E-24 33E-24 33E-24 33E-27E-23 37E-23 37E-22 93E-22 93E-22 93E-21 93E-2
GOBP_NITOTIC_CELL_CYCLE 58 2.22E-27 2 GOBP_LOCOMOTION 78 1.26E-26 1 GOBP_CELL_CYCLE_PROCESS 66 1.92E-26 1 GOBP_CELL_MIGRATION 69 1.20E-25 7 GOBP_CELL_DIVISION 64 1.20E-25 1 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 64 1.20E-25 1 GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION 64 1.20E-24 1 GOBP_POSITIVE_REGULATION_OF_ORGANELCEASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 72 4.51E-24 1 GOBP_REGULATION_OF_CELL_CYCLE 58 8.10E-24 3 3 GOBP_REGULATION_OF_CELL_CYCLE 58 8.10E-24 3 3 GOBP_NEGULATION_OF_CELL_CYCLE 58 8.10E-24 3 3 GOBP_NOSTIVE_REGULATION_OF_DEVELOPMENT 47 2.44E-23 8 3	43E-24 30E-23 27E-23 27E-23 93E-22 98E-21 99E-21 48E-21 19E-21 35E-21 70E-21 48E-20 13E-20 70E-21 48E-20 13E-20 70E-21 803E-18 20E-18 20E-18 20E-18 87E-18 87E-18 85E-18 85E-18 85E-18 85E-18 83E-18 55E-18 83E-18 55E-18
GOBP_CELL_CYCLE_PROCESS 66 192E-26 1 GOBP_CELL_MIGRATION 69 120E-25 7 GOBP_CELL_DIVISION 44 200E-25 7 GOBP_CELL_DIVISION 44 200E-25 7 GOBP_REGULATION OF_ORGANELLE_ORGANIZATION 58 19E-24 5 GOBP_REGULATION OF_ORGANELLE_ORGANIZATION 67 59E-24 1 GOBP_REGULATION OF_OLCIBORSE_CONTAINING_COMPOUND_METABOLIC_PROCESS 74 4.23E-24 1 GOBP_REGULATION OF_OLCIL CONCLE 58 10E-24 35 60E-24 3 GOBP_REGULATION OF_CELL_OYCLE 56 2.33E-23 8 60B 2.33E-23 8 GOBP_NERGULATION OF_CELL_OYCLE 66 3.52E-22 4 60B 2.03E-22 4 GOBP_REGULATION OF CELL_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_REGULATION OF CELL_DEATH 66 5.81E-22 1 GOBP_REGULATION OF CELL_OYCLE_PROCESS 64 1.94E-20 3 GOBP_REGULATION OF CELL_OYCLE_ROCESS 24 1.94E-20 3 <td>30E-23 27E-23 07E-22 93E-22 93E-22 99E-21 48E-21 48E-21 70E-21 70E-21 48E-20 63E-20 74E-19 03E-18 27E-18 70E-18 97E-18 20E-18 55E-18 83E-18 63E-21 74E-19 74</td>	30E-23 27E-23 07E-22 93E-22 93E-22 99E-21 48E-21 48E-21 70E-21 70E-21 48E-20 63E-20 74E-19 03E-18 27E-18 70E-18 97E-18 20E-18 55E-18 83E-18 63E-21 74E-19 74
GOBP CELL_MIGRATION 69 120E-25 7 GOBP CELL DIVISION 55 126E-25 7 GOBP REGULATION OF ORGANELLE ORGANIZATION 58 1.98E-24 5 GOBP POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 74 423E-24 1 GOBP POSITIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS 72 4.51E-24 1 GOBP REGULATION OF CELL DIFFERENTIATION 67 596E-24 2 GOBP REGULATION OF CELL DIFFERENTIATION 67 2.32E-23 8 GOBP NEUROGENESIS 68 8.10E-24 3 GOBP NEUROGENESIS 65 1.32E-22 4 GOBP NEUROGENESIS 66 1.32E-22 4 GOBP CYTOSKELETON, ORGANIZATION 60 1.64E-22 5 GOBP REGULATION OF CELL DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP REGULATION OF CELL DEVELOPMENTAL 65 3.58E-21 1 GOBP REGULATION OF CELL CYCLE PROCESS 64 1.01E-20 2 GOBP REGULATION OF CELL CYCLE PROCESS 64 1.64E-20 2	27E-23 27E-23 07E-22 93E-22 93E-21 48E-21 19E-21 35E-21 35E-21 70E-21 48E-20 63E-20 63E-20 63E-20 63E-20 63E-20 63E-28 74E-19 03E-18 25E-18 25E-18 43E-18 43E-18 55E-18 83E-18 67E-17 84E-16
GOBP EMBRYO_DEVELOPMENT 55 126E-25 7 GOBP CELL DIVISION 44 200E-25 1 GOBP REGULATION OF_ORGANELLE_ORGANIZATION 58 1.19E-24 5 GOBP POSITIVE_REGULATION OF_OLCEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 74 4.23E-24 1 GOBP PREGULATION_OF_CELL_OTOLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 72 4.51E-24 1 GOBP REGULATION_OF_CELL_CYCLE 58 8.10E-24 3 GOBP_NUBE_MORPHOGENESIS 50 2.23E-23 8 GOBP_NEUROGENESIS 65 1.32E-22 4 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENT 47 2.44E-23 8 GOBP_ROSTIVE_REGULATION OF_CELL_DEATH 65 5.81E-22 1 GOBP_ROSTIVE_REGULATION OF CELL_DEATH 65 5.81E-22 1 GOBP_ROSTOE_TO_ENDGENOUS_SIMULUS 63 4.52E-21 1 GOBP_ROSTOE_NONE_TO_ENDGENOUS_SIMULUS 63 4.84E-20 4 GOBP_ROSTOE_NONE_TO_ENDGENOUS_SIMULUS 63 1.84E-20 4 <td>27E-23 07E-22 93E-21 99E-21 48E-21 19E-21 35E-21 35E-21 70E-21 48E-20 63E-20 03E-18 97E-18 97E-18 97E-18 97E-18 83E-18 85E-18</td>	27E-23 07E-22 93E-21 99E-21 48E-21 19E-21 35E-21 35E-21 70E-21 48E-20 63E-20 03E-18 97E-18 97E-18 97E-18 97E-18 83E-18 85E-18
GOBP CELL DIVISION 44 200E-25 1 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 58 119E-24 5 GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION 58 119E-24 5 GOBP_REGULATION_OF_ORCALLE_ORGASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 74 4.23E-24 1 GOBP_REGULATION_OF_CELL_OFFERENTATION 67 596E-24 2 GOBP_REGULATION_OF_CELL_OVICLE 58 8.10E-24 3 GOBP_NEUROGENESIS 50 2.23E-23 8 GOBP_NEUROGENESIS 65 1.32E-22 4 GOBP_NEUROGENESIS 66 1.32E-22 4 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_REGULATION_ORGANIZATION 60 1.64E-22 5 GOBP_REGULATION_OR_CELL_OYCLE_PROCESS 58 1.42E-22 1 GOBP_REGULATION_OR_CELL_OYCLE_PROCESS 63 4.52E-21 1 GOBP_REGULATION_OR_CELL_OYCLE_PROCESS 64 1.01E-20 2 GOBP_REGULATION_OR_CELL_OYCLE_PROCESS 64 1.01E-20 2 1.65E-20 <td>07E-22 93E-21 99E-21 99E-21 48E-21 19E-21 35E-21 70E-21 48E-20 63E-20 13E-20 70E-18 903E-18 225E-18 70E-18 97E-18 20E-18 33E-18 33E-18 83E-18 83E-18 83E-18 83E-18</td>	07E-22 93E-21 99E-21 99E-21 48E-21 19E-21 35E-21 70E-21 48E-20 63E-20 13E-20 70E-18 903E-18 225E-18 70E-18 97E-18 20E-18 33E-18 33E-18 83E-18 83E-18 83E-18 83E-18
GOBP_REGULATION_OF_DROANELLE_ORGANIZATION 58 119E-24 55 GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 74 4.23E-24 1 GOBP_REGULATION_OF_CELL_DIFFERENTATION 67 5.99E-24 1 GOBP_REGULATION_OF_CELL_DIFFERENTATION 67 5.99E-24 2 GOBP_REGULATION_OF_CELL_CYCLE 58 8.10E-24 3 GOBP_TUBE_MORPHOGENESIS 50 2.23E-23 8 GOBP_NERGULATION_OF_DEVELOPMENT 47 2.44E-23 8 GOBP_NOSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_CHROMATIN_ORGANIZATION 60 1.64E-22 5 GOBP_REGULATION_OF_CELLOPATH 65 5.81E-22 1 GOBP_REGULATION_OF_CELLOPATH 65 5.81E-22 1 GOBP_CHROMATIN_ORGANIZATION 45 3.58E-21 1 GOBP_REGULATION_OF_CELLOCYCLE_PROCESS 24 5.45E-20 3 GOBP_REGULATION_OF_CELLOCYCLE_ROCESS 24 5.45E-20 3 GOBP_REGULATION_OF_CELLUCYCLE_ROCESS 24 5.45E-20 4 <td>93E-22 98E-21 99E-21 48E-21 19E-21 35E-21 70E-21 48E-20 63E-20 63E-20 74E-19 03E-18 20E-18 97E-18 20E-18 43E-18 55E-18 83E-18 83E-18</td>	93E-22 98E-21 99E-21 48E-21 19E-21 35E-21 70E-21 48E-20 63E-20 63E-20 74E-19 03E-18 20E-18 97E-18 20E-18 43E-18 55E-18 83E-18 83E-18
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 74 4.23E-24 1 GOBP_POSITIVE_REGULATION_OF_ENCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 72 4.51E-24 1 GOBP_REGULATION_OF_CELL_OFFERENTIATION 67 5.96E-24 2 GOBP_REGULATION_OF_CELL_OYCLE 58 8.10E-24 3 GOBP_NEUROGENESIS 50 2.23E-23 8 GOBP_NEUROGENESIS 50 2.23E-23 8 GOBP_NEUROGENESIS 56 1.32E-22 4 GOBP_NEUROGENESIS 56 1.32E-22 4 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 5 GOBP_REGULATION_ORGANIZATION 60 1.64E-22 5 GOBP_RESPONSE TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_REGULATION_OF_CELL_PROCESS 644 1.01E-20 2 GOBP_REGULATION_OFCELL_PROCESS 64 4.52E-21 1 GOBP_PROTEIN_PHOSPHORYLATION 62 1.68E-20 3 GOBP_REGULATION_OFCELL_PROCESS 64 1.44E-20 2 GOBP_POSIT	98E-21 99E-21 48E-21 19E-21 35E-21 70E-21 48E-20 63E-20 74E-19 0.3E-18 25E-18 20E-18 20E-18 20E-18 43E-18 55E-18 83E-18 83E-18 83E-18
GOBP POSITIVE_REGULATION OF NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 72 4.51E-24 1 GOBP_REGULATION_OF_CELL_DIFFERENTIATION 67 5.96E-24 2 GOBP_TUBE_MORPHOGENESIS 50 2.23E-23 8 GOBP_NEUROGENESIS 65 1.32E-22 4 GOBP_NEUROGENESIS 65 1.32E-22 4 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_POSITIVE_REGULATION_OF_OEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_REGULATION_OF_CELL DEATH 65 5.81E-22 1 GOBP_REGULATION_OF_ORGANIZATION 64 3.58E-21 1 GOBP_REGULATION_OF_CELL_QCLE_PROCESS 64 1.01E-20 2 GOBP_REGULATION_OF_CELL_YCLE_PROCESS 64 1.01E-20 2 GOBP_POSITIVE_REGULATION_OF_CELLUYCLE_PROCESS 68 1.84E-20 4 GOBP_REGULATION_OF_CELLUYCLE_PROCESS 68 1.84E-20 4 GOBP_REGULATION_OF_CELLUYCLE_PROCESS 68 1.84E-20 4 GOBP_ROTOTIC_PROCESS 68 1.84E-20	99E-21 48E-21 35E-21 35E-21 48E-20 63E-20 13E-20 74E-19 03E-18 20E-18 20E-18 20E-18 43E-18 55E-18 83E-18 63F-17 84E-16
GOBP_REGULATION OF_CELL_CYCLE 58 8.10E-24 3 GOBP_TUBE_MORPHOGENESIS 50 2.23E-23 8 GOBP_NEUROGENESIS 65 1.22E-22 4 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_CYTOSKELETON_ORGANIZATION 60 1.84E-22 5 GOBP_REGULATION OF_CELL_DEATH 65 5.81E-22 1 GOBP_RESONSE_TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_REGULATION OF_CELL_CYCLE_PROCESS 444 1.01E-20 2 GOBP_PROTEIN_PHOSPHORYLATION 62 1.88E-20 4 GOBP_POSTIVE_REGULATION_OF_CELL_CYCLE_PROCESS 68 1.84E-20 4 GOBP_POSTIVE_REGULATION_OF_CELLUAR_COMPONENT_ORGANIZATION 62 1.88E-20 4 GOBP_POSTIVE_REGULATION_OF_CELLUAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSTIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_REGUNATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-	19E-21 35E-21 70E-21 48E-20 63E-20 13E-20 03E-18 25E-18 70E-18 97E-18 97E-18 97E-18 843E-18 63E-17 84E-16
GOBP_TUBE_MORPHOGENESIS 50 2.23E-23 8 GOBP_VASCULATURE_DEVELOPMENT 47 2.44E-23 8 GOBP_REUROGENESIS 65 1.32E-22 4 GOBP_CYTOSKELETON_ORGANIZATION 60 1.42E-22 5 GOBP_CHROGENESIS 68 1.42E-22 4 GOBP_CEQULATION_ORGANIZATION 60 1.64E-22 5 GOBP_RESULATION_ORGANIZATION 65 5.81E-22 1 GOBP_RESULATION_ORGANIZATION 45 3.58E-21 1 GOBP_RESULATION_OCELL_CYCLE_PROCESS 64 1.01E-20 2 GOBP_POSTIVE_REGULATION_OF_CELL_CYCLE_PROCESS 68 1.84E-20 3 GOBP_POTOTIC_PROCESS 68 1.84E-20 4 GOBP_POTOTIC_PROCESS 68 1.84E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 4 GOBP_RESPONSE_TO_GROWTH_FACTOR	35E-21 70E-21 48E-20 63E-20 13E-20 74E-19 03E-18 25E-18 70E-18 97E-18 43E-18 55E-18 83E-18 67E-17 84E-16
GOBP VASCULATURE_DEVELOPMENT 47 2.44E.23 8 GOBP_NEUROGENESIS 65 1.32E.22 4 GOBP_CYTOSKELETON_ORGANIZATION 60 1.42E.22 4 GOBP_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E.22 4 GOBP_REGULATION_ORGANIZATION 60 1.84E.22 5 GOBP_REGULATION_ORGANIZATION 45 3.58E.21 1 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 44 1.01E.20 2 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 44 1.01E.20 2 GOBP_PROTEIN_PHOSPHORYLATION 62 1.68E.20 4 GOBP_POSTIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 63 1.45E.20 4 GOBP_POSTIVE_REGULATION_OF_CELLULAR_FUNCTION 63 1.47E-19 3 GOBP_POSTIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.47E-18 2 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 4 GOBP_RESULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_RESULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 63 <td>70E-21 48E-20 63E-20 13E-20 74E-19 03E-18 25E-18 97E-18 97E-18 43E-18 55E-18 83E-18 83E-18 67E-17 84E-16</td>	70E-21 48E-20 63E-20 13E-20 74E-19 03E-18 25E-18 97E-18 97E-18 43E-18 55E-18 83E-18 83E-18 67E-17 84E-16
GOBP_NEUROGENESIS 65 1.32E-22 4 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_CYTOSKELETON_ORGANIZATION 60 1.64E-22 5 GOBP_REGULATION_OF_CELL_DEATH 65 5.81E-22 1 GOBP_CHROMATIN_ORGANIZATION 63 4.52E-21 1 GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 444 1.01E-20 2 GOBP_PROTOTIC_NUCLEAR DIVISION 29 1.54E-20 3 GOBP_POSITIVE_REGULATION_OF_CELLUCAR_COMPONENT_ORGANIZATION 62 1.88E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_CELLULAR_FUNCTION 63 1.67E-19 3 GOBP_REPODUCTON 56 8.63E-19 1 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS	48E-20 63E-20 13E-20 74E-19 03E-18 225E-18 70E-18 97E-18 20E-18 43E-18 55E-18 83E-18 67E-17 84E-16
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 58 1.42E-22 4 GOBP_CYTOSKELETON_ORGANIZATION 60 1.64E-22 5 GOBP_RESULATION_OF_CELL_DEATH 65 5.81E-22 1 GOBP_RESULATION_OF_CELL_DEATH 65 5.81E-22 1 GOBP_RESULATION_OF_CELL_CYCLE_PROCESS 63 4.52E-21 1 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 641 1.01E-20 2 GOBP_PROTEIN_PHOSPHORYLATION 29 1.54E-20 3 GOBP_PROTEIN_PHOSPHORYLATION 66 1.88E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_ROSTIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_ROSTIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_RESONSE_TO_GROWTH_FACTOR 40 1.25E-18 4 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_ROCESS	63E-20 13E-20 74E-19 03E-18 25E-18 70E-18 97E-18 20E-18 43E-18 55E-18 83E-18 67E-17 84E-16
GOBP CYTOSKELETON_ORGANIZATION 60 1.484-22 5 GOBP REGULATION OF CELL DEATH 65 5.81E-22 1 GOBP REGULATION OF CELL DEATH 65 5.81E-22 1 GOBP RESULATION OF CALL DEATH 63 3.58E-21 1 GOBP REGULATION_OF_CELL CYCLE_PROCESS 44 1.01E-20 2 GOBP_MITOTIC_NUCLEAR_DIVISION 29 1.54E-20 3 GOBP_PROTEIN_PHOSPHORYLATION 62 1.88E-20 4 GOBP_APOPTOTIC_PROCESS 68 1.84E-20 4 GOBP_POSITIVE REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 63 1.47E-19 3 GOBP_POSITIVE REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_REPRODUCTION 63 1.67E-19 3 GOBP_RESULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 63 1.67E-19 3 GOBP_RESULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_REGULATION_OF_CELL_CYCLE 36 6.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 6.11E-18 1 <td>13E-20 74E-19 0.3E-18 25E-18 70E-18 97E-18 20E-18 43E-18 55E-18 83E-18 67E-17 84E-16</td>	13E-20 74E-19 0.3E-18 25E-18 70E-18 97E-18 20E-18 43E-18 55E-18 83E-18 67E-17 84E-16
GOBP REGULATION OF CELL DEATH 65 5.81E-22 1 GOBP_CHROMATIN_ORGANIZATION 45 3.58E-21 1 GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_RESUNSE_TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 441 1.01E-20 2 GOBP_POTOTIC_NUCLEAR, DIVISION 29 1.54E-20 4 GOBP_APOPTOTIC_PROCESS 68 1.84E-20 4 GOBP_ADOPTOTIC_PROCESS 68 1.84E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_REPODUCTION 63 1.67E-19 3 60B 1.67E-19 3 GOBP_REPODUCTION 56 6.83E-19 1 1 60B 1.25E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 3 6.41E-18 9 GOBP_REGULATION_OF_INTRACELLULAR_COMPONENT_ORGANIZATION 59 8.11E-18 9 3 6.41E-18 1	74E-19 03E-18 25E-18 97E-18 20E-18 43E-18 55E-18 83E-18 67E-17 84E-16
GOBP_CHROMATIN_ORGANIZATION 45 3.58E-21 1 GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 44 1.01E-20 2 GOBP_PROTEIN_PHOSPHORYLATION 62 1.58E-20 4 GOBP_PROTEIN_PHOSPHORYLATION 68 1.84E-20 3 GOBP_PROTEIN_PHOSPHORYLATION 68 1.84E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_COMPONENT_ORGANIZATION 63 1.67E-19 3 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 4 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36	03E-18 25E-18 70E-18 97E-18 20E-18 43E-18 55E-18 83E-18 67E-17 .84E-16
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS 63 4.52E-21 1 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 44 1.01E-20 2 GOBP_PROTEIN_PHOSPHORYLATION 29 1.54E-20 3 GOBP_PROTEIN_PHOSPHORYLATION 62 1.88E-20 4 GOBP_PROTEIN_PHOSPHORYLATION 62 1.88E-20 4 GOBP_APOPTOTIC_PROCESS 68 1.84E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.87E-19 3 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.87E-19 3 GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_REPRODUCTION 62 2.08E-18 2 GOBP_RESONSE_TO_GROWTH_FACTOR 40 125E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.31E-18 1 </td <td>25E-18 .70E-18 .97E-18 .20E-18 .43E-18 .55E-18 .83E-18 .67E-17 .84E-16</td>	25E-18 .70E-18 .97E-18 .20E-18 .43E-18 .55E-18 .83E-18 .67E-17 .84E-16
GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 44 1.01E-20 2 GOBP_MITOTIC_NUCLEAR_DIVISION 29 1.54E-20 3 GOBP_PROTEIN_PHOSPHORYLATION 62 1.68E-20 4 GOBP_PROTEIN_PHOSPHORYLATION 62 1.68E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_CELLULAR_FUNCTION 63 1.67E-19 3 GOBP_REPODUCTION 56 8.63E-19 1 GOBP_RESULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_REGULATION OF_INTRACELLULAR_COMPONENT_ORGANIZATION 62 2.08E-18 4 GOBP_NEURON_DIFFERENTIATION 53 6.41E-18 9 6.511E-18 9 GOBP_NEURON_DIFFERENTIATION 59 8.13E-16 1 6.	.70E-18 .97E-18 .20E-18 .43E-18 .55E-18 .83E-18 .67E-17 .84E-16
GOBP_PROTEIN_PHOSPHORYLATION 62 1.88E-20 4 GOBP_APOPTOTIC_PROCESS 68 1.84E-20 4 GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS 52 1.95E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 63 1.67E-19 3 GOBP_REPRODUCTION 63 1.67E-19 3 GOBP_ANIMAL_ORGAN_MORPHOGENESIS 47 1.17E-18 2 GOBP_REPRODUCTION 62 2.08E-18 4 GOBP_RESONSE_TO_GROWTH_FACTOR 40 125E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.31E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 <td>20E-18 .43E-18 .55E-18 .83E-18 .67E-17 .84E-16</td>	20E-18 .43E-18 .55E-18 .83E-18 .67E-17 .84E-16
GOBP_APOPTOTIC_PROCESS 68 1.84E-20 4 GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED IN_MORPHOGENESIS 52 1.95E-20 4 GOBP_DOSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_REPRODUCTION 63 1.67E-19 3 GOBP_REPRODUCTION 63 1.67E-19 3 GOBP_REPRODUCTION 63 1.67E-19 3 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 2 GOBP_REQULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 5 GOBP_REGULATION_OF_INTRACELL CYCLE_PROCESS 29 3.10E-18 9 GOBP_NEURON_DIFFERENTIATION 53 6.41E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1	.43E-18 .55E-18 .83E-18 .67E-17 .84E-16
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS 52 1.95E-20 4 GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_REPRODUCTION 63 1.67E-19 3 GOBP_REPRODUCTION 64 1.77E-18 2 GOBP_RESONSE_TO_GROWTH_FACTOR 40 1.25E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NECATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NECATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY	.55E-18 .83E-18 .67E-17 .84E-16
GOBP POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 51 4.33E-20 9 GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 2 GOBP_RESPONSE_TO_GROWTH_FACTOR 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEGATIVE_REGULATION_OF_CELLLOYCLE PROCESS 29 3.10E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLLOYCLE 36 5.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLLOYCLE 36 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2	.83E-18 .67E-17 .84E-16
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION 63 1.67E-19 3 GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_NEPRODUCTION 56 8.63E-19 1 GOBP_REPRODUCTION 40 1.7E-18 2 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.01E-18 5 GOBP_NEURON_DIFFERENTIATION 53 6.41E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELLLOYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELLLOYCLE 36 6.41E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLOYCLE 36 1.38E-17 2 GOBP_NEGATIVE_REGULATION_OF_CEL_CYCLE 36 1.38E-17 2 GOBP_DNA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_DNA_CONFORMATION_CHANGE 24 2.05E-17 3 GOBP_DOLCEOSOME_ASSEMBLY 2.05E-17 3 3.00E-17 3	.67E-17 .84E-16
GOBP_REPRODUCTION 56 8.63E-19 1 GOBP_ANIMAL_ORGAN_MORPHOGENESIS 47 1.17E-18 2 GOBP_RESUBATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 40 1.25E-18 4 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_REGULATION_OF_INTRACELLUCYCLE_PROCESS 29 3.10E-18 5 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NECATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_INA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_NACCONFORMATION_CHANGE 24 2.05E-17 3 GOBP_NORGANELLE_FISSION 32 2.15E-17 3 GOBP_ONGANELLE_FISSION 32 2.15E-17 3 <t< td=""><td>.84E-16</td></t<>	.84E-16
GOBP ANIMAL ORGAN MORPHOGENESIS 47 1.17E-18 2 GOBP_RESPONSE_TO_GROWTH_FACTOR 40 1.25E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEGULATION_OF_INTRACELLULAR_COLL CYCLE 36 5.11E-18 9 GOBP_NEGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEURON_DIFFERENTIATION 53 6.41E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLLAR_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 28 1.79E-17 2 GOBP_DA_ACKAGING 24 2.05E-17 3 GOBP_DONA_DACKAGING 32 2.16E-17 3 GOBP_DONACALING 59 3.30E-17 4	
GOBP_RESPONSE_TO_GROWTH_FACTOR 40 125E-18 2 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 5 GOBP_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEURON_DIFFERENTIATION 53 6.41E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLLOYCLE 36 6.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLURAR_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.38E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.38E-17 2 GOBP_DNA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_DA_CONFORMATION_CHANGE 24 2.05E-17 3 GOBP_ORGANELLE_FISSION 32 2.15E-17 3 GOBP_ORGANELLE_FISSION 32 2.15E-17 3 GOBP_ORGANELLE_FISSION 32 3.30E-17 4 GOBP_NONTIN_ASSEMBLY 23 3.30E-17 5	
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 62 2.08E-18 4 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLURA_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLURA_COMPONENT_ORGANIZATION 59 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_INA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_PACKAGING 24 2.05E-17 3 GOBP_ONGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 4 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 3 GOBP_CHROMATIN_ASSEMBLY OR DISASSEMBLY 23 3.38E-17 5 GOBP_CHROMATIN_ASSEMBLY OR DISASSEMBLY 23	.52E-16
GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 29 3.10E-18 5 GOBP_REGULATION_OF_MITOTIC_CELL_CYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 5.11E-18 9 GOBP_NEGATIVE_REGULATION_OF_CELLLAR_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLLAR_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLCYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_HEART_DEVELOPMENT 34 1.36E-17 2 GOBP_NOCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_DAL_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_DOR DAA_CAGAING 24 2.05E-17 3 GOBP_ORGANELLE_FISSION 32 2.16E-17 3 GOBP_ORGANELLE_FISSION 32 3.30E-17 4 GOBP_ORGANELLE_FISSION 23 3.30E-17 5 GOBP_CHROMATIN_ASSEMBLY 23 3.30E-17 5	.10E-16
GOBP_NEURON_DIFFERENTATION 53 6.41E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 59 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 59 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_HAR_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_HEART_DEVELOPMENT 34 1.85E-17 2 GOBP_ONGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 4 GOBP_CHROMATIN_ASSEMBLY OR DISASSEMBLY 23 3.89E-17 5 GOBP_UNCLEDSOME_ORGANIZATION 21 1.28E-16 1	.94E-16
GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION 39 7.40E-18 1 GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 59 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 36 1.36E-17 2 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_HEART_DEVELOPMENT 34 1.85E-17 2 GOBP_ORGANELLE_FISSION 22 1.5E-17 3 GOBP_ORGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 5 GOBP_NUCLEOSOME_ORGANIZATION 21 1.28E-16 1	.55E-16
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 59 8.13E-18 1 GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_DNA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_HEART_DEVELOPMENT 34 1.85E-17 2 GOBP_ORGANELLE_FISSION 24 2.05E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 4 GOBP_PONDATIN_ASSEMBLY 23 3.98E-17 5 GOBP_URGANUTIA_SEMBLY 23 3.98E-17 5 GOBP_NORGANELLE_FISSION 21 1.28E-16 1	.17E-15
GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE 36 1.36E-17 2 GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_DNA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_HEART_DEVELOPMENT 34 1.85E-17 2 GOBP_DINA_CONFORMATION_CHANGE 24 2.05E-17 3 GOBP_ORGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 4 GOBP_CHROMATIN_ASSEMBLY 23 3.89E-17 5 GOBP_UCLEOSOME_ORGANIZATION 21 1.28E-16 1	.32E-15
GOBP_NUCLEOSOME_ASSEMBLY 20 1.76E-17 2 GOBP_DNA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_HEART_DEVELOPMENT 34 185E-17 2 GOBP_INA_PACKAGING 24 2.05E-17 3 GOBP_ORGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.08E-17 4 GOBP_NUCLEOSOME_ORGANIZATION 21 1.28E-16 1	.41E-15
GOBP_DNA_CONFORMATION_CHANGE 28 1.79E-17 2 GOBP_HEART_DEVELOPMENT 34 1.85E-17 2 GOBP_ORA_PACKAGING 24 2.05E-17 3 GOBP_ONGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 4 GOBP_CHROMATIN_ASSEMBLY 23 3.98E-17 5 GOBP_UNCLEOSOME_ORGANIZATION 21 1.28E-16 1	.32E-15 .91E-15
GOBP_HEART_DEVELOPMENT 34 1.85E-17 2 GOBP_DNA_PACKAGING 24 2.05E-17 3 GOBP_ORGANELLE_FISSION 32 2.15E-17 3 GOBP_POSITIVE_REGULATION_OF_SIGNALING 32 2.15E-17 3 GOBP_ORGANELLE_FISSION 59 3.30E-17 4 GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 5 GOBP_UNCLEOSOME_ORGANIZATION 21 1.28E-16 1	.91E-15
GOBP_DNA_PACKAGING 24 2.05E-17 3. GOBP_ORGANELLE_FISSION 32 2.15E-17 3. GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.02E-17 4. GOBP_URCMATIN_ASSEMBLY OR DISASSEMBLY 23 3.98E-17 5. GOBP_NUCLEOSOME_ORGANIZATION 21 1.28E-16 1.	.95E-15
GOBP_POSITIVE_REGULATION_OF_SIGNALING 59 3.30E-17 4. GOBP_CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 23 3.98E-17 5. GOBP_NUCLEOSOME_ORGANIZATION 21 1.28E-16 1.	.20E-15
GOBP_CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 23 3.98E-17 5. GOBP_NUCLEOSOME_ORGANIZATION 21 1.28E-16 1.	.28E-15
GOBP_NUCLEOSOME_ORGANIZATION 21 1.28E-16 1.	.94E-15
	.83E-15
	.82E-14
	.82E-14
	.05E-14 .27E-14
	.27E-14
	.29E-14
	29E-14
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION 62 1.81E-16 2.	.29E-14
	.70E-14
	.09E-14
	.11E-14
	29E-14
	.59E-14 .09E-14
	.14E-14
	.98E-14
	.86E-14
GOBP_PROTEIN_DNA_COMPLEX_SUBUNIT_ORGANIZATION 24 7.55E-16 8.	.19E-14
	.62E-14
	.02E-13
	.19E-13
	.21E-13 .29E-13
	.32E-13
	.34E-13
	.91E-13
GOBP_RESPONSE_TO_LIPID 39 2.13E-15 2	.04E-13
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS 42 2.37E-15 2.	.24E-13
	.38E-13
	.38E-13
	.81E-13
	.81E-13 .38E-13
	.38E-13
	.94E-13
	.21E-13
	.91E-13
GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC 17 5.96E-15 5.	.01E-13
	.81E-13
	.26E-13
	.44E-13
	.14E-12
	.15E-12 .34E-12
	.J+C-12
	.94E-12 .64E-12
	.94E-12
GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT 26 5.00E-14 3.	.94E-12 .64E-12

Figure 105 Gene ontology analysis of genes downregulated in response to CD in $dKO^{MRTF-NLS}$ cells by TTseq

Gene ontology analysis of genes downregulated by CD treatment in dKO^{MRTF-NLS} cells by TTseq. FDR<0.05. Relates to Figure 48. Bioinformatic analysis of TTseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS GOBP_CELL_CYCLE	# Genes	p-value	FDR q-value
	# Genes 152		3.40E-28
GOBP_CELL_CYCLE_PROCESS	120		2.17E-23
GOBP_MITOTIC_CELL_CYCLE	96		1.07E-20
GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS	85	1.43E-23	2.71E-20
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	131	4.21E-22	6.37E-19
	107		8.47E-18
GOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION	130		1.95E-16
GOBP_CELLULAR_MACROMOLECULE_LOCALIZATION GOBP_REGULATION_OF_CELL_CYCLE	128		1.84E-15 4.66E-15
GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	96		1.14E-14
GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS	88	5.08E-17	4.22E-15
GOBP_CELL_POPULATION_PROLIFERATION	123		1.36E-14
GOBP_DNA_METABOLIC_PROCESS	77	6.21E-17	3.57E-14
GOBP ACTIN FILAMENT BASED PROCESS	69		3.57E-14
GOBP SMALL MOLECULE METABOLIC PROCESS	118		7.29E-14
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	109	1.46E-16	7.29E-14
GOBP_APOPTOTIC_PROCESS	117	1.95E-15	8.56E-13
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	104	2.38E-15	9.88E-13
GOBP_REGULATION_OF_CELL_DEATH	105	3.73E-15	1.47E-12
GOBP_NEGATIVE_REGULATION_OF_SIGNALING	94		1.88E-12
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	85		2.95E-12
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	102		3.04E-12
GOBP_ORGANELLE_FISSION	49	1 1	3.13E-12
GOBP_ORGANELLE_ASSEMBLY	69		3.20E-12
GOBP_CHROMOSOME_ORGANIZATION	86		3.20E-12
	87		3.43E-12
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	101 S 110	4.33E-14	1.20E-11 1.72E-11
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCES			1.72E-11 1.97E-11
GOBP_DNA_REPAIR GOBP_CELL_DIVISION	52		4.24E-11
GOBP_CELL_DIVISION GOBP_REGULATION_OF_CELL_DIFFERENTIATION	99		4.24E-11 4.53E-11
GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	85		4.53E-11 6.72E-11
GOBP_REGULATION_OF_HTDROLASE_ACTIVITY	103		7.17E-11
GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION	113		7.68E-11
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	69		1.55E-10
GOBP_REGULATION_OF_CELLOLAR_COMPONENT_BIOGENESIS	102		1.55E-10
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	102	7.98E-13	1.61E-10
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	104		1.83E-10
GOBP_HOMEOSTATIC_PROCESS	109	9.54E-13	1.83E-10
GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	85		2.22E-10
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	93		2.61E-10
GOBP BIOLOGICAL ADHESION	91		2.67E-10
GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS	55		3.56E-10
GOBP_PROTEIN_PHOSPHORYLATION	96		4.12E-10
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	101	2.89E-12	4.81E-10
GOBP_POSITIVE_REGULATION_OF_SIGNALING	100		5.55E-10
GOBP_CELL_CYCLE_CHECKPOINT	28	6.62E-12	1.05E-09
GOBP RESPONSE TO OXYGEN CONTAINING COMPOUND	96		1.39E-09
GOBP_REGULATION_OF_MITOTIC_CELL_CYCLE	50	9.58E-12	1.46E-09
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	68	1.00E-11	1.50E-09
GOBP_CELL_PROJECTION_ORGANIZATION	92	1.35E-11	1.98E-09
GOBP_RESPONSE_TO_WOUNDING	52	1.55E-11	2.23E-09
GOBP_WOUND_HEALING	46	1.72E-11	2.42E-09
GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS	50	1.94E-11	2.69E-09
GOBP_CELL_CYCLE_PHASE_TRANSITION	51	2.38E-11	3.23E-09
GOBP_LOCOMOTION	107		4.38E-09
GOBP_CELL_SUBSTRATE_ADHESION	36	3.93E-11	5.16E-09
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	84		5.19E-09
GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS	68		5.31E-09
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	76		5.31E-09
	92		5.34E-09
	74		5.84E-09
GOBP_REGULATION_OF_ION_TRANSPORT GOBP_SECRETION	80		6.63E-09 7.38E-09
GOBP_RESPONSE_TO_HORMONE	61	6.64E-11	7.65E-09
GOBP REGULATION OF APOPTOTIC SIGNALING PATHWAY	35		7.65E-09
GOBP_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR	30		8.02E-09
GOBP_DNA_REPLICATION	31		8.20E-09
GOBP_APOPTOTIC_SIGNALING_PATHWAY	47		8.47E-09
GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION	27		1.05E-08
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	53		1.12E-08
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	71		1.18E-08
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	83		1.47E-08
GOBP_MUSCLE_SYSTEM_PROCESS	40		1.64E-08
GOBP_ACTIN_FILAMENT_ORGANIZATION	39		1.64E-08
GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE	48	2.87E-10	2.82E-08
GOBP_NEUROGENESIS	90		3.01E-08
GOBP_POSITIVE_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY	20		3.01E-08
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	65		3.20E-08
	22		4.04E-08
GOBP_DNA_INTEGRITY_CHECKPOINT	76		5.64E-08
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS		6.27E-10	5.72E-08
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_MITOTIC_CELL_CYCLE_CHECKPOINT	22		
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS	47	6.37E-10	
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_MITOTC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION	47 45	6.37E-10 9.27E-10	8.25E-08
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_POSITIVE REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS	47 45 50	6.37E-10 9.27E-10 1.04E-09	8.25E-08 9.13E-08
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP_MACROMOLECULE_CATABOLIC_PROCESS	47 45 50 81	6.37E-10 9.27E-10 1.04E-09 1.22E-09	8.25E-08 9.13E-08 1.06E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP_MECROMOLECULE_CATABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	47 45 50 81 68	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP_MACROMOLECULE_CATABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION	47 45 50 81 68 33	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.43E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_ANTOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP_MACROMOLECULE_CATABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION GOBP_REGULATION_OF_CELL_CYCLE_PROCESS	47 45 50 81 68 33 54	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.43E-09 1.54E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.22E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC_CELL_CYCLE_CHECKPOINT GOBP OGBOCONTOR GOBP OGBOCONTOR GOBP OGBOCONTOR GOBP OGBOCONTOR GOBP OGBOCONTOR GOBOCONTOR G	47 45 50 81 68 33 54 26	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.43E-09 1.54E-09 1.59E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.22E-07 1.29E-07 1.32E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_ARBOHYDRATE_METABOLIC_PROCESS GOBPOSITIVE REGULATION OF ORGANELLE_ORGANIZATION GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP GOBP_MACROMOLECULE_BIOSYNTHETIC_PROCESS GOBP_MACROMOLECULE_BIOSYNTHETIC_PROCESS GOBP_MACROMOLECULE_CATABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION OF_PROTEIN_METABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION OF_PROTEIN_METABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND	47 45 50 81 68 33 54 26 68	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.43E-09 1.54E-09 1.59E-09 1.62E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.22E-07 1.32E-07 1.32E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC_CELL_CYCLE_CHECKPOINT GOBP CORDCARD GOBP CARONHYDRATE METABOLIC PROCESS GOBP POSITIVE REGULATION OF ORGANELLE ORGANIZATION GOBP SMALL MOLECULE BIOSYNTHETIC PROCESS GOBP MACROMOLECULE_CATABOLIC PROCESS GOBP NEGATIVE REGULATION, OF_PROTEIN_METABOLIC_PROCESS GOBP MUSCLE_CONTRACTION GOBP REGULATION, OF_CELL_PROCESS GOBP CONTRACTION GOBP REGULATION, OF_CELL_PROCESS GOBP CELL_MATRIX_ADHESION GOBP GOBP GOBP RESPONSE_TO_NITROGEN_COMPOUND GOBP GOBP GOBP RETONINTROGEN_COMPOUND GOBP GOBP GOBP	47 45 50 81 68 33 54 26 68 68 63	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.43E-09 1.54E-09 1.59E-09 1.62E-09 1.63E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.29E-07 1.32E-07 1.32E-07 1.32E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_MINITYE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_MOLECULE_BIOSYNTHETIC_PROCESS GOBP_MOLECULE_CATABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_ROTEIN_LOCALIZATION_TO_MEMBRANE	47 45 50 81 68 33 54 26 68 68 63 48	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.43E-09 1.54E-09 1.54E-09 1.62E-09 1.63E-09 1.64E-09	5.74E-08 8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP CARBOHYDRATE_METABOLIC_PROCESS GOBPOSITIVE REGULATION_OF ORGANELLE_ORGANIZATION GOBP SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP GOBP MACROMOLECULE_BIOSYNTHETIC_PROCESS GOBP MACROMOLECULE_CATABOLIC_PROCESS GOBP MUSCLE_CONTRACTION GOBP MUSCLE_CONTRACTION PROTEIN_METABOLIC_PROCESS GOBP REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP GOBP_RESONSE_TO_NITROGEN_COMPOUND GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY MEMBRANE	47 45 50 81 68 33 54 26 68 63 63 48 29	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.54E-09 1.54E-09 1.62E-09 1.63E-09 1.64E-09 1.85E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_CARBOHYDRATE METABOLIC_PROCESS GOBP_CARBOHYDRATE METABOLIC_PROCESS GOBP_SMALL MOLECULE BIOSYNTHETIC_PROCESS GOBP_MICATION GOBP_MICATION GOBP_MACROMOLECULE_CATABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MUSCLE_CONTRACTION GOBP_MEGULATION_OF_CELL_CYCLE_PROCESS GOBP_CELL_MATRIX_ADHESION GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY	47 45 50 81 68 33 54 26 68 63 68 63 48 29 55	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.54E-09 1.59E-09 1.62E-09 1.63E-09 1.63E-09 1.85E-09 1.85E-09	8.25E-08 9.13E-08 1.06E-07 1.22E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.47E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC CELL CYCLE CHECKPOINT GOBP CARBOHYDRATE METABOLIC PROCESS GOBP SMALL MOLECULE BIOSYNTHETIC PROCESS GOBP MACMONLECULE CARBONYNTHETIC PROCESS GOBP MECOMOLECULE CATABOLIC PROCESS GOBP MECOMOLECULE CATABOLIC PROCESS GOBP MECOMOLECULE CATABOLIC PROCESS GOBP MEGATIVE REGULATION OF PROTEIN GOBP MEGATIVE CONTRACTION GOBP REGULATION OF GOBP REGULATION CYCLE PROCESS GOBP GOBP REGULATION COMPOUND GOBP REGULATION TO COMPOUND GOBP ROTEIN LOCALIZATION TO MEMBRANE GOBP PROTEIN LOCALIZATION TO MEMBRANE GOBP GOBP ROTEIN LOCALIZATION CALAUNALY GOBP ROTEIN LOCALIZATION	47 45 50 81 68 33 54 26 68 68 63 48 29 55 59	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.43E-09 1.59E-09 1.59E-09 1.62E-09 1.62E-09 1.63E-09 1.63E-09 1.85E-09 1.85E-09 1.88E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.47E-07 1.47E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC_CELL_CYCLE_CHECKPOINT GOBP_CARBOHYDRATE METABOLIC_PROCESS GOBP POSITIVE REGULATION_OF_ORGANELLE ORGANIZATION GOBP MARCROMOLECULE_BIOSYNTHETIC_PROCESS GOBP MEGATIVE REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP MEGATIVE REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP MEGATIVE REGULATION_OF_CELL_CYCLE_PROCESS GOBP REGULATION_OF_CELL_CYCLE_PROCESS GOBP REGULATION_OF_CELL_CYCLE_PROCESS GOBP REGULATION_OF_CELL_CYCLE_PROCESS GOBP RESPONSE_TO_NITROGEN_COMPOUND GOBP RESPONSE_TO_NITROGEN_COMPOUND GOBP PROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_INEGATIVE REGULATION_OF_CATALYTIC_ACTIVITY GOBP_REGULATION_OF_CATALYTIC_ACTIVITY GOBP_GROWTH GOBP_ROP GOBVTH GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	47 45 50 81 68 33 54 26 68 63 63 48 29 55 59 67	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.54E-09 1.54E-09 1.62E-09 1.63E-09 1.64E-09 1.85E-09 1.85E-09 1.86E-09 2.10E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.47E-07 1.47E-07 1.47E-07 1.47E-07 1.47E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP MITOTIC CELL CYCLE_CHECKPOINT GOBP_CARBOHYDRATE METABOLIC_PROCESS GOBP_SMALL MOLECULE BIOSYNTHETIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_RESTO_NITROGEN_COMPOUND GOBP_RESTO_NITROGEN_COMPOUND GOBP_ROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY GOBP_REGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY GOBP_GROWTH GOBP_GROWTH GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT GOBP_REGULATION_OF_CATALAR_COMPONENT_MOVEMENT	47 45 50 81 68 333 54 26 68 63 63 48 29 55 55 59 67 63	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.25E-09 1.54E-09 1.54E-09 1.62E-09 1.62E-09 1.64E-09 1.86E-09 1.86E-09 1.86E-09 1.86E-09 2.10E-09 2.22E-09	8.25E-08 9.13E-08 1.06E-07 1.08E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.47E-07 1.47E-07 1.47E-07 1.62E-07 1.70E-07
GOBP POSITIVE REGULATION OF DEVELOPMENTAL PROCESS GOBP_ACARBOHYDRATE_METABOLIC_PROCESS GOBP_CARBOHYDRATE_METABOLIC_PROCESS GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_ORGANELLE_ORGANIZATION GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS GOBP_MEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_REGULATION_OF_CELL_CYCLE_PROCESS GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_PROTEIN_LOCALIZATION_TO_MEMBRANE GOBP_INEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY GOBP_REGULATION_OF_CATALYTIC_ACTIVITY GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	47 45 50 81 68 33 54 26 68 63 63 48 29 55 59 67	6.37E-10 9.27E-10 1.04E-09 1.22E-09 1.43E-09 1.54E-09 1.63E-09 1.63E-09 1.64E-09 1.86E-09 1.86E-09 1.86E-09 2.10E-09 2.22E-09 2.31E-09	8 25E-06 9.13E-06 1.06E-07 1.08E-07 1.22E-07 1.32E-07 1.32E-07 1.32E-07 1.32E-07 1.47E-07 1.47E-07 1.47E-07 1.47E-07 1.47E-07 1.47E-07 1.47E-07

Figure 106 Gene ontology analysis of genes upregulated in response to CD in

Mtr4-depeted NIH3T3 cells by RNAseq

Gene ontology analysis of genes upregulated by CD treatment in Mtr4-depleted NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 53. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	225	2.25E-67	1.68E-63
COBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	228	4.01E-65	1.50E-61
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	213 215	3.57E-64 7.33E-64	8.91E-61 1.37E-60
GOBP_REGULATION_OF_INTRACEELULAR_SIGNAL_TRANSDUCTION	177	4.07E-55	6.09E-52
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	161		1.61E-51
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY	147	4.50E-50	4.81E-47
	183 187		6.45E-47
GOBP_POSITIVE_REGULATION_OF_SIGNALING GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	187	2.81E-48 1.05E-47	2.33E-45 7.86E-45
GOBP_NEUROGENESIS	179	1.37E-47	9.31E-45
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	179	4.66E-47	2.91E-44
GOBP_PROTEIN_PHOSPHORYLATION	178	7.35E-47	4.23E-44
GOBP NEGATIVE REGULATION OF RESPONSE TO STIMULUS GOBP REGULATION OF HYDROLASE ACTIVITY	179 155	2.35E-45 4.29E-45	1.25E-42 2.14E-42
GOBP_CELL_PROJECTION_ORGANIZATION	171	1.99E-44	9.29E-42
GOBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	178	2.71E-44	1.19E-41
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	152	1.06E-43	4.39E-41
GOBP_APOPTOTIC_PROCESS GOBP NEGATIVE REGULATION OF SIGNALING	191 159	1.75E-43 4.37E-43	6.88E-41 1.64E-40
GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION	93	9.63E-43	3.43E-40
GOBP_CELL_POPULATION_PROLIFERATION	191		3.50E-40
GOBP_NEURON_DIFFERENTIATION	155	1.23E-42	3.85E-40
GOBP_LOCOMOTION	192	1.24E-42	3.85E-40
GOBP NEGATIVE REGULATION OF NUCLEOBASE CONTAINING COMPOUND METABOLIC PROCESS GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	165 171	1.40E-42 2.33E-42	4.19E-40 6.71E-40
GOBP_INTRACELLULAR_TRANSPORT	176	1.32E-41	3.66E-39
GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION	189	9.06E-41	2.42E-38
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	161	7.09E-40	1.83E-37
	187	1.02E-39	2.55E-37
GOBP_MACROMOLECULE_CATABOLIC_PROCESS GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	153 115	1.07E-38 1.61E-37	2.59E-36 3.76E-35
GOBP_CELL_MIGRATION	160	8.65E-37	1.96E-34
GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION	69	2.36E-36	5.19E-34
	122	3.41E-36	7.30E-34
GOBP_CYTOSKELETON_ORGANIZATION GOBP_REGULATION_OF_CATABOLIC_PROCESS	145	9.58E-36 1.84E-35	1.99E-33 3.71E-33
GOBP_REGULATION_OF_CATABOLIC_PROCESS	121	2.71E-35	5.33E-33
GOBP_CELL_CELL_SIGNALING_BY_WNT	85	3.34E-35	6.40E-33
GOBP_NEURON_DEVELOPMENT	127	4.96E-35	9.27E-33
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	133	9.02E-35	1.65E-32
GOBP_POSITIVE_REGULATION_OF_HYDROLASE_ACTIVITY GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	104	1.08E-34 3.15E-34	1.93E-32 5.49E-32
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	127	7.90E-34	1.34E-31
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	142	1.91E-33	3.17E-31
GOBP_REGULATION_OF_CELL_DEATH	157	2.30E-33	3.73E-31
GOBP_HOMEOSTATIC_PROCESS	171	2.41E-33	3.83E-31
GOBP_REGULATION_OF_GTPASE_ACTIVITY GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY	80 99	4.15E-33 4.78E-33	6.46E-31 7.29E-31
GOBP_CELLULAR_MACROMOLECULE_CATABOLIC_PROCESS	129		1.27E-30
GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION	106	9.37E-33	1.37E-30
GOBP_PEPTIDYL_AMINO_ACID_MODIFICATION	133	1.11E-32	1.60E-30
GOBP_CELL_CELL_SIGNALING	156	1.89E-32	2.66E-30
GOBP_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_INVOLVED_IN_CELL_CELL_SIGNALING GOBP_TUBE_DEVELOPMENT	89	2.32E-32 2.73E-32	3.21E-30 3.71E-30
GOBP_EMBRYO_DEVELOPMENT	115	3.03E-32	4.05E-30
GOBP_PROTEOLYSIS	162	5.74E-32	7.53E-30
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION_OR_REMOVAL	125	6.83E-32	8.82E-30
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	122	1.18E-31 3.98E-31	1.50E-29 4.96E-29
GOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	134	4.08E-31	5.00E-29
GOBP_PROTEIN_CATABOLIC_PROCESS	110		7.34E-29
GOBP_SKELETAL_SYSTEM_DEVELOPMENT	77	9.29E-31	1.10E-28
GOBP_REGULATION_OF_CELLULAR_CATABOLIC_PROCESS	103	1.27E-30	1.48E-28
GOBP_ANIMAL_ORGAN_MORPHOGENESIS GOBP POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS	114	2.40E-30 3.25E-30	2.77E-28 3.68E-28
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	93	3.43E-30	3.83E-28
GOBP_POSITIVE_REGULATION_OF_GTPASE_ACTIVITY	70		4.41E-28
GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	115	5.70E-30	6.18E-28
	118		6.37E-28
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_DIFFERENTIATION GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	93 118		1.32E-27 1.39E-27
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	135	1.36E-29	1.39E-27
GOBP_HEAD_DEVELOPMENT	94	4.60E-29	4.65E-27
GOBP_BIOLOGICAL_ADHESION	138		1.18E-26
GOBP_RESPONSE_TO_GROWTH_FACTOR	92		1.32E-26
GOBP_CHROMATIN_ORGANIZATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	97 118		1.53E-26 1.68E-26
GOBP_CELLULAR_COMPONENT_MORPHOGENESIS	94		2.20E-26
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	147	2.35E-28	2.20E-26
GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY	64	2.93E-28	2.71E-26
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	106 106	4.11E-28 4.11E-28	3.70E-26 3.70E-26
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	79		3.70E-26 1.44E-25
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	108		1.51E-25
GOBP_IMMUNE_SYSTEM_DEVELOPMENT	106	6.13E-27	5.33E-25
GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	117		1.13E-24
GOBP_CELL_CYCLE GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY	155		1.14E-24 1.26E-24
GOBP_CELLULAR_PROTEIN_CATABOLIC_PROCESS	93		1.20E-24 1.51E-24
GOBP_REGULATION_OF_TRANSPORT	147		1.92E-24
GOBP_CELL_PART_MORPHOGENESIS	85	2.46E-26	2.00E-24
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_NEURON_DIFFERENTIATION	78	2.56E-26	2.06E-24
GOBP_TUBE_MORPHOGENESIS GOBP_REGULATION_OF_RESPONSE_TO_STRESS	99 129		3.55E-24 4.62E-24
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	129		4.02E-24 5.21E-24
GOBP_CHROMOSOME_ORGANIZATION	119	9.40E-26	7.25E-24
GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY	84	1.10E-25	8.41E-24
GOBP_MAPK_CASCADE	99	1.23E-25	9.32E-24
GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT	103	1.58E-25	1.18E-23.

Figure 107 Gene ontology analysis of genes downregulated in response to CD in

Mtr4-depeted NIH3T3 cells by RNAseq

Gene ontology analysis of genes downregulated by CD treatment in Mtr4-depleted NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 53. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

Gene Set Name	# Genes	p-value	FDR q-value
GOBP_ACTIN_FILAMENT_BASED_PROCESS	85	3.13E-45	2.37E-41
GOBP_CYTOSKELETON_ORGANIZATION	105	4.22E-42	1.60E-38
GOBP_BIOLOGICAL_ADHESION	104	4.96E-39	1.25E-35
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	115	6.91E-38	1.31E-34
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS GOBP_REGULATION_OF_CELL_DIFFERENTIATION	114 115	4.19E-37 3.74E-36	6.35E-34 4.68E-33
GOBP_CELL_MOTILITY	111	4.33E-36	4.68E-33
GOBP_APOPTOTIC_PROCESS	115	3.76E-35	3.56E-32
GOBP_REGULATION_OF_CELL_DEATH	105	1.53E-33	1.29E-30
GOBP_REGULATION_OF_PHOSPHORYLATION	102	3.66E-33	2.77E-30
GOBP_CELL_MIGRATION	102	8.81E-33	1.10E-31
	103	8.84E-33	6.61E-30
GOBP_ACTIN_FILAMENT_ORGANIZATION	54	1.46E-32 1.59E-31	9.93E-30 9.18E-29
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	98 101	4.97E-31	2.65E-28
GOBP SUPRAMOLECULAR FIBER ORGANIZATION	65	5.49E-31	2.74E-28
GOBP_RESPONSE_TO_WOUNDING	62	1.82E-30	8.52E-28
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	79	2.41E-30	1.06E-27
GOBP_WOUND_HEALING	56	8.64E-30	3.59E-27
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	94	8.60E-29	3.22E-26
GOBP_NEUROGENESIS	93	2.04E-28	7.26E-26
GOBP_CELL_MORPHOGENESIS GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	72 93	1.21E-27 1.30E-27	4.11E-25 4.23E-25
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	79	1.30E-27	4.23E-25 4.34E-25
GOBP_CELL_SUBSTRATE_ADHESION	45	1.96E-27	5.88E-25
GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	70	2.12E-27	6.11E-25
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	93	3.01E-27	8.34E-25
GOBP_REGULATION_OF_CELL_ADHESION	61	6.09E-27	1.63E-24
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	71	7.51E-27	1.94E-24
GOBP_CELL_POPULATION_PROLIFERATION	100	1.64E-26	4.08E-24
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	83	4.02E-26	9.70E-24
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	79	6.12E-26	1.43E-23 1.43E-23
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY GOBP_REGULATION_OF_ORGANELLE_ORGANIZATION	72	6.32E-26 7.56E-26	1.43E-23 1.66E-23
GOBP_RESPONSE_TO_HORMONE	65	7.91E-26	1.69E-23
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	86	1.47E-25	3.05E-23
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	73	1.54E-25	3.11E-23
GOBP_NEGATIVE_REGULATION_OF_SIGNALING	82	2.53E-25	4.98E-23
GOBP_CELL_PROJECTION_ORGANIZATION	86	8.04E-25	1.54E-22
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	72	2.42E-24	4.53E-22
GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	69	2.65E-24	4.78E-22
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	72	2.68E-24	4.78E-22
GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION	34 64	3.70E-24	6.44E-22
GOBP_MAPK_CASCADE GOBP_SMALL_MOLECULE_METABOLIC_PROCESS	94	3.95E-24 4.20E-24	6.72E-22 6.98E-22
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	66	7.46E-24	1.21E-21
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	79	1.26E-23	2.00E-21
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	66	1.30E-23	2.03E-21
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	78	5.41E-23	8.26E-21
GOBP_REGULATION_OF_MAPK_CASCADE	55	6.05E-23	9.05E-21
GOBP_TUBE_DEVELOPMENT	68	7.75E-23	1.14E-20
GOBP_POSITIVE_REGULATION_OF_PROTEIN_PHOSPHORYLATION	58	5.26E-22	7.56E-20
GOBP_REGULATION_OF_TRANSPORT	86	5.50E-22	7.76E-20
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	63 72	3.24E-21 4.02E-21	4.49E-19 5.47E-19
GOBP_TUBE_MORPHOGENESIS	59	7.41E-21	9.89E-19
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	75	7.89E-21	1.04E-18
GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	68	8.22E-21	1.06E-18
GOBP_VASCULATURE_DEVELOPMENT	55	8.51E-21	1.08E-18
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	90	9.55E-21	1.19E-18
GOBP_BLOOD_VESSEL_MORPHOGENESIS	51	9.78E-21	1.20E-18
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY GOBP_CELLULAR_COMPONENT_MORPHOGENESIS	53 54	1.33E-20	1.60E-18
GOBP_APOPTOTIC_SIGNALING_PATHWAY	47	1.40E-20 1.79E-20	1.66E-18 2.09E-18
GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS	39	2.14E-20	2.46E-18
GOBP POSITIVE REGULATION OF LOCOMOTION		2.53E-20	2.87E-18
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	68	3.74E-20	4.18E-18
GOBP_EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	39	4.03E-20	4.43E-18
GOBP_NEURON_DIFFERENTIATION	72	5.00E-20	5.42E-18
GOBP_CELL_JUNCTION_ASSEMBLY	40	6.79E-20	7.25E-18
GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY GOBP POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS	54 44	7.03E-20 1.05E-19	7.41E-18 1.09E-17
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS	44	1.05E-19 1.13E-19	1.09E-17 1.16E-17
GOBP_CELL_MORPHOGENESIS_INVOLVED_IN_DIFFERENTIATION	51	1.66E-19	1.68E-17
GOBP_RESPONSE_TO_CYTOKINE	66	1.95E-19	1.95E-17
GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION	55	2.18E-19	2.14E-17
GOBP_SECRETION	74	2.21E-19	2.15E-17
GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY	36	2.27E-19	2.18E-17
GOBP_HOMEOSTATIC_PROCESS	86	3.10E-19	2.93E-17
GOBP_CELL_MATRIX_ADHESION	30	3.42E-19	3.20E-17
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION	60 39	4.05E-19 4.82E-19	3.74E-17
GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION GOBP_CELL_SUBSTRATE_JUNCTION_ORGANIZATION	39	4.82E-19 6.98E-19	4.40E-17 6.30E-17
GOBP_CELL_SUBSTRATE_JUNCTION_ORGANIZATION	45	7.87E-19	7.01E-17
GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION	40	1.13E-18	9.94E-17
GOBP_GROWTH	56	1.23E-18	1.07E-16
GOBP_CELL_CELL_ADHESION	55	1.41E-18	1.21E-16
GOBP_NEURON_DEVELOPMENT	62	1.94E-18	1.65E-16
GOBP_REGULATION_OF_ACTIN_FILAMENT_ORGANIZATION	31	5.09E-18	4.28E-16
	55	5.38E-18	4.47E-16
GOBP_CELL_JUNCTION_ORGANIZATION GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS	48 45	5.93E-18 7.80E-18	4.87E-16 6.34E-16
GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS GOBP_REGULATION_OF_SUPRAMOLECULAR_FIBER_ORGANIZATION	45	1.24E-17	6.34E-16 1.00E-15
GOBP_REGULATION_OF_CELL_MORPHOGENESIS	32	1.54E-17	1.22E-15
GOBP_REGULATION_OF_ION_TRANSPORT	66	3.16E-17	2.49E-15
GOBP_TAXIS	45	3.48E-17	2.71E-15
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE	39	7.78E-17	6.00E-15
GOBP_REGULATION_OF_CELLULAR_COMPONENT_SIZE	34	8.82E-17	6.74E-15
GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE	40	1.05E-16	7.95E-15
GOBP_REGULATION_OF_ANION_TRANSPORT	51	1.35E-16	1.01E-14

Figure 108 Gene ontology analysis of genes upregulated in response to LMB in

Mtr4-depeted NIH3T3 cells by RNAseq

Gene ontology analysis of genes upregulated by LMB treatment in Mtr4-depleted NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 53. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

Gene Set Name	# Genes	p-value	FDR q-value
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	18		
GOBP_TUBE_DEVELOPMENT	17	6.64E-09	
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	19		
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT GOBP_EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	17		
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	17	1	
GOBP_BIOLOGICAL_ADHESION	19		
GOBP_BLOOD_VESSEL_MORPHOGENESIS	13	4.50E-08	4.21E-05
GOBP_LIPID_METABOLIC_PROCESS	18	1	
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	17		
GOBP_REGULATION_OF_EPITHELIAL_CELL_MIGRATION GOBP_TUBE_MORPHOGENESIS	9		
GOBP_POSITIVE_REGULATION_OF_SIGNALING	19		
GOBP_HOMEOSTATIC_PROCESS	20	1	
GOBP_VASCULATURE_DEVELOPMENT	13		
GOBP_REGULATION_OF_ENDOTHELIAL_CELL_MIGRATION	8		
GOBP_CELL_MIGRATION	18		
GOBP_TISSUE_MIGRATION GOBP_ENDOTHELIAL_CELL_MIGRATION	8	1 1 1	
GOBP POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS	16	1	
GOBP_OSSIFICATION	9		
GOBP_LOCOMOTION	19		
GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS	9	1.67E-06	5.44E-04
GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	14		
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	17	1	
GOBP_SMALL_MOLECULE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	18		
GOBP_CHEMICAL_HOMEOSTASIS	13		
GOBP_LIPID_CATABOLIC_PROCESS	8	1 1 1 1 1 1	1
GOBP_REGULATION_OF_VASCULATURE_DEVELOPMENT	8		
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	10	4.91E-06	1.18E-03
GOBP_AMEBOIDAL_TYPE_CELL_MIGRATION	9		
	9		
GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_MIGRATION	16		
GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_MIGRATION	12	1	
GOBP_MONOSACCHARIDE_METABOLIC_PROCESS	7		
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	5 17	1	
GOBP_LIPID_OXIDATION	5	1.35E-05	2.58E-03
GOBP_COLLAGEN_FIBRIL_ORGANIZATION	4		
	17		
GOBP_SKELETAL_SYSTEM_MORPHOGENESIS	13		
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS GOBP_UROGENITAL_SYSTEM_DEVELOPMENT	7		
GOBP_NEGATIVE_REGULATION_OF_SIGNALING	14		
GOBP_HORMONE_METABOLIC_PROCESS	6		
GOBP_POSITIVE_REGULATION_OF_ENDOTHELIAL_CELL_MIGRATION	5	3.24E-05	5.10E-03
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	15	1	
GOBP_CELL_AGGREGATION	3	1	
GOBP_PROTEIN_PHOSPHORYLATION GOBP_STEROID_METABOLIC_PROCESS	15		
GOBP_ORGANIC_ACID_METABOLIC_PROCESS	12		
GOBP_CELLULAR_HORMONE_METABOLIC_PROCESS	5		
GOBP_SENSORY_ORGAN_MORPHOGENESIS	6	1	1
GOBP_ION_HOMEOSTASIS	10		
GOBP_REGULATION_OF_HORMONE_LEVELS	8		
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	11	1	
GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION GOBP_MULTICELLULAR_ORGANISMAL_HOMEOSTASIS	8	0.000 00	
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	12		
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	11		
GOBP_REGULATION_OF_FATTY_ACID_OXIDATION	3	1.02E-04	1.22E-02
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	15		
GOBP_FATTY_ACID_METABOLIC_PROCESS	7		
GOBP_REGULATION_OF_MESENCHYMAL_STEM_CELL_DIFFERENTIATION GOBP_POSITIVE_REGULATION_OF_PHOSPHATIDYLINOSITOL_3_KINASE_SIGNALING	2	1	
GOBP_POSITIVE_REGULATION_OF_PROSPRATID TELINOSTICE_3_NINASE_SIGNALING	5	1	1
GOBP_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE	4		
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	14	1.39E-04	1.50E-02
GOBP_CARTILAGE_DEVELOPMENT	5		
GOBP_CELLULAR_LIPID_METABOLIC_PROCESS	11		
GOBP_NOTCH_SIGNALING_PATHWAY	5		
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY GOBP_POSITIVE_REGULATION_OF_GENE_EXPRESSION	11		
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY	9		
GOBP_REGULATION_OF_SMALL_MOLECULE_METABOLIC_PROCESS	7		
GOBP_INOSITOL_LIPID_MEDIATED_SIGNALING	5	2.09E-04	2.03E-02
GOBP_IMMUNE_EFFECTOR_PROCESS	12		
GOBP_NEGATIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION	9	1	
GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING GOBP_RESPONSE_TO_MECHANICAL_STIMULUS	8		
GOBP_RESPONSE_IO_MECHANICAL_STIMULUS GOBP_EAR_MORPHOGENESIS	4		
GOBP_APOPTOTIC_PROCESS	15		
GOBP_REGULATION_OF_OSSIFICATION	4	1	
GOBP_MESENCHYMAL_STEM_CELL_DIFFERENTIATION	1	2.62E-04	
	8		
GOBP_INFLAMMATORY_RESPONSE	9		
GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	11		
GOBP_POSITIVE_REGULATION_OF_BIOSTINTHETIC_PROCESS	5		
GOBP_REGULATION_OF_IMMUNE_EFFECTOR_PROCESS	7		
GOBP_VASCULAR_ENDOTHELIAL_GROWTH_FACTOR_SIGNALING_PATHWAY	3	3.13E-04	2.54E-02
GOBP_REGULATION_OF_GLUCOSE_METABOLIC_PROCESS	4		
GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_APOPTOTIC_PROCESS	3		
	10	1	
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS			2.85E-02
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	14		
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS GOBP_EMBRYO_DEVELOPMENT	10	3.97E-04	3.02E-02
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS		3.97E-04 3.98E-04	3.02E-02 3.02E-02

Figure 109 Gene ontology analysis of genes downregulated in response to LMB

in Mtr4-depeted NIH3T3 cells by RNAseq

Gene ontology analysis of genes downregulated by LMB treatment in Mtr4depleted NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 53. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP_CELL_CYCLE	145	4.08E-30	3.09E-26
GOBP_CELLULAR_RESPONSE_TO_DNA_DAMAGE_STIMULUS	88	1.63E-26 4.77E-24	6.16E-23 1.20E-20
GOBP_CELL_CYCLE_PROCESS GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS	94	5.01E-22	9.48E-19
GOBP_REGULATION_OF_CELL_CYCLE	95	5.09E-20	7.72E-17
GOBP_DNA_METABOLIC_PROCESS	80	2.67E-19	3.37E-16
GOBP_MITOTIC_CELL_CYCLE	82 56	1.55E-17	1.68E-14
GOBP_DNA_REPAIR GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS	50 60	7.74E-17 9.78E-16	7.33E-14 7.99E-13
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS		1.05E-15	7.99E-13
GOBP_SMALL_MOLECULE_METABOLIC_PROCESS	116	1.54E-15	1.20E-13
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	108	5.48E-15	3.41E-12
GOBP_CELL_POPULATION_PROLIFERATION	114	1.09E-14	6.03E-12
SOBP_DNA_REPLICATION SOBP_PROTEIN_CONTAINING_COMPLEX_SUBUNIT_ORGANIZATION	36 112	1.13E-14 7.06E-14	6.03E-12 3.52E-11
GOBP_PROTEIN_PHOSPHORYLATION	98	9.27E-14	4.34E-11
GOBP_CELL_DIVISION	52	2.29E-13	1.01E-10
SOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	96	4.52E-13	1.88E-10
SOBP_APOPTOTIC_PROCESS	108	8.14E-13	3.13E-10
SOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS SOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	92	8.36E-13 9.78E-13	3.13E-10 3.49E-10
SOBP_CELLULAR_LIPID_METABOLIC_PROCESS	72	1.13E-12	3.85E-10
SOBP_CELLULAR_MACROMOLECULE_LOCALIZATION	108	3.90E-12	1.27E-09
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	94	4.71E-12	1.47E-09
SOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS	69	5.10E-12	1.47E-09
SOBP_ORGANONITROGEN_COMPOUND_CATABOLIC_PROCESS	82	5.14E-12	1.47E-09
OBP_REGULATION_OF_ORGANELLE_ORGANIZATION OBP_NEGATIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	75 96	5.31E-12 6.22E-12	1.47E-09 1.66E-09
SOBP_INEGATIVE_REGOLATION_OF_BIOSTIVITIETIC_PROCESS	33	6.46E-12	1.67E-09
GOBP_HOMEOSTATIC_PROCESS	104	1.16E-11	2.88E-09
GOBP_CYTOSKELETON_ORGANIZATION	83	1.23E-11	2.97E-09
OBP_REGULATION_OF_CELL_DEATH	94	1.37E-11	3.20E-09
OBP_NEUROGENESIS	92	1.61E-11	3.65E-09
OBP_DNA_DEPENDENT_DNA_REPLICATION OBP_DOUBLE STRAND BREAK REPAIR	23	4.84E-11 6.23E-11	1.07E-08 1.33E-08
OBP_DOUBLE_STRAND_BREAK_REPAIR	83	6.93E-11	1.33E-08
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT	71	8.72E-11	1.76E-08
SOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	92	1.10E-10	2.17E-08
OBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	69	1.19E-10	2.29E-08
GOBP_CELL_CYCLE_DNA_REPLICATION	15	1.24E-10	2.32E-08
GOBP_LIPID_METABOLIC_PROCESS	82	1.47E-10	2.68E-08
OBP_ORGANELLE_ASSEMBLY OBP_NEGATIVE_REGULATION_OF_SIGNALING	59 81	1.79E-10 1.94E-10	3.19E-08 3.37E-08
IOBP_NEGATIVE_REGULATION_OF_SIGNALING	94	2.01E-10	3.42E-08
OBP_RECOMBINATIONAL_REPAIR	21	2.12E-10	3.53E-08
GOBP_CELL_PROJECTION_ORGANIZATION	87	2.27E-10	3.70E-08
OBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS	47	2.66E-10	4.23E-08
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	80	3.02E-10	4.64E-08
OBP_CELL_CYCLE_PHASE_TRANSITION	48	3.04E-10	4.64E-08
0BP_NEGATIVE_REGULATION_OF_CELL_CYCLE 0BP_REGULATION_OF_MITOTIC_CELL_CYCLE	47	3.85E-10 4.37E-10	5.76E-08 6.41E-08
SOBP_REGULATION_OF_NITOTIC_CELL_CYCLE	92	4.37E-10 5.26E-10	7.56E-08
GOBP_CELL_MIGRATION	87	6.69E-10	9.44E-08
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	79	8.17E-10	1.13E-07
SOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCES		1.27E-09	1.73E-07
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	71	1.39E-09	1.86E-07
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND GOBP_PEPTIDYL_AMINO_ACID_MODIFICATION	88	1.43E-09 1.53E-09	1.88E-07 1.98E-07
GOBP_REGULATION_OF_CELL_CYCLE_PROCESS	53	1.74E-09	2.20E-07
OBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	99	1.81E-09	2.25E-07
OBP_REGULATION_OF_CATABOLIC_PROCESS	62	2.09E-09	2.57E-07
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	69	2.25E-09	2.68E-07
GOBP_NEURON_DIFFERENTIATION	76	2.26E-09	2.68E-07
60BP_MUSCLE_TISSUE_DEVELOPMENT 60BP_PROTEIN_LOCALIZATION_TO_ORGANELLE	33	2.87E-09 3.85E-09	3.36E-07 4.43E-07
OBP_EXTERNAL_ENCAPSULATING_STRUCTURE_ORGANIZATION	34	4.09E-09	4.43E-07
OBP ANIMAL ORGAN MORPHOGENESIS	62	4.24E-09	4.74E-07
GOBP_GROWTH	57	4.92E-09	5.41E-07
OBP_REGULATION_OF_CELLULAR_RESPONSE_TO_STRESS	48	5.08E-09	5.51E-07
SOBP_HOMOLOGOUS_RECOMBINATION	13	5.99E-09	6.41E-07
OBP_TUBE_DEVELOPMENT	64 38	6.24E-09 6.73E-09	6.57E-07 7.00E-07
JOBP_ORGANELLE_FISSION JOBP_CARBOHYDRATE_METABOLIC_PROCESS	38	6.73E-09 7.63E-09	7.00E-07
OBP_LOCOMOTION	97	1.15E-08	1.17E-06
IOBP_CELL_CYCLE_G1_S_PHASE_TRANSITION	28	1.37E-08	1.36E-06
OBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS	42	1.38E-08	1.36E-06
OBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	68	1.46E-08	1.42E-06
	33	1.71E-08	1.64E-06
OBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS	57	2.01E-08 2.29E-08	1.90E-06 2.15E-06
OBP_INTRACELLULAR_TRANSPORT	87	2.29E-08 2.40E-08	2.13E-00
OBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION	96	2.69E-08	2.45E-06
	59	2.90E-08	2.62E-06
OBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION		3.39E-08	3.02E-06
OBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION OBP_DEVELOPMENTAL_GROWTH	42		
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_REGULATION_OF_HYDROLASE_ACTIVITY	70	4.22E-08	
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH OBP_REGULATION_OF_HYDROLASE_ACTIVITY IOBP_POSITIVE_REGULATION_OF_CELL_CYCLE	70 32	4.22E-08 4.56E-08	3.96E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_REGULATION_OF_HYDROLASE_ACTIVITY IOBP_POSITIVE_REGULATION_OF_CELL_CYCLE IOBP_REGULATION_OF_TRANSPORT	70 32 86	4.22E-08	3.96E-06 4.15E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_REGULATION_OF_IPPORIASE_ACTIVITY IOBP_ROSITIVE_REGULATION_OF_CELL_CYCLE IOBP_REGULATION_OF_TRANSPORT IOBP_REPRODUCTION	70 32 86 75	4.22E-08 4.56E-08 4.83E-08 6.15E-08	3.96E-06 4.15E-06 5.23E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_REGULATION_OF_IPUROLASE_ACTIVITY IOBP_POSITIVE_REGULATION_OF_CELL_CYCLE IOBP_REGULATION_OF_TRANSPORT IOBP_REPRODUCTION IOBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS	70 32 86	4.22E-08 4.56E-08 4.83E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_REGULATION_OF_HPOROLASE_ACTIVITY IOBP_POSITIVE_REGULATION_OF_CELL_CYCLE IOBP_REGULATION_OF_TRANSPORT IOBP_REPRODUCTION IOBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS IOBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY IOBP_HEART_DEVELOPMENT IOBP_HEART_DEVELOPMENT	70 32 86 75 35	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.09E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06 6.00E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION OBP_DEVELOPMENTAL_GROWTH OBP_REGULATION_OF_POROLASE_ACTIVITY OBP_POSITIVE_REGULATION_OF_CELL_CYCLE OBP_REGULATION_OF_TRANSPORT OBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS OBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY OBB_HEART_DEVELOPMENT OBP_RET_DEVELOPMENT OBP_RET_DEVELOPMENT OBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	70 32 86 75 35 62 39 73	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.09E-08 7.22E-08 7.58E-08 7.72E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06 6.00E-06 6.23E-06 6.28E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION OBP_DEVELOPMENTAL_GROWTH OBP_ROSUNTION_OF_INTROLASE_ACTIVITY OBP_POSITIVE_REGULATION_OF_CELL_CYCLE OBP_REGULATION_OF_TRANSPORT OBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS OBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY OBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT IOBP_CHROMOSOME_ORGANIZATION	70 32 86 75 35 62 39 73 67	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.09E-08 7.22E-08 7.58E-08 7.72E-08 8.92E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06 6.00E-06 6.23E-06 6.28E-06 7.17E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION OOBP_DEVELOPMENTAL_GROWTH OOBP_ROSITIVE_REGULATION_OF_CELL_CYCLE OOBP_REFROUND OF_TRANSPORT OOBP_ROSITIVE_REGULATION_OF_CELL_CYCLE OOBP_REFRODUCTION OOBP_RATERODUCTION OOBP_REATRODUCTION OOBP_CENT_DEVELOPMENT OOBP_CEGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT OOBP_CENT_ONDE_ORGANIZATION OOBP_CATOMICAL_STRONCOME_ORGANIZATION OOBP_REFROTEIN_ON_COMELDEVELOPMENT OOBP_CELLDATION_OF_CELL_DIFFERENTIATION	70 32 86 75 35 62 39 73 67 81	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.09E-08 7.22E-08 7.58E-08 7.72E-08 8.92E-08 9.00E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06 6.00E-06 6.23E-06 6.23E-06 7.17E-06 7.17E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION OBP_DEVELOPMENTAL_GROWTH OBP_REGULATION_OF_POROLASE_ACTIVITY OBP_POSITIVE_REGULATION_OF_CELL_CYCLE OBP_REFROUDUCTION OBP_REFROUDUCTION OBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS OBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY OBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT OBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT OBP_TRAN_AMETABOLIC_PROCESS	70 32 86 75 35 62 39 73 67 81 81 20	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.02E-08 7.52E-08 7.72E-08 8.92E-08 9.00E-08 9.60E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06 6.00E-06 6.23E-06 6.23E-06 7.17E-06 7.17E-06 7.56E-06
IOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_REGULATION_OF_IPUROLASE_ACTIVITY IOBP_POSITIVE_REGULATION_OF_CELL_CYCLE IOBP_REGULATION_OF_TRANSPORT IOBP_REGULATION_OF_TRANSPORT IOBP_REGULATION_OF_TRANSPORT IOBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS IOBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY IOBP_HEART_DEVELOPMENT IOBP_REGULATION_OF_CELL_DIFFERENTIATION IOBP_REGULATION_OF_CELL_DIFFERENTIATION IOBP_REGULATION_OF_CELL_DIFFERENTIATION IOBP_REGULATION_OF_CELL_DIFFERENTIATION IOBP_REGULATION_OF_CELL_DIFFERENTIATION IOBP_REGULATION_OF_CELS IOBP_RESUBATION_STIMULUS	70 32 86 75 35 62 39 73 67 81	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.09E-08 7.22E-08 7.58E-08 7.72E-08 8.92E-08 9.00E-08	3.96E-06 4.15E-06 5.23E-06 5.96E-06 6.00E-06 6.23E-06 6.28E-06 7.17E-06 7.17E-06 7.56E-06 8.18E-06
IOBP POSITIVE REGULATION OF INTRACELLULAR_SIGNAL_TRANSDUCTION IOBP_DEVELOPMENTAL_GROWTH IOBP_ROFULATION, OF HYDROLASE_ACTIVITY IOBP_POSITIVE_REGULATION_OF_CELL_CYCLE IOBP_REGULATION_OF_TRANSPORT IOBP_ANATOMICAL_STRUCTURE_HOMEOSTASIS IOBP_CELLULAR_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY IOBP_HEART_DEVELOPMENT IOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT IOBP_REGULATION_OF_CELL_OFFERENTIATION IOBP_TRANA_METABOLIC_PROCESS IOBP_TRAVE_REGULATION_OF_DEVELOPMENTAL_PROCESS IOBP_POSITIVE_REGULATION_OF_CYSTEINULUS IOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS IOBP_POSITIVE_REGULATION_OF_CYSTEINE_TYPE_ENDOPEPTIDASE_ACTIVITY_INVOLVED_IN_APOF	70 32 86 75 35 62 39 73 67 81 20 81 68	4.22E-08 4.56E-08 4.83E-08 6.15E-08 7.02E-08 7.22E-08 7.72E-08 8.92E-08 9.00E-08 9.60E-08 1.05E-07	3.71E-00 3.96E-00 4.15E-00 5.23E-00 5.23E-00 6.00E-00 6.23E-00 6.23E-00 7.17E-00 7.17E-00 7.17E-00 8.18E-00 1.03E-00 1.03E-00 1.19E-00

Figure 110 Gene ontology analysis of genes upregulated by Mtr4 depletion

Gene ontology analysis of genes upregulated by Mtr4 depletion NIH3T3 cells by RNAseq. FDR<0.05. Relates to Figure 57. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Conos	n-valuo	FDR q-value
GOBP REGULATION OF CELL POPULATION PROLIFERATION	# Genes 65	1.56E-24	1.18E-20
GOBP_POSITIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION	45	3.79E-24	1.44E-20
GOBP_BIOLOGICAL_ADHESION	55	1.14E-23	2.89E-20
GOBP_RESPONSE_TO_CYTOKINE	47	1.43E-22	2.71E-19
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	47	5.68E-22	8.60E-19
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION	28 53	5.28E-20 3.58E-19	6.66E-17 3.88E-16
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	52	2.72E-18	2.57E-15
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	34	4.47E-18	3.76E-15
GOBP_REGULATION_OF_PHOSPHORYLATION	46	1.18E-17	8.96E-15
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	53	1.40E-17	6.84E-15
GOBP_REGULATION_OF_CELL_ADHESION	34	2.64E-17	2.13E-14
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	46	2.85E-17	2.13E-14
GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	49	7.51E-17	5.11E-14
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT GOBP_TUBE_DEVELOPMENT	41 40	9.04E-17 9.66E-17	5.56E-14 5.56E-14
GOBP_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT	40	1.53E-16	7.62E-14
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	45	1.69E-16	7.62E-14
GOBP_POSITIVE_REGULATION_OF_SIGNALING	50	1.73E-16	7.62E-14
GOBP_VASCULATURE_DEVELOPMENT	34	2.20E-16	9.14E-14
GOBP_REGULATION_OF_HYDROLASE_ACTIVITY	43	2.73E-16	1.07E-13
GOBP_REGULATION_OF_CELL_DIFFERENTIATION	48	3.11E-16	1.16E-13
GOBP_CELL_MIGRATION	47	1.00E-15	3.45E-13
GOBP_NEGATIVE_REGULATION_OF_SIGNALING GOBP_TUBE_MORPHOGENESIS	35	1.02E-15 1.91E-15	3.45E-13 5.95E-13
GOBP_LOCOMOTION	52	1.99E-15	5.95E-13
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY	38	2.11E-15	6.08E-13
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	47	5.03E-15	1.39E-12
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	43	5.60E-15	1.50E-12
GOBP_BLOOD_VESSEL_MORPHOGENESIS	30	7.52E-15	1.88E-12
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	46	8.10E-15	1.95E-12
	46	2.17E-14	5.06E-12
GOBP_NEUROGENESIS GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	45 45	2.64E-14 6.37E-14	5.98E-12 1.40E-11
GOBP_RESPONSE_TO_OXTGEN_CONTAINING_COMPOUND	45	7.46E-14	1.59E-11
GOBP_REGULATION_OF_IMMONE_STSTEM_PROCESS	33	8.48E-14	1.76E-11
GOBP_ANIMAL_ORGAN_MORPHOGENESIS	35	8.72E-14	1.76E-11
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	38	9.51E-14	1.83E-11
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	49	9.53E-14	1.83E-11
GOBP NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS	36	1.72E-13	3.21E-11
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	34	2.63E-13	4.79E-11
GOBP_RESPONSE_TO_GROWTH_FACTOR	29	3.45E-13	6.15E-11
GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	31 36	3.82E-13	6.61E-11
GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	22	3.94E-13 3.98E-13	6.61E-11 6.61E-11
GOBP_CYTOKINE_MEDIATED_SIGNALING_PATHWAY	30	6.09E-13	9.91E-11
GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS	33	1.39E-12	2.21E-10
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	41	1.46E-12	2.27E-10
GOBP_MAPK_CASCADE	31	2.81E-12	4.29E-10
GOBP_NEURON_DIFFERENTIATION	38	2.96E-12	4.43E-10
GOBP_OSSIFICATION	21	3.85E-12	5.65E-10
GOBP_IMMUNE_SYSTEM_DEVELOPMENT	32	4.45E-12	6.40E-10
GOBP_RESPONSE_TO_NITROGEN_COMPOUND GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_SYMBIOTIC_INTERACTION	34	4.85E-12 5.48E-12	6.84E-10 7.60E-10
GOBP_CELL_CELL_ADHESION	30	6.00E-12	8.17E-10
GOBP POSITIVE REGULATION OF GENE EXPRESSION	33	8.17E-12	1.09E-09
GOBP_EPITHELIAL_CELL_PROLIFERATION	21	1.44E-11	1.89E-09
GOBP_NEGATIVE_REGULATION_OF_MOLECULAR_FUNCTION	34	1.58E-11	2.04E-09
GOBP_CELL_CYCLE	44	1.64E-11	2.07E-09
GOBP_CENTRAL_NERVOUS_SYSTEM_DEVELOPMENT	31	1.73E-11	2.16E-09
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	31	1.78E-11	2.18E-09
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION GOBP_SKELETAL_SYSTEM_DEVELOPMENT	24	2.05E-11 2.13E-11	2.47E-09 2.49E-09
GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	32	2.13E-11	2.49E-09
GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	30	2.21E-11	2.54E-09
GOBP NEGATIVE REGULATION OF BIOSYNTHETIC PROCESS		3.11E-11	3.52E-09
GOBP_DEVELOPMENTAL_GROWTH	24	4.08E-11	4.56E-09
GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	43	4.59E-11	5.05E-09
	41	6.80E-11	7.37E-09
GOBP_MESENCHYME_DEVELOPMENT GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS	17	7.28E-11 7.90E-11	7.78E-09 8.33E-09
GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION	44	1.02E-10	1.05E-08
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	32	1.02E-10	1.05E-08
GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS	32	1.46E-10	1.47E-08
GOBP_APOPTOTIC_PROCESS	43	1.55E-10	1.55E-08
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	30	1.69E-10	1.67E-08
GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	31	3.24E-10	3.15E-08
GOBP_REGULATION_OF_ION_TRANSPORT	34	3.59E-10	3.44E-08
GOBP_RESPONSE_TO_BIOTIC_STIMULUS GOBP_HOMEOSTATIC_PROCESS	38	3.81E-10	3.61E-08
GOBP_HOMEOSTATIC_PROCESS GOBP_GLAND_DEVELOPMENT	42	3.92E-10 4.05E-10	3.67E-08 3.74E-08
GOBP_GLAND_DEVELOPMENT GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	29	4.05E-10 4.89E-10	4.46E-08
GOBP_RESPONSE_TO_LIPID	27	5.01E-10	4.51E-08
GOBP_TISSUE_MORPHOGENESIS	23	5.97E-10	5.32E-08
GOBP_ORGANONITROGEN_COMPOUND_BIOSYNTHETIC_PROCESS	40	6.18E-10	5.44E-08
GOBP_REGULATION_OF_CELL_CELL_ADHESION	19	1.03E-09	9.00E-08
GOBP_POSITIVE_REGULATION_OF_HYDROLASE_ACTIVITY	25	1.13E-09	9.74E-08
GOBP_PROTEIN_KINASE_B_SIGNALING	15	2.71E-09	2.30E-07
GOBP_POSITIVE_REGULATION_OF_CELL_CELL_ADHESION GOBP_RESPONSE_TO_PEPTIDE	15	3.14E-09 3.14E-09	2.61E-07 2.61E-07
GOBP_RESPONSE_TO_PEPTIDE GOBP_POSITIVE_REGULATION_OF_PROTEIN_PHOSPHORYLATION	20	3.14E-09 3.98E-09	2.61E-07 3.27E-07
GOBP REGULATION OF GROWTH	23	4.27E-09	3.43E-07
GOBP_TAXIS	22	4.27E-09	3.43E-07
GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION	22		5.73E-07
GOBP_HEART_DEVELOPMENT	20	9.08E-09	7.11E-07
GOBP POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION	12		7.11E-07
GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_B_SIGNALING	12	9.22E-09	7.11E-07
GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY	22	1.10E-08	8.42E-07
GOBP_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION GOBP_HEAD_DEVELOPMENT	14	1.31E-08	9.92E-07
	23	1.40E-08	1.05E-06

Figure 111 Gene ontology analysis of genes upregulated in response to CD,

relative to LatB-treated cells, in Mtr4-depleted dKO^{MRTF-NLS} cells

Gene ontology analysis of genes upregulated in response to CD, relative to LatBtreated cells, in Mtr4-depleted dKO^{MRTF-NLS} cells by RNAseq. FDR<0.05. Relates to Figure 62. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GO BIOLOGICAL PROCESS	# Genes	p-value	FDR q-value
GOBP REGULATION OF CELL DEATH	# Genes 23		
GOBP APOPTOTIC PROCESS	23		2.76E-12
GOBP_RESPONSE_TO_WOUNDING	16	1.10E-15	2.76E-12
GOBP_LOCOMOTION	23	1.72E-15	3.22E-12
GOBP_MUSCLE_STRUCTURE_DEVELOPMENT	15		
GOBP_CELL_POPULATION_PROLIFERATION	22		2.14E-11
GOBP_WOUND_HEALING	14		
GOBP_PROTEIN_PHOSPHORYLATION	20		5.99E-11
GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION	20		
GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT GOBP_ANATOMICAL_STRUCTURE_FORMATION_INVOLVED_IN_MORPHOGENESIS	17 5 17		
GOBP_CELL_MIGRATION	19		2.67E-10 4.18E-10
GOBP_CELL_MIGRATION GOBP_RESPONSE_TO_ENDOGENOUS_STIMULUS	19		
GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	19		6.27E-10
GOBP RESPONSE TO HORMONE	15		
GOBP REGULATION OF CELLULAR COMPONENT MOVEMENT	16		
GOBP VASCULATURE DEVELOPMENT	14		
GOBP NEGATIVE REGULATION OF SIGNALING	17		4.53E-09
GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY	15		
GOBP_ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY	15	2.86E-11	1.07E-08
GOBP_MUSCLE_ORGAN_DEVELOPMENT	10	3.51E-11	1.25E-08
GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	17	3.87E-11	1.31E-08
GOBP_MAPK_CASCADE	14	4.32E-11	1.38E-08
GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	18	4.42E-11	1.38E-08
GOBP_POSITIVE_REGULATION_OF_CELL_POPULATION_PROLIFERATION	14		1.95E-08
GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	17		2.50E-08
GOBP_ACTIN_FILAMENT_BASED_PROCESS	13		
GOBP_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS	16		2.67E-08
GOBP_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT	16		
GOBP_REGULATION_OF_PROTEIN_KINASE_ACTIVITY	13		2.67E-08
GOBP_REGULATION_OF_RESPONSE_TO_STRESS	16		
GOBP_NEGATIVE_REGULATION_OF_CELL_DEATH	14		2.99E-08
GOBP_REGULATION_OF_PROTEIN_PHOSPHORYLATION	15		
GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS	17		3.45E-08
GOBP_BIOLOGICAL_ADHESION	16		
GOBP_TUBE_DEVELOPMENT	14		8.63E-08
GOBP_RESPONSE_TO_GROWTH_FACTOR GOBP_REGULATION_OF_CELL_DIFFERENTIATION	12		1.20E-07 1.78E-07
GOBP_REGULATION_OF_CELL_DIFFERENTIATION GOBP_REGULATION_OF_WOUND_HEALING	7		
GOBP_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS			
GOBP_RESPONSE_TO_MINERALOCORTICOID	16		1.83E-07 2.01E-07
GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	15		2.06E-07
GOBP_RESPONSE_TO_STEROID_HORMONE	9		2.26E-07
GOBP_POSITIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS	13		2.37E-07
GOBP_RESPONSE_TO_ABIOTIC_STIMULUS	14		
GOBP_TAXIS	11		3.61E-07
GOBP_POSITIVE_REGULATION_OF_PROTEIN_PHOSPHORYLATION	12		
GOBP_POSITIVE_REGULATION_OF_CELL_DEATH	11		3.93E-07
GOBP_RESPONSE_TO_CORTICOSTEROID	7		
GOBP_EPITHELIUM_DEVELOPMENT	14		4.92E-07
GOBP_MUSCLE_TISSUE_DEVELOPMENT	9	3.60E-09	
GOBP_BLOOD_VESSEL_MORPHOGENESIS	11	3.73E-09	5.36E-07
GOBP_RESPONSE_TO_LIPID	12	3.92E-09	5.54E-07
GOBP_SMOOTH_MUSCLE_CELL_PROLIFERATION	7	4.25E-09	5.78E-07
GOBP_RESPONSE_TO_PEPTIDE	10	4.25E-09	5.78E-07
GOBP_REGULATION_OF_RESPONSE_TO_WOUNDING	7	4.63E-09	6.19E-07
GOBP_SUPRAMOLECULAR_FIBER_ORGANIZATION	11	6.18E-09	8.11E-07
GOBP_RESPONSE_TO_NITROGEN_COMPOUND	13		8.42E-07
GOBP_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND	12		
GOBP_EPITHELIAL_CELL_PROLIFERATION	9		1.55E-06
GOBP_POSITIVE_REGULATION_OF_LOCOMOTION	10		
GOBP_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS	16		1.63E-06
GOBP_ACTIN_FILAMENT_ORGANIZATION	9		1.64E-06
GOBP_RESPONSE_TO_PEPTIDE_HORMONE	9		1.64E-06
GOBP_RESPONSE_TO_KETONE	7		1.64E-06
GOBP_CELLULAR_RESPONSE_TO_EXTERNAL_STIMULUS GOBP_RESPONSE_TO_MECHANICAL_STIMULUS	8		1.67E-06 2.18E-06
GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	12		3.16E-06 3.64E-06
GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	7		3.99E-06
GOBP_SKELETAL_MUSCLE_CELL_DIFFERENTIATION	5		4.25E-06
GOBP_COAGULATION	8		4.37E-06
GOBP REGULATION OF BODY FLUID LEVELS	9		
GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY	10		5.20E-06
GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS	12		
GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION	12		6.47E-06
GOBP_TUBE_MORPHOGENESIS	11		6.55E-06
GOBP_REGULATION_OF_COAGULATION	5		6.55E-06
GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	9		
GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY	9		6.97E-06
GOBP_CYTOSKELETON_ORGANIZATION	13		7.24E-06
GOBP_RESPONSE_TO_OXYGEN_LEVELS	8		8.35E-06
GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS	8		
GOBP_REGULATION_OF_PROTEOLYSIS	10		9.09E-06
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING			
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II	12		1.02E-05
GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND	12		
GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT	6		1.02E-05
GOBP_RESPONSE_TO_CYTOKINE	12		
GOBP_POSITIVE_REGULATION_OF_SIGNALING	14		1.18E-05
	9		
GOBP_INFLAMMATORY_RESPONSE	10		1.39E-05
GOBP_EPITHELIAL_CELL_DIFFERENTIATION	10		
	11		1.64E-05
GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION	14	2.23E-07	
GOBP_DEFENSE_RESPONSE		0.045.05	
GOBP_DEFENSE_RESPONSE GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY	7		2.06E-05
GOBP_DEFENSE_RESPONSE GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY	7 10	2.81E-07	2.16E-05
GOBP_DEFENSE_RESPONSE GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS	7 10 12	2.81E-07 2.91E-07	2.16E-05 2.22E-05
GOBP_DEFENSE_RESPONSE GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY	7 10	2.81E-07 2.91E-07 3.17E-07	2.16E-05 2.22E-05 2.40E-05

Figure 112 Gene ontology analysis of genes active in untreated cells, relative to

LatB-treated cells, in Mtr4-depleted dKO^{MRTF-NLS} cells

Gene ontology analysis of genes active in untreated cells, relative to LatB-treated cells, in Mtr4-depleted dKO^{MRTF-NLS} cells by RNAseq. FDR<0.05. Relates to Figure 62. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.

GORP_MACL_GINUCTURE_DIVENCEMENT 10 4.16.10 1.46.10 GORP_MACL_GINUCTURE_OFFICIENCE 10 4.16.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 4.16.10 1.16.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 4.26.10 1.16.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 4.26.10 1.26.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 2.46.10 1.26.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 2.46.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 2.46.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 2.46.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 2.46.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 1.46.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 1.46.10 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 1.46.11 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 1.46.11 1.46.10 GORP_MACL_CINUCTURE_OFFICIENCE 10 1.46.11 1.46.10 <th>GO BIOLOGICAL PROCESS</th> <th># Genes</th> <th>p-value F</th> <th>DR q-value</th>	GO BIOLOGICAL PROCESS	# Genes	p-value F	DR q-value
GORP ARCHINE, PROCESS 21 8458-110.00.00.00.00.00.00.00.00.00.00.00.00.	GOBP_MUSCLE_STRUCTURE_DEVELOPMENT			1.64E-15
CORP. FEGUNES. TO FOLLATION (PROLIPERATION 20 1551-10 3775-10 CORP. FEGUNES. TO ENCOURDER. 17 446-10 1281-10 CORP. FEGUNES. TO MUNCING 17 446-10 1281-10 CORP. FEGUNES. TO MUNCING 18 286-10 488-15 488-15 CORP. FEGUNES. TO MUNCING 18 286-10 488-15 488-15 CORP. FEGUNES. TO MUNCING COMPOLING 12 476-14 488-15 488-				1.64E-15
COOP_RESPONSE_TO_DISCOGNOUS_STRUCTURE 197 7.062-16 1126-11 COOP_RESPONSE_TO_UNCNENCE 195 4.052-11 126-11 COOP_RESPONSE_TO_UNCNENCE 105 4.052-11 4.052-11 COOP_RESPONSE_TO_UNCNENCE 105 4.052-11 4.052-11 COOP_RESPONSE_TO_UNCNENCE 105 4.052-11 4.052-11 COOP_RESPONSE_TO_UNCNENCE 105 4.052-11 4.052-11 4.052-11 COOP_RESPONSE_TO_UNCNENCE 105 4.052-11				
OGP RESINCE TO JORNANCE 16 1356-15 1756-15 ORP DELLATORY SYSTEM DEVELOPMENT 16 4465-15 456-15 ORP DECLATORY SYSTEM DEVELOPMENT 16 7456-15 6156-15 ORP DECLATORY SYSTEM DEVELOPMENT 16 7456-15 6156-15 ORP DEVELLOPMENT NOVACED IN MORPHODENESS 12 2456-11 4666-15 ORP DESTINGTORY SYSTEM DEVELOPMENT 18 466-15 4566-15 ORP DESTINGTORY ON MARCE COMPANY 18 3456-13 1966-15 ORP DESTINGTORY ON MARCE COMPANY 16 646-12 2866-05 ORP DESTINGTORY ON MARCE COMPANY 16 646-12 2866-05 ORP DESTINGTORY ON MARCE COMPANY 16 646-12 2866-05 ORD POSTINGTOR COMPANY ON MARCE COMPANY 16 646-12 2866-05 ORD POSTINGTOR COMPANY ON MARCE COMPANY 16 646-12 2866-05 ORD POSTING FORDER MORPHYNY 16 1646-11 256-05 ORD POSTINGTING COMPANY 17 166-16-11 256-05 ORD POSTINGTINGTON MARCE COMPANY 16 166-16-11 <td></td> <td></td> <td></td> <td></td>				
OGP RESPONSE TO, WOUNDING 16 4485-15 4255-1 OGP RESPONSE TO, WOUNDING PORTONICO PORTOS 16 7465-16 6455-1 OORD INCOMO PLANTONICO PORTONICO PORTOS 12 4786-14 6456-1 OORD INCOMO PLANTONICO PORTONICO PORTONICO PORTOS 12 4786-14 6456-1 OORD INCOMO PLANTONICO PORTONICO P				1.70E-12
00PP CONCULATORY SYSTEM DEVELOPMENT 16 7.956-15 6.186-1 00PP ALLOCALACTORY SYSTEM DEVELOPMENT 12 4.756-14 5.956-1 00PP ALLOCALACTORY TO COVERE CONTRAINING COMPOLIDO 12 4.756-14 5.956-1 00PP ALSTONALS, TO COVERE CONTRAINING COMPOLIDO 13 5.956-1 5.956-1 00PP ADDITN PROSPECTYLATION 13 5.956-1<				4.62E-12
CORP_MATCHACL, STRUCTURE FORMATION MOULDE IN MORPHOGENESIS 16 1775-15 6.186-15 CORP_MOUND FROMMERCONTAINING COMPONIO 17 2465-13 3465-12 2465-13 3465-12 2465-13 3465-12 2465-13 3465-12 2465-13 3465-12 2465-13 3465-12 2465-13 3465-12 2465-03 345-12 2465-03 345-12 2465-03 345-13 3455-12 2465-03 345-13 3455-13 345-13 3455-13 345-13 345-13 345-13 3455-13 345-13 345-13 3455-13 345-13 3455-13 345-13 345-13 345-13 345-13 345-13 345-13 345-13 345-13 345-13 345-13 345-13 345-13 345-1				
OGP_MOUND_FEAR 14 2865-14 4865-1 OGP_DOCOMON_SCRUCTURE 2861-13 2865-13				
030P J.CONTON 21 4.796-14 5.886-13 030P J.CONTONE CONTABL CONTABL COMPOUND 10 3.866-13 3.866-13 030P J.CONTONE CONTABL CONTABL CONTABL COMPOUND 10 3.866-13 3.866-13 030P J.CONTABL CONTABL CONTABL CONTABL COMPOUND 10 5.866-13 3.866-13 030P J.CONTABL CONTABL CONTABL CONTABL COMPOUND 10 5.866-13 3.866-12 3.866-13 030P J.CONTABL CONTABL CONTABL CONTABL COMPOUND 10 13.861-11 3.566-13 3.866-14 3.866-14 3.866-14 3.866-14 3.866-14 3.866-14 3.866-11 3.866-13 3.866-13 3.866-13 3.866-13 3.866-13 3.866-13 3.866-13 3.866-13 3.866-13 <				
GORP PORTUN FROSHOOTLA TOON 198-13 198-13 198-13 198-13 GORP PORTUN FROSHOOTLAND, OR COLLAR PLACESS 11 6.05-12 298-02 GORP PORTUN FROSHOOTLAND, OF STRESS 11 6.05-12 298-02 GORP PORTUN FROSULATION OF STRESS 11 6.05-12 298-02 GORP PORTUN FROSULATION OF STRESS 10 7.32-12 298-02 GORP PORTUN FROSULATION OF STRESS 10 7.32-12 298-02 GORP REQUATION OF STRESS 10 1.46-11 352-02 GORP REQUATION OF PORTUN HOMER ACTIVITY 15 1.16-11 352-02 GORP REQUATION OF PORTUN HOMER ACTIVITY 15 1.16-11 352-02 GORP REQUATION OF PORTUN HOMER ACTIVITY 14 3.16-11 1.72-02 GORP REQUATION OF PORTUN HOMER ACTIVITY 14 3.16-11 1.72-02 GORP REQUATION OF PORTUN HOMER ACTIVITY 15 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11 3.16-11				5.98E-12
GORP POSITIVE REQUILATION OF MACLEQUAR PUNCTION 11 126-12 6.725-11 GORP POSITIVE REQUILATION OF METHING AND		19		3.40E-11
GORP_POSITIVE_REGULATION OF_PORTEN_METABOLIC_PROCESS 11 190E-12 9.455-12 2.855-02 GORP_MISCIE_CONAL DEVELOPMENT 16 0.552-12 2.855-02 GORP_MISCIE_CONAL DEVELOPMENT 16 7.825-12 2.855-02 GORP_MISCIE_CON_PERSONALING_OF_STRESS 16 7.725-12 2.855-02 GORP_MISCILLATURE_DEVELOPMENT 16 7.725-12 2.855-02 GORP_MISCILLATURE_DEVELOPMENT 16 1.125-111 3.526-02 GORP_MISCILLATURE_DEVELOPMENT 16 1.125-111 3.526-02 GORP_MISCILLATURE_DEVELOPMENT 16 3.126-11 3.526-02 GORP_MISCILLATURE_DEVELOPMENT 16 3.526-11 3.526-02 GORP_MISCILLATURE_OFENDER_SOLUTION (CPURTATION) 16 3.526-11 1.456-02 GORP_MISCILLATURE_OFENDER/SOLUTION PROCESS 16 3.526-11 1.456-02 GORP_MISCILLATURA_CONDITION PROCESS 16 3.526-11 1.456-02 GORP_MISCILLATURA_CONDITION PROLIFERATION 11 1.566-01 1.456-02 GORP_MISCILLATURA_CONDITION PROLIFERATION 15 1.566-01 1.566-01				1.99E-10
0GP_MOSCIE_ORGAN_DEVELOPMENT 10 0.10E-12 2.886-06 0GP_PORTURE_CALLATON OF MULTICELLULAR, CORMUNSAM_PROCESS 10 0.77.8-71 2.886-06 0GP_PORTURE_CALLATON OF MULTICELLULAR, CORMUNSAM_PROCESS 10 0.77.8-71 2.886-06 0GP_PORTURE_CALLATON OF MULTICELLULAR, CORMUNSAM_PROCESS 10 0.77.8-71 2.886-06 0GP_MOSCILLATON OF MULTICELLULAR, CORMUNSAM_PROCESS 11 0.161-11 3.72.6-0 0GP_PORTURE_CALLON OF TRANSPORTUNE OF MORTURE SCHUTTON 11 1.161-11 3.72.6-0 0GP_REQULATON OF TRANSPERSER_ACTIVITY 14 3.75.1-11 6.75.6-0 0GP_REQULATON OF TRANSPERSER_ACTIVITY 14 3.75.1-11 6.75.6-0 0GP_REQULATON OF CALLULAR, COMMINIAM MULTICENT 15 3.75.1-11 1.75.6-0 0GP_REQULATON OF CALLULAR, COMMINIAM MULTICENT 15 3.75.1-11 1.75.6-0 0GP_REQULATON OF CALLULAR, COMMINIAM MULTICENT 15 3.75.1-11 1.75.6-0 3.75.6-0 0GP_REQULATON OF CALLULAR, COMMINIAM MULTICENT 15 3.75.1-11 1.75.6-0 3.75.6-0 3.75.6-0 3.75.6-0 3.75.6-0 3.75.6-0 3.75.6-0 </td <td></td> <td></td> <td></td> <td>6.72E-10</td>				6.72E-10
008P POSITIVE REQUIATION OF MULTICELLURA, ORGANISMAL PROCESS 10 8.446-12 2.886-06 008P REGULATION OF RESOLUTION OF SIGNARG 10 7.726-12 2.886-06 008P REGULATION OF RESOLUTION OF RESOLUTION 10 11.161-11 3.526-06 008P REGULATION OF PROTEN NORME, TO STIRESS 10 10.161-11 3.526-06 008P REGULATION OF PROTEN NORMER ACTIONT 10 14.161-11 3.526-06 008P REGULATION OF PROTEN NORMER ACTIONT 14 3.462-11 3.526-06 008P REGULATION OF PROTEN NORMER ACTIONT 16 1.726-11 3.526-06 008P REGULATION OF PROTEN SORALING NORMENT 16 1.726-11 3.526-06 008P REGULATION OF OCCULAR ON PROTEN SORALING NORMENT 15 3.546-11 3.546-06 008P REGULATION OF OLICIALURA COMPONENTI MOVEMENT 15 3.546-11 3.546-06 008P REGULATION OF OLICIALURA COMPONENTIALUS 16 3.546-06 3.546-06 008P REGULATION OF OLICIALURA COMPONENTIALUS 16 3.546-06 3.546-06				
GORP INCENTIVE REGULATION OF SIGNALING 10 7.32-12 2.886-06 GORP INCELLATION OF INSTRUME 10 7.32-12 2.886-06 GORP INCELLATION OF INSTRUME 10 7.12-12 2.886-06 GORP INCELLATION OF INSTRUME 10 11.13-11 3.526-07 GORP INCELLATION OF INSTRUMENT 10 11.13-11 3.526-07 GORP INCELLATION OF INSTRUMENT 11 3.126-11 3.526-07 GORP INCELLATION OF INTRACELLULAR SIGNAL TRANSDUCTION 11 2.166-11 3.526-07 GORP INCELLATION OF INTRACELLULAR SIGNAL TRANSDUCTION 11 3.506-11 3.526-07 GORP INCELLATION OF INTRACELLULAR SIGNAL TRANSDUCTION 10 5.506-11 3.526-07 GORP INCELLATION OF INTRACELLULAR SIGNAL TRANSDUCTION 10 5.506-11 3.566-07 GORP INCELLATION OF INTRACELLULAR SIGNAL TRANSDUCTION 10 5.506-11 3.566-07 GORP INCELLATION OF INTRACELLATION OF RESIDENCE TO STRUMUS 10 5.506-11 3.566-07 GORP INCELLATION OF INTRACESSIDENCE TO STRUMUS 10 5.566-11 3.566-07 GORP INCELLATION OF INTRACESTRUMUS 10 <td></td> <td></td> <td></td> <td></td>				
0GP_REQUATION OF RESPONSE TO STRESS 10 1772-12 288-64 0GP_VSCULATURE DEVELOPMENT 10 10.45-11 332-60 0GP_ATTN_FLAMENT DESCONSS 10 10.45-11 332-60 0GP_ATTN_FLAMENT DESCONSS 10 10.45-11 332-60 0GP_REQUATION OF FROTTEN FORMATION 10 14.45-11 428-60 0GP_REQUATION OF TRANSFERASE ACTIVITY 10 13.15-11 837-60 0GP_REQUATION OF TRANSFERASE ACTIVITY 10 13.15-11 837-60 0GP_REQUATION OF CELLULAR COMMENTION 10 57.6-11 145.6-0 0GP_REQUATION OF CELLULAR COMMENTION 10 57.6-11 145.6-0 0GP_REQUATION OF CELLULAR COMMENTION 10 57.6-11 145.6-0 0GP_REQUATION OF CELLULAR COMMENTION 10 58.2-11 145.6-0 0GP_REQUATION OF CELLULAR COMMENTIC 10 57.6-11 145.6-0 0GP_REQUATION OF CELLULAR COMMENTIC 10 57.6-11 145.6-0 0GP_REQUATION OF CELLULER COMMENTIC 10 57.6-10 346-00 0GP_RESONE TO ANDOTO OF CELLULERATIN 17.72				
0.00P ACTIN FLAMENT BASE OFTNOCESS 13 1.041-01 3.525-05 0.00P REGULATION OF PROTEN PHOSPHORYLATION 15 1.135-11 3.525-05 0.00P REGULATION OF PROTEN PHOSPHORYLATION 15 1.135-11 3.525-05 0.00P REGULATION OF PROTEN PHOSPHORYLATION 17 1.165-11 6.275-05 0.00P REGULATION OF PHOSPHORYLAS SIGNALING PATHWAY 14 3.135-11 6.75-05 0.00P REGULATION OF CELLLARGE ORDERING TRADEOLOGING PHORESS 16 5.306-11 1.175-05 0.00P REGULATION OF PHOTEN MODERICATION PROCESS 16 8.195-11 1.185-05 0.00P REGULATION OF CHULLAR GRANIBULE DEVELOPMENT 15 8.495-11 1.185-05 0.00P REGULATION OF CHULLAR GRANIBULE DEVELOPMENT 15 8.495-11 1.885-05 0.00P REGULATION OF CHULLAR GRANIBULE DEVELOPMENT 15 8.495-11 1.885-05 0.00P REGULATION OF CHULL ROBORNEL DEVELOPMENT 15 8.495-11 1.885-05 0.00P REGULATION OF CHULL ROBORNEL DEVELOPMENT 15 3.495-01 1.885-05 0.00P REGULATION OF CHULL ROBORNEL DEVELOPMENT 15 3.495-01 3.495-01 0.00P				2.89E-09
GORP_REGULATION_OF_PROTEIN_INVASE_ACTIVITY 13 1116-11 3.526-06 GORP_REGULATION_OF_PROTEIN_INVASE_ACTIVITY 14 1.486-11 3.526-06 GORP_REGULATION_OF_PROTEIN_INVASE_ACTIVITY 14 1.486-11 3.526-06 GORP_REGULATION_OF_CLULAR_COMPONENT_MOVEMENT 14 3.366-11 1.726-06 GORP_REGULATION_OF_CLULAR_COMPONENT_MOVEMENT 16 5.706-11 1.426-06 GORP_REGULATION_OF_CHULAR_COMPONENT_MOVEMENT 16 5.706-11 1.426-06 GORP_REGULATION_OF_CHULAR_COMPONENT_MOVEMENT 15 3.546-11 1.426-06 GORP_REGULATION_OF_CHULAR_COMPONENTSIN_UNICATION 13 0.006-11 1.986-06 GORP_REGULATION_OF_CHULPPENTATION 13 0.006-11 1.986-06 GORP_REGULATION_OF_CHULPPENTATION 13 0.006-11 1.986-06 GORP_REGULATION_OF_CHULPPENTATION 13 0.006-11 1.986-06 GORP_REGULATION_OF_CHULPPENTATION 13 0.006-11 0.986-01 GORP_REGULATION_OF_CHULPPENTATION 13 0.006-11 0.986-01 GORP_REGULATION_OF_CHULPPENTATION 13 0.986-01	GOBP_VASCULATURE_DEVELOPMENT	13	9.75E-12	3.47E-09
0GBP_REGULATION_OF_PROTENN_PHOSPHORYLATION 16 1.135-11 3.525-65 0GBP_REGULATION_OF_NTRACELULAR_SIGNAL_TIMABOUCTION 17 2.165-11 4.265-65 0GBP_REGULATION_OF_PROTENN_RECENTURY 14 3.85-11 1.75-65 0GBP_REGULATION_OF_PROTENN_MODIFICATION_PROCESS 16 5.375-11 1.75-65 0GBP_REGULATION_OF_PROTENN_MODIFICATION_PROCESS 16 6.376-11 1.455-66 0GBP_REGULATION_OF_CELL_PROFENTATION 16 3.076-11 1.455-66 0GBP_REGULATION_OF_CELL_PROFENTATION 16 3.036-11 1.985-66 0GBP_REGULATION_OF_CELL_PROFENTATION 16 3.036-61 3.036-61 0GBP_RESPONSE TO_ABRODHORMONE 17 3.036-61 3.036-61 0GBP_RESPONSE TO_ABRODHORMONE 7 2.786-10 3.485-60 0GBP_RESPONSE TO_ABRODHORMONE 7 2.886-10 3.485-60 0GBP_RESPONSE TO_ABRODHORMONE 7 2.486-10 3.485-60 0GBP_RESPONSE TO_ABRODHORMONE 7 2.486-10 3.485-60 0GBP_RESPONSE TO_ABRODHORMONE 7 2.486-10 3.485-60 0				3.52E-09
CORP REGULATION OF TRANSPERSE ACTIVITY 14 4.286-05 CORP REGULATION OF TRANSPERSE ACTIVITY 47 4.286-05 CORP REGULATION OF INTRACELLING SIGNALING PATHWAY 14 3.136-11 3.136-11 CORP REGULATION OF CALL DIFFERENTIATION 16 3.766-11 1.356-01 CORP REGULATION OF CALL DIFFERENTIATION 16 3.766-11 1.356-00 CORP REGULATION OF CALL DIFFERENTIATION 16 3.766-11 1.356-00 CORP REGULATION OF CALL DIFFERENTIATION 13 3.006-11 1.356-00 CORP REGULATION OF CALL DIFFERENTIATION 13 3.006-11 1.356-00 CORP REGULATION OF CALL POPULATION PROCESS 14 1.456-00 3.466-00 CORP REGULATION OF CALL POPULATION PROCESS 14 1.456-00 3.466-00 CORP REGULATION OF CALL POPULATION PROCESS 14 3.456-00 3.466-00 CORP REGULATION OF COLL POPULATION PROCESS 14 3.456-00 3.466-00 CORP REGULATION OF CONTROLLING ON PROCESS 12 3.456-00 3.456-00 CORP REGULATION OF CONTROLLING ON PROTEIN PROCEMPROLING 12 3.456-00 3.456-00 </td <td></td> <td></td> <td></td> <td></td>				
0G8P. REGULATION OF INTRACELLULAR, GORANA, TRANSDUCTION 17 2165-11 8572-65 0G8P. EXAMEL, REDER DECENCIP, DEPOREN, SIGNAN, PARTWAY 14 318-11 8572-65 0G8P. REGULATION OF CELLURAR, COMPONENT MOVEMENT 14 438-11 1172-04 0G8P. REGULATION OF CELLURAR, COMPONENT MOVEMENT 15 8172-11 1425-05 0G8P. REGULATION OF COLD FERETURITON 15 8145-11 1456-06 0G8P. REGULATION OF MOLTIN MODIFICATION, PROCESS 16 8145-11 156-06 0G8P. REGULATION OF MULTINE, MODIFICATION, PROCESS 16 8345-11 156-06 0G8P. REGULATION OF MULTINE, MODIFICATION, PROCESS 16 8345-11 156-06 0G8P. REGULATION OF MULTINE, MODIFICATION, PROCESS 16 8345-11 156-06 0G8P. REGULATION OF COLL, DEATH 15 156-06 345-06 0G8P. REGULATION OF COLL, DEATH 16 345-06 345-06 0G8P. RESIDNER, TO JENDER MODIFICATION 12 2485-10 5466-06 0G8P. RESIDNER, TO JENDER MODIFICATION 12 2485-10 5466-06 0G8P. RESIDNER, TO JENDER MODIFICATION 17				
GOBP_EXPME_LINCED_RECEPTOR_PROTEN_SIGNALING_PATHWAY 14 313E-11 8776-05 GOBP_REGULATION_OF_CLUELAR_ORD/ENDERVICENS 16 530E-11 1376-05 GOBP_REGULATION_OF_CLUELAR_ORD/ENDERVICENS 16 530E-11 1376-05 GOBP_REGULATION_OF_PORTEN_MODIF/CATON_PROCESS 16 619E-11 1366-05 GOBP_REGULATION_OF_PORTEN_MODIF/CATON_PROCESS 16 619E-11 1366-05 GOBP_REGULATION_OF_ORDIT_NALAR_ORD/BATON_DEVICID/ENDERVICENS 16 831E-11 1366-06 GOBP_REGULATION_OF_ORDIT_STIMULUS 16 831E-11 1366-06 GOBP_REGULATION_OF_ORDITS_PHOREMULUS 16 831E-11 1366-06 GOBP_REGULATION_OF_ORDITS_PHOREMULUS 16 831E-01 1366-06 GOBP_REGULATION OF_WORDING 12 231E-10 544E-06 GOBP_REGULATION OF_ORDITEN_PHOREMORYLATION 12 231E-10 544E-06 GOBP_RESPONSE_TO_NERVINCENCENCION 12 231E-10 544E-06 GOBP_RESPONSE_TO_NERVINCENCINTON 12 231E-10 134E-01 GOBP_REGULATION OF REGULATION OF REGINERVINCENTINO 12 234E-01 <				
GGBP REGULATION OF CELLULAR, COMPONENT_MOVEMENT 14 4.396-11 1.175-04 GGBP REGULATION OF CHUCH PRENTATION 16 5.706-11 1.425-04 GGBP REGULATION OF CHUCH PRENTATION 16 5.706-11 1.425-04 GGBP REGULATION OF CHUCH PRENTATION 15 3.346-11 1.425-04 GGBP ADRIC, SCAQE 15 3.346-11 1.586-06 GGBP REGULATION OF CHUL POPULATION PROCESS 16 3.336-01 3.356-06 GGBP REGULATION OF CELL POPULATION PROLIFERATION 19 9.006-11 1.986-06 GGBP REGULATION OF CELL POPULATION PROLIFERATION 17 2.456-10 3.446-06 GGBP REGULATION OF CELL POPULATION PROLIFERATION 17 2.456-10 3.446-06 GGBP REGULATION OF CELL POPULATION 17 2.456-10 3.446-06 GGBP RESPONSE TO ANTION OF PROTEIN PHOSPHORYLATION 12 2.456-10 3.446-06 GGBP RESPONSE TO MINFRACTION OF PROTEIN PHOSPHORYLATION 13 7.276-10 3.446-07 GGBP RESPONSE TO MINFRACTION OF PROTEIN PHOSPHORYLATION 13 7.276-10 3.446-07 GGBP RESPONSE TO MINFRACTION OF PROTEIN PHOSPHORYLATION </td <td></td> <td>14</td> <td></td> <td>8.67E-09</td>		14		8.67E-09
GORP REGULATION OF CILL_DIFFERENTIATION 16 6.752-11 1.445-04 GORP MARY, GASCADE 15 6.752-11 1.445-04 GORP REGULATION, OF MULTICALLA ORGANISMAL, DEVELOPMENT 15 8.345-11 1.985-04 GORP REGULATION, OF CELL, PORTIN, MOLIFICATION 13 8.345-11 1.985-04 GORP REGULATION, OF CELL, DEPTHENTON 13 1.985-10 3.345-01 GORP RESPONSE TO, ATRICID, HORINGIE 14 1.985-10 3.345-01 GORP RESPONSE TO, MIRCALCORTODID 7 2.985-10 5.445-00 GORP RESPONSE TO, LIMIREAL/CORTODID 5 4.996-10 8.996-01 GORP RESPONSE TO, LIMIREAL/CORTODID 5 4.996-10 8.996-01 GORP RESPONSE TO, LIMIREAL/CORTODID 7 2.225-10 1.356-01 GORP RESPONSE TO, LIMIREAL/CORTODID 7 2.225-10 1.356-01 GORP RESPONSE TO, CORTODID 7 2.225-10 1.356-01 GORP RESPONSE TO, CORTODID 7 2.225-10 <td></td> <td>14</td> <td></td> <td>1.17E-08</td>		14		1.17E-08
GOBP 13 6122 11 1.456-00 GOBP REGULATION OF MULTIOELLULAR ORAANISMAL DEVELOPMENT 15 8.456-11 1.456-00 GOBP REGULATION OF AULTION FUNCTION PROJERTATION 13 0.00E-11 1.456-00 GOBP REGULATION OF AULTIOELL PORULATION PROJERTATION 13 0.00E-11 1.456-00 GOBP REGULATION OF AULTION CONTRELINGENTION 13 1.00E-10 3.456-00 GOBP REGULATION OF CILL DEATH 13 1.00E-10 3.456-00 GOBP REGULATION OF CILL DEATH 12 5.466E-10 5.466-00 GOBP REGULATION OF PROTEN PHOSPHORYLATION 12 5.466E-10 5.	GOBP_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS			1.37E-08
GOBP FEGULATION, OF PROTEIN, MODIFICATION, PROCESS 16 6.195-11 1.456-02 GOBP REGULATION, OF MULTICELLUAR, ORGANIZAL, DEVELOPMENT 15 8.345-11 1.386-04 GOBP REGULATION, OF MULTICELULAR, ORGANIZAL, DEVELOPMENT 16 9.315-11 1.386-04 GOBP REGULATION, OF CILL, PORTULATION PROLIFERATION 12 1.386-04 3.356-05 GOBP RESPONSE, TO ARDON, C. STIMULUS 16 0.325-11 1.386-04 GOBP RESPONSE, TO STERCO, PORTONE PROSPORTVLATION 12 2.385-10 5.445-07 GOBP RESPONSE, TO, UNIDO 13 5.175-10 1.386-07 3.867-10 GOBP RESPONSE, TO, UNIDO 13 5.775-10 1.386-07 3.875-10 1.386-07 GOBP RESPONSE, TO, UNIDO 13 5.775-10 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07 1.386-07				1.42E-08
GOBP REGULATION OF MULTICELULAR, ORGANISMAL, DEVELOPMENT 15 3.956-11 1.986-00 GOBP POSITIVE, REGULATION, OF REPORSE TO STIMULUS 16 9.956-11 1.986-00 GOBP REGATIVE, REGULATION, OF CELL DEVALTION 13 1.956-00 3.956-01 GOBP REGATIVE, REGULATION, OF CELL DEVALTION 13 1.956-10 3.856-00 GOBP REGULATION, OF PROTEN PROSPHORYLATION 12 2.886-10 5.486-10 GOBP REGULATION, OF PROTEN PROSPHORYLATION 12 5.486-10 5.486-10 GOBP REGULATION, OF PROTEN PROSPHORYLATION 12 5.486-10 5.486-10 GOBP REGULATION, OF PROTEN PROSPHORYLATION 12 5.486-10 5.486-10 GOBP RESPONSE, TO, INTROCEN, CONPOUND 13 7.72E-10 1.266-01 GOBP RESPONSE, TO, PROTOCENCE, CONPOUND 1 2.826-10 1.186-00 GOBP RESPONSE, TO, CONPOUND 1 2.826-10 1.486-01 GOBP RESPONSE, TO, CONPOUND 1 2.826-10 1.486-01 GOBP R				1.45E-08
GOBP POSITIVE REGULATION C FOLL POPULATION PROLIPERATION 13 9.00E7 GOBP NEGATIVE REGULATION C FREEPRONE, TO STIMULUS 14 1353-11 1395-02 GOBP NEGATIVE REGULATION C CELL DEATH 13 170E-10 3.45E-01 GOBP RESTOR REGULATION C CELL DEATH 13 170E-10 3.45E-01 GOBP RESTOR REGULATION C CELL DEATH 13 170E-10 3.45E-01 GOBP RESTORSE TO STREAD HORMONE 0 2.75E-10 5.44E-01 GOBP RESPONSE TO LINERAL OCONTICOD 12 5.96E-10 8.86E-00 GOBP RESPONSE TO LINERAL OCONTICOD 13 1.72E-10 1.24E-01 GOBP RESPONSE TO LINERAL OCONTICOD 13 1.72E-10 1.24E-01 GOBP RESPONSE TO LINERAL CONTICOD 13 1.72E-10 1.24E-01 GOBP RESPONSE TO LINERAL CONTICOD 13 2.82E-10 1.35E-01 GOBP RESPONSE TO CONTICOSTREAD 17 1.24E-01 1.35E-01 GOBP RESPONSE TO CONTICOSTREAD 17 1.24E-01 1.35E-01 GOBP RESPONSE TO CONTICOSTREAD 17 1.24E-01 1.35E-01 GOBP RESPONSE TO CONTICOSTREAD				
GORP INCATIVE REGULATION OF RESPONSE TO STIMULUS 16 1382-11 1395-00 GORP RESONSE TO ABUTICS TIMULUS 14 1638-10 3395-00 GORP RESONSE TO SETRICOL HORMONE 17 2885-10 5.445-00 GORP RESONSE TO SETRICOL HORMONE 7 2885-10 5.445-00 GORP RESONSE TO SETRICOL PORTICOLO 12 6.868-10 5.445-00 GORP RESONSE TO LINIC 13 5.145-10 5.445-00 GORP RESONSE TO LINIC 14 6.868-00 5.485-00 GORP RESONSE TO LINIC 16.868-00 8.865-00 5.145-10 8.865-00 GORP RESONSE TO CONTROCENCOMPOUND 12 5.686-10 8.865-00 5.7728-10 1.366-01 GORP RESPONSE TO CONTROCENCOMPOUND 12 8.667-10 1.366-01 1.366-01 GORP RESPONSE TO CONTROCENCOL 14 1.567-00 1.366-01 1.366-01 GORP RESPONSE TO CONTROCENCOL 14 1.366-01 1.366-01 1.366-01 GORP RESPONSE TO CONTROCENCOL 1.366-01 1.366-01 1.366-01 1.366-01 1.366-01 1.366-01				
GOBP RESPONSE TO ABIOTIC STIMULUS 141 158-10 3382-00 GOBP NEGATIVE REGULATION OF CELL DEATH 13 170E-10 544E-00 GOBP NEGATIVE REGULATION OF PROTEIN PHOSPHORYLATION 12 288E-10 548E-00 GOBP RESULTION OF PROTEIN PHOSPHORYLATION 12 588E-10 548E-00 GOBP RESONSE TO MERCINATION OF PROTEIN PHOSPHORYLATION 12 548E-00 548E-00 GOBP RESONSE TO MERCINATION OF PROTEIN PHOSPHORYLATION 12 548E-00 548E-00 GOBP RESONSE TO MERCINATION OF PROTEIN PHOSPHORYLATION 12 548E-00 548E-00 GOBP RESONSE TO MERCINATION OF PROTEIN 10 772E-10 128E-00 GOBP RESONSE TO CONTICOSTEROID 722E-10 138E-00 138E-00 GOBP RESONSE TO CONTICOSTEROID 722E-10 138E-00 138E-00 GOBP RESPONSE TO CONTICOSTEROID 722E-10 138E-00 138E-00 GOBP RESONSE TO CONTICOSTEROID 722E-10 138E-00 138E-00 GOBP RESONSE TO CONTICOSTEROID 728E-10 148E-00 138E-00 GOBP RESONSE TO CONTICOSTEROID 728E-00 138E-00				1.99E-08
GOBP_RECATIVE_REGULATION_OF_CELL_DEATH 19 376E-10 34820 GOBP_RESPONSE TO_STREOD_INDRIMONE 7 289E-10 548E-00 GOBP_REGULATION_OF_WOUND_HEALING 7 289E-10 548E-00 GOBP_RESPONSE TO_IMPERALOCORTICOD 5 689E-10 568E-10 GOBP_RESPONSE TO_IMPERALOCORTICOD 10 5 689E-10 568E-10 GOBP_RESPONSE TO_IMPERALOCORTICOD 10 772E-10 135E-10 689E-10 GOBP_RESPONSE TO_ORGANIC_CYCLIC_COMPOUND 10 772E-10 138E-01 138E-01 GOBP_RESPONSE TO_ORGANIC_CYCLIC_COMPOUND 11 132E-01 138E-01 138E-01 GOBP_RESPONSE TO_ORGANIC_CYCLIC_COMPOUND 11 132E-01 138E-01 138E-01 GOBP_SIDERAMON_ELLULAR_PRERE_TACTON 7 142E-01 138E-01 138E-01 GOBP_RESPONSE TO_GRANIC_TON_CARANTIC_ACTIVITY 14 138E-01 138E-01 138E-01 138E-01 GOBP_SIDERAMON_FREQUALATION_OF_RESPONSE TO_MONING 7 148E-01 138E-01 138E-01 GOBP_RESPONSE TO_REGULATION_OF_RESPONSE TO_MONINE 208E-01 </td <td></td> <td></td> <td></td> <td>3.39E-08</td>				3.39E-08
CORP PEGULATION OF MOUND HEALING 7 2.89E-10 5.48E-00 CORP POSITIVE REGULATION OF PHOTEIN PHOSPHORYLATION 12 2.83E-10 5.48E-00 CORP POSITIVE REGULATION OF PHOTEIN PHOSPHORYLATION 13 5.11E-10 8.89E-00 CORP RESPONSE TO LIPID 13 5.22E-10 1.34E-01 CORP TUBE DEVELOPMENT 10 7.72E-10 1.34E-01 CORP RESPONSE TO CONTOCON COMPOUND 17 1.24E-01 1.34E-01 CORP RESPONSE TO CONTOCON CONDOND 1 1.24E-01 1.34E-01 CORP RESPONSE TO CONTOCONTENCIO 7 2.24E-10 1.34E-01 CORP RESPONSE TO CONTOCONTENCIO 7 2.84E-10 1.44E-01 CORP RESPONSE TO CONTOCONTENCIO 1 1.44E-01 1.44E-01 CORP RESULTATION OF PERFORMENT 1 1.44E-01 1.44E-01 CORP RESULTATION OF PERFORMENT 1 1.44E-01 1.44E-01 CORP RESULTATION OF PERFORMENT 1 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 <t< td=""><td></td><td></td><td></td><td>3.43E-08</td></t<>				3.43E-08
GOBP POSITIVE REGULATION OF PROTEIN PHOSPHORYLATION 12 2.582-10 5.486E-10 GOBP RESPONSE TO LIPID 12 5.486E-10 8.88E-00 GOBP TUBE DEVELOPMENT 13 5.11E-10 8.88E-00 GOBP RESPONSE TO LIPID 13 5.11E-10 8.88E-00 GOBP RESPONSE TO PEPTIDE 10 7.72E-10 1.28E-01 GOBP RESPONSE TO CONTROCONTROL 13 7.72E-10 1.28E-01 GOBP RESPONSE TO CONTROCONTROL 13 7.72E-10 1.28E-01 GOBP RESPONSE TO CONTING CATALYTIC, ACTIVITY 11 1.05E-00 1.54E-01 GOBP RESPONSE TO CONTING CATALYTIC, ACTIVITY 11 1.05E-00 1.54E-01 GOBP RESOLUCATION OF PHOSPHORUS METABOLIC PROCESS 12 2.88E-00 2.88E-01 GOBP RESPONSE TO WOUNDING 9 3.38E-00 4.08E-00 2.88E-00 GOBP RESOLUCATION OF PHOSPHORUS METABOLIC PROCESS 12 4.28E-00 2.88E-00 GOBP RESPONSE TO WOUNDING 9 3.38E-00 4.08E-00 2.88E-00 GOBP RESOLUCAL ADHESION 9 3.98E-00 4.28E-00 2.88E-				5.44E-08
CORP_RESPONSE_TO_LIPIO 5 4 688E-00 8.58E-00 CORP_RESPONSE_TO_LIPIO 12 5.08E-10 8.89E-00 CORP_RESPONSE_TO_NITROCEN_COMPOUND 13 72E-10 1.24E-01 CORP_RESPONSE_TO_NITROCEN_COMPOUND 17 72E-10 1.24E-01 CORP_RESPONSE_TO_CONTICOSTERCID 9 778E-10 1.24E-01 CORP_RESPONSE_TO_CONTICOSTERCID 9 778E-10 1.36E-01 CORP_RESPONSE_TO_CONTICOSTERCID 12 867E-10 1.36E-01 CORP_RESPONSE_TO_CONTICOSTERCID 12 867E-10 1.36E-01 CORP_RESPONSE_TO_CONTIC_ACTIVITY 14 103E-01 1.45E-01 CORP_RESPONSE_TO_CONTIC_ACTIVITY 14 103E-02 1.45E-01 CORP_RESPONSE_TO_CONTIC_ACTIVITY 14 103E-02 1.45E-01 CORP_RESPONSE_TO_PERDEPTORE 12 20E-00 2.25E-01 CORP_RESPONSE_TO_PERDEPTORE 2.05E-00 2.25E-01 CORP_RESPONSE_TO_PERDEPTORE 9 30E-09 4.05E-00 CORP_RESPONSE_TO_PERDENCE 9 30E-09 4.05E-00 CORP_RESPONSE_TO_PERDENCE 7 342-09 5.05E-01 CORP_RESPONSE_TO_PERDENCE 7 342-09 5.05E-01 C				
GOBP EBSPONSE TO_LIPID 508E-10 8 89E-06 GOBP TUBE DEVELOPMENT 13 511E-10 8 89E-06 GOBP TUBE DEVELOPMENT 13 727E-10 128E-01 GOBP TESED DE DEVELOPMENT 97 778E-10 128E-01 GOBP RESPONSE TO_CORTOCOTERCIO 78 22E-10 131E-00 GOBP RESPONSE TO_CORTOCOTERCIO 78 22E-10 131E-01 GOBP RESPONSE TO_CORTOCOTENCIO 78 22E-10 131E-01 GOBP RESPONSE TO_CORTOCOTENCIO 78 22E-01 131E-01 GOBP RESPONSE TO_CONTORE CRAMUNDINO 11 12E-09 138E-01 GOBP REGULATION OF RESPONSE TO WONDINO 71 146E-09 236E-01 GOBP REGULATION OF RESPONSE TO PERDENANCIA 93 306E-04 408E-01 GOBP REGULATION OF RESPONSE TO PERDENANCIA 93 306E-04 408E-01 GOBP RESPONSE TO PERDENANCIA FINDULUS 245E-00 725E-00 725E-00 GOBP				
CORP_TUBE_DEVELOPMENT 511E-10 8.89E-06 CORP_RESPONSE_TO_IPERIODE 13 722E-10 1.32E-01 CORP_MISCLE_TISSUE_DEVELOPMENT 9 7.73E-10 1.32E-01 CORP_MISCLE_TISSUE_DEVELOPMENT 9 7.73E-10 1.32E-01 CORP_MISCLE_TISSUE_DEVELOPMENT 9 7.73E-10 1.35E-01 CORP_RESPONSE_TO_CONTICOTERCIDIO 7 8.22E-10 1.35E-01 CORP_RESPONSE_TO_CONTIC_ACTUNY 14 1.95E-01 1.35E-01 CORP_RESPONSE_TO_CONTIC_ACTUNY 14 1.95E-01 1.95E-01 CORP_RESPONSE_TO_CONTIC_ACTUNY 14 1.95E-01 1.95E-01 CORP_RESPONSE_TO_RESPONSE_TO_WOUNDING 7 1.26E-09 2.85E-01 CORP_RESPONSE_TO_PERFONSE_TO_WOUNDING 9 3.06E-09 4.96E-01 CORP_RESPONSE_TO_PERFONSE_TO_WOUNDING 9 3.06E-09 4.96E-01 CORP_RESPONSE_TO_RESPONSE_TO_WOUNDING 9 3.06E-09 4.96E-01 CORP_RESPONSE_TO_RESPONSE_TO_WOUNDING 9 3.06E-09 4.96E-01 CORP_RESPONSE_TO_RESPONSE_TO_MERESON_MOUNCATION 9 3				
GOBP RESPONSE TO NITROGEN COMPOUND 113 727E-10 124E-07 GOBP RESPONSE TO PERTOR 9773E-10 128E-07 GOBP RESPONSE TO CORTOCOSTEROID 782E-21 131E-07 GOBP RESPONSE TO CORTOCOSTEROID 782E-21 131E-07 GOBP RESPONSE TO CORTOCOSTEROID 128E-07 132E-07 GOBP SUFRANCE CLUAR, FREE ORGANIZATION 11 125E-09 GOBP SUFRANCE TO AND CLUAR, FREE ORGANIZATION 11 125E-09 GOBP SUFTIC REGULATION OF CATAVITIC, ACTIVITY 14 104E-09 135E-07 GOBP SUFTIC REGULATION OF CATAVITIC, ACTIVITY 14 104E-09 135E-07 GOBP SUFTIC REGULATION OF CATAVITIC, ACTIVITY 14 126E-09 235E-07 GOBP ACCINT, FLANDER TO WOUNDING 7 140E-09 135E-07 GOBP ACCINT, FLANDER TO ROMONES TO WOUNDING 7 140E-09 235E-07 GOBP ACCINT, FLANDER TO ROMONES TO WOUNDING 7 140E-09 245E-07 GOBP ACCINT, FLANDER TO ROMONES TO WOUNDING 8 30E-09 245E-07 GOBP ACCINT, FLANDER TO ROMONES TO WOUNDING 8 30E-09 30E-09				
GOBP_RESPONSE_TO_CPEPTOE 10 7.72E-10 1.26E-00 GOBP_MUSCLE_TISSUE_DEVELOPMENT 9 7.73E-10 1.26E-00 GOBP_RESPONSE_TO_CORRICO_CYCLE_COMPOUND 12 8.75E-10 1.35E-00 GOBP_RESPONSE_TO_CORRUCA_COMPOUND 12 8.75E-10 1.35E-00 GOBP_SOURCE_COULAR_FIBER_ORGANIZATION 11 1.27E-09 1.85E-00 GOBP_RESPONSE_TO_GROWTH_FACTOR 11 1.27E-09 1.85E-00 GOBP_RESPONSE_TO_GROWTH_FACTOR 11 1.27E-09 1.85E-00 GOBP_REGULATION_OF_PROSPHORUS_METABOLIC_PROCESS 12 2.09E-09 2.85E-00 GOBP_RESPONSE_TO_PEPTOE HORMONE 8 3.09E-09 4.06E-01 GOBP_RESPONSE_TO_REPTOE HORMONE 8 3.09E-09 4.06E-01 GOBP_RESPONSE_TO_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 12 4.25E-09 5.65E-01 GOBP_RESPONSE_TO_OREGULATION_OF_PROTEIN_METABOLIC_PROCESS 12 8.25E-09 7.29E-09 GOBP_RESPONSE_TO_OREGULATION_OF_PROTEIN_METABOLIC_PROCESS 12 8.25E-09 7.29E-09 GOBP_RESPONSE_TO_OREGULATION_OF_PROTEIN_METABOLIC_PROCESS 12 8.25E-09<				1.24E-07
GOBP RESPONSE TO CORRICOSTEROID 7 8.22E-10 1.31E-07 GOBP RESPONSE TO CORRICE (VCUC COMPOUND 12 8.87E-10 1.35E-07 GOBP SUPRAMOLECULAR, FIBER, ORGANIZATION 14 9.52E-10 1.35E-07 GOBP SUPRAMOLECULAR, FIBER, ORGANIZATION 14 9.52E-10 1.35E-07 GOBP PASITIVE, REGULATION OF CATAL YTC ACTIVITY 14 1.32E-09 1.85E-07 GOBP SINCET, REGULATION OF CATAL YTC ACTIVITY 14 1.40E-09 1.85E-07 GOBP PASITIVE, REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 2.09E-09 2.85E-07 GOBP POSITIVE, REGULATION OF PHOTEN MODIFICATION PROCESS 12 2.42E-09 5.63E-07 GOBP PASITIVE, REGULATION OF PROTEIN MODIFICATION PROCESS 12 8.27E-09 4.08E-07 GOBP PASITIVE, REGULATION OF PROTEIN METABOLIC, PROCESS 12 8.27E-09 7.62E-09 GOBP PASITIVE, REGULATION OF PROTEIN METABOLIC, PROCESS 12 8.27E-09 7.63E-09 GOBP PASITIVE, REGULATION OF PROTEIN METABOLIC, PROCESS 15 8.35E-09 7.62E-09 GOBP PASITIVE, REGULATION OF PROTEIN METABOLIC, PROCESS 15 8.35E-09 7.62E-09 </td <td>GOBP_RESPONSE_TO_PEPTIDE</td> <td>10</td> <td>7.72E-10</td> <td>1.26E-07</td>	GOBP_RESPONSE_TO_PEPTIDE	10	7.72E-10	1.26E-07
GOBP RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND 11 28.67E-10 1.45E-03 GOBP SURANUCEOULAR_IRER_ORGANIZATION 11 1.45E-03 1.45E-03 GOBP POSITIVE_REGULATION OF_CATALYTIC_ACTIVITY 11 1.27E-03 1.85E-03 GOBP RESIDUADICE_CELL_PROLIFERATION 7 1.28E-09 1.85E-03 GOBP REGULATION OF_RESPONSE TO_WONDING 7 1.40E-03 1.97E-03 GOBP REGULATION OF_RESPONSE TO_WONDING 7 1.40E-03 1.97E-03 GOBP REGULATION OF_RESPONSE TO_WONDING 9 3.03E-09 4.05E-03 GOBP COBP COBP.POSITIVE REGULATION OF PHORING MATION 9 3.03E-09 4.05E-03 GOBP COBP.RESPONSE TO_VECTORE 7 4.42E-09 5.63E-01 GOBP COBP.RESPONSE TO_VECTORE 7 4.42E-09 5.63E-01 GOBP COBP.RESPONSE TO_VECTORE 7 4.42E-09 5.63E-01 GOBP COBP.RESPONSE TO_VECTORE 10 6.67E-09 7.22E-03 7.62E-03 GOBP ROSTIVE, REGUL		-		1.26E-07
GOBP_SUPRAMOLECULAR, FIBER_ORGANIZATION 11 9.52E-10 1.45E-00 GOBP_POSITIVE_REGULATION OF_CATATYTY 14 1.03E-00 1.85E-00 GOBP_MINDELC_ELL_PROLIFERATION 7 1.40E-09 1.97E-00 GOBP_MINDELL_PROLIFERATION 7 1.40E-09 1.97E-00 GOBP_MINDELQUATION OF_RESPONSE_TO_WOUNDING 7 1.40E-09 9.85E-00 GOBP_MINDELQUATION OF_RESPONSE_TO_WOUNDING 7 1.40E-09 9.85E-00 GOBP_POSITIVE_REGULATION OF_PHOSPHORUS_METADOLIC_PROCESS 9 3.03E-00 4.06E-00 GOBP_DESPONSE_TO_EXTERNAL_STIMULUS 8 3.79E-00 4.84E-00 5.50E-00 GOBP_POSITIVE_REGULATION OF_PROTEIN_MODIFICATION_PROCESS 12 4.22E-00 6.76E-00 GOBP_NEGATIVE_REGULATION OF_PROTEIN_METABOLIC_PROCESS 12 8.95E-00 7.29E-00 GOBP_NEGATIVE_REGULATION OF_PROTEIN_METABOLIC_PROCESS 12 8.95E-00 7.29E-00 GOBP_NEGATIVE_REGULATION OF_PROTEIN_METABOLIC_PROCESS 16 8.95E-00 7.29E-00 GOBP_NEGATIVE_REGULATION OF_PROTEIN_MINTELC_PROCESS 16 8.95E-00 7.29E-00 GOBP_DESTIVE_RE				
GOBP. POSITIVE, REGULATION, OF_CATALYTIC, ACTIVITY 14 1.08E-09 1.54E-09 GOBP. RESPONSE TO, GOWINF FACTOR 11 1.27E-09 1.88E-07 GOBP. RESOLATION, OF, RESPONSE, TO, WOUNDING 7 1.28E-09 1.88E-07 GOBP. PAGULATION, OF, RESPONSE, TO, WOUNDING 7 1.28E-09 2.85E-07 GOBP. ACTIVITY 6000 ACTIVITY 9 3.03E-09 4.05E-09 GOBP. ACTIVITY 6000 ACTIVITY 9 3.03E-09 4.05E-09 GOBP. ACTIVITY 6000 ACTIVITY 9 3.03E-09 4.05E-09 GOBP. ACTIVITY RESONSE, TO, EXTONDE 9 3.03E-09 4.05E-09 GOBP. RESPONSE, TO, EXTORE 7 5.95E-09 7.29E-00 6.50E-01 GOBP. POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 12 4.22E-09 6.53E-09 7.29E-01 GOBP. POSITIVE REGULATION OF, ROTEIN METABOLIC, PROCESS 15 8.35E-09 7.9E-01 7.9E-01 GOBP. RESOLATION, OF, BODY FLUID, LEVELS 9 1.9EE-08 1.9E-08 1.29E-08 GOBP. COSTIVE, REGULATION, OF, SIOXALINO 14 1.44E-08<				
GOBP RESPONSE TO, GROWTH FACTOR 11 127E-09 1.85E-07 GOBP SMOOTH, MUSCLE CELL PROLIFERATION 71 1.25E-09 1.85E-07 GOBP DEGULATION OF RESPONSE TO WOUNDING 71 1.26E-09 2.85E-01 GOBP DOSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 2.09E-09 2.85E-01 GOBP COSTIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 9 3.09E-09 4.86E-01 GOBP CELLULAR RESPONSE TO PETTIE HORMONE 9 3.09E-09 4.86E-01 GOBP CELLULAR RESPONSE TO PETTIEN MODIFICATION PROCESS 12 4.52E-09 6.55E-01 GOBP POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 12 4.52E-09 6.56E-01 GOBP POSITIVE REGULATION OF COREIN METABOLIC PROCESS 12 4.52E-09 6.56E-01 GOBP POSITIVE REGULATION OF COREIN METABOLIC PROCESS 12 8.25E-09 7.75E-09 GOBP POSITIVE REGULATION OF COREIN METABOLIC PROCESS 16 8.35E-09 7.76E-01 GOBP POSITIVE REGULATION OF GOSINTHETIC PROCESS 16 8.35E-09 7.76E-01 GOBP COSTINGKELTON OF GOSINALING 10 9.37E-09 1.06E-06 1.22E-06				
GOBP SMOOTH_MUSCLE_CELL_PROLIFERATION 7 128E-09 188E-00 GOBP REGULATION OF RESPONSE TO WOUNDING 7 140E-09 285E-01 GOBP DEGULGICAL_ADHESION 14 208E-09 285E-01 GOBP ACTIN, FLAMENT, ORGANIZATION 9 303E-09 405E-01 GOBP POSITIVE REGULATION OF PROTEIN MODIFICATION_PROCESS 12 422E-09 558E-00 GOBP POSITIVE REGULATION OF CELL DEATH 10 657E-08 7.92E-01 GOBP POSITIVE REGULATION OF CELL DEATH 10 6.57E-08 7.92E-01 GOBP POSITIVE REGULATION OF ROTEIN METABOLIC_PROCESS 15 8.35E-08 7.92E-01 GOBP POSITIVE REGULATION OF ROTEIN METABOLIC_PROCESS 10 8.97EE-01 10.92E-08 GOBP POSITIVE REGULATION OF SIONALING 11 14.92E-08 1.92E-08 GOBP COSITIVE REGULATION OF SIONALING 10.92E-08 1.02E-06 1.02E-06				
GORP BIOLOGICAL ADHESION 141 2.085-03 GORP POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 2.085-03 GORP ACTIN FLAMENT, ORGANIZATION 9 3.035-09 4.055-03 GORP ADSPONSE TO PERTORE HORMONE 9 3.095-09 4.055-03 GORP RESPONSE TO, EXTERNAL STIMULUS 8 3.795-09 4.985-03 GORP RESPONSE TO, MECHANICAL STIMULUS 7 4.945-09 5.636-03 GORP RESPONSE TO, MECHANICAL STIMULUS 7 5.995-09 7.295-07 GORP NOSTITVE, REGULATION OF PROTEIN METABOLIC_PROCESS 12 8.255-09 9.765-07 GORP NEGATIVE, REGULATION OF PROTEIN METABOLIC_PROCESS 13 9.155-09 1.085-06 GORP NEGATIVE, REGULATION OF BORY FLUTHETIC PROCESS 10 9.765-07 1.085-06 1.205-06 GORP REGULATION, OF, BORY FLUTHETIC PROCESS 10 9.1086-08 1.205-06 1.005-08 1.006-08 1.206-06 1.205-06 1.006-08 1.205-06 1.006-08 1.205-06 1.205-06 1.205-06 1.205-06 1.205-06 1.205-06 1.205-06 1.205-06 1.205-06 1		7		1.85E-07
GOBP POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 209E-09 258E-07 GOBP ACTIN FLAMENT, ORANIZATION 9 303E-09 405E-07 GOBP RESPONSE TO PETIDE HORMONE 9 303E-09 405E-07 GOBP RESPONSE TO PETIDE HORMONE 9 303E-09 4.89E-07 GOBP RESPONSE TO DECTORE 7 4.34E-09 5.55E-07 GOBP POSITIVE, REGULATION OF PROTEIN MODIFICATION PROCESS 12 4.52E-09 7.59E-07 GOBP POSITIVE, REGULATION OF CELL DEATH 10 6.57E-09 7.79E-07 GOBP POSITIVE, REGULATION OF BIOSYNTHETIC PROCESS 12 8.29E-09 9.76E-07 GOBP POSITIVE, REGULATION OF BIOSYNTHETIC PROCESS 10 9.37E-00 1.06E-00 GOBP POSITIVE, REGULATION OF BIOSYNTHETIC PROCESS 10 9.37E-00 1.06E-00 GOBP POSITIVE, REGULATION OF SIGNALIZATION 11 1.48E-01 1.20E-00 GOBP POSITIVE, REGULATION OF SIGNALIZATION 1.09E-08 1.20E-06 1.20E-06 GOBP MOSITIVE, REGULATION OF SIGNALINGA 1 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.44E-01 1.20E-06	GOBP_REGULATION_OF_RESPONSE_TO_WOUNDING	7	1.40E-09	1.97E-07
GOBP ACTIN FILAMENT, ORGANIZATION 9 3082-09 4.06E-07 GOBP RESPONSE TO PERTORE 9 3082-09 4.06E-07 GOBP CELULAR RESPONSE TO EXTERNAL STIMULUS 8 3.79E-09 4.38E-00 GOBP RESPONSE TO KERONE 7 4.34E-09 5.68E-07 GOBP RESPONSE TO MECHANICAL STIMULUS 7 5.98E-09 7.29E-07 GOBP NESTORE REGULATION OF PROTEIN METABOLIC PROCESS 12 4.52E-09 9.76E-07 GOBP NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 12 8.29E-09 9.76E-07 GOBP NEGATIVE REGULATION OF BOOTY FLUID LEVELS 9 1.09E-08 1.20E-06 GOBP NOSITIVE REGULATION OF BOOTY FLUID LEVELS 9 1.09E-08 1.20E-06 GOBP NUSCLE CELL PROLIFERATION 1 1.44E-08 1.24E-06 GOBP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP RESONSE TO CYTOKINE 1.09E-08 1.72E-06				2.85E-07
GOBP RESPONSE TO PERTURE HORMONE 9 3.09E-09 4.08E-07 GORP CELLULAR RESPONSE TO XETRAL STIMULUS 8 3.79E-09 4.89E-07 GORP RESPONSE TO XETONE 7 4.34E-09 5.63E-07 GORP RESPONSE TO MECHANICAL STIMULUS 7 5.95E-09 7.29E-07 GORP RESPONSE TO MECHANICAL STIMULUS 7 5.95E-09 7.29E-07 GORP POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 18 6.57E-09 7.29E-07 GORP POSITIVE REGULATION OF BORSYNTHETIC PROCESS 15 8.35E-09 9.76E-07 GORP CONSULTION OF DOV FLUID LEVELS 9 1.09E-08 1.20E-09 GORP COAGULATION OF BORY FLUID LEVELS 9 1.09E-08 1.20E-00 GORP COAGULATION OF PROTEIN KINASE ACTIVITY 9 1.56E-08 1.72E-00 GORP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.56E-08 1.72E-00 GORP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.56E-08 1.72E-00 GORP REGULATION OF PROTEIN KINASE ACTIVITY 9 1.56E-08 1.72E-00 GORP REGULATION OF PROTEIN KINASE ACTIVITY 9 1.56E-08 </td <td></td> <td></td> <td></td> <td></td>				
GORP CELLULAR RESPONSE TO EXTERNAL STIMULUS 8 378E-09 4.48E-09 GORP RESPONSE TO VERCHANICAL STIMULUS 7 535E-09 7.29E-01 GORP RESPONSE TO MECHANICAL STIMULUS 7 535E-09 7.29E-01 GORP RESPONSE TO MECHANICAL STIMULUS 7 535E-09 7.29E-01 GORP NEGATIVE REGULATION OF CELL DEATH 10 657E-09 7.29E-01 GORP NEGATIVE REGULATION OF DROTEIN METADOLIC PROCESS 12 8.29E-09 9.76E-01 GORP CYTOSKELETON, ORGANIZATION 13 9.15E-09 1.09E-08 1.09E-08 1.09E-08 1.09E-08 1.20E-06 00BP COBP CAGULATION, OF BIODY FLUID LEVELS 9 1.09E-08 1.20E-06 00BP 00BP CAGULATION, OF SIGNALING 1.14E-08 1.24E-06 1.24E-06 0.24E-08 1.20E-06 00BP 0.00E-00 00BC CAGULATION, OF SIGNALING 1.12E-06 1.72E-06 0.77E-06 0.24E-08 1.22E-06 1.72E-06 0.77E-06 0.24E-08 1.22E-06 1.72E-06 0.77E-06 00BP REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 0.77E-06 0.29E-09E-10		-		
GOBP_RESPONSE_TO_VETONE 7 4.34E-09 5.50E-07 GORP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS 12 4.52E-09 5.63E-07 GOBP_RESPONSE_TO_MECHANICAL_STIMULUS 7 595E-09 7.29E-01 GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 12 8.29E-09 9.76E-07 GOBP_POSITIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS 13 9.15E-09 1.09E-06 GOBP_CONSELETON_ORGANIZATION 13 9.15E-09 1.09E-06 GOBP_REGULATION_OF_PROTEINSIS 10 9.37E-09 1.09E-06 GOBP_COAGULATION_OF_OPOLIFEATION 8 1.09E-08 1.20E-06 GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.66E-08 1.72E-06 GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.66E-08 1.72E-06 GOBP_REGULATION OF_PROTEIN_KINASE_ACTIVITY 9 1.66E-08 1.72E-08 GOBP_REGULATION OF_PROTEIN_KINASE_ACTIVITY 9 1.66E-08 1.72E-08 GOBP_REGULATION OF_PROTEIN_KINASE_ACTIVITY 9 1.66E-08 1.72E-08 GOBP_REGULATION OF_COCKINE 2 1.72E-08				
GOBP RESPONSE TO, MECHANICAL STIMULUS 7 5.95E-09 7.29E-07 GOBP POSITIVE REGULATION OF CALL DEATH 10 6.87E-09 7.92E-07 GOBP NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 12 8.29E-09 9.76E-07 GOBP POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 15 8.35E-09 1.05E-06 GOBP COTOSKELETON_ORGANIZATION 13 9.37E-09 1.06E-06 GOBP REGULATION OF BIOSYNTHETIC PROCESS 9 1.09E-08 1.20E-06 GOBP REGULATION OF DOLY FLUID LEVELS 9 1.09E-08 1.20E-06 GOBP NUSCLE CELL PROLIFERATION 7 1.14E-08 1.24E-00 GOBP POSITIVE REGULATION OF SIGNALING 7 1.44E-08 1.24E-00 GOBP POSITIVE REGULATION OF SIGNALING COMPOUND 12 1.65E-08 1.72E-06 GOBP RESEDING FO OXYGEN CONTAINING COMPOUND 12 1.75E-08 1.77E-06 GOBP RESPONSE TO OXYGEN LEVELS 8 2.39E-08 2.35E-00 GOBP REGULATION OF CATIN FILAMENT BASED PROCESS 8 2.38E-08 2.38E-08 GOBP REGULATION OF COAGULATION OF CATAL PROCESS 8 2.38E-08		7		5.50E-07
GOBP POSITIVE REGULATION, OF CELL DEATH 10 657E-09 7.92E-07 GOBP NEGATIVE REGULATION, OF BIOSYNTHETIC PROCESS 12 8.29E-09 9.76E-07 GOBP POSITIVE REGULATION, OF BIOSYNTHETIC PROCESS 13 9.15E-09 9.76E-07 GOBP CYTOSKELETON_ORGANIZATION 13 9.15E-09 1.08E-06 GOBP REOULATION, OF BODY FLUID LEVELS 9 1.09E-06 1.20E-06 GOBP POSITIVE REGULATION OF SIGNALING 7 1.44E-08 1.24E-07 GOBP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP CELLULAR RESPONSE TO CAYGEN CONTAINING COMPOUND 12 1.66E-08 1.72E-06 GOBP REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.77E-06 GOBP REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.77E-06 GOBP REGULATION OF PROTEOLYSIS 10 1.93E-08 1.72E-06 GOBP REGULATION OF CACHUNSIS 10 1.93E-08 2.39E-08	GOBP_POSITIVE_REGULATION_OF_PROTEIN_MODIFICATION_PROCESS	12	4.52E-09	5.63E-07
GOBP, NEGATIVE, REGULATION, OF, PROTEIN, METABOLIC, PROCESS 12 8.29E-09 9.76E-03 GOBP, POSITIVE, REGULATION, OF, BIOSYNTHETIC, PROCESS 15 8.35E-09 1.05E-00 GOBP, DODV VESSEL, MORPHOGENESIS 10 9.37E-09 1.06E-06 GOBP, CAGULATION, OF, BIOSYNTHETIC, PROCESS 9 1.09E-08 1.20E-06 GOBP, CAGULATION, OF, SIGNALING 10 9.37E-09 1.00E-06 GOBP, CAGULATION, OF, SIGNALING 14 1.44E-08 1.20E-06 GOBP, POSITIVE, REGULATION, OF, SIGNALING, COMPOUND 11 1.44E-08 1.54E-08 GOBP, POSITIVE, REGULATION, OF, PROTEIN, KINASE, ACTIVITY 9 1.65E-08 1.72E-06 GOBP, SELD, CYTOKINE 1.72E-06 1.77E-06 GOBP, REGULATION, OF, PROTEIN, KINASE, ACTIVITY 9 1.65E-08 1.72E-06 GOBP, RESUDASE, TO, CYTOKINE 12 1.75E-08 1.77E-06 GOBP, REGULATION, OF, PROTEIN, KINASE, ACTIVITY 1 1.93E-08 1.93E-08 1.93E-08 1.93E-08 1.93E-08 1.93E-08 1.93E-08 1.93E-08 1.93E-08 1.92E-06 COBOP, CONSTULAR, RESPONSE, TO, CYTOKINE 1 1.93E-08 <td></td> <td></td> <td></td> <td>7.29E-07</td>				7.29E-07
GOEP POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 15 8.35E-09 9.76E-07 GOBP CYTOSKELETON ORGANIZATION 13 9.15E-09 1.05E-00 GOBP RECULATION OF BODY FLUID LEVELS 9 1.99E-08 1.20E-00 GOBP NUSCLE CELL PROLIFERATION 8 1.09E-08 1.20E-00 GOBP POSITIVE REGULATION OF SIGNALING 14 1.44E-08 1.34E-08 GOBP POSITIVE REGULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-00 GOBP CALLULAR, RESPONSE TO OXIGEN CONTAINING COMPOUND 12 1.66E-08 1.72E-06 GOBP REQUATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP RESULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP RESULATION OF PROTEIN KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP RESULATION OF COLLOPINS 10 1.93E-08 1.92E-08 GOBP RESULATION OF ACTIN KINASE ACTIVITY 8 2.39E-08 2.39E-08 GOBP RESULATION OF ACTIN KINASE ACTIVITY 1 1.93E-08 1.93E-08 GOBP RESULATION OF ACTIN KINASE ACTIVITY 1 1.93E-08				
GOBP EVTOSKELETON_ORGANIZATION 13 9.15E-09 1.05E-06 GOBP BLOOD_VESSEL_MORPHOGENESIS 10 9.37E-09 1.06E-06 GOBP REGULATION_OF_BODY_FLUID_LEVELS 9 1.06E-06 1.20E-06 GOBP PCOLLATION_OF_SIGNALING 8 1.09E-08 1.20E-06 GOBP POSITIVE_REGULATION_OF_SIGNALING 7 1.44E-08 1.24E-06 GOBP POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.65E-08 1.72E-06 GOBP POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.65E-08 1.72E-06 GOBP SKELETAL_MUSCLE_CELL DIFFERENTIATION 5 1.72E-08 1.77E-06 GOBP RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 10 1.93E-08 2.36E-06 GOBP RESULATION_OF_PROTEOLYSIS 10 1.93E-08 2.36E-06 GOBP REGULATION_OF_COAGULATION 13 3.06E-06 3.66E-06 GOBP REGULATION_OF_COAGULATION 13 3.06E-06 3.66E-06 GOBP REGULATION_OF_COAGULATION 13				
GOBP BLOOD VESSEL MORPHOGENESIS 10 9.37E-09 1.06E-06 GOBP REGULATION_OF BODY_FLUID_LEVELS 9 1.09E-08 1.20E-06 GOBP_CAQULATION 8 1.09E-08 1.20E-06 GOBP_MUSCLE_CELL_PROLIFERATION 7 1.14E-08 1.54E-06 GOBP_POSITIVE_REGULATION_OF_SIGNALING 14 1.44E-08 1.54E-06 GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.65E-08 1.72E-06 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 12 1.66E-08 1.72E-08 GOBP_RESPONSE_TO_CYTOKINE 12 1.77E-06 1.77E-06 GOBP_REGULATION_OF_ROTEOLYSIS 10 1.93E-08 1.93E-08 1.93E-08 1.93E-08 GOBP_REGULATION_OF_ACTNRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-08 3.66E-06 GOBP_REGULATION_OF_ACTNRACELLULAR_SIGNAL_TRANSDUCTION 13 3.36E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENT 12 3.80E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.75E-08 GOBP_REGULATION_OF_CELL_DROLIFERATIATION				
GOBP REGULATION OF BODY FLUID_LEVELS 9 1.09E-08 1.20E-06 GOBP COACULATION 8 1.09E-08 1.20E-06 GOBP MUSCLE_CELL_PROLIFERATION 7 1.14E-08 1.24E-06 GOBP POSITIVE_REGULATION_OF_SIGNALING 14 1.44E-08 1.24E-06 GOBP_OSITIVE_REGULATION_OF_SOTEIN_KINASE_ACTIVITY 9 1.65E-08 1.72E-06 GOBP_SKELETAL_MUSCLE_CELL DIFFERENTATION 5 1.72E-06 1.77E-06 GOBP_RESPONSE_TO_CYTOKINE 12 1.75E-08 1.77E-06 GOBP_REGULATION OF_PROTEOLYSIS 10 1.93E-08 2.35E-06 GOBP_REGULATION OF_ACTIN FILAMENT BASED PROCESS 8 2.39E-08 2.35E-06 GOBP_REGULATION OF_CONGULATION 11 3.36E-08 3.19E-06 GOBP_REGULATION OF_CONGULATION 12 3.86E-06 3.56E-06 GOBP_POSITIVE_REGULATION OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-06 3.66E-06 GOBP_POSITIVE_REGULATION OF_DEVELOPMENT 12 3.86E-06 3.66E-06 GOBP_POSITIVE_REGULATION OF_CATALYTIC_ACTIVITY 14 4.58E-08 4.06E-06 GOBP_POSITIVE_REGULATION				
GOBP_COAGULATION 8 1.09E-08 1.20E-00 GOBP_MUSCLE_CELL_PROLIFERATION 7 1.14E-08 1.24E-00 GOBP_POSITIVE_REGULATION_OF_SIGNALING 114 1.44E-08 1.54E-00 GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.65E-08 1.72E-00 GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 12 1.66E-08 1.77E-00 GOBP_RESPONSE_TO_CYTOKINE 12 1.75E-00 1.77E-00 GOBP_RESPONSE_TO_CYTOKINE 12 1.75E-00 1.77E-00 GOBP_REGULATION_OF_PROTEOLYSIS 10 1.93E-08 1.93E-08 GOBP_REGULATION OF ACTIN_FILAMENT BASED_PROCESS 8 2.46E-00 2.56E-00 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-00 3.36E-00 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENT 12 3.06E-00 3.56E-00 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.75E-00 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-00 4.06E-00 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-00				1.20E-06
GOBP_POSITIVE_REGULATION_OF_SIGNALING 14 1.44E-08 1.54E-06 GOBP_POSITIVE_REGULATION_OF_PROTEIN_KINASE_ACTIVITY 9 1.55E-08 1.72E-06 GOBP_COLLULAR_RESPONSE_TO_CVYGEN_CONTAINING_COMPOUND 12 1.66E-08 1.72E-06 GOBP_RESPONSE_TO_CVYGEN_CONTAINING_COMPOUND 5 1.72E-08 1.77E-06 GOBP_RESPONSE_TO_CVYGEN_LEVELS 12 1.56E-08 1.77E-06 GOBP_REGULATION OF PROTEOL/SIS 10 1.93E-08 2.35E-06 GOBP_REGULATION OF ACTIN FILAMENT BASED PROCESS 8 2.39E-08 2.35E-06 GOBP_REGULATION OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-06 3.66E-06 GOBP_POSITIVE_REGULATION OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-06 3.66E-06 GOBP_POSITIVE_REGULATION OF_OPMENT 12 3.06E-06 3.66E-06 GOBP_POSITIVE_REGULATION OF_LOCOMOTION 9 3.96E-08 3.66E-06 GOBP_POSITIVE_REGULATION OF_LOCOMOTION 9 3.96E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 14 4.45E-08 4.08E-06 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY	GOBP_COAGULATION			1.20E-06
GOBP POSITIVE REGULATION OF PROTEIN, KINASE ACTIVITY 9 1.65E-08 1.72E-06 GOBP CELLULAR, RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND 12 1.66E-08 1.72E-06 GOBP SELETAL_MUSCLE_CELL_DIFFERENTIATION 5 1.72E-08 1.77E-06 GOBP REGULATION OF_PROTEOLYSIS 10 1.93E-08 1.93E-08 GOBP REGULATION OF_OXGEN_LEVELS 8 2.39E-08 2.35E-06 GOBP REGULATION OF ACTIN FILAMENT BASED PROCESS 8 2.46E-08 2.66E-06 GOBP PREGULATION OF ACTIN FILAMENT BASED PROCESS 8 2.46E-08 2.66E-06 GOBP POSITIVE REGULATION OF LOCOMOTION 11 3.36E-08 3.19E-06 GOBP POSITIVE REGULATION OF LOCOMOTION 9 3.96E-08 3.66E-06 GOBP POSITIVE REGULATION OF COCOMOTION 9 3.96E-08 3.66E-06 GOBP POSITIVE REGULATION OF CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP SOBLATION OF CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06				1.24E-06
GOBP CELLULAR RESPONSE TO_OXYGEN_CONTAINING_COMPOUND 12 1.66E-08 1.77E-06 GOBP SKELETAL_MUSCLE_CELL DIFFERENTATION 5 1.72E-08 1.77E-06 GOBP RESPONSE_TO_CYTOKINE 12 1.75E-08 1.77E-06 GOBP RESPONSE_TO_CYTOKINE 12 1.75E-08 1.33E-06 GOBP RESPONSE_TO_CYTOKINE 8 2.39E-08 2.35E-06 GOBP RESPONSE_TO_CYTOKINE 8 2.39E-08 2.35E-06 GOBP REGULATION OF ACTIN FILAMENT BASED PROCESS 8 2.46E-08 2.56E-06 GOBP POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 11 3.36E-08 3.56E-06 GOBP POSITIVE REGULATION OF LOCOMOTION 9 3.96E-06 3.66E-06 GOBP POSITIVE REGULATION OF LOCOMOTION 9 3.66E-06 3.66E-06 GOBP POSITIVE REGULATION OF LOCOMOTION 9 3.96E-06 3.66E-06 GOBP POSITIVE REGULATION OF CATALYTIC ACTIVITY 10 5.40E-08 4				
GOBP SKELETAL MUSCLE_CELL DIFFERENTIATION 5 1.72E-08 1.77E-06 GOBP RESPONSE_TO_CYTOKINE 12 1.75E-08 1.77E-06 GOBP RESULATION_OF_PROTEOLYSIS 10 1.93E-08 1.93E-08 GOBP REGULATION_OF_PROTEOLYSIS 8 2.39E-08 2.36E-06 GOBP REGULATION_OF_COAGULATION 5 2.93E-08 2.86E-06 GOBP PEGULATION_OF_COAGULATION 11 3.36E-08 3.19E-06 GOBP POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-08 3.66E-06 GOBP POSITIVE_REGULATION_OF_LOCOMOTION 9 3.96E-08 3.66E-06 GOBP POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.76E-06 GOBP POSITIVE_REGULATION_OF_CATA_VTIC_ACTIVITY 6 4.37E-08 3.94E-00 GOBP_REGULATION_OF_CATA_VTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_DESITIVE_REGULATION_OF_CATA_VTIC_ACTIVITY 10 5.40E-08 4.76E-00 GOBP_DEGINTUR_REGULATION_OF_CATA_VTIC_ACTIVITY				
GOBP_RESPONSE_TO_CYTOKINE 12 1.77E-08 1.77E-08 1.77E-08 1.77E-08 1.77E-08 1.93E-08 1.93E-08 1.93E-08 1.93E-08 2.35E-06 2.35E-07 </td <td></td> <td></td> <td></td> <td>1.72E-06</td>				1.72E-06
GOBP_REGULATION_OF_PROTEOLYSIS 10 193E-08 193E-08 235E-06 GOBP_RESPONSE_TO_OXYGEN_LEVELS 8 235E-06 235E-06 235E-06 GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS 8 2.44E-08 2.56E-06 GOBP_REGULATION_OF_COAGULATION 5 2.93E-08 2.31E-06 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-08 3.36E-06 GOBP_POSITIVE_REGULATION_OF_LOCCMOTION 9 3.96E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENT 12 3.06E-06 3.36E-06 GOBP_REGULATION_OF_LOCCMOTION 9 3.96E-08 3.66E-06 GOBP_REGULATION_OF_LOCCMOTION 9 3.96E-08 3.66E-06 GOBP_REGULATION_OF_LOCCMOTION 9 3.96E-08 3.66E-06 GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 11 4.58E-08 4.08E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY 11 4.36E-07 1.11E-08 GOBP_TAXIS 9 8.96E-00				1.77E-06
GOBP REGULATION OF ACTIN FILAMENT BASED PROCESS 8 2.64E-08 2.66E-06 COBD COBD PREGULATION OF 2.93E-08 2.81E-06 COBD COBD POSITIVE REGULATION OF 11 3.36E-08 3.19E-06 COBD POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 11 3.36E-08 3.66E-08 3.66E-08 3.66E-06 3	GOBP_REGULATION_OF_PROTEOLYSIS			1.93E-06
GOBP_REGULATION_OF_COAGULATION 5 2.93E-08 2.81E-00 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-08 3.19E-00 GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 9 3.96E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENT 9 3.96E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.76E-06 GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 11 4.58E-08 4.08E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.59E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.59E-06 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.33E-07 1.11E-05 GOBP_CELLULAR_RESPONSE_TO_ABIOTC_STIMULUS 7 1.67E-07 1.35E-07 GOBP_CELLULAR_RESPONSE_TO_ABIOTC_STIMULUS 7 1.67E-07 1.35E-05 GOBP_CELLULAR_RE				2.35E-06
GOBP POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 11 3.36E-08 3.19E-06 GOBP POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 12 3.40E-08 3.56E-06 GOBP POSITIVE_REGULATION_OF_LOCOMOTION 9 3.96E-08 3.66E-06 GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.75E-06 GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT 6 4.37E-08 3.94E-06 GOBP_REGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.78E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.78E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 10 7.40E-08 6.36E-06 GOBP_TAXIS 9 8.96E-08 7.53E-06 GOBP_TAXIS 9 8.96E-08 7.53E-06 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-07 GOBP_DOSITIV				2.56E-06
GOBP EPITHELIUM DEVELOPMENT 12 3.80E-08 3.66E-06 GOBP POSITIVE REGULATION OF DCOMOTION 9 3.96E-08 3.66E-06 GOBP POSITIVE REGULATION OF DCOMOTION 9 3.96E-08 3.66E-06 GOBP POSITIVE REGULATION OF DEVELOPMENT 6 4.37E-08 3.94E-06 GOBP SKELETAL MUSCLE ORGAN DEVELOPMENT 6 4.37E-08 3.94E-06 GOBP REGULATION OF DEXPELOPMENT 6 4.37E-08 3.94E-06 GOBP REGULATION OF CATALYTIC A.07E-08 3.94E-06 4.76E-06 GOBP POSITIVE REGULATION OF CATALYTIC 10 5.40E-08 4.76E-06 GOBP POSITIVE REGULATION OF CATALYTIC 7 8.17E-08 6.35E-06 GOBP NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 7 8.17E-07 1.11E-06 GOBP ACTOMYOSIN STRUCTURE ORGANIZATION 6				
GOBP POSITIVE REGULATION OF DEVELOPMENTAL_PROCESS 12 4.11E-08 3.75E-00 GOBP POSITIVE REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.75E-00 GOBP SELETAL_MUSCLE ORGAN DEVELOPMENT 6 4.37E-00 3.94E-00 GOBP REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 11 4.58E-08 4.08E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-00 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.95E-00 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-07 1.11E-05 GOBP_ACTOMYOSIN_S TRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-05 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-05 GOBP_OSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-05 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-05 GOBP_CELLULAR_RESPONSE_TO_				
GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS 12 4.11E-08 3.75E-06 GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT 6 4.37E-08 3.94E-06 GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 11 4.58E-08 4.08E-06 GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 11 4.58E-08 4.08E-06 GOBP_REGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.95E-06 GOBP_TAXIS 9 8.96E-08 7.53E-06 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-06 GOBP_COLLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-06 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-06 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY				3.66E-06
GOBP SKELETAL MUSCLE_ORGAN_DEVELOPMENT 6 4.37E-08 3.94E-06 GOBP REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS 11 4.58E-08 4.08E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_DEPTITHELIAL_CELL_PROLIFERATION 8 5.50E-08 4.76E-06 GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.39E-06 GOBP_TAXIS 9 8.96E-08 7.53E-06 6.06D GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-05 6.06D GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.14E-07 1.35E-07 GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 11 1.69E-07 1.35E-07 GOBP_STRIATED_MUSCLE_CELL DEVELOPMENT 5 1.91E-07 1.35E-07 1.90E-07 GOBP_STRIATED_MUSCLE_CELL DEVELOPMENT 5 1.91E-07 1.35E-07 1.90E-07 1.35E-07 GOBP_STRIATED_MUSCLE_CELL DE		-		3.75E-06
GOBP_NEGATIVE_REGULATION_OF_CATALYTIC_ACTIVITY 10 5.40E-08 4.76E-06 GOBP_DEPITHELIAL_CELL_PROLIFERATION 8 5.50E-08 4.76E-06 GOBP_DEPITHELIAL_CELL_PROLIFERATION 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.95E-06 GOBP_TAXIS 9 8.96E-08 7.53E-06 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-06 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-06 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-06 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-06 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.35E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.35E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.35E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.35E-07 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9	GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT		4.37E-08	3.94E-06
GOBP_EPITHELIAL_CELL_PROLIFERATION 8 5.50E-08 4.78E-06 GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_CELL_DIFFERENTIATION 10 7.40E-08 6.36E-06 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.95E-06 GOBP_TAXIS 9 8.96E-08 7.53E-07 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 1 1.34E-07 1.11E-00 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-07 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.14E-00 GOBP_OSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.13E-07 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-00 GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 11 1.69E-07 1.35E-00 GOBP_REGULATION_OF_APOPTOTIC_SIGNALING PATHWAY 7 2.44E-07 1.90E-00 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-00 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_				4.08E-06
GOBP_OSITIVE_REGULATION_OF_CELL_DIFFERENTIATION 10 7.40E-08 6.36E-00 GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.95E-00 GOBP_TAIS 9 8.96E-08 7.53E-00 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 10 1.34E-07 1.11E-02 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-02 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-02 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.11E-02 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-02 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.14E-02 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-02 GOBP_POSITIVE_REGULATION_OF_TRANSFERIPTION_BY_RNA_POLYMERASE_II 11 1.90E-07 1.35E-02 GOBP_REGULATION_OF_APOPTOTIC_SIGNALING PATHWAY 7 2.44E-07 1.90E-02 GOBP_REGULATION_OF_APOPTOTIC_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-02 GOBP_REGULATION_OF_OF_INCLELDARSE_CONTAINING_COMPOUND_MET				
GOBP_NEGATIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 7 8.17E-08 6.99E-06 GOBP_TAXIS 9 8.96E-08 7.53E-00 GOBP_TAXIS 9 8.96E-08 7.53E-00 GOBP_TAXIS 9 8.96E-08 7.53E-00 GOBP_TUBE_MORPHOGENESIS 10 1.34E-07 1.11E-00 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-00 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.13E-07 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE ACTIVITY 9 1.40E-07 1.35E-07 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE ACTIVITY 9 1.40E-07 1.35E-07 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE ACTIVITY 9 1.40E-07 1.35E-07 GOBP_STRIATED_MUSCLE_CELL_DEVELOPMENT 5 1.91E-07 1.35E-07 GOBP_STRIATED_MUSCLE_CELL_DEVELOPMENT 5 1.91E-07 1.50E-07 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-07 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-07 </td <td></td> <td>-</td> <td></td> <td></td>		-		
GOBP_TAXIS 9 8.96E-08 7.53E-06 GOBP_TUBE_MORPHOGENESIS 10 1.34E-07 1.11E-00 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-00 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-00 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.14E-05 GOBP_DOSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 9 1.40E-07 1.35E-00 GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 11 1.69E-07 1.35E-00 GOBP_REGULATION_OF_APOPTOTIC SIGNALING PATHWAY 5 1.91E-07 1.50E-00 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.99E-00 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.99E-00 GOBP_OSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.99E-07 GOBP_OSITIVE_REGULATION_OF_INCLEDASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.09E-07 2.19E-07				
GOBP_TUBE_MORPHOGENESIS 10 1.34E-07 1.11E-05 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-05 GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION 6 1.35E-07 1.11E-05 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-05 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_ACTIVITY 11 1.69E-07 1.35E-05 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_NULL 11 1.69E-07 1.35E-05 GOBP_POSITIVE_REGULATION_OF_TRANSFERASE_NULL 11 1.69E-07 1.35E-05 GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY 5 1.91E-07 1.90E-05 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-05 GOBP_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 2.19E-05 GOBP_REGULATION_OF_INUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.08E-07 2.19E-07		-		7.53E-06
GOBP POSITIVE REGULATION OF TRANSFERASE ACTIVITY 9 1.40E-07 1.14E-05 GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-06 1.35E-06 GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 11 1.69E-07 1.35E-06 GOBP_STRIATED_MUSCLE_CELL_DEVELOPMENT 5 1.91E-07 1.50E-06 GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY 7 2.44E-07 1.90E-06 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-06 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-02 GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.89E-07 2.19E-05				1.11E-05
GOBP_CELLULAR_RESPONSE_TO_ABIOTIC_STIMULUS 7 1.67E-07 1.35E-06 GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 11 1.69E-07 1.35E-06 GOBP_STRITLED_MUSCLE_CELL_DEVELOPMENT 5 1.91E-07 1.50E-06 GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY 7 2.44E-07 1.90E-05 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-06 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-06 GOBP_OSITIVE_REGULATION_OF_INUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.69E-07 2.19E-07				1.11E-05
GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II 11 1.98E-07 1.35E-05 GOBP_STRIATED_MUSCLE_CELL_DEVELOPMENT 5 1.91E-07 1.50E-02 GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY 5 1.91E-07 1.90E-02 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-02 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-02 GOBP_OSITIVE_REGULATION_OF_INUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.69E-07 2.18E-07				1.14E-05
GOBP_STRIATED_MUSCLE_CELL_DEVELOPMENT 5 1.91E-07 1.50E-05 GOBP_REGULATION OF APOPTOTIC_SIGNALING_PATHWAY 7 2.44E-07 1.90E-05 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-05 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-05 GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.89E-07 2.19E-05				
GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY 7 2.44E-07 1.90E-05 GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-05 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-05 GOBP_OSITIVE_REGULATION_OF_INUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.69E-07 2.19E-07				
GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION 8 2.57E-07 1.98E-06 GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-05 GOBP_OSTITVE_REGULATION_OF_INUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.69E-07 2.19E-05				
GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY 9 2.79E-07 2.13E-05 GOBP_POSITIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS 13 2.89E-07 2.19E-05				1.98E-05
	GOBP_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_SIGNALING_PATHWAY			2.13E-05
				2.19E-05
GOBP_RESPONSE_TO_PROGESTERONE 4 3.00E-07 2.25E-05	GOBP_RESPONSE_TO_PROGESTERONE	4	3.00E-07	2.25E-05

Figure 113 Gene ontology analysis of the 55 Mtr4-controlled MRTF-NLS-induced genes

Gene ontology analysis of the 55 Mtr4-controlled MRTF-NLS-induced genes by RNAseq. FDR<0.05. Relates to Figure 63. Bioinformatic analysis of RNAseq data was performed by Francesco Gualdrini.




Figure 114 Correlation plots of full datasets

(A) Scatter plot comparing fold change expression at 45070 genes between CDtreated NIH3T3 cells by RNAseq and TTseq. Relates to Figure 35. (B) Scatter plot comparing fold change expression at 45070 genes between CD-treated dKO^{MRTF} and dKO^{MRTF-NLS} cells by RNAseq. Relates to Figure 46. (C) Scatter plots comparing fold change expression at 45070 genes between Mtr4-depleted LMBtreated NIH3T3 cells by RNAseg and LMB-treated NIH3T3 cells by TTseg; Mtr4depleted LMB-treated NIH3T3 cells by RNAseg and CD-treated NIH3T3 cells by TTseq; Mtr4-depleted LMB-treated NIH3T3 cells by RNAseq and CD-treated NIH3T3 cells by RNAseq. Relates to Figure 54. (D) Scatter plots comparing fold change expression at 45070 genes between Mtr4-depleted CD-treated and LMBtreated NIH3T3 cells by RNAseq; Mtr4-depleted CD-treated NIH3T3 cells by RNAseq and CD-treated NIH3T3 cells by RNAseq; Mtr4-depleted CD-treated NIH3T3 cells by RNAseq and CD-treated NIH3T3 cells by TTseq. Relates to Figure 55. The black lines represent the 95% confidence bands of the best-fit line (red). Bioinformatic analysis of RNAseg and TTseg data was performed by Francesco Gualdrini.

Chapter 11. Reference List

- Adelman, K., Marr, M. T., Werner, J., Saunders, A., Ni, Z., Andrulis, E. D., & Lis, J. T. (2005). Efficient release from promoter-proximal stall sites requires transcript cleavage factor TFIIS. *Mol Cell*, *17*(1), 103-112. https://doi.org/10.1016/j.molcel.2004.11.028
- Adelman, K., Wei, W., Ardehali, M. B., Werner, J., Zhu, B., Reinberg, D., & Lis, J. T. (2006). Drosophila Paf1 modulates chromatin structure at actively transcribed genes. *Mol Cell Biol*, 26(1), 250-260. <u>https://doi.org/10.1128/MCB.26.1.250-260.2006</u>
- Ahn, S. H., Kim, M., & Buratowski, S. (2004). Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3' end processing. *Mol Cell*, *13*(1), 67-76. <u>https://doi.org/10.1016/s1097-2765(03)00492-1</u>
- Akhtar, M. S., Heidemann, M., Tietjen, J. R., Zhang, D. W., Chapman, R. D., Eick, D., & Ansari, A. Z. (2009). TFIIH kinase places bivalent marks on the carboxyterminal domain of RNA polymerase II. *Mol Cell*, *34*(3), 387-393. <u>https://doi.org/10.1016/j.molcel.2009.04.016</u>
- Albert, T., Mautner, J., Funk, J. O., Hörtnagel, K., Pullner, A., & Eick, D. (1997). Nucleosomal structures of c-myc promoters with transcriptionally engaged RNA polymerase II. *Mol Cell Biol*, *17*(8), 4363-4371. <u>https://doi.org/10.1128/mcb.17.8.4363</u>
- Alberti, S., Krause, S. M., Kretz, O., Philippar, U., Lemberger, T., Casanova, E., Wiebel, F. F., Schwarz, H., Frotscher, M., Schütz, G., & Nordheim, A. (2005). Neuronal migration in the murine rostral migratory stream requires serum response factor. *Proc Natl Acad Sci U S A*, *102*(17), 6148-6153. <u>https://doi.org/10.1073/pnas.0501191102</u>
- Allen, B. L., & Taatjes, D. J. (2015). The Mediator complex: a central integrator of transcription. *Nat Rev Mol Cell Biol*, *16*(3), 155-166. <u>https://doi.org/10.1038/nrm3951</u>
- Allison, L. A., Wong, J. K., Fitzpatrick, V. D., Moyle, M., & Ingles, C. J. (1988). The Cterminal domain of the largest subunit of RNA polymerase II of Saccharomyces cerevisiae, Drosophila melanogaster, and mammals: a conserved structure with an essential function. *Mol Cell Biol*, 8(1), 321-329. <u>https://doi.org/10.1128/mcb.8.1.321</u>
- Alpert, T., Herzel, L., & Neugebauer, K. M. (2017). Perfect timing: splicing and transcription rates in living cells. *Wiley Interdiscip Rev RNA*, 8(2). https://doi.org/10.1002/wrna.1401
- Amrani, N., Minet, M., Wyers, F., Dufour, M. E., Aggerbeck, L. P., & Lacroute, F. (1997). PCF11 encodes a third protein component of yeast cleavage and polyadenylation factor I. *Mol Cell Biol*, *17*(3), 1102-1109. https://doi.org/10.1128/mcb.17.3.1102
- Anamika, K., Gyenis, À., Poidevin, L., Poch, O., & Tora, L. (2012). RNA polymerase II pausing downstream of core histone genes is different from genes producing polyadenylated transcripts. *PLoS One*, *7*(6), e38769. https://doi.org/10.1371/journal.pone.0038769
- Andersen, P. R., Domanski, M., Kristiansen, M. S., Storvall, H., Ntini, E., Verheggen, C., Schein, A., Bunkenborg, J., Poser, I., Hallais, M., Sandberg, R., Hyman, A., LaCava, J., Rout, M. P., Andersen, J. S., Bertrand, E., & Jensen, T. H. (2013). The human cap-binding complex is functionally connected to the nuclear RNA

exosome. *Nat Struct Mol Biol*, *20*(12), 1367-1376. https://doi.org/10.1038/nsmb.2703

- Anderson, J. R., Mukherjee, D., Muthukumaraswamy, K., Moraes, K. C., Wilusz, C. J., & Wilusz, J. (2006). Sequence-specific RNA binding mediated by the RNase PH domain of components of the exosome. *RNA*, *12*(10), 1810-1816. https://doi.org/10.1261/rna.144606
- Andersson, R., Gebhard, C., Miguel-Escalada, I., Hoof, I., Bornholdt, J., Boyd, M., Chen, Y., Zhao, X., Schmidl, C., Suzuki, T., Ntini, E., Arner, E., Valen, E., Li, K., Schwarzfischer, L., Glatz, D., Raithel, J., Lilje, B., Rapin, N., Bagger, F. O., Jørgensen, M., Andersen, P. R., Bertin, N., Rackham, O., Burroughs, A. M., Baillie, J. K., Ishizu, Y., Shimizu, Y., Furuhata, E., Maeda, S., Negishi, Y., Mungall, C. J., Meehan, T. F., Lassmann, T., Itoh, M., Kawaji, H., Kondo, N., Kawai, J., Lennartsson, A., Daub, C. O., Heutink, P., Hume, D. A., Jensen, T. H., Suzuki, H., Hayashizaki, Y., Müller, F., Forrest, A. R. R., Carninci, P., Rehli, M., & Sandelin, A. (2014). An atlas of active enhancers across human cell types and tissues. *Nature*, *507*(7493), 455-461. https://doi.org/10.1038/nature12787
- Andrulis, E. D., Guzmán, E., Döring, P., Werner, J., & Lis, J. T. (2000). High-resolution localization of Drosophila Spt5 and Spt6 at heat shock genes in vivo: roles in promoter proximal pausing and transcription elongation. *Genes Dev*, 14(20), 2635-2649. <u>https://doi.org/10.1101/gad.844200</u>
- Andrulis, E. D., Werner, J., Nazarian, A., Erdjument-Bromage, H., Tempst, P., & Lis, J. T. (2002). The RNA processing exosome is linked to elongating RNA polymerase II in Drosophila. *Nature*, *420*(6917), 837-841. <u>https://doi.org/10.1038/nature01181</u>
- Ansari, A., & Hampsey, M. (2005). A role for the CPF 3'-end processing machinery in RNAP II-dependent gene looping. *Genes Dev*, *19*(24), 2969-2978. <u>https://doi.org/10.1101/gad.1362305</u>
- Aoki, K., Kumagai, Y., Sakurai, A., Komatsu, N., Fujita, Y., Shionyu, C., & Matsuda, M. (2013). Stochastic ERK activation induced by noise and cell-to-cell propagation regulates cell density-dependent proliferation. *Mol Cell*, 52(4), 529-540. https://doi.org/10.1016/j.molcel.2013.09.015
- Ardehali, M. B., & Lis, J. T. (2009). Tracking rates of transcription and splicing in vivo. Nat Struct Mol Biol, 16(11), 1123-1124. <u>https://doi.org/10.1038/nsmb1109-1123</u>
- Baarlink, C., Plessner, M., Sherrard, A., Morita, K., Misu, S., Virant, D., Kleinschnitz, E. M., Harniman, R., Alibhai, D., Baumeister, S., Miyamoto, K., Endesfelder, U., Kaidi, A., & Grosse, R. (2017). A transient pool of nuclear F-actin at mitotic exit controls chromatin organization. *Nat Cell Biol*, *19*(12), 1389-1399. https://doi.org/10.1038/ncb3641
- Baarlink, C., Wang, H., & Grosse, R. (2013). Nuclear actin network assembly by formins regulates the SRF coactivator MAL. *Science*, *340*(6134), 864-867. https://doi.org/10.1126/science.1235038
- Baluapuri, A., Hofstetter, J., Dudvarski Stankovic, N., Endres, T., Bhandare, P., Vos, S. M., Adhikari, B., Schwarz, J. D., Narain, A., Vogt, M., Wang, S. Y., Düster, R., Jung, L. A., Vanselow, J. T., Wiegering, A., Geyer, M., Maric, H. M., Gallant, P., Walz, S., Schlosser, A., Cramer, P., Eilers, M., & Wolf, E. (2019). MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation. *Mol Cell*, *74*(4), 674-687.e611. <u>https://doi.org/10.1016/j.molcel.2019.02.031</u>
- Banerjee, A., Apponi, L. H., Pavlath, G. K., & Corbett, A. H. (2013). PABPN1: molecular function and muscle disease. *FEBS J*, 280(17), 4230-4250. <u>https://doi.org/10.1111/febs.12294</u>
- Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001). Selective recognition of methylated lysine 9 on

histone H3 by the HP1 chromo domain. *Nature*, *410*(6824), 120-124. <u>https://doi.org/10.1038/35065138</u>

- Barboric, M., Nissen, R. M., Kanazawa, S., Jabrane-Ferrat, N., & Peterlin, B. M. (2001). NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. *Mol Cell*, *8*(2), 327-337. <u>https://doi.org/10.1016/s1097-2765(01)00314-8</u>
- Barillà, D., Lee, B. A., & Proudfoot, N. J. (2001). Cleavage/polyadenylation factor IA associates with the carboxyl-terminal domain of RNA polymerase II in Saccharomyces cerevisiae. *Proc Natl Acad Sci U S A*, *98*(2), 445-450. https://doi.org/10.1073/pnas.98.2.445
- Bartkowiak, B., Liu, P., Phatnani, H. P., Fuda, N. J., Cooper, J. J., Price, D. H., Adelman, K., Lis, J. T., & Greenleaf, A. L. (2010). CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. *Genes Dev*, 24(20), 2303-2316. <u>https://doi.org/10.1101/gad.1968210</u>
- Bartolomei, M. S., Halden, N. F., Cullen, C. R., & Corden, J. L. (1988). Genetic analysis of the repetitive carboxyl-terminal domain of the largest subunit of mouse RNA polymerase II. *Mol Cell Biol*, 8(1), 330-339. https://doi.org/10.1128/mcb.8.1.330
- Baskaran, R., Dahmus, M. E., & Wang, J. Y. (1993). Tyrosine phosphorylation of mammalian RNA polymerase II carboxyl-terminal domain. *Proc Natl Acad Sci U* S A, 90(23), 11167-11171. <u>https://doi.org/10.1073/pnas.90.23.11167</u>
- Bataille, A. R., Jeronimo, C., Jacques, P., Laramée, L., Fortin, M., Forest, A., Bergeron, M., Hanes, S. D., & Robert, F. (2012). A universal RNA polymerase II CTD cycle is orchestrated by complex interplays between kinase, phosphatase, and isomerase enzymes along genes. *Mol Cell*, 45(2), 158-170. https://doi.org/10.1016/j.molcel.2011.11.024
- Belin, B. J., Cimini, B. A., Blackburn, E. H., & Mullins, R. D. (2013). Visualization of actin filaments and monomers in somatic cell nuclei. *Mol Biol Cell*, 24(7), 982-994. <u>https://doi.org/10.1091/mbc.E12-09-0685</u>
- Belin, B. J., Lee, T., & Mullins, R. D. (2015). DNA damage induces nuclear actin filament assembly by Formin -2 and Spire-1/2 that promotes efficient DNA repair. [corrected]. *Elife*, 4, e07735. <u>https://doi.org/10.7554/eLife.07735</u>
- Bellier, S., Chastant, S., Adenot, P., Vincent, M., Renard, J. P., & Bensaude, O. (1997). Nuclear translocation and carboxyl-terminal domain phosphorylation of RNA polymerase II delineate the two phases of zygotic gene activation in mammalian embryos. *EMBO J*, *16*(20), 6250-6262. <u>https://doi.org/10.1093/emboj/16.20.6250</u>
- Belotserkovskaya, R., Oh, S., Bondarenko, V. A., Orphanides, G., Studitsky, V. M., & Reinberg, D. (2003). FACT facilitates transcription-dependent nucleosome alteration. *Science*, 301(5636), 1090-1093. <u>https://doi.org/10.1126/science.1085703</u>
- Bernecky, C., Plitzko, J. M., & Cramer, P. (2017). Structure of a transcribing RNA polymerase II-DSIF complex reveals a multidentate DNA-RNA clamp. *Nat Struct Mol Biol*, 24(10), 809-815. <u>https://doi.org/10.1038/nsmb.3465</u>
- Bernstein, B. E., Kamal, M., Lindblad-Toh, K., Bekiranov, S., Bailey, D. K., Huebert, D. J., McMahon, S., Karlsson, E. K., Kulbokas, E. J., Gingeras, T. R., Schreiber, S. L., & Lander, E. S. (2005). Genomic maps and comparative analysis of histone modifications in human and mouse. *Cell*, *120*(2), 169-181. https://doi.org/10.1016/j.cell.2005.01.001
- Bernstein, B. E., Liu, C. L., Humphrey, E. L., Perlstein, E. O., & Schreiber, S. L. (2004). Global nucleosome occupancy in yeast. *Genome Biol*, *5*(9), R62. <u>https://doi.org/10.1186/gb-2004-5-9-r62</u>

- Biglione, S., Byers, S. A., Price, J. P., Nguyen, V. T., Bensaude, O., Price, D. H., & Maury, W. (2007). Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. *Retrovirology*, *4*, 47. <u>https://doi.org/10.1186/1742-4690-4-47</u>
- Blasius, M., Wagner, S. A., Choudhary, C., Bartek, J., & Jackson, S. P. (2014). A quantitative 14-3-3 interaction screen connects the nuclear exosome targeting complex to the DNA damage response. *Genes Dev*, *28*(18), 1977-1982. https://doi.org/10.1101/gad.246272.114
- Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011). The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. *Genes Dev*, 25(20), 2158-2172. <u>https://doi.org/10.1101/gad.16962311</u>
- Boehm, A. K., Saunders, A., Werner, J., & Lis, J. T. (2003). Transcription factor and polymerase recruitment, modification, and movement on dhsp70 in vivo in the minutes following heat shock. *Mol Cell Biol*, 23(21), 7628-7637. https://doi.org/10.1128/mcb.23.21.7628-7637.2003
- Boeing, S., Rigault, C., Heidemann, M., Eick, D., & Meisterernst, M. (2010). RNA polymerase II C-terminal heptarepeat domain Ser-7 phosphorylation is established in a mediator-dependent fashion. *J Biol Chem*, *285*(1), 188-196. https://doi.org/10.1074/jbc.M109.046565
- Bohnsack, M. T., Stüven, T., Kuhn, C., Cordes, V. C., & Görlich, D. (2006). A selective block of nuclear actin export stabilizes the giant nuclei of Xenopus oocytes. *Nat Cell Biol*, 8(3), 257-263. <u>https://doi.org/10.1038/ncb1357</u>
- Boros, J., Donaldson, I. J., O'Donnell, A., Odrowaz, Z. A., Zeef, L., Lupien, M., Meyer, C. A., Liu, X. S., Brown, M., & Sharrocks, A. D. (2009). Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. *Genome Res*, 19(11), 1963-1973. https://doi.org/10.1101/gr.093047.109
- Bortvin, A., & Winston, F. (1996). Evidence that Spt6p controls chromatin structure by a direct interaction with histones. *Science*, *272*(5267), 1473-1476. <u>https://doi.org/10.1126/science.272.5267.1473</u>
- Boulon, S., Verheggen, C., Jady, B. E., Girard, C., Pescia, C., Paul, C., Ospina, J. K., Kiss, T., Matera, A. G., Bordonné, R., & Bertrand, E. (2004). PHAX and CRM1 are required sequentially to transport U3 snoRNA to nucleoli. *Mol Cell*, *16*(5), 777-787. https://doi.org/10.1016/j.molcel.2004.11.013
- Bousquet-Antonelli, C., Presutti, C., & Tollervey, D. (2000). Identification of a regulated pathway for nuclear pre-mRNA turnover. *Cell*, *102*(6), 765-775. https://doi.org/10.1016/s0092-8674(00)00065-9
- Bowman, E. A., Bowman, C. R., Ahn, J. H., & Kelly, W. G. (2013). Phosphorylation of RNA polymerase II is independent of P-TEFb in the C. elegans germline. *Development*, *140*(17), 3703-3713. <u>https://doi.org/10.1242/dev.095778</u>
- Brannan, K., Kim, H., Erickson, B., Glover-Cutter, K., Kim, S., Fong, N., Kiemele, L., Hansen, K., Davis, R., Lykke-Andersen, J., & Bentley, D. L. (2012). mRNA decapping factors and the exonuclease Xrn2 function in widespread premature termination of RNA polymerase II transcription. *Mol Cell*, *46*(3), 311-324. <u>https://doi.org/10.1016/j.molcel.2012.03.006</u>
- Brenner, S. L., & Korn, E. D. (1980). The effects of cytochalasins on actin polymerization and actin ATPase provide insights into the mechanism of polymerization. *J Biol Chem*, 255(3), 841-844.
- Brookes, E., de Santiago, I., Hebenstreit, D., Morris, K. J., Carroll, T., Xie, S. Q., Stock, J. K., Heidemann, M., Eick, D., Nozaki, N., Kimura, H., Ragoussis, J.,

Teichmann, S. A., & Pombo, A. (2012). Polycomb associates genome-wide with a specific RNA polymerase II variant, and regulates metabolic genes in ESCs. *Cell Stem Cell*, *10*(2), 157-170. <u>https://doi.org/10.1016/j.stem.2011.12.017</u>

- Brown, S. A., Imbalzano, A. N., & Kingston, R. E. (1996). Activator-dependent regulation of transcriptional pausing on nucleosomal templates. *Genes Dev*, 10(12), 1479-1490. https://doi.org/10.1101/gad.10.12.1479
- Brown, S. A., & Kingston, R. E. (1997). Disruption of downstream chromatin directed by a transcriptional activator. *Genes Dev*, *11*(23), 3116-3121. https://doi.org/10.1101/gad.11.23.3116
- Brugiolo, M., Herzel, L., & Neugebauer, K. M. (2013). Counting on co-transcriptional splicing. *F1000Prime Rep*, 5, 9. <u>https://doi.org/10.12703/P5-9</u>
- Brès, V., Gomes, N., Pickle, L., & Jones, K. A. (2005). A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat. *Genes Dev*, *19*(10), 1211-1226. <u>https://doi.org/10.1101/gad.1291705</u>
- Buchwalter, G., Gross, C., & Wasylyk, B. (2005). The ternary complex factor Net regulates cell migration through inhibition of PAI-1 expression. *Mol Cell Biol*, 25(24), 10853-10862. <u>https://doi.org/10.1128/MCB.25.24.10853-10862.2005</u>
- Buckley, M. S., Kwak, H., Zipfel, W. R., & Lis, J. T. (2014). Kinetics of promoter Pol II on Hsp70 reveal stable pausing and key insights into its regulation. *Genes Dev*, 28(1), 14-19. <u>https://doi.org/10.1101/gad.231886.113</u>
- Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M. (2014). The structure and substrate specificity of human Cdk12/Cyclin K. *Nat Commun*, *5*, 3505. <u>https://doi.org/10.1038/ncomms4505</u>
- Cadena, D. L., & Dahmus, M. E. (1987). Messenger RNA synthesis in mammalian cells is catalyzed by the phosphorylated form of RNA polymerase II. *J Biol Chem*, 262(26), 12468-12474.
- Caridi, C. P., D'Agostino, C., Ryu, T., Zapotoczny, G., Delabaere, L., Li, X., Khodaverdian, V. Y., Amaral, N., Lin, E., Rau, A. R., & Chiolo, I. (2018). Nuclear F-actin and myosins drive relocalization of heterochromatic breaks. *Nature*, 559(7712), 54-60. https://doi.org/10.1038/s41586-018-0242-8
- Carter, R., & Drouin, G. (2009). Structural differentiation of the three eukaryotic RNA polymerases. *Genomics*, *94*(6), 388-396. https://doi.org/10.1016/j.ygeno.2009.08.011
- Cassart, C., Drogat, J., Migeot, V., & Hermand, D. (2012). Distinct requirement of RNA polymerase II CTD phosphorylations in budding and fission yeast. *Transcription*, *3*(5), 231-234. <u>https://doi.org/10.4161/trns.21066</u>
- Cassart, C., Yague-Sanz, C., Bauer, F., Ponsard, P., Stubbe, F. X., Migeot, V., Wery, M., Morillon, A., Palladino, F., Robert, V., & Hermand, D. (2020). RNA polymerase II CTD S2P is dispensable for embryogenesis but mediates exit from developmental diapause in. *Sci Adv*, *6*(50). https://doi.org/10.1126/sciadv.abc1450
- Cen, B., Selvaraj, A., Burgess, R. C., Hitzler, J. K., Ma, Z., Morris, S. W., & Prywes, R. (2003). Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. *Mol Cell Biol*, 23(18), 6597-6608. https://doi.org/10.1128/mcb.23.18.6597-6608.2003
- Chao, S. H., & Price, D. H. (2001). Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. *J Biol Chem*, 276(34), 31793-31799. <u>https://doi.org/10.1074/jbc.M102306200</u>
- Chapman, R. D., Heidemann, M., Albert, T. K., Mailhammer, R., Flatley, A., Meisterernst, M., Kremmer, E., & Eick, D. (2007). Transcribing RNA polymerase

II is phosphorylated at CTD residue serine-7. *Science*, *318*(5857), 1780-1782. <u>https://doi.org/10.1126/science.1145977</u>

- Charbonney, E., Speight, P., Masszi, A., Nakano, H., & Kapus, A. (2011). β-catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial-myofibroblast transition. *Mol Biol Cell*, 22(23), 4472-4485. https://doi.org/10.1091/mbc.E11-04-0335
- Chen, F., Gao, X., & Shilatifard, A. (2015). Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide. *Genes Dev*, 29(1), 39-47. <u>https://doi.org/10.1101/gad.246173.114</u>
- Chen, F. X., Smith, E. R., & Shilatifard, A. (2018). Born to run: control of transcription elongation by RNA polymerase II. *Nat Rev Mol Cell Biol*, *19*(7), 464-478. https://doi.org/10.1038/s41580-018-0010-5
- Chen, H. H., Wang, Y. C., & Fann, M. J. (2006). Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. *Mol Cell Biol*, 26(7), 2736-2745. <u>https://doi.org/10.1128/MCB.26.7.2736-2745.2006</u>
- Chen, H. H., Wong, Y. H., Geneviere, A. M., & Fann, M. J. (2007). CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. *Biochem Biophys Res Commun*, 354(3), 735-740. <u>https://doi.org/10.1016/j.bbrc.2007.01.049</u>
- Chen, R., Liu, M., Li, H., Xue, Y., Ramey, W. N., He, N., Ai, N., Luo, H., Zhu, Y., Zhou, N., & Zhou, Q. (2008). PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. *Genes Dev*, 22(10), 1356-1368. https://doi.org/10.1101/gad.1636008
- Chen, Y., Zhang, L., Estarás, C., Choi, S. H., Moreno, L., Karn, J., Moresco, J. J., Yates, J. R., & Jones, K. A. (2014). A gene-specific role for the Ssu72 RNAPII CTD phosphatase in HIV-1 Tat transactivation. *Genes Dev*, *28*(20), 2261-2275. <u>https://doi.org/10.1101/gad.250449.114</u>
- Cheng, C., & Sharp, P. A. (2003). RNA polymerase II accumulation in the promoterproximal region of the dihydrofolate reductase and gamma-actin genes. *Mol Cell Biol*, 23(6), 1961-1967. https://doi.org/10.1128/mcb.23.6.1961-1967.2003
- Cheng, H., Dufu, K., Lee, C. S., Hsu, J. L., Dias, A., & Reed, R. (2006). Human mRNA export machinery recruited to the 5' end of mRNA. *Cell*, *127*(7), 1389-1400. <u>https://doi.org/10.1016/j.cell.2006.10.044</u>
- Chi, B., Wang, Q., Wu, G., Tan, M., Wang, L., Shi, M., Chang, X., & Cheng, H. (2013). Aly and THO are required for assembly of the human TREX complex and association of TREX components with the spliced mRNA. *Nucleic Acids Res*, *41*(2), 1294-1306. https://doi.org/10.1093/nar/gks1188
- Chiu, A. C., Suzuki, H. I., Wu, X., Mahat, D. B., Kriz, A. J., & Sharp, P. A. (2018). Transcriptional Pause Sites Delineate Stable Nucleosome-Associated Premature Polyadenylation Suppressed by U1 snRNP. *Mol Cell*, 69(4), 648-663.e647. https://doi.org/10.1016/j.molcel.2018.01.006
- Chlebowski, A., Tomecki, R., López, M. E., Séraphin, B., & Dziembowski, A. (2010). Catalytic properties of the eukaryotic exosome. *Adv Exp Med Biol*, *702*, 63-78.
- Cho, E. J., Kobor, M. S., Kim, M., Greenblatt, J., & Buratowski, S. (2001). Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain. *Genes Dev*, *15*(24), 3319-3329. https://doi.org/10.1101/gad.935901
- Cho, E. J., Takagi, T., Moore, C. R., & Buratowski, S. (1997). mRNA capping enzyme is recruited to the transcription complex by phosphorylation of the RNA polymerase II carboxy-terminal domain. *Genes Dev*, *11*(24), 3319-3326. <u>https://doi.org/10.1101/gad.11.24.3319</u>
- Cho, H., Kim, T. K., Mancebo, H., Lane, W. S., Flores, O., & Reinberg, D. (1999). A protein phosphatase functions to recycle RNA polymerase II. *Genes Dev*, *13*(12), 1540-1552. <u>https://doi.org/10.1101/gad.13.12.1540</u>

- Chopra, V. S., Cande, J., Hong, J. W., & Levine, M. (2009). Stalled Hox promoters as chromosomal boundaries. *Genes Dev*, *23*(13), 1505-1509. https://doi.org/10.1101/gad.1807309
- Chu, C., Zhang, Q. C., da Rocha, S. T., Flynn, R. A., Bharadwaj, M., Calabrese, J. M., Magnuson, T., Heard, E., & Chang, H. Y. (2015). Systematic discovery of Xist RNA binding proteins. *Cell*, *161*(2), 404-416. https://doi.org/10.1016/j.cell.2015.03.025
- Chu, Y., Simic, R., Warner, M. H., Arndt, K. M., & Prelich, G. (2007). Regulation of histone modification and cryptic transcription by the Bur1 and Paf1 complexes. *EMBO J*, 26(22), 4646-4656. <u>https://doi.org/10.1038/sj.emboj.7601887</u>
- Col, E., Hoghoughi, N., Dufour, S., Penin, J., Koskas, S., Faure, V., Ouzounova, M., Hernandez-Vargash, H., Reynoird, N., Daujat, S., Folco, E., Vigneron, M., Schneider, R., Verdel, A., Khochbin, S., Herceg, Z., Caron, C., & Vourc'h, C. (2017). Bromodomain factors of BET family are new essential actors of pericentric heterochromatin transcriptional activation in response to heat shock. *Sci Rep*, 7(1), 5418. <u>https://doi.org/10.1038/s41598-017-05343-8</u>
- Colgan, D. F., & Manley, J. L. (1997). Mechanism and regulation of mRNA polyadenylation. *Genes Dev*, *11*(21), 2755-2766. https://doi.org/10.1101/gad.11.21.2755
- Conaway, J. W., Bradsher, J. N., Tan, S., & Conaway, R. C. (1993). Transcription factor SIII: a novel component of the RNA polymerase II elongation complex. *Cell Mol Biol Res*, 39(4), 323-329.
- Connelly, S., & Manley, J. L. (1988). A functional mRNA polyadenylation signal is required for transcription termination by RNA polymerase II. *Genes Dev*, 2(4), 440-452. <u>https://doi.org/10.1101/gad.2.4.440</u>
- Copeland, J. W., & Treisman, R. (2002). The diaphanous-related formin mDia1 controls serum response factor activity through its effects on actin polymerization. *Mol Biol Cell*, *13*(11), 4088-4099. <u>https://doi.org/10.1091/mbc.02-06-0092</u>
- Corden, J. L., Cadena, D. L., Ahearn, J. M., & Dahmus, M. E. (1985). A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II. *Proc Natl Acad Sci U S A*, *82*(23), 7934-7938. <u>https://doi.org/10.1073/pnas.82.23.7934</u>
- Core, L., & Adelman, K. (2019). Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation. *Genes Dev*, *33*(15-16), 960-982. <u>https://doi.org/10.1101/gad.325142.119</u>
- Core, L. J., & Lis, J. T. (2008). Transcription regulation through promoter-proximal pausing of RNA polymerase II. *Science*, *319*(5871), 1791-1792. <u>https://doi.org/10.1126/science.1150843</u>
- Core, L. J., Waterfall, J. J., & Lis, J. T. (2008). Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. *Science*, 322(5909), 1845-1848. <u>https://doi.org/10.1126/science.1162228</u>
- Cortazar, M. A., Sheridan, R. M., Erickson, B., Fong, N., Glover-Cutter, K., Brannan, K., & Bentley, D. L. (2019). Control of RNA Pol II Speed by PNUTS-PP1 and Spt5 Dephosphorylation Facilitates Termination by a "Sitting Duck Torpedo" Mechanism. *Mol Cell*, *76*(6), 896-908.e894. https://doi.org/10.1016/j.molcel.2019.09.031
- Costello, P., Nicolas, R., Willoughby, J., Wasylyk, B., Nordheim, A., & Treisman, R. (2010). Ternary complex factors SAP-1 and Elk-1, but not net, are functionally equivalent in thymocyte development. *J Immunol*, *185*(2), 1082-1092. https://doi.org/10.4049/jimmunol.1000472
- Costello, P., Sargent, M., Maurice, D., Esnault, C., Foster, K., Anjos-Afonso, F., & Treisman, R. (2015). MRTF-SRF signaling is required for seeding of HSC/Ps in

bone marrow during development. *Blood*, *125*(8), 1244-1255. <u>https://doi.org/10.1182/blood-2014-08-595603</u>

- Costello, P. S., Nicolas, R. H., Watanabe, Y., Rosewell, I., & Treisman, R. (2004). Ternary complex factor SAP-1 is required for Erk-mediated thymocyte positive selection. *Nat Immunol*, *5*(3), 289-298. <u>https://doi.org/10.1038/ni1038</u>
- Coudreuse, D., van Bakel, H., Dewez, M., Soutourina, J., Parnell, T., Vandenhaute, J., Cairns, B., Werner, M., & Hermand, D. (2010). A gene-specific requirement of RNA polymerase II CTD phosphorylation for sexual differentiation in S. pombe. *Curr Biol*, 20(12), 1053-1064. <u>https://doi.org/10.1016/j.cub.2010.04.054</u>
- Cramer, P. (2019). Organization and regulation of gene transcription. *Nature*, 573(7772), 45-54. <u>https://doi.org/10.1038/s41586-019-1517-4</u>
- Cramer, P., Armache, K. J., Baumli, S., Benkert, S., Brueckner, F., Buchen, C., Damsma, G. E., Dengl, S., Geiger, S. R., Jasiak, A. J., Jawhari, A., Jennebach, S., Kamenski, T., Kettenberger, H., Kuhn, C. D., Lehmann, E., Leike, K., Sydow, J. F., & Vannini, A. (2008). Structure of eukaryotic RNA polymerases. *Annu Rev Biophys*, 37, 337-352. https://doi.org/10.1146/annurev.biophys.37.032807.130008
- Cramer, P., Bushnell, D. A., & Kornberg, R. D. (2001). Structural basis of transcription: RNA polymerase II at 2.8 angstrom resolution. *Science*, *292*(5523), 1863-1876. https://doi.org/10.1126/science.1059493
- Czudnochowski, N., Bösken, C. A., & Geyer, M. (2012). Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. *Nat Commun*, 3, 842. https://doi.org/10.1038/ncomms1846
- Dalton, S., & Treisman, R. (1992). Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element. *Cell*, *68*(3), 597-612. <u>https://doi.org/10.1016/0092-8674(92)90194-h</u>
- Danko, C. G., Hah, N., Luo, X., Martins, A. L., Core, L., Lis, J. T., Siepel, A., & Kraus, W. L. (2013). Signaling pathways differentially affect RNA polymerase II initiation, pausing, and elongation rate in cells. *Mol Cell*, *50*(2), 212-222. <u>https://doi.org/10.1016/j.molcel.2013.02.015</u>
- Daury, L., Chailleux, C., Bonvallet, J., & Trouche, D. (2006). Histone H3.3 deposition at E2F-regulated genes is linked to transcription. *EMBO Rep*, 7(1), 66-71. https://doi.org/10.1038/sj.embor.7400561
- de la Mata, M., Alonso, C. R., Kadener, S., Fededa, J. P., Blaustein, M., Pelisch, F., Cramer, P., Bentley, D., & Kornblihtt, A. R. (2003). A slow RNA polymerase II affects alternative splicing in vivo. *Mol Cell*, *12*(2), 525-532. <u>https://doi.org/10.1016/j.molcel.2003.08.001</u>
- de Vries, H., Rüegsegger, U., Hübner, W., Friedlein, A., Langen, H., & Keller, W. (2000). Human pre-mRNA cleavage factor II(m) contains homologs of yeast proteins and bridges two other cleavage factors. *EMBO J*, *19*(21), 5895-5904. https://doi.org/10.1093/emboj/19.21.5895
- Dengl, S., Mayer, A., Sun, M., & Cramer, P. (2009). Structure and in vivo requirement of the yeast Spt6 SH2 domain. *J Mol Biol*, 389(1), 211-225. <u>https://doi.org/10.1016/j.jmb.2009.04.016</u>
- Dermody, J. L., Dreyfuss, J. M., Villén, J., Ogundipe, B., Gygi, S. P., Park, P. J., Ponticelli, A. S., Moore, C. L., Buratowski, S., & Bucheli, M. E. (2008). Unphosphorylated SR-like protein Npl3 stimulates RNA polymerase II elongation. *PLoS One*, *3*(9), e3273. https://doi.org/10.1371/journal.pone.0003273
- Descostes, N., Heidemann, M., Spinelli, L., Schüller, R., Maqbool, M. A., Fenouil, R., Koch, F., Innocenti, C., Gut, M., Gut, I., Eick, D., & Andrau, J. C. (2014). Tyrosine phosphorylation of RNA polymerase II CTD is associated with

antisense promoter transcription and active enhancers in mammalian cells. *Elife*, 3, e02105. <u>https://doi.org/10.7554/eLife.02105</u>

- Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., & Singer, D. S. (2012). BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. *Proc Natl Acad Sci U S A*, 109(18), 6927-6932. https://doi.org/10.1073/pnas.1120422109
- Di Vona, C., Bezdan, D., Islam, A. B., Salichs, E., López-Bigas, N., Ossowski, S., & de la Luna, S. (2015). Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase. *Mol Cell*, *57*(3), 506-520. <u>https://doi.org/10.1016/j.molcel.2014.12.026</u>
- Dias, J. D., Rito, T., Torlai Triglia, E., Kukalev, A., Ferrai, C., Chotalia, M., Brookes, E., Kimura, H., & Pombo, A. (2015). Methylation of RNA polymerase II nonconsensus Lysine residues marks early transcription in mammalian cells. *Elife*, <u>4. https://doi.org/10.7554/eLife.11215</u>
- Diring, J., Mouilleron, S., McDonald, N. Q., & Treisman, R. (2019). RPEL-family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability. *Nat Cell Biol*, 21(7), 845-855. <u>https://doi.org/10.1038/s41556-019-0337-y</u>
- Domingo-Prim, J., Endara-Coll, M., Bonath, F., Jimeno, S., Prados-Carvajal, R., Friedländer, M. R., Huertas, P., & Visa, N. (2019). EXOSC10 is required for RPA assembly and controlled DNA end resection at DNA double-strand breaks. *Nat Commun*, *10*(1), 2135. <u>https://doi.org/10.1038/s41467-019-10153-9</u>
- Donner, A. J., Ebmeier, C. C., Taatjes, D. J., & Espinosa, J. M. (2010). CDK8 is a positive regulator of transcriptional elongation within the serum response network. *Nat Struct Mol Biol*, 17(2), 194-201. <u>https://doi.org/10.1038/nsmb.1752</u>
- Dou, Y., Milne, T. A., Tackett, A. J., Smith, E. R., Fukuda, A., Wysocka, J., Allis, C. D., Chait, B. T., Hess, J. L., & Roeder, R. G. (2005). Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. *Cell*, *121*(6), 873-885. <u>https://doi.org/10.1016/j.cell.2005.04.031</u>
- Dover, J., Schneider, J., Tawiah-Boateng, M. A., Wood, A., Dean, K., Johnston, M., & Shilatifard, A. (2002). Methylation of histone H3 by COMPASS requires ubiquitination of histone H2B by Rad6. *J Biol Chem*, 277(32), 28368-28371. https://doi.org/10.1074/jbc.C200348200
- Dowen, J. M., Fan, Z. P., Hnisz, D., Ren, G., Abraham, B. J., Zhang, L. N., Weintraub, A. S., Schujiers, J., Lee, T. I., Zhao, K., & Young, R. A. (2014). Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. *Cell*, *159*(2), 374-387. <u>https://doi.org/10.1016/j.cell.2014.09.030</u>
- Du, K. L., Chen, M., Li, J., Lepore, J. J., Mericko, P., & Parmacek, M. S. (2004). Megakaryoblastic leukemia factor-1 transduces cytoskeletal signals and induces smooth muscle cell differentiation from undifferentiated embryonic stem cells. *J Biol Chem*, 279(17), 17578-17586. https://doi.org/10.1074/ibc.M400961200
- Eberhardy, S. R., & Farnham, P. J. (2001). c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. *J Biol Chem*, 276(51), 48562-48571. https://doi.org/10.1074/jbc.M109014200
- Eberhardy, S. R., & Farnham, P. J. (2002). Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. *J Biol Chem*, 277(42), 40156-40162. <u>https://doi.org/10.1074/jbc.M207441200</u>
- Egloff, S., O'Reilly, D., Chapman, R. D., Taylor, A., Tanzhaus, K., Pitts, L., Eick, D., & Murphy, S. (2007). Serine-7 of the RNA polymerase II CTD is specifically required for snRNA gene expression. *Science*, *318*(5857), 1777-1779. <u>https://doi.org/10.1126/science.1145989</u>

- Egloff, S., O'Reilly, D., & Murphy, S. (2008). Expression of human snRNA genes from beginning to end. *Biochem Soc Trans*, *36*(Pt 4), 590-594. https://doi.org/10.1042/BST0360590
- Egloff, S., Szczepaniak, S. A., Dienstbier, M., Taylor, A., Knight, S., & Murphy, S. (2010). The integrator complex recognizes a new double mark on the RNA polymerase II carboxyl-terminal domain. *J Biol Chem*, *285*(27), 20564-20569. https://doi.org/10.1074/jbc.M110.132530
- Egloff, S., Zaborowska, J., Laitem, C., Kiss, T., & Murphy, S. (2012). Ser7 phosphorylation of the CTD recruits the RPAP2 Ser5 phosphatase to snRNA genes. *Mol Cell*, *45*(1), 111-122. <u>https://doi.org/10.1016/j.molcel.2011.11.006</u>
- Ehara, H., Yokoyama, T., Shigematsu, H., Yokoyama, S., Shirouzu, M., & Sekine, S. I. (2017). Structure of the complete elongation complex of RNA polymerase II with basal factors. *Science*, 357(6354), 921-924. https://doi.org/10.1126/science.aan8552
- Eick, D., & Geyer, M. (2013). The RNA polymerase II carboxy-terminal domain (CTD) code. *Chem Rev*, *113*(11), 8456-8490. https://doi.org/10.1021/cr400071f
- Eifler, T. T., Shao, W., Bartholomeeusen, K., Fujinaga, K., Jäger, S., Johnson, J. R., Luo, Z., Krogan, N. J., & Peterlin, B. M. (2015). Cyclin-dependent kinase 12 increases 3' end processing of growth factor-induced c-FOS transcripts. *Mol Cell Biol*, 35(2), 468-478. <u>https://doi.org/10.1128/MCB.01157-14</u>
- Elowitz, M. B., Levine, A. J., Siggia, E. D., & Swain, P. S. (2002). Stochastic gene expression in a single cell. *Science*, *297*(5584), 1183-1186. <u>https://doi.org/10.1126/science.1070919</u>
- Esnault, C., Stewart, A., Gualdrini, F., East, P., Horswell, S., Matthews, N., & Treisman, R. (2014). Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. *Genes Dev*, 28(9), 943-958. https://doi.org/10.1101/gad.239327.114
- Eyboulet, F., Cibot, C., Eychenne, T., Neil, H., Alibert, O., Werner, M., & Soutourina, J. (2013). Mediator links transcription and DNA repair by facilitating Rad2/XPG recruitment. *Genes Dev*, 27(23), 2549-2562. https://doi.org/10.1101/gad.225813.113
- Eyboulet, F., Wydau-Dematteis, S., Eychenne, T., Alibert, O., Neil, H., Boschiero, C., Nevers, M. C., Volland, H., Cornu, D., Redeker, V., Werner, M., & Soutourina, J. (2015). Mediator independently orchestrates multiple steps of preinitiation complex assembly in vivo. *Nucleic Acids Res*, *43*(19), 9214-9231. <u>https://doi.org/10.1093/nar/gkv782</u>
- Falk, S., Finogenova, K., Melko, M., Benda, C., Lykke-Andersen, S., Jensen, T. H., & Conti, E. (2016). Structure of the RBM7-ZCCHC8 core of the NEXT complex reveals connections to splicing factors. *Nat Commun*, 7, 13573. <u>https://doi.org/10.1038/ncomms13573</u>
- Fan, J., Kuai, B., Wu, G., Wu, X., Chi, B., Wang, L., Wang, K., Shi, Z., Zhang, H., Chen, S., He, Z., Wang, S., Zhou, Z., Li, G., & Cheng, H. (2017). Exosome cofactor hMTR4 competes with export adaptor ALYREF to ensure balanced nuclear RNA pools for degradation and export. *EMBO J*, 36(19), 2870-2886. https://doi.org/10.15252/embj.201696139
- Fang, M., Xie, H., Dougan, S. K., Ploegh, H., & van Oudenaarden, A. (2013). Stochastic cytokine expression induces mixed T helper cell States. *PLoS Biol*, *11*(7), e1001618. <u>https://doi.org/10.1371/journal.pbio.1001618</u>
- Feng, Q., Wang, H., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Struhl, K., & Zhang, Y. (2002). Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. *Curr Biol*, *12*(12), 1052-1058. <u>https://doi.org/10.1016/s0960-9822(02)00901-6</u>

- Fish, R. N., & Kane, C. M. (2002). Promoting elongation with transcript cleavage stimulatory factors. *Biochim Biophys Acta*, 1577(2), 287-307. https://doi.org/10.1016/s0167-4781(02)00459-1
- Fitz, J., Neumann, T., & Pavri, R. (2018). Regulation of RNA polymerase II processivity by Spt5 is restricted to a narrow window during elongation. *EMBO J*, 37(8). https://doi.org/10.15252/embj.201797965
- Flaherty, S. M., Fortes, P., Izaurralde, E., Mattaj, I. W., & Gilmartin, G. M. (1997). Participation of the nuclear cap binding complex in pre-mRNA 3' processing. *Proc Natl Acad Sci U S A*, 94(22), 11893-11898. https://doi.org/10.1073/pnas.94.22.11893
- Flynn, R. A., Almada, A. E., Zamudio, J. R., & Sharp, P. A. (2011). Antisense RNA polymerase II divergent transcripts are P-TEFb dependent and substrates for the RNA exosome. *Proc Natl Acad Sci U S A*, *108*(26), 10460-10465. https://doi.org/10.1073/pnas.1106630108
- Fong, N., & Bentley, D. L. (2001). Capping, splicing, and 3' processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD. *Genes Dev*, 15(14), 1783-1795. https://doi.org/10.1101/gad.889101
- Fong, N., Brannan, K., Erickson, B., Kim, H., Cortazar, M. A., Sheridan, R. M., Nguyen, T., Karp, S., & Bentley, D. L. (2015). Effects of Transcription Elongation Rate and Xrn2 Exonuclease Activity on RNA Polymerase II Termination Suggest Widespread Kinetic Competition. *Mol Cell*, 60(2), 256-267. <u>https://doi.org/10.1016/j.molcel.2015.09.026</u>
- Foster, C. T., Gualdrini, F., & Treisman, R. (2017). Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics. *Genes Dev*, *31*(23-24), 2361-2375. <u>https://doi.org/10.1101/gad.304501.117</u>
- Franco, C. A., Blanc, J., Parlakian, A., Blanco, R., Aspalter, I. M., Kazakova, N., Diguet, N., Mylonas, E., Gao-Li, J., Vaahtokari, A., Penard-Lacronique, V., Fruttiger, M., Rosewell, I., Mericskay, M., Gerhardt, H., & Li, Z. (2013). SRF selectively controls tip cell invasive behavior in angiogenesis. *Development*, 140(11), 2321-2333. <u>https://doi.org/10.1242/dev.091074</u>
- Fresco, L. D., & Buratowski, S. (1996). Conditional mutants of the yeast mRNA capping enzyme show that the cap enhances, but is not required for, mRNA splicing. *RNA*, *2*(6), 584-596.
- Fuchs, G., Hollander, D., Voichek, Y., Ast, G., & Oren, M. (2014). Cotranscriptional histone H2B monoubiquitylation is tightly coupled with RNA polymerase II elongation rate. *Genome Res*, 24(10), 1572-1583. https://doi.org/10.1101/gr.176487.114
- Fujinaga, K., Irwin, D., Huang, Y., Taube, R., Kurosu, T., & Peterlin, B. M. (2004). Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. *Mol Cell Biol*, *24*(2), 787-795. <u>https://doi.org/10.1128/mcb.24.2.787-795.2004</u>
- Galbraith, M. D., Bender, H., & Espinosa, J. M. (2019). Therapeutic targeting of transcriptional cyclin-dependent kinases. *Transcription*, *10*(2), 118-136. https://doi.org/10.1080/21541264.2018.1539615
- Gates, L. A., Foulds, C. E., & O'Malley, B. W. (2017). Histone Marks in the 'Driver's Seat': Functional Roles in Steering the Transcription Cycle. *Trends Biochem Sci*, *42*(12), 977-989. <u>https://doi.org/10.1016/j.tibs.2017.10.004</u>
- Gau, D., Veon, W., Capasso, T. L., Bottcher, R., Shroff, S., Roman, B. L., & Roy, P. (2017). Pharmacological intervention of MKL/SRF signaling by CCG-1423

impedes endothelial cell migration and angiogenesis. *Angiogenesis*, 20(4), 663-672. <u>https://doi.org/10.1007/s10456-017-9560-y</u>

- Gelbart, M. E., Larschan, E., Peng, S., Park, P. J., & Kuroda, M. I. (2009). Drosophila MSL complex globally acetylates H4K16 on the male X chromosome for dosage compensation. *Nat Struct Mol Biol*, *16*(8), 825-832. https://doi.org/10.1038/nsmb.1644
- Geneste, O., Copeland, J. W., & Treisman, R. (2002). LIM kinase and Diaphanous cooperate to regulate serum response factor and actin dynamics. *J Cell Biol*, *157*(5), 831-838. <u>https://doi.org/10.1083/jcb.200203126</u>
- Gerlach, P., Schuller, J. M., Bonneau, F., Basquin, J., Reichelt, P., Falk, S., & Conti, E. (2018). Distinct and evolutionary conserved structural features of the human nuclear exosome complex. *Elife*, 7. <u>https://doi.org/10.7554/eLife.38686</u>
- Ghosh, A., Shuman, S., & Lima, C. D. (2008). The structure of Fcp1, an essential RNA polymerase II CTD phosphatase. *Mol Cell*, *32*(4), 478-490. https://doi.org/10.1016/j.molcel.2008.09.021
- Giacometti, S., Benbahouche, N. E. H., Domanski, M., Robert, M. C., Meola, N., Lubas, M., Bukenborg, J., Andersen, J. S., Schulze, W. M., Verheggen, C., Kudla, G., Jensen, T. H., & Bertrand, E. (2017). Mutually Exclusive CBC-Containing Complexes Contribute to RNA Fate. *Cell Rep*, *18*(11), 2635-2650. <u>https://doi.org/10.1016/j.celrep.2017.02.046</u>
- Gibson, B. A., Zhang, Y., Jiang, H., Hussey, K. M., Shrimp, J. H., Lin, H., Schwede, F., Yu, Y., & Kraus, W. L. (2016). Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation. *Science*, 353(6294), 45-50. <u>https://doi.org/10.1126/science.aaf7865</u>
- Gilchrist, D. A., Dos Santos, G., Fargo, D. C., Xie, B., Gao, Y., Li, L., & Adelman, K. (2010). Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation. *Cell*, *143*(4), 540-551. https://doi.org/10.1016/j.cell.2010.10.004
- Gilchrist, D. A., Fromm, G., dos Santos, G., Pham, L. N., McDaniel, I. E., Burkholder, A., Fargo, D. C., & Adelman, K. (2012). Regulating the regulators: the pervasive effects of Pol II pausing on stimulus-responsive gene networks. *Genes Dev*, 26(9), 933-944. <u>https://doi.org/10.1101/gad.187781.112</u>
- Gilchrist, D. A., Nechaev, S., Lee, C., Ghosh, S. K., Collins, J. B., Li, L., Gilmour, D. S., & Adelman, K. (2008). NELF-mediated stalling of Pol II can enhance gene expression by blocking promoter-proximal nucleosome assembly. *Genes Dev*, 22(14), 1921-1933. <u>https://doi.org/10.1101/gad.1643208</u>
- Gilman, M. Z., Wilson, R. N., & Weinberg, R. A. (1986). Multiple protein-binding sites in the 5'-flanking region regulate c-fos expression. *Mol Cell Biol*, 6(12), 4305-4316. https://doi.org/10.1128/mcb.6.12.4305
- Gineitis, D., & Treisman, R. (2001). Differential usage of signal transduction pathways defines two types of serum response factor target gene. *J Biol Chem*, 276(27), 24531-24539. https://doi.org/10.1074/jbc.M102678200
- Glover-Cutter, K., Kim, S., Espinosa, J., & Bentley, D. L. (2008). RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. *Nat Struct Mol Biol*, *15*(1), 71-78. <u>https://doi.org/10.1038/nsmb1352</u>
- Glover-Cutter, K., Larochelle, S., Erickson, B., Zhang, C., Shokat, K., Fisher, R. P., & Bentley, D. L. (2009). TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. *Mol Cell Biol*, 29(20), 5455-5464. <u>https://doi.org/10.1128/MCB.00637-09</u>
- Gomes, N. P., Bjerke, G., Llorente, B., Szostek, S. A., Emerson, B. M., & Espinosa, J. M. (2006). Gene-specific requirement for P-TEFb activity and RNA polymerase

II phosphorylation within the p53 transcriptional program. *Genes Dev*, 20(5), 601-612. <u>https://doi.org/10.1101/gad.1398206</u>

- Goodrich, J. A., & Tjian, R. (1994). Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II. *Cell*, 77(1), 145-156. <u>https://doi.org/10.1016/0092-8674(94)90242-9</u>
- Gorski, S. A., Dundr, M., & Misteli, T. (2006). The road much traveled: trafficking in the cell nucleus. *Curr Opin Cell Biol*, *18*(3), 284-290. <u>https://doi.org/10.1016/j.ceb.2006.03.002</u>
- Graham, R., & Gilman, M. (1991). Distinct protein targets for signals acting at the c-fos serum response element. *Science*, *251*(4990), 189-192. https://doi.org/10.1126/science.1898992
- Greenberg, M. E., Siegfried, Z., & Ziff, E. B. (1987). Mutation of the c-fos gene dyad symmetry element inhibits serum inducibility of transcription in vivo and the nuclear regulatory factor binding in vitro. *Mol Cell Biol*, 7(3), 1217-1225. https://doi.org/10.1128/mcb.7.3.1217
- Greenleaf, A. L. (2019). Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium. *Transcription*, *10*(2), 91-110. https://doi.org/10.1080/21541264.2018.1535211
- Greger, I. H., Demarchi, F., Giacca, M., & Proudfoot, N. J. (1998). Transcriptional interference perturbs the binding of Sp1 to the HIV-1 promoter. *Nucleic Acids Res*, 26(5), 1294-1301. <u>https://doi.org/10.1093/nar/26.5.1294</u>
- Greger, I. H., & Proudfoot, N. J. (1998). Poly(A) signals control both transcriptional termination and initiation between the tandem GAL10 and GAL7 genes of Saccharomyces cerevisiae. *EMBO J*, *17*(16), 4771-4779. <u>https://doi.org/10.1093/emboj/17.16.4771</u>
- Gregersen, L. H., Mitter, R., & Svejstrup, J. Q. (2020). Using TT. *Nat Protoc*, *15*(2), 604-627. <u>https://doi.org/10.1038/s41596-019-0262-3</u>
- Gregersen, L. H., Mitter, R., Ugalde, A. P., Nojima, T., Proudfoot, N. J., Agami, R., Stewart, A., & Svejstrup, J. Q. (2019). SCAF4 and SCAF8, mRNA Anti-Terminator Proteins. *Cell*, *177*(7), 1797-1813.e1718. <u>https://doi.org/10.1016/j.cell.2019.04.038</u>
- Greimann, J. C., & Lima, C. D. (2008). Reconstitution of RNA exosomes from human and Saccharomyces cerevisiae cloning, expression, purification, and activity assays. *Methods Enzymol*, 448, 185-210. <u>https://doi.org/10.1016/S0076-</u> 6879(08)02610-4
- Groeneweg, F. L., van Royen, M. E., Fenz, S., Keizer, V. I., Geverts, B., Prins, J., de Kloet, E. R., Houtsmuller, A. B., Schmidt, T. S., & Schaaf, M. J. (2014). Quantitation of glucocorticoid receptor DNA-binding dynamics by singlemolecule microscopy and FRAP. *PLoS One*, *9*(3), e90532. <u>https://doi.org/10.1371/journal.pone.0090532</u>
- Gromak, N., West, S., & Proudfoot, N. J. (2006). Pause sites promote transcriptional termination of mammalian RNA polymerase II. *Mol Cell Biol*, *26*(10), 3986-3996. <u>https://doi.org/10.1128/MCB.26.10.3986-3996.2006</u>
- Gross, S., & Moore, C. (2001). Five subunits are required for reconstitution of the cleavage and polyadenylation activities of Saccharomyces cerevisiae cleavage factor I. *Proc Natl Acad Sci U S A*, *98*(11), 6080-6085. https://doi.org/10.1073/pnas.101046598
- Gruber, J. J., Olejniczak, S. H., Yong, J., La Rocca, G., Dreyfuss, G., & Thompson, C. B. (2012). Ars2 promotes proper replication-dependent histone mRNA 3' end formation. *Mol Cell*, 45(1), 87-98. <u>https://doi.org/10.1016/j.molcel.2011.12.020</u>
- Gruber, J. J., Zatechka, D. S., Sabin, L. R., Yong, J., Lum, J. J., Kong, M., Zong, W. X., Zhang, Z., Lau, C. K., Rawlings, J., Cherry, S., Ihle, J. N., Dreyfuss, G., & Thompson, C. B. (2009). Ars2 links the nuclear cap-binding complex to RNA

interference and cell proliferation. *Cell*, *138*(2), 328-339. <u>https://doi.org/10.1016/j.cell.2009.04.046</u>

- Gu, B., Eick, D., & Bensaude, O. (2013). CTD serine-2 plays a critical role in splicing and termination factor recruitment to RNA polymerase II in vivo. *Nucleic Acids Res*, 41(3), 1591-1603. <u>https://doi.org/10.1093/nar/gks1327</u>
- Gualdrini, F., Esnault, C., Horswell, S., Stewart, A., Matthews, N., & Treisman, R. (2016). SRF Co-factors Control the Balance between Cell Proliferation and Contractility. *Mol Cell*, 64(6), 1048-1061. <u>https://doi.org/10.1016/j.molcel.2016.10.016</u>
- Gudipati, R. K., Xu, Z., Lebreton, A., Séraphin, B., Steinmetz, L. M., Jacquier, A., & Libri, D. (2012). Extensive degradation of RNA precursors by the exosome in wild-type cells. *Mol Cell*, *48*(3), 409-421. https://doi.org/10.1016/j.molcel.2012.08.018
- Guenther, M. G., Levine, S. S., Boyer, L. A., Jaenisch, R., & Young, R. A. (2007). A chromatin landmark and transcription initiation at most promoters in human cells. *Cell*, *130*(1), 77-88. https://doi.org/10.1016/j.cell.2007.05.042
- Guettler, S., Vartiainen, M. K., Miralles, F., Larijani, B., & Treisman, R. (2008). RPEL motifs link the serum response factor cofactor MAL but not myocardin to Rho signaling via actin binding. *Mol Cell Biol*, *28*(2), 732-742. https://doi.org/10.1128/mcb.01623-07
- Guo, R., Zheng, L., Park, J. W., Lv, R., Chen, H., Jiao, F., Xu, W., Mu, S., Wen, H., Qiu, J., Wang, Z., Yang, P., Wu, F., Hui, J., Fu, X., Shi, X., Shi, Y. G., Xing, Y., Lan, F., & Shi, Y. (2014). BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA processing. *Mol Cell*, *56*(2), 298-310. https://doi.org/10.1016/j.molcel.2014.08.022
- Haak, A. J., Appleton, K. M., Lisabeth, E. M., Misek, S. A., Ji, Y., Wade, S. M., Bell, J. L., Rockwell, C. E., Airik, M., Krook, M. A., Larsen, S. D., Verhaegen, M., Lawlor, E. R., & Neubig, R. R. (2017). Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. *Mol Cancer Ther*, *16*(1), 193-204. https://doi.org/10.1158/1535-7163.MCT-16-0482
- Hager, G. L., McNally, J. G., & Misteli, T. (2009). Transcription dynamics. *Mol Cell*, *35*(6), 741-753. <u>https://doi.org/10.1016/j.molcel.2009.095</u>
- Hallais, M., Pontvianne, F., Andersen, P. R., Clerici, M., Lener, D., Benbahouche, N. I. H., Gostan, T., Vandermoere, F., Robert, M. C., Cusack, S., Verheggen, C., Jensen, T. H., & Bertrand, E. (2013). CBC-ARS2 stimulates 3'-end maturation of multiple RNA families and favors cap-proximal processing. *Nat Struct Mol Biol*, 20(12), 1358-1366. <u>https://doi.org/10.1038/nsmb.2720</u>
- Hargreaves, D. C., Horng, T., & Medzhitov, R. (2009). Control of inducible gene expression by signal-dependent transcriptional elongation. *Cell*, *138*(1), 129-145. <u>https://doi.org/10.1016/j.cell.2009.05.047</u>
- Harlen, K. M., Trotta, K. L., Smith, E. E., Mosaheb, M. M., Fuchs, S. M., & Churchman, L. S. (2016). Comprehensive RNA Polymerase II Interactomes Reveal Distinct and Varied Roles for Each Phospho-CTD Residue. *Cell Rep*, *15*(10), 2147-2158. <u>https://doi.org/10.1016/j.celrep.2016.05.010</u>
- Hartzog, G. A., Wada, T., Handa, H., & Winston, F. (1998). Evidence that Spt4, Spt5, and Spt6 control transcription elongation by RNA polymerase II in Saccharomyces cerevisiae. *Genes Dev*, *12*(3), 357-369. <u>https://doi.org/10.1101/gad.12.3.357</u>
- Hassler, M., & Richmond, T. J. (2001). The B-box dominates SAP-1-SRF interactions in the structure of the ternary complex. *EMBO J*, *20*(12), 3018-3028. https://doi.org/10.1093/emboj/20.12.3018

- Hausmann, S., & Shuman, S. (2002). Characterization of the CTD phosphatase Fcp1 from fission yeast. Preferential dephosphorylation of serine 2 versus serine 5. *J Biol Chem*, 277(24), 21213-21220. <u>https://doi.org/10.1074/jbc.M202056200</u>
- Hazelbaker, D. Z., Marquardt, S., Wlotzka, W., & Buratowski, S. (2013). Kinetic competition between RNA Polymerase II and Sen1-dependent transcription termination. *Mol Cell*, 49(1), 55-66. https://doi.org/10.1016/j.molcel.2012.10.014
- He, N., Chan, C. K., Sobhian, B., Chou, S., Xue, Y., Liu, M., Alber, T., Benkirane, M., & Zhou, Q. (2011). Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. *Proc Natl Acad Sci U S A*, *108*(36), E636-645. https://doi.org/10.1073/pnas.1107107108
- Heidemann, M., Hintermair, C., Voß, K., & Eick, D. (2013). Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription. *Biochim Biophys Acta*, *1829*(1), 55-62. <u>https://doi.org/10.1016/j.bbagrm.2012.08.013</u>
- Hengartner, C. J., Myer, V. E., Liao, S. M., Wilson, C. J., Koh, S. S., & Young, R. A. (1998). Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclindependent kinases. *Mol Cell*, 2(1), 43-53. <u>https://doi.org/10.1016/s1097-2765(00)80112-4</u>
- Henriques, T., Scruggs, B. S., Inouye, M. O., Muse, G. W., Williams, L. H., Burkholder, A. B., Lavender, C. A., Fargo, D. C., & Adelman, K. (2018). Widespread transcriptional pausing and elongation control at enhancers. *Genes Dev*, 32(1), 26-41. <u>https://doi.org/10.1101/gad.309351.117</u>
- Herzel, L., Ottoz, D. S. M., Alpert, T., & Neugebauer, K. M. (2017). Splicing and transcription touch base: co-transcriptional spliceosome assembly and function. *Nat Rev Mol Cell Biol*, 18(10), 637-650. <u>https://doi.org/10.1038/nrm.2017.63</u>
- Hill, C. S., Marais, R., John, S., Wynne, J., Dalton, S., & Treisman, R. (1993). Functional analysis of a growth factor-responsive transcription factor complex. *Cell*, 73(2), 395-406.
- Hill, C. S., Wynne, J., & Treisman, R. (1994). Serum-regulated transcription by serum response factor (SRF): a novel role for the DNA binding domain. *EMBO J*, *13*(22), 5421-5432.
- Hill, C. S., Wynne, J., & Treisman, R. (1995). The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. *Cell*, *81*(7), 1159-1170.
- Hilleren, P., McCarthy, T., Rosbash, M., Parker, R., & Jensen, T. H. (2001). Quality control of mRNA 3'-end processing is linked to the nuclear exosome. *Nature*, 413(6855), 538-542. <u>https://doi.org/10.1038/35097110</u>
- Hinojosa, L. S., Holst, M., Baarlink, C., & Grosse, R. (2017). MRTF transcription and Ezrin-dependent plasma membrane blebbing are required for entotic invasion. J *Cell Biol*, 216(10), 3087-3095. https://doi.org/10.1083/jcb.201702010
- Hintermair, C., Heidemann, M., Koch, F., Descostes, N., Gut, M., Gut, I., Fenouil, R., Ferrier, P., Flatley, A., Kremmer, E., Chapman, R. D., Andrau, J. C., & Eick, D. (2012). Threonine-4 of mammalian RNA polymerase II CTD is targeted by Pololike kinase 3 and required for transcriptional elongation. *EMBO J*, *31*(12), 2784-2797. <u>https://doi.org/10.1038/emboj.2012.123</u>
- Hintermair, C., Voß, K., Forné, I., Heidemann, M., Flatley, A., Kremmer, E., Imhof, A., & Eick, D. (2016). Specific threonine-4 phosphorylation and function of RNA polymerase II CTD during M phase progression. *Sci Rep*, *6*, 27401. <u>https://doi.org/10.1038/srep27401</u>
- Hipp, L., Beer, J., Kuchler, O., Reisser, M., Sinske, D., Michaelis, J., Gebhardt, J. C. M., & Knöll, B. (2019). Single-molecule imaging of the transcription factor SRF reveals prolonged chromatin-binding kinetics upon cell stimulation. *Proc Natl Acad Sci U S A*, *116*(3), 880-889. <u>https://doi.org/10.1073/pnas.1812734116</u>

- Hipskind, R. A., Rao, V. N., Mueller, C. G., Reddy, E. S., & Nordheim, A. (1991). Etsrelated protein Elk-1 is homologous to the c-fos regulatory factor p62TCF. *Nature*, *354*(6354), 531-534. <u>https://doi.org/10.1038/354531a0</u>
- Hirano, H., & Matsuura, Y. (2011). Sensing actin dynamics: structural basis for G-actinsensitive nuclear import of MAL. *Biochem Biophys Res Commun*, 414(2), 373-378. <u>https://doi.org/10.1016/j.bbrc.2011.09.079</u>
- Hirose, Y., & Manley, J. L. (1998). RNA polymerase II is an essential mRNA polyadenylation factor. *Nature*, *395*(6697), 93-96. <u>https://doi.org/10.1038/25786</u>
- Hirose, Y., & Manley, J. L. (2000). RNA polymerase II and the integration of nuclear events. *Genes Dev*, *14*(12), 1415-1429.
- Hirose, Y., Tacke, R., & Manley, J. L. (1999). Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. *Genes Dev*, *13*(10), 1234-1239. https://doi.org/10.1101/gad.13.10.1234
- Ho, C. K., & Shuman, S. (1999). Distinct roles for CTD Ser-2 and Ser-5 phosphorylation in the recruitment and allosteric activation of mammalian mRNA capping enzyme. *Mol Cell*, *3*(3), 405-411. <u>https://doi.org/10.1016/s1097-2765(00)80468-2</u>
- Hobson, D. J., Wei, W., Steinmetz, L. M., & Svejstrup, J. Q. (2012). RNA polymerase II collision interrupts convergent transcription. *Mol Cell*, *48*(3), 365-374. <u>https://doi.org/10.1016/j.molcel.2012.08.027</u>
- Holz-Schietinger, C., Matje, D. M., & Reich, N. O. (2012). Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. *J Biol Chem*, 287(37), 30941-30951. <u>https://doi.org/10.1074/jbc.M112.366625</u>
- Hosoda, N., Kim, Y. K., Lejeune, F., & Maquat, L. E. (2005). CBP80 promotes interaction of Upf1 with Upf2 during nonsense-mediated mRNA decay in mammalian cells. *Nat Struct Mol Biol*, *12*(10), 893-901. <u>https://doi.org/10.1038/nsmb995</u>
- Hottiger, M. O. (2015). Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics. *Annu Rev Biochem*, *84*, 227-263. <u>https://doi.org/10.1146/annurev-biochem-060614-034506</u>
- Howe, K. J., Kane, C. M., & Ares, M. (2003). Perturbation of transcription elongation influences the fidelity of internal exon inclusion in Saccharomyces cerevisiae. *RNA*, 9(8), 993-1006. <u>https://doi.org/10.1261/rna.5390803</u>
- Hrossova, D., Sikorsky, T., Potesil, D., Bartosovic, M., Pasulka, J., Zdrahal, Z., Stefl, R., & Vanacova, S. (2015). RBM7 subunit of the NEXT complex binds U-rich sequences and targets 3'-end extended forms of snRNAs. *Nucleic Acids Res*, 43(8), 4236-4248. <u>https://doi.org/10.1093/nar/gkv240</u>
- Hsin, J. P., Li, W., Hoque, M., Tian, B., & Manley, J. L. (2014). RNAP II CTD tyrosine 1 performs diverse functions in vertebrate cells. *Elife*, *3*, e02112. https://doi.org/10.7554/eLife.02112
- Hsin, J. P., Sheth, A., & Manley, J. L. (2011). RNAP II CTD phosphorylated on threonine-4 is required for histone mRNA 3' end processing. *Science*, 334(6056), 683-686. <u>https://doi.org/10.1126/science.1206034</u>
- Hsin, J. P., Xiang, K., & Manley, J. L. (2014). Function and control of RNA polymerase II C-terminal domain phosphorylation in vertebrate transcription and RNA processing. *Mol Cell Biol*, *34*(13), 2488-2498. <u>https://doi.org/10.1128/MCB.00181-14</u>
- Hsu, C., Scherrer, S., Buetti-Dinh, A., Ratna, P., Pizzolato, J., Jaquet, V., & Becskei, A. (2012). Stochastic signalling rewires the interaction map of a multiple feedback network during yeast evolution. *Nat Commun*, *3*, 682. <u>https://doi.org/10.1038/ncomms1687</u>

- Huang, B., Yang, X. D., Zhou, M. M., Ozato, K., & Chen, L. F. (2009). Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. *Mol Cell Biol*, 29(5), 1375-1387. <u>https://doi.org/10.1128/MCB.01365-08</u>
- Huertas, P., & Aguilera, A. (2003). Cotranscriptionally formed DNA:RNA hybrids mediate transcription elongation impairment and transcription-associated recombination. *Mol Cell*, *12*(3), 711-721. https://doi.org/10.1016/j.molcel.2003.08.010
- Huet, G., Rajakylä, E. K., Viita, T., Skarp, K. P., Crivaro, M., Dopie, J., & Vartiainen, M. K. (2013). Actin-regulated feedback loop based on Phactr4, PP1 and cofilin maintains the actin monomer pool. *J Cell Sci*, *126*(Pt 2), 497-507. <u>https://doi.org/10.1242/jcs.113241</u>
- Iasillo, C., Schmid, M., Yahia, Y., Maqbool, M. A., Descostes, N., Karadoulama, E., Bertrand, E., Andrau, J. C., & Jensen, T. H. (2017). ARS2 is a general suppressor of pervasive transcription. *Nucleic Acids Res*, 45(17), 10229-10241. https://doi.org/10.1093/nar/gkx647
- Inoue, K., Ohno, M., Sakamoto, H., & Shimura, Y. (1989). Effect of the cap structure on pre-mRNA splicing in Xenopus oocyte nuclei. *Genes Dev*, *3*(9), 1472-1479. https://doi.org/10.1101/gad.3.9.1472
- Ivanov, D., Kwak, Y. T., Guo, J., & Gaynor, R. B. (2000). Domains in the SPT5 protein that modulate its transcriptional regulatory properties. *Mol Cell Biol*, 20(9), 2970-2983. <u>https://doi.org/10.1128/mcb.20.9.2970-2983.2000</u>
- Izaurralde, E., Lewis, J., McGuigan, C., Jankowska, M., Darzynkiewicz, E., & Mattaj, I. W. (1994). A nuclear cap binding protein complex involved in pre-mRNA splicing. *Cell*, *78*(4), 657-668. <u>https://doi.org/10.1016/0092-8674(94)90530-4</u>
- Jarmolowski, A., Boelens, W. C., Izaurralde, E., & Mattaj, I. W. (1994). Nuclear export of different classes of RNA is mediated by specific factors. *J Cell Biol*, 124(5), 627-635. <u>https://doi.org/10.1083/jcb.124.5.627</u>
- Jasiak, A. J., Armache, K. J., Martens, B., Jansen, R. P., & Cramer, P. (2006). Structural biology of RNA polymerase III: subcomplex C17/25 X-ray structure and 11 subunit enzyme model. *Mol Cell*, 23(1), 71-81. https://doi.org/10.1016/j.molcel.2006.05.013
- Jelinic, P., Pellegrino, J., & David, G. (2011). A novel mammalian complex containing Sin3B mitigates histone acetylation and RNA polymerase II progression within transcribed loci. *Mol Cell Biol*, *31*(1), 54-62. <u>https://doi.org/10.1128/MCB.00840-</u>10
- Jensen, T. H., Boulay, J., Rosbash, M., & Libri, D. (2001). The DECD box putative ATPase Sub2p is an early mRNA export factor. *Curr Biol*, *11*(21), 1711-1715. https://doi.org/10.1016/s0960-9822(01)00529-2
- Jeronimo, C., & Robert, F. (2017). The Mediator Complex: At the Nexus of RNA Polymerase II Transcription. *Trends Cell Biol*, 27(10), 765-783. <u>https://doi.org/10.1016/j.tcb.2017.07.001</u>
- Jin, C., Zang, C., Wei, G., Cui, K., Peng, W., Zhao, K., & Felsenfeld, G. (2009). H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. *Nat Genet*, *41*(8), 941-945. https://doi.org/10.1038/ng.409
- Johnson, S. A., Cubberley, G., & Bentley, D. L. (2009). Cotranscriptional recruitment of the mRNA export factor Yra1 by direct interaction with the 3' end processing factor Pcf11. *Mol Cell*, 33(2), 215-226. https://doi.org/10.1016/i.molcel.2008.12.007
- Johnson, S. J., & Jackson, R. N. (2013). Ski2-like RNA helicase structures: common themes and complex assemblies. *RNA Biol*, *10*(1), 33-43. <u>https://doi.org/10.4161/rna.22101</u>

- Jonkers, I., Kwak, H., & Lis, J. T. (2014). Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons. *Elife*, *3*, e02407. <u>https://doi.org/10.7554/eLife.02407</u>
- Jove, R., & Manley, J. L. (1984). In vitro transcription from the adenovirus 2 major late promoter utilizing templates truncated at promoter-proximal sites. *J Biol Chem*, 259(13), 8513-8521.
- Kagey, M. H., Newman, J. J., Bilodeau, S., Zhan, Y., Orlando, D. A., van Berkum, N. L., Ebmeier, C. C., Goossens, J., Rahl, P. B., Levine, S. S., Taatjes, D. J., Dekker, J., & Young, R. A. (2010). Mediator and cohesin connect gene expression and chromatin architecture. *Nature*, *467*(7314), 430-435. <u>https://doi.org/10.1038/nature09380</u>
- Kamenski, T., Heilmeier, S., Meinhart, A., & Cramer, P. (2004). Structure and mechanism of RNA polymerase II CTD phosphatases. *Mol Cell*, *15*(3), 399-407. <u>https://doi.org/10.1016/j.molcel.2004.06.035</u>
- Kamieniarz-Gdula, K., Gdula, M. R., Panser, K., Nojima, T., Monks, J., Wiśniewski, J. R., Riepsaame, J., Brockdorff, N., Pauli, A., & Proudfoot, N. J. (2019). Selective Roles of Vertebrate PCF11 in Premature and Full-Length Transcript Termination. *Mol Cell*, *74*(1), 158-172.e159. https://doi.org/10.1016/j.molcel.2019.01.027
- Kamieniarz-Gdula, K., & Proudfoot, N. J. (2019). Transcriptional Control by Premature Termination: A Forgotten Mechanism. *Trends Genet*, *35*(8), 553-564. <u>https://doi.org/10.1016/j.tig.2019.05.005</u>
- Kanin, E. I., Kipp, R. T., Kung, C., Slattery, M., Viale, A., Hahn, S., Shokat, K. M., & Ansari, A. Z. (2007). Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis. *Proc Natl Acad Sci U S A*, 104(14), 5812-5817. https://doi.org/10.1073/pnas.0611505104
- Kao, C. F., Hillyer, C., Tsukuda, T., Henry, K., Berger, S., & Osley, M. A. (2004). Rad6 plays a role in transcriptional activation through ubiquitylation of histone H2B. *Genes Dev*, 18(2), 184-195. <u>https://doi.org/10.1101/gad.1149604</u>
- Katan-Khaykovich, Y., & Struhl, K. (2002). Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. *Genes Dev*, 16(6), 743-752. <u>https://doi.org/10.1101/gad.967302</u>
- Kettenberger, H., Armache, K. J., & Cramer, P. (2004). Complete RNA polymerase II elongation complex structure and its interactions with NTP and TFIIS. *Mol Cell*, *16*(6), 955-965. <u>https://doi.org/10.1016/j.molcel.2004.11.040</u>
- Khodor, Y. L., Rodriguez, J., Abruzzi, K. C., Tang, C. H., Marr, M. T., & Rosbash, M. (2011). Nascent-seq indicates widespread cotranscriptional pre-mRNA splicing in Drosophila. *Genes Dev*, 25(23), 2502-2512. https://doi.org/10.1101/gad.178962.111
- Kilchert, C., Wittmann, S., & Vasiljeva, L. (2016). The regulation and functions of the nuclear RNA exosome complex. *Nat Rev Mol Cell Biol*, *17*(4), 227-239. https://doi.org/10.1038/nrm.2015.15
- Kim, J., Guermah, M., McGinty, R. K., Lee, J. S., Tang, Z., Milne, T. A., Shilatifard, A., Muir, T. W., & Roeder, R. G. (2009). RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. *Cell*, 137(3), 459-471. <u>https://doi.org/10.1016/j.cell.2009.02.027</u>
- Kim, J., Guermah, M., & Roeder, R. G. (2010). The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS. *Cell*, *140*(4), 491-503. <u>https://doi.org/10.1016/j.cell.2009.12.050</u>
- Kim, J. B., & Sharp, P. A. (2001). Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain

independently of cyclin-dependent kinase-activating kinase. *J Biol Chem*, 276(15), 12317-12323. <u>https://doi.org/10.1074/jbc.M010908200</u>

- Kim, K. M., Cho, H., Choi, K., Kim, J., Kim, B. W., Ko, Y. G., Jang, S. K., & Kim, Y. K. (2009). A new MIF4G domain-containing protein, CTIF, directs nuclear capbinding protein CBP80/20-dependent translation. *Genes Dev*, 23(17), 2033-2045. <u>https://doi.org/10.1101/gad.1823409</u>
- Kim, M., Krogan, N. J., Vasiljeva, L., Rando, O. J., Nedea, E., Greenblatt, J. F., & Buratowski, S. (2004). The yeast Rat1 exonuclease promotes transcription termination by RNA polymerase II. *Nature*, 432(7016), 517-522. https://doi.org/10.1038/nature03041
- Kim, T. K., Ebright, R. H., & Reinberg, D. (2000). Mechanism of ATP-dependent promoter melting by transcription factor IIH. Science, 288(5470), 1418-1422. <u>https://doi.org/10.1126/science.288.5470.1418</u>
- Kim, W. Y., & Dahmus, M. E. (1986). Immunochemical analysis of mammalian RNA polymerase II subspecies. Stability and relative in vivo concentration. *J Biol Chem*, 261(30), 14219-14225.
- Kim, Y. K., Bourgeois, C. F., Isel, C., Churcher, M. J., & Karn, J. (2002). Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. *Mol Cell Biol*, 22(13), 4622-4637. https://doi.org/10.1128/mcb.22.13.4622-4637.2002
- Kiriyama, M., Kobayashi, Y., Saito, M., Ishikawa, F., & Yonehara, S. (2009). Interaction of FLASH with arsenite resistance protein 2 is involved in cell cycle progression at S phase. *Mol Cell Biol*, 29(17), 4729-4741. https://doi.org/10.1128/MCB.00289-09
- Kiseleva, E., Drummond, S. P., Goldberg, M. W., Rutherford, S. A., Allen, T. D., & Wilson, K. L. (2004). Actin- and protein-4.1-containing filaments link nuclear pore complexes to subnuclear organelles in Xenopus oocyte nuclei. *J Cell Sci*, *117*(Pt 12), 2481-2490. <u>https://doi.org/10.1242/jcs.01098</u>
- Kizer, K. O., Phatnani, H. P., Shibata, Y., Hall, H., Greenleaf, A. L., & Strahl, B. D. (2005). A novel domain in Set2 mediates RNA polymerase II interaction and couples histone H3 K36 methylation with transcript elongation. *Mol Cell Biol*, 25(8), 3305-3316. https://doi.org/10.1128/MCB.25.8.3305-3316.2005
- Knöll, B., Kretz, O., Fiedler, C., Alberti, S., Schütz, G., Frotscher, M., & Nordheim, A. (2006). Serum response factor controls neuronal circuit assembly in the hippocampus. *Nat Neurosci*, 9(2), 195-204. <u>https://doi.org/10.1038/nn1627</u>
- Kobor, M. S., Venkatasubrahmanyam, S., Meneghini, M. D., Gin, J. W., Jennings, J. L., Link, A. J., Madhani, H. D., & Rine, J. (2004). A protein complex containing the conserved Swi2/Snf2-related ATPase Swr1p deposits histone variant H2A.Z into euchromatin. *PLoS Biol*, 2(5), E131. https://doi.org/10.1371/journal.pbio.0020131
- Kokai, E., Beck, H., Weissbach, J., Arnold, F., Sinske, D., Sebert, U., Gaiselmann, G., Schmidt, V., Walther, P., Münch, J., Posern, G., & Knöll, B. (2014). Analysis of nuclear actin by overexpression of wild-type and actin mutant proteins. *Histochem Cell Biol*, *141*(2), 123-135. <u>https://doi.org/10.1007/s00418-013-1151-</u> <u>4</u>
- Komarnitsky, P., Cho, E. J., & Buratowski, S. (2000). Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. *Genes Dev*, *14*(19), 2452-2460. <u>https://doi.org/10.1101/gad.824700</u>
- Konarska, M. M., Padgett, R. A., & Sharp, P. A. (1984). Recognition of cap structure in splicing in vitro of mRNA precursors. *Cell*, *38*(3), 731-736. <u>https://doi.org/10.1016/0092-8674(84)90268-x</u>

- Kortenjann, M., Thomae, O., & Shaw, P. E. (1994). Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogenactivated protein kinase Erk2. *Mol Cell Biol*, *14*(7), 4815-4824. <u>https://doi.org/10.1128/mcb.14.7.4815</u>
- Krajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., Dodd, O., Chipumuro, E., Zhang, T., Greenleaf, A. L., Yuan, G. C., Gray, N. S., Young, R. A., Geyer, M., Gerber, S. A., & George, R. E. (2019). CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. *Nat Commun*, *10*(1), 1757. https://doi.org/10.1038/s41467-019-09703-y
- Krishnamurthy, S., Ghazy, M. A., Moore, C., & Hampsey, M. (2009). Functional interaction of the Ess1 prolyl isomerase with components of the RNA polymerase II initiation and termination machineries. *Mol Cell Biol*, 29(11), 2925-2934. <u>https://doi.org/10.1128/MCB.01655-08</u>
- Krishnamurthy, S., He, X., Reyes-Reyes, M., Moore, C., & Hampsey, M. (2004). Ssu72 Is an RNA polymerase II CTD phosphatase. *Mol Cell*, *14*(3), 387-394. <u>https://doi.org/10.1016/s1097-2765(04)00235-7</u>
- Krogan, N. J., Dover, J., Wood, A., Schneider, J., Heidt, J., Boateng, M. A., Dean, K., Ryan, O. W., Golshani, A., Johnston, M., Greenblatt, J. F., & Shilatifard, A. (2003). The Paf1 complex is required for histone H3 methylation by COMPASS and Dot1p: linking transcriptional elongation to histone methylation. *Mol Cell*, *11*(3), 721-729. <u>https://doi.org/10.1016/s1097-2765(03)00091-1</u>
- Krumm, A., Meulia, T., Brunvand, M., & Groudine, M. (1992). The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region. *Genes Dev*, 6(11), 2201-2213. <u>https://doi.org/10.1101/gad.6.11.2201</u>
- Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M., & Horinouchi, S. (1999). Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. *Proc Natl Acad Sci U S A*, *96*(16), 9112-9117.
- Kuhlman, T. C., Cho, H., Reinberg, D., & Hernandez, N. (1999). The general transcription factors IIA, IIB, IIF, and IIE are required for RNA polymerase II transcription from the human U1 small nuclear RNA promoter. *Mol Cell Biol*, *19*(3), 2130-2141. <u>https://doi.org/10.1128/mcb.19.3.2130</u>
- Kuhn, C. D., Geiger, S. R., Baumli, S., Gartmann, M., Gerber, J., Jennebach, S., Mielke, T., Tschochner, H., Beckmann, R., & Cramer, P. (2007). Functional architecture of RNA polymerase I. *Cell*, *131*(7), 1260-1272. https://doi.org/10.1016/j.cell.2007.10.051
- Kumar, G. S., Chang, W., Xie, T., Patel, A., Zhang, Y., Wang, G. G., David, G., & Radhakrishnan, I. (2012). Sequence requirements for combinatorial recognition of histone H3 by the MRG15 and Pf1 subunits of the Rpd3S/Sin3S corepressor complex. J Mol Biol, 422(4), 519-531. <u>https://doi.org/10.1016/j.jmb.2012.06.013</u>
- Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002). Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. *Genes Dev*, *16*(22), 2893-2905. <u>https://doi.org/10.1101/gad.1035902</u>
- Kwak, H., Fuda, N. J., Core, L. J., & Lis, J. T. (2013). Precise maps of RNA polymerase reveal how promoters direct initiation and pausing. *Science*, 339(6122), 950-953. <u>https://doi.org/10.1126/science.1229386</u>
- Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B.,
 Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., Jenkins, C. E., Hannett,
 N. M., McMillin, D., Sanda, T., Sim, T., Kim, N. D., Look, T., Mitsiades, C. S.,
 Weng, A. P., Brown, J. R., Benes, C. H., Marto, J. A., Young, R. A., & Gray, N.

S. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature*, *511*(7511), 616-620. <u>https://doi.org/10.1038/nature13393</u>

- Kyburz, A., Friedlein, A., Langen, H., & Keller, W. (2006). Direct interactions between subunits of CPSF and the U2 snRNP contribute to the coupling of pre-mRNA 3' end processing and splicing. *Mol Cell*, 23(2), 195-205. https://doi.org/10.1016/j.molcel.2006.05.037
- LaCava, J., Houseley, J., Saveanu, C., Petfalski, E., Thompson, E., Jacquier, A., & Tollervey, D. (2005). RNA degradation by the exosome is promoted by a nuclear polyadenylation complex. *Cell*, *121*(5), 713-724. https://doi.org/10.1016/j.cell.2005.04.029
- Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. *Nature*, *410*(6824), 116-120. <u>https://doi.org/10.1038/35065132</u>
- Lagha, M., Bothma, J. P., Esposito, E., Ng, S., Stefanik, L., Tsui, C., Johnston, J., Chen, K., Gilmour, D. S., Zeitlinger, J., & Levine, M. S. (2013). Paused Pol II coordinates tissue morphogenesis in the Drosophila embryo. *Cell*, *153*(5), 976-987. <u>https://doi.org/10.1016/j.cell.2013.04.045</u>
- Laribee, R. N., Krogan, N. J., Xiao, T., Shibata, Y., Hughes, T. R., Greenblatt, J. F., & Strahl, B. D. (2005). BUR kinase selectively regulates H3 K4 trimethylation and H2B ubiquitylation through recruitment of the PAF elongation complex. *Curr Biol*, 15(16), 1487-1493. https://doi.org/10.1016/j.cub.2005.07.028
- Latos, P. A., Pauler, F. M., Koerner, M. V., Şenergin, H. B., Hudson, Q. J., Stocsits, R. R., Allhoff, W., Stricker, S. H., Klement, R. M., Warczok, K. E., Aumayr, K., Pasierbek, P., & Barlow, D. P. (2012). Airn transcriptional overlap, but not its IncRNA products, induces imprinted Igf2r silencing. *Science*, *338*(6113), 1469-1472. <u>https://doi.org/10.1126/science.1228110</u>
- Lebreton, A., Tomecki, R., Dziembowski, A., & Séraphin, B. (2008). Endonucleolytic RNA cleavage by a eukaryotic exosome. *Nature*, *456*(7224), 993-996. <u>https://doi.org/10.1038/nature07480</u>
- Lee, C. K., Shibata, Y., Rao, B., Strahl, B. D., & Lieb, J. D. (2004). Evidence for nucleosome depletion at active regulatory regions genome-wide. *Nat Genet*, 36(8), 900-905. <u>https://doi.org/10.1038/ng1400</u>
- Lee, D. Y., Hayes, J. J., Pruss, D., & Wolffe, A. P. (1993). A positive role for histone acetylation in transcription factor access to nucleosomal DNA. *Cell*, 72(1), 73-84. https://doi.org/10.1016/0092-8674(93)90051-q
- Lee, J. S., Garrett, A. S., Yen, K., Takahashi, Y. H., Hu, D., Jackson, J., Seidel, C., Pugh, B. F., & Shilatifard, A. (2012). Codependency of H2B monoubiquitination and nucleosome reassembly on Chd1. *Genes Dev*, *26*(9), 914-919. https://doi.org/10.1101/gad.186841.112
- Lee, J. S., Shukla, A., Schneider, J., Swanson, S. K., Washburn, M. P., Florens, L., Bhaumik, S. R., & Shilatifard, A. (2007). Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. *Cell*, *131*(6), 1084-1096. <u>https://doi.org/10.1016/j.cell.2007.09.046</u>
- Lee, K. M., Miklos, I., Du, H., Watt, S., Szilagyi, Z., Saiz, J. E., Madabhushi, R., Penkett, C. J., Sipiczki, M., Bähler, J., & Fisher, R. P. (2005). Impairment of the TFIIH-associated CDK-activating kinase selectively affects cell cycle-regulated gene expression in fission yeast. *Mol Biol Cell*, *16*(6), 2734-2745. <u>https://doi.org/10.1091/mbc.e04-11-0982</u>
- Lei, H., Wu, D., Wang, J. Y., Li, L., Zhang, C. L., Feng, H., Fu, F. Y., & Wu, L. L. (2015). C1q/tumor necrosis factor-related protein-6 attenuates post-infarct cardiac fibrosis by targeting RhoA/MRTF-A pathway and inhibiting myofibroblast differentiation. *Basic Res Cardiol*, *110*(4), 35. <u>https://doi.org/10.1007/s00395-015-0492-7</u>

- Levine, J. H., Lin, Y., & Elowitz, M. B. (2013). Functional roles of pulsing in genetic circuits. *Science*, *342*(6163), 1193-1200. https://doi.org/10.1126/science.1239999
- Li, B., Carey, M., & Workman, J. L. (2007). The role of chromatin during transcription. *Cell*, *128*(4), 707-719. <u>https://doi.org/10.1016/j.cell.2007.01.015</u>
- Li, B., Howe, L., Anderson, S., Yates, J. R., & Workman, J. L. (2003). The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. *J Biol Chem*, *278*(11), 8897-8903. https://doi.org/10.1074/jbc.M212134200
- Li, H., Zhang, Z., Wang, B., Zhang, J., Zhao, Y., & Jin, Y. (2007). Wwp2-mediated ubiquitination of the RNA polymerase II large subunit in mouse embryonic pluripotent stem cells. *Mol Cell Biol*, *27*(15), 5296-5305. https://doi.org/10.1128/MCB.01667-06
- Li, J., Zhu, X., Chen, M., Cheng, L., Zhou, D., Lu, M. M., Du, K., Epstein, J. A., & Parmacek, M. S. (2005). Myocardin-related transcription factor B is required in cardiac neural crest for smooth muscle differentiation and cardiovascular development. *Proc Natl Acad Sci U S A*, *102*(25), 8916-8921. https://doi.org/10.1073/pnas.0503741102
- Li, S., Chang, S., Qi, X., Richardson, J. A., & Olson, E. N. (2006). Requirement of a myocardin-related transcription factor for development of mammary myoepithelial cells. *Mol Cell Biol*, 26(15), 5797-5808. <u>https://doi.org/10.1128/MCB.00211-06</u>
- Liang, G., Lin, J. C., Wei, V., Yoo, C., Cheng, J. C., Nguyen, C. T., Weisenberger, D. J., Egger, G., Takai, D., Gonzales, F. A., & Jones, P. A. (2004). Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. *Proc Natl Acad Sci U S A*, 101(19), 7357-7362. <u>https://doi.org/10.1073/pnas.0401866101</u>
- Liang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015). Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. *Mol Cell Biol*, 35(6), 928-938. <u>https://doi.org/10.1128/MCB.01426-14</u>
- Liao, S. M., Zhang, J., Jeffery, D. A., Koleske, A. J., Thompson, C. M., Chao, D. M., Viljoen, M., van Vuuren, H. J., & Young, R. A. (1995). A kinase-cyclin pair in the RNA polymerase II holoenzyme. *Nature*, *374*(6518), 193-196. https://doi.org/10.1038/374193a0
- Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011). Molecular signatures database (MSigDB) 3.0. *Bioinformatics*, 27(12), 1739-1740. <u>https://doi.org/10.1093/bioinformatics/btr260</u>
- Libri, D., Dower, K., Boulay, J., Thomsen, R., Rosbash, M., & Jensen, T. H. (2002). Interactions between mRNA export commitment, 3'-end quality control, and nuclear degradation. *Mol Cell Biol*, 22(23), 8254-8266. <u>https://doi.org/10.1128/mcb.22.23.8254-8266.2002</u>
- Licatalosi, D. D., Geiger, G., Minet, M., Schroeder, S., Cilli, K., McNeil, J. B., & Bentley, D. L. (2002). Functional interaction of yeast pre-mRNA 3' end processing factors with RNA polymerase II. *Mol Cell*, *9*(5), 1101-1111. <u>https://doi.org/10.1016/s1097-2765(02)00518-x</u>
- Lim, J., Giri, P. K., Kazadi, D., Laffleur, B., Zhang, W., Grinstein, V., Pefanis, E., Brown, L. M., Ladewig, E., Martin, O., Chen, Y., Rabadan, R., Boyer, F., Rothschild, G., Cogné, M., Pinaud, E., Deng, H., & Basu, U. (2017). Nuclear Proximity of Mtr4 to RNA Exosome Restricts DNA Mutational Asymmetry. *Cell*, 169(3), 523-537.e515. <u>https://doi.org/10.1016/j.cell.2017.03.043</u>

- Lin, C., Smith, E. R., Takahashi, H., Lai, K. C., Martin-Brown, S., Florens, L., Washburn, M. P., Conaway, J. W., Conaway, R. C., & Shilatifard, A. (2010). AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. *Mol Cell*, 37(3), 429-437. <u>https://doi.org/10.1016/j.molcel.2010.01.026</u>
- Lin, P. S., Dubois, M. F., & Dahmus, M. E. (2002). TFIIF-associating carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II. *J Biol Chem*, 277(48), 45949-45956. <u>https://doi.org/10.1074/jbc.M208588200</u>
- Lin, S., Coutinho-Mansfield, G., Wang, D., Pandit, S., & Fu, X. D. (2008). The splicing factor SC35 has an active role in transcriptional elongation. *Nat Struct Mol Biol*, *15*(8), 819-826. <u>https://doi.org/10.1038/nsmb.1461</u>
- Lis, J. T., Mason, P., Peng, J., Price, D. H., & Werner, J. (2000). P-TEFb kinase recruitment and function at heat shock loci. *Genes Dev*, *14*(7), 792-803.
- Liu, L. F., & Wang, J. C. (1987). Supercoiling of the DNA template during transcription. *Proc Natl Acad Sci U S A*, 84(20), 7024-7027. https://doi.org/10.1073/pnas.84.20.7024
- Ljungman, M., & Hanawalt, P. C. (1996). The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. *Carcinogenesis*, *17*(1), 31-35. <u>https://doi.org/10.1093/carcin/17.1.31</u>
- Lloret-Llinares, M., Karadoulama, E., Chen, Y., Wojenski, L. A., Villafano, G. J., Bornholdt, J., Andersson, R., Core, L., Sandelin, A., & Jensen, T. H. (2018). The RNA exosome contributes to gene expression regulation during stem cell differentiation. *Nucleic Acids Res*, *46*(21), 11502-11513. <u>https://doi.org/10.1093/nar/gky817</u>
- Logan, J., Falck-Pedersen, E., Darnell, J. E., & Shenk, T. (1987). A poly(A) addition site and a downstream termination region are required for efficient cessation of transcription by RNA polymerase II in the mouse beta maj-globin gene. *Proc Natl Acad Sci U S A*, *84*(23), 8306-8310. https://doi.org/10.1073/pnas.84.23.8306
- Lu, H., Flores, O., Weinmann, R., & Reinberg, D. (1991). The nonphosphorylated form of RNA polymerase II preferentially associates with the preinitiation complex. *Proc Natl Acad Sci U S A*, *88*(22), 10004-10008. <u>https://doi.org/10.1073/pnas.88.22.10004</u>
- Lu, H., Zawel, L., Fisher, L., Egly, J. M., & Reinberg, D. (1992). Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II. *Nature*, *358*(6388), 641-645. <u>https://doi.org/10.1038/358641a0</u>
- Lubas, M., Andersen, P. R., Schein, A., Dziembowski, A., Kudla, G., & Jensen, T. H. (2015). The human nuclear exosome targeting complex is loaded onto newly synthesized RNA to direct early ribonucleolysis. *Cell Rep*, *10*(2), 178-192. <u>https://doi.org/10.1016/j.celrep.2014.12.026</u>
- Lubas, M., Christensen, M. S., Kristiansen, M. S., Domanski, M., Falkenby, L. G., Lykke-Andersen, S., Andersen, J. S., Dziembowski, A., & Jensen, T. H. (2011). Interaction profiling identifies the human nuclear exosome targeting complex. *Mol Cell*, *43*(4), 624-637. <u>https://doi.org/10.1016/j.molcel.2011.06.028</u>
- Lubas, M., Damgaard, C. K., Tomecki, R., Cysewski, D., Jensen, T. H., & Dziembowski, A. (2013). Exonuclease hDIS3L2 specifies an exosomeindependent 3'-5' degradation pathway of human cytoplasmic mRNA. *EMBO J*, 32(13), 1855-1868. <u>https://doi.org/10.1038/emboj.2013.135</u>
- Luco, R. F., Pan, Q., Tominaga, K., Blencowe, B. J., Pereira-Smith, O. M., & Misteli, T. (2010). Regulation of alternative splicing by histone modifications. *Science*, 327(5968), 996-1000. <u>https://doi.org/10.1126/science.1184208</u>

- Lundquist, M. R., Storaska, A. J., Liu, T. C., Larsen, S. D., Evans, T., Neubig, R. R., & Jaffrey, S. R. (2014). Redox modification of nuclear actin by MICAL-2 regulates SRF signaling. *Cell*, *156*(3), 563-576. <u>https://doi.org/10.1016/j.cell.2013.12.035</u>
- Luo, M. L., Zhou, Z., Magni, K., Christoforides, C., Rappsilber, J., Mann, M., & Reed, R. (2001). Pre-mRNA splicing and mRNA export linked by direct interactions between UAP56 and Aly. *Nature*, *413*(6856), 644-647. https://doi.org/10.1038/35098106
- Luo, Z., Lin, C., & Shilatifard, A. (2012). The super elongation complex (SEC) family in transcriptional control. *Nat Rev Mol Cell Biol*, *13*(9), 543-547. https://doi.org/10.1038/nrm3417
- Lynch, C. J., Bernad, R., Calvo, I., Nóbrega-Pereira, S., Ruiz, S., Ibarz, N., Martinez-Val, A., Graña-Castro, O., Gómez-López, G., Andrés-León, E., Espinosa Angarica, V., Del Sol, A., Ortega, S., Fernandez-Capetillo, O., Rojo, E., Munoz, J., & Serrano, M. (2018). The RNA Polymerase II Factor RPAP1 Is Critical for Mediator-Driven Transcription and Cell Identity. *Cell Rep*, 22(2), 396-410. <u>https://doi.org/10.1016/j.celrep.2017.12.062</u>
- Malik, S., & Roeder, R. G. (2010). The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. *Nat Rev Genet*, *11*(11), 761-772. <u>https://doi.org/10.1038/nrg2901</u>
- Mandel, C. R., Kaneko, S., Zhang, H., Gebauer, D., Vethantham, V., Manley, J. L., & Tong, L. (2006). Polyadenylation factor CPSF-73 is the pre-mRNA 3'-endprocessing endonuclease. *Nature*, *444*(7121), 953-956. <u>https://doi.org/10.1038/nature05363</u>
- Marais, R., Wynne, J., & Treisman, R. (1993). The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. *Cell*, 73(2), 381-393. <u>https://doi.org/10.1016/0092-8674(93)90237-k</u>
- Margueron, R., & Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. *Nature*, 469(7330), 343-349. <u>https://doi.org/10.1038/nature09784</u>
- Marshall, N. F., Peng, J., Xie, Z., & Price, D. H. (1996). Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. *J Biol Chem*, 271(43), 27176-27183. https://doi.org/10.1074/jbc.271.43.27176
- Marzluff, W. F., Wagner, E. J., & Duronio, R. J. (2008). Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. *Nat Rev Genet*, 9(11), 843-854. <u>https://doi.org/10.1038/nrg2438</u>
- Mason, P. B., & Struhl, K. (2005). Distinction and relationship between elongation rate and processivity of RNA polymerase II in vivo. *Mol Cell*, *17*(6), 831-840. <u>https://doi.org/10.1016/j.molcel.2005.02.017</u>
- Maurice, D., Costello, P., Sargent, M., & Treisman, R. (2018). ERK Signaling Controls Innate-like CD8. *J Immunol*, 201(6), 1681-1691. https://doi.org/10.4049/jimmunol.1800704
- Mayer, A., Heidemann, M., Lidschreiber, M., Schreieck, A., Sun, M., Hintermair, C., Kremmer, E., Eick, D., & Cramer, P. (2012). CTD tyrosine phosphorylation impairs termination factor recruitment to RNA polymerase II. *Science*, 336(6089), 1723-1725. https://doi.org/10.1126/science.1219651
- McCracken, S., Fong, N., Rosonina, E., Yankulov, K., Brothers, G., Siderovski, D., Hessel, A., Foster, S., Shuman, S., & Bentley, D. L. (1997). 5'-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxyterminal domain of RNA polymerase II. *Genes Dev*, *11*(24), 3306-3318. <u>https://doi.org/10.1101/gad.11.24.3306</u>
- McHugh, C. A., Chen, C. K., Chow, A., Surka, C. F., Tran, C., McDonel, P., Pandya-Jones, A., Blanco, M., Burghard, C., Moradian, A., Sweredoski, M. J., Shishkin, A. A., Su, J., Lander, E. S., Hess, S., Plath, K., & Guttman, M. (2015). The Xist

IncRNA interacts directly with SHARP to silence transcription through HDAC3. *Nature*, *521*(7551), 232-236. <u>https://doi.org/10.1038/nature14443</u>

- Medjkane, S., Perez-Sanchez, C., Gaggioli, C., Sahai, E., & Treisman, R. (2009). Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. *Nat Cell Biol*, *11*(3), 257-268. <u>https://doi.org/10.1038/ncb1833</u>
- Meinhart, A., & Cramer, P. (2004). Recognition of RNA polymerase II carboxy-terminal domain by 3'-RNA-processing factors. *Nature*, *430*(6996), 223-226. <u>https://doi.org/10.1038/nature02679</u>
- Meneghini, M. D., Wu, M., & Madhani, H. D. (2003). Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. *Cell*, *112*(5), 725-736. <u>https://doi.org/10.1016/s0092-8674(03)00123-5</u>
- Meola, N., Domanski, M., Karadoulama, E., Chen, Y., Gentil, C., Pultz, D., Vitting-Seerup, K., Lykke-Andersen, S., Andersen, J. S., Sandelin, A., & Jensen, T. H. (2016). Identification of a Nuclear Exosome Decay Pathway for Processed Transcripts. *Mol Cell*, 64(3), 520-533. https://doi.org/10.1016/j.molcel.2016.09.025
- Michels, A. A., Fraldi, A., Li, Q., Adamson, T. E., Bonnet, F., Nguyen, V. T., Sedore, S. C., Price, J. P., Price, D. H., Lania, L., & Bensaude, O. (2004). Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. *EMBO J*, 23(13), 2608-2619. https://doi.org/10.1038/sj.emboj.7600275
- Milligan, L., Torchet, C., Allmang, C., Shipman, T., & Tollervey, D. (2005). A nuclear surveillance pathway for mRNAs with defective polyadenylation. *Mol Cell Biol*, 25(22), 9996-10004. <u>https://doi.org/10.1128/MCB.25.22.9996-10004.2005</u>
- Milne, T. A., Briggs, S. D., Brock, H. W., Martin, M. E., Gibbs, D., Allis, C. D., & Hess, J. L. (2002). MLL targets SET domain methyltransferase activity to Hox gene promoters. *Mol Cell*, *10*(5), 1107-1117. <u>https://doi.org/10.1016/s1097-2765(02)00741-4</u>
- Miralles, F., Posern, G., Zaromytidou, A. I., & Treisman, R. (2003). Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell*, *113*(3), 329-342.
- Misteli, T. (2001). Protein dynamics: implications for nuclear architecture and gene expression. *Science*, *291*(5505), 843-847. https://doi.org/10.1126/science.291.5505.843
- Mitchell, P., Petfalski, E., Shevchenko, A., Mann, M., & Tollervey, D. (1997). The exosome: a conserved eukaryotic RNA processing complex containing multiple 3'-->5' exoribonucleases. *Cell*, *91*(4), 457-466. <u>https://doi.org/10.1016/s0092-8674(00)80432-8</u>
- Mito, Y., Henikoff, J. G., & Henikoff, S. (2005). Genome-scale profiling of histone H3.3 replacement patterns. *Nat Genet*, *37*(10), 1090-1097. https://doi.org/10.1038/ng1637
- Mizuguchi, G., Shen, X., Landry, J., Wu, W. H., Sen, S., & Wu, C. (2004). ATP-driven exchange of histone H2AZ variant catalyzed by SWR1 chromatin remodeling complex. *Science*, *303*(5656), 343-348. https://doi.org/10.1126/science.1090701
- Mohan, M., Herz, H. M., Takahashi, Y. H., Lin, C., Lai, K. C., Zhang, Y., Washburn, M. P., Florens, L., & Shilatifard, A. (2010). Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). *Genes Dev*, 24(6), 574-589. <u>https://doi.org/10.1101/gad.1898410</u>
- Mohun, T., Garrett, N., & Treisman, R. (1987). Xenopus cytoskeletal actin and human c-fos gene promoters share a conserved protein-binding site. *EMBO J*, *6*(3), 667-673.
- Mokalled, M. H., Johnson, A., Kim, Y., Oh, J., & Olson, E. N. (2010). Myocardin-related transcription factors regulate the Cdk5/Pctaire1 kinase cascade to control

neurite outgrowth, neuronal migration and brain development. *Development*, *137*(14), 2365-2374. <u>https://doi.org/10.1242/dev.047605</u>

- Morisaki, T., Müller, W. G., Golob, N., Mazza, D., & McNally, J. G. (2014). Singlemolecule analysis of transcription factor binding at transcription sites in live cells. *Nat Commun*, *5*, 4456. <u>https://doi.org/10.1038/ncomms5456</u>
- Morris, D. P., Phatnani, H. P., & Greenleaf, A. L. (1999). Phospho-carboxyl-terminal domain binding and the role of a prolyl isomerase in pre-mRNA 3'-End formation. *J Biol Chem*, 274(44), 31583-31587. https://doi.org/10.1074/jbc.274.44.31583
- Morton, W. M., Ayscough, K. R., & McLaughlin, P. J. (2000). Latrunculin alters the actin-monomer subunit interface to prevent polymerization. *Nat Cell Biol*, *2*(6), 376-378. <u>https://doi.org/10.1038/35014075</u>
- Mosley, A. L., Pattenden, S. G., Carey, M., Venkatesh, S., Gilmore, J. M., Florens, L., Workman, J. L., & Washburn, M. P. (2009). Rtr1 is a CTD phosphatase that regulates RNA polymerase II during the transition from serine 5 to serine 2 phosphorylation. *Mol Cell*, *34*(2), 168-178. https://doi.org/10.1016/j.molcel.2009.02.025
- Mouilleron, S., Guettler, S., Langer, C. A., Treisman, R., & McDonald, N. Q. (2008). Molecular basis for G-actin binding to RPEL motifs from the serum response factor coactivator MAL. *EMBO J*, 27(23), 3198-3208. https://doi.org/10.1038/emboj.2008.235
- Mouilleron, S., Langer, C. A., Guettler, S., McDonald, N. Q., & Treisman, R. (2011). Structure of a pentavalent G-actin*MRTF-A complex reveals how G-actin controls nucleocytoplasmic shuttling of a transcriptional coactivator. *Sci Signal*, *4*(177), ra40. <u>https://doi.org/10.1126/scisignal.2001750</u>
- Muehlich, S., Wang, R., Lee, S. M., Lewis, T. C., Dai, C., & Prywes, R. (2008). Seruminduced phosphorylation of the serum response factor coactivator MKL1 by the extracellular signal-regulated kinase 1/2 pathway inhibits its nuclear localization. *Mol Cell Biol*, 28(20), 6302-6313. <u>https://doi.org/10.1128/MCB.00427-08</u>
- Muse, G. W., Gilchrist, D. A., Nechaev, S., Shah, R., Parker, J. S., Grissom, S. F., Zeitlinger, J., & Adelman, K. (2007). RNA polymerase is poised for activation across the genome. *Nat Genet*, *39*(12), 1507-1511. https://doi.org/10.1038/ng.2007.21
- Muthukrishnan, S., Both, G. W., Furuichi, Y., & Shatkin, A. J. (1975). 5'-Terminal 7methylguanosine in eukaryotic mRNA is required for translation. *Nature*, 255(5503), 33-37. <u>https://doi.org/10.1038/255033a0</u>
- Nag, A., Narsinh, K., & Martinson, H. G. (2007). The poly(A)-dependent transcriptional pause is mediated by CPSF acting on the body of the polymerase. *Nat Struct Mol Biol*, 14(7), 662-669. <u>https://doi.org/10.1038/nsmb1253</u>
- Nakajima, N., Horikoshi, M., & Roeder, R. G. (1988). Factors involved in specific transcription by mammalian RNA polymerase II: purification, genetic specificity, and TATA box-promoter interactions of TFIID. *Mol Cell Biol*, *8*(10), 4028-4040. <u>https://doi.org/10.1128/mcb.8.10.4028</u>
- Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Wassell, R., Dubois, G., Mazo, A., Croce, C. M., & Canaani, E. (2002). ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. *Mol Cell*, *10*(5), 1119-1128. <u>https://doi.org/10.1016/s1097-2765(02)00740-2</u>
- Narita, T., Yung, T. M., Yamamoto, J., Tsuboi, Y., Tanabe, H., Tanaka, K., Yamaguchi, Y., & Handa, H. (2007). NELF interacts with CBC and participates in 3' end processing of replication-dependent histone mRNAs. *Mol Cell*, *26*(3), 349-365. https://doi.org/10.1016/j.molcel.2007.04.011

- Neil, H., Malabat, C., d'Aubenton-Carafa, Y., Xu, Z., Steinmetz, L. M., & Jacquier, A. (2009). Widespread bidirectional promoters are the major source of cryptic transcripts in yeast. *Nature*, 457(7232), 1038-1042. <u>https://doi.org/10.1038/nature07747</u>
- Nemec, C. M., Yang, F., Gilmore, J. M., Hintermair, C., Ho, Y. H., Tseng, S. C., Heidemann, M., Zhang, Y., Florens, L., Gasch, A. P., Eick, D., Washburn, M. P., Varani, G., & Ansari, A. Z. (2017). Different phosphoisoforms of RNA polymerase II engage the Rtt103 termination factor in a structurally analogous manner. *Proc Natl Acad Sci U S A*, *114*(20), E3944-E3953. https://doi.org/10.1073/pnas.1700128114
- Ng, H. H., Ciccone, D. N., Morshead, K. B., Oettinger, M. A., & Struhl, K. (2003). Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation. *Proc Natl Acad Sci U S A*, *100*(4), 1820-1825. https://doi.org/10.1073/pnas.0437846100
- Ng, H. H., Robert, F., Young, R. A., & Struhl, K. (2003). Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. *Mol Cell*, *11*(3), 709-719. https://doi.org/10.1016/s1097-2765(03)00092-3
- Nguyen, V. T., Kiss, T., Michels, A. A., & Bensaude, O. (2001). 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. *Nature*, *414*(6861), 322-325. <u>https://doi.org/10.1038/35104581</u>
- Ni, Z., Olsen, J. B., Guo, X., Zhong, G., Ruan, E. D., Marcon, E., Young, P., Guo, H., Li, J., Moffat, J., Emili, A., & Greenblatt, J. F. (2011). Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. *Transcription*, 2(5), 237-242. <u>https://doi.org/10.4161/trns.2.5.17803</u>
- Ni, Z., Saunders, A., Fuda, N. J., Yao, J., Suarez, J. R., Webb, W. W., & Lis, J. T. (2008). P-TEFb is critical for the maturation of RNA polymerase II into productive elongation in vivo. *Mol Cell Biol*, *28*(3), 1161-1170. <u>https://doi.org/10.1128/MCB.01859-07</u>
- Ni, Z., Schwartz, B. E., Werner, J., Suarez, J. R., & Lis, J. T. (2004). Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes. *Mol Cell*, *13*(1), 55-65. <u>https://doi.org/10.1016/s1097-2765(03)00526-4</u>
- Ni, Z., Xu, C., Guo, X., Hunter, G. O., Kuznetsova, O. V., Tempel, W., Marcon, E., Zhong, G., Guo, H., Kuo, W. W., Li, J., Young, P., Olsen, J. B., Wan, C., Loppnau, P., El Bakkouri, M., Senisterra, G. A., He, H., Huang, H., Sidhu, S. S., Emili, A., Murphy, S., Mosley, A. L., Arrowsmith, C. H., Min, J., & Greenblatt, J. F. (2014). RPRD1A and RPRD1B are human RNA polymerase II C-terminal domain scaffolds for Ser5 dephosphorylation. *Nat Struct Mol Biol*, *21*(8), 686-695. https://doi.org/10.1038/nsmb.2853
- Nojima, T., Dienstbier, M., Murphy, S., Proudfoot, N. J., & Dye, M. J. (2013). Definition of RNA polymerase II CoTC terminator elements in the human genome. *Cell Rep*, *3*(4), 1080-1092. <u>https://doi.org/10.1016/j.celrep.2013.03.012</u>
- Nojima, T., Gomes, T., Grosso, A. R. F., Kimura, H., Dye, M. J., Dhir, S., Carmo-Fonseca, M., & Proudfoot, N. J. (2015). Mammalian NET-Seq Reveals Genome-wide Nascent Transcription Coupled to RNA Processing. *Cell*, *161*(3), 526-540. https://doi.org/10.1016/j.cell.2015.03.027
- Norman, C., Runswick, M., Pollock, R., & Treisman, R. (1988). Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. *Cell*, *55*(6), 989-1003. <u>https://doi.org/10.1016/0092-8674(88)90244-9</u>

- Ntini, E., Järvelin, A. I., Bornholdt, J., Chen, Y., Boyd, M., Jørgensen, M., Andersson, R., Hoof, I., Schein, A., Andersen, P. R., Andersen, P. K., Preker, P., Valen, E., Zhao, X., Pelechano, V., Steinmetz, L. M., Sandelin, A., & Jensen, T. H. (2013). Polyadenylation site-induced decay of upstream transcripts enforces promoter directionality. *Nat Struct Mol Biol*, *20*(8), 923-928. https://doi.org/10.1038/nsmb.2640
- O'Reilly, D., & Greaves, D. R. (2007). Cell-type-specific expression of the human CD68 gene is associated with changes in Pol II phosphorylation and short-range intrachromosomal gene looping. *Genomics*, *90*(3), 407-415. https://doi.org/10.1016/j.ygeno.2007.04.010
- O'Sullivan, C., Christie, J., Pienaar, M., Gambling, J., Nickerson, P. E., Alford, S. C., Chow, R. L., & Howard, P. L. (2015). Mutagenesis of ARS2 Domains To Assess Possible Roles in Cell Cycle Progression and MicroRNA and Replication-Dependent Histone mRNA Biogenesis. *Mol Cell Biol*, *35*(21), 3753-3767. <u>https://doi.org/10.1128/MCB.00272-15</u>
- Odawara, J., Harada, A., Yoshimi, T., Maehara, K., Tachibana, T., Okada, S., Akashi, K., & Ohkawa, Y. (2011). The classification of mRNA expression levels by the phosphorylation state of RNAPII CTD based on a combined genome-wide approach. *BMC Genomics*, *12*, 516. <u>https://doi.org/10.1186/1471-2164-12-516</u>
- Ogami, K., Chen, Y., & Manley, J. L. (2018). RNA surveillance by the nuclear RNA exosome: mechanisms and significance. *Noncoding RNA*, *4*(1). https://doi.org/10.3390/ncrna4010008
- Ogami, K., Richard, P., Chen, Y., Hoque, M., Li, W., Moresco, J. J., Yates, J. R., Tian, B., & Manley, J. L. (2017). An Mtr4/ZFC3H1 complex facilitates turnover of unstable nuclear RNAs to prevent their cytoplasmic transport and global translational repression. *Genes Dev*, *31*(12), 1257-1271. <u>https://doi.org/10.1101/gad.302604.117</u>
- Oh, J., Richardson, J. A., & Olson, E. N. (2005). Requirement of myocardin-related transcription factor-B for remodeling of branchial arch arteries and smooth muscle differentiation. *Proc Natl Acad Sci U S A*, *102*(42), 15122-15127. https://doi.org/10.1073/pnas.0507346102
- Ohkawa, T., & Welch, M. D. (2018). Baculovirus Actin-Based Motility Drives Nuclear Envelope Disruption and Nuclear Egress. *Curr Biol*, *28*(13), 2153-2159.e2154. <u>https://doi.org/10.1016/j.cub.2018.05.027</u>
- Ohno, M., Sakamoto, H., & Shimura, Y. (1987). Preferential excision of the 5' proximal intron from mRNA precursors with two introns as mediated by the cap structure. *Proc Natl Acad Sci U S A*, *84*(15), 5187-5191. https://doi.org/10.1073/pnas.84.15.5187
- Ohno, M., Segref, A., Bachi, A., Wilm, M., & Mattaj, I. W. (2000). PHAX, a mediator of U snRNA nuclear export whose activity is regulated by phosphorylation. *Cell*, *101*(2), 187-198. <u>https://doi.org/10.1016/S0092-8674(00)80829-6</u>
- Olson, E. N., & Nordheim, A. (2010). Linking actin dynamics and gene transcription to drive cellular motile functions. *Nat Rev Mol Cell Biol*, *11*(5), 353-365. <u>https://doi.org/10.1038/nrm2890</u>
- Osman, S., & Cramer, P. (2020a). Structural Biology of RNA Polymerase II Transcription: 20 Years On. *Annu Rev Cell Dev Biol*, 36, 1-34. <u>https://doi.org/10.1146/annurev-cellbio-042020-021954</u>
- Osman, S., & Cramer, P. (2020b). Structural Biology of RNA Polymerase II Transcription: 20 Years On. *Annu Rev Cell Dev Biol.* <u>https://doi.org/10.1146/annurev-cellbio-042020-021954</u>
- Ozbudak, E. M., Thattai, M., Kurtser, I., Grossman, A. D., & van Oudenaarden, A. (2002). Regulation of noise in the expression of a single gene. *Nat Genet*, *31*(1), 69-73. <u>https://doi.org/10.1038/ng869</u>

- Pabis, M., Neufeld, N., Steiner, M. C., Bojic, T., Shav-Tal, Y., & Neugebauer, K. M. (2013). The nuclear cap-binding complex interacts with the U4/U6·U5 tri-snRNP and promotes spliceosome assembly in mammalian cells. *RNA*, *19*(8), 1054-1063. https://doi.org/10.1261/rna.037069.112
- Palancade, B., Bellier, S., Almouzni, G., & Bensaude, O. (2001). Incomplete RNA polymerase II phosphorylation in Xenopus laevis early embryos. *J Cell Sci*, *114*(Pt 13), 2483-2489.
- Panayiotou, R., Miralles, F., Pawlowski, R., Diring, J., Flynn, H. R., Skehel, M., & Treisman, R. (2016). Phosphorylation acts positively and negatively to regulate MRTF-A subcellular localisation and activity. *Elife*, 5. https://doi.org/10.7554/eLife.15460
- Papamichos-Chronakis, M., Watanabe, S., Rando, O. J., & Peterson, C. L. (2011). Global regulation of H2A.Z localization by the INO80 chromatin-remodeling enzyme is essential for genome integrity. *Cell*, *144*(2), 200-213. <u>https://doi.org/10.1016/j.cell.2010.12.021</u>
- Parker, C. S., & Topol, J. (1984). A Drosophila RNA polymerase II transcription factor contains a promoter-region-specific DNA-binding activity. *Cell*, *36*(2), 357-369. https://doi.org/10.1016/0092-8674(84)90229-0
- Pavri, R., Zhu, B., Li, G., Trojer, P., Mandal, S., Shilatifard, A., & Reinberg, D. (2006). Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. *Cell*, *125*(4), 703-717. <u>https://doi.org/10.1016/j.cell.2006.04.029</u>
- Pawłowski, R., Rajakylä, E. K., Vartiainen, M. K., & Treisman, R. (2010). An actinregulated importin α/β-dependent extended bipartite NLS directs nuclear import of MRTF-A. *EMBO J*, 29(20), 3448-3458. https://doi.org/10.1038/emboj.2010.216
- Payne, J. M., Laybourn, P. J., & Dahmus, M. E. (1989). The transition of RNA polymerase II from initiation to elongation is associated with phosphorylation of the carboxyl-terminal domain of subunit IIa. *J Biol Chem*, *264*(33), 19621-19629.
- Pei, Y., Schwer, B., & Shuman, S. (2003). Interactions between fission yeast Cdk9, its cyclin partner Pch1, and mRNA capping enzyme Pct1 suggest an elongation checkpoint for mRNA quality control. *J Biol Chem*, 278(9), 7180-7188. <u>https://doi.org/10.1074/jbc.M211713200</u>
- Pellegrini, L., Tan, S., & Richmond, T. J. (1995). Structure of serum response factor core bound to DNA. *Nature*, 376(6540), 490-498. <u>https://doi.org/10.1038/376490a0</u>
- Pengelly, A. R., Copur, Ö., Jäckle, H., Herzig, A., & Müller, J. (2013). A histone mutant reproduces the phenotype caused by loss of histone-modifying factor Polycomb. *Science*, 339(6120), 698-699. <u>https://doi.org/10.1126/science.1231382</u>
- Phillips-Cremins, J. E., Sauria, M. E., Sanyal, A., Gerasimova, T. I., Lajoie, B. R., Bell, J. S., Ong, C. T., Hookway, T. A., Guo, C., Sun, Y., Bland, M. J., Wagstaff, W., Dalton, S., McDevitt, T. C., Sen, R., Dekker, J., Taylor, J., & Corces, V. G. (2013). Architectural protein subclasses shape 3D organization of genomes during lineage commitment. *Cell*, *153*(6), 1281-1295. <u>https://doi.org/10.1016/j.cell.2013.04.053</u>
- Ping, Y. H., & Rana, T. M. (2001). DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. *J Biol Chem*, 276(16), 12951-12958. <u>https://doi.org/10.1074/jbc.M006130200</u>
- Pirngruber, J., Shchebet, A., Schreiber, L., Shema, E., Minsky, N., Chapman, R. D., Eick, D., Aylon, Y., Oren, M., & Johnsen, S. A. (2009). CDK9 directs H2B

monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. *EMBO Rep*, *10*(8), 894-900. https://doi.org/10.1038/embor.2009.108

- Plessner, M., Melak, M., Chinchilla, P., Baarlink, C., & Grosse, R. (2015). Nuclear Factin formation and reorganization upon cell spreading. *J Biol Chem*, 290(18), 11209-11216. https://doi.org/10.1074/jbc.M114.627166
- Plet, A., Eick, D., & Blanchard, J. M. (1995). Elongation and premature termination of transcripts initiated from c-fos and c-myc promoters show dissimilar patterns. *Oncogene*, *10*(2), 319-328.
- Pohl, M. O., von Recum-Knepper, J., Rodriguez-Frandsen, A., Lanz, C., Yángüez, E., Soonthornvacharin, S., Wolff, T., Chanda, S. K., & Stertz, S. (2017). Identification of Polo-like kinases as potential novel drug targets for influenza A virus. *Sci Rep*, 7(1), 8629. <u>https://doi.org/10.1038/s41598-017-08942-7</u>
- Pokholok, D. K., Hannett, N. M., & Young, R. A. (2002). Exchange of RNA polymerase Il initiation and elongation factors during gene expression in vivo. *Mol Cell*, 9(4), 799-809. <u>https://doi.org/10.1016/s1097-2765(02)00502-6</u>
- Pokholok, D. K., Harbison, C. T., Levine, S., Cole, M., Hannett, N. M., Lee, T. I., Bell, G. W., Walker, K., Rolfe, P. A., Herbolsheimer, E., Zeitlinger, J., Lewitter, F., Gifford, D. K., & Young, R. A. (2005). Genome-wide map of nucleosome acetylation and methylation in yeast. *Cell*, *122*(4), 517-527. https://doi.org/10.1016/j.cell.2005.06.026
- Pollock, R., & Treisman, R. (1991). Human SRF-related proteins: DNA-binding properties and potential regulatory targets. *Genes Dev*, *5*(12A), 2327-2341.
- Posern, G., Miralles, F., Guettler, S., & Treisman, R. (2004). Mutant actins that stabilise F-actin use distinct mechanisms to activate the SRF coactivator MAL. *EMBO J*, 23(20), 3973-3983. <u>https://doi.org/10.1038/sj.emboj.7600404</u>
- Posern, G., Sotiropoulos, A., & Treisman, R. (2002). Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. *Mol Biol Cell*, 13(12), 4167-4178. <u>https://doi.org/10.1091/mbc.02-05-0068</u>
- Posern, G., & Treisman, R. (2006). Actin' together: serum response factor, its cofactors and the link to signal transduction. *Trends Cell Biol*, *16*(11), 588-596. <u>https://doi.org/10.1016/j.tcb.2006.09.008</u>
- Preker, P., Almvig, K., Christensen, M. S., Valen, E., Mapendano, C. K., Sandelin, A., & Jensen, T. H. (2011). PROMoter uPstream Transcripts share characteristics with mRNAs and are produced upstream of all three major types of mammalian promoters. *Nucleic Acids Res*, 39(16), 7179-7193. <u>https://doi.org/10.1093/nar/gkr370</u>
- Preker, P., Nielsen, J., Kammler, S., Lykke-Andersen, S., Christensen, M. S., Mapendano, C. K., Schierup, M. H., & Jensen, T. H. (2008). RNA exosome depletion reveals transcription upstream of active human promoters. *Science*, *322*(5909), 1851-1854. <u>https://doi.org/10.1126/science.1164096</u>
- Prescott, E. M., & Proudfoot, N. J. (2002). Transcriptional collision between convergent genes in budding yeast. *Proc Natl Acad Sci U S A*, *99*(13), 8796-8801. https://doi.org/10.1073/pnas.132270899
- Price, M. A., Cruzalegui, F. H., & Treisman, R. (1996). The p38 and ERK MAP kinase pathways cooperate to activate Ternary Complex Factors and c-fos transcription in response to UV light. *EMBO J*, *15*(23), 6552-6563.
- Protacio, R. U., Li, G., Lowary, P. T., & Widom, J. (2000). Effects of histone tail domains on the rate of transcriptional elongation through a nucleosome. *Mol Cell Biol*, *20*(23), 8866-8878. <u>https://doi.org/10.1128/mcb.20.23.8866-8878.2000</u>
- Proudfoot, N. (1996). Ending the message is not so simple. *Cell*, *87*(5), 779-781. <u>https://doi.org/10.1016/s0092-8674(00)81982-0</u>

- Puno, M. R., & Lima, C. D. (2018). Structural basis for MTR4-ZCCHC8 interactions that stimulate the MTR4 helicase in the nuclear exosome-targeting complex. *Proc Natl Acad Sci U S A*, 115(24), E5506-E5515. <u>https://doi.org/10.1073/pnas.1803530115</u>
- Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010). c-Myc regulates transcriptional pause release. *Cell*, 141(3), 432-445. <u>https://doi.org/10.1016/j.cell.2010.03.030</u>
- Raingeaud, J., Whitmarsh, A. J., Barrett, T., Dérijard, B., & Davis, R. J. (1996). MKK3and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. *Mol Cell Biol*, *16*(3), 1247-1255. https://doi.org/10.1128/mcb.16.3.1247
- Rajakylä, E. K., Viita, T., Kyheröinen, S., Huet, G., Treisman, R., & Vartiainen, M. K. (2015). RNA export factor Ddx19 is required for nuclear import of the SRF coactivator MKL1. *Nat Commun*, 6, 5978. https://doi.org/10.1038/ncomms6978
- Ramanathan, A., Robb, G. B., & Chan, S. H. (2016). mRNA capping: biological functions and applications. *Nucleic Acids Res*, *44*(16), 7511-7526. <u>https://doi.org/10.1093/nar/gkw551</u>
- Ramanathan, Y., Rajpara, S. M., Reza, S. M., Lees, E., Shuman, S., Mathews, M. B., & Pe'ery, T. (2001). Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences. *J Biol Chem*, 276(14), 10913-10920. <u>https://doi.org/10.1074/jbc.M010975200</u>
- Rando, O. J., & Chang, H. Y. (2009). Genome-wide views of chromatin structure. *Annu Rev Biochem*, 78, 245-271.

https://doi.org/10.1146/annurev.biochem.78.071107.134639

- Ranuncolo, S. M., Ghosh, S., Hanover, J. A., Hart, G. W., & Lewis, B. A. (2012). Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo. *J Biol Chem*, *287*(28), 23549-23561. <u>https://doi.org/10.1074/jbc.M111.330910</u>
- Rasmussen, E. B., & Lis, J. T. (1993). In vivo transcriptional pausing and cap formation on three Drosophila heat shock genes. *Proc Natl Acad Sci U S A*, 90(17), 7923-7927. <u>https://doi.org/10.1073/pnas.90.17.7923</u>
- Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., & Jenuwein, T. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature*, 406(6796), 593-599. <u>https://doi.org/10.1038/35020506</u>
- Reinberg, D., & Sims, R. J. (2006). de FACTo nucleosome dynamics. *J Biol Chem*, 281(33), 23297-23301. <u>https://doi.org/10.1074/jbc.R600007200</u>
- Reines, D., Chamberlin, M. J., & Kane, C. M. (1989). Transcription elongation factor SII (TFIIS) enables RNA polymerase II to elongate through a block to transcription in a human gene in vitro. *J Biol Chem*, 264(18), 10799-10809.
- Richard, P., Ogami, K., Chen, Y., Feng, S., Moresco, J. J., Yates, J. R., & Manley, J. L. (2018). NRDE-2, the human homolog of fission yeast Nrl1, prevents DNA damage accumulation in human cells. *RNA Biol*, *15*(7), 868-876. <u>https://doi.org/10.1080/15476286.2018.1467180</u>
- Rickert, P., Corden, J. L., & Lees, E. (1999). Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. *Oncogene*, *18*(4), 1093-1102. <u>https://doi.org/10.1038/sj.onc.1202399</u>
- Rodriguez, C. R., Cho, E. J., Keogh, M. C., Moore, C. L., Greenleaf, A. L., & Buratowski, S. (2000). Kin28, the TFIIH-associated carboxy-terminal domain kinase, facilitates the recruitment of mRNA processing machinery to RNA polymerase II. *Mol Cell Biol*, *20*(1), 104-112. <u>https://doi.org/10.1128/mcb.20.1.104-112.2000</u>

- Roeder, R. G. (2019). 50+ years of eukaryotic transcription: an expanding universe of factors and mechanisms. *Nat Struct Mol Biol*, *26*(9), 783-791. https://doi.org/10.1038/s41594-019-0287-x
- Rollins, R. A., Korom, M., Aulner, N., Martens, A., & Dorsett, D. (2004). Drosophila nipped-B protein supports sister chromatid cohesion and opposes the stromalin/Scc3 cohesion factor to facilitate long-range activation of the cut gene. *Mol Cell Biol*, 24(8), 3100-3111. <u>https://doi.org/10.1128/mcb.24.8.3100-3111.2004</u>
- Rougvie, A. E., & Lis, J. T. (1988). The RNA polymerase II molecule at the 5' end of the uninduced hsp70 gene of D. melanogaster is transcriptionally engaged. *Cell*, 54(6), 795-804. https://doi.org/10.1016/s0092-8674(88)91087-2
- Sainsbury, S., Bernecky, C., & Cramer, P. (2015). Structural basis of transcription initiation by RNA polymerase II. *Nat Rev Mol Cell Biol*, *16*(3), 129-143. https://doi.org/10.1038/nrm3952
- Saldi, T., Cortazar, M. A., Sheridan, R. M., & Bentley, D. L. (2016). Coupling of RNA Polymerase II Transcription Elongation with Pre-mRNA Splicing. *J Mol Biol*, 428(12), 2623-2635. <u>https://doi.org/10.1016/j.jmb.2016.04.017</u>
- Santos-Rosa, H., Schneider, R., Bannister, A. J., Sherriff, J., Bernstein, B. E., Emre, N. C., Schreiber, S. L., Mellor, J., & Kouzarides, T. (2002). Active genes are trimethylated at K4 of histone H3. *Nature*, *419*(6905), 407-411. <u>https://doi.org/10.1038/nature01080</u>
- Saunders, A., Werner, J., Andrulis, E. D., Nakayama, T., Hirose, S., Reinberg, D., & Lis, J. T. (2003). Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo. *Science*, *301*(5636), 1094-1096. https://doi.org/10.1126/science.1085712
- Schaeffer, D., Tsanova, B., Barbas, A., Reis, F. P., Dastidar, E. G., Sanchez-Rotunno, M., Arraiano, C. M., & van Hoof, A. (2009). The exosome contains domains with specific endoribonuclease, exoribonuclease and cytoplasmic mRNA decay activities. *Nat Struct Mol Biol*, *16*(1), 56-62. <u>https://doi.org/10.1038/nsmb.1528</u>
- Schlackow, M., Nojima, T., Gomes, T., Dhir, A., Carmo-Fonseca, M., & Proudfoot, N. J. (2017). Distinctive Patterns of Transcription and RNA Processing for Human lincRNAs. *Mol Cell*, 65(1), 25-38. <u>https://doi.org/10.1016/j.molcel.2016.11.029</u>
- Schmid, M., & Jensen, T. H. (2018). Controlling nuclear RNA levels. *Nat Rev Genet*, *19*(8), 518-529. <u>https://doi.org/10.1038/s41576-018-0013-2</u>
- Schmidt, D., Wilson, M. D., Spyrou, C., Brown, G. D., Hadfield, J., & Odom, D. T. (2009). ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. *Methods*, 48(3), 240-248. https://doi.org/10.1016/j.ymeth.2009.03.001
- Schneider, C., Leung, E., Brown, J., & Tollervey, D. (2009). The N-terminal PIN domain of the exosome subunit Rrp44 harbors endonuclease activity and tethers Rrp44 to the yeast core exosome. *Nucleic Acids Res*, *37*(4), 1127-1140. https://doi.org/10.1093/nar/gkn1020
- Schneider, C., & Tollervey, D. (2014). Looking into the barrel of the RNA exosome. *Nat Struct Mol Biol*, 21(1), 17-18. <u>https://doi.org/10.1038/nsmb.2750</u>
- Schneider, J., Bajwa, P., Johnson, F. C., Bhaumik, S. R., & Shilatifard, A. (2006). Rtt109 is required for proper H3K56 acetylation: a chromatin mark associated with the elongating RNA polymerase II. *J Biol Chem*, 281(49), 37270-37274. <u>https://doi.org/10.1074/jbc.C600265200</u>
- Schrank, B. R., Aparicio, T., Li, Y., Chang, W., Chait, B. T., Gundersen, G. G., Gottesman, M. E., & Gautier, J. (2018). Nuclear ARP2/3 drives DNA break clustering for homology-directed repair. *Nature*, *559*(7712), 61-66. <u>https://doi.org/10.1038/s41586-018-0237-5</u>

- Schratt, G., Philippar, U., Berger, J., Schwarz, H., Heidenreich, O., & Nordheim, A. (2002). Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells. *J Cell Biol*, *156*(4), 737-750. https://doi.org/10.1083/jcb.200106008
- Schroeder, S. C., Schwer, B., Shuman, S., & Bentley, D. (2000). Dynamic association of capping enzymes with transcribing RNA polymerase II. *Genes Dev*, *14*(19), 2435-2440. <u>https://doi.org/10.1101/gad.836300</u>
- Schröder, S., Herker, E., Itzen, F., He, D., Thomas, S., Gilchrist, D. A., Kaehlcke, K., Cho, S., Pollard, K. S., Capra, J. A., Schnölzer, M., Cole, P. A., Geyer, M., Bruneau, B. G., Adelman, K., & Ott, M. (2013). Acetylation of RNA polymerase II regulates growth-factor-induced gene transcription in mammalian cells. *Mol Cell*, 52(3), 314-324. https://doi.org/10.1016/j.molcel.2013.10.009
- Schulze, W. M., & Cusack, S. (2017). Structural basis for mutually exclusive cotranscriptional nuclear cap-binding complexes with either NELF-E or ARS2. Nat Commun, 8(1), 1302. <u>https://doi.org/10.1038/s41467-017-01402-w</u>
- Schulze, W. M., Stein, F., Rettel, M., Nanao, M., & Cusack, S. (2018). Structural analysis of human ARS2 as a platform for co-transcriptional RNA sorting. *Nat Commun*, 9(1), 1701. <u>https://doi.org/10.1038/s41467-018-04142-7</u>
- Schwalb, B., Michel, M., Zacher, B., Frühauf, K., Demel, C., Tresch, A., Gagneur, J., & Cramer, P. (2016). TT-seq maps the human transient transcriptome. *Science*, 352(6290), 1225-1228. <u>https://doi.org/10.1126/science.aad9841</u>
- Schwartz, B. E., Larochelle, S., Suter, B., & Lis, J. T. (2003). Cdk7 is required for full activation of Drosophila heat shock genes and RNA polymerase II phosphorylation in vivo. *Mol Cell Biol*, *23*(19), 6876-6886. https://doi.org/10.1128/mcb.23.19.6876-6886.2003
- Schübeler, D., MacAlpine, D. M., Scalzo, D., Wirbelauer, C., Kooperberg, C., van Leeuwen, F., Gottschling, D. E., O'Neill, L. P., Turner, B. M., Delrow, J., Bell, S. P., & Groudine, M. (2004). The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. *Genes Dev*, *18*(11), 1263-1271. https://doi.org/10.1101/gad.1198204
- Schüller, R., Forné, I., Straub, T., Schreieck, A., Texier, Y., Shah, N., Decker, T. M., Cramer, P., Imhof, A., & Eick, D. (2016). Heptad-Specific Phosphorylation of RNA Polymerase II CTD. *Mol Cell*, 61(2), 305-314. <u>https://doi.org/10.1016/j.molcel.2015.12.003</u>
- Seila, A. C., Calabrese, J. M., Levine, S. S., Yeo, G. W., Rahl, P. B., Flynn, R. A., Young, R. A., & Sharp, P. A. (2008). Divergent transcription from active promoters. *Science*, 322(5909), 1849-1851. https://doi.org/10.1126/science.1162253
- Sharili, A. S., Kenny, F. N., Vartiainen, M. K., & Connelly, J. T. (2016). Nuclear actin modulates cell motility via transcriptional regulation of adhesive and cytoskeletal genes. *Sci Rep*, 6, 33893. https://doi.org/10.1038/srep33893
- Shatkin, A. J., & Manley, J. L. (2000). The ends of the affair: capping and polyadenylation. *Nat Struct Biol*, 7(10), 838-842. <u>https://doi.org/10.1038/79583</u>
- Shaw, P. E., Frasch, S., & Nordheim, A. (1989). Repression of c-fos transcription is mediated through p67SRF bound to the SRE. *EMBO J*, 8(9), 2567-2574.
- Shcherbik, N., Wang, M., Lapik, Y. R., Srivastava, L., & Pestov, D. G. (2010). Polyadenylation and degradation of incomplete RNA polymerase I transcripts in mammalian cells. *EMBO Rep*, *11*(2), 106-111. <u>https://doi.org/10.1038/embor.2009.271</u>
- Shearwin, K. E., Callen, B. P., & Egan, J. B. (2005). Transcriptional interference--a crash course. *Trends Genet*, *21*(6), 339-345. <u>https://doi.org/10.1016/j.tig.2005.04.009</u>

- Shetty, A., Kallgren, S. P., Demel, C., Maier, K. C., Spatt, D., Alver, B. H., Cramer, P., Park, P. J., & Winston, F. (2017). Spt5 Plays Vital Roles in the Control of Sense and Antisense Transcription Elongation. *Mol Cell*, 66(1), 77-88.e75. https://doi.org/10.1016/j.molcel.2017.02.023
- Shim, E. Y., Walker, A. K., Shi, Y., & Blackwell, T. K. (2002). CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. *Genes Dev*, 16(16), 2135-2146. https://doi.org/10.1101/gad.999002
- Shore, P., & Sharrocks, A. D. (1995). The MADS-box family of transcription factors. *Eur J Biochem*, 229(1), 1-13. <u>https://doi.org/10.1111/j.1432-</u> 1033.1995.tb20430.x
- Shukla, S., & Oberdoerffer, S. (2012). Co-transcriptional regulation of alternative premRNA splicing. *Biochim Biophys Acta*, *1819*(7), 673-683. <u>https://doi.org/10.1016/j.bbagrm.2012.01.014</u>
- Sigova, A. A., Abraham, B. J., Ji, X., Molinie, B., Hannett, N. M., Guo, Y. E., Jangi, M., Giallourakis, C. C., Sharp, P. A., & Young, R. A. (2015). Transcription factor trapping by RNA in gene regulatory elements. *Science*, *350*(6263), 978-981. <u>https://doi.org/10.1126/science.aad3346</u>
- Sigova, A. A., Mullen, A. C., Molinie, B., Gupta, S., Orlando, D. A., Guenther, M. G., Almada, A. E., Lin, C., Sharp, P. A., Giallourakis, C. C., & Young, R. A. (2013). Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells. *Proc Natl Acad Sci U S A*, *110*(8), 2876-2881. https://doi.org/10.1073/pnas.1221904110
- Silla, T., Karadoulama, E., Mąkosa, D., Lubas, M., & Jensen, T. H. (2018). The RNA Exosome Adaptor ZFC3H1 Functionally Competes with Nuclear Export Activity to Retain Target Transcripts. *Cell Rep*, *23*(7), 2199-2210. <u>https://doi.org/10.1016/j.celrep.2018.04.061</u>
- Silla, T., Schmid, M., Dou, Y., Garland, W., Milek, M., Imami, K., Johnsen, D., Polak, P., Andersen, J. S., Selbach, M., Landthaler, M., & Jensen, T. H. (2020). The human ZC3H3 and RBM26/27 proteins are critical for PAXT-mediated nuclear RNA decay. *Nucleic Acids Res*, 48(5), 2518-2530. https://doi.org/10.1093/nar/gkz1238
- Simic, R., Lindstrom, D. L., Tran, H. G., Roinick, K. L., Costa, P. J., Johnson, A. D., Hartzog, G. A., & Arndt, K. M. (2003). Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes. *EMBO J*, 22(8), 1846-1856. https://doi.org/10.1093/emboj/cdg179
- Sims, R. J., Rojas, L. A., Beck, D. B., Bonasio, R., Schüller, R., Drury, W. J., Eick, D., & Reinberg, D. (2011). The C-terminal domain of RNA polymerase II is modified by site-specific methylation. *Science*, 332(6025), 99-103. <u>https://doi.org/10.1126/science.1202663</u>
- Skaar, D. A., & Greenleaf, A. L. (2002). The RNA polymerase II CTD kinase CTDK-I affects pre-mRNA 3' cleavage/polyadenylation through the processing component Pti1p. *Mol Cell*, *10*(6), 1429-1439. <u>https://doi.org/10.1016/s1097-2765(02)00731-1</u>
- Solier, S., Ryan, M. C., Martin, S. E., Varma, S., Kohn, K. W., Liu, H., Zeeberg, B. R., & Pommier, Y. (2013). Transcription poisoning by Topoisomerase I is controlled by gene length, splice sites, and miR-142-3p. *Cancer Res*, 73(15), 4830-4839. <u>https://doi.org/10.1158/0008-5472.CAN-12-3504</u>
- Songyang, Z., Lu, K. P., Kwon, Y. T., Tsai, L. H., Filhol, O., Cochet, C., Brickey, D. A., Soderling, T. R., Bartleson, C., Graves, D. J., DeMaggio, A. J., Hoekstra, M. F., Blenis, J., Hunter, T., & Cantley, L. C. (1996). A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II,

CDK5, and Erk1. *Mol Cell Biol*, *16*(11), 6486-6493. <u>https://doi.org/10.1128/mcb.16.11.6486</u>

- Sotiropoulos, A., Gineitis, D., Copeland, J., & Treisman, R. (1999). Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. *Cell*, *98*(2), 159-169.
- Spector, B. M., Turek, M. E., & Price, D. H. (2019). Functional interaction of human Ssu72 with RNA polymerase II complexes. *PLoS One*, *14*(3), e0213598. <u>https://doi.org/10.1371/journal.pone.0213598</u>
- Spector, I., Shochet, N. R., Blasberger, D., & Kashman, Y. (1989). Latrunculins--novel marine macrolides that disrupt microfilament organization and affect cell growth:
 I. Comparison with cytochalasin D. *Cell Motil Cytoskeleton*, *13*(3), 127-144. https://doi.org/10.1002/cm.970130302
- Spector, I., Shochet, N. R., Kashman, Y., & Groweiss, A. (1983). Latrunculins: novel marine toxins that disrupt microfilament organization in cultured cells. *Science*, *219*(4584), 493-495. https://doi.org/10.1126/science.6681676
- Srivastava, R., & Ahn, S. H. (2015). Modifications of RNA polymerase II CTD: Connections to the histone code and cellular function. *Biotechnol Adv*, 33(6 Pt 1), 856-872. <u>https://doi.org/10.1016/j.biotechadv.2015.07.008</u>
- Staals, R. H., Bronkhorst, A. W., Schilders, G., Slomovic, S., Schuster, G., Heck, A. J., Raijmakers, R., & Pruijn, G. J. (2010). Dis3-like 1: a novel exoribonuclease associated with the human exosome. *EMBO J*, 29(14), 2358-2367. https://doi.org/10.1038/emboj.2010.122
- Stavreva, D. A., Müller, W. G., Hager, G. L., Smith, C. L., & McNally, J. G. (2004). Rapid glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by chaperones and proteasomes. *Mol Cell Biol*, 24(7), 2682-2697. <u>https://doi.org/10.1128/mcb.24.7.2682-2697.2004</u>
- Steger, D. J., Lefterova, M. I., Ying, L., Stonestrom, A. J., Schupp, M., Zhuo, D., Vakoc, A. L., Kim, J. E., Chen, J., Lazar, M. A., Blobel, G. A., & Vakoc, C. R. (2008). DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. *Mol Cell Biol*, 28(8), 2825-2839. <u>https://doi.org/10.1128/MCB.02076-07</u>
- Stern, S., Debre, E., Stritt, C., Berger, J., Posern, G., & Knöll, B. (2009). A nuclear actin function regulates neuronal motility by serum response factor-dependent gene transcription. *J Neurosci*, 29(14), 4512-4518. https://doi.org/10.1523/JNEUROSCI.0333-09.2009
- Sterner, D. E., & Berger, S. L. (2000). Acetylation of histones and transcription-related factors. *Microbiol Mol Biol Rev*, 64(2), 435-459. https://doi.org/10.1128/mmbr.64.2.435-459.2000
- Strahl, B. D., & Allis, C. D. (2000). The language of covalent histone modifications. *Nature*, 403(6765), 41-45. https://doi.org/10.1038/47412
- Strahl, B. D., Grant, P. A., Briggs, S. D., Sun, Z. W., Bone, J. R., Caldwell, J. A., Mollah, S., Cook, R. G., Shabanowitz, J., Hunt, D. F., & Allis, C. D. (2002). Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. *Mol Cell Biol*, 22(5), 1298-1306. https://doi.org/10.1128/mcb.22.5.1298-1306.2002
- Strässer, K., & Hurt, E. (2000). Yra1p, a conserved nuclear RNA-binding protein, interacts directly with Mex67p and is required for mRNA export. *EMBO J*, 19(3), 410-420. <u>https://doi.org/10.1093/emboj/19.3.410</u>
- Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., & Mesirov, J. P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*, 102(43), 15545-15550. https://doi.org/10.1073/pnas.0506580102

- Suh, H., Ficarro, S. B., Kang, U. B., Chun, Y., Marto, J. A., & Buratowski, S. (2016). Direct Analysis of Phosphorylation Sites on the Rpb1 C-Terminal Domain of RNA Polymerase II. *Mol Cell*, 61(2), 297-304. https://doi.org/10.1016/j.molcel.2015.12.021
- Sun, M., Larivière, L., Dengl, S., Mayer, A., & Cramer, P. (2010). A tandem SH2 domain in transcription elongation factor Spt6 binds the phosphorylated RNA polymerase II C-terminal repeat domain (CTD). *J Biol Chem*, 285(53), 41597-41603. https://doi.org/10.1074/jbc.M110.144568
- Sun, X., Zhang, Y., Cho, H., Rickert, P., Lees, E., Lane, W., & Reinberg, D. (1998). NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription. *Mol Cell*, 2(2), 213-222. https://doi.org/10.1016/s1097-2765(00)80131-8
- Sun, Y., Boyd, K., Xu, W., Ma, J., Jackson, C. W., Fu, A., Shillingford, J. M., Robinson, G. W., Hennighausen, L., Hitzler, J. K., Ma, Z., & Morris, S. W. (2006). Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland function. *Mol Cell Biol*, 26(15), 5809-5826. <u>https://doi.org/10.1128/MCB.00024-06</u>
- Sun, Z. W., & Allis, C. D. (2002). Ubiquitination of histone H2B regulates H3 methylation and gene silencing in yeast. *Nature*, *418*(6893), 104-108. https://doi.org/10.1038/nature00883
- Taatjes, D. J. (2010). The human Mediator complex: a versatile, genome-wide regulator of transcription. *Trends Biochem Sci*, *35*(6), 315-322. https://doi.org/10.1016/j.tibs.2010.02.004
- Takagaki, Y., Ryner, L. C., & Manley, J. L. (1989). Four factors are required for 3'-end cleavage of pre-mRNAs. *Genes Dev*, *3*(11), 1711-1724. https://doi.org/10.1101/gad.3.11.1711
- Takahashi, H., Parmely, T. J., Sato, S., Tomomori-Sato, C., Banks, C. A., Kong, S. E., Szutorisz, H., Swanson, S. K., Martin-Brown, S., Washburn, M. P., Florens, L., Seidel, C. W., Lin, C., Smith, E. R., Shilatifard, A., Conaway, R. C., & Conaway, J. W. (2011). Human mediator subunit MED26 functions as a docking site for transcription elongation factors. *Cell*, *146*(1), 92-104. <u>https://doi.org/10.1016/j.cell.2011.06.005</u>
- Talbert, P. B., & Henikoff, S. (2010). Histone variants--ancient wrap artists of the epigenome. *Nat Rev Mol Cell Biol*, *11*(4), 264-275. https://doi.org/10.1038/nrm2861
- Tan-Wong, S. M., French, J. D., Proudfoot, N. J., & Brown, M. A. (2008). Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene. *Proc Natl Acad Sci U S A*, 105(13), 5160-5165. <u>https://doi.org/10.1073/pnas.0801048105</u>
- Tan-Wong, S. M., Wijayatilake, H. D., & Proudfoot, N. J. (2009). Gene loops function to maintain transcriptional memory through interaction with the nuclear pore complex. *Genes Dev*, 23(22), 2610-2624. <u>https://doi.org/10.1101/gad.1823209</u>
- Tan-Wong, S. M., Zaugg, J. B., Camblong, J., Xu, Z., Zhang, D. W., Mischo, H. E., Ansari, A. Z., Luscombe, N. M., Steinmetz, L. M., & Proudfoot, N. J. (2012). Gene loops enhance transcriptional directionality. *Science*, *338*(6107), 671-675. <u>https://doi.org/10.1126/science.1224350</u>
- Tellam, R., & Frieden, C. (1982). Cytochalasin D and platelet gelsolin accelerate actin polymer formation. A model for regulation of the extent of actin polymer formation in vivo. *Biochemistry*, *21*(13), 3207-3214.
- Tian, B., Yang, J., & Brasier, A. R. (2012). Two-step cross-linking for analysis of protein-chromatin interactions. *Methods Mol Biol*, 809, 105-120. <u>https://doi.org/10.1007/978-1-61779-376-9_7</u>

- Tie, F., Banerjee, R., Stratton, C. A., Prasad-Sinha, J., Stepanik, V., Zlobin, A., Diaz, M. O., Scacheri, P. C., & Harte, P. J. (2009). CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. *Development*, 136(18), 3131-3141. <u>https://doi.org/10.1242/dev.037127</u>
- Tietjen, J. R., Zhang, D. W., Rodríguez-Molina, J. B., White, B. E., Akhtar, M. S., Heidemann, M., Li, X., Chapman, R. D., Shokat, K., Keles, S., Eick, D., & Ansari, A. Z. (2010). Chemical-genomic dissection of the CTD code. *Nat Struct Mol Biol*, *17*(9), 1154-1161. <u>https://doi.org/10.1038/nsmb.1900</u>
- Tomecki, R., Kristiansen, M. S., Lykke-Andersen, S., Chlebowski, A., Larsen, K. M., Szczesny, R. J., Drazkowska, K., Pastula, A., Andersen, J. S., Stepien, P. P., Dziembowski, A., & Jensen, T. H. (2010). The human core exosome interacts with differentially localized processive RNases: hDIS3 and hDIS3L. *EMBO J*, 29(14), 2342-2357. https://doi.org/10.1038/emboj.2010.121
- Tominaga, T., Sahai, E., Chardin, P., McCormick, F., Courtneidge, S. A., & Alberts, A. S. (2000). Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. *Mol Cell*, *5*(1), 13-25. <u>https://doi.org/10.1016/s1097-2765(00)80399-8</u>
- Topisirovic, I., Svitkin, Y. V., Sonenberg, N., & Shatkin, A. J. (2011). Cap and capbinding proteins in the control of gene expression. *Wiley Interdiscip Rev RNA*, 2(2), 277-298. <u>https://doi.org/10.1002/wrna.52</u>
- Torchet, C., Bousquet-Antonelli, C., Milligan, L., Thompson, E., Kufel, J., & Tollervey, D. (2002). Processing of 3'-extended read-through transcripts by the exosome can generate functional mRNAs. *Mol Cell*, 9(6), 1285-1296. https://doi.org/10.1016/s1097-2765(02)00544-0
- Treisman, R. (1985). Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5' element and c-fos 3' sequences. *Cell*, 42(3), 889-902. <u>https://doi.org/10.1016/0092-8674(85)90285-5</u>
- Treisman, R. (1986). Identification of a protein-binding site that mediates transcriptional response of the c-fos gene to serum factors. *Cell*, *46*(4), 567-574. <u>https://doi.org/10.1016/0092-8674(86)90882-2</u>
- Treisman, R. (1990). The SRE: a growth factor responsive transcriptional regulator. *Semin Cancer Biol*, *1*(1), 47-58.
- Treisman, R. (1994). Ternary complex factors: growth factor regulated transcriptional activators. *Curr Opin Genet Dev*, *4*(1), 96-101.
- Trigon, S., Serizawa, H., Conaway, J. W., Conaway, R. C., Jackson, S. P., & Morange, M. (1998). Characterization of the residues phosphorylated in vitro by different C-terminal domain kinases. *J Biol Chem*, 273(12), 6769-6775. <u>https://doi.org/10.1074/jbc.273.12.6769</u>
- Tropberger, P., Pott, S., Keller, C., Kamieniarz-Gdula, K., Caron, M., Richter, F., Li, G., Mittler, G., Liu, E. T., Bühler, M., Margueron, R., & Schneider, R. (2013). Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. *Cell*, *152*(4), 859-872. https://doi.org/10.1016/j.cell.2013.01.032
- Tufegdžić Vidaković, A., Mitter, R., Kelly, G. P., Neumann, M., Harreman, M., Rodríguez-Martínez, M., Herlihy, A., Weems, J. C., Boeing, S., Encheva, V., Gaul, L., Milligan, L., Tollervey, D., Conaway, R. C., Conaway, J. W., Snijders, A. P., Stewart, A., & Svejstrup, J. Q. (2020). Regulation of the RNAPII Pool Is Integral to the DNA Damage Response. *Cell*, *180*(6), 1245-1261.e1221. <u>https://doi.org/10.1016/j.cell.2020.02.009</u>
- Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T., & Mulligan, R. C. (1991). Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. *Cell*, *65*(7), 1153-1163. <u>https://doi.org/10.1016/0092-8674(91)90011-m</u>

- Ule, J., Jensen, K., Mele, A., & Darnell, R. B. (2005). CLIP: a method for identifying protein-RNA interaction sites in living cells. *Methods*, *37*(4), 376-386. https://doi.org/10.1016/j.ymeth.2005.07.018
- Vakoc, C. R., Sachdeva, M. M., Wang, H., & Blobel, G. A. (2006). Profile of histone lysine methylation across transcribed mammalian chromatin. *Mol Cell Biol*, 26(24), 9185-9195. <u>https://doi.org/10.1128/MCB.01529-06</u>
- Valen, E., Preker, P., Andersen, P. R., Zhao, X., Chen, Y., Ender, C., Dueck, A., Meister, G., Sandelin, A., & Jensen, T. H. (2011). Biogenic mechanisms and utilization of small RNAs derived from human protein-coding genes. *Nat Struct Mol Biol*, 18(9), 1075-1082. <u>https://doi.org/10.1038/nsmb.2091</u>
- Vanácová, S., Wolf, J., Martin, G., Blank, D., Dettwiler, S., Friedlein, A., Langen, H., Keith, G., & Keller, W. (2005). A new yeast poly(A) polymerase complex involved in RNA quality control. *PLoS Biol*, *3*(6), e189. https://doi.org/10.1371/journal.pbio.0030189
- Vartiainen, M. K., Guettler, S., Larijani, B., & Treisman, R. (2007). Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. *Science*, *316*(5832), 1749-1752. <u>https://doi.org/10.1126/science.1141084</u>
- Vitaliano-Prunier, A., Babour, A., Hérissant, L., Apponi, L., Margaritis, T., Holstege, F. C., Corbett, A. H., Gwizdek, C., & Dargemont, C. (2012). H2B ubiquitylation controls the formation of export-competent mRNP. *Mol Cell*, *45*(1), 132-139. https://doi.org/10.1016/j.molcel.2011.12.011
- Vogelauer, M., Wu, J., Suka, N., & Grunstein, M. (2000). Global histone acetylation and deacetylation in yeast. *Nature*, 408(6811), 495-498. <u>https://doi.org/10.1038/35044127</u>
- Volanakis, A., Kamieniarz-Gdula, K., Schlackow, M., & Proudfoot, N. J. (2017). WNK1 kinase and the termination factor PCF11 connect nuclear mRNA export with transcription. *Genes Dev*, 31(21), 2175-2185. https://doi.org/10.1101/gad.303677.117
- Voss, K., Forné, I., Descostes, N., Hintermair, C., Schüller, R., Maqbool, M. A., Heidemann, M., Flatley, A., Imhof, A., Gut, M., Gut, I., Kremmer, E., Andrau, J. C., & Eick, D. (2015). Site-specific methylation and acetylation of lysine residues in the C-terminal domain (CTD) of RNA polymerase II. *Transcription*, 6(5), 91-101. https://doi.org/10.1080/21541264.2015.1114983
- Wada, T., Takagi, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S., Sugimoto, S., Yano, K., Hartzog, G. A., Winston, F., Buratowski, S., & Handa, H. (1998).
 DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. *Genes Dev*, 12(3), 343-356. https://doi.org/10.1101/gad.12.3.343
- Wagschal, A., Rousset, E., Basavarajaiah, P., Contreras, X., Harwig, A., Laurent-Chabalier, S., Nakamura, M., Chen, X., Zhang, K., Meziane, O., Boyer, F., Parrinello, H., Berkhout, B., Terzian, C., Benkirane, M., & Kiernan, R. (2012). Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. *Cell*, *150*(6), 1147-1157. https://doi.org/10.1016/j.cell.2012.08.004
- Wang, D. Z., Li, S., Hockemeyer, D., Sutherland, L., Wang, Z., Schratt, G., Richardson, J. A., Nordheim, A., & Olson, E. N. (2002). Potentiation of serum response factor activity by a family of myocardin-related transcription factors. *Proc Natl Acad Sci U S A*, 99(23), 14855-14860. <u>https://doi.org/10.1073/pnas.222561499</u>
- Wang, D. Z., & Olson, E. N. (2004). Control of smooth muscle development by the myocardin family of transcriptional coactivators. *Curr Opin Genet Dev*, 14(5), 558-566. <u>https://doi.org/10.1016/j.gde.2004.08.003</u>
- Wang, J., Chen, J., Wu, G., Zhang, H., Du, X., Chen, S., Zhang, L., Wang, K., Fan, J., Gao, S., Wu, X., Zhang, S., Kuai, B., Zhao, P., Chi, B., Wang, L., Li, G., Wong,

C. C. L., Zhou, Y., Li, J., Yun, C., & Cheng, H. (2019). NRDE2 negatively regulates exosome functions by inhibiting MTR4 recruitment and exosome interaction. *Genes Dev*, *33*(9-10), 536-549. https://doi.org/10.1101/gad.322602.118

- Wang, Y., Fairley, J. A., & Roberts, S. G. (2010). Phosphorylation of TFIIB links transcription initiation and termination. *Curr Biol*, *20*(6), 548-553. <u>https://doi.org/10.1016/j.cub.2010.01.052</u>
- Wang, Y., Sherrard, A., Zhao, B., Melak, M., Trautwein, J., Kleinschnitz, E. M., Tsopoulidis, N., Fackler, O. T., Schwan, C., & Grosse, R. (2019). GPCRinduced calcium transients trigger nuclear actin assembly for chromatin dynamics. *Nat Commun*, *10*(1), 5271. <u>https://doi.org/10.1038/s41467-019-13322-y</u>
- Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Peng, W., Zhang, M. Q., & Zhao, K. (2008). Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat Genet*, 40(7), 897-903. <u>https://doi.org/10.1038/ng.154</u>
- Wani, S., Yuda, M., Fujiwara, Y., Yamamoto, M., Harada, F., Ohkuma, Y., & Hirose, Y. (2014). Vertebrate Ssu72 regulates and coordinates 3'-end formation of RNAs transcribed by RNA polymerase II. *PLoS One*, *9*(8), e106040. <u>https://doi.org/10.1371/journal.pone.0106040</u>
- Wasylyk, B., & Chambon, P. (1979). Transcription by eukaryotic RNA polymerases A and B of chromatin assembled in vitro. *Eur J Biochem*, *98*(2), 317-327. https://doi.org/10.1111/j.1432-1033.1979.tb13191.x
- Weick, E. M., Puno, M. R., Januszyk, K., Zinder, J. C., DiMattia, M. A., & Lima, C. D. (2018). Helicase-Dependent RNA Decay Illuminated by a Cryo-EM Structure of a Human Nuclear RNA Exosome-MTR4 Complex. *Cell*, *173*(7), 1663-1677.e1621. https://doi.org/10.1016/j.cell.2018.05.041
- Weil, P. A., Luse, D. S., Segall, J., & Roeder, R. G. (1979). Selective and accurate initiation of transcription at the Ad2 major late promotor in a soluble system dependent on purified RNA polymerase II and DNA. *Cell*, 18(2), 469-484. <u>https://doi.org/10.1016/0092-8674(79)90065-5</u>
- Weinl, C., Riehle, H., Park, D., Stritt, C., Beck, S., Huber, G., Wolburg, H., Olson, E. N., Seeliger, M. W., Adams, R. H., & Nordheim, A. (2013). Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae. *J Clin Invest*, 123(5), 2193-2206. <u>https://doi.org/10.1172/JCI64201</u>
- Weinl, C., Wasylyk, C., Garcia Garrido, M., Sothilingam, V., Beck, S. C., Riehle, H., Stritt, C., Roux, M. J., Seeliger, M. W., Wasylyk, B., & Nordheim, A. (2014).
 Elk3 deficiency causes transient impairment in post-natal retinal vascular development and formation of tortuous arteries in adult murine retinae. *PLoS One*, *9*(9), e107048. https://doi.org/10.1371/journal.pone.0107048
- Weissbach, J., Schikora, F., Weber, A., Kessels, M., & Posern, G. (2016). Myocardin-Related Transcription Factor A Activation by Competition with WH2 Domain Proteins for Actin Binding. *Mol Cell Biol*, *36*(10), 1526-1539. <u>https://doi.org/10.1128/MCB.01097-15</u>
- West, M. L., & Corden, J. L. (1995). Construction and analysis of yeast RNA polymerase II CTD deletion and substitution mutations. *Genetics*, *140*(4), 1223-1233.
- West, S., Gromak, N., & Proudfoot, N. J. (2004). Human 5' --> 3' exonuclease Xrn2 promotes transcription termination at co-transcriptional cleavage sites. *Nature*, 432(7016), 522-525. <u>https://doi.org/10.1038/nature03035</u>
- West, S., & Proudfoot, N. J. (2008). Human Pcf11 enhances degradation of RNA polymerase II-associated nascent RNA and transcriptional termination. *Nucleic Acids Res*, 36(3), 905-914. <u>https://doi.org/10.1093/nar/gkm1112</u>

- White, E., Kamieniarz-Gdula, K., Dye, M. J., & Proudfoot, N. J. (2013). AT-rich sequence elements promote nascent transcript cleavage leading to RNA polymerase II termination. *Nucleic Acids Res*, *41*(3), 1797-1806. https://doi.org/10.1093/nar/gks1335
- White, M. D., Angiolini, J. F., Alvarez, Y. D., Kaur, G., Zhao, Z. W., Mocskos, E., Bruno, L., Bissiere, S., Levi, V., & Plachta, N. (2016). Long-Lived Binding of Sox2 to DNA Predicts Cell Fate in the Four-Cell Mouse Embryo. *Cell*, *165*(1), 75-87. <u>https://doi.org/10.1016/j.cell.2016.02.032</u>
- Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017). Inhibitors of cyclindependent kinases as cancer therapeutics. *Pharmacol Ther*, *173*, 83-105. <u>https://doi.org/10.1016/j.pharmthera.2017.02.008</u>
- Wiezlak, M., Diring, J., Abella, J., Mouilleron, S., Way, M., McDonald, N. Q., & Treisman, R. (2012). G-actin regulates the shuttling and PP1 binding of the RPEL protein Phactr1 to control actomyosin assembly. *J Cell Sci*, 125(Pt 23), 5860-5872. <u>https://doi.org/10.1242/jcs.112078</u>
- Williams, S. K., Truong, D., & Tyler, J. K. (2008). Acetylation in the globular core of histone H3 on lysine-56 promotes chromatin disassembly during transcriptional activation. *Proc Natl Acad Sci U S A*, 105(26), 9000-9005. <u>https://doi.org/10.1073/pnas.0800057105</u>
- Wirbelauer, C., Bell, O., & Schübeler, D. (2005). Variant histone H3.3 is deposited at sites of nucleosomal displacement throughout transcribed genes while active histone modifications show a promoter-proximal bias. *Genes Dev*, 19(15), 1761-1766. <u>https://doi.org/10.1101/gad.347705</u>
- Wong, K. H., Jin, Y., & Struhl, K. (2014). TFIIH phosphorylation of the Pol II CTD stimulates mediator dissociation from the preinitiation complex and promoter escape. *Mol Cell*, 54(4), 601-612. <u>https://doi.org/10.1016/j.molcel.2014.03.024</u>
- Wood, A., Schneider, J., Dover, J., Johnston, M., & Shilatifard, A. (2005). The Bur1/Bur2 complex is required for histone H2B monoubiquitination by Rad6/Bre1 and histone methylation by COMPASS. *Mol Cell*, *20*(4), 589-599. <u>https://doi.org/10.1016/j.molcel.2005.09.010</u>
- Wright, R. H., Lioutas, A., Le Dily, F., Soronellas, D., Pohl, A., Bonet, J., Nacht, A. S., Samino, S., Font-Mateu, J., Vicent, G. P., Wierer, M., Trabado, M. A., Schelhorn, C., Carolis, C., Macias, M. J., Yanes, O., Oliva, B., & Beato, M. (2016). ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling. *Science*, *352*(6290), 1221-1225. <u>https://doi.org/10.1126/science.aad9335</u>
- Wu, C. H., Yamaguchi, Y., Benjamin, L. R., Horvat-Gordon, M., Washinsky, J., Enerly, E., Larsson, J., Lambertsson, A., Handa, H., & Gilmour, D. (2003). NELF and DSIF cause promoter proximal pausing on the hsp70 promoter in Drosophila. *Genes Dev*, *17*(11), 1402-1414. <u>https://doi.org/10.1101/gad.1091403</u>
- Wu, G., Schmid, M., Rib, L., Polak, P., Meola, N., Sandelin, A., & Jensen, T. H. (2020). A Two-Layered Targeting Mechanism Underlies Nuclear RNA Sorting by the Human Exosome. *Cell Rep*, *30*(7), 2387-2401.e2385. <u>https://doi.org/10.1016/j.celrep.2020.01.068</u>
- Wu, T., Pinto, H. B., Kamikawa, Y. F., & Donohoe, M. E. (2015). The BET family member BRD4 interacts with OCT4 and regulates pluripotency gene expression. *Stem Cell Reports*, *4*(3), 390-403. <u>https://doi.org/10.1016/j.stemcr.2015.01.012</u>
- Wu, X., Wilcox, C. B., Devasahayam, G., Hackett, R. L., Arévalo-Rodríguez, M., Cardenas, M. E., Heitman, J., & Hanes, S. D. (2000). The Ess1 prolyl isomerase is linked to chromatin remodeling complexes and the general transcription machinery. *EMBO J*, *19*(14), 3727-3738. <u>https://doi.org/10.1093/emboj/19.14.3727</u>

- Wyers, F., Rougemaille, M., Badis, G., Rousselle, J. C., Dufour, M. E., Boulay, J., Régnault, B., Devaux, F., Namane, A., Séraphin, B., Libri, D., & Jacquier, A. (2005). Cryptic pol II transcripts are degraded by a nuclear quality control pathway involving a new poly(A) polymerase. *Cell*, *121*(5), 725-737. <u>https://doi.org/10.1016/j.cell.2005.04.030</u>
- Xiang, K., Manley, J. L., & Tong, L. (2012). An unexpected binding mode for a Pol II CTD peptide phosphorylated at Ser7 in the active site of the CTD phosphatase Ssu72. Genes Dev, 26(20), 2265-2270. <u>https://doi.org/10.1101/gad.198853.112</u>
- Xiao, T., Hall, H., Kizer, K. O., Shibata, Y., Hall, M. C., Borchers, C. H., & Strahl, B. D. (2003). Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. *Genes Dev*, *17*(5), 654-663. <u>https://doi.org/10.1101/gad.1055503</u>
- Xiao, T., Kao, C. F., Krogan, N. J., Sun, Z. W., Greenblatt, J. F., Osley, M. A., & Strahl, B. D. (2005). Histone H2B ubiquitylation is associated with elongating RNA polymerase II. *Mol Cell Biol*, 25(2), 637-651. https://doi.org/10.1128/MCB.25.2.637-651.2005
- Xu, F., Zhang, K., & Grunstein, M. (2005). Acetylation in histone H3 globular domain regulates gene expression in yeast. *Cell*, *121*(3), 375-385. https://doi.org/10.1016/j.cell.2005.03.011
- Xu, Y. X., Hirose, Y., Zhou, X. Z., Lu, K. P., & Manley, J. L. (2003). Pin1 modulates the structure and function of human RNA polymerase II. *Genes Dev*, *17*(22), 2765-2776. <u>https://doi.org/10.1101/gad.1135503</u>
- Xu, Y. X., & Manley, J. L. (2007). Pin1 modulates RNA polymerase II activity during the transcription cycle. *Genes Dev*, *21*(22), 2950-2962. https://doi.org/10.1101/gad.1592807
- Xu, Z., Wei, W., Gagneur, J., Perocchi, F., Clauder-Münster, S., Camblong, J., Guffanti, E., Stutz, F., Huber, W., & Steinmetz, L. M. (2009). Bidirectional promoters generate pervasive transcription in yeast. *Nature*, 457(7232), 1033-1037. <u>https://doi.org/10.1038/nature07728</u>
- Yamada, T., Yamaguchi, Y., Inukai, N., Okamoto, S., Mura, T., & Handa, H. (2006). P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. *Mol Cell*, *21*(2), 227-237. <u>https://doi.org/10.1016/j.molcel.2005.11.024</u>
- Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J., & Handa, H. (1999). NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. *Cell*, 97(1), 41-51. <u>https://doi.org/10.1016/s0092-8674(00)80713-8</u>
- Yamaguchi, Y., Wada, T., Watanabe, D., Takagi, T., Hasegawa, J., & Handa, H. (1999). Structure and function of the human transcription elongation factor DSIF. *J Biol Chem*, 274(12), 8085-8092. https://doi.org/10.1074/jbc.274.12.8085
- Yamazaki, S., Gerhold, C., Yamamoto, K., Ueno, Y., Grosse, R., Miyamoto, K., & Harata, M. (2020). The Actin-Family Protein Arp4 Is a Novel Suppressor for the Formation and Functions of Nuclear F-Actin. *Cells*, *9*(3). <u>https://doi.org/10.3390/cells9030758</u>
- Yang, X. C., Burch, B. D., Yan, Y., Marzluff, W. F., & Dominski, Z. (2009). FLASH, a proapoptotic protein involved in activation of caspase-8, is essential for 3' end processing of histone pre-mRNAs. *Mol Cell*, *36*(2), 267-278. <u>https://doi.org/10.1016/j.molcel.2009.08.016</u>
- Yang, Z., Zhu, Q., Luo, K., & Zhou, Q. (2001). The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. *Nature*, *414*(6861), 317-322. https://doi.org/10.1038/35104575

- Yao, J., Munson, K. M., Webb, W. W., & Lis, J. T. (2006). Dynamics of heat shock factor association with native gene loci in living cells. *Nature*, 442(7106), 1050-1053. <u>https://doi.org/10.1038/nature05025</u>
- Yeo, M., Lin, P. S., Dahmus, M. E., & Gill, G. N. (2003). A novel RNA polymerase II Cterminal domain phosphatase that preferentially dephosphorylates serine 5. J Biol Chem, 278(28), 26078-26085. <u>https://doi.org/10.1074/jbc.M301791200</u>
- Yik, J. H., Chen, R., Nishimura, R., Jennings, J. L., Link, A. J., & Zhou, Q. (2003). Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. *Mol Cell*, 12(4), 971-982. <u>https://doi.org/10.1016/s1097-2765(03)00388-5</u>
- Yoh, S. M., Cho, H., Pickle, L., Evans, R. M., & Jones, K. A. (2007). The Spt6 SH2 domain binds Ser2-P RNAPII to direct lws1-dependent mRNA splicing and export. *Genes Dev*, 21(2), 160-174. <u>https://doi.org/10.1101/gad.1503107</u>
- Yu, L., Kim, J., Jiang, L., Feng, B., Ying, Y., Ji, K. Y., Tang, Q., Chen, W., Mai, T., Dou, W., Zhou, J., Xiang, L. Y., He, Y. F., Yang, D., Li, Q., Fu, X., & Xu, Y. (2020).
 MTR4 drives liver tumorigenesis by promoting cancer metabolic switch through alternative splicing. *Nat Commun*, *11*(1), 708. <u>https://doi.org/10.1038/s41467-020-14437-3</u>
- Yue, Z., Maldonado, E., Pillutla, R., Cho, H., Reinberg, D., & Shatkin, A. J. (1997). Mammalian capping enzyme complements mutant Saccharomyces cerevisiae lacking mRNA guanylyltransferase and selectively binds the elongating form of RNA polymerase II. *Proc Natl Acad Sci U S A*, 94(24), 12898-12903. https://doi.org/10.1073/pnas.94.24.12898
- Zaborowska, J., Egloff, S., & Murphy, S. (2016). The pol II CTD: new twists in the tail. Nat Struct Mol Biol, 23(9), 771-777. <u>https://doi.org/10.1038/nsmb.3285</u>
- Zaromytidou, A. I., Miralles, F., & Treisman, R. (2006). MAL and ternary complex factor use different mechanisms to contact a common surface on the serum response factor DNA-binding domain. *Mol Cell Biol*, *26*(11), 4134-4148. https://doi.org/10.1128/MCB.01902-05
- Zeitlinger, J., Stark, A., Kellis, M., Hong, J. W., Nechaev, S., Adelman, K., Levine, M., & Young, R. A. (2007). RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. *Nat Genet*, *39*(12), 1512-1516. <u>https://doi.org/10.1038/ng.2007.26</u>
- Zhang, D. W., Mosley, A. L., Ramisetty, S. R., Rodríguez-Molina, J. B., Washburn, M. P., & Ansari, A. Z. (2012). Ssu72 phosphatase-dependent erasure of phospho-Ser7 marks on the RNA polymerase II C-terminal domain is essential for viability and transcription termination. *J Biol Chem*, 287(11), 8541-8551. <u>https://doi.org/10.1074/jbc.M111.335687</u>
- Zhang, H., Rigo, F., & Martinson, H. G. (2015). Poly(A) Signal-Dependent Transcription Termination Occurs through a Conformational Change Mechanism that Does Not Require Cleavage at the Poly(A) Site. *Mol Cell*, *59*(3), 437-448. <u>https://doi.org/10.1016/j.molcel.2015.06.008</u>
- Zhang, J., & Corden, J. L. (1991). Identification of phosphorylation sites in the repetitive carboxyl-terminal domain of the mouse RNA polymerase II largest subunit. *J Biol Chem*, 266(4), 2290-2296.
- Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., Manz, T., Hao, M., Bartkowiak, B., Greenleaf, A. L., Marto, J. A., Geyer, M., Bullock, A. N., Young, R. A., & Gray, N. S. (2016). Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. *Nat Chem Biol*, *12*(10), 876-884. <u>https://doi.org/10.1038/nchembio.2166</u>

- Zhang, Z., Fu, J., & Gilmour, D. S. (2005). CTD-dependent dismantling of the RNA polymerase II elongation complex by the pre-mRNA 3'-end processing factor, Pcf11. *Genes Dev*, *19*(13), 1572-1580. <u>https://doi.org/10.1101/gad.1296305</u>
- Zhang, Z., & Gilmour, D. S. (2006). Pcf11 is a termination factor in Drosophila that dismantles the elongation complex by bridging the CTD of RNA polymerase II to the nascent transcript. *Mol Cell*, *21*(1), 65-74. https://doi.org/10.1016/j.molcel.2005.11.002
- Zhao, J., Hyman, L., & Moore, C. (1999). Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. *Microbiol Mol Biol Rev*, 63(2), 405-445.
- Zhu, B., Mandal, S. S., Pham, A. D., Zheng, Y., Erdjument-Bromage, H., Batra, S. K., Tempst, P., & Reinberg, D. (2005). The human PAF complex coordinates transcription with events downstream of RNA synthesis. *Genes Dev*, 19(14), 1668-1673. <u>https://doi.org/10.1101/gad.1292105</u>
- Zhu, B., Zheng, Y., Pham, A. D., Mandal, S. S., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2005). Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. *Mol Cell*, *20*(4), 601-611. https://doi.org/10.1016/j.molcel.2005.09.025
- Zippo, A., Serafini, R., Rocchigiani, M., Pennacchini, S., Krepelova, A., & Oliviero, S. (2009). Histone crosstalk between H3S10ph and H4K16ac generates a histone code that mediates transcription elongation. *Cell*, *138*(6), 1122-1136. https://doi.org/10.1016/j.cell.2009.07.031